model,disease_category,disease,incident_rate,protein,hazard_ratio,ci_lower,ci_upper,pvalue
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535644721464744,CDH3;Cadherin-3,3.71277552434008,3.29390872421749,4.18490712653658,2.49081641314836e-102
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066025827750267,CDH3;Cadherin-3,2.85751250386775,2.04449196337894,3.99384192064301,7.9202946033775e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0543953375424963,CDH3;Cadherin-3,3.8193549347281,2.63410081538368,5.5379323495282,1.55758859623325e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34671603975833,CDH3;Cadherin-3,1.25797431494694,1.16721277922343,1.35579339537313,1.89166937978642e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.777423618129518,CDH3;Cadherin-3,1.25228064716411,1.13507721459879,1.38158602700529,7.22064013733306e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.795642447232759,CDH3;Cadherin-3,1.24852054332597,1.13273107212923,1.37614618814759,7.83044522003499e-06
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402598412945386,CDH3;Cadherin-3,1.41323252984775,1.23303780241501,1.61976070766697,6.69281758642455e-07
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0485540600905047,CDH3;Cadherin-3,2.44261454102406,1.65134039712242,3.61304417091654,7.77910290129335e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,COL1A1;Collagen alpha-1(I) chain,1.55697413080904,1.3832718490851,1.75248881527655,2.20520651065366e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104513431911434,COL1A1;Collagen alpha-1(I) chain,2.05993912689931,1.57500288503897,2.69418503727102,1.3139333956555e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,CHRDL2;Chordin-like protein 2,1.73751973789919,1.53690670364975,1.9643188701175,1.08766675586526e-18
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,CHRDL2;Chordin-like protein 2,2.8245521258199,2.31169834560469,3.45118329415374,3.08465986897018e-24
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105795227459739,CHRDL2;Chordin-like protein 2,4.35300124718436,3.21173789431722,5.89980268673725,2.50957363174833e-21
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.397664007998727,CSF1R;Macrophage colony-stimulating factor 1 receptor,1.40527256603734,1.21133087180227,1.63026554579508,7.11695397463159e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.211023121780762,CSF1R;Macrophage colony-stimulating factor 1 receptor,3.09715856429388,2.55381747284759,3.75609896727785,1.54120808525843e-30
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.265999772649767,CSF1R;Macrophage colony-stimulating factor 1 receptor,1.79882985097915,1.50550478591028,2.14930491291477,1.01511175175924e-10
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.108878101891757,CSF1R;Macrophage colony-stimulating factor 1 receptor,4.42542474850662,3.43183522995486,5.7066796312807,1.98063107979795e-30
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.55491656072805,CST6;Cystatin-M,3.29254320527441,2.90769740013541,3.72832494815101,9.06674307278355e-79
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0683939491470872,CST6;Cystatin-M,3.38294898073991,2.41122538421698,4.74627709263503,1.73375949048567e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0583594944860339,CST6;Cystatin-M,3.1551023986675,2.17905576026469,4.56834163108712,1.16879206771603e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535644721464744,OXT;Oxytocin-neurophysin 1,1.35372302394244,1.20290868434688,1.52344566915057,5.02130323135108e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.536427393558897,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,4.08385571310111,3.64484238889115,4.57574723567193,6.84788424833494e-130
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0673534072900158,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,2.48294496168989,1.81189251428704,3.40252836974,1.53730022067295e-08
primary,Circulatory system disorders,I15 (secondary hypertension),0.057471264367816,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,2.84553161504281,2.02975782904265,3.98917055835531,1.30329234126014e-09
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01787733883608,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.21964466540441,1.1196578265354,1.32856045355604,5.3709084111097e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34004016144104,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.36067267688286,1.26245501527194,1.46653156842722,7.82742694545757e-16
primary,Circulatory system disorders,I46 (cardiac arrest),0.78114157695434,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.31766678025455,1.19579933708861,1.45195409458378,2.52863910931794e-08
primary,Circulatory system disorders,I50 (heart failure),4.41388133695826,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.25195268677522,1.20069229073706,1.30540151045821,5.98176224532006e-26
primary,Circulatory system disorders,I70 (atherosclerosis),0.797682355742519,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.33139324252541,1.20884741801381,1.46636204026047,6.25224928369437e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12778782399035,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.25722994101545,1.18396481299061,1.33502880089244,7.87553349944901e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700994896439422,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.26864444750328,1.14409185203005,1.406756574068,6.38937607927084e-06
primary,Circulatory system disorders,I95 (hypotension),4.82705060039428,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.22017912784496,1.17246656962275,1.26983330919834,1.39818644416923e-22
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516916380030704,KLK4;Kallikrein-4,1.35083785891015,1.19995048465492,1.52069851581394,6.48290747309464e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13059890259563,KLK4;Kallikrein-4,1.26632355378679,1.19417457811039,1.3428315861594,3.04913242025593e-15
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,KLK4;Kallikrein-4,2.27448291402093,2.03745478893884,2.53908580168669,1.67883283110924e-48
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0660399347370056,KLK4;Kallikrein-4,2.30613983265008,1.69071480994985,3.14558132243076,1.32262029544744e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544069640914037,KLK4;Kallikrein-4,2.63856920454533,1.88196346339466,3.69935313973467,1.82909863150441e-08
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97515713858126,KLK4;Kallikrein-4,1.25277514589106,1.19118619752531,1.31754848186025,1.92036495029757e-18
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.101114200711688,KLK4;Kallikrein-4,1.79355939868518,1.38876859676935,2.31633644661553,7.58835964128944e-06
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02719738531574,KLK4;Kallikrein-4,1.29265259344372,1.1885511158831,1.40587199406669,2.06985196757606e-09
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72309957443375,KLK4;Kallikrein-4,1.21364387184229,1.17799756909255,1.25036883462755,4.01978858422187e-37
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,KLK4;Kallikrein-4,1.52402392843815,1.41743586306528,1.63862718234688,4.68172267338795e-30
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60931213624467,KLK4;Kallikrein-4,1.22769212440718,1.14694098472714,1.31412860156008,3.43437133897576e-09
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70988496782998,KLK4;Kallikrein-4,1.24861730654536,1.1694727696264,1.33311798162061,3.01821056835354e-11
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.84672529100941,KLK4;Kallikrein-4,1.25441051474001,1.19241695366217,1.31962711085044,1.86245697642101e-18
primary,Circulatory system disorders,I45 (other conduction disorders),1.75073028237585,KLK4;Kallikrein-4,1.33703935196983,1.25404593644237,1.42552531511516,6.47125965176252e-19
primary,Circulatory system disorders,I46 (cardiac arrest),0.777574744372302,KLK4;Kallikrein-4,1.4207865721918,1.29170418879659,1.56276839637811,4.93729369297495e-13
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37326630020149,KLK4;Kallikrein-4,1.22591639855335,1.13906626811033,1.31938857142632,5.53858448358353e-08
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.39571544860722,KLK4;Kallikrein-4,1.21203255206306,1.17379735950005,1.25151321509719,6.42358070558436e-32
primary,Circulatory system disorders,I50 (heart failure),4.43006958737626,KLK4;Kallikrein-4,1.4155476261649,1.35915693610367,1.47427793561896,5.21084497366208e-63
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22702211331343,KLK4;Kallikrein-4,1.28521755519467,1.2324001169229,1.34029861040974,1.01046595102422e-31
primary,Circulatory system disorders,I63 (cerebral infarction),2.07622575299736,KLK4;Kallikrein-4,1.22855278199647,1.15750431289268,1.30396225857623,1.26712789420381e-11
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620429438307141,KLK4;Kallikrein-4,1.34816033696705,1.21070507410395,1.50122134039646,5.18682154886758e-08
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77792255780937,KLK4;Kallikrein-4,1.37299316860389,1.24727950081281,1.51137755395202,9.80596746207424e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,KLK4;Kallikrein-4,1.4808134104354,1.34827050785776,1.62638605809855,2.28721902744188e-16
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08369975485427,KLK4;Kallikrein-4,1.34466129415916,1.24017770077052,1.45794751420414,7.19142534079098e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15331271301641,KLK4;Kallikrein-4,1.43875166088596,1.35716032132197,1.52524820331159,2.66250812586093e-34
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,KLK4;Kallikrein-4,1.71601507923841,1.50812743902961,1.95255896548661,2.48659704050906e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697054070367413,KLK4;Kallikrein-4,1.53757254765755,1.39066303077695,1.70000157262346,4.61009226385342e-17
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0446792804693267,KLK4;Kallikrein-4,3.71704829764964,2.58772093008056,5.33923418342872,1.1983548000703e-12
primary,Circulatory system disorders,I95 (hypotension),4.82261749028642,KLK4;Kallikrein-4,1.29794451309163,1.24808242344776,1.34979864103117,6.55333406190456e-39
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54156995774564,ACAN;Aggrecan core protein,1.4979861059174,1.32893317579449,1.68854417542855,3.72604517577532e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.794421221546446,ACAN;Aggrecan core protein,0.792774426497159,0.716801026785853,0.876800210688961,6.24533677344066e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,NPTXR;Neuronal pentraxin receptor,1.67662553618134,1.49835845886855,1.87610192470103,2.05470381116073e-19
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,CCN5;CCN family member 5,2.59984813622928,2.31841401337027,2.91544577132235,4.71371458206735e-60
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066585719321609,CCN5;CCN family member 5,2.40346090919858,1.72658715261592,3.34568940426414,2.0340121222827e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.0548557098916599,CCN5;CCN family member 5,2.50116220733153,1.73597256746461,3.60363550935607,8.64421672658851e-07
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01214177830956,CCN5;CCN family member 5,1.23057920340331,1.12408764309365,1.34715934754081,7.02738719096967e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,CCN5;CCN family member 5,1.20757221136072,1.117012196688,1.30547423741152,2.11451712130322e-06
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,CCN5;CCN family member 5,1.29849145224008,1.17138856706528,1.43938578448376,6.7044707905797e-07
primary,Circulatory system disorders,I50 (heart failure),4.43289393071009,CCN5;CCN family member 5,1.21616888488424,1.16440496047464,1.27023398797414,1.15735058483474e-18
primary,Circulatory system disorders,I63 (cerebral infarction),2.08153156694708,CCN5;CCN family member 5,1.22145116374614,1.14686338956931,1.30088985225788,4.89414601211471e-10
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.7818561623396,CCN5;CCN family member 5,1.28524171398097,1.1592571057412,1.42491795407248,1.86562132950993e-06
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772533871884865,CCN5;CCN family member 5,1.29573177289358,1.16903361211484,1.43616129586617,8.02451297167243e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702842783100361,CCN5;CCN family member 5,1.29668358438,1.16405867267675,1.44441887463817,2.364528070258e-06
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0470072077718583,CCN5;CCN family member 5,2.73416154119251,1.85427263837161,4.03157506541282,3.84391200041138e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.252238331136663,SRPX;Sushi repeat-containing protein SRPX,1.95252405055074,1.62657073906207,2.34379610823283,6.96074455295837e-13
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519993641999137,SRPX;Sushi repeat-containing protein SRPX,1.60641208031102,1.41155168683243,1.82817235517605,6.75464241977791e-13
primary,Circulatory system disorders,I08 (multiple valve diseases),2.04378566394616,SRPX;Sushi repeat-containing protein SRPX,1.2817278652045,1.19972018676514,1.36934123353489,1.8743531516324e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.393423236986332,SRPX;Sushi repeat-containing protein SRPX,1.88983910669157,1.63462714471976,2.18489694161607,8.04910616818126e-18
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36945723009615,SRPX;Sushi repeat-containing protein SRPX,1.60862323406842,1.48454044731406,1.74307726937756,3.80173529858572e-31
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59527124175548,SRPX;Sushi repeat-containing protein SRPX,1.20608782960801,1.11849402673436,1.30054145838905,1.11076191205432e-06
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.6805957233621,SRPX;Sushi repeat-containing protein SRPX,1.27969412583964,1.1899707274002,1.3761826387833,2.94077082316217e-11
primary,Circulatory system disorders,I42 (cardiomyopathy),0.687535571997723,SRPX;Sushi repeat-containing protein SRPX,1.30384825785906,1.16376590294638,1.46079230815927,4.75650617342312e-06
primary,Circulatory system disorders,I46 (cardiac arrest),0.76098314479124,SRPX;Sushi repeat-containing protein SRPX,1.33297976137301,1.19742114369674,1.48388480826763,1.49945126073072e-07
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.33485714285714,SRPX;Sushi repeat-containing protein SRPX,1.21599147210071,1.12011329036667,1.32007652523935,3.05816118573884e-06
primary,Circulatory system disorders,I50 (heart failure),4.32233089767963,SRPX;Sushi repeat-containing protein SRPX,1.27240950023607,1.21508387979868,1.33243964734291,1.27656212531446e-24
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.07117634840407,SRPX;Sushi repeat-containing protein SRPX,1.22875335343962,1.17185722157266,1.28841191212943,1.6494779379254e-17
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.745403722473467,SRPX;Sushi repeat-containing protein SRPX,1.3450856198451,1.20637330574134,1.49974747957662,9.36762858652073e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.768391379467127,SRPX;Sushi repeat-containing protein SRPX,1.32681186766854,1.19198510148201,1.4768890399698,2.31477169377487e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.20891048639811,SRPX;Sushi repeat-containing protein SRPX,2.82829906419878,2.34976200488712,3.40429183036857,4.1177970926029e-28
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.263918276340636,SRPX;Sushi repeat-containing protein SRPX,1.87973411326584,1.57726678725925,2.24020461542536,1.77728508864144e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102149683335981,SRPX;Sushi repeat-containing protein SRPX,3.19182296709116,2.468664213353,4.12682040681968,8.44568677277883e-19
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246966397013067,ANGPT2;Angiopoietin-2,2.60040058599752,2.1922868503003,3.08448833086325,5.23537879679451e-28
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516916380030704,ANGPT2;Angiopoietin-2,2.02554042918258,1.79858839721879,2.28113004431555,2.5343174955904e-31
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13059890259563,ANGPT2;Angiopoietin-2,1.57512503221536,1.48468782084509,1.6710710711557,2.98319979980729e-51
primary,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0310860695550806,ANGPT2;Angiopoietin-2,4.40011379414069,2.74053586985596,7.06467724591567,8.61132815907462e-10
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.207900207900207,ANGPT2;Angiopoietin-2,2.18758744906374,1.81781194571821,2.63258191177219,1.17254078946033e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,ANGPT2;Angiopoietin-2,2.30552516639084,2.05522155493461,2.58631303282075,4.77349872109852e-46
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0660399347370056,ANGPT2;Angiopoietin-2,3.13004552469445,2.260765537,4.33356968085265,6.24302013310848e-12
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.101114200711688,ANGPT2;Angiopoietin-2,2.23374825839617,1.71569361958654,2.90822978236076,2.37692990847509e-09
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02719738531574,ANGPT2;Angiopoietin-2,1.28706071720945,1.18207384181101,1.40137208961988,6.14219362402453e-09
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72309957443375,ANGPT2;Angiopoietin-2,1.26476011854388,1.22715950489091,1.30351282867776,1.55592344700288e-52
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,ANGPT2;Angiopoietin-2,2.32012054141485,2.15446086915332,2.49851803008638,7.64032633176874e-110
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.751206601276662,ANGPT2;Angiopoietin-2,1.35811964518951,1.22936542135667,1.50035859038088,1.70807449209781e-09
primary,Circulatory system disorders,I33 (acute and subacute endocarditis),0.126311698406529,ANGPT2;Angiopoietin-2,1.83118281298414,1.44198565562508,2.32542569441507,6.96528524137285e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60931213624467,ANGPT2;Angiopoietin-2,1.54744367748083,1.44513137605584,1.65699947745296,6.59024742094233e-36
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70988496782998,ANGPT2;Angiopoietin-2,1.38631382060529,1.2976792780603,1.48100231058165,3.32880692296351e-22
primary,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.186505546597245,ANGPT2;Angiopoietin-2,1.91102136105115,1.56873352863407,2.32799425506871,1.26491068627235e-10
primary,Circulatory system disorders,I37 (pulmonary valve disorders),0.215642848816878,ANGPT2;Angiopoietin-2,1.57898099660155,1.31313422720986,1.89864900020643,1.1976229641909e-06
primary,Circulatory system disorders,"I38 (endocarditis, valve unspecified)",0.250709371477436,ANGPT2;Angiopoietin-2,1.78635906391136,1.50597467309523,2.11894579784643,2.73741345932948e-11
primary,Circulatory system disorders,I42 (cardiomyopathy),0.678005727979426,ANGPT2;Angiopoietin-2,1.52394784002504,1.37246360676639,1.69215198688492,3.09607512439035e-15
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.84672529100941,ANGPT2;Angiopoietin-2,1.33540984316989,1.26862165359115,1.40571418136124,2.21535742435428e-28
primary,Circulatory system disorders,I45 (other conduction disorders),1.75073028237585,ANGPT2;Angiopoietin-2,1.37709967784317,1.29021829650305,1.4698315221972,6.36044079331791e-22
primary,Circulatory system disorders,I46 (cardiac arrest),0.777574744372302,ANGPT2;Angiopoietin-2,1.74033314555142,1.57976209792901,1.91722504386922,3.31082689012176e-29
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37326630020149,ANGPT2;Angiopoietin-2,1.40982996395808,1.30936292762705,1.51800580674466,8.55279341919662e-20
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.39571544860722,ANGPT2;Angiopoietin-2,1.36649105918147,1.32219422938763,1.41227194410592,5.48168527607067e-77
primary,Circulatory system disorders,I49 (other cardiac arrhythmias),1.98099659669899,ANGPT2;Angiopoietin-2,1.22067411988745,1.14717653058334,1.29888057089636,3.10392377154366e-10
primary,Circulatory system disorders,I50 (heart failure),4.43006958737626,ANGPT2;Angiopoietin-2,1.66355620554738,1.5954738362397,1.73454379893662,5.97408377011604e-126
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22702211331343,ANGPT2;Angiopoietin-2,1.52507046756391,1.4611779803725,1.59175676219995,3.13562687135255e-83
primary,Circulatory system disorders,I63 (cerebral infarction),2.07622575299736,ANGPT2;Angiopoietin-2,1.27527393395181,1.20094053282031,1.35420827440777,2.09294977886613e-15
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.775499733606961,ANGPT2;Angiopoietin-2,1.33610505043891,1.21038255798861,1.47488634401252,9.09208147308303e-09
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620429438307141,ANGPT2;Angiopoietin-2,1.40822037103422,1.26265181909675,1.57057122430977,7.7907466081779e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73646870797357,ANGPT2;Angiopoietin-2,1.29101782896415,1.22521994073252,1.3603492559114,1.06443363397379e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77792255780937,ANGPT2;Angiopoietin-2,1.50777067673366,1.36800840423147,1.66181173053175,1.29976741841638e-16
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,ANGPT2;Angiopoietin-2,1.85676224649592,1.68848091356392,2.04181522711779,2.51846390010133e-37
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08369975485427,ANGPT2;Angiopoietin-2,1.26563462548695,1.1651949765218,1.37473215857236,2.35023653852598e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15331271301641,ANGPT2;Angiopoietin-2,1.58974280043507,1.49851255493264,1.68652719205863,2.45042648192086e-53
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,ANGPT2;Angiopoietin-2,1.72874437020786,1.51285359607477,1.97544369480263,8.7893010927664e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697054070367413,ANGPT2;Angiopoietin-2,1.58041106320064,1.42613034702904,1.7513820766035,2.48216718200825e-18
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.08700882117081,ANGPT2;Angiopoietin-2,1.22064142193463,1.14835423277257,1.29747898202566,1.54179872061237e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.211835584491303,ANGPT2;Angiopoietin-2,1.93011952175336,1.6050370937678,2.32104378317398,2.7878189648614e-12
primary,Circulatory system disorders,I87 (other disorders of veins),0.460892225117653,ANGPT2;Angiopoietin-2,1.5331896320462,1.35084848319028,1.74014367789229,3.71211911117034e-11
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.533156911581569,ANGPT2;Angiopoietin-2,1.52162898879286,1.35208645433587,1.71243101512475,3.29127479217453e-12
primary,Circulatory system disorders,I95 (hypotension),4.82261749028642,ANGPT2;Angiopoietin-2,1.35361463911699,1.30111401149712,1.40823369438894,7.14992866677769e-51
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10490936996095,ANGPT2;Angiopoietin-2,2.80545203393532,2.16622845555628,3.63330150821544,5.32191548900291e-15
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54903967254408,SOST;Sclerostin,1.50058890498148,1.33059085016973,1.6923061371317,3.69160179772228e-11
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.247975512418148,GDF15;Growth/differentiation factor 15,1.7674339530203,1.52633400583726,2.04661808381542,2.71598249961563e-14
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.507260406582768,GDF15;Growth/differentiation factor 15,1.50649560216922,1.34912116983339,1.68222769763184,3.3508777504968e-13
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13615569512289,GDF15;Growth/differentiation factor 15,1.40096896553271,1.32561072792175,1.48061116362786,6.34716495709797e-33
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.209059233449477,GDF15;Growth/differentiation factor 15,1.78741777001353,1.52055541310157,2.10111532735487,1.92666131165954e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,GDF15;Growth/differentiation factor 15,2.74392195581237,2.54326890154762,2.96040567908788,1.26528635534835e-149
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0657932929543123,GDF15;Growth/differentiation factor 15,2.35334910198991,1.83112164801806,3.02451341877321,2.30446984164854e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0561395357841144,GDF15;Growth/differentiation factor 15,2.3342738934182,1.77316577896334,3.07294144413241,1.5115563368348e-09
primary,Circulatory system disorders,I20 (angina pectoris),4.00803229143425,GDF15;Growth/differentiation factor 15,1.29663825787074,1.2428662032005,1.35273673662107,2.75411081490973e-33
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97029702970297,GDF15;Growth/differentiation factor 15,1.42858031833507,1.36225542855946,1.49813440500835,5.95959214072024e-49
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.102671393425156,GDF15;Growth/differentiation factor 15,2.00020035608496,1.59943556930378,2.50138332625922,1.22644532775601e-09
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0136641147398,GDF15;Growth/differentiation factor 15,1.46704211566781,1.3554964917919,1.58776697850244,2.12742779037801e-21
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69827360974335,GDF15;Growth/differentiation factor 15,1.38731796751606,1.34869570235567,1.42704624892868,2.51256549012374e-114
primary,Circulatory system disorders,I26 (pulmonary embolism),1.98999139885839,GDF15;Growth/differentiation factor 15,1.3056424202299,1.23126274452234,1.38451531737455,5.02727661921469e-19
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35161378024624,GDF15;Growth/differentiation factor 15,1.91427406297701,1.80076409027243,2.03493906169136,2.84455392404647e-96
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.752317058983208,GDF15;Growth/differentiation factor 15,1.41547851531898,1.29010609710666,1.55303461616303,2.08675867762342e-13
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60521451503064,GDF15;Growth/differentiation factor 15,1.39651241325833,1.30997003075958,1.48877216622564,1.4241630119997e-24
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72480770724885,GDF15;Growth/differentiation factor 15,1.36771176248042,1.285576356654,1.45509479506612,3.76907933735056e-23
primary,Circulatory system disorders,"I38 (endocarditis, valve unspecified)",0.247836273162042,GDF15;Growth/differentiation factor 15,1.45853311838185,1.24294811282987,1.71151058958795,3.74538767897679e-06
primary,Circulatory system disorders,I42 (cardiomyopathy),0.671609922745448,GDF15;Growth/differentiation factor 15,1.45939383190559,1.32394564704761,1.60869924030009,2.8165056855404e-14
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.855644268314,GDF15;Growth/differentiation factor 15,1.32935165113546,1.26626036738026,1.39558645117562,1.74862873618841e-30
primary,Circulatory system disorders,I45 (other conduction disorders),1.75584959838578,GDF15;Growth/differentiation factor 15,1.36527089269087,1.28385698446651,1.45184754453275,3.23510575399269e-23
primary,Circulatory system disorders,I46 (cardiac arrest),0.782415028565895,GDF15;Growth/differentiation factor 15,1.78858147831264,1.64502093895597,1.94467050771603,3.05256487045974e-42
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3583567196757,GDF15;Growth/differentiation factor 15,1.32909058152033,1.23857761852129,1.42621806455297,2.66415076140076e-15
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.41172979922856,GDF15;Growth/differentiation factor 15,1.26030176633658,1.22189234692533,1.29991856175213,1.33680364720574e-48
primary,Circulatory system disorders,I50 (heart failure),4.42925495557074,GDF15;Growth/differentiation factor 15,1.64996921497356,1.59041438918111,1.71175413708512,4.99286040842332e-157
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21309603496476,GDF15;Growth/differentiation factor 15,1.47755846818423,1.42076818887779,1.53661874188451,7.06779381313061e-85
primary,Circulatory system disorders,I63 (cerebral infarction),2.0683226194869,GDF15;Growth/differentiation factor 15,1.40448043813334,1.32772606559926,1.48567189588833,2.2597477546901e-32
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.774553746952897,GDF15;Growth/differentiation factor 15,1.46078850545117,1.3332085686475,1.60057706486468,4.37242033325262e-16
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.621996589676019,GDF15;Growth/differentiation factor 15,1.5262217846749,1.38163509908124,1.68593931752689,8.36437652848466e-17
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73036217108457,GDF15;Growth/differentiation factor 15,1.3721892290869,1.30628791211978,1.44141522167699,2.11110888495283e-36
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771153436282963,GDF15;Growth/differentiation factor 15,1.75871332654708,1.6163378516547,1.91362997643582,2.96732058491748e-39
primary,Circulatory system disorders,I70 (atherosclerosis),0.804481836157096,GDF15;Growth/differentiation factor 15,1.90287829540464,1.75667387267122,2.06125101730809,4.77495287687586e-56
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07968753028746,GDF15;Growth/differentiation factor 15,1.37264216331481,1.2693883742073,1.4842947570606,2.04952586041266e-15
primary,Circulatory system disorders,I72 (other aneurysm),0.335128433613575,GDF15;Growth/differentiation factor 15,1.38533677640931,1.20444697781127,1.59339349878202,4.97969748862129e-06
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16089968793546,GDF15;Growth/differentiation factor 15,1.6363259357222,1.55252039435064,1.72465532669351,2.80780951959064e-75
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406976744186046,GDF15;Growth/differentiation factor 15,1.91002278582965,1.70651450719104,2.13780019274108,2.12110212867491e-29
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704198029021494,GDF15;Growth/differentiation factor 15,1.76974337015318,1.62027804478792,1.93299638063732,7.66328811206732e-37
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0483830388419035,GDF15;Growth/differentiation factor 15,2.83507867603211,2.1760858614676,3.69363692932188,1.15794185827783e-14
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.67421353670162,GDF15;Growth/differentiation factor 15,1.24012976126616,1.1617173827662,1.3238347360492,1.06085051552383e-10
primary,Circulatory system disorders,I81 (portal vein thrombosis),0.0735393725930369,GDF15;Growth/differentiation factor 15,1.90732035672523,1.46051120685624,2.49082028682889,2.12218571935295e-06
primary,Circulatory system disorders,I82 (other venous embolism and thrombosis),0.220840355669204,GDF15;Growth/differentiation factor 15,1.47284445907031,1.24420485686512,1.74349970476709,6.84395687319594e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.218776015953224,GDF15;Growth/differentiation factor 15,2.60937740502908,2.3001861564418,2.96013017155492,3.06468874973643e-50
primary,Circulatory system disorders,I87 (other disorders of veins),0.457240283643972,GDF15;Growth/differentiation factor 15,1.46021021157856,1.29828509261627,1.64233100582056,2.73705974469659e-10
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.538916351652612,GDF15;Growth/differentiation factor 15,1.42715507527592,1.28000704395266,1.59121906282349,1.49014288391284e-10
primary,Circulatory system disorders,I95 (hypotension),4.80432583832568,GDF15;Growth/differentiation factor 15,1.50311342480173,1.44957860708551,1.55862535275805,1.64959894446046e-107
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104513431911434,GDF15;Growth/differentiation factor 15,3.24928829506719,2.76408682010328,3.81966092659354,2.85216097497356e-46
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0948895214856987,GDF15;Growth/differentiation factor 15,1.99513434128988,1.58911533399165,2.50489121503571,2.68555926700613e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.768391379467127,PTPRB;Receptor-type tyrosine-protein phosphatase beta,1.37581013201291,1.23501570602142,1.53265542302063,6.95016309546927e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.682454104961441,PTPRB;Receptor-type tyrosine-protein phosphatase beta,1.32374071356131,1.18033101802941,1.48457462353678,1.63612210006385e-06
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102149683335981,PTPRB;Receptor-type tyrosine-protein phosphatase beta,2.03369911742573,1.51440721394131,2.73105678719943,2.37088261954343e-06
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513153922957252,COL5A1;Collagen alpha-1(V) chain,1.38752008185953,1.21553822418213,1.58383499528273,1.22908430402764e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.399990697890746,COL5A1;Collagen alpha-1(V) chain,1.59759149865257,1.37718202183159,1.85327615094229,6.20329992883917e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.38176903718892,COL5A1;Collagen alpha-1(V) chain,1.51286962247466,1.39550492683372,1.64010491872619,9.3214769750833e-24
primary,Circulatory system disorders,I50 (heart failure),4.33509766265398,COL5A1;Collagen alpha-1(V) chain,1.24259937927509,1.18678072730787,1.30104338724595,1.99688808742597e-20
primary,Circulatory system disorders,I70 (atherosclerosis),0.762471523548282,COL5A1;Collagen alpha-1(V) chain,1.34230177560799,1.20466413944542,1.49566505534881,9.64327072109897e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.211303580550782,COL5A1;Collagen alpha-1(V) chain,3.28600699702564,2.68897994124653,4.01559038015581,2.94006354461053e-31
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.265208793765266,COL5A1;Collagen alpha-1(V) chain,1.94834384625396,1.62804960195066,2.33165116019032,3.36722072667098e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109096817622617,COL5A1;Collagen alpha-1(V) chain,5.55775552339651,4.21563286202301,7.32716711080515,4.907717197822e-34
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.398733167764132,VGF;Neurosecretory protein VGF,3.18686381755349,2.75367984113681,3.68819237440428,1.62033293926526e-54
primary,Circulatory system disorders,I15 (secondary hypertension),0.0432122631854261,VGF;Neurosecretory protein VGF,2.74239923326304,1.77831537844083,4.22914497944435,5.00204839870314e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.801823755994025,DPP10;Inactive dipeptidyl peptidase 10,1.2587448238619,1.14329268920628,1.38585556136032,2.75617932890642e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.217869199968595,DPP10;Inactive dipeptidyl peptidase 10,3.34435393575498,2.81893702384943,3.96770241866788,1.37350006899733e-43
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103994976846401,DPP10;Inactive dipeptidyl peptidase 10,4.93226499758529,3.86264846093552,6.29807197119694,1.74572546963233e-37
primary,Circulatory system disorders,I85 (oesophageal varices),0.222469410456062,NELL2;Protein kinase C-binding protein NELL2,2.57117747542647,2.14612663298683,3.08041170941518,1.27109826953481e-24
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105347353635459,NELL2;Protein kinase C-binding protein NELL2,3.83758859844186,2.97029740274376,4.95811841510789,7.90296191784624e-25
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.390095772015884,PRRT3;Proline-rich transmembrane protein 3,3.79496450681799,3.28140793279249,4.38889522515182,2.9303550584856e-72
primary,Circulatory system disorders,I15 (secondary hypertension),0.0443004033668306,PRRT3;Proline-rich transmembrane protein 3,2.83892746820332,1.86819015317889,4.31407325212872,1.02281557612542e-06
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.253458900127892,C7;Complement component C7,1.70164538472726,1.41201311031458,2.05068706105604,2.34687265521276e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.520494469746259,C7;Complement component C7,1.62691044259457,1.42922334882843,1.85194118917309,1.79902408089131e-13
primary,Circulatory system disorders,I08 (multiple valve diseases),2.05192629815745,C7;Complement component C7,1.23513394652153,1.15630247168964,1.31933979490734,3.47763339732958e-10
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.195149149707276,C7;Complement component C7,1.6375984460043,1.33018277992759,2.0160602819574,3.32613429180875e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.388625151261286,C7;Complement component C7,2.02587555221383,1.75067351189905,2.3443387502937,2.60274131790735e-21
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.38033948890132,C7;Complement component C7,1.75555461290069,1.62108326530048,1.90118056539533,1.43041154904218e-43
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.6020551144325,C7;Complement component C7,1.35580626395356,1.25816247731396,1.46102801388584,1.43993804755116e-15
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70573705550636,C7;Complement component C7,1.24369236236533,1.15710051528017,1.33676432754103,3.16363439389753e-09
primary,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.183507549361207,C7;Complement component C7,1.66399107114517,1.33863696762516,2.06842209786198,4.48961472264284e-06
primary,Circulatory system disorders,I42 (cardiomyopathy),0.696547546941247,C7;Complement component C7,1.34373951128586,1.20078610712712,1.50371149655515,2.62817269602258e-07
primary,Circulatory system disorders,I45 (other conduction disorders),1.72068548011548,C7;Complement component C7,1.23670723387643,1.15122543283957,1.32853630461396,6.11562763255624e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.764742800027893,C7;Complement component C7,1.57387697060159,1.41590228797445,1.74947716352212,4.31770065399543e-17
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.34705332086061,C7;Complement component C7,1.22504773411908,1.1291282885697,1.32911553635003,1.06431551862651e-06
primary,Circulatory system disorders,I50 (heart failure),4.33335676955166,C7;Complement component C7,1.39411926284425,1.33185659798742,1.45929263103125,4.26938856939888e-46
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.10201912858661,C7;Complement component C7,1.29426381106978,1.23478857433554,1.35660375181742,6.13099399532705e-27
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.609217318513695,C7;Complement component C7,1.32125885183837,1.17174049375087,1.48985629742383,5.45327059828003e-06
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.755761225960979,C7;Complement component C7,1.34731066592442,1.20950120465145,1.50082201119991,6.13076313442176e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.77467082305867,C7;Complement component C7,1.47099489359143,1.32306129889421,1.63546917953125,9.55832495416297e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08716136631331,C7;Complement component C7,1.2776176553447,1.19614605581188,1.36463842798911,3.15939693835872e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686685288640595,C7;Complement component C7,1.32692891810127,1.1846220696058,1.48633087198799,1.02330770660051e-06
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0371609067261241,C7;Complement component C7,3.1892479541665,2.05809622077855,4.94209279938697,2.10558140620883e-07
primary,Circulatory system disorders,I81 (portal vein thrombosis),0.0743235396585762,C7;Complement component C7,2.28760546106745,1.65510999239309,3.16180723308854,5.40346174624185e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.216098150385723,C7;Complement component C7,4.52776851671962,3.7361741459738,5.48708035011949,1.5568068027777e-53
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.272390752683165,C7;Complement component C7,1.78321124133783,1.49771657782959,2.12312688415433,8.15773354289001e-11
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.509551176155797,C7;Complement component C7,1.43695545275065,1.25828764253912,1.64099280910299,8.72476632310789e-08
primary,Circulatory system disorders,I95 (hypotension),4.57028149946314,C7;Complement component C7,1.22481035108763,1.17159929351345,1.28043811944667,3.60773734290911e-19
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109172841513553,C7;Complement component C7,7.9874632793987,6.0843404498103,10.4858645182703,1.25991617757211e-50
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.549050477221293,CLC;Galectin-10,1.80744597865469,1.60845352397196,2.0310571098677,2.6220372509827e-23
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3605040362276,CLC;Galectin-10,1.23579534528099,1.14694212202159,1.33153199808056,2.67880485529649e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539501304612245,KLK6;Kallikrein-6,3.29769975035378,2.91877811749471,3.72581375004196,7.9788045333038e-82
primary,Circulatory system disorders,I15 (secondary hypertension),0.0567459152724782,KLK6;Kallikrein-6,2.80955896648075,1.94728463352149,4.05365576775361,3.33201486720534e-08
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248279637159837,PLA2G15;Phospholipase A2 group XV,1.58373795962717,1.33106452984554,1.88437590253802,2.16222722515859e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,PLA2G15;Phospholipase A2 group XV,1.31093076319372,1.1659514738592,1.47393738454607,5.96545534458702e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34833222278838,PLA2G15;Phospholipase A2 group XV,1.42457081788862,1.3222962970648,1.53475587860652,1.28290610583041e-20
primary,Circulatory system disorders,I33 (acute and subacute endocarditis),0.123078125305253,PLA2G15;Phospholipase A2 group XV,1.73460827733873,1.36138909862195,2.21014394698601,8.36154175527624e-06
primary,Circulatory system disorders,I46 (cardiac arrest),0.773890951729529,PLA2G15;Phospholipase A2 group XV,1.29755278665585,1.17703442922772,1.43041120323306,1.63039657956844e-07
primary,Circulatory system disorders,I50 (heart failure),4.4257901789233,PLA2G15;Phospholipase A2 group XV,1.2575036888532,1.20674149931316,1.31040121548769,1.16762799132778e-27
primary,Circulatory system disorders,I63 (cerebral infarction),2.06569457510191,PLA2G15;Phospholipase A2 group XV,1.2398184113269,1.16761381633128,1.31648809868916,2.19124094031579e-12
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.773640673662494,PLA2G15;Phospholipase A2 group XV,1.2622723914841,1.14360031234669,1.39325914229025,3.77056329500263e-06
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.621798130694927,PLA2G15;Phospholipase A2 group XV,1.28292681954074,1.1504059775485,1.43071337981424,7.50843416992722e-06
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72775371832807,PLA2G15;Phospholipase A2 group XV,1.23538519848507,1.17232736147567,1.30183482770114,2.62040253753065e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78013491054844,PLA2G15;Phospholipase A2 group XV,1.46843503687959,1.33218584141127,1.61861910741466,1.05016108847336e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.798106453316641,PLA2G15;Phospholipase A2 group XV,1.47799980839922,1.34273796482458,1.62688736809011,1.48497480753493e-15
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08755183475471,PLA2G15;Phospholipase A2 group XV,1.21150531802905,1.11639187598993,1.314722157317,4.2393198767611e-06
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15488215488215,PLA2G15;Phospholipase A2 group XV,1.30865867131627,1.23330974019304,1.38861103759968,6.06738746474861e-19
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404810794954532,PLA2G15;Phospholipase A2 group XV,1.43644477482808,1.25565226464822,1.64326832294525,1.31307521354534e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704721634954193,PLA2G15;Phospholipase A2 group XV,1.29539308389658,1.16900468959215,1.43544611646728,7.7660629024904e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.21492350677009,PLA2G15;Phospholipase A2 group XV,3.43708593825452,2.87352696622651,4.11117065745183,1.32479575513956e-41
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.268159486386501,PLA2G15;Phospholipase A2 group XV,1.54061208762394,1.30690309809459,1.8161144525508,2.62338315510018e-07
primary,Circulatory system disorders,I95 (hypotension),4.84405974602053,PLA2G15;Phospholipase A2 group XV,1.24240293517292,1.19433003428181,1.29241081528565,4.2729856723876e-27
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101564483681321,PLA2G15;Phospholipase A2 group XV,5.51790502311269,4.26695928833451,7.13559089427744,9.31464055845176e-39
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544146395533968,GFAP;Glial fibrillary acidic protein,1.43568899808207,1.27248288197217,1.61982760508283,4.26109761156583e-09
primary,Circulatory system disorders,I81 (portal vein thrombosis),0.0747898994272668,CDHR2;Cadherin-related family member 2,2.43499603116494,1.79763045843993,3.29834513203268,9.051337397216e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.212665406427221,CDHR2;Cadherin-related family member 2,3.27680924303937,2.80738124109479,3.82473126844752,3.7254527041506e-51
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.270254275738267,CDHR2;Cadherin-related family member 2,1.75814589909822,1.47133794669573,2.10086133471762,5.29757752473804e-10
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102358174875004,CDHR2;Cadherin-related family member 2,4.63013473340562,3.82914535417055,5.5986769021812,2.48435446315106e-56
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13757353369444,SPP1;Osteopontin,1.20102193519742,1.13145724452799,1.27486362900712,1.77691465251398e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.552121000038881,SPP1;Osteopontin,3.09408895739398,2.7629827469885,3.46487378059159,3.44230746144821e-85
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0658965811303201,SPP1;Osteopontin,2.72282468417432,1.97505114101159,3.75371255295787,9.68215468569874e-10
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01331676825717,SPP1;Osteopontin,1.22454807429288,1.12274036981577,1.33558748448713,4.78155556078818e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35374321669616,SPP1;Osteopontin,1.41183868333023,1.31030387053207,1.52124137963374,1.33772002934236e-19
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72558021905336,SPP1;Osteopontin,1.20487609414373,1.12731675031559,1.287771517484,4.01715106566345e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.781704620398029,SPP1;Osteopontin,1.27022586650592,1.15079908982686,1.40204642687323,2.05394566898959e-06
primary,Circulatory system disorders,I50 (heart failure),4.42844847820984,SPP1;Osteopontin,1.23790917419499,1.18703800898839,1.29096045109969,2.09462582297732e-23
primary,Circulatory system disorders,I70 (atherosclerosis),0.805747014852926,SPP1;Osteopontin,1.29955157492441,1.17922317794979,1.4321583288625,1.25422829636223e-07
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08138541585773,SPP1;Osteopontin,1.35551898408829,1.24628136910385,1.47433136832092,1.28604803742644e-12
primary,Circulatory system disorders,I72 (other aneurysm),0.335655109524456,SPP1;Osteopontin,1.44988268859329,1.24841282027834,1.68386592682845,1.13525663947168e-06
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705306312782948,SPP1;Osteopontin,1.36236973360979,1.22838279855669,1.5109714115476,4.79239339585935e-09
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0465206435355689,SPP1;Osteopontin,2.44974941862152,1.67015684077511,3.59323871119274,4.55508580981149e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.219119643203412,SPP1;Osteopontin,1.68696938798282,1.40417875613396,2.02671184388696,2.32315212609258e-08
primary,Circulatory system disorders,I95 (hypotension),4.80606261323566,SPP1;Osteopontin,1.22729560456345,1.17924503345263,1.27730408715032,9.08677501743571e-24
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104677535037897,SPP1;Osteopontin,2.09970032821099,1.61805995612102,2.72470834693815,2.40899671589055e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,PODXL2;Podocalyxin-like protein 2,2.35994640437027,2.09999796418344,2.65207258601592,3.84907071751412e-47
primary,Circulatory system disorders,I15 (secondary hypertension),0.0566516897831607,PODXL2;Podocalyxin-like protein 2,2.3366693376532,1.64063274273351,3.32799867472565,2.55362856204594e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,SEZ6L;Seizure 6-like protein,2.74939776980395,2.44508985982657,3.09157884984198,4.56342926747267e-64
primary,Circulatory system disorders,I85 (oesophageal varices),0.21492350677009,SEZ6L;Seizure 6-like protein,1.59305070106349,1.31926032588993,1.92366168098548,1.30069834842876e-06
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101564483681321,SEZ6L;Seizure 6-like protein,2.0306829053086,1.55587138601419,2.65039456280287,1.85914944193743e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246966397013067,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.69407066127103,1.44231495395448,1.98977026308348,1.34706685726853e-10
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516916380030704,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.45735353887999,1.29886420683932,1.63518197368323,1.44116600481893e-10
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13059890259563,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.40458840376839,1.32650751112961,1.48726529435224,2.50730770117078e-31
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.207900207900207,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.59381505081836,1.33739581638298,1.89939760921735,1.90398704608634e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,EDA2R;Tumor necrosis factor receptor superfamily member 27,3.63198788006717,3.32919784732771,3.96231661976571,2.03943303890787e-185
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0660399347370056,EDA2R;Tumor necrosis factor receptor superfamily member 27,2.63495862781803,2.02544255131987,3.42789627174974,5.2699855799848e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544069640914037,EDA2R;Tumor necrosis factor receptor superfamily member 27,2.60543311053701,1.9443948767251,3.49120529720585,1.42341383415977e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97515713858126,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.36323687470628,1.29768604681722,1.43209891261218,6.72524459060851e-35
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02719738531574,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.37692445374564,1.26882808677185,1.49422996786455,1.75135937185954e-14
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72309957443375,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.27508186112388,1.23797497828041,1.31330098030371,1.64280277106622e-58
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00521906331547,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.30066203133771,1.22487728073571,1.38113568303546,9.29478620636203e-18
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.90114399381911,1.77771986652713,2.03313725254997,1.63140415886219e-78
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.751206601276662,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.26549735160949,1.14791269048312,1.39512661564584,2.21882452858316e-06
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60931213624467,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.42047781356444,1.32966860034491,1.51748880759117,2.15803481183521e-25
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70988496782998,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.31676098446707,1.2349665725432,1.40397281089489,4.10497770872683e-17
primary,Circulatory system disorders,I42 (cardiomyopathy),0.678005727979426,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.44303850609676,1.30540410654613,1.59518429552632,7.43990080956704e-13
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.84672529100941,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.27524876997319,1.21307466227989,1.34060950730081,1.51065165606696e-21
primary,Circulatory system disorders,I45 (other conduction disorders),1.75073028237585,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.33284883683631,1.2514076245161,1.41959021749037,4.19878116819191e-19
primary,Circulatory system disorders,I46 (cardiac arrest),0.777574744372302,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.61088418897539,1.47106397491806,1.76399389457923,7.66366913706916e-25
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37326630020149,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.27255761260286,1.18373149397001,1.36804916118462,6.62791410645263e-11
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.39571544860722,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.26031259196247,1.22094167324064,1.30095307930905,2.60733064580154e-46
primary,Circulatory system disorders,I49 (other cardiac arrhythmias),1.98099659669899,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.21976167771346,1.14801151405782,1.29599619184952,1.34070141891875e-10
primary,Circulatory system disorders,I50 (heart failure),4.43006958737626,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.54995839761286,1.48973241026138,1.61261916420892,3.73781905943151e-104
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22702211331343,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.45388208442345,1.3957054744975,1.51448364574805,3.91348544938727e-72
primary,Circulatory system disorders,I63 (cerebral infarction),2.07622575299736,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.31029394407281,1.23590092988265,1.38916492282023,1.28129098049597e-19
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.775499733606961,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.3671084167486,1.24218446646706,1.50459571311538,1.59815160313235e-10
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620429438307141,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.48898672373248,1.34219878953921,1.65182794138321,5.56810227563198e-14
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73646870797357,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.3410324946707,1.27440565513684,1.41114263304929,1.53954755586978e-29
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77792255780937,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.59013198690277,1.45118342704106,1.74238465562342,2.73536152462304e-23
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.74270368994423,1.59555314631628,1.90342525283906,5.48707986674917e-35
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08369975485427,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.30775361347354,1.20772029977545,1.4160725077413,3.88252183504086e-11
primary,Circulatory system disorders,I72 (other aneurysm),0.332497229189756,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.45572038623536,1.26263706369564,1.67833014239161,2.31595931814746e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15331271301641,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.52858597953499,1.44417328937041,1.61793263594397,1.5380878884057e-48
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.70468787610513,1.50705504769538,1.928237962763,2.1800416936303e-17
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697054070367413,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.70727454724545,1.55219794838828,1.87784449960054,3.44416946906775e-28
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0446792804693267,EDA2R;Tumor necrosis factor receptor superfamily member 27,3.58660357882762,2.68922031995857,4.78344044040886,3.52024393413085e-18
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.6683941955031,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.21520634533601,1.13639051778317,1.29948854609033,1.21920701816307e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.211835584491303,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.89120267610479,1.60216019180175,2.23239073121878,5.07691034535691e-14
primary,Circulatory system disorders,I87 (other disorders of veins),0.460892225117653,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.46153041259758,1.29396761310094,1.65079181682813,1.0089642958456e-09
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.533156911581569,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.36606285524216,1.21708340631945,1.53327842182621,1.19385765989816e-07
primary,Circulatory system disorders,I95 (hypotension),4.82261749028642,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.42487308133091,1.37108732035633,1.48076877946315,1.02195154999547e-72
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10490936996095,EDA2R;Tumor necrosis factor receptor superfamily member 27,2.42666987497603,1.95581428037209,3.01088234256877,7.9549269429362e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.541915289054093,CRLF1;Cytokine receptor-like factor 1,1.51268732092772,1.34244941932461,1.70451333060035,1.08708090846981e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35066358689269,CRLF1;Cytokine receptor-like factor 1,1.23584465431629,1.14593317907686,1.33281070614651,3.91745614615584e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.776903706884772,CRLF1;Cytokine receptor-like factor 1,1.28092872752009,1.1589518498771,1.41574337636221,1.23947445846041e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.808909730363423,CRLF1;Cytokine receptor-like factor 1,1.38102848057117,1.25225479167772,1.52304441302513,1.01845500604987e-10
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15034619188921,CRLF1;Cytokine receptor-like factor 1,1.23993473200018,1.16735301322009,1.31702931521924,2.79107313722307e-12
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40436005625879,CRLF1;Cytokine receptor-like factor 1,1.40143961876079,1.21985558511498,1.61005370553537,1.87102656906797e-06
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699984357891443,CRLF1;Cytokine receptor-like factor 1,1.31823855809323,1.18681027322353,1.46422131258078,2.52139579966118e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.222469410456062,CRLF1;Cytokine receptor-like factor 1,1.63420435627083,1.35670109275575,1.96846887815942,2.30676423426578e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105347353635459,CRLF1;Cytokine receptor-like factor 1,2.02188753685965,1.54350503083774,2.6485363701663,3.20265077260696e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.398733167764132,VWC2L;von Willebrand factor C domain-containing protein 2-like,2.0713815292871,1.81067307766588,2.36962789848444,2.66690623924034e-26
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,ITGA11;Integrin alpha-11,0.691404339480737,0.613792118364944,0.778830399331659,1.24343251672695e-09
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01780170550556,ITGA11;Integrin alpha-11,0.761595656982787,0.698332281556174,0.830590193313848,7.50259888389943e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35063298615896,ITGA11;Integrin alpha-11,0.748402619698768,0.694200610565526,0.806836629999058,4.17167339265168e-14
primary,Circulatory system disorders,I50 (heart failure),4.40480668342802,ITGA11;Integrin alpha-11,0.769274254301691,0.737671507027772,0.80223090182219,1.56581739115181e-34
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.765336628532706,ITGA11;Integrin alpha-11,0.773265797867773,0.699153514476264,0.855234196455409,5.67202056164758e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71488758514785,ITGA11;Integrin alpha-11,0.793755837888683,0.752712080089704,0.837037622814929,1.50527854886351e-17
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781802467195725,ITGA11;Integrin alpha-11,0.655514806236057,0.593925637156295,0.723490676799354,4.88410611640065e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.801823755994025,ITGA11;Integrin alpha-11,0.756062981510632,0.685665800641396,0.833687827912696,2.05020647567129e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15077296512206,ITGA11;Integrin alpha-11,0.785680273842859,0.739955543367057,0.834230513223656,3.15774388633265e-15
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.390978034500373,ITGA11;Integrin alpha-11,0.694558612962882,0.603855170825025,0.798886372342926,3.31289856719946e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686372844022262,ITGA11;Integrin alpha-11,0.767656461608136,0.690754171077582,0.853120354133246,9.13030198218039e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.401231049811923,PTPRR;Receptor-type tyrosine-protein phosphatase R,2.93637536104674,2.55575274629457,3.37368326160005,3.15992805418408e-52
primary,Circulatory system disorders,I08 (multiple valve diseases),2.15062392167877,CHI3L1;Chitinase-3-like protein 1,1.244936547148,1.17286686635774,1.32143472620877,5.99416194830489e-13
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.212352505158563,CHI3L1;Chitinase-3-like protein 1,1.56453176152332,1.29790482495173,1.88593153038499,2.66175084408346e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.554461810438346,CHI3L1;Chitinase-3-like protein 1,2.1091028023484,1.88127964452646,2.36451536793913,1.73951861473575e-37
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0660898822398461,CHI3L1;Chitinase-3-like protein 1,2.12765896946746,1.53161404578768,2.95566151459993,6.73090152713677e-06
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.98722406237784,CHI3L1;Chitinase-3-like protein 1,1.22846302368945,1.16719096394113,1.29295157964258,3.21361435187238e-15
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00696046376346,CHI3L1;Chitinase-3-like protein 1,1.26206736237398,1.15721456863078,1.3764206486393,1.44449711068599e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35452882895556,CHI3L1;Chitinase-3-like protein 1,1.46840350657877,1.36258499147481,1.58243990035368,7.68994837531009e-24
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.6069271043093,CHI3L1;Chitinase-3-like protein 1,1.20821037273777,1.12726241105865,1.29497115354022,9.0115262655695e-08
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.73287230620778,CHI3L1;Chitinase-3-like protein 1,1.27011982027801,1.18866417199696,1.35715738378222,1.54228269384806e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.681051108968177,CHI3L1;Chitinase-3-like protein 1,1.28705453927387,1.15796109881514,1.43053975540325,2.87481365155032e-06
primary,Circulatory system disorders,I46 (cardiac arrest),0.773686636868373,CHI3L1;Chitinase-3-like protein 1,1.43601475331181,1.30140068786177,1.58455300582123,5.77715881192567e-13
primary,Circulatory system disorders,I50 (heart failure),4.42279315154332,CHI3L1;Chitinase-3-like protein 1,1.37434807149803,1.31832666302074,1.43275007220319,1.05997517150442e-50
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21743205248359,CHI3L1;Chitinase-3-like protein 1,1.26178863918216,1.20894851067017,1.31693827811293,1.67853197144183e-26
primary,Circulatory system disorders,I63 (cerebral infarction),2.05619874577906,CHI3L1;Chitinase-3-like protein 1,1.25949258398978,1.18497772005344,1.33869316045344,1.21960187697408e-13
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.617680089844376,CHI3L1;Chitinase-3-like protein 1,1.33261831684127,1.19285050012207,1.48876290716995,3.78656991663239e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71910609136035,CHI3L1;Chitinase-3-like protein 1,1.25034624457061,1.18562519823449,1.31860029091809,1.73901971206813e-16
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.768027592845111,CHI3L1;Chitinase-3-like protein 1,1.45093091564939,1.31412168462535,1.60198294162338,1.75773977374195e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.794399085237417,CHI3L1;Chitinase-3-like protein 1,1.73186790986843,1.57270506511418,1.90713854985537,6.00063636691495e-29
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13660458598208,CHI3L1;Chitinase-3-like protein 1,1.39586628940197,1.31439192027118,1.48239095800803,1.61835282134665e-27
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.411167716314332,CHI3L1;Chitinase-3-like protein 1,1.53629184447136,1.34285742323929,1.75758989044115,4.01207135875775e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698682942499196,CHI3L1;Chitinase-3-like protein 1,1.58672547701775,1.43053342093859,1.75997128243624,2.50049291699163e-18
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0480711452950366,CHI3L1;Chitinase-3-like protein 1,2.48831291324953,1.69947600830391,3.64330012544498,2.78555207105473e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.222418146114695,CHI3L1;Chitinase-3-like protein 1,2.50771259862009,2.0981398601852,2.99723702724128,5.24595488125602e-24
primary,Circulatory system disorders,I95 (hypotension),4.81549332635435,CHI3L1;Chitinase-3-like protein 1,1.27665631959555,1.22652071958447,1.32884127625291,6.57452248937785e-33
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106163491777337,CHI3L1;Chitinase-3-like protein 1,3.91444905988475,3.0410110023974,5.03875567380477,3.19180238961751e-26
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,FLT3LG;Fms-related tyrosine kinase 3 ligand,1.2724721482468,1.18126048494966,1.37072676915357,2.15952643075468e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,FLT3LG;Fms-related tyrosine kinase 3 ligand,1.28404746673263,1.16681079560408,1.41306362868273,3.08584470432786e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.21132221791392,FLT3LG;Fms-related tyrosine kinase 3 ligand,1.79160675812268,1.49081298302879,2.15309016777518,5.02377515858961e-10
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104659275912861,FLT3LG;Fms-related tyrosine kinase 3 ligand,2.12061726101324,1.63700416686083,2.7471020897466,1.25544518730096e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,COL9A1;Collagen alpha-1(IX) chain,1.49732692959653,1.32826245470932,1.68791034192533,4.00724524293339e-11
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250960708964002,TIMP4;Metalloproteinase inhibitor 4,1.56742858176733,1.31394336308253,1.86981602706025,5.92812578052922e-07
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.205700852189244,TIMP4;Metalloproteinase inhibitor 4,1.60240345543687,1.32350277913711,1.94007664696413,1.34659578947749e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,TIMP4;Metalloproteinase inhibitor 4,2.32650283852179,2.07039384992162,2.614292666033,1.05850587160982e-45
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,TIMP4;Metalloproteinase inhibitor 4,1.42603094501007,1.32145659546613,1.53888085549188,6.65588942023639e-20
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,TIMP4;Metalloproteinase inhibitor 4,1.32994570112003,1.20390946386493,1.46917656270381,1.98757538925076e-08
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.4119295436349,TIMP4;Metalloproteinase inhibitor 4,1.20997330380627,1.17064273964259,1.25062527306227,1.24462258057079e-29
primary,Circulatory system disorders,I50 (heart failure),4.43289393071009,TIMP4;Metalloproteinase inhibitor 4,1.30687493567667,1.25258631160258,1.3635164951745,4.11794799272703e-35
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22577303155881,TIMP4;Metalloproteinase inhibitor 4,1.23418085660422,1.18159220103714,1.2891100546122,2.78402517247225e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772533871884865,TIMP4;Metalloproteinase inhibitor 4,1.31320815920147,1.18750815231437,1.45221375199182,1.11029449211639e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,TIMP4;Metalloproteinase inhibitor 4,1.2617525933102,1.14316785838476,1.39263853077052,3.89248874463839e-06
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13543632426848,TIMP4;Metalloproteinase inhibitor 4,1.23772092930441,1.16398638260386,1.31612630674525,1.00656051124216e-11
primary,Circulatory system disorders,I87 (other disorders of veins),0.466666666666666,TIMP4;Metalloproteinase inhibitor 4,1.37163967054811,1.20476112416195,1.56163354551307,1.80241141318559e-06
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.541473750294279,TIMP4;Metalloproteinase inhibitor 4,1.34076776130765,1.18750453926153,1.51381163635791,2.19314807064725e-06
primary,Circulatory system disorders,I95 (hypotension),4.81299212598425,TIMP4;Metalloproteinase inhibitor 4,1.25445586042202,1.20437658342471,1.30661748775649,1.07347874519811e-27
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.390095772015884,FSHB;Follitropin subunit beta,1.71064019966184,1.38817254941603,2.10801596237449,4.71524636822611e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.253144684942797,ESM1;Endothelial cell-specific molecule 1,1.51139404837817,1.27421956797045,1.79271455790884,2.11152807060296e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35143110061965,ESM1;Endothelial cell-specific molecule 1,1.24336760725648,1.15404898726713,1.33959911912894,1.02253067335167e-08
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60823035534795,ESM1;Endothelial cell-specific molecule 1,1.22497968214885,1.14400223443697,1.31168906537672,6.04847234356641e-09
primary,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.188209461446468,ESM1;Endothelial cell-specific molecule 1,1.60169524209973,1.31569808132117,1.94986044669825,2.68057925634858e-06
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36805116866708,ESM1;Endothelial cell-specific molecule 1,1.20837417743648,1.12209585025606,1.30128647420101,5.5024437674184e-07
primary,Circulatory system disorders,I81 (portal vein thrombosis),0.0764511006998216,ESM1;Endothelial cell-specific molecule 1,2.06481372359355,1.52642152848371,2.79310507194918,2.55491839667912e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.22356886509384,ESM1;Endothelial cell-specific molecule 1,2.45165395786199,2.05548241986377,2.92418318493755,2.01714038789706e-23
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.271130496286691,ESM1;Endothelial cell-specific molecule 1,1.79040860392259,1.52222602960972,2.10583901907256,1.99271652469323e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105867822063638,ESM1;Endothelial cell-specific molecule 1,3.09018209574999,2.40797443580716,3.96566726078753,7.65917089294545e-19
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.399178832116788,GSN;Gelsolin,1.40449034659121,1.21025702060444,1.62989604694276,7.71766863948067e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.38053987337432,GSN;Gelsolin,0.758314891198373,0.700165745079277,0.821293355544108,1.07182107636494e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.761652832253945,GSN;Gelsolin,0.749619703598297,0.673401376986863,0.834464732663832,1.38043574655943e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54903967254408,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,2.31756990895893,2.06851494140735,2.59661178916,1.39345853586851e-47
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97117516629711,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.20583506855102,1.14603805698158,1.26875211838695,5.48352861949747e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02175151789047,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.22174957697614,1.12178128908299,1.33062660553161,4.2570018913179e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35848165065364,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.38495022980009,1.28562890781905,1.49194462520074,9.7123949126258e-18
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71517466818951,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.20722425987409,1.13004724319826,1.28967211096753,2.30893701183801e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.783382090196925,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.25886880946092,1.14213691565131,1.38753126504964,3.53995403651576e-06
primary,Circulatory system disorders,I50 (heart failure),4.43476539299148,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.28055424663712,1.22860849640137,1.33469627093045,1.21108509542903e-31
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773914751522294,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.33958390393366,1.21449708309734,1.47755401034118,5.05519405614055e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.801807998427827,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.46845511577122,1.33395756161925,1.61651351518044,4.53428413159066e-15
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15678471945881,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.29677138174097,1.2218448888084,1.37629254900136,1.14584951905545e-17
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.414554599394868,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.38629099764714,1.21306172325912,1.58425799224315,1.61890509158025e-06
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.711925739458779,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.44513228886328,1.30473047625141,1.60064271535635,1.65363104943021e-12
primary,Circulatory system disorders,I85 (oesophageal varices),0.221790417868849,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.71813440184084,1.43322076935196,2.05968674604383,4.8966704339266e-09
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105952988266687,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,2.16931674738139,1.67690592840326,2.80632030143178,3.73955747717804e-09
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250438266967192,OCLN;Occludin,1.52813976137964,1.27322009445094,1.83409855097869,5.26201484799635e-06
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.507325507325507,OCLN;Occludin,1.38171287918071,1.21370956225774,1.57297144214837,1.01823084993984e-06
primary,Circulatory system disorders,I08 (multiple valve diseases),2.02952029520295,OCLN;Occludin,1.30994984045097,1.22716165502177,1.39832317728919,5.25202919173834e-16
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.195619043286399,OCLN;Occludin,1.73116639858708,1.4080130596111,2.12848672044614,1.93070291386832e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.398733167764132,OCLN;Occludin,3.2525036693375,2.83121129120588,3.73648556429292,2.39646693824986e-62
primary,Circulatory system disorders,I15 (secondary hypertension),0.0432122631854261,OCLN;Occludin,2.73000316502587,1.79159719397069,4.15992908792933,2.96311101425046e-06
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.95936705020188,OCLN;Occludin,1.33882073645932,1.2670795959286,1.41462380905901,2.93052176816877e-25
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.974765418602532,OCLN;Occludin,1.2506021935151,1.13759991933755,1.37482942802556,3.69120288401325e-06
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.54926555537217,OCLN;Occludin,1.25584963279773,1.21536830236588,1.29767931015481,2.75240229895116e-42
primary,Circulatory system disorders,I26 (pulmonary embolism),1.95916304922023,OCLN;Occludin,1.21129152545017,1.13281406255596,1.29520563711656,2.03566216825147e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36745502693817,OCLN;Occludin,1.79718291498669,1.66234876057711,1.94295355253778,3.98696751397859e-49
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.754158122579175,OCLN;Occludin,1.38471196230007,1.24477510292736,1.54038043822348,2.12342894754027e-09
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59372570540083,OCLN;Occludin,1.32314170953024,1.22913455684104,1.42433875425163,9.57475835375966e-14
primary,Circulatory system disorders,I42 (cardiomyopathy),0.684259744999201,OCLN;Occludin,1.33459622746556,1.19255927488917,1.49355015542588,4.97564692053199e-07
primary,Circulatory system disorders,I45 (other conduction disorders),1.71659143755984,OCLN;Occludin,1.22695686169685,1.14215996231603,1.3180493014414,2.17192970668902e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.762403277196176,OCLN;Occludin,1.58633591200654,1.42752434021328,1.76281521430707,1.00362855812441e-17
primary,Circulatory system disorders,I50 (heart failure),4.30063109581181,OCLN;Occludin,1.43940523757822,1.37579152617414,1.50596031342715,3.44997659214633e-56
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.07648908620051,OCLN;Occludin,1.27520611373509,1.21692240596761,1.33628128180805,2.31356473903569e-24
primary,Circulatory system disorders,I63 (cerebral infarction),2.05390355781738,OCLN;Occludin,1.2814036943286,1.2007121851291,1.36751791826153,7.90139081409767e-14
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.734529831612501,OCLN;Occludin,1.29051191106526,1.15641095513708,1.44016362453424,5.21526371298935e-06
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.598747865680136,OCLN;Occludin,1.39717735369782,1.2395514680101,1.57484752191843,4.34711532838613e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.60113628585118,OCLN;Occludin,1.20656319659867,1.13852477800484,1.27866760171662,2.28637612078502e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.744535519125683,OCLN;Occludin,1.50690726923123,1.35428997527528,1.67672327161718,5.20946910090929e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.749345177086892,OCLN;Occludin,1.73479832357502,1.56127658295065,1.92760543285099,1.24217511948435e-24
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.06564656055741,OCLN;Occludin,1.28076260940593,1.16935050504919,1.40278971494804,9.85951868528454e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.07550215621612,OCLN;Occludin,1.43565457576111,1.345551697343,1.53179106010848,7.85072380310131e-28
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.396210948173786,OCLN;Occludin,1.82438541393174,1.57849350374423,2.10858146116652,3.9598241030523e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.681481481481481,OCLN;Occludin,1.78675893807252,1.60002518711934,1.99528577955061,6.64962224739988e-25
primary,Circulatory system disorders,I85 (oesophageal varices),0.204754862927994,OCLN;Occludin,2.58498308091213,2.1270740579899,3.14146914796028,1.3336754293832e-21
primary,Circulatory system disorders,I95 (hypotension),4.54555842493772,OCLN;Occludin,1.33586332565467,1.27870962973978,1.39557158507699,1.59136485196987e-38
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102342506254264,OCLN;Occludin,3.87484637391605,2.96904136474946,5.05699738633225,2.05433938439548e-23
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0773694390715667,OCLN;Occludin,2.16362412649445,1.56596370934099,2.98938559867325,2.88156169063616e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,OMG;Oligodendrocyte-myelin glycoprotein,0.736891923996358,0.654991552025465,0.829033147025907,3.79387245531516e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,OMG;Oligodendrocyte-myelin glycoprotein,0.776178889592427,0.719961539095393,0.83678590582199,3.97443711179326e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774430015567422,OMG;Oligodendrocyte-myelin glycoprotein,0.737385659117585,0.667910868626383,0.814087082293658,1.60056112763308e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,OMG;Oligodendrocyte-myelin glycoprotein,0.68827765412287,0.624318291470587,0.758789443841242,6.05110197734229e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15586074736505,OMG;Oligodendrocyte-myelin glycoprotein,0.769207974509664,0.724478307916516,0.816699273924211,9.13785801885424e-18
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,OMG;Oligodendrocyte-myelin glycoprotein,0.607219981035434,0.529729797204834,0.696045620454496,7.96344987825482e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,OMG;Oligodendrocyte-myelin glycoprotein,0.68416483930655,0.616494660424115,0.759262905896611,9.14498018464803e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.808909730363423,OMD;Osteomodulin,0.757739822968779,0.686581791458605,0.836272744858213,3.5153381824049e-08
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40436005625879,OMD;Osteomodulin,0.621625817836042,0.540782710921797,0.714554384961113,2.25989121222711e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.222469410456062,OMD;Osteomodulin,1.64048538965603,1.35731941032991,1.98272587365472,3.05304908983949e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,PAEP;Glycodelin,1.4901197993367,1.3108732674999,1.69387619034304,1.06326673486218e-09
primary,Circulatory system disorders,I45 (other conduction disorders),1.73598052217977,PAEP;Glycodelin,1.21826761924528,1.13674826136072,1.3056329554663,2.30823701244445e-08
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08381788695067,PAEP;Glycodelin,1.2267322869076,1.12222552390951,1.3409711966798,6.850982332068e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,SUSD2;Sushi domain-containing protein 2,1.28149176232108,1.19002173284094,1.3799925594437,5.22216172124965e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,SUSD2;Sushi domain-containing protein 2,1.31629948533741,1.19412219186886,1.45097741830578,3.21134874138349e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,SUSD2;Sushi domain-containing protein 2,1.3847431267598,1.25858949634314,1.52354165729167,2.40598272055283e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13543632426848,SUSD2;Sushi domain-containing protein 2,1.29848022202532,1.22393422322982,1.37756658404537,4.77585124894396e-18
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406001765225066,SUSD2;Sushi domain-containing protein 2,1.43316855369354,1.25302313086662,1.63921323772807,1.51230266574814e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702842783100361,SUSD2;Sushi domain-containing protein 2,1.27298153564214,1.148727934949,1.41067518320407,4.10608756773827e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,SUSD2;Sushi domain-containing protein 2,2.05500523082517,1.7216514571087,2.45290443735393,1.51067140250016e-15
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,SUSD2;Sushi domain-containing protein 2,3.16332066009572,2.46578868963762,4.05817320869415,1.29512095642752e-19
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.242211153432952,TFRC;Transferrin receptor protein 1,1.51588408655368,1.27106150813639,1.8078626007925,3.67830351186706e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551923904959486,TFRC;Transferrin receptor protein 1,1.55656783120261,1.38288118671206,1.75206911223913,2.30028072713334e-13
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34515977443609,TFRC;Transferrin receptor protein 1,1.33177841191595,1.23502428329733,1.43611244121454,9.67152732071666e-14
primary,Circulatory system disorders,I46 (cardiac arrest),0.781066937436538,TFRC;Transferrin receptor protein 1,1.26383228218194,1.14438402016814,1.39574828845524,3.79301121620021e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,MOG;Myelin-oligodendrocyte glycoprotein,3.34877799609593,2.99022499105992,3.75032450757534,3.73664165859156e-97
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544069640914037,MOG;Myelin-oligodendrocyte glycoprotein,3.22858023395728,2.30292332169057,4.52630368928116,1.05284130848165e-11
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248365252148941,IGFBP2;Insulin-like growth factor-binding protein 2,1.56534892425958,1.32756076552261,1.84572888738243,9.79607822122654e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.504169090556525,IGFBP2;Insulin-like growth factor-binding protein 2,1.35869932859906,1.20704038074671,1.52941351008779,3.85358107765277e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13757353369444,IGFBP2;Insulin-like growth factor-binding protein 2,1.32892273563885,1.2541615248003,1.40814050054602,6.21685489723024e-22
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.552121000038881,IGFBP2;Insulin-like growth factor-binding protein 2,2.91092917380629,2.62655121754605,3.22609686737167,3.01551328263585e-92
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0658965811303201,IGFBP2;Insulin-like growth factor-binding protein 2,2.85311157682853,2.17020748650472,3.75090663932021,5.87901914879761e-14
primary,Circulatory system disorders,I15 (secondary hypertension),0.0562277028075073,IGFBP2;Insulin-like growth factor-binding protein 2,3.10656124688823,2.32649769116754,4.14817638431636,1.5501409427311e-14
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35374321669616,IGFBP2;Insulin-like growth factor-binding protein 2,1.56120825308828,1.45354569098226,1.67684526508682,2.46637126532397e-34
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60381954594173,IGFBP2;Insulin-like growth factor-binding protein 2,1.36969107793597,1.28139374046855,1.46407274339534,2.18748838639344e-20
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72558021905336,IGFBP2;Insulin-like growth factor-binding protein 2,1.24820697642771,1.1695733577301,1.33212734858001,2.42005876544597e-11
primary,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.184162062615101,IGFBP2;Insulin-like growth factor-binding protein 2,1.54613155553058,1.27626496668267,1.87306151105986,8.48855023368675e-06
primary,Circulatory system disorders,I45 (other conduction disorders),1.75660183044128,IGFBP2;Insulin-like growth factor-binding protein 2,1.22883261097141,1.15171048632741,1.31111907351128,4.6309216877101e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.781704620398029,IGFBP2;Insulin-like growth factor-binding protein 2,1.45143384805693,1.3207296152856,1.595073049702,1.01230192769936e-14
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35852592129918,IGFBP2;Insulin-like growth factor-binding protein 2,1.2269658516897,1.13999011647864,1.3205774150594,4.96442589761671e-08
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.40975551769227,IGFBP2;Insulin-like growth factor-binding protein 2,1.27245768378305,1.23234848394998,1.31387231623701,3.32381518914516e-49
primary,Circulatory system disorders,I50 (heart failure),4.42844847820984,IGFBP2;Insulin-like growth factor-binding protein 2,1.41660344495551,1.36007705419848,1.47547913852752,4.58877516857947e-63
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21185471467444,IGFBP2;Insulin-like growth factor-binding protein 2,1.30551341909709,1.25181628031585,1.36151391721198,1.57161541832548e-35
primary,Circulatory system disorders,I63 (cerebral infarction),2.06959600085584,IGFBP2;Insulin-like growth factor-binding protein 2,1.22441693829267,1.15358516315642,1.29959788549631,2.75290352582043e-11
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72882872369393,IGFBP2;Insulin-like growth factor-binding protein 2,1.24219251571598,1.17950006770285,1.30821717467636,2.24799336477453e-16
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.7723656122647,IGFBP2;Insulin-like growth factor-binding protein 2,1.42241576955052,1.29311309284825,1.5646478507224,4.28171302086795e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.805747014852926,IGFBP2;Insulin-like growth factor-binding protein 2,1.34594368200653,1.22460144508419,1.47930937237195,7.13015776833026e-10
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08138541585773,IGFBP2;Insulin-like growth factor-binding protein 2,1.2848406885232,1.1835503103437,1.39479968063662,2.20139250172014e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16228966818682,IGFBP2;Insulin-like growth factor-binding protein 2,1.34487775431187,1.26894022895852,1.4253596290563,1.65269218964523e-23
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407616607465207,IGFBP2;Insulin-like growth factor-binding protein 2,1.47186307338332,1.29158493310368,1.67730425716841,6.70412745711114e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705306312782948,IGFBP2;Insulin-like growth factor-binding protein 2,1.41718731648135,1.2823492266614,1.56620353351367,8.18756665854685e-12
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0465206435355689,IGFBP2;Insulin-like growth factor-binding protein 2,3.12548325281384,2.28427091556008,4.27648292375365,1.05130897999706e-12
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.08850124029767,IGFBP2;Insulin-like growth factor-binding protein 2,1.2949880665472,1.22014482178485,1.37442216903934,1.73005129665922e-17
primary,Circulatory system disorders,I87 (other disorders of veins),0.457958977742417,IGFBP2;Insulin-like growth factor-binding protein 2,1.53232758233733,1.35617375222011,1.73136208818962,7.40063793838953e-12
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.539763901832867,IGFBP2;Insulin-like growth factor-binding protein 2,1.47175570920827,1.31435072937736,1.64801131020276,2.1376648464997e-11
primary,Circulatory system disorders,I95 (hypotension),4.80606261323566,IGFBP2;Insulin-like growth factor-binding protein 2,1.34454665438796,1.29323700463425,1.39789203320634,2.69393635872362e-50
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.247573004795508,C1QA;Complement C1q subcomponent subunit A,1.52484768962369,1.28196857039025,1.81374218546004,1.87875715209266e-06
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.514329131679947,C1QA;Complement C1q subcomponent subunit A,1.36619298663659,1.2108932678135,1.5414102351938,4.01848805994229e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12035501804349,C1QA;Complement C1q subcomponent subunit A,1.20903908534995,1.13886480339588,1.28353734837103,4.90116675526182e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544953805887063,C1QA;Complement C1q subcomponent subunit A,2.09038234807183,1.8603917326022,2.34880551474943,2.66106687144554e-35
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066205822217895,C1QA;Complement C1q subcomponent subunit A,2.43815353007955,1.75355074128097,3.39003172038058,1.15938605519911e-07
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02198037953698,C1QA;Complement C1q subcomponent subunit A,1.24362773079919,1.1408884421263,1.35561889813721,7.19457612311767e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34643945907918,C1QA;Complement C1q subcomponent subunit A,1.41506614479245,1.31290413071744,1.52517776986774,1.0796504038114e-19
primary,Circulatory system disorders,I46 (cardiac arrest),0.773698160274399,C1QA;Complement C1q subcomponent subunit A,1.33461088238882,1.20881142686951,1.47350212597134,1.10186961396443e-08
primary,Circulatory system disorders,I50 (heart failure),4.43505600314403,C1QA;Complement C1q subcomponent subunit A,1.26426329159694,1.21260393898186,1.31812343593536,3.19199412811517e-28
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774030025346071,C1QA;Complement C1q subcomponent subunit A,1.26304751883528,1.14406820398006,1.39440028949862,3.72376169967324e-06
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08447599914178,C1QA;Complement C1q subcomponent subunit A,1.23471783632913,1.13520194840097,1.34295764511038,8.75673161757583e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.212359725685785,C1QA;Complement C1q subcomponent subunit A,1.92455772781077,1.59642438646355,2.3201364744128,6.67215256625777e-12
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.269357640583217,C1QA;Complement C1q subcomponent subunit A,1.46918588304493,1.24229059802005,1.73752193116388,6.96251375958735e-06
primary,Circulatory system disorders,I87 (other disorders of veins),0.456175920149719,C1QA;Complement C1q subcomponent subunit A,1.42855847418032,1.25665196953205,1.62398131195571,4.97521593108822e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105172951075101,C1QA;Complement C1q subcomponent subunit A,1.91734834452815,1.47046440096315,2.50004330050895,1.52589307823758e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.533124107268593,RBKS;Ribokinase,0.747542330215589,0.660542183670489,0.846001283913336,4.04479427382183e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.214760251289565,RBKS;Ribokinase,2.0065323112235,1.66072468732884,2.42434639931784,5.35396062448241e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102329500993198,RBKS;Ribokinase,3.05975770822875,2.35130665279022,3.98166577802836,8.59991454453721e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,APLP1;Amyloid-like protein 1,0.739625677294441,0.670818694412552,0.815490306203106,1.41274076623377e-09
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.413944637357032,APLP1;Amyloid-like protein 1,0.673850461080378,0.588327307407058,0.771805826759065,1.19503465066606e-08
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,DPP6;Dipeptidyl aminopeptidase-like protein 6,0.726567318390807,0.632117284777156,0.835129936906745,6.93279341127055e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.212665406427221,DPP6;Dipeptidyl aminopeptidase-like protein 6,2.05782500998312,1.70941511220483,2.47724718324861,2.4421341977336e-14
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102358174875004,DPP6;Dipeptidyl aminopeptidase-like protein 6,3.22503255235989,2.50028663245625,4.15985704549533,1.94421977672569e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.762471523548282,CHAD;Chondroadherin,0.748906302333438,0.670671040116976,0.836267881161112,2.80301837774908e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.211303580550782,CHAD;Chondroadherin,0.571786889883323,0.464314380630086,0.704135519125592,1.42399368577096e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109096817622617,CHAD;Chondroadherin,0.444925476163027,0.333000166979692,0.594470210433764,4.30598878359394e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.552596804548912,DPP4;Dipeptidyl peptidase 4,0.715570019093653,0.634820950605869,0.806590349195317,4.29425586758225e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34396218478979,DPP4;Dipeptidyl peptidase 4,0.754986615193201,0.699491186601197,0.814884876377814,5.38518531970242e-13
primary,Circulatory system disorders,I50 (heart failure),4.41816423563542,DPP4;Dipeptidyl peptidase 4,0.78387323849673,0.751123930843687,0.818050429229665,4.9213053337692e-29
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08563088549893,DPP4;Dipeptidyl peptidase 4,0.744336861876045,0.682536390204721,0.811733076651487,2.44767533305855e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13364643008967,DPP4;Dipeptidyl peptidase 4,0.799822080997986,0.752389128760744,0.850245354163505,8.01208938361267e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.223660036744148,DPP4;Dipeptidyl peptidase 4,2.33699368416228,1.94339527599218,2.81030809701134,1.86254574216202e-19
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105803206036771,DPP4;Dipeptidyl peptidase 4,3.56825794707846,2.74766937446646,4.63391443497854,1.41830207473379e-21
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.541562456921168,MMP10;Stromelysin-2,2.16283554647427,1.91782642360932,2.43914545315785,2.86975508036497e-36
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34964731843795,MMP10;Stromelysin-2,1.32384472697091,1.22758351473949,1.42765428183564,3.25314380579621e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.782017526623963,MMP10;Stromelysin-2,1.41078371764995,1.27645095270322,1.55925356455821,1.57347248775617e-11
primary,Circulatory system disorders,I50 (heart failure),4.41424127751471,MMP10;Stromelysin-2,1.25645920785047,1.2045714808595,1.31058203359237,2.68302662922962e-26
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78238647532927,MMP10;Stromelysin-2,1.25783709241019,1.13884370149479,1.3892636443142,6.06607593457443e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.810321768546927,MMP10;Stromelysin-2,1.3290552763085,1.20489868473528,1.46600535784596,1.3078612394484e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15456301399868,MMP10;Stromelysin-2,1.27689955944996,1.20237587617274,1.35604224704959,1.62907236428972e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702645252716107,MMP10;Stromelysin-2,1.37938523540237,1.24182893831855,1.53217852228692,1.96363338072228e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.22197340247903,MMP10;Stromelysin-2,1.68278109654531,1.39479571660674,2.03022721189546,5.49436437650382e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106042456257486,MMP10;Stromelysin-2,2.06978002293389,1.57467359064415,2.72055705308665,1.83783274445765e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34671603975833,NCAN;Neurocan core protein,0.71908792378252,0.665032684538281,0.777536885256789,1.33082598698049e-16
primary,Circulatory system disorders,I42 (cardiomyopathy),0.664199454616283,NCAN;Neurocan core protein,0.761871702158432,0.681576906367185,0.851625818197958,1.69735870555776e-06
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771877977174187,NCAN;Neurocan core protein,0.766092918647676,0.690829173530649,0.849556420732248,4.41564863096612e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.795642447232759,NCAN;Neurocan core protein,0.698445718662268,0.630880614881708,0.77324680836662,4.71476953850363e-12
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07181761593526,NCAN;Neurocan core protein,0.799456596331782,0.732130269592776,0.87297421779036,6.1469039594388e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14304004412141,NCAN;Neurocan core protein,0.773339779335585,0.726541578800285,0.823152358727162,7.00144113562597e-16
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402598412945386,NCAN;Neurocan core protein,0.679111976111652,0.588613084036118,0.783525016018797,1.13797807707818e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702772153870113,NCAN;Neurocan core protein,0.76852502440998,0.689653595800041,0.856416491904448,1.88406426648472e-06
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250960708964002,OGN;Mimecan,1.64344085328498,1.37835283306204,1.95951121763648,3.1050325797553e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519251494072695,OGN;Mimecan,1.42549843959493,1.26113561724509,1.61128254051418,1.41282962861602e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14427245796794,OGN;Mimecan,1.27024728559739,1.19579176068736,1.34933875580482,8.36276858771547e-15
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.205700852189244,OGN;Mimecan,1.69299034231898,1.40214991646168,2.04415823553178,4.3839131376802e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,OGN;Mimecan,4.51565366087096,4.01834951143581,5.07450333200392,1.7488677698467e-141
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066585719321609,OGN;Mimecan,3.91928004801764,2.8847751669732,5.32476716752457,2.42298781487357e-18
primary,Circulatory system disorders,I15 (secondary hypertension),0.0548557098916599,OGN;Mimecan,3.05816118955047,2.16651607731368,4.31676919419355,2.07061904381845e-10
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01214177830956,OGN;Mimecan,1.33434660426032,1.22334615374765,1.45541869310386,7.55570906028479e-11
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00589503669561,OGN;Mimecan,1.21607290284538,1.14178649392638,1.29519250131378,1.18023786321705e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,OGN;Mimecan,1.52287535291883,1.41159065416334,1.64293333459495,1.71879347472252e-27
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.749578117028374,OGN;Mimecan,1.31291800782287,1.18593065862463,1.45350293689572,1.55780040747661e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60299330445057,OGN;Mimecan,1.26716316301189,1.18103751592736,1.35956941252073,4.30298264604395e-11
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72606994711699,OGN;Mimecan,1.24973127997844,1.16870904047915,1.33637048919913,7.09806017454835e-11
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.83692126216455,OGN;Mimecan,1.20307386838968,1.14171454461155,1.26773083485116,4.45311939137021e-12
primary,Circulatory system disorders,I45 (other conduction disorders),1.75541941564561,OGN;Mimecan,1.22831057401534,1.14960546844738,1.31240404438539,1.15482484906705e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,OGN;Mimecan,1.49315137346224,1.35377167721624,1.6468811259641,1.0740094672369e-15
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37675299315568,OGN;Mimecan,1.24462830570293,1.15408304887267,1.34227742177666,1.35767079679001e-08
primary,Circulatory system disorders,I50 (heart failure),4.43289393071009,OGN;Mimecan,1.40767995380195,1.3492086098023,1.46868530036006,3.24756657372309e-56
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22577303155881,OGN;Mimecan,1.31190566528796,1.25625635042821,1.37002011892556,1.22092847164865e-34
primary,Circulatory system disorders,I63 (cerebral infarction),2.08153156694708,OGN;Mimecan,1.28568633896865,1.20932914954521,1.3668647306089,8.6774366449722e-16
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.7818561623396,OGN;Mimecan,1.26460738799323,1.14321971746307,1.39888406518734,5.12485817456441e-06
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7258077195189,OGN;Mimecan,1.30319509968631,1.23504817402391,1.37510220537643,4.29445417922429e-22
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772533871884865,OGN;Mimecan,1.50042152988683,1.35866684411892,1.65696600096829,1.11755494793784e-15
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,OGN;Mimecan,1.44846656452791,1.31391816592263,1.59679304462774,9.43373028025603e-14
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08680725846002,OGN;Mimecan,1.2948996595585,1.1917699389658,1.40695370264145,1.04021643751361e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13543632426848,OGN;Mimecan,1.33800586458705,1.25861217983325,1.42240773000189,1.0618838034352e-20
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406001765225066,OGN;Mimecan,1.55145497290377,1.35500234084889,1.77638994441875,2.04464348410289e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702842783100361,OGN;Mimecan,1.495594152584,1.34750137658944,1.65996258564487,3.84510749838624e-14
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0470072077718583,OGN;Mimecan,2.99395983643356,2.06885377468027,4.33273516566563,6.05810731068146e-09
primary,Circulatory system disorders,I95 (hypotension),4.81299212598425,OGN;Mimecan,1.32695286297118,1.27395366581063,1.3821569400854,3.86152925825834e-42
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.543712950967691,SCG3;Secretogranin-3,2.25122141768115,1.99913404145466,2.53509657998651,6.70403757960157e-41
primary,Circulatory system disorders,I15 (secondary hypertension),0.0567725768876881,SCG3;Secretogranin-3,2.40933042739484,1.67883089386383,3.45768780500023,1.83407936736266e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.223205544895641,SCG3;Secretogranin-3,1.55250055627446,1.28923831470652,1.86952090217795,3.48951592058806e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34152382839591,BCAN;Brevican core protein,0.701763001813393,0.649983652469506,0.757667225695724,1.351467196208e-19
primary,Circulatory system disorders,I50 (heart failure),4.41132519077885,BCAN;Brevican core protein,0.761650713519582,0.73001440396278,0.794658031753667,2.76739517005338e-36
primary,Circulatory system disorders,I63 (cerebral infarction),2.07280581812417,BCAN;Brevican core protein,0.790300686649091,0.743131307408516,0.840464086348447,6.61864963817941e-14
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.782252888318356,BCAN;Brevican core protein,0.783662992268495,0.70850885845069,0.866789000767241,2.14532264717039e-06
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769002668775328,BCAN;Brevican core protein,0.70168800347783,0.634257245976705,0.776287629897707,6.31232723197323e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.79898742188118,BCAN;Brevican core protein,0.645628042736815,0.584732723233453,0.712865131376871,4.88270700968221e-18
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12868213949576,BCAN;Brevican core protein,0.747361063319984,0.702990577189425,0.794532070685598,1.10659682840651e-20
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401415831207609,BCAN;Brevican core protein,0.580444316590634,0.504818291204393,0.667399756570938,2.21659413199164e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700643245917862,BCAN;Brevican core protein,0.698522653442791,0.628350395574098,0.776531535286061,3.0896471766927e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.401231049811923,SYT1;Synaptotagmin-1,2.68074762740051,2.32635646065251,3.08912583405116,2.63501803988424e-42
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245001185489607,PTGDS;Prostaglandin-H2 D-isomerase,1.5946882309857,1.33179217701123,1.90948002093787,3.83024148724857e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.15100531820248,PTGDS;Prostaglandin-H2 D-isomerase,1.21916241938643,1.14572984154856,1.29730146753901,4.04967428049767e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.552343997465948,PTGDS;Prostaglandin-H2 D-isomerase,4.44593171214039,3.97486633158391,4.97282352162496,2.8274295252952e-150
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0651272942569567,PTGDS;Prostaglandin-H2 D-isomerase,3.39257861080896,2.4233485338572,4.74945698883802,1.10707814082325e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0572556762092793,PTGDS;Prostaglandin-H2 D-isomerase,4.12352340529331,2.89635771210825,5.87063027571443,3.83091816407846e-15
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97445255474452,PTGDS;Prostaglandin-H2 D-isomerase,1.27013271026692,1.20341732651639,1.34054667997837,3.75024342349432e-18
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01209773068711,PTGDS;Prostaglandin-H2 D-isomerase,1.34032429356643,1.22406844884977,1.46762153179625,2.49295353442529e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35068227279028,PTGDS;Prostaglandin-H2 D-isomerase,1.43812008601681,1.33004058531343,1.55498215967419,7.87024005871389e-20
primary,Circulatory system disorders,I46 (cardiac arrest),0.784135574473128,PTGDS;Prostaglandin-H2 D-isomerase,1.48764215655869,1.34189534841976,1.64921891157663,4.35027680379746e-14
primary,Circulatory system disorders,I50 (heart failure),4.42377405091025,PTGDS;Prostaglandin-H2 D-isomerase,1.29348815396282,1.23789565998589,1.35157724396676,1.63265792552768e-30
primary,Circulatory system disorders,I63 (cerebral infarction),2.07388333168267,PTGDS;Prostaglandin-H2 D-isomerase,1.24382465989066,1.16745108685995,1.32519452160801,1.49281892973558e-11
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73899352385479,PTGDS;Prostaglandin-H2 D-isomerase,1.23111492299064,1.16513458986658,1.30083165223325,1.38105627893331e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772620388483806,PTGDS;Prostaglandin-H2 D-isomerase,1.45444062441769,1.31164314073059,1.61278434984858,1.2025008782918e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.802625336074648,PTGDS;Prostaglandin-H2 D-isomerase,1.52592366782988,1.37803444943436,1.68968420274192,4.47218512959663e-16
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.0754601348279,PTGDS;Prostaglandin-H2 D-isomerase,1.23693113618034,1.13187815263715,1.35173440010982,2.65891773756242e-06
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1457595228087,PTGDS;Prostaglandin-H2 D-isomerase,1.30266163398672,1.22344948559978,1.38700236718727,1.44897118363805e-16
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.411099691675231,PTGDS;Prostaglandin-H2 D-isomerase,1.47868770619621,1.28229406134239,1.70516061672065,7.45538221598031e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70235834124723,PTGDS;Prostaglandin-H2 D-isomerase,1.52143115765855,1.36502237095713,1.69576178145064,3.40229301462319e-14
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0493447023527554,PTGDS;Prostaglandin-H2 D-isomerase,3.12801924398433,2.10678948298667,4.64427246753927,1.55639049939415e-08
primary,Circulatory system disorders,I95 (hypotension),4.81877517011526,PTGDS;Prostaglandin-H2 D-isomerase,1.26637851933649,1.21461958507445,1.32034307197393,1.37382027439868e-28
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.393423236986332,PTPRZ1;Receptor-type tyrosine-protein phosphatase zeta,1.45298315672163,1.24435712690963,1.69658694281748,2.30806651414826e-06
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102149683335981,PTPRZ1;Receptor-type tyrosine-protein phosphatase zeta,2.15897519464717,1.60535027579227,2.90352452133936,3.55969130607474e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35848165065364,SSC4D;Scavenger receptor cysteine-rich domain-containing group B protein,0.759347545339321,0.703494625314865,0.819634825717079,1.6354305098769e-12
primary,Circulatory system disorders,I85 (oesophageal varices),0.221790417868849,SSC4D;Scavenger receptor cysteine-rich domain-containing group B protein,0.557875516240601,0.465824431366921,0.668116720944528,2.24858112734812e-10
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.53061866205487,SSC4D;Scavenger receptor cysteine-rich domain-containing group B protein,0.727626708546605,0.644101897109968,0.821982716346471,3.20267771909297e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105952988266687,SSC4D;Scavenger receptor cysteine-rich domain-containing group B protein,0.477893702060909,0.370813444148532,0.615895658783075,1.16678666022861e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.529100529100529,STC2;Stanniocalcin-2,1.99579454589339,1.76875872188444,2.25197242570999,3.42672292775339e-29
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666771258236586,STC2;Stanniocalcin-2,2.20828658086575,1.57267806124789,3.10078060055236,4.77612717968762e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35206943378402,STC2;Stanniocalcin-2,1.31222144711387,1.21635265156021,1.41564629637376,2.21993717585992e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.781173330192938,STC2;Stanniocalcin-2,1.32831734627683,1.20112412476932,1.46897971328216,3.23208806119651e-08
primary,Circulatory system disorders,I50 (heart failure),4.43481358347185,STC2;Stanniocalcin-2,1.21256254259814,1.16204217511323,1.26527930844575,6.90187482497471e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.805453509616329,STC2;Stanniocalcin-2,1.4381521035665,1.30286625438333,1.58748564254717,5.64634497522652e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13434646828317,STC2;Stanniocalcin-2,1.27240671138094,1.19713094430987,1.35241582958213,9.72364359722536e-15
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406551967947207,STC2;Stanniocalcin-2,1.55156103299039,1.34998368274932,1.78323758268804,6.16056759794874e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701830263235496,STC2;Stanniocalcin-2,1.40914418421701,1.26821155589699,1.56573824191989,1.77728176229613e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36745502693817,LRTM2;Leucine-rich repeat and transmembrane domain-containing protein 2,0.782188205277097,0.720439408538074,0.849229485816326,4.76867599037553e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,RTBDN;Retbindin,2.97502926604495,2.65262444911055,3.33661975286087,1.86053970558732e-77
primary,Circulatory system disorders,I15 (secondary hypertension),0.0570944815230445,RTBDN;Retbindin,2.69254402115911,1.8994155694169,3.81685473290361,2.64465412766833e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,RTBDN;Retbindin,1.2516670101613,1.13485507459126,1.38050253235232,7.0970366805856e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.386548125241592,BGLAP;Osteocalcin,1.60073618121098,1.37494969405967,1.86360005235704,1.32333201685914e-09
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0499217136762803,BGLAP;Osteocalcin,2.81968533712563,1.87322501516611,4.24435149863521,6.76330063195196e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.393553223388305,SLITRK1;SLIT and NTRK-like protein 1,2.01114241784486,1.73121203374881,2.33633647756965,6.43342271965759e-20
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37774022438154,SLITRK1;SLIT and NTRK-like protein 1,0.777420836690301,0.715055666230483,0.845225324213343,3.60863276528845e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.754214729370008,DMP1;Dentin matrix acidic phosphoprotein 1,0.737511272764506,0.659334371304478,0.824957564973571,1.00514932794037e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250226583126453,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.68391814350075,1.37776490264185,2.05810171864141,3.57878512981322e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13307047806801,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.26437158829918,1.17713699284582,1.358070915292,1.26689005001653e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,4.20512932049268,3.74596806067336,4.7205721767122,6.25711136595332e-131
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0629760100761616,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,3.33521193747923,2.33426524348921,4.76537047318436,3.69045377668164e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0570944815230445,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,3.94745144772395,2.73305198495404,5.70145500997485,2.48167036799092e-13
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9594291374396,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.20044688990461,1.12824803067886,1.27726589924961,7.79731589327906e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.36232477987037,1.24569036648065,1.48987971312025,1.28060205674919e-11
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60473307214373,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.23656134022742,1.13858312220691,1.34297085414477,4.62102025988965e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.42099524019652,1.26265726015253,1.59918889819495,5.57168304483178e-09
primary,Circulatory system disorders,I50 (heart failure),4.39523336643495,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.21211282558993,1.15234380010456,1.27498191236529,8.91789616073977e-14
primary,Circulatory system disorders,I63 (cerebral infarction),2.07802469135802,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.21362678608647,1.12861655517226,1.30504020090487,1.7373861981039e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774430015567422,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.39102672894798,1.23623379324656,1.56520180180983,4.17637515655236e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.44705592831601,1.2787690344989,1.6374894943363,4.67915968562413e-09
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96667443486366,SERPIND1;Heparin cofactor 2,1.24723206242993,1.18059436162405,1.31763107475232,3.1211048097057e-15
primary,Circulatory system disorders,I70 (atherosclerosis),0.766483953874496,SERPIND1;Heparin cofactor 2,1.36444305048576,1.22640689085237,1.51801563731021,1.12749941889548e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08649993091059,SERPIND1;Heparin cofactor 2,1.22118485024028,1.14365010772697,1.3039761272968,2.36556043146248e-09
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.266320677410543,SERPIND1;Heparin cofactor 2,0.635935096667259,0.530296880651777,0.762617058346902,1.04042646440955e-06
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109009152226739,SERPIND1;Heparin cofactor 2,0.475916200162529,0.359208673050426,0.630542207273888,2.30642957699401e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13488023361351,LY6D;Lymphocyte antigen 6D,1.21223237200207,1.14185422581187,1.28694827282784,2.84521647773141e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545292897362442,LY6D;Lymphocyte antigen 6D,4.06750956939417,3.62873654820325,4.55933735539581,3.11309820325472e-128
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0649990151664368,LY6D;Lymphocyte antigen 6D,3.0505099324535,2.192831154187,4.2436513318544,3.547959749483e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0551724137931034,LY6D;Lymphocyte antigen 6D,3.12917418926924,2.18494669797251,4.48145079048148,4.81682247809765e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35602601356026,LY6D;Lymphocyte antigen 6D,1.37196782795852,1.27252889295138,1.47917719698104,1.75023976561564e-16
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60811185487384,LY6D;Lymphocyte antigen 6D,1.21050246700902,1.12972445265399,1.29705630359026,5.90802635394449e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.778647322044589,LY6D;Lymphocyte antigen 6D,1.39436505565026,1.26323470588613,1.53910741951529,4.18817144532583e-11
primary,Circulatory system disorders,I50 (heart failure),4.42059232756907,LY6D;Lymphocyte antigen 6D,1.24043221976528,1.18941339729366,1.29363944893579,8.75916064799528e-24
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2258600997856,LY6D;Lymphocyte antigen 6D,1.23184005726086,1.18005636714602,1.28589613930253,1.80450154244251e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77702835956297,LY6D;Lymphocyte antigen 6D,1.38825222604491,1.25751648614387,1.53257970321206,7.99801630327181e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14155862316958,LY6D;Lymphocyte antigen 6D,1.217771242544,1.14658176798023,1.29338076060591,1.44946313591295e-10
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406367743080898,LY6D;Lymphocyte antigen 6D,1.48219787938682,1.2928969504901,1.69921551197564,1.65459407182524e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697008589199328,LY6D;Lymphocyte antigen 6D,1.30744067073602,1.17752544309002,1.45168931807443,5.15802911411618e-07
primary,Circulatory system disorders,I95 (hypotension),4.84318073815935,LY6D;Lymphocyte antigen 6D,1.20007313580997,1.15306305721453,1.24899980298721,3.70619038985044e-19
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0985571237089016,LY6D;Lymphocyte antigen 6D,1.98596246068965,1.50787405511702,2.61563416512424,1.04587791058657e-06
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24261396986891,CST3;Cystatin-C,1.87193711401589,1.57999064764368,2.21782867136336,4.24585962848935e-13
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.510353727928667,CST3;Cystatin-C,1.42973178142433,1.26657179980772,1.61391005794152,7.36758596474035e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.1359071242585,CST3;Cystatin-C,1.30562827106538,1.22949777271885,1.38647276963793,3.31493671512531e-18
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550883177478484,CST3;Cystatin-C,4.26022598841361,3.85546456662549,4.70748081293875,4.30302255308876e-178
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0625390869293308,CST3;Cystatin-C,3.03049902877034,2.22557802811782,4.12653443166172,1.93392985478066e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0566982091186361,CST3;Cystatin-C,2.94643076620776,2.12034492832237,4.09435943373821,1.21731235730899e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96775229910445,CST3;Cystatin-C,1.31454953962849,1.24782370539165,1.38484345558663,7.81612119251603e-25
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00614649806209,CST3;Cystatin-C,1.42922696343835,1.31015931368195,1.55911551495109,8.48389126356117e-16
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.71232876712328,CST3;Cystatin-C,1.24231059371299,1.20463206155641,1.281167636579,2.29231080501348e-43
primary,Circulatory system disorders,I26 (pulmonary embolism),1.98606202988964,CST3;Cystatin-C,1.20136599155592,1.12834423703798,1.27911341086467,9.80332103281368e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34345336157527,CST3;Cystatin-C,1.59723358729691,1.48243268504454,1.72092477326394,8.53523161859638e-35
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61135019355852,CST3;Cystatin-C,1.33836221533713,1.24901919194012,1.43409599388124,1.36142525594331e-16
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.7145323289391,CST3;Cystatin-C,1.25459216549568,1.17293714092291,1.34193167460334,3.96448633031908e-11
primary,Circulatory system disorders,I42 (cardiomyopathy),0.68024543725863,CST3;Cystatin-C,1.39898303611534,1.25840624694008,1.55526368380439,5.16850636176547e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.784321395740019,CST3;Cystatin-C,1.6229103387425,1.4719942516737201,1.78929908496756,2.39076992037414e-22
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.34640368489429,CST3;Cystatin-C,1.22252995102087,1.13299294456603,1.31914279635304,2.2485169675688e-07
primary,Circulatory system disorders,I50 (heart failure),4.42029271371651,CST3;Cystatin-C,1.40313414277375,1.34508301829515,1.46369063904531,1.25998153308867e-55
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21305869254016,CST3;Cystatin-C,1.31378062912858,1.25797888056443,1.3720576459114,6.73066146263009e-35
primary,Circulatory system disorders,I63 (cerebral infarction),2.06939840332673,CST3;Cystatin-C,1.32352122087182,1.24510003004278,1.40688168005091,2.3779043491314e-19
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.776301943732999,CST3;Cystatin-C,1.3415772570953,1.21327781036709,1.4834438752414,1.00749524736947e-08
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.622309197651663,CST3;Cystatin-C,1.32545991782141,1.18606676926566,1.48123532272882,6.69919362291523e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72607817372374,CST3;Cystatin-C,1.24753436221863,1.18271812703578,1.31590270694242,4.48484935833594e-16
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.770976831559173,CST3;Cystatin-C,1.56355350595927,1.41711709026708,1.72512178618691,5.17431797810672e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.800704776820673,CST3;Cystatin-C,1.72490367457251,1.56690477331292,1.89883440093366,9.76342000415442e-29
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08848864526233,CST3;Cystatin-C,1.35962209344418,1.24935997009446,1.47961538806287,1.08507740204185e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15254102909696,CST3;Cystatin-C,1.43290478392271,1.34936843533425,1.52161267895673,8.23658924531437e-32
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405143561740355,CST3;Cystatin-C,1.83245890326874,1.60300693698958,2.09475427378684,7.09088560968219e-19
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703342345519376,CST3;Cystatin-C,1.5240559891309,1.37422823089154,1.69021899404503,1.45344466416462e-15
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0488643915405965,CST3;Cystatin-C,2.84274618352601,1.99113313719998,4.05859644087681,8.87564805281922e-09
primary,Circulatory system disorders,I95 (hypotension),4.80718228788087,CST3;Cystatin-C,1.33269524032403,1.2800808132635,1.3874722479859,2.22068470043267e-44
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0977899471934285,CST3;Cystatin-C,1.98370119007694,1.51691559745263,2.59412614526535,5.61465041001974e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.20891048639811,IGSF9;Protein turtle homolog A,2.43569260304506,2.01531451587354,2.94375811308882,3.27212036537149e-20
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102149683335981,IGSF9;Protein turtle homolog A,3.3538390013807,2.62263394627862,4.28890812732099,5.20173944992554e-22
primary,Circulatory system disorders,I85 (oesophageal varices),0.212736066791097,C19orf12;Protein C19orf12,2.6220395545269,2.1764435225593,3.1588650724183,3.54559635341184e-24
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102327447833065,C19orf12;Protein C19orf12,3.80622314813069,2.94452474889999,4.92009267668,1.865158063782e-24
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516371317920431,RNASE4;Ribonuclease 4,1.38276581651739,1.21338710680529,1.57578837998634,1.16751550432167e-06
primary,Circulatory system disorders,I08 (multiple valve diseases),2.03506133383465,RNASE4;Ribonuclease 4,1.20592937376623,1.1285293635828,1.28863785156221,3.15567530897983e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.394913142615359,RNASE4;Ribonuclease 4,3.25232428994482,2.85389301484911,3.706380453622,5.22323399464997e-70
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0516129032258064,RNASE4;Ribonuclease 4,2.58247156823366,1.77325029499459,3.76098028550198,7.56025133485709e-07
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.93735253045697,RNASE4;Ribonuclease 4,1.21463213705764,1.14852692312977,1.28454213711673,9.75632310176514e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3683466792275,RNASE4;Ribonuclease 4,1.48813640018023,1.37336311787026,1.61250139655387,2.80459890011878e-22
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.58056145317291,RNASE4;Ribonuclease 4,1.25007236500449,1.15912783547478,1.3481523520724,6.9683448274154e-09
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70189727413963,RNASE4;Ribonuclease 4,1.20031383320442,1.11647119778103,1.29045272376518,7.72939389015531e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.756063772335579,RNASE4;Ribonuclease 4,1.49382341503692,1.34242897462169,1.66229159046678,1.82202151815767e-13
primary,Circulatory system disorders,I50 (heart failure),4.27753053688097,RNASE4;Ribonuclease 4,1.3192643010734,1.25989528434287,1.3814309155022,4.19860532266842e-32
primary,Circulatory system disorders,I63 (cerebral infarction),2.05056973349656,RNASE4;Ribonuclease 4,1.21173300623494,1.13429445867434,1.29445830152003,1.19999478708862e-08
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.744673353849045,RNASE4;Ribonuclease 4,1.41279697847762,1.26752242576482,1.57472188406536,4.31878917644293e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.76138553367486,RNASE4;Ribonuclease 4,1.38158066300005,1.24060336688395,1.53857806558267,3.95583782692092e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.07490601056488,RNASE4;Ribonuclease 4,1.27709837336354,1.19534604222532,1.36444192529511,4.27804581020817e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.681903686982693,RNASE4;Ribonuclease 4,1.47692985480443,1.31880178130028,1.6540179327495,1.48428079437715e-11
primary,Circulatory system disorders,I95 (hypotension),4.54116759407714,RNASE4;Ribonuclease 4,1.24884649481366,1.19433540613434,1.30584554355323,1.68983078060174e-22
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,MIA;Melanoma-derived growth regulatory protein,2.45049361674492,2.17575421267988,2.75992523912493,2.19385598502309e-49
primary,Circulatory system disorders,I46 (cardiac arrest),0.773890951729529,MIA;Melanoma-derived growth regulatory protein,1.2815555014851,1.16029507556295,1.41548864420533,1.00065168460315e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535644721464744,SCARA5;Scavenger receptor class A member 5,3.30824187332078,2.93864169173983,3.72432757731457,3.38151609639074e-87
primary,Circulatory system disorders,I15 (secondary hypertension),0.0543953375424963,SCARA5;Scavenger receptor class A member 5,3.04387225767864,2.12192478074811,4.36639338261516,1.47830810592698e-09
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60899789111926,SCARA5;Scavenger receptor class A member 5,1.20860439584224,1.12861112184642,1.29426740298237,5.86639756339324e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.795642447232759,SCARA5;Scavenger receptor class A member 5,1.28996821705025,1.17080310748078,1.42126202977055,2.62443816849972e-07
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0485540600905047,SCARA5;Scavenger receptor class A member 5,3.41714415322983,2.33797470336159,4.99443990867975,2.21063931287952e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.391303341128528,BCHE;Cholinesterase,0.68370177634191,0.58748368455668,0.795678469480942,8.94741179532928e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106316592322093,BCHE;Cholinesterase,0.487359671688426,0.366381792476192,0.648283988085147,7.92294393874105e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,ERBB2;Receptor tyrosine-protein kinase erbB-2,0.730355838037961,0.646928000783866,0.824542529477472,3.82735901542099e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.21492350677009,ERBB2;Receptor tyrosine-protein kinase erbB-2,2.78905198700354,2.31452944400919,3.36086067357781,4.29919336062197e-27
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101564483681321,ERBB2;Receptor tyrosine-protein kinase erbB-2,4.41725356917681,3.43426008647195,5.68161077003642,6.06878527591156e-31
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248244989317326,EPHA2;Ephrin type-A receptor 2,1.54478934257172,1.29441067419209,1.84359891377799,1.43421913526733e-06
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12532063026749,EPHA2;Ephrin type-A receptor 2,1.22603208335835,1.15372005145528,1.30287643655667,5.02737118897628e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534094383854856,EPHA2;Ephrin type-A receptor 2,4.58214524694996,4.10549791027416,5.11413122671496,1.86726123305217e-162
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0609718919578074,EPHA2;Ephrin type-A receptor 2,3.4801563327673,2.50318124020297,4.8384383463653,1.19213918559028e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0548959011060507,EPHA2;Ephrin type-A receptor 2,3.27547532911685,2.30396548108327,4.65664035322643,3.85648466247193e-11
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9667828882811,EPHA2;Ephrin type-A receptor 2,1.21366642364985,1.15190403604045,1.27874036535044,3.68274123490254e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00968976467714,EPHA2;Ephrin type-A receptor 2,1.29267143800128,1.18408209520741,1.4112192502426,9.79221751284691e-09
primary,Circulatory system disorders,I26 (pulmonary embolism),1.98525939764725,EPHA2;Ephrin type-A receptor 2,1.25337147616102,1.17660368723065,1.33514799783737,2.50322085659426e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3563954555653,EPHA2;Ephrin type-A receptor 2,1.53607655001861,1.42361048537799,1.65742749983369,1.86872124426482e-28
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59388601671536,EPHA2;Ephrin type-A receptor 2,1.28036043969305,1.1933301909596,1.37373785390675,5.9378863450346e-12
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.67918060883049,EPHA2;Ephrin type-A receptor 2,1.23132807847472,1.15008342469562,1.31831204961633,2.29907483510655e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.762753234073712,EPHA2;Ephrin type-A receptor 2,1.44214643595731,1.30410414547908,1.59480080632696,9.88385438447852e-13
primary,Circulatory system disorders,I50 (heart failure),4.38519126243462,EPHA2;Ephrin type-A receptor 2,1.39393505742934,1.33552445943443,1.45490030572213,3.17385392599968e-52
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19509572840425,EPHA2;Ephrin type-A receptor 2,1.25693048986597,1.20307022667678,1.31320202372456,1.40167505559217e-24
primary,Circulatory system disorders,I63 (cerebral infarction),2.07054119663001,EPHA2;Ephrin type-A receptor 2,1.23753639596138,1.16366228652598,1.31610034033263,1.14879541614226e-11
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71857728468582,EPHA2;Ephrin type-A receptor 2,1.2671405747811,1.20076154029276,1.33718909406866,6.44855485927679e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.767195767195767,EPHA2;Ephrin type-A receptor 2,1.52277234745199,1.37722423380687,1.68370230877714,2.31862844075963e-16
primary,Circulatory system disorders,I70 (atherosclerosis),0.796058391188387,EPHA2;Ephrin type-A receptor 2,1.66335486752035,1.50736443578051,1.83548805426806,4.16856646242951e-24
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16853562005277,EPHA2;Ephrin type-A receptor 2,1.42535079308562,1.34142071252726,1.51453221526763,2.46064764186704e-30
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407091534531539,EPHA2;Ephrin type-A receptor 2,1.57680099982697,1.37444201258881,1.80895328452038,8.11516542473357e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.694727406079374,EPHA2;Ephrin type-A receptor 2,1.62857544673903,1.46550691274879,1.80978879229336,1.30280548341276e-19
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0467498678808081,EPHA2;Ephrin type-A receptor 2,3.98752400634387,2.75245047022844,5.77679702982959,2.6025006741546e-13
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.65620241546901,EPHA2;Ephrin type-A receptor 2,1.22834677547107,1.14558131284188,1.31709184140509,7.52828876412242e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.215556685307575,EPHA2;Ephrin type-A receptor 2,2.30779868950783,1.91927696491761,2.77496937057373,6.02965944763126e-19
primary,Circulatory system disorders,I87 (other disorders of veins),0.463952139674012,EPHA2;Ephrin type-A receptor 2,1.38513544930028,1.21672974924582,1.57684992423134,8.3966787802183e-07
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.525319161932685,EPHA2;Ephrin type-A receptor 2,1.3491218738937,1.1938806927097,1.52454917960636,1.5773687122675e-06
primary,Circulatory system disorders,I95 (hypotension),4.76414227052646,EPHA2;Ephrin type-A receptor 2,1.38124037512616,1.32590886103144,1.43888092911193,4.46830654747843e-54
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101642543503008,EPHA2;Ephrin type-A receptor 2,3.60780839448831,2.79842930546097,4.65128112614453,4.19350093027038e-23
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.390580648091377,AFM;Afamin,0.652939442068161,0.565461308274801,0.753950639538886,6.31231421259511e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.76531195028899,GPD1;Glycerol-3-phosphate dehydrogenase,1.31233078083453,1.18152745520945,1.45761494642583,3.90042624248046e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.207653515277365,GPD1;Glycerol-3-phosphate dehydrogenase,2.05805615906115,1.69762200469879,2.49501664217711,2.0204498720786e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104931794333683,GPD1;Glycerol-3-phosphate dehydrogenase,2.90133216964846,2.24013995168708,3.75767967188727,6.91118708729388e-16
primary,Circulatory system disorders,I85 (oesophageal varices),0.211303580550782,ADH1B;All-trans-retinol dehydrogenase,2.06044680889163,1.68207776981903,2.52392673421304,2.87924746585279e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109096817622617,ADH1B;All-trans-retinol dehydrogenase,2.82690404953184,2.14265058579337,3.72967321795052,1.99324422775993e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550198304689322,IGFBP1;Insulin-like growth factor-binding protein 1,1.95391152127833,1.74343824084025,2.18979378996772,1.06033340222326e-30
primary,Circulatory system disorders,I15 (secondary hypertension),0.0562298832745181,IGFBP1;Insulin-like growth factor-binding protein 1,2.60788471781888,1.84620447937883,3.68380792994367,5.3553331047702e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35185077123572,IGFBP1;Insulin-like growth factor-binding protein 1,1.32920701496146,1.23399846515543,1.43176133399826,6.1564372357611e-14
primary,Circulatory system disorders,I50 (heart failure),4.42862172841438,IGFBP1;Insulin-like growth factor-binding protein 1,1.22753939321326,1.17797174665833,1.27919278723366,1.86945855654879e-22
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.539784862723777,IGFBP1;Insulin-like growth factor-binding protein 1,1.34422650143586,1.19402308086364,1.51332492321298,9.92229810399001e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249070925911283,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.81425150854694,1.54136727661279,2.13544726568871,7.92624405493391e-13
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.50768440598949,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.53898416116202,1.36838327548977,1.73085442560663,6.39373224809632e-13
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12025316455696,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.38458846099873,1.30601286633885,1.46789151603461,9.62799170412025e-28
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.209345499071769,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.7671030643473,1.4788168512111,2.11158889450595,3.71517369524213e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,3.35448967888944,3.0411633533845,3.70009752789267,2.77678624444443e-129
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0671299952614121,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.81006517587973,2.11054070046549,3.74144231899927,1.50447688312275e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0572805562139527,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.61050545413329,1.90421160533919,3.57877176410013,2.50115036279238e-09
primary,Circulatory system disorders,I20 (angina pectoris),3.98857450375675,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.25988556039615,1.205515822891,1.31670741698614,1.02058602250626e-24
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9690922365539,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.39824812348204,1.32989440949052,1.47011507144393,2.93286815105838e-39
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02042834259497,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.47049547179155,1.35297450724302,1.59822444619871,1.15332739581239e-19
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68682726806765,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.35374125491357,1.314175152207,1.3944985812411,4.31362564399469e-89
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00259299890296,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.33690789959483,1.25827742289525,1.42045203981051,6.08319438084605e-21
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34152382839591,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.94124397249785,1.8105082217557,2.08142007612916,1.33349833477812e-77
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.735919602761676,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.39024520141904,1.25928881050094,1.53482005394762,6.69488381186392e-11
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.610181269482,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.4336628013252,1.3407340445868,1.53303262209403,5.92387482240306e-26
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71217946177321,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.34959921478721,1.26455761732971,1.44035986624353,1.74299308702948e-19
primary,Circulatory system disorders,I42 (cardiomyopathy),0.675327761714263,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.39967128921223,1.26235083718829,1.55192966973318,1.74821760644059e-10
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85606691243508,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.26890471889823,1.2061287217444,1.33494805041498,3.59177534054933e-20
primary,Circulatory system disorders,I45 (other conduction disorders),1.73598052217977,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.28672831960557,1.20583127124549,1.37305260524953,2.75159173030462e-14
primary,Circulatory system disorders,I46 (cardiac arrest),0.782500444602525,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.73055218879355,1.5774254172096,1.89854356691922,4.00586280601551e-31
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37800755617418,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.29959152558063,1.20794742293783,1.39818844867714,2.16419067971625e-12
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.34193053621521,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.25271874545307,1.2130130708363,1.29372410977202,8.73582329416809e-43
primary,Circulatory system disorders,I50 (heart failure),4.41132519077885,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.622667877741,1.55894330567945,1.68899730468704,5.58886172348841e-124
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19838894357284,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.41980437509416,1.3615975637426,1.4804994641703,1.57457281443273e-60
primary,Circulatory system disorders,I63 (cerebral infarction),2.07280581812417,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.3924743285262,1.3126381762426,1.47716620672636,4.25026639150247e-28
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.782252888318356,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.40823476881632,1.27832538001785,1.55134615576157,4.13503605217508e-12
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620774188446482,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.49901777255403,1.34762091544061,1.66742312818599,9.19109965974586e-14
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72257118513087,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.31117459405896,1.24472744383318,1.38116888530344,1.78483898931102e-24
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769002668775328,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.59085138159017,1.44685809234011,1.74917507923262,8.71870152930129e-22
primary,Circulatory system disorders,I70 (atherosclerosis),0.79898742188118,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.98501444952175,1.81499996454132,2.17095451338256,6.53535388590888e-51
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08381788695067,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.46636089180256,1.35264141435228,1.58964101068696,1.48783501112107e-20
primary,Circulatory system disorders,I72 (other aneurysm),0.336008222318852,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.46979439497882,1.27119167095774,1.69942551769832,1.99628337019537e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12868213949576,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.61275695819905,1.52214949157554,1.70875792464197,4.97970533967302e-59
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401415831207609,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.12224870523719,1.87399395641817,2.40339065740077,2.02459615824094e-32
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700643245917862,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.84509317942181,1.6742328509141,2.0333903010505,4.61127544168655e-35
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473914932269657,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,3.12844151930535,2.23978885138965,4.36967365635436,2.23529408929253e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.215321401762079,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.26880088321087,1.91936179055759,2.68185887255942,7.98533521700495e-22
primary,Circulatory system disorders,I95 (hypotension),4.82087922992954,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.48398168871011,1.4276129007358,1.54257617824264,8.53603851335503e-89
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100714878154745,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,3.10589410949673,2.47069263027882,3.9044023935579,2.78635169254768e-22
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.50768440598949,GGT5;Glutathione hydrolase 5 proenzyme,1.4129924576021,1.25152608537487,1.5952905085813,2.35248051786677e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12025316455696,GGT5;Glutathione hydrolase 5 proenzyme,1.24560352444568,1.17359393551184,1.32203149075991,4.88668539358038e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,GGT5;Glutathione hydrolase 5 proenzyme,2.28424362626843,2.0330271060256,2.56650239865628,6.70737486610057e-44
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0671299952614121,GGT5;Glutathione hydrolase 5 proenzyme,2.87291919013758,2.07931881325814,3.96940797170391,1.5740115514041e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34152382839591,GGT5;Glutathione hydrolase 5 proenzyme,1.50919236995248,1.4005228091958,1.62629383439365,3.64980570870855e-27
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71217946177321,GGT5;Glutathione hydrolase 5 proenzyme,1.23053027283379,1.15174683515435,1.31470276812828,7.99739677577051e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.782500444602525,GGT5;Glutathione hydrolase 5 proenzyme,1.34611912199337,1.22133194082118,1.48365618717696,2.12210789806848e-09
primary,Circulatory system disorders,I50 (heart failure),4.41132519077885,GGT5;Glutathione hydrolase 5 proenzyme,1.31865023748554,1.26480878655839,1.37478365686575,1.1480311931474e-38
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19838894357284,GGT5;Glutathione hydrolase 5 proenzyme,1.21220407629255,1.16148081570363,1.26514248252141,1.10476301156906e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.79898742188118,GGT5;Glutathione hydrolase 5 proenzyme,1.45103714448163,1.31786597112338,1.5976653474637,3.46520206490239e-14
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401415831207609,GGT5;Glutathione hydrolase 5 proenzyme,1.46709802717237,1.28137320718215,1.67974217758644,2.85516391662751e-08
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473914932269657,GGT5;Glutathione hydrolase 5 proenzyme,3.20673875463246,2.1860155757114,4.70407144153822,2.51674272353056e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.215321401762079,GGT5;Glutathione hydrolase 5 proenzyme,2.44766096988661,2.03954538851516,2.9374409891745,6.69522435065141e-22
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100714878154745,GGT5;Glutathione hydrolase 5 proenzyme,3.82124408589086,2.93733750675196,4.97113672854788,1.72593465718624e-23
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,DPT;Dermatopontin,3.06195088452764,2.73068336770811,3.43340547283173,8.72245461946743e-82
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35161378024624,DPT;Dermatopontin,1.22453214049868,1.13597064670591,1.31999798362965,1.23385177204671e-07
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0483830388419035,DPT;Dermatopontin,2.75364131731071,1.88017154952177,4.0328982248079,1.96007523211242e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.38176903718892,GHR;Growth hormone receptor,0.776136060676008,0.715316100560398,0.842127255642291,1.15139463882739e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3798128372686,LCAT;Phosphatidylcholine-sterol acyltransferase,0.72581682760151,0.670181847136562,0.786070332224581,3.38521678221006e-15
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.108878101891757,LCAT;Phosphatidylcholine-sterol acyltransferase,0.496514880979442,0.37543747167166,0.656639375756374,9.14057758201248e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,"KRT18;Keratin, type I cytoskeletal 18",1.57357921154212,1.39306288486721,1.77748726342211,3.04644906011012e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774430015567422,"KRT18;Keratin, type I cytoskeletal 18",1.34226088841906,1.21136036748023,1.48730661902635,1.88284772831495e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,"KRT18;Keratin, type I cytoskeletal 18",1.32894933401794,1.20072783407656,1.4708631567161,3.93674133085407e-08
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,"KRT18;Keratin, type I cytoskeletal 18",1.42708650017892,1.23795051781955,1.64511896855137,9.4606709681911e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.212665406427221,"KRT18;Keratin, type I cytoskeletal 18",3.34677499654874,2.79740763294225,4.00402956852696,8.25815226930971e-40
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.270254275738267,"KRT18;Keratin, type I cytoskeletal 18",1.78761017475232,1.50306165940025,2.12602731025226,5.14459532446699e-11
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102358174875004,"KRT18;Keratin, type I cytoskeletal 18",5.23107343481679,4.15328697601069,6.58854768247429,7.06085010145805e-45
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13307047806801,TAFA5;Chemokine-like protein TAFA-5,1.20716549020933,1.13691517069795,1.28175659742294,7.523229390024e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,TAFA5;Chemokine-like protein TAFA-5,4.59301283004355,4.09374511947436,5.15317056662614,1.2067990285979e-148
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0629760100761616,TAFA5;Chemokine-like protein TAFA-5,2.91604599083366,2.07771468521185,4.09263325767465,6.07900150558223e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0570944815230445,TAFA5;Chemokine-like protein TAFA-5,4.17567517852936,2.94920546230347,5.91219005235655,7.89540036820392e-16
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9594291374396,TAFA5;Chemokine-like protein TAFA-5,1.23755023876758,1.1752055558703,1.30320230858637,6.40166182096568e-16
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0131672317275,TAFA5;Chemokine-like protein TAFA-5,1.29204453272648,1.18479159295316,1.4090065159792,6.82992617871527e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,TAFA5;Chemokine-like protein TAFA-5,1.42527797022742,1.32161321257091,1.53707398888963,3.65983557202123e-20
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60473307214373,TAFA5;Chemokine-like protein TAFA-5,1.26978536385935,1.18464073259006,1.36104966334073,1.53421627987118e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,TAFA5;Chemokine-like protein TAFA-5,1.44127165171637,1.30543295950918,1.59124523316943,4.58065134108955e-13
primary,Circulatory system disorders,I50 (heart failure),4.39523336643495,TAFA5;Chemokine-like protein TAFA-5,1.33280646850767,1.2775096244738,1.39049682950732,2.71523343009249e-40
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20671151689892,TAFA5;Chemokine-like protein TAFA-5,1.23510406845509,1.18289182754159,1.28962093100661,9.56016163113142e-22
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72922961470861,TAFA5;Chemokine-like protein TAFA-5,1.21391154477749,1.15111473066285,1.28013411634088,8.50334380361961e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774430015567422,TAFA5;Chemokine-like protein TAFA-5,1.35193855167735,1.22414409998441,1.49307409767749,2.65094569309145e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,TAFA5;Chemokine-like protein TAFA-5,1.46389574790179,1.32694416265178,1.61498186663887,2.85750191341975e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15586074736505,TAFA5;Chemokine-like protein TAFA-5,1.27651253080062,1.20184919361612,1.35581423189063,2.03743931314911e-15
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,TAFA5;Chemokine-like protein TAFA-5,1.47572686304989,1.28703739819877,1.69207963760408,2.47337554313383e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,TAFA5;Chemokine-like protein TAFA-5,1.44026527300803,1.29734269705734,1.598933004624,7.81143546515997e-12
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0472375853720943,TAFA5;Chemokine-like protein TAFA-5,2.83886002583068,1.91849836229735,4.20074700330147,1.80102065441414e-07
primary,Circulatory system disorders,I95 (hypotension),4.82266136529978,TAFA5;Chemokine-like protein TAFA-5,1.26948462846752,1.21946065306599,1.3215606570523,2.80472915461214e-31
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.242215884673985,AOC3;Membrane primary amine oxidase,1.71224832108955,1.43366573481278,2.04496364939408,2.91945285378272e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511469009272816,AOC3;Membrane primary amine oxidase,1.36284065225245,1.20542280472559,1.54081591633294,7.67995777825103e-07
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.208841612179174,AOC3;Membrane primary amine oxidase,1.59425500672457,1.31804952480567,1.92834106657798,1.54866210829098e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.549977492024347,AOC3;Membrane primary amine oxidase,1.47217640980555,1.30777040421436,1.65725067229211,1.5431539906612e-10
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0643877312104893,AOC3;Membrane primary amine oxidase,2.28717954206993,1.64300797971136,3.18391043881735,9.48948344618278e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34711779448621,AOC3;Membrane primary amine oxidase,1.60037308588301,1.48350352319135,1.7264495661655,5.45701154563142e-34
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61068822098406,AOC3;Membrane primary amine oxidase,1.27917145422921,1.19319146845576,1.37134705751171,4.05234470951398e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.679127116156179,AOC3;Membrane primary amine oxidase,1.31963823733992,1.18590291307764,1.46845501283932,3.62898101075808e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.78303489484681,AOC3;Membrane primary amine oxidase,1.31701539268048,1.19234928382757,1.45471596962703,5.71904774644876e-08
primary,Circulatory system disorders,I50 (heart failure),4.4228269859399,AOC3;Membrane primary amine oxidase,1.24974370485182,1.19770164261237,1.30404707837763,9.32836230811003e-25
primary,Circulatory system disorders,I70 (atherosclerosis),0.801344695489015,AOC3;Membrane primary amine oxidase,1.44648474776529,1.31139240861402,1.59549354699174,1.59405123226962e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15300589701982,AOC3;Membrane primary amine oxidase,1.23943426381116,1.16663164085783,1.31678007051098,3.65191943033195e-12
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0487842953596378,AOC3;Membrane primary amine oxidase,2.58270642792351,1.77933929491765,3.74879176326296,6.00151970112641e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.218638972396829,AOC3;Membrane primary amine oxidase,2.27132706035963,1.89481624290366,2.72265272922522,7.21942243457139e-19
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103428761001502,AOC3;Membrane primary amine oxidase,3.79949518669222,2.97341379064373,4.85508062117784,1.37795843274121e-26
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.252733043376043,SPON1;Spondin-1,2.02954052939638,1.71154607517686,2.40661634542144,3.9289717873219e-16
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51298116458472,SPON1;Spondin-1,1.47735675141711,1.3090270015593,1.66733227684216,2.56684875326842e-10
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13278968106169,SPON1;Spondin-1,1.29684138795708,1.22180191807498,1.37648956073683,1.26074493694838e-17
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.207501370292067,SPON1;Spondin-1,1.60199014740399,1.32855337922293,1.93170441813977,8.01254550891322e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.543712950967691,SPON1;Spondin-1,2.67718629701647,2.38997058695683,2.99891827457968,7.21968755511119e-65
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645779926028844,SPON1;Spondin-1,2.55950429040039,1.848402693179,3.54417478223378,1.52140348133331e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34922817078439,SPON1;Spondin-1,1.85462393662115,1.72213801064995,1.9973021471084,5.61348210539959e-60
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60953917594742,SPON1;Spondin-1,1.37496382043694,1.28361018140218,1.47281903408197,1.10795227286651e-19
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71292749523641,SPON1;Spondin-1,1.23072826751214,1.15152314021484,1.31538135496855,9.54049533047662e-10
primary,Circulatory system disorders,I45 (other conduction disorders),1.76577919912103,SPON1;Spondin-1,1.20796161432432,1.13160799457477,1.28946708460587,1.41735086156385e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.779475127301214,SPON1;Spondin-1,1.65662410287994,1.50378008212366,1.82500317092049,1.60318735382288e-24
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36783806689398,SPON1;Spondin-1,1.25764636453042,1.1672335186863,1.35506250711232,1.71828614338643e-09
primary,Circulatory system disorders,I50 (heart failure),4.42158063114656,SPON1;Spondin-1,1.41846329671488,1.36052722441953,1.47886649235238,1.17033274789017e-60
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22655783396376,SPON1;Spondin-1,1.2990939237097,1.24474429057863,1.35581664072944,3.5379948954374e-33
primary,Circulatory system disorders,I63 (cerebral infarction),2.07404497692232,SPON1;Spondin-1,1.21031639157483,1.13927375929452,1.28578908779732,6.21945101264054e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71607847758204,SPON1;Spondin-1,1.22078972262394,1.15781214707864,1.28719287548037,1.55594513176343e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781785763269784,SPON1;Spondin-1,1.35951678911622,1.23287215888283,1.4991707668731,7.45497479064791e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.807668934151457,SPON1;Spondin-1,1.58601001562543,1.44158332208811,1.74490626460677,2.85869620902601e-21
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08991825613079,SPON1;Spondin-1,1.23249862899739,1.13481989282759,1.33858498611219,6.97379389534451e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14949190219117,SPON1;Spondin-1,1.36854266288221,1.28915879282868,1.45281483595919,7.76734703484132e-25
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.403739490033906,SPON1;Spondin-1,1.54097082284197,1.34673283671675,1.76322356751869,3.16637539922224e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700343305541932,SPON1;Spondin-1,1.62997961924509,1.47092202121001,1.80623685065834,1.09952640398147e-20
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0489284665818573,SPON1;Spondin-1,2.9771939699232,2.05834930023053,4.30620980294954,6.88933332176062e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.223205544895641,SPON1;Spondin-1,2.82071253939513,2.36589367247365,3.36296568289231,6.64768172604214e-31
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.272650595319825,SPON1;Spondin-1,1.55222943319118,1.31841924469273,1.82750382548196,1.30160507532327e-07
primary,Circulatory system disorders,I87 (other disorders of veins),0.454545454545454,SPON1;Spondin-1,1.44764177462678,1.27297265708319,1.6462778646373,1.71098056261564e-08
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.537160109000372,SPON1;Spondin-1,1.37741565152198,1.22279099270075,1.55159294465136,1.35906523573651e-07
primary,Circulatory system disorders,I95 (hypotension),4.8313170059998,SPON1;Spondin-1,1.27671266193355,1.22682839385453,1.3286252823186,3.03287506677298e-33
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10569583088667,SPON1;Spondin-1,4.30797592666394,3.35156573795542,5.53730943557069,4.06744282815664e-30
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,ITGAM;Integrin alpha-M,1.67427741636531,1.39101666474605,2.01522018966082,5.03857953425033e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,ITGAM;Integrin alpha-M,2.2725333165281,1.73944238304077,2.96900186236818,1.76058067397256e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12977396726422,AMBP;Protein AMBP,1.22217222879129,1.15168549154662,1.29697297377841,3.60121525269946e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.546320143604152,AMBP;Protein AMBP,3.99997654123446,3.59368914429199,4.45219708439145,5.78537447821451e-142
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544853084257637,AMBP;Protein AMBP,3.20238554237818,2.2874303421926,4.48331604808681,1.20303607392577e-11
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97356167942287,AMBP;Protein AMBP,1.25922463229414,1.19659645357049,1.32513068198135,8.32871227692842e-19
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02865826335989,AMBP;Protein AMBP,1.28932106648348,1.18407946555716,1.40391659583074,4.94024529040409e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3528550512445,AMBP;Protein AMBP,1.2526909842662,1.16269319974694,1.34965500994016,3.16663288023931e-09
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60968549522766,AMBP;Protein AMBP,1.29783209459279,1.21208422583148,1.38964612347763,7.71343537305446e-14
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71036960384247,AMBP;Protein AMBP,1.20549017935311,1.12814165312229,1.28814193545185,3.32256445387309e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.778694907335306,AMBP;Protein AMBP,1.41068329034033,1.27964440996344,1.55514088925866,4.6060198139018e-12
primary,Circulatory system disorders,I50 (heart failure),4.42865275514811,AMBP;Protein AMBP,1.29104991508771,1.23840024408772,1.34593794793366,2.61142342490814e-33
primary,Circulatory system disorders,I63 (cerebral infarction),2.07727299349876,AMBP;Protein AMBP,1.22671350992024,1.15502977923846,1.30284609320896,2.90356905487127e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.777096114519427,AMBP;Protein AMBP,1.35140472258078,1.22549645206744,1.49024888740611,1.58779117698952e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.804754481683554,AMBP;Protein AMBP,1.67002181184117,1.51844796330888,1.83672599879403,4.37682049176305e-26
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15645654532899,AMBP;Protein AMBP,1.34571395277545,1.2681450503611,1.42802752901088,1.09967319735184e-22
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409093565542633,AMBP;Protein AMBP,1.7463722242975,1.52978588681086,1.99362274949191,1.5489362297947e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.69805986155796,AMBP;Protein AMBP,1.4851982327268,1.34007488807069,1.64603770291563,4.70786605423781e-14
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0447435997198661,AMBP;Protein AMBP,3.27057248165399,2.2628036368298,4.72716420623153,2.88314280173352e-10
primary,Circulatory system disorders,I95 (hypotension),4.82158568775051,AMBP;Protein AMBP,1.27783088697506,1.22806293068681,1.32961571830383,1.11305745040384e-33
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,IL12A_IL12B;Interleukin-12,2.19181372599012,1.94675569103983,2.46771972032745,1.76091390031051e-38
primary,Circulatory system disorders,I15 (secondary hypertension),0.0570944815230445,IL12A_IL12B;Interleukin-12,2.78083508865801,1.94076855786887,3.98452652118556,2.49869320087535e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,IL12A_IL12B;Interleukin-12,1.34445510166033,1.21664239286254,1.48569500042459,6.34363732821908e-09
primary,Circulatory system disorders,I50 (heart failure),4.39523336643495,IL12A_IL12B;Interleukin-12,1.21300234814091,1.16248073873918,1.26571963522699,5.77713791943964e-19
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0472375853720943,IL12A_IL12B;Interleukin-12,2.74502452245631,1.8518018803455,4.06909600258132,4.95778694388767e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.210737581535373,GFER;FAD-linked sulfhydryl oxidase ALR,1.69042195529006,1.39794344610418,2.04409298165106,6.08962333570804e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102329500993198,GFER;FAD-linked sulfhydryl oxidase ALR,2.38521163368177,1.82370461635918,3.11960307958686,2.18894208821101e-10
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14217305474659,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.25258181181333,1.17754986691175,1.3323946945876,8.95331344909673e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.549977492024347,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.89933535721838,1.68629829465738,2.13928627610504,4.16781228346978e-26
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.103523712790061,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,2.05248541333568,1.57133195418945,2.68097161820197,1.32172740197268e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34711779448621,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.44805727199711,1.3400276969784,1.56479591258592,8.05323371319725e-21
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61068822098406,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.21246220817884,1.12878435791393,1.30234317649359,1.29081429106483e-07
primary,Circulatory system disorders,I45 (other conduction disorders),1.75671974646895,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.2350982346204,1.15357799282653,1.32237929177609,1.3540609560713e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.78303489484681,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.28320472965417,1.15885585873547,1.42089662471361,1.62708764739647e-06
primary,Circulatory system disorders,I50 (heart failure),4.4228269859399,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.35668997588666,1.2993773773377,1.41653050358825,1.23982360550081e-43
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21819481112412,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.20426041403184,1.15182840245026,1.25907916640974,2.75652017128224e-16
primary,Circulatory system disorders,I63 (cerebral infarction),2.07382747478703,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.22703982212562,1.15212643077759,1.30682422072888,1.94232032282515e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73138448886887,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.23636286542068,1.17034201086864,1.30610806140054,3.51481052983924e-14
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771665234039227,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.47552372819833,1.33235412764161,1.63407777805297,8.00668822942114e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.801344695489015,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.32848560250366,1.20116049726623,1.4693073907078,3.28452208345854e-08
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.09061058556797,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.30307414841182,1.19545093069371,1.42038639367142,1.75503802876061e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15300589701982,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.31297963685334,1.23398778264984,1.39702803466143,7.87914748456029e-18
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406432577134259,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.5249947175888,1.32575504162499,1.75417691478149,3.47563716533999e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702200488997555,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.36748456048534,1.22811519639749,1.52266988361615,1.15255200607521e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.218638972396829,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,2.0399015899644,1.693159919624,2.45765237442152,6.38862552499252e-14
primary,Circulatory system disorders,I87 (other disorders of veins),0.455175916700853,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.43674209681135,1.25747728580715,1.64156273520671,9.85542514936637e-08
primary,Circulatory system disorders,I95 (hypotension),4.80514640986918,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.25937995156031,1.20830057864655,1.31261864011404,9.58095089469158e-28
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,OPTC;Opticin,1.99166268687503,1.78033970347932,2.22806931201844,2.21766858993593e-33
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96863330843913,BPIFB2;BPI fold-containing family B member 2,1.20444568519927,1.13805919770021,1.2747047003589,1.26984173523985e-10
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.247975512418148,NOTCH3;Neurogenic locus notch homolog protein 3,1.66915889115177,1.40274101046893,1.9861766235662,7.72054464062538e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.507260406582768,NOTCH3;Neurogenic locus notch homolog protein 3,1.51243533470489,1.33868836075102,1.70873274821078,3.03495175031804e-11
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13615569512289,NOTCH3;Neurogenic locus notch homolog protein 3,1.2484919683727,1.17566417921261,1.32583115370164,4.57547143507668e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,NOTCH3;Neurogenic locus notch homolog protein 3,1.78020046338652,1.58506398629251,1.99936009981162,2.11709642916231e-22
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35161378024624,NOTCH3;Neurogenic locus notch homolog protein 3,1.54326261242568,1.43169204400075,1.66352778231245,9.03730785652396e-30
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60521451503064,NOTCH3;Neurogenic locus notch homolog protein 3,1.21344228232764,1.13194357484828,1.30080880819335,4.92997200184389e-08
primary,Circulatory system disorders,I50 (heart failure),4.42925495557074,NOTCH3;Neurogenic locus notch homolog protein 3,1.21766146513049,1.16730507946174,1.27019017543162,6.30408857980225e-20
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.08716146041383,NOTCH3;Neurogenic locus notch homolog protein 3,1.27837157960566,1.20200056297914,1.35959495018291,5.53919833231488e-15
primary,Circulatory system disorders,I85 (oesophageal varices),0.218776015953224,NOTCH3;Neurogenic locus notch homolog protein 3,2.90458361159079,2.43542725024426,3.46411741753965,1.84115768278472e-32
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.271549383194972,NOTCH3;Neurogenic locus notch homolog protein 3,1.76050398860961,1.4940882495773,2.07442518525073,1.41826181943552e-11
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104513431911434,NOTCH3;Neurogenic locus notch homolog protein 3,4.41534756832254,3.46283746320989,5.62986116334218,4.61453392781954e-33
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,EGLN1;Egl nine homolog 1,1.5091592315341,1.34361608467738,1.69509848244446,3.85402681549068e-12
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01780170550556,EGLN1;Egl nine homolog 1,1.24620759235029,1.14366453175536,1.35794485192947,5.06060636085859e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35063298615896,EGLN1;Egl nine homolog 1,1.31917269175324,1.22500856856074,1.42057503541552,2.2826000704733e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.787339734150124,EGLN1;Egl nine homolog 1,1.29075345456329,1.17082702698008,1.4229638042814,2.90087271461062e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.801823755994025,EGLN1;Egl nine homolog 1,1.36480125144487,1.23993825209493,1.5022380774191,2.109653837594e-10
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.390978034500373,EGLN1;Egl nine homolog 1,1.43269010603059,1.24873024825447,1.64375047596319,2.92962704485167e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.798106453316641,FURIN;Furin,1.38407246061014,1.25645963269459,1.52464633671607,4.52814693735844e-11
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.251899006072914,AGRN;Agrin,1.95995590274179,1.65608522207428,2.31958300786048,4.92072868970303e-15
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513240832894248,AGRN;Agrin,1.34521109154647,1.19253711364931,1.5174310804316,1.4016866138713e-06
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12965495682075,AGRN;Agrin,1.27898918643667,1.20530979991507,1.35717252040695,4.34839687601085e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.541915289054093,AGRN;Agrin,3.79273232355791,3.39435767740119,4.23786172386359,1.42372219020804e-122
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.064365125804564,AGRN;Agrin,3.37990786336358,2.47163009449936,4.62196070125974,2.4080018403241e-14
primary,Circulatory system disorders,I15 (secondary hypertension),0.0565853658536585,AGRN;Agrin,2.59928119411516,1.83940056132963,3.67307853880228,6.15417612347451e-08
primary,Circulatory system disorders,I20 (angina pectoris),3.99828294597412,AGRN;Agrin,1.20721432977693,1.15477127411859,1.26203904676372,9.53783252405791e-17
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96103375738755,AGRN;Agrin,1.30395968806236,1.23907263544678,1.37224470902676,2.1694614787494e-24
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01000234429944,AGRN;Agrin,1.40213554481522,1.28716934754286,1.52737018620529,9.67431813265646e-15
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.7123820324841,AGRN;Agrin,1.22905157758052,1.19266065975607,1.26655286899638,3.11577416020257e-41
primary,Circulatory system disorders,I26 (pulmonary embolism),1.98802064861882,AGRN;Agrin,1.21616443950884,1.14339233003939,1.29356818746099,5.08591650850714e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35066358689269,AGRN;Agrin,1.58378794374452,1.47065308968905,1.70562607071452,5.06123943886343e-34
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60619729358697,AGRN;Agrin,1.25875323863121,1.17533495300314,1.34809205811166,4.77459177661506e-11
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.7092176364633,AGRN;Agrin,1.20429646183823,1.12716355900132,1.28670764452418,3.70244618650908e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.776903706884772,AGRN;Agrin,1.51663156616251,1.37615674434559,1.67144572515565,4.52272430491031e-17
primary,Circulatory system disorders,I50 (heart failure),4.4187694366807,AGRN;Agrin,1.33918549423123,1.2846582239206,1.39602717249268,3.82791653735831e-43
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22057306135407,AGRN;Agrin,1.25425783264935,1.20196986440096,1.30882042666375,1.86097211272211e-25
primary,Circulatory system disorders,I63 (cerebral infarction),2.07109858272649,AGRN;Agrin,1.25198070479143,1.17888333306347,1.32961052311837,2.45184493934892e-13
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.623034706353391,AGRN;Agrin,1.32085315732984,1.18423627195086,1.47323055757627,5.86641746681992e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71492326965236,AGRN;Agrin,1.22780745606134,1.16475073319913,1.294277913884,2.35876697788999e-14
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77920556184822,AGRN;Agrin,1.33431322560344,1.21013714945577,1.47123140944887,7.1677545268084e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.808909730363423,AGRN;Agrin,1.61504044888868,1.46813051184889,1.77665107461171,6.76053930428904e-23
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15034619188921,AGRN;Agrin,1.40828506298746,1.32684300737727,1.49472605847609,1.96126541173252e-29
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40436005625879,AGRN;Agrin,1.81556981690269,1.58876749227297,2.07474899636335,1.95513369184732e-18
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699984357891443,AGRN;Agrin,1.58499185967808,1.43039661575516,1.756295538996,1.41691161390146e-18
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0487671660424469,AGRN;Agrin,2.54767200760828,1.75926274000595,3.6894049483074,7.4205775195103e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.222469410456062,AGRN;Agrin,2.08947308632287,1.74994734495739,2.49487379780215,3.79304231973141e-16
primary,Circulatory system disorders,I95 (hypotension),4.82511175594071,AGRN;Agrin,1.29104755196861,1.24077070694485,1.34336164781671,1.98517753119446e-36
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105347353635459,AGRN;Agrin,2.81367662575744,2.19184580869662,3.61192202613992,4.72169176140354e-16
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0975952529668957,AGRN;Agrin,2.02916837437299,1.55063328647948,2.65538237019524,2.5152961814572e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12740623139511,VWC2;Brorin,1.23406836117263,1.16119638096063,1.31151349161752,1.26562631568104e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534451243741556,VWC2;Brorin,4.26467756574949,3.80282995127809,4.7826158342143,8.84169725306736e-136
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0673560759142596,VWC2;Brorin,2.91012363606969,2.11496043658158,4.00424491670382,5.38770393987281e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0574735423520551,VWC2;Brorin,3.98201216410395,2.84090589182259,5.58146643319434,1.05272727074374e-15
primary,Circulatory system disorders,I20 (angina pectoris),3.98969864379322,VWC2;Brorin,1.22326461161697,1.16861041334076,1.28047490673701,5.55439772848e-18
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97086114276412,VWC2;Brorin,1.31809013317319,1.25114878125504,1.38861310916656,2.88607546723925e-25
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0179177331984,VWC2;Brorin,1.43346252057256,1.31408976540047,1.56367917321085,4.77530996772921e-16
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68957004731536,VWC2;Brorin,1.24022439699128,1.20244556479057,1.27919017702917,2.3017739728716e-42
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34208171786459,VWC2;Brorin,1.33292850421267,1.23450527661903,1.43919870655273,2.09189671683778e-13
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61165009861147,VWC2;Brorin,1.26439445485733,1.1785041704733,1.35654448879203,6.31602445353326e-11
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85771104703191,VWC2;Brorin,1.2053077876958,1.14381837180888,1.2701027530994,2.75729157234762e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.783155223347939,VWC2;Brorin,1.47773688790737,1.33873523951741,1.63117115724044,9.34146555489517e-15
primary,Circulatory system disorders,I50 (heart failure),4.41605693494862,VWC2;Brorin,1.36431227274126,1.30741280845027,1.42368803909665,2.43720827176411e-46
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20042729874632,VWC2;Brorin,1.23477968232092,1.1819358506359,1.2899861384628,3.38158863543331e-21
primary,Circulatory system disorders,I63 (cerebral infarction),2.06982940310971,VWC2;Brorin,1.27687004499186,1.20056916618666,1.35802014387567,7.57041894926457e-15
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.612949297786241,VWC2;Brorin,1.34201636283792,1.19930841209643,1.50170539951147,2.92320763858175e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72779688649422,VWC2;Brorin,1.24275127032649,1.17765665708797,1.31144396849679,2.4290760693446e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.767628681939898,VWC2;Brorin,1.37289230552531,1.24156765274198,1.51810759438519,6.49801956648712e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.793745287137357,VWC2;Brorin,1.56884519350157,1.42177814367574,1.73112468504392,3.04292308546762e-19
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08152087632957,VWC2;Brorin,1.34150301975515,1.23348736684981,1.45897753019413,6.91204501896062e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12787333226169,VWC2;Brorin,1.31663113235286,1.23819371330346,1.40003742552996,1.6709566391819e-18
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.400785698696454,VWC2;Brorin,1.72786693644623,1.50720800224304,1.98083087776936,4.32253447767519e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703008638665475,VWC2;Brorin,1.63586937917229,1.4735040397584,1.81612574754279,2.74973986542311e-20
primary,Circulatory system disorders,I95 (hypotension),4.8272428557204,VWC2;Brorin,1.25623431200881,1.20613006791542,1.30841995291249,4.51668940007929e-28
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.399990697890746,CELSR2;Cadherin EGF LAG seven-pass G-type receptor 2,3.30717754363988,2.8374010127559,3.85473299543678,7.46231001379877e-53
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,NPY;Pro-neuropeptide Y,1.69329837004847,1.50510196949778,1.9050266547492,1.92509829645138e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,NPY;Pro-neuropeptide Y,1.30932922510548,1.18795294285311,1.44310684192419,5.63832444619135e-08
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248285916038359,PALM2;Paralemmin-2,1.74201454299415,1.46200714424431,2.07564968471592,5.36190431285562e-10
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.521248264402613,PALM2;Paralemmin-2,1.43160590649257,1.26337639679871,1.62223663248549,1.85051336659265e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.04421148587055,PALM2;Paralemmin-2,1.24124575151256,1.1638986614804,1.32373295600179,4.59754031920971e-11
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.202548930359581,PALM2;Paralemmin-2,1.70174570390785,1.40367265733405,2.06311523248518,6.25497327469265e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.401231049811923,PALM2;Paralemmin-2,2.91196586530437,2.58083371993919,3.28558369924647,1.85008230709982e-67
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37277295568752,PALM2;Paralemmin-2,1.52750909860008,1.4150442411832,1.64891243566706,1.8474604187983e-27
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59227654366177,PALM2;Paralemmin-2,1.28455186589778,1.19404476995001,1.38191928620109,1.85025200426535e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.762802559373363,PALM2;Paralemmin-2,1.44204615219567,1.30154892177895,1.59770952152923,2.57494214366503e-12
primary,Circulatory system disorders,I50 (heart failure),4.31178969119504,PALM2;Paralemmin-2,1.32676377733222,1.26927511824077,1.38685624223111,6.55803048086478e-36
primary,Circulatory system disorders,I63 (cerebral infarction),2.04123570107541,PALM2;Paralemmin-2,1.2674587217573,1.18873857894246,1.35139183653633,4.33392252029244e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.744891683181849,PALM2;Paralemmin-2,1.37840394593104,1.24105238539033,1.53095667880343,2.06737910340335e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.770247481883232,PALM2;Paralemmin-2,1.48316311614541,1.33945712758465,1.64228685173437,3.43601077400567e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.07910282444157,PALM2;Paralemmin-2,1.23064333700878,1.1538899172971,1.31250217219307,2.67732878221132e-10
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.400975098535073,PALM2;Paralemmin-2,1.50013044228345,1.30349365977103,1.72643060209502,1.53809166396229e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686399708109094,PALM2;Paralemmin-2,1.58780614365428,1.42678517769715,1.76699925765657,2.35678596429598e-17
primary,Circulatory system disorders,I85 (oesophageal varices),0.209414549758718,PALM2;Paralemmin-2,2.70254682574997,2.28119848229176,3.20172023700177,1.37355417198067e-30
primary,Circulatory system disorders,I95 (hypotension),4.54576635492648,PALM2;Paralemmin-2,1.25743717683943,1.20412019571545,1.31311496918998,3.66413465534381e-25
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106947004346144,PALM2;Paralemmin-2,3.74527950529886,3.014212608167,4.65365931215511,9.51563149778569e-33
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545479608514995,IL1RN;Interleukin-1 receptor antagonist protein,1.60273976784214,1.43432196594152,1.79093315477218,8.25332801344821e-17
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96626403984593,IL1RN;Interleukin-1 receptor antagonist protein,1.27222598000946,1.20987603969566,1.33778907186076,5.9464693365805e-21
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01464949365844,IL1RN;Interleukin-1 receptor antagonist protein,1.30004715923344,1.19468020009912,1.41470714597153,1.16670332723132e-09
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.7245449171372,IL1RN;Interleukin-1 receptor antagonist protein,1.22100315238331,1.18543419773818,1.25763935355882,5.32327401104564e-40
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35555818260629,IL1RN;Interleukin-1 receptor antagonist protein,1.31824632013462,1.22511631718865,1.41845581204586,1.45284121281624e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.776107672659396,IL1RN;Interleukin-1 receptor antagonist protein,1.38185457364269,1.2556990963503,1.52068442849666,3.55536076176633e-11
primary,Circulatory system disorders,I50 (heart failure),4.42388461843252,IL1RN;Interleukin-1 receptor antagonist protein,1.25175437139279,1.20158312190983,1.30402048574924,5.38448050150538e-27
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.627113312888259,IL1RN;Interleukin-1 receptor antagonist protein,1.40934264162992,1.26733280745952,1.56726525962664,2.42076215045873e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778424280547255,IL1RN;Interleukin-1 receptor antagonist protein,1.3897211920184,1.26290163757361,1.52927586288957,1.57571638679042e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.812224669603524,IL1RN;Interleukin-1 receptor antagonist protein,1.41131551754271,1.28563132425877,1.54928668310506,4.50129317951956e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14646967464457,IL1RN;Interleukin-1 receptor antagonist protein,1.25352334775906,1.1817108067658,1.32969993536541,6.05424015215274e-14
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40504935310079,IL1RN;Interleukin-1 receptor antagonist protein,1.52894189921701,1.34252498721755,1.74124381552573,1.55365880032159e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.696699533565566,IL1RN;Interleukin-1 receptor antagonist protein,1.33150972343027,1.20257396774447,1.4742695178365,3.59335666890564e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.223924572775486,IL1RN;Interleukin-1 receptor antagonist protein,1.96346492018518,1.66705486996772,2.31257804541997,6.44466926512062e-16
primary,Circulatory system disorders,I95 (hypotension),4.83915531872903,IL1RN;Interleukin-1 receptor antagonist protein,1.24329125586769,1.19554856387948,1.29294049076612,1.15423184569422e-27
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106038291605301,IL1RN;Interleukin-1 receptor antagonist protein,2.35768717135849,1.88663553978831,2.94635009293427,4.62535203094473e-14
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24802749785173,COL18A1;Collagen alpha-1(XVIII) chain,1.75551068026912,1.47752885933156,2.08579191470629,1.57153990387924e-10
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.503542361964986,COL18A1;Collagen alpha-1(XVIII) chain,1.56499521974272,1.38586625443241,1.76727734727957,5.13937585405425e-13
primary,Circulatory system disorders,I08 (multiple valve diseases),2.1417125884238,COL18A1;Collagen alpha-1(XVIII) chain,1.35388475114881,1.27577755008283,1.43677392604555,1.63004908723872e-23
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.20879270981716,COL18A1;Collagen alpha-1(XVIII) chain,1.61315666554569,1.33628750250233,1.94739112857187,6.44297997371974e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.555707744687512,COL18A1;Collagen alpha-1(XVIII) chain,4.50544289429227,4.03935531627125,5.02531074499949,9.28392230277775e-161
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0663246396036127,COL18A1;Collagen alpha-1(XVIII) chain,3.19842283202364,2.33464458439895,4.38178413998024,4.52602353798304e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0565930956423316,COL18A1;Collagen alpha-1(XVIII) chain,2.91171216160584,2.05974514407469,4.11607607690319,1.43727124738238e-09
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9781349580135,COL18A1;Collagen alpha-1(XVIII) chain,1.27799128264045,1.21400073834551,1.34535479832643,8.04452118630051e-21
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.103499453210435,COL18A1;Collagen alpha-1(XVIII) chain,2.11139352929264,1.62176199587593,2.74885134000876,2.82641410025736e-08
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01793599312258,COL18A1;Collagen alpha-1(XVIII) chain,1.39176162913973,1.27726453912773,1.51652251589831,4.45437501482184e-14
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.71811495836456,COL18A1;Collagen alpha-1(XVIII) chain,1.23244303623291,1.19559056800439,1.27043143213674,1.71429255133416e-41
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35857330227277,COL18A1;Collagen alpha-1(XVIII) chain,1.73649956653867,1.61207492462343,1.8705276650174,5.99528186715634e-48
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.6083477169308,COL18A1;Collagen alpha-1(XVIII) chain,1.35336796119461,1.26338255037122,1.44976265332291,6.70314860813372e-18
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.73483973292083,COL18A1;Collagen alpha-1(XVIII) chain,1.24825255735941,1.16851858840942,1.33342718071368,4.57216623065756e-11
primary,Circulatory system disorders,I42 (cardiomyopathy),0.673123960473534,COL18A1;Collagen alpha-1(XVIII) chain,1.3245118276634,1.19143519440872,1.47245237496184,1.96949548611698e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.780929696804045,COL18A1;Collagen alpha-1(XVIII) chain,1.56049933962782,1.41519522029607,1.72072245161302,4.50650251743494e-19
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35952848722986,COL18A1;Collagen alpha-1(XVIII) chain,1.26256929761199,1.17165685965936,1.36053590958012,9.66393785948842e-10
primary,Circulatory system disorders,I50 (heart failure),4.437444630377,COL18A1;Collagen alpha-1(XVIII) chain,1.48266551866654,1.42172260831899,1.54622077990442,1.54858813301796e-75
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21347199618941,COL18A1;Collagen alpha-1(XVIII) chain,1.30044292020254,1.24576746478006,1.35751802524678,4.14182487240344e-33
primary,Circulatory system disorders,I63 (cerebral infarction),2.06734534064213,COL18A1;Collagen alpha-1(XVIII) chain,1.27023923444238,1.19565921910502,1.34947122636207,9.30964731448586e-15
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.625073250771574,COL18A1;Collagen alpha-1(XVIII) chain,1.32687953264032,1.18912865218016,1.48058773195977,4.25027218695284e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73672258872814,COL18A1;Collagen alpha-1(XVIII) chain,1.2462630503188,1.18238530482461,1.31359175748579,2.38999391470524e-16
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771514512285636,COL18A1;Collagen alpha-1(XVIII) chain,1.51789353134367,1.37572041971941,1.67475944928176,9.02533879997291e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.808972956073159,COL18A1;Collagen alpha-1(XVIII) chain,1.73703042114808,1.57798091199047,1.91211101545449,1.8502719135769e-29
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07863060809754,COL18A1;Collagen alpha-1(XVIII) chain,1.32793018204587,1.22159011457891,1.44352720879395,2.74042462228949e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15657954612903,COL18A1;Collagen alpha-1(XVIII) chain,1.4354751551441,1.3522004311651,1.52387831976988,2.01425209547572e-32
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.410268432774586,COL18A1;Collagen alpha-1(XVIII) chain,1.64424937137274,1.43730689415588,1.88098728688519,4.29760236375632e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705960575719649,COL18A1;Collagen alpha-1(XVIII) chain,1.56572333523131,1.41244978991289,1.73562952821073,1.46768911504327e-17
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0468228729734475,COL18A1;Collagen alpha-1(XVIII) chain,3.09387466501501,2.12310666749603,4.50851602953655,4.13217854776898e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.220543747682338,COL18A1;Collagen alpha-1(XVIII) chain,1.62115376137028,1.34976833842827,1.94710413867413,2.35721240050942e-07
primary,Circulatory system disorders,I95 (hypotension),4.81970234710484,COL18A1;Collagen alpha-1(XVIII) chain,1.31820687968859,1.26658532479473,1.37193234726601,7.42372686612627e-42
primary,Circulatory system disorders,I70 (atherosclerosis),0.762471523548282,HEG1;Protein HEG homolog 1,1.35980426544693,1.21919294583421,1.51663249582081,3.41487437312189e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.211303580550782,HEG1;Protein HEG homolog 1,2.73871574896234,2.22793876122403,3.36659341098476,1.10589261005478e-21
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109096817622617,HEG1;Protein HEG homolog 1,4.29289612524313,3.23334577097488,5.69965554181079,7.15363834964493e-24
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249490129299249,LAYN;Layilin,1.71488812287006,1.44225287790631,2.03906077707396,1.02526805472953e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12382367508667,LAYN;Layilin,1.30056122353832,1.22497524268799,1.38081116844443,7.80703665655897e-18
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53554427165979,LAYN;Layilin,5.38532549767829,4.78352023502051,6.06284269555716,1.15751917182576e-170
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0672428455590056,LAYN;Layilin,3.55758414038398,2.6227429921937,4.82563672978327,3.37868135688667e-16
primary,Circulatory system disorders,I15 (secondary hypertension),0.0573768870071028,LAYN;Layilin,4.12826065851535,2.9737424364748,5.7310061071895,2.4225862330143e-17
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96997521634908,LAYN;Layilin,1.23244400737533,1.17058497932543,1.29757194748105,1.7959621882468e-15
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01818469949685,LAYN;Layilin,1.33791907221595,1.22799342528605,1.45768487594486,2.8293906060542e-11
primary,Circulatory system disorders,I26 (pulmonary embolism),2.005994005994,LAYN;Layilin,1.21710954581065,1.14375029934753,1.29517399676176,5.84539555730527e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33981738785232,LAYN;Layilin,1.72047526986682,1.59641281177827,1.85417902711898,7.97210189361986e-46
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61091444254405,LAYN;Layilin,1.36545937679001,1.27434254571622,1.46309115702943,9.5520296467655e-19
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71109831867717,LAYN;Layilin,1.24000114972791,1.16005931610365,1.32545192300249,2.50613190446923e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.781837615296306,LAYN;Layilin,1.6114891671426,1.46320975557333,1.77479498474258,3.36776709893063e-22
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37431035512976,LAYN;Layilin,1.2316267358377,1.14299133140594,1.32713553878345,4.57139882389574e-08
primary,Circulatory system disorders,I50 (heart failure),4.41264519219255,LAYN;Layilin,1.48576925630612,1.42462352228193,1.54953940353905,3.91420302098791e-76
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19533985271037,LAYN;Layilin,1.33722014558538,1.28089305942691,1.39602420717263,5.54706321122123e-40
primary,Circulatory system disorders,I63 (cerebral infarction),2.07233316130056,LAYN;Layilin,1.21374164478641,1.14222048935035,1.28974116120671,4.07226179872859e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72716446349886,LAYN;Layilin,1.20889307269217,1.14638456495429,1.2748099598335,2.50134920513598e-12
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.768316831683168,LAYN;Layilin,1.44844316155572,1.31251276474565,1.59845119118829,1.72420260119428e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.796370768042156,LAYN;Layilin,1.59904237606732,1.45223011966516,1.76069652173897,1.25748648936422e-21
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12428789216079,LAYN;Layilin,1.40520478317288,1.32283475561371,1.49270381222775,2.51272339064769e-28
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402091668977538,LAYN;Layilin,1.67897210407871,1.46831219577141,1.91985555550978,3.58075471316547e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701823949246629,LAYN;Layilin,1.52497717816143,1.37554374604649,1.69064444558539,1.06086403684183e-15
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0474711711533516,LAYN;Layilin,3.48731088412784,2.43136487192039,5.00185609449518,1.13767755279851e-11
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.09239185906464,LAYN;Layilin,1.20716476898019,1.13514361681826,1.28375542783878,1.9891337277599e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.215683558580841,LAYN;Layilin,1.73982439733622,1.44961561947614,2.0881321178508,2.71695032148494e-09
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.536931367887145,LAYN;Layilin,1.42174300511925,1.26170139062451,1.60208523793811,7.68979571680092e-09
primary,Circulatory system disorders,I95 (hypotension),4.82306163021868,LAYN;Layilin,1.32780824398241,1.27558173016055,1.38217308315145,1.29679910621929e-43
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100884220521037,LAYN;Layilin,2.06289690502609,1.58762659617978,2.68044365785134,5.97381906958138e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535644721464744,RGMB;RGM domain family member B,4.4180619428566,3.88606747639754,5.02288533317301,4.95335211640206e-114
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066025827750267,RGMB;RGM domain family member B,2.91940133528403,2.05905814647063,4.13922461153757,1.80373865723629e-09
primary,Circulatory system disorders,I15 (secondary hypertension),0.0543953375424963,RGMB;RGM domain family member B,3.46688922070367,2.35040490827391,5.11372352326222,3.62369975393686e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97404202719406,CFH;Complement factor H,1.20668394087819,1.14088996434804,1.27627218984733,5.11211608466327e-11
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250960708964002,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.66686508479145,1.40597256980741,1.97616886030529,4.02094891947343e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519251494072695,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.36546639310661,1.21154874726566,1.53893805338957,3.3107782316811e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14427245796794,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.24256086061317,1.17113932069446,1.31833801926504,6.45930949188499e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,3.78004408491791,3.39142292222751,4.21319711861177,1.57370404619761e-127
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066585719321609,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,3.0349951189258,2.22120596258287,4.14693438027352,3.15362523460903e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0548557098916599,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,3.02072786098322,2.13724932356052,4.26941148584337,3.78519839227397e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97159182359568,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.27579279095389,1.21228487170863,1.34262769703284,8.82198995455526e-21
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01214177830956,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.34509484230687,1.23458034760421,1.4655021346416,1.2225746998338e-11
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.7253645737995,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.20083219665683,1.16518144910495,1.23757374066962,1.15539545639364e-32
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00589503669561,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.20540269246321,1.13345741287635,1.28191463966018,2.68709871136205e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.56269155805605,1.4511775133322,1.68277476958164,3.14664973162036e-32
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.749578117028374,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.28687609870362,1.16455111061643,1.42205016020126,7.45124139391443e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60299330445057,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.22859722235745,1.14705908958331,1.31593145330708,4.20709472335644e-09
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72606994711699,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.27932920631213,1.19774303797938,1.36647274601098,2.35818311853575e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.61360389827022,1.46461811533516,1.77774500619025,3.65661289087174e-22
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37675299315568,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.20604098657943,1.11990178891997,1.29880573073485,7.22809154036076e-07
primary,Circulatory system disorders,I50 (heart failure),4.43289393071009,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.43106043527412,1.37293978753867,1.49164150386986,2.1674755865708e-64
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22577303155881,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.25389012349477,1.20148792028376,1.3085778185988,2.82658838038157e-25
primary,Circulatory system disorders,I63 (cerebral infarction),2.08153156694708,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.28422738145515,1.20934017171368,1.36375190856524,3.33778724397366e-16
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.7818561623396,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.28042949281269,1.15990547359537,1.41347698013925,9.5369692389432e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7258077195189,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.265236617078,1.20047376985665,1.33349327356492,1.69871817491574e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772533871884865,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.58910855177882,1.44155981057385,1.75175942809568,1.21017691786373e-20
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.74329167861849,1.5851584341164,1.91720008002514,2.21027591131904e-30
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08680725846002,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.32416304116276,1.21880120155482,1.43863310714216,3.19416614171214e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13543632426848,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.47664464978488,1.39120509824911,1.56733139095202,1.31114494133018e-37
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406001765225066,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.77092875272853,1.54985017491063,2.02354311275377,4.45844435654858e-17
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702842783100361,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.62855628457482,1.47022992836079,1.80393251481771,9.10305482362877e-21
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0470072077718583,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,3.12623718498219,2.15804991948332,4.52879187294487,1.66284389851184e-09
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.666298164861,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.20482225507146,1.12554823831379,1.2896796573465,8.06040205101885e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,2.39645375999415,2.0101961629262,2.85693044773805,1.91299189466814e-22
primary,Circulatory system disorders,I87 (other disorders of veins),0.466666666666666,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.37123173141377,1.20875054435845,1.55555376583841,9.28639350729386e-07
primary,Circulatory system disorders,I95 (hypotension),4.81299212598425,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.39727223610792,1.34298953226986,1.45374900912162,1.68581455372177e-61
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,3.26455657270655,2.54697629079679,4.18430656575431,9.43997356582452e-21
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13307047806801,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.20349271086287,1.13449667320845,1.27668484122028,7.78872931908646e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",2.46670726761126,2.2139219035317,2.74835563728777,3.26888347134892e-60
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.44968388727697,1.3474312861361,1.55969613786909,2.51277920054319e-23
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60473307214373,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.21469824190761,1.13466283973084,1.3003790793426,2.23464397131215e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.35497607220576,1.22967436888654,1.49304580359156,8.46130370818462e-10
primary,Circulatory system disorders,I50 (heart failure),4.39523336643495,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.27180708203077,1.22047116758762,1.32530230689574,2.71161730223962e-30
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20671151689892,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.21565711891532,1.16517756654335,1.26832362139761,1.80108082532756e-19
primary,Circulatory system disorders,I63 (cerebral infarction),2.07802469135802,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.20148179683123,1.13159297002703,1.27568705917493,1.93566028271411e-09
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774430015567422,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.29925198989045,1.17861445200151,1.43223742960869,1.39980780009266e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.50849787639921,1.37200105160758,1.65857441613083,1.96698103742342e-17
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15586074736505,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.26178149641357,1.18948158768443,1.33847598918367,1.13193066654931e-14
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.52642085468415,1.33652006188839,1.74330389199144,4.39785760040178e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.40946383617914,1.27321002748392,1.56029897865528,3.68019442832555e-11
primary,Circulatory system disorders,I95 (hypotension),4.82266136529978,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.22864608016922,1.18122065598894,1.27797561163654,1.15394198110005e-24
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.247975512418148,CCL15;C-C motif chemokine 15,1.63058897711717,1.37485950303337,1.93388517621605,1.9361240432919e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13615569512289,CCL15;C-C motif chemokine 15,1.26924191702443,1.1964453017448,1.3464677754867,2.54225638220287e-15
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,CCL15;C-C motif chemokine 15,3.19234846570465,2.84377650472426,3.58364615136132,3.44781293653778e-86
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0657932929543123,CCL15;C-C motif chemokine 15,2.48609962563168,1.78507617917745,3.46242441676299,7.10401858667141e-08
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0136641147398,CCL15;C-C motif chemokine 15,1.27864065782915,1.17321560866207,1.39353919244069,2.16097775167434e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35161378024624,CCL15;C-C motif chemokine 15,1.40512323694261,1.30479729313277,1.51316324871866,2.27474432859977e-19
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60521451503064,CCL15;C-C motif chemokine 15,1.28953781332514,1.20470019853242,1.38034987793739,2.4158252787106e-13
primary,Circulatory system disorders,I45 (other conduction disorders),1.75584959838578,CCL15;C-C motif chemokine 15,1.20530133010797,1.12873779770753,1.287058251536,2.45407984810721e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.782415028565895,CCL15;C-C motif chemokine 15,1.38773767574887,1.25844630020145,1.53031230365935,5.13457251638633e-11
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3583567196757,CCL15;C-C motif chemokine 15,1.23238052547685,1.14406923350129,1.32750861145581,3.63611158719958e-08
primary,Circulatory system disorders,I50 (heart failure),4.42925495557074,CCL15;C-C motif chemokine 15,1.34166901096389,1.28726413754915,1.39837324949331,5.05508114653891e-44
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21309603496476,CCL15;C-C motif chemokine 15,1.22494172971523,1.17390145317011,1.27820119580371,9.32115901264668e-21
primary,Circulatory system disorders,I63 (cerebral infarction),2.0683226194869,CCL15;C-C motif chemokine 15,1.22388775508841,1.1523796944238,1.29983307090838,4.79028301099159e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771153436282963,CCL15;C-C motif chemokine 15,1.39977740841462,1.26895640572273,1.54408519021739,1.84204262369258e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.804481836157096,CCL15;C-C motif chemokine 15,1.50018628641232,1.36259323793663,1.65167331767154,1.41525216593277e-16
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16089968793546,CCL15;C-C motif chemokine 15,1.38058966133111,1.30135133747979,1.46465274832359,1.0830908035087e-26
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406976744186046,CCL15;C-C motif chemokine 15,1.56212304033348,1.36450297355239,1.78836429120249,1.02262002054415e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704198029021494,CCL15;C-C motif chemokine 15,1.39026555894039,1.25448865738467,1.54073798355847,3.29728036428833e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.218776015953224,CCL15;C-C motif chemokine 15,1.83285404522459,1.52641025146568,2.20081983062578,8.54944006206511e-11
primary,Circulatory system disorders,I95 (hypotension),4.80432583832568,CCL15;C-C motif chemokine 15,1.275199799422,1.22575018544069,1.32664432586748,2.00140897358252e-33
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104513431911434,CCL15;C-C motif chemokine 15,1.95086961394265,1.49693182156199,2.54246198509794,7.60344194586954e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53489968107868,NEFL;Neurofilament light polypeptide,2.7049179630423,2.46166980417129,2.97220251651582,3.69316636352793e-95
primary,Circulatory system disorders,I15 (secondary hypertension),0.0563709206579291,NEFL;Neurofilament light polypeptide,2.71323042235967,2.04332391525747,3.60276668317192,5.23394923754394e-12
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02596146093687,NEFL;Neurofilament light polypeptide,1.24149655450003,1.14128173834798,1.35051113414513,4.71930881410864e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33303710286602,NEFL;Neurofilament light polypeptide,1.25592543913926,1.16588913884545,1.35291483222766,1.92633526156328e-09
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60069613080783,NEFL;Neurofilament light polypeptide,1.25789598872247,1.17516604415488,1.34644999854637,3.83938443997937e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.78147029204431,NEFL;Neurofilament light polypeptide,1.45331114888971,1.32360333824502,1.59572980398162,4.58827858922135e-15
primary,Circulatory system disorders,I50 (heart failure),4.43311739739658,NEFL;Neurofilament light polypeptide,1.26171930147416,1.21111496267354,1.31443805483027,8.84476460836648e-29
primary,Circulatory system disorders,I63 (cerebral infarction),2.06435453572222,NEFL;Neurofilament light polypeptide,1.25149291440194,1.17879669248566,1.32867230183319,2.02041675674027e-13
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.70816083365308,NEFL;Neurofilament light polypeptide,1.3549278013754,1.28689418480136,1.42655811846981,6.86670156151567e-31
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769680240172472,NEFL;Neurofilament light polypeptide,1.54422788039554,1.40592073816952,1.69614095720335,1.12245193289071e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.804386831441646,NEFL;Neurofilament light polypeptide,1.57695391809534,1.43970658608655,1.72728504809852,1.07704339751559e-22
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14112220113077,NEFL;Neurofilament light polypeptide,1.34609267337104,1.26964820268396,1.42713980256326,2.2074148191843e-23
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407151351460302,NEFL;Neurofilament light polypeptide,1.40220112990276,1.23066003946942,1.59765324755997,3.82797252186451e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.69396812588259,NEFL;Neurofilament light polypeptide,1.43033936677654,1.29373270114134,1.58137048120206,2.78085724684427e-12
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.046291637315085,NEFL;Neurofilament light polypeptide,2.60167683733279,1.89551193798594,3.57092046231374,3.25910905304562e-09
primary,Circulatory system disorders,I95 (hypotension),4.79668217681569,NEFL;Neurofilament light polypeptide,1.27852225046234,1.22916887959336,1.32985724912598,2.07136286132491e-34
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.251899006072914,IL10RB;Interleukin-10 receptor subunit beta,1.56749834965834,1.31978387459244,1.86170715030169,3.03094757738709e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.541915289054093,IL10RB;Interleukin-10 receptor subunit beta,3.64590537769316,3.27141053538814,4.06327053095303,5.03117097069513e-121
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.064365125804564,IL10RB;Interleukin-10 receptor subunit beta,2.45904240643727,1.76851628429011,3.41918794323348,8.79623390313949e-08
primary,Circulatory system disorders,I15 (secondary hypertension),0.0565853658536585,IL10RB;Interleukin-10 receptor subunit beta,2.60308367051183,1.83275587898753,3.69718884733774,9.0903381967454e-08
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01000234429944,IL10RB;Interleukin-10 receptor subunit beta,1.27288984584382,1.16763052205043,1.38763806619842,4.27489888300273e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35066358689269,IL10RB;Interleukin-10 receptor subunit beta,1.35482116829669,1.25705938061057,1.46018591196007,1.91160025128275e-15
primary,Circulatory system disorders,I46 (cardiac arrest),0.776903706884772,IL10RB;Interleukin-10 receptor subunit beta,1.45519223250495,1.31914578008924,1.60526945960399,6.84133281309538e-14
primary,Circulatory system disorders,I50 (heart failure),4.4187694366807,IL10RB;Interleukin-10 receptor subunit beta,1.27835707172555,1.22602266173387,1.33292544570066,1.11228735368655e-30
primary,Circulatory system disorders,I63 (cerebral infarction),2.07109858272649,IL10RB;Interleukin-10 receptor subunit beta,1.22139713121526,1.14969607949379,1.2975698349756,9.21430339228294e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77920556184822,IL10RB;Interleukin-10 receptor subunit beta,1.3660425765858,1.23819252232652,1.50709383831432,4.92724075889e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.808909730363423,IL10RB;Interleukin-10 receptor subunit beta,1.5942547311033,1.44801579921215,1.75526271814723,2.07306537087035e-21
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08631940916728,IL10RB;Interleukin-10 receptor subunit beta,1.22687400122794,1.12884179681124,1.3334196334163,1.49227036188041e-06
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15034619188921,IL10RB;Interleukin-10 receptor subunit beta,1.27498694780894,1.20092912605515,1.35361170098601,1.76367051812487e-15
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40436005625879,IL10RB;Interleukin-10 receptor subunit beta,1.52799414050343,1.33390011613809,1.75033052712556,9.55685505056384e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699984357891443,IL10RB;Interleukin-10 receptor subunit beta,1.52611098534321,1.37604402014267,1.69254377439448,1.20179655174014e-15
primary,Circulatory system disorders,I85 (oesophageal varices),0.222469410456062,IL10RB;Interleukin-10 receptor subunit beta,2.29112361260682,1.91638284314437,2.73914339560233,9.2180806335616e-20
primary,Circulatory system disorders,I95 (hypotension),4.82511175594071,IL10RB;Interleukin-10 receptor subunit beta,1.27332664154111,1.2235878562909,1.32508730592771,1.4043497631653e-32
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105347353635459,IL10RB;Interleukin-10 receptor subunit beta,2.81997970443353,2.18804154553819,3.63443077652396,1.16065071762786e-15
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0975952529668957,IL10RB;Interleukin-10 receptor subunit beta,1.95528068623888,1.48827712495652,2.56882437945855,1.46826999343693e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.765004994097884,LGALS3BP;Galectin-3-binding protein,1.34175693287885,1.20703768022142,1.4915123996777,5.16665565597003e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.210870008842935,LGALS3BP;Galectin-3-binding protein,2.61369577781842,2.15716249538068,3.16684794660324,1.02896237863705e-22
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.108799129606963,LGALS3BP;Galectin-3-binding protein,3.43355225650426,2.64761646413686,4.45279037120237,1.38419502785612e-20
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544600200538702,MEPE;Matrix extracellular phosphoglycoprotein,2.72565253116765,2.41130690754179,3.08097724824017,6.94321011739763e-58
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0646830530401035,MEPE;Matrix extracellular phosphoglycoprotein,2.50893757248037,1.76292168764493,3.5706451322933,3.23906829232468e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.252219331519472,IGFBP4;Insulin-like growth factor-binding protein 4,1.82802743830214,1.54423918800451,2.16396808288724,2.41429659115081e-12
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516057322059465,IGFBP4;Insulin-like growth factor-binding protein 4,1.57235421176185,1.39469904923652,1.77263888478207,1.37877860821249e-13
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14825119236883,IGFBP4;Insulin-like growth factor-binding protein 4,1.34078422383195,1.2631793765924,1.4231568122385,5.41475464783783e-22
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.200428639466582,IGFBP4;Insulin-like growth factor-binding protein 4,1.87311746399149,1.5514936508285,2.26141372350209,6.59546257585608e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.533237828050697,IGFBP4;Insulin-like growth factor-binding protein 4,4.86451995166236,4.38173336301138,5.40050076069853,2.23112471148563e-193
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0674482731258307,IGFBP4;Insulin-like growth factor-binding protein 4,3.45384617931121,2.58012055184759,4.62344808726105,8.1102952148984e-17
primary,Circulatory system disorders,I15 (secondary hypertension),0.055566580670768,IGFBP4;Insulin-like growth factor-binding protein 4,3.22749186622228,2.32159285628105,4.48687792881023,3.15431875343535e-12
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97528071569766,IGFBP4;Insulin-like growth factor-binding protein 4,1.35172310912329,1.28364011110887,1.42341716180834,2.96856396031863e-30
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.101286939942802,IGFBP4;Insulin-like growth factor-binding protein 4,2.19972823237937,1.69640224638923,2.85239205891539,2.7353988165645e-09
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01531919966619,IGFBP4;Insulin-like growth factor-binding protein 4,1.44054456979663,1.32175262791919,1.5700128857224,9.34044316825458e-17
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.74008447512104,IGFBP4;Insulin-like growth factor-binding protein 4,1.28572551243374,1.24702676315224,1.32562519279403,1.90516226576962e-58
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99979961927662,IGFBP4;Insulin-like growth factor-binding protein 4,1.26325682162726,1.18715173184984,1.34424080307003,1.68862046579099e-13
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34387194393565,IGFBP4;Insulin-like growth factor-binding protein 4,1.85226138980903,1.72045491372289,1.99416574582197,3.32849935556797e-60
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.751356616112425,IGFBP4;Insulin-like growth factor-binding protein 4,1.31729613247495,1.19128518810922,1.45663617574868,7.79429471422378e-08
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60183522840614,IGFBP4;Insulin-like growth factor-binding protein 4,1.43726347952964,1.34139525622619,1.53998331215309,7.10618872640303e-25
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.7166185402768,IGFBP4;Insulin-like growth factor-binding protein 4,1.31756506688631,1.23257258840131,1.40841823176575,5.227334120014e-16
primary,Circulatory system disorders,I42 (cardiomyopathy),0.670553355751437,IGFBP4;Insulin-like growth factor-binding protein 4,1.45515315811389,1.30874940374593,1.61793442465622,4.11045776509421e-12
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.82789660254112,IGFBP4;Insulin-like growth factor-binding protein 4,1.26898992744552,1.20455353848589,1.33687327670164,3.25854708694411e-19
primary,Circulatory system disorders,I45 (other conduction disorders),1.75435106911984,IGFBP4;Insulin-like growth factor-binding protein 4,1.2631072764569,1.18238969158837,1.34933516689841,4.13684897023272e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.778287370699068,IGFBP4;Insulin-like growth factor-binding protein 4,1.71657148708361,1.55805124381083,1.89121999804147,8.30059828449408e-28
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36463536463536,IGFBP4;Insulin-like growth factor-binding protein 4,1.23653705592316,1.1470681942145,1.33298429717004,3.01440178176155e-08
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.39727138194571,IGFBP4;Insulin-like growth factor-binding protein 4,1.25710266419681,1.21652789158824,1.29903072445594,1.55828583727307e-42
primary,Circulatory system disorders,I50 (heart failure),4.42189126431259,IGFBP4;Insulin-like growth factor-binding protein 4,1.59892611985478,1.5332073582291,1.66746182310707,1.77970937834488e-106
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21207717768628,IGFBP4;Insulin-like growth factor-binding protein 4,1.3930187824727,1.33420116196914,1.45442934966249,2.98836232421512e-51
primary,Circulatory system disorders,I63 (cerebral infarction),2.08868446727594,IGFBP4;Insulin-like growth factor-binding protein 4,1.39512120817576,1.31336827127587,1.48196300159664,3.16806363404147e-27
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.785957558291852,IGFBP4;Insulin-like growth factor-binding protein 4,1.39986546946151,1.26754173486528,1.54600300620395,3.14656412913262e-11
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.627706487624647,IGFBP4;Insulin-like growth factor-binding protein 4,1.41919724046547,1.27200807328995,1.58341825782241,3.68847741817284e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72535435578913,IGFBP4;Insulin-like growth factor-binding protein 4,1.35257687900037,1.28278073075834,1.42617063831702,5.56285223844646e-29
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.768650194645268,IGFBP4;Insulin-like growth factor-binding protein 4,1.70732558407803,1.54857333369474,1.8823523475589,6.40270137204144e-27
primary,Circulatory system disorders,I70 (atherosclerosis),0.80483297231772,IGFBP4;Insulin-like growth factor-binding protein 4,1.91991628022578,1.74642175208893,2.11064625063619,1.60271149544471e-41
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08896528426365,IGFBP4;Insulin-like growth factor-binding protein 4,1.42428975140159,1.31053126171169,1.54792285786304,8.25658817269601e-17
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12890114091393,IGFBP4;Insulin-like growth factor-binding protein 4,1.5646999485094,1.47354998726943,1.66148820875913,2.10569727205762e-48
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405300697355611,IGFBP4;Insulin-like growth factor-binding protein 4,2.12396774070178,1.86365329619715,2.42064281631522,1.43532183402405e-29
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698021278711345,IGFBP4;Insulin-like growth factor-binding protein 4,1.77981535236688,1.60671168830433,1.97156883315137,2.36503364263959e-28
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0456322044322758,IGFBP4;Insulin-like growth factor-binding protein 4,3.63495442910578,2.56013541280594,5.1610136071647,5.34807304770977e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.220308034296602,IGFBP4;Insulin-like growth factor-binding protein 4,1.63232003243406,1.3599059663958,1.95930362401987,1.44139247838466e-07
primary,Circulatory system disorders,I87 (other disorders of veins),0.464746772591857,IGFBP4;Insulin-like growth factor-binding protein 4,1.39720974095054,1.23013987259227,1.58696998910637,2.63620829645682e-07
primary,Circulatory system disorders,I95 (hypotension),4.80577490627741,IGFBP4;Insulin-like growth factor-binding protein 4,1.43388291616746,1.37739222551771,1.49269044734452,3.94315823961526e-69
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0952891429932702,IGFBP4;Insulin-like growth factor-binding protein 4,1.9517809216273,1.48645362219994,2.56277673863136,1.48969660354217e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,2.87665720513782,2.57531448479331,3.21326064243199,3.7337939866091e-78
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0629760100761616,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,2.54154920050905,1.82869170682629,3.53229159102967,2.79321369774241e-08
primary,Circulatory system disorders,I15 (secondary hypertension),0.0570944815230445,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,2.87328071305265,2.0532241318308,4.02086743868479,7.46459045843587e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,1.30801546888792,1.21139673220495,1.41234033522275,6.97721947066958e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,1.39742848826083,1.26371098818497,1.54529508571237,6.99303424796793e-11
primary,Circulatory system disorders,I50 (heart failure),4.39523336643495,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,1.20322237377315,1.15271054325654,1.25594763509167,2.79686810744815e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,1.41579533884011,1.2815389305338,1.56411669885554,7.92217352856062e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15586074736505,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,1.2022967383436,1.1309360979537,1.27816014507553,3.60550641499095e-09
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,1.44985756613915,1.26157075274418,1.66624579518703,1.6608260896659e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,1.338753363359,1.20381021367266,1.48882319451096,7.3757269568313e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,VMO1;Vitelline membrane outer layer protein 1 homolog,2.17884676721263,1.93467106710904,2.45383999156346,9.50482385530467e-38
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0131672317275,VMO1;Vitelline membrane outer layer protein 1 homolog,1.25572742238571,1.15137007102167,1.36954346740336,2.68828492664575e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,VMO1;Vitelline membrane outer layer protein 1 homolog,1.23491180179388,1.14545462510825,1.33135536299894,3.80856938723484e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,VMO1;Vitelline membrane outer layer protein 1 homolog,1.37817331479531,1.24940267727149,1.5202157960489,1.46519990581356e-10
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,VMO1;Vitelline membrane outer layer protein 1 homolog,1.45272991063796,1.26623721929563,1.66668943315073,9.97057344909963e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,VMO1;Vitelline membrane outer layer protein 1 homolog,1.3241181163514,1.1928560128038,1.4698243268514,1.35818069687181e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,NOMO1;Nodal modulator 1,1.45934083264008,1.2943714817664,1.6453357446537,6.58636560039816e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,NOMO1;Nodal modulator 1,1.33084774943565,1.20724767667943,1.46710220809831,9.07752769258846e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,NOMO1;Nodal modulator 1,2.08660549490183,1.73748511887357,2.50587613330307,3.44968305514482e-15
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,NOMO1;Nodal modulator 1,3.06004631759801,2.36002791808491,3.96770029459805,3.20099474388284e-17
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.32879663371519,"NOS3;Nitric oxide synthase, endothelial",1.3776123654629,1.27614108288343,1.48715205154919,2.27981727644631e-16
primary,Circulatory system disorders,I46 (cardiac arrest),0.780999036299389,"NOS3;Nitric oxide synthase, endothelial",1.39735519737962,1.26248602998293,1.54663220128482,1.0411106869402e-10
primary,Circulatory system disorders,I50 (heart failure),4.42914979757085,"NOS3;Nitric oxide synthase, endothelial",1.22075662795008,1.16959055401557,1.27416106394461,6.79783397294636e-20
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771270185586888,"NOS3;Nitric oxide synthase, endothelial",1.34083341893356,1.21160327892777,1.48384730265841,1.41131087057177e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.803842366511927,"NOS3;Nitric oxide synthase, endothelial",1.44011263250611,1.3042822137518,1.59008868819729,5.36877446155094e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1445430129405,"NOS3;Nitric oxide synthase, endothelial",1.21076857293271,1.13876292524132,1.28732724319318,9.72936850044553e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.695799062883343,"NOS3;Nitric oxide synthase, endothelial",1.48749802083973,1.33819122257902,1.65346351453255,1.86841140736591e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.212736066791097,"NOS3;Nitric oxide synthase, endothelial",1.92981493743723,1.59854752340323,2.32973098280321,7.81452826970834e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102327447833065,"NOS3;Nitric oxide synthase, endothelial",2.15621815819742,1.6459096574825,2.8247460148278,2.45690299127461e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,CLMP;CXADR-like membrane protein,4.13803954021586,3.77555373150923,4.53532712128695,1.66256842442386e-202
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0660399347370056,CLMP;CXADR-like membrane protein,2.66533239845521,2.00789977898765,3.5380235949011,1.17143932050789e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544069640914037,CLMP;CXADR-like membrane protein,3.66327233214871,2.75547078482778,4.8701529529463,4.02984743464001e-19
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02719738531574,CLMP;CXADR-like membrane protein,1.26161727313993,1.15536668340294,1.37763894939137,2.25077773176415e-07
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00521906331547,CLMP;CXADR-like membrane protein,1.24140150860907,1.16396048374298,1.32399486675113,4.70954027139266e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,CLMP;CXADR-like membrane protein,1.35926158202965,1.25794611571907,1.46873703515164,8.07545260037628e-15
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60931213624467,CLMP;CXADR-like membrane protein,1.24804740893774,1.16140842597093,1.34114950445106,1.57732989715528e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.777574744372302,CLMP;CXADR-like membrane protein,1.49808087140536,1.35822111263021,1.65234237371309,6.3294337296222e-16
primary,Circulatory system disorders,I50 (heart failure),4.43006958737626,CLMP;CXADR-like membrane protein,1.33798251221638,1.28156907932672,1.39687920992707,4.66965807578571e-40
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22702211331343,CLMP;CXADR-like membrane protein,1.20122874967472,1.14890329985083,1.2559373005826,7.11469652375738e-16
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73646870797357,CLMP;CXADR-like membrane protein,1.20844731259453,1.14370009673499,1.27686000157374,1.59645907044104e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77792255780937,CLMP;CXADR-like membrane protein,1.37787674948316,1.24607720175145,1.52361694291312,4.14174649463121e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,CLMP;CXADR-like membrane protein,1.48467132973089,1.34653583961679,1.63697756307192,2.16709543014711e-15
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15331271301641,CLMP;CXADR-like membrane protein,1.30201224159466,1.22354133732984,1.38551581833917,8.71102090792034e-17
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,CLMP;CXADR-like membrane protein,1.63910807640587,1.43551694654584,1.87157336777086,2.82305116304354e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697054070367413,CLMP;CXADR-like membrane protein,1.4739848575466,1.32641160408385,1.63797674386097,5.67084308357553e-13
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0446792804693267,CLMP;CXADR-like membrane protein,2.6205861705851,1.85912009022309,3.69393667121192,3.79136202760709e-08
primary,Circulatory system disorders,I95 (hypotension),4.82261749028642,CLMP;CXADR-like membrane protein,1.34298304083276,1.28841465976024,1.39986256311305,3.95389058402346e-44
primary,Circulatory system disorders,I70 (atherosclerosis),0.804481836157096,SELE;E-selectin,1.33334823403043,1.20868408556576,1.47087029143758,9.22903543269687e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.218776015953224,SELE;E-selectin,3.22040528447456,2.65792722204632,3.90191654242777,7.23931749438302e-33
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.271549383194972,SELE;E-selectin,1.58700094479674,1.33944438339955,1.88031099312501,9.42098068094959e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104513431911434,SELE;E-selectin,5.80546862122081,4.42428647515186,7.61783083018434,6.90341398468499e-37
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,SERPINB8;Serpin B8,2.131767870724,1.90038141215475,2.3913274596274,3.83094293477343e-38
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,SERPINB8;Serpin B8,1.30609470216104,1.21232078600223,1.40712210061041,2.14188075494203e-12
primary,Circulatory system disorders,I50 (heart failure),4.42893177685223,SERPINB8;Serpin B8,1.20422390125532,1.15549216318909,1.25501085213096,1.17321369357412e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,SERPINB8;Serpin B8,1.30186294793026,1.18228747193195,1.43353217845076,8.03032095006361e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,IL18R1;Interleukin-18 receptor 1,1.39908122001567,1.24435372631354,1.573048096219,1.95480132577602e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,IL18R1;Interleukin-18 receptor 1,1.28441399127519,1.19214424428361,1.38382524505229,4.68263894601548e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.77379567139865,IL18R1;Interleukin-18 receptor 1,1.28102101277007,1.16101445665406,1.41343187051065,8.02472986128245e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,IL18R1;Interleukin-18 receptor 1,1.38627491414526,1.25883761207083,1.52661321775023,3.16811139817116e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15212264150943,IL18R1;Interleukin-18 receptor 1,1.21051887192315,1.14071215908667,1.28459745748249,2.8959004167616e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699300699300699,IL18R1;Interleukin-18 receptor 1,1.3368747473067,1.20561450503645,1.48242583555539,3.66541616431862e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.21132221791392,IL18R1;Interleukin-18 receptor 1,2.87616959833161,2.39197256793334,3.45838061408634,2.82171991541102e-29
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104659275912861,IL18R1;Interleukin-18 receptor 1,4.08045025928255,3.18670110468474,5.22486225457478,7.29184585024909e-29
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539766035958231,SCGB1A1;Uteroglobin,3.03977213636082,2.68447415051333,3.44209484722687,8.32025983611137e-69
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.553067185978578,FAS;Tumor necrosis factor receptor superfamily member 6,2.47224672979192,2.22869825090577,2.74240978583928,1.34788343199586e-65
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97004029201739,FAS;Tumor necrosis factor receptor superfamily member 6,1.20460942664322,1.14465025134516,1.26770938900544,8.92174920594398e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01699529420915,FAS;Tumor necrosis factor receptor superfamily member 6,1.24431726135074,1.14203097150735,1.35576484834891,5.89862462254489e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35406316363707,FAS;Tumor necrosis factor receptor superfamily member 6,1.20570844580347,1.11915115936561,1.29896023795916,8.58295422096991e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.805149847332698,FAS;Tumor necrosis factor receptor superfamily member 6,1.3630842772146,1.23890271307897,1.49971319553581,2.07797302846778e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702608018684313,FAS;Tumor necrosis factor receptor superfamily member 6,1.33661429277649,1.20656318387986,1.48068314326445,2.77105805748757e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.219494192144827,FAS;Tumor necrosis factor receptor superfamily member 6,2.08650851774532,1.75851579412359,2.47567739179362,3.48735649600166e-17
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104856404978737,FAS;Tumor necrosis factor receptor superfamily member 6,2.66054233832797,2.10031263720479,3.37020565826623,5.00512311864545e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550330198118871,"CA5A;Carbonic anhydrase 5A, mitochondrial",1.55677813855238,1.38089310692728,1.75506573283391,4.61909506462798e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.797521487107735,"CA5A;Carbonic anhydrase 5A, mitochondrial",1.3087077524192,1.18296440867332,1.44781699997458,1.78904800815254e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.209597572660491,"CA5A;Carbonic anhydrase 5A, mitochondrial",2.51938807070378,2.08902584012932,3.03840963997439,4.11371718989022e-22
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0997804829375374,"CA5A;Carbonic anhydrase 5A, mitochondrial",3.56970346450478,2.73770450062127,4.65455012460464,5.53300356003188e-21
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.242215884673985,IL18BP;Interleukin-18-binding protein,1.66540320673543,1.40008181305319,1.98100412072083,8.37050817263903e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.549977492024347,IL18BP;Interleukin-18-binding protein,3.21324910758871,2.8752600272072,3.59096907052559,3.72278561503269e-94
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0643877312104893,IL18BP;Interleukin-18-binding protein,2.52509202558736,1.81633085400631,3.51042307276839,3.57899571984428e-08
primary,Circulatory system disorders,I15 (secondary hypertension),0.0566052467207995,IL18BP;Interleukin-18-binding protein,2.99330868488778,2.11353256847441,4.23929917933181,6.63452335109033e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97095202774492,IL18BP;Interleukin-18-binding protein,1.24577575249239,1.18367549447478,1.31113403356095,3.65932284622681e-17
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00644909126441,IL18BP;Interleukin-18-binding protein,1.26304955310516,1.15860472760608,1.37690977396179,1.13967204428456e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34711779448621,IL18BP;Interleukin-18-binding protein,1.43116336229617,1.32844822480113,1.54182039716714,3.9398505568647e-21
primary,Circulatory system disorders,I46 (cardiac arrest),0.78303489484681,IL18BP;Interleukin-18-binding protein,1.43944201710102,1.30575611235956,1.5868149503445,2.4007162375011e-13
primary,Circulatory system disorders,I50 (heart failure),4.4228269859399,IL18BP;Interleukin-18-binding protein,1.32265454209661,1.26879559873831,1.37879973690673,1.0875308732295e-39
primary,Circulatory system disorders,I63 (cerebral infarction),2.07382747478703,IL18BP;Interleukin-18-binding protein,1.21544338591063,1.14425517043843,1.29106047542512,2.35880370409457e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73138448886887,IL18BP;Interleukin-18-binding protein,1.20062023712756,1.13911738501286,1.26544373105495,9.43540944859089e-12
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771665234039227,IL18BP;Interleukin-18-binding protein,1.46726249480237,1.33016115436623,1.61849503842971,1.8572639283659e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.801344695489015,IL18BP;Interleukin-18-binding protein,1.63464302832167,1.48503861637439,1.79931875210374,1.07207388953383e-23
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.09061058556797,IL18BP;Interleukin-18-binding protein,1.24560409088805,1.14632274544685,1.35348404923454,2.19175900311323e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15300589701982,IL18BP;Interleukin-18-binding protein,1.35395044331724,1.27578133762824,1.43690909162141,1.73273608277933e-23
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406432577134259,IL18BP;Interleukin-18-binding protein,1.62100665949374,1.41680491072319,1.85463966862016,2.04187717124294e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702200488997555,IL18BP;Interleukin-18-binding protein,1.50115196007341,1.35451326780725,1.66366565820374,9.49373191504356e-15
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0487842953596378,IL18BP;Interleukin-18-binding protein,2.938255523564,2.0187661998744,4.27654550699902,1.81956329405634e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.218638972396829,IL18BP;Interleukin-18-binding protein,2.93334284527429,2.45689318966799,3.50218734949752,1.18469356850339e-32
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.271845419698036,IL18BP;Interleukin-18-binding protein,1.51643322098078,1.2852690127325,1.78917385458881,8.05532383694728e-07
primary,Circulatory system disorders,I95 (hypotension),4.80514640986918,IL18BP;Interleukin-18-binding protein,1.30934550463818,1.2583868099044,1.36236778470879,2.09459900712158e-40
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103428761001502,IL18BP;Interleukin-18-binding protein,3.97267281048056,3.08808237966221,5.11065681507429,7.08529297844302e-27
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,SLITRK2;SLIT and NTRK-like protein 2,1.56211702189339,1.38863439864462,1.75727289520615,1.11723304806182e-13
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.251899006072914,CSF1;Macrophage colony-stimulating factor 1,1.80887892051088,1.52653034561893,2.14345096935623,7.64100654323108e-12
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12965495682075,CSF1;Macrophage colony-stimulating factor 1,1.23545332321589,1.16416386131605,1.31110831092087,3.11309591503972e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.541915289054093,CSF1;Macrophage colony-stimulating factor 1,3.33580576270275,2.98549510418382,3.72722101298603,1.67090959488357e-100
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.064365125804564,CSF1;Macrophage colony-stimulating factor 1,2.76052218885465,1.99842871790366,3.81323721326059,7.25387727393732e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0565853658536585,CSF1;Macrophage colony-stimulating factor 1,2.49215914966601,1.7593622555939,3.53017532774536,2.7473024996173e-07
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96103375738755,CSF1;Macrophage colony-stimulating factor 1,1.26112471919196,1.19823283534992,1.32731762178135,6.17413888140702e-19
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01000234429944,CSF1;Macrophage colony-stimulating factor 1,1.28184039367437,1.17610913031477,1.3970768124345,1.57530672536621e-08
primary,Circulatory system disorders,I26 (pulmonary embolism),1.98802064861882,CSF1;Macrophage colony-stimulating factor 1,1.22933112269543,1.15571248156282,1.30763925572907,5.63589571546269e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35066358689269,CSF1;Macrophage colony-stimulating factor 1,1.57251412653876,1.46013059445759,1.69354760974827,5.39731388218106e-33
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60619729358697,CSF1;Macrophage colony-stimulating factor 1,1.22316696219393,1.14209039917784,1.30999911957912,8.57044507895299e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.776903706884772,CSF1;Macrophage colony-stimulating factor 1,1.52301789866621,1.38158850234674,1.67892503138065,2.66579036517656e-17
primary,Circulatory system disorders,I50 (heart failure),4.4187694366807,CSF1;Macrophage colony-stimulating factor 1,1.40054448202044,1.34354018253011,1.45996738439488,7.55327550274821e-57
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22057306135407,CSF1;Macrophage colony-stimulating factor 1,1.22096572103115,1.16997602016259,1.27417764658625,4.61881778466493e-20
primary,Circulatory system disorders,I63 (cerebral infarction),2.07109858272649,CSF1;Macrophage colony-stimulating factor 1,1.23455786569613,1.16230389848486,1.31130346008389,7.49295330330572e-12
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.780661779274816,CSF1;Macrophage colony-stimulating factor 1,1.324697486771,1.19988797808616,1.46248938526442,2.55830912108369e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71492326965236,CSF1;Macrophage colony-stimulating factor 1,1.2209600722477,1.15817851834178,1.28714483511356,1.24222519797192e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77920556184822,CSF1;Macrophage colony-stimulating factor 1,1.44927086051524,1.31444765588989,1.59792291288816,9.46730656740596e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.808909730363423,CSF1;Macrophage colony-stimulating factor 1,1.58645469548445,1.44178792866029,1.7456371015419,3.08487904680654e-21
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08631940916728,CSF1;Macrophage colony-stimulating factor 1,1.25560557628926,1.15545789007166,1.36443342224347,7.99975779261949e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15034619188921,CSF1;Macrophage colony-stimulating factor 1,1.37872127703082,1.29894690763883,1.46339496137899,4.52460945141983e-26
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40436005625879,CSF1;Macrophage colony-stimulating factor 1,1.6759492474825,1.46495272884263,1.91733550498672,5.40987141785359e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699984357891443,CSF1;Macrophage colony-stimulating factor 1,1.54910489167502,1.39768309875821,1.71693137560549,7.44854311100367e-17
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0487671660424469,CSF1;Macrophage colony-stimulating factor 1,3.35788337796499,2.33355734951017,4.83184215823122,6.854295334687e-11
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.67744260063654,CSF1;Macrophage colony-stimulating factor 1,1.26390465113865,1.18098716631587,1.35264379896121,1.3338114831304e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.222469410456062,CSF1;Macrophage colony-stimulating factor 1,2.51358239732645,2.10899466184899,2.9957858985808,7.52439128540652e-25
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.539294227988588,CSF1;Macrophage colony-stimulating factor 1,1.344674772338,1.19535152733601,1.51265146863696,8.17728585705295e-07
primary,Circulatory system disorders,I95 (hypotension),4.82511175594071,CSF1;Macrophage colony-stimulating factor 1,1.30801523689534,1.25711318717314,1.36097837283664,4.0247142987222e-40
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105347353635459,CSF1;Macrophage colony-stimulating factor 1,2.95685931444148,2.30048321213473,3.80051328315771,2.5558873514882e-17
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0975952529668957,CSF1;Macrophage colony-stimulating factor 1,1.98107023462624,1.51172251780291,2.59613733889869,7.21456567526588e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,CD83;CD83 antigen,2.93575752795023,2.62342775499884,3.28527143409759,1.44637021852107e-78
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0647388864911523,CD83;CD83 antigen,2.38509629144384,1.7266714449861,3.29459570086591,1.33607551062454e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.0569140793657024,CD83;CD83 antigen,3.19997656121777,2.28380307474011,4.48368342507306,1.39234624725884e-11
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96630662582621,CD83;CD83 antigen,1.30169987850274,1.23697796515686,1.36980821115855,3.93931769520612e-24
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01780170550556,CD83;CD83 antigen,1.32215563455202,1.21410569617272,1.43982153076808,1.36225197720218e-10
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.71982890314696,CD83;CD83 antigen,1.20899389654149,1.17314837882732,1.24593467310218,4.34806763669112e-35
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35063298615896,CD83;CD83 antigen,1.44629878818636,1.34244549084883,1.55818630921595,2.84225426973663e-22
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.752869948105047,CD83;CD83 antigen,1.28287428046054,1.16091527251479,1.41764559260391,1.02127842579963e-06
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61923357592252,CD83;CD83 antigen,1.20373489618682,1.12377627993053,1.28938270559286,1.23988955456447e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.787339734150124,CD83;CD83 antigen,1.49119065461523,1.35450039166477,1.64167510182761,3.76877606677282e-16
primary,Circulatory system disorders,I50 (heart failure),4.40480668342802,CD83;CD83 antigen,1.3627505088353,1.3074126176606,1.42043064618256,1.72515807044628e-48
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20325722497205,CD83;CD83 antigen,1.22008137509952,1.16909201561235,1.27329460982166,6.68873453605277e-20
primary,Circulatory system disorders,I63 (cerebral infarction),2.06544853114909,CD83;CD83 antigen,1.2625591333901,1.1886457377363,1.34106867563631,3.60172918049318e-14
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.616811047596597,CD83;CD83 antigen,1.37566342285525,1.23300117664194,1.53483215493425,1.1331406314889e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71488758514785,CD83;CD83 antigen,1.27681891327794,1.21111890642655,1.34608297224458,1.2284088076937e-19
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781802467195725,CD83;CD83 antigen,1.38983869280601,1.26092733600215,1.53192934824075,3.39679501145722e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.801823755994025,CD83;CD83 antigen,1.76885650097223,1.60875432105934,1.94489194532289,4.81061294826329e-32
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08672155953386,CD83;CD83 antigen,1.34907141446282,1.24317847253841,1.46398423196996,7.02401460285361e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15077296512206,CD83;CD83 antigen,1.41513052569055,1.33308823086538,1.50222195228686,4.43477477514525e-30
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.390978034500373,CD83;CD83 antigen,1.8325179784899,1.60225086955837,2.09587787111909,9.51858112116146e-19
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686372844022262,CD83;CD83 antigen,1.52761340658519,1.37685826210188,1.69487505301845,1.3212543693398e-15
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0470883691728143,CD83;CD83 antigen,2.80085677139236,1.93003702129723,4.0645845480113,5.93457187452567e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.217869199968595,CD83;CD83 antigen,2.09632576052438,1.753614928798,2.50601293480682,4.39778608146505e-16
primary,Circulatory system disorders,I95 (hypotension),4.8255733696188,CD83;CD83 antigen,1.33708140401634,1.28495958447362,1.39131744108409,1.66654754313806e-46
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103994976846401,CD83;CD83 antigen,2.46626296784693,1.9120662838074,3.18108900203055,3.61677090905609e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544600200538702,CRHBP;Corticotropin-releasing factor-binding protein,2.14932862301584,1.91099822102584,2.41738243337313,2.74286673576138e-37
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96983852132243,CRHBP;Corticotropin-releasing factor-binding protein,1.21147097352764,1.15039319345434,1.27579155374954,3.6455328487854e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.783059229893629,CRHBP;Corticotropin-releasing factor-binding protein,1.29021331540332,1.1687544416253,1.42429439406376,4.38886319186419e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.807021677662582,CRHBP;Corticotropin-releasing factor-binding protein,1.4913487051104,1.35301895744555,1.6438209886087,8.45293639120276e-16
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1509223918575,CRHBP;Corticotropin-releasing factor-binding protein,1.2448757799535,1.1721166778318,1.32215140081577,1.01569398731324e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701485498703136,CRHBP;Corticotropin-releasing factor-binding protein,1.44592592208425,1.30252371300052,1.60511609215851,4.52595272728659e-12
primary,Circulatory system disorders,I85 (oesophageal varices),0.20292018472734,KHK;Ketohexokinase,2.1101626752564,1.70968551679993,2.60444770239362,3.53586466949245e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10259040779687,KHK;Ketohexokinase,3.11656118415535,2.32434380007178,4.17879386615864,3.04614495318654e-14
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243020567838302,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.92208249958292,1.62131854284738,2.27863990793245,5.24057025420923e-14
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.515362135692283,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.50373225490251,1.33306144837109,1.69625391027341,3.20227509606267e-11
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14700881736586,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.27531015672256,1.20122873252687,1.35396028399889,1.6563557747208e-15
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.552343997465948,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,4.40937081250874,4.00624575452061,4.85305998521564,4.46991585089014e-202
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.06512600895976,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,3.25341478948063,2.43154954413901,4.35307099455347,2.00848720052472e-15
primary,Circulatory system disorders,I15 (secondary hypertension),0.0572545458135081,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,3.16287983992387,2.30604549238264,4.33807958899404,9.12256273234667e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01207772440649,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.25008771375312,1.14597819712,1.36365534353431,4.87354521855815e-07
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99760765550239,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.21563323553689,1.14221334598316,1.29377245375285,8.08068405519447e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35266274533103,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.622296194019,1.50577884435078,1.74782967034129,4.37613696756616e-37
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61328729610667,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.35986781511283,1.26915559343361,1.45706364463695,2.61724545658145e-18
primary,Circulatory system disorders,I46 (cardiac arrest),0.780169859766936,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.51957166459364,1.37753259048438,1.67625656175869,6.43658528847385e-17
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35366144549574,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.21144550222942,1.12336547663378,1.30643164259386,6.34419142976e-07
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.36922797603437,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.20326613243894,1.16425796864394,1.24358125472907,3.62287918127354e-28
primary,Circulatory system disorders,I50 (heart failure),4.41987849815755,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.34643804937235,1.29062783679185,1.40466164537718,3.76338062540724e-43
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19611307420494,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.27511668090731,1.22102800636152,1.33160135677239,4.2818966978718e-28
primary,Circulatory system disorders,I63 (cerebral infarction),2.08176524184922,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.23521918556345,1.1622791357728,1.31273666490584,1.02805031136993e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77459639970755,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.3589794388331,1.2307748554988,1.50053854847615,1.30254899571079e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.80260946921024,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.46898183083895,1.33275531270192,1.6191326335516,9.56532029215129e-15
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14567362542783,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.2841409222657,1.20876093445649,1.36422170938116,5.37421040993271e-16
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405162361404826,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.51973668638089,1.32627556467845,1.74141758880396,1.69577488059649e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.706301315659313,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.45911906494466,1.31557219270888,1.61832885909599,8.63126201058292e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.221147201105736,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.63509194241819,1.36193837396082,1.96302983400466,1.34771698693049e-07
primary,Circulatory system disorders,I95 (hypotension),4.80866511932393,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.24919629724112,1.1998135002756,1.30061162729247,3.02112198100179e-27
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104614898740673,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.96570940185319,1.51616964521025,2.54853634930686,3.37234412305711e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.541915289054093,BTN2A1;Butyrophilin subfamily 2 member A1,4.38065742061838,3.88880325296588,4.93472109245513,1.5367211636263e-130
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.064365125804564,BTN2A1;Butyrophilin subfamily 2 member A1,2.99258002381882,2.14657512812869,4.17201107084782,1.00673332058354e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0565853658536585,BTN2A1;Butyrophilin subfamily 2 member A1,3.18230549821769,2.22953739615185,4.54222849164391,1.81074774766348e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35066358689269,BTN2A1;Butyrophilin subfamily 2 member A1,1.34840163973355,1.25101375088162,1.4533709008033,5.48737210000755e-15
primary,Circulatory system disorders,I46 (cardiac arrest),0.776903706884772,BTN2A1;Butyrophilin subfamily 2 member A1,1.39991635076713,1.26919666625831,1.54409938289759,1.74173204877977e-11
primary,Circulatory system disorders,I50 (heart failure),4.4187694366807,BTN2A1;Butyrophilin subfamily 2 member A1,1.24999885993438,1.1988645932605,1.303314117892,1.17339162376705e-25
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77920556184822,BTN2A1;Butyrophilin subfamily 2 member A1,1.39091646808114,1.26088197898924,1.5343613862498,4.42928050245657e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.808909730363423,BTN2A1;Butyrophilin subfamily 2 member A1,1.49421890180789,1.3568412066152,1.64550583784943,3.30920186912837e-16
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15034619188921,BTN2A1;Butyrophilin subfamily 2 member A1,1.31304472034994,1.23675131788479,1.39404455261673,4.7790448409983e-19
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40436005625879,BTN2A1;Butyrophilin subfamily 2 member A1,1.51967128673713,1.32673998569979,1.7406581882095,1.52804483911877e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699984357891443,BTN2A1;Butyrophilin subfamily 2 member A1,1.51562813263976,1.36632157727619,1.68125035471408,3.88046302305012e-15
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0487671660424469,BTN2A1;Butyrophilin subfamily 2 member A1,3.0544995086818,2.08811032034783,4.46813904304786,8.72147542060355e-09
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.67744260063654,BTN2A1;Butyrophilin subfamily 2 member A1,1.20542797187503,1.12618988781196,1.29024120275297,7.22153502855609e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.222469410456062,BTN2A1;Butyrophilin subfamily 2 member A1,1.70528142796835,1.42065865453012,2.0469271343267,1.01279832346842e-08
primary,Circulatory system disorders,I95 (hypotension),4.82511175594071,BTN2A1;Butyrophilin subfamily 2 member A1,1.2782850652143,1.22827831455148,1.33032773483965,1.74761760435942e-33
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105347353635459,BTN2A1;Butyrophilin subfamily 2 member A1,2.07724071199137,1.59628976581291,2.70309881574481,5.31181203743643e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513808606294155,CD28;T-cell-specific surface glycoprotein CD28,1.35826200758451,1.20076910095,1.5364116879656,1.11800445037988e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.543270488339805,CD28;T-cell-specific surface glycoprotein CD28,1.76489170734079,1.56825389193019,1.98618524377235,4.26913605212416e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775318362591893,CD28;T-cell-specific surface glycoprotein CD28,1.28174742735708,1.15960097725901,1.41676016125806,1.1863729666949e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.803777755450617,CD28;T-cell-specific surface glycoprotein CD28,1.30995216446835,1.18744959275987,1.44509264532825,7.05914560891376e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.210737581535373,CD28;T-cell-specific surface glycoprotein CD28,2.30073570573251,1.90967955494848,2.77187069103606,1.84685422862265e-18
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102329500993198,CD28;T-cell-specific surface glycoprotein CD28,3.14215994071396,2.4233739235386,4.07414183883384,5.66963630860693e-18
primary,Circulatory system disorders,I85 (oesophageal varices),0.208560736004989,SCLY;Selenocysteine lyase,2.66748771097921,2.21354478647869,3.21452302735851,6.44056341968434e-25
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.265573130247998,SCLY;Selenocysteine lyase,1.55008592611282,1.30031976134762,1.84782731890721,1.01131615037912e-06
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103269553018198,SCLY;Selenocysteine lyase,4.1959844320647,3.26580943874064,5.39109390317601,3.42141317354936e-29
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544600200538702,TREM2;Triggering receptor expressed on myeloid cells 2,1.93525500263232,1.7319772111419,2.16239099517031,2.0251238279197e-31
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96983852132243,TREM2;Triggering receptor expressed on myeloid cells 2,1.27495274384319,1.21279436129341,1.34029688042062,1.64587876023801e-21
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01107271870582,TREM2;Triggering receptor expressed on myeloid cells 2,1.25666369328207,1.1549175541631,1.36737348248005,1.13660804834496e-07
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99184255335999,TREM2;Triggering receptor expressed on myeloid cells 2,1.23958984152182,1.16611863266383,1.31769009787108,5.58885294943406e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35143110061965,TREM2;Triggering receptor expressed on myeloid cells 2,1.39760842980326,1.29907035304003,1.5036208920372,2.85906129941026e-19
primary,Circulatory system disorders,I46 (cardiac arrest),0.780744257214037,TREM2;Triggering receptor expressed on myeloid cells 2,1.39582089851976,1.26927411284663,1.53498441433976,6.09413288271285e-12
primary,Circulatory system disorders,I50 (heart failure),4.42479626552733,TREM2;Triggering receptor expressed on myeloid cells 2,1.30995927036913,1.25784270063515,1.36423520139643,7.76560626531996e-39
primary,Circulatory system disorders,I63 (cerebral infarction),2.07739067141423,TREM2;Triggering receptor expressed on myeloid cells 2,1.22160885074168,1.15114509656278,1.29638582370405,4.0158977292277e-11
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.622190818269249,TREM2;Triggering receptor expressed on myeloid cells 2,1.40018974898782,1.25816032370997,1.55825239138801,6.90477335351394e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71854591234558,TREM2;Triggering receptor expressed on myeloid cells 2,1.20306341933822,1.14192906256763,1.26747066730693,3.71126344133832e-12
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.783059229893629,TREM2;Triggering receptor expressed on myeloid cells 2,1.34695919725888,1.22389790353453,1.48239413911955,1.10732733225791e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.807021677662582,TREM2;Triggering receptor expressed on myeloid cells 2,1.64549604383804,1.50034671230933,1.8046876819019,4.08107510536598e-26
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.0916944826232,TREM2;Triggering receptor expressed on myeloid cells 2,1.2767098534088,1.17817221975402,1.38348878242216,2.50840942739885e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1509223918575,TREM2;Triggering receptor expressed on myeloid cells 2,1.35006001310874,1.27317695992965,1.43158578607634,1.08976447501589e-23
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404397330192383,TREM2;Triggering receptor expressed on myeloid cells 2,1.63297903803399,1.43389959228318,1.85969823341145,1.4332826810625e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701485498703136,TREM2;Triggering receptor expressed on myeloid cells 2,1.51292514516155,1.3684584632134,1.6726430186907,6.16473879989219e-16
primary,Circulatory system disorders,I85 (oesophageal varices),0.22356886509384,TREM2;Triggering receptor expressed on myeloid cells 2,2.32149472271815,1.96033324397389,2.74919469134911,1.64072278059494e-22
primary,Circulatory system disorders,I95 (hypotension),4.83724779319041,TREM2;Triggering receptor expressed on myeloid cells 2,1.25701533402747,1.2086782696456,1.30728547841228,2.85753340005195e-30
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105867822063638,TREM2;Triggering receptor expressed on myeloid cells 2,3.02068266775116,2.38053991194189,3.83296399841036,9.21262028756477e-20
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250960708964002,RELT;Tumor necrosis factor receptor superfamily member 19L,1.94356473609682,1.62703145333685,2.32167846273163,2.35889225950331e-13
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519251494072695,RELT;Tumor necrosis factor receptor superfamily member 19L,1.4431445805792,1.2692474477732,1.64086702250928,2.15113525742314e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14427245796794,RELT;Tumor necrosis factor receptor superfamily member 19L,1.30483543822649,1.22378810550704,1.3912502607192,4.20661979102008e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,RELT;Tumor necrosis factor receptor superfamily member 19L,4.82264779201587,4.29059418518657,5.42067851723998,2.38272144852295e-153
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066585719321609,RELT;Tumor necrosis factor receptor superfamily member 19L,3.77441243909144,2.72676508550673,5.22457520674932,1.17523536029797e-15
primary,Circulatory system disorders,I15 (secondary hypertension),0.0548557098916599,RELT;Tumor necrosis factor receptor superfamily member 19L,3.58843207061487,2.48208245731092,5.18791979996026,1.09294124944859e-11
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97159182359568,RELT;Tumor necrosis factor receptor superfamily member 19L,1.27316533006619,1.20418770308663,1.34609409606796,1.92982292987984e-17
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.101950789138319,RELT;Tumor necrosis factor receptor superfamily member 19L,2.0892487385132,1.56487453709327,2.78933562270546,5.82469264754591e-07
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01214177830956,RELT;Tumor necrosis factor receptor superfamily member 19L,1.33460595381254,1.21576812731079,1.46505983496354,1.31125029615643e-09
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00589503669561,RELT;Tumor necrosis factor receptor superfamily member 19L,1.2469230658492,1.16664279768634,1.33272766542615,8.06740652361732e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,RELT;Tumor necrosis factor receptor superfamily member 19L,1.6881519917501,1.55928634599591,1.82766760869035,3.26382523814432e-38
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60299330445057,RELT;Tumor necrosis factor receptor superfamily member 19L,1.31714509968865,1.22299285262632,1.41854566844628,3.34515338947934e-13
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72606994711699,RELT;Tumor necrosis factor receptor superfamily member 19L,1.23547743242924,1.14996438768187,1.32734935306902,7.55105892200306e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,RELT;Tumor necrosis factor receptor superfamily member 19L,1.59981243275439,1.43989694222999,1.77748819719816,2.233526180367e-18
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37675299315568,RELT;Tumor necrosis factor receptor superfamily member 19L,1.28618106068745,1.18718282615811,1.39343467949627,7.33329347503315e-10
primary,Circulatory system disorders,I50 (heart failure),4.43289393071009,RELT;Tumor necrosis factor receptor superfamily member 19L,1.41732269108041,1.3546857225244,1.48285582201907,1.13692364057166e-51
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22577303155881,RELT;Tumor necrosis factor receptor superfamily member 19L,1.27451286573484,1.21671592984992,1.33505529521915,1.2574208180535e-24
primary,Circulatory system disorders,I63 (cerebral infarction),2.08153156694708,RELT;Tumor necrosis factor receptor superfamily member 19L,1.30985206595304,1.22722301281011,1.3980445418415,4.70894678075537e-16
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772533871884865,RELT;Tumor necrosis factor receptor superfamily member 19L,1.43461233148324,1.29020061345024,1.59518800424377,2.61215207714036e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,RELT;Tumor necrosis factor receptor superfamily member 19L,1.57557673865971,1.42008038053014,1.7480996804412,9.88286345172558e-18
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08680725846002,RELT;Tumor necrosis factor receptor superfamily member 19L,1.26324036870892,1.15341545196294,1.38352249956428,4.76257675984231e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13543632426848,RELT;Tumor necrosis factor receptor superfamily member 19L,1.38168966820005,1.29515730564485,1.47400345185116,1.15103732074769e-22
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406001765225066,RELT;Tumor necrosis factor receptor superfamily member 19L,1.65908526536237,1.43430760421764,1.91908898038922,9.37797138733977e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702842783100361,RELT;Tumor necrosis factor receptor superfamily member 19L,1.67090471367107,1.49661110816546,1.86549635168119,6.624563150952e-20
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,RELT;Tumor necrosis factor receptor superfamily member 19L,1.80525222568151,1.48552156217602,2.19379891972372,2.86442876403332e-09
primary,Circulatory system disorders,I95 (hypotension),4.81299212598425,RELT;Tumor necrosis factor receptor superfamily member 19L,1.28969799534566,1.23528933497715,1.3465031002064,5.95901538321992e-31
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,ISM1;Isthmin-1,1.72210493636348,1.5302465867741,1.93801798839449,1.89478527119913e-19
primary,Circulatory system disorders,I85 (oesophageal varices),0.217869199968595,ISM1;Isthmin-1,1.73677840067321,1.44353232950491,2.08959588323146,4.90443716734446e-09
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103994976846401,ISM1;Isthmin-1,2.26169890490405,1.73925375732667,2.94107856021347,1.13022473986919e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.386548125241592,COL15A1;Collagen alpha-1(XV) chain,3.99430276068524,3.45596610134038,4.6164962491472,1.95808747258974e-78
primary,Circulatory system disorders,I15 (secondary hypertension),0.043122035360069,COL15A1;Collagen alpha-1(XV) chain,3.20119026892125,2.10193326470967,4.87533039696744,5.92376659484429e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37382666545156,COL15A1;Collagen alpha-1(XV) chain,1.30461024842865,1.20183469761288,1.41617470662618,2.13387920541871e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.397450832590968,PBXIP1;Pre-B-cell leukemia transcription factor-interacting protein 1,2.63521011552442,2.27729889134286,3.04937238557534,1.07098735078567e-38
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.402000867956419,HIP1R;Huntingtin-interacting protein 1-related protein,2.51780897211835,2.18453449292438,2.90192809525902,3.26623341739707e-37
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37083485902599,HIP1R;Huntingtin-interacting protein 1-related protein,1.3745073868403,1.26863675591917,1.48921316339262,7.3466850690164e-15
primary,Circulatory system disorders,I50 (heart failure),4.31552069195555,HIP1R;Huntingtin-interacting protein 1-related protein,1.22806442141537,1.17334854614167,1.28533182071558,1.00584435030892e-18
primary,Circulatory system disorders,I63 (cerebral infarction),2.03596101935306,HIP1R;Huntingtin-interacting protein 1-related protein,1.20666162442216,1.12951853628779,1.28907337867905,2.50221487385669e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.771724736289328,HIP1R;Huntingtin-interacting protein 1-related protein,1.46830740388737,1.3200928341704,1.63316289317285,1.4940806199865e-12
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401743933894861,HIP1R;Huntingtin-interacting protein 1-related protein,1.46302864487987,1.261782494747,1.69637225484589,4.66395437311529e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.683147505026503,HIP1R;Huntingtin-interacting protein 1-related protein,1.51614413255637,1.35436814724484,1.69724386634555,4.86806098632332e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.209815727057106,HIP1R;Huntingtin-interacting protein 1-related protein,2.24497607238417,1.84056049457785,2.7382515165487,1.46407730925933e-15
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10715181360144,HIP1R;Huntingtin-interacting protein 1-related protein,3.10636404237115,2.37148929323336,4.06896104961115,1.87423547220252e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.399990697890746,RIDA;2-iminobutanoate/2-iminopropanoate deaminase,1.85571098176708,1.60276749102536,2.14857318178316,1.34501415650257e-16
primary,Circulatory system disorders,I70 (atherosclerosis),0.762471523548282,RIDA;2-iminobutanoate/2-iminopropanoate deaminase,1.34385660418366,1.2052854714253,1.4983591982341,1.02234645287302e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.211303580550782,RIDA;2-iminobutanoate/2-iminopropanoate deaminase,2.17614620639212,1.78605789645244,2.65143270047457,1.21347334741216e-14
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109096817622617,RIDA;2-iminobutanoate/2-iminopropanoate deaminase,3.04903441544802,2.33989940425881,3.97308142805877,1.52973571130119e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,LPL;Lipoprotein lipase,1.68954973125019,1.48053994740527,1.92806570290142,7.02289545088114e-15
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,ELOA;Elongin-A,1.22087464685535,1.13282953539872,1.31576274872595,1.7341359293284e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,ELOA;Elongin-A,1.28148903544267,1.16248089757306,1.41268054502081,6.1157547749655e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24885778166618,CD74;HLA class II histocompatibility antigen gamma chain,1.68726417283099,1.42684101916176,1.99521905432149,9.61187625238309e-10
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516825988964016,CD74;HLA class II histocompatibility antigen gamma chain,1.47203452927821,1.30840684745643,1.65612527907493,1.26676136620177e-10
primary,Circulatory system disorders,I08 (multiple valve diseases),2.11847096585935,CD74;HLA class II histocompatibility antigen gamma chain,1.282939892915,1.20942655818423,1.36092163488114,1.27674266179234e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535644721464744,CD74;HLA class II histocompatibility antigen gamma chain,3.11104407287062,2.79784617675131,3.45930212452981,1.39296163068115e-97
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066025827750267,CD74;HLA class II histocompatibility antigen gamma chain,2.70804688095517,1.99179376972561,3.6818660751516,2.06821996517575e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0543953375424963,CD74;HLA class II histocompatibility antigen gamma chain,2.65561354576146,1.89045830602536,3.73046222810331,1.7759190976683e-08
primary,Circulatory system disorders,I20 (angina pectoris),3.99405573763817,CD74;HLA class II histocompatibility antigen gamma chain,1.20141461367976,1.14940864330595,1.255773638357,4.38748690874037e-16
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96840089371209,CD74;HLA class II histocompatibility antigen gamma chain,1.30274686724929,1.23842947805735,1.37040455689899,1.33936518100863e-24
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01919747923676,CD74;HLA class II histocompatibility antigen gamma chain,1.32646334795929,1.21848332788153,1.44401238262197,6.96877870426719e-11
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69196950752228,CD74;HLA class II histocompatibility antigen gamma chain,1.22057052194504,1.18458157132435,1.25765285827942,6.11881500244153e-39
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34671603975833,CD74;HLA class II histocompatibility antigen gamma chain,1.51430533206719,1.40745005001968,1.62927319423879,1.07100568895889e-28
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60899789111926,CD74;HLA class II histocompatibility antigen gamma chain,1.22194070840267,1.14168061829264,1.3078430788153,7.36053427803218e-09
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70951833297596,CD74;HLA class II histocompatibility antigen gamma chain,1.24465189304384,1.16528575917577,1.32942355354395,7.50845429766845e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.777423618129518,CD74;HLA class II histocompatibility antigen gamma chain,1.54011473508096,1.39882229958998,1.69567885635562,1.41544635890921e-18
primary,Circulatory system disorders,I50 (heart failure),4.42118878240931,CD74;HLA class II histocompatibility antigen gamma chain,1.4320588439645,1.37457535929963,1.49194623539728,3.72809253978032e-66
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21786716187917,CD74;HLA class II histocompatibility antigen gamma chain,1.28956322912053,1.2361794209444,1.34525239113697,4.43579214709445e-32
primary,Circulatory system disorders,I63 (cerebral infarction),2.07569969595384,CD74;HLA class II histocompatibility antigen gamma chain,1.25522575605035,1.18241547195148,1.33251952129126,8.93167014736971e-14
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620296731289011,CD74;HLA class II histocompatibility antigen gamma chain,1.32201745307294,1.18574870591703,1.47394649263212,4.9153456530619e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71644874018356,CD74;HLA class II histocompatibility antigen gamma chain,1.2102363693433,1.14854713754295,1.27523897087461,8.7763605859264e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771877977174187,CD74;HLA class II histocompatibility antigen gamma chain,1.47934767757017,1.34298304066197,1.62955859074255,2.0793648999786e-15
primary,Circulatory system disorders,I70 (atherosclerosis),0.795642447232759,CD74;HLA class II histocompatibility antigen gamma chain,1.67972707037547,1.52850155603783,1.84591439884822,4.54489315854496e-27
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07181761593526,CD74;HLA class II histocompatibility antigen gamma chain,1.26215851658155,1.16102011603214,1.3721072520463,4.67145907586332e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14304004412141,CD74;HLA class II histocompatibility antigen gamma chain,1.42915397606856,1.34757416693421,1.51567248573731,1.08459728256653e-32
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402598412945386,CD74;HLA class II histocompatibility antigen gamma chain,1.61515197838633,1.41384201929646,1.84512546499601,1.67866876336475e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702772153870113,CD74;HLA class II histocompatibility antigen gamma chain,1.49773202798832,1.35335228802082,1.65751463792367,5.69521754112103e-15
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0485540600905047,CD74;HLA class II histocompatibility antigen gamma chain,3.04886295922891,2.14568322526145,4.33221699956452,4.99378499507196e-10
primary,Circulatory system disorders,I81 (portal vein thrombosis),0.0757399207643905,CD74;HLA class II histocompatibility antigen gamma chain,2.22586880703208,1.65616341880025,2.99154774817302,1.12943400185873e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.21954963181721,CD74;HLA class II histocompatibility antigen gamma chain,2.70619051554693,2.2849345585825,3.20511022030293,9.12581438706249e-31
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.268613138686131,CD74;HLA class II histocompatibility antigen gamma chain,1.54750079387743,1.31338613966011,1.82334702243089,1.81586919494754e-07
primary,Circulatory system disorders,I95 (hypotension),4.80382588327152,CD74;HLA class II histocompatibility antigen gamma chain,1.33380100751593,1.28246787620916,1.3871888416489,6.49274394557077e-47
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102942604642128,CD74;HLA class II histocompatibility antigen gamma chain,3.41290426010233,2.69172188599848,4.32731016871154,3.84568979153731e-24
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.543270488339805,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.89298369985235,1.68457797175489,2.12717211550246,7.91115950363706e-27
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066198595787362,LTBP3;Latent-transforming growth factor beta-binding protein 3,2.32729243051468,1.67291310569534,3.23763980250465,5.30794014758988e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35088884862394,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.3022971627049,1.20714136480118,1.40495384338732,8.92262375117176e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.803777755450617,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.40491784721454,1.27303827385628,1.5504593993415,1.38025202264378e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14250834215024,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.20732241530168,1.13587729154228,1.28326133935711,1.41657112488054e-09
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407859840874387,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.45943221284168,1.27035140404817,1.67665606311181,9.2896509810523e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.675648501910315,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.37121735623948,1.23159654401543,1.52666638047081,8.31633738380917e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.210737581535373,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.73484340165408,1.43558641697667,2.09648238007229,1.17897843393053e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102329500993198,LTBP3;Latent-transforming growth factor beta-binding protein 3,2.63867024406172,2.0322990679787,3.42596262853263,3.25929977445505e-13
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.514593083092219,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.4099653211568,1.25042691976589,1.58985877178413,2.05011581814406e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.11731767542239,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.26809947411105,1.194859657065,1.34582858056379,5.06599773378862e-15
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545118271196339,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,3.54198105590594,3.16824623962376,3.95980263260294,1.79089644962651e-109
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0659899462376026,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,2.98652330821984,2.16089050091573,4.12761380864072,3.42661920311021e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.054365765101062,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,3.17076000988478,2.22206886690225,4.5244858024136,1.99714591275467e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96674375947045,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.31115878318394,1.24590766746766,1.3798272533426,2.43506371827571e-25
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02253066620011,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.40409444439474,1.2893985336863,1.5289929042682,5.90560786294843e-15
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.70941083990083,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.21722445503128,1.18107560525586,1.25447970251255,2.1305395597822e-37
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00756758876232,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.22606056202258,1.15307138477396,1.30366993891,7.60685832432314e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34982469809115,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.63724810364617,1.51999272783589,1.76354880112452,1.1711005990018e-38
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.752625437572928,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.28787620877951,1.16586873015111,1.42265169846806,6.28926060138754e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61579892280071,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.22181073775432,1.14121418805345,1.30809929855328,8.7250551125127e-09
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.6949812967581,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.26454192601838,1.18327909679717,1.351385558138,4.33140902273093e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.775058275058275,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.55900560136023,1.41394599168556,1.71894717292221,5.04054027149681e-19
primary,Circulatory system disorders,I50 (heart failure),4.42838396302172,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.42209320014924,1.36427745356379,1.4823590792532,4.33778129589226e-62
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21931764334228,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.26149451989309,1.20889401601009,1.31638373806542,1.13552350172455e-26
primary,Circulatory system disorders,I63 (cerebral infarction),2.07265997857212,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.26897466771963,1.19493730239079,1.3475993293475,8.07438565283621e-15
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.619959187639685,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.30835561332246,1.1726229910248,1.45979946156129,1.51261016791156e-06
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73470977795091,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.21314710781711,1.15122459970678,1.27840032742513,4.89246951175684e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773446305725057,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.3816653860859,1.25264777770686,1.5239712815382,1.02179189183704e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.802986409503626,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.75221607174911,1.59193394594316,1.92863602784528,2.11295398993114e-30
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1537128907788,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.50534713947422,1.41820197015134,1.59784717410975,3.37218928968603e-41
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406267008786253,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.79195163865285,1.56671201257681,2.04957302267013,1.72357061444884e-17
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700443614289049,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.77724587905707,1.60395288349912,1.96926165794513,4.45723516932171e-28
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0446454568394898,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,2.90770482337706,1.95955893514481,4.31461753369791,1.15195851400144e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.211666925586453,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,2.12564314910052,1.76691170964653,2.55720688965374,1.28704035307116e-15
primary,Circulatory system disorders,I95 (hypotension),4.79739352673781,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.32553434345905,1.27388012100648,1.3792830790869,6.68039985092371e-44
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104829942537661,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,2.55586205487067,1.97088473591183,3.31446620114264,1.47932151557638e-12
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246966397013067,HSPB6;Heat shock protein beta-6,1.55799622449716,1.3156647520112,1.84496258019896,2.73973942181941e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13059890259563,HSPB6;Heat shock protein beta-6,1.21798454290106,1.14642998137765,1.29400519076029,1.72848934095279e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,HSPB6;Heat shock protein beta-6,2.93651402062559,2.66416711758308,3.23670183316184,2.441588856511e-104
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544069640914037,HSPB6;Heat shock protein beta-6,2.61396557226632,1.90061208386306,3.59506080751925,3.43445534033379e-09
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00521906331547,HSPB6;Heat shock protein beta-6,1.21583277556803,1.14190329702511,1.29454862070772,1.02284816265828e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,HSPB6;Heat shock protein beta-6,1.3304189208393,1.23420976693733,1.43412777336827,9.02020527649334e-14
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60931213624467,HSPB6;Heat shock protein beta-6,1.29279266221723,1.20642888560792,1.38533890179572,3.34238856462438e-13
primary,Circulatory system disorders,I42 (cardiomyopathy),0.678005727979426,HSPB6;Heat shock protein beta-6,1.29726715584507,1.16643686410219,1.44277167965683,1.59935125452943e-06
primary,Circulatory system disorders,I46 (cardiac arrest),0.777574744372302,HSPB6;Heat shock protein beta-6,1.31766507348802,1.19361079931464,1.45461254781468,4.54838084422251e-08
primary,Circulatory system disorders,I50 (heart failure),4.43006958737626,HSPB6;Heat shock protein beta-6,1.25743484133649,1.20559373269696,1.31150514250755,1.49829115347964e-26
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22702211331343,HSPB6;Heat shock protein beta-6,1.23323361948843,1.18096348841811,1.28781725697018,2.37085407376806e-21
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,HSPB6;Heat shock protein beta-6,1.3274184124881,1.20438687125053,1.46301797526477,1.14715918373715e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15331271301641,HSPB6;Heat shock protein beta-6,1.22902948743608,1.15664798596852,1.30594052755174,2.75672462626282e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697054070367413,HSPB6;Heat shock protein beta-6,1.35372829806979,1.2199787703839,1.50214114333995,1.15597262736313e-08
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0446792804693267,HSPB6;Heat shock protein beta-6,2.48980446466806,1.74238087265162,3.5578479823685,5.47802210479781e-07
primary,Circulatory system disorders,I87 (other disorders of veins),0.460892225117653,HSPB6;Heat shock protein beta-6,1.41573164195843,1.2474419420938,1.60672494198659,7.27796490796798e-08
primary,Circulatory system disorders,I95 (hypotension),4.82261749028642,HSPB6;Heat shock protein beta-6,1.221959919781,1.17352451874576,1.27239441673284,2.62213853620124e-22
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,CNTN3;Contactin-3,0.736027060992155,0.678927625717903,0.797928695182957,1.01550635963129e-13
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14675102463093,CSTB;Cystatin-B,1.20894292809513,1.13944163390109,1.28268351788004,3.36019094159908e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.553851057895366,CSTB;Cystatin-B,2.65939570663021,2.38354334740862,2.96717302503949,1.30112175159148e-68
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0675259677066989,CSTB;Cystatin-B,2.19541360513956,1.59594742202151,3.02004992841607,1.34490699188402e-06
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02050965803974,CSTB;Cystatin-B,1.27473601923958,1.17034471882399,1.38843871605589,2.57235902324928e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35132441751539,CSTB;Cystatin-B,1.49216280024334,1.38574282766269,1.60675543685515,2.92315573064561e-26
primary,Circulatory system disorders,I46 (cardiac arrest),0.779169151262174,CSTB;Cystatin-B,1.46691668647951,1.33118627776425,1.61648643846155,1.03597837156043e-14
primary,Circulatory system disorders,I50 (heart failure),4.41598011506003,CSTB;Cystatin-B,1.29947150766023,1.24670830199302,1.35446775843337,3.09656020737329e-35
primary,Circulatory system disorders,I63 (cerebral infarction),2.06709589969501,CSTB;Cystatin-B,1.24984453541246,1.17670843175294,1.32752627630389,4.19415594287927e-13
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72074945186366,CSTB;Cystatin-B,1.20550626758834,1.14364188914156,1.27071714930413,3.56641567686227e-12
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771601869344735,CSTB;Cystatin-B,1.36183630629652,1.23459883954756,1.50218683651687,6.78464218623686e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.809724653827789,CSTB;Cystatin-B,1.47490556233342,1.34072583397657,1.62251398658443,1.4054271796503e-15
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16546139435569,CSTB;Cystatin-B,1.30168480355784,1.22676400849853,1.38118115307867,2.84710322083828e-18
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.411743644826351,CSTB;Cystatin-B,1.5753760729253,1.37922764695141,1.79941997003267,2.09596872940568e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.706833386428799,CSTB;Cystatin-B,1.47653413986863,1.33317469115678,1.63530937142672,7.52844713995517e-14
primary,Circulatory system disorders,I95 (hypotension),4.79955278709471,CSTB;Cystatin-B,1.22353221071846,1.17580634935672,1.2731952599887,2.84759375031197e-23
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25298582102724,CDH2;Cadherin-2,1.78286655737513,1.50231723611772,2.11580689150634,3.61188174347158e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,CDH2;Cadherin-2,1.62826366343468,1.44848589270664,1.83035442113117,3.15956543226824e-16
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,CDH2;Cadherin-2,1.39997120499943,1.29847166380485,1.50940480987049,1.92444332888463e-18
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60909126718399,CDH2;Cadherin-2,1.21813286619641,1.13620411307414,1.30596929075811,2.78418565352992e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,CDH2;Cadherin-2,1.34720574069298,1.22003454623764,1.48763271773995,3.83391745800607e-09
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,CDH2;Cadherin-2,1.2133883537201,1.16330289582775,1.26563021739575,2.40374005947902e-19
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77276115011964,CDH2;Cadherin-2,1.30318605578109,1.17942114951214,1.43993847887563,1.97972029509601e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,CDH2;Cadherin-2,1.46123993821154,1.32547934980263,1.61090563752834,2.46709068371893e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15754445217045,CDH2;Cadherin-2,1.20824430876095,1.13742638624008,1.2834714644514,8.33332102266823e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,CDH2;Cadherin-2,3.21698037391403,2.71359841677836,3.813741437259,2.76482689219077e-41
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105795227459739,CDH2;Cadherin-2,4.31607625965284,3.41524552491959,5.45451685485409,1.82238883942052e-34
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14760861412131,REG1A;Lithostathine-1-alpha,1.27614301876125,1.20258621794763,1.35419895890076,8.26697414316176e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.549472269439063,REG1A;Lithostathine-1-alpha,3.6440312998758,3.24851688054406,4.08770051157948,7.81763739968173e-108
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0650246305418719,REG1A;Lithostathine-1-alpha,2.47759429892344,1.77402379951005,3.46019794759984,1.01786199063588e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.0571653853735462,REG1A;Lithostathine-1-alpha,2.84046243242937,1.9878795614584,4.05871008811185,9.8605640262884e-09
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96797181843948,REG1A;Lithostathine-1-alpha,1.22788220077888,1.16637279967293,1.29263533872906,4.90721280300137e-15
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01045983816854,REG1A;Lithostathine-1-alpha,1.25960840690841,1.15510857792065,1.37356207812988,1.75877550803915e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35255383520199,REG1A;Lithostathine-1-alpha,1.50339871551016,1.39547372633101,1.6196705499717,7.56788019279878e-27
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60878093237968,REG1A;Lithostathine-1-alpha,1.25821195123257,1.17468266598262,1.34768083335955,5.61825998065032e-11
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71285033327399,REG1A;Lithostathine-1-alpha,1.24161046510791,1.16155650910598,1.32718170401542,1.96485999591243e-10
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.84256127232805,REG1A;Lithostathine-1-alpha,1.21018614599007,1.1490626057486,1.27456110800172,5.4135776806762e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.784870535802323,REG1A;Lithostathine-1-alpha,1.5644175076714,1.41895572990463,1.72479104649255,2.529376638391e-19
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.355454563496,REG1A;Lithostathine-1-alpha,1.22375844510173,1.13539883631821,1.31899442209582,1.28516195036836e-07
primary,Circulatory system disorders,I50 (heart failure),4.41501103752759,REG1A;Lithostathine-1-alpha,1.36065426718664,1.30496231265288,1.4187229905893,2.7682716058421e-47
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20934474533464,REG1A;Lithostathine-1-alpha,1.24883933228909,1.19642773391648,1.30354691191163,3.04190752243758e-24
primary,Circulatory system disorders,I63 (cerebral infarction),2.07653515277365,REG1A;Lithostathine-1-alpha,1.25693830898314,1.18316666534905,1.33530968954683,1.26095387832378e-13
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.782704433990591,REG1A;Lithostathine-1-alpha,1.32649643072326,1.20134368543935,1.46468725149043,2.29742473613456e-08
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769428058476532,REG1A;Lithostathine-1-alpha,1.53254931895247,1.38872818844026,1.69126502549041,2.04267431153841e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.805305542396968,REG1A;Lithostathine-1-alpha,1.60273008268028,1.45539931989262,1.76497520839701,9.00044761530852e-22
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1462829736211,REG1A;Lithostathine-1-alpha,1.40206196407996,1.32078754005796,1.48833759518468,1.37434313228715e-28
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408477385744731,REG1A;Lithostathine-1-alpha,1.74814131624985,1.52752765774989,2.00061717120159,4.85506263188922e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703223767383059,REG1A;Lithostathine-1-alpha,1.50783109809628,1.3599015824556,1.67185232351951,6.44494999328214e-15
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0492669084029638,REG1A;Lithostathine-1-alpha,2.91610739133968,1.9877578364447,4.27802731394865,4.41403669367782e-08
primary,Circulatory system disorders,I95 (hypotension),4.80727330349007,REG1A;Lithostathine-1-alpha,1.28851272828733,1.23816330637651,1.34090958955748,1.16630432251649e-35
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250304107794516,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.58012632743425,1.32147080126474,1.88940929172347,5.2703723197199e-07
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518909821887709,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.4179277139558,1.24977070076003,1.60871030244288,5.90432127740936e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.03618320968006,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.23467320620463,1.15689911719297,1.31767576227248,2.14836027984933e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.402649998829505,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,2.20563024383012,1.93170683783853,2.51839703479104,1.41429901237426e-31
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.95401141322591,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.28936935052468,1.22108624612807,1.36147084396696,5.44903901688478e-20
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.973440973440973,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.28291160499324,1.16832658396636,1.40873468841117,1.79872303756287e-07
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.55516531427879,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.25340265749715,1.21365930517636,1.29444747394956,5.9702640543545e-43
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36054421768707,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.61037400832747,1.4915299328177,1.73868749774106,3.91677937264355e-34
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.739752323430952,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.30037362850313,1.16818509174505,1.4475202479946,1.57001263528779e-06
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59748161721521,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.23864357365558,1.15076630253575,1.33323151640566,1.19720262438307e-08
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.68327276989801,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.20546605133247,1.12198366971462,1.29516002785024,3.33843290977406e-07
primary,Circulatory system disorders,I42 (cardiomyopathy),0.693630782209307,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.31211668191401,1.17475752191485,1.46553663614833,1.47428223263706e-06
primary,Circulatory system disorders,I45 (other conduction disorders),1.71933194350097,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.20622416981092,1.12347986222234,1.29506259681235,2.32650783492273e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.755308203161537,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.36826196647461,1.23152225930631,1.52018430422484,5.32999244607213e-09
primary,Circulatory system disorders,I50 (heart failure),4.31184874345796,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.36545944043549,1.30616727889156,1.42744311054604,4.94356678067735e-43
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08124480342083,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.24325515232487,1.18699006403216,1.30218728919407,3.12473928181684e-20
primary,Circulatory system disorders,I63 (cerebral infarction),2.05158264947245,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.27265667549618,1.19304055614015,1.35758588033677,2.5736270015617e-13
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.738068680731898,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.30405523403944,1.17041319150968,1.4529570119012,1.49109741276534e-06
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.587107035928143,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.34846339741382,1.19637508793173,1.51988582218671,9.75571489067714e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.64212870706833,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.25619927721642,1.18654837306146,1.32993871965582,4.60777930759365e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.746251198914543,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.5034975561499,1.35447565453947,1.66891512134067,1.89951415121866e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.75821398483572,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.63769970097208,1.47887697913681,1.81357905248448,2.59483682126165e-21
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.05984745683402,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.36524696763698,1.24914398680558,1.49214126019891,6.61432003468984e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08279032296282,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.45038236696501,1.36112479205018,1.54549312648585,1.78630881771959e-30
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40007486781152,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.62646479916953,1.4129241252174,1.8722786989928,1.25758378941347e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.688427855570645,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.66892394753598,1.49961110532722,1.85735297155679,6.34294250877225e-21
primary,Circulatory system disorders,I85 (oesophageal varices),0.205698791519599,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,2.29270999625261,1.9079950510782,2.75499620606784,8.47122831347131e-19
primary,Circulatory system disorders,I95 (hypotension),4.55324644827991,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.3246911982696,1.26862252571116,1.38323790978664,3.4141304084237e-37
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102815749503446,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,3.18939409505278,2.49676121552995,4.07417202345416,1.62208768423567e-20
primary,Circulatory system disorders,I08 (multiple valve diseases),2.11847096585935,CXCL13;C-X-C motif chemokine 13,1.22607879281358,1.15520697073464,1.301298593473,1.95567050246438e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535644721464744,CXCL13;C-X-C motif chemokine 13,1.62266021172503,1.44191462532393,1.82606245645369,9.44895604572129e-16
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96840089371209,CXCL13;C-X-C motif chemokine 13,1.2384944971487,1.17659852546695,1.30364655935538,2.9080742218258e-16
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01919747923676,CXCL13;C-X-C motif chemokine 13,1.23704667135876,1.13477459662651,1.34853606316979,1.35403155523655e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34671603975833,CXCL13;C-X-C motif chemokine 13,1.53068480787425,1.42132914290895,1.64845419004197,2.14361355570221e-29
primary,Circulatory system disorders,I46 (cardiac arrest),0.777423618129518,CXCL13;C-X-C motif chemokine 13,1.47456151220275,1.3362332981163,1.62720960204692,1.09959788053695e-14
primary,Circulatory system disorders,I50 (heart failure),4.42118878240931,CXCL13;C-X-C motif chemokine 13,1.25335755135038,1.20235190157592,1.30652694063031,1.68109571253579e-26
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21786716187917,CXCL13;C-X-C motif chemokine 13,1.22997920967934,1.17845465480484,1.28375652815759,2.52767443212355e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771877977174187,CXCL13;C-X-C motif chemokine 13,1.38867794793185,1.25821483095302,1.53266866327713,6.88655076575093e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.795642447232759,CXCL13;C-X-C motif chemokine 13,1.43362858088734,1.30076627235188,1.58006165413633,3.89346142975123e-13
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07181761593526,CXCL13;C-X-C motif chemokine 13,1.25393749064912,1.15166134347798,1.36529652519806,1.86051650216436e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14304004412141,CXCL13;C-X-C motif chemokine 13,1.27001968191671,1.19649643745747,1.34806083993306,3.9636597359181e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702772153870113,CXCL13;C-X-C motif chemokine 13,1.40562795339969,1.26769034706996,1.55857457457595,1.04040172824738e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.21954963181721,CXCL13;C-X-C motif chemokine 13,2.02105064230433,1.68394663573251,2.42563844487978,4.11011448459677e-14
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250960708964002,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.66839749681288,1.40581921297105,1.98002003507177,4.66987085714644e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519251494072695,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.43024773563314,1.26886847645939,1.61215178975186,4.67620242808782e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,5.0767979250057,4.53052940350485,5.68893276609203,3.62338472448885e-172
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066585719321609,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,3.18818661367462,2.3445349815371,4.33541574924596,1.43083411385186e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0548557098916599,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,3.58268785429667,2.56203097691957,5.00995201734744,8.7109993629602e-14
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97159182359568,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.20578484504704,1.1456333739332,1.26909456866948,7.65247441759134e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01214177830956,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.33785952652678,1.2280492013447,1.45748892695714,2.71680302612789e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.47547640962786,1.36946995160277,1.58968850161364,1.52346837858813e-24
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60299330445057,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.25086926254958,1.16768810321997,1.33997589568365,1.82381729170691e-10
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72606994711699,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.20480184105031,1.12789194862805,1.28695614678681,3.09723946246129e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.53340691258138,1.39178118188931,1.68944428201025,5.33100718702248e-18
primary,Circulatory system disorders,I50 (heart failure),4.43289393071009,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.36481787261823,1.30904583031839,1.42296608894518,2.40454245184618e-48
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22577303155881,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.23141754925267,1.1799533078741,1.28512642872243,1.21251654864936e-21
primary,Circulatory system disorders,I63 (cerebral infarction),2.08153156694708,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.2092967491767,1.13867434061558,1.2842992727655,6.02220960326619e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7258077195189,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.21147092082918,1.14931630278265,1.27698683857637,9.4099901834302e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772533871884865,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.41822898631119,1.28581991556656,1.56427306286279,2.80483740187478e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.54403468471627,1.40287545212098,1.69939755093903,6.66275570977877e-19
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08680725846002,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.24668799125747,1.14790833736236,1.35396781864731,1.64883241636184e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13543632426848,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.3788712784128,1.2987280523247,1.46396006387056,7.32731224713526e-26
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406001765225066,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.7159900807674,1.50161045941991,1.96097592342934,2.18003220365751e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702842783100361,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.55933133501318,1.40727539058995,1.72781690677804,2.12965302888842e-17
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0470072077718583,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,3.27976972390427,2.28053041445944,4.7168366506477,1.48646270938804e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.61277532750535,1.34549343048622,1.93315269928151,2.34123040237657e-07
primary,Circulatory system disorders,I95 (hypotension),4.81299212598425,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.32260302056423,1.27087028306177,1.37644161903863,6.29831969703117e-43
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.92383455361096,1.4823256463758,2.49684635674797,8.69515305164612e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.543960267250044,CANT1;Soluble calcium-activated nucleotidase 1,2.48477697559239,2.2120242312488,2.79116138567273,3.98715793013381e-53
primary,Circulatory system disorders,I46 (cardiac arrest),0.782632634601014,CANT1;Soluble calcium-activated nucleotidase 1,1.31409348006938,1.1911944211543,1.4496723991433,4.97392420367463e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.793213399992127,CANT1;Soluble calcium-activated nucleotidase 1,1.35545537412314,1.22944934633443,1.49437573554131,1.00021157556852e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.22213485354826,CANT1;Soluble calcium-activated nucleotidase 1,1.92713929667491,1.6056811126219,2.31295357440204,1.84182740405964e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106117475976182,CANT1;Soluble calcium-activated nucleotidase 1,2.20602196694269,1.69653125892777,2.86851945286844,3.52465733990435e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,ACY1;Aminoacylase-1,0.715131771620642,0.632591100881656,0.808442373072446,8.40178649078994e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,ACY1;Aminoacylase-1,3.12077965321603,2.60968611999721,3.73196821230653,1.06516652220774e-35
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105795227459739,ACY1;Aminoacylase-1,4.95101346185177,3.89596162882755,6.29178021622718,4.16878881835076e-39
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24885778166618,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.56714644425521,1.3168089108638,1.86507545436542,4.21051558966606e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535644721464744,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,3.68243568032986,3.28097476868952,4.13301945177185,1.50319836521112e-108
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066025827750267,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,2.4368106624161,1.75995002472965,3.37398569335906,8.10534123466471e-08
primary,Circulatory system disorders,I15 (secondary hypertension),0.0543953375424963,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,3.12629486100692,2.19036343112938,4.46214514863354,3.40063757782073e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34671603975833,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.25613817390265,1.16549929878557,1.35382587838501,2.40261151981485e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.777423618129518,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.36679199903057,1.23988255793561,1.50669138512957,3.28908852483262e-10
primary,Circulatory system disorders,I50 (heart failure),4.42118878240931,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.22295613220393,1.17308335026356,1.27494921904669,2.67447349282511e-21
primary,Circulatory system disorders,I70 (atherosclerosis),0.795642447232759,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.38043224354612,1.25312806186937,1.52066914548151,6.53914284694098e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14304004412141,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.2240358199304,1.15296021659645,1.29949296333535,3.51149589663212e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702772153870113,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.32174498539317,1.19219971494841,1.46536673722287,1.15630262797752e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.21954963181721,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,2.08894034843375,1.74314192311705,2.50333706134007,1.48321728444644e-15
primary,Circulatory system disorders,I95 (hypotension),4.80382588327152,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.21020659362796,1.16297874848597,1.25935233224793,5.77425584562415e-21
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102942604642128,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,3.17463778741536,2.45226860554139,4.10979656083004,1.79286457224063e-18
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.549977492024347,PRSS2;Trypsin-2,2.90633039001739,2.58352699605629,3.2694670304713,1.4245996981979e-70
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34711779448621,PRSS2;Trypsin-2,1.32085142253948,1.22581304354453,1.42325821185568,2.79164947278084e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.78303489484681,PRSS2;Trypsin-2,1.28936232337651,1.17073390803931,1.42001114815841,2.45681671628441e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.801344695489015,PRSS2;Trypsin-2,1.45655998202679,1.32320446644631,1.60335536573551,1.63591579870543e-14
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406432577134259,PRSS2;Trypsin-2,1.43231137662634,1.25254550110453,1.63787732885085,1.51432452336952e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249070925911283,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.81724919822863,1.53291518193669,2.15432314023424,5.96477108088421e-12
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.50768440598949,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.40321971158847,1.24263926581787,1.58455121542813,4.67126629610951e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12025316455696,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.24368317311539,1.17130598255142,1.32053268584964,1.01302455970141e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,2.43338129291625,2.17031922022937,2.72832883822915,2.08185555048699e-52
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9690922365539,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.26140240290054,1.19825297738578,1.32787988185485,7.85472327861792e-19
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.102783048703352,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.99130131403025,1.5234567729305,2.6028181394547,4.63211497835413e-07
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02042834259497,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.2867511696486,1.1803674889337,1.40272295544819,1.02661301226556e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34152382839591,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.57955888183052,1.46602601564447,1.70188402834917,3.06792439262485e-33
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.610181269482,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.24562321127255,1.16265948833152,1.33450696444885,4.22380253913277e-10
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71217946177321,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.23906819273592,1.15908650627473,1.32456894109159,3.04798888565009e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.782500444602525,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.4866800582668,1.34787568571494,1.63977851894837,2.20040978422618e-15
primary,Circulatory system disorders,I50 (heart failure),4.41132519077885,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.36721291775577,1.31136060931785,1.4254440381968,6.67108467288493e-49
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19838894357284,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.25895627331464,1.20599631181378,1.31424191151509,8.45241316261524e-26
primary,Circulatory system disorders,I63 (cerebral infarction),2.07280581812417,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.20422947502056,1.13325264580495,1.27965165920987,2.02345954215727e-09
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620774188446482,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.31976512925278,1.18173219873506,1.47392107810554,8.5450538585476e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72257118513087,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.2034064673317,1.14124021065353,1.26895907811245,7.81439877051222e-12
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769002668775328,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.40757673437262,1.27484885534776,1.55412326318999,1.330012210438e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.79898742188118,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.70767306193057,1.55092786855685,1.88025977581847,1.23348408438971e-27
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08381788695067,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.24776378001617,1.14732765434829,1.35699200208383,2.34238699420666e-07
primary,Circulatory system disorders,I72 (other aneurysm),0.336008222318852,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.47249183175931,1.26799715320355,1.70996613763677,3.92725442462328e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12868213949576,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.40604051051089,1.32408675745188,1.49306675417722,9.83365590792176e-29
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401415831207609,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.69745154705466,1.48157490749862,1.94478304135353,2.45412432658151e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700643245917862,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.57561121416374,1.42100590217649,1.74703756993275,6.24364694502213e-18
primary,Circulatory system disorders,I85 (oesophageal varices),0.215321401762079,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,2.30735797927633,1.92425500542879,2.76673353038456,1.78662123935127e-19
primary,Circulatory system disorders,I95 (hypotension),4.82087922992954,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.27972758522915,1.22968322498977,1.33180859843806,8.41583122032774e-34
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100714878154745,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,2.44667476416186,1.87758949931996,3.18824610158645,3.4966643992626e-11
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0928633525646091,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,2.13474134862156,1.61695049707504,2.81834269741599,8.78126508137599e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,CD99L2;CD99 antigen-like protein 2,2.95723052126843,2.6353124049811,3.31847273188254,6.41638191962251e-76
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,CD99L2;CD99 antigen-like protein 2,1.28210964548389,1.18973378805445,1.38165794696889,7.34029449157569e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772533871884865,CD99L2;CD99 antigen-like protein 2,1.29048336220709,1.16956000172498,1.42390925277634,3.77303316144466e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,CD99L2;CD99 antigen-like protein 2,1.43639512924613,1.30474760653491,1.58132573456213,1.53926884086708e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13543632426848,CD99L2;CD99 antigen-like protein 2,1.25269170109591,1.17983340376825,1.33004921964627,1.71722229080855e-13
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406001765225066,CD99L2;CD99 antigen-like protein 2,1.72300967812054,1.50766803495813,1.96910877067146,1.38005874845231e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702842783100361,CD99L2;CD99 antigen-like protein 2,1.35772306848011,1.22470258611798,1.50519150655689,6.13978290714226e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,NPPC;C-type natriuretic peptide,3.90264967606193,3.43708828289841,4.43127241445852,5.42564859195192e-98
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0647388864911523,NPPC;C-type natriuretic peptide,3.01489102325768,2.06931226429404,4.39255497537038,9.07313044072585e-09
primary,Circulatory system disorders,I15 (secondary hypertension),0.0569140793657024,NPPC;C-type natriuretic peptide,3.0212924271321,2.01708481575139,4.52544576160791,8.15353640175182e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,SLC39A5;Zinc transporter ZIP5,2.15760695005321,1.9293464697341,2.41287286858306,2.07610192894403e-41
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,SFTPD;Pulmonary surfactant-associated protein D,1.55042684332824,1.4390117395129,1.67046823212607,9.8072299670749e-31
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,SFTPD;Pulmonary surfactant-associated protein D,1.3590915557816,1.23289500808551,1.49820531747075,6.79630233561815e-10
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,SFTPD;Pulmonary surfactant-associated protein D,1.2375840083033,1.18751062317943,1.28976882203155,4.71748821107716e-24
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,SFTPD;Pulmonary surfactant-associated protein D,1.36550284034349,1.23992005039724,1.50380502871032,2.47123918087603e-10
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15754445217045,SFTPD;Pulmonary surfactant-associated protein D,1.24766219303887,1.17565081272626,1.32408443994418,2.98700775358502e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.710863247191893,SFTPD;Pulmonary surfactant-associated protein D,1.33300860449317,1.20295811812929,1.47711870668956,4.06529114085621e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.399660059259939,PALM;Paralemmin-1,4.01272880856115,3.49057239000187,4.61299485928952,5.51734243411757e-85
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36926404933953,PALM;Paralemmin-1,1.27061195969862,1.17101686969676,1.37867762105531,8.88669501945417e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,ADAM22;Disintegrin and metalloproteinase domain-containing protein 22,3.20125311853467,2.83719940839916,3.61202018391447,1.37675474477361e-79
primary,Circulatory system disorders,I15 (secondary hypertension),0.0572805562139527,ADAM22;Disintegrin and metalloproteinase domain-containing protein 22,2.68922773621073,1.87393295195449,3.85923402951117,7.97343202697042e-08
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24885778166618,THY1;Thy-1 membrane glycoprotein,1.59940693283226,1.33850015112086,1.91117089874793,2.35692965777386e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535644721464744,THY1;Thy-1 membrane glycoprotein,3.9557441177857,3.53580286388142,4.42556107560213,1.89037889933339e-127
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066025827750267,THY1;Thy-1 membrane glycoprotein,3.45668654436837,2.53012508708408,4.72256566563197,6.67399780335082e-15
primary,Circulatory system disorders,I15 (secondary hypertension),0.0543953375424963,THY1;Thy-1 membrane glycoprotein,3.3205742923875,2.34688975534387,4.69822393921915,1.21988144396872e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34671603975833,THY1;Thy-1 membrane glycoprotein,1.53549874592968,1.4224664990934,1.65751277815985,4.13920822499297e-28
primary,Circulatory system disorders,I46 (cardiac arrest),0.777423618129518,THY1;Thy-1 membrane glycoprotein,1.50430205702407,1.36263072529607,1.66070281313756,5.91060993813624e-16
primary,Circulatory system disorders,I50 (heart failure),4.42118878240931,THY1;Thy-1 membrane glycoprotein,1.28448110503397,1.23096413132253,1.34032476431028,9.30708202837067e-31
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21786716187917,THY1;Thy-1 membrane glycoprotein,1.21331488758531,1.16174533818335,1.26717359480707,2.65059827440335e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771877977174187,THY1;Thy-1 membrane glycoprotein,1.30030259862377,1.17628723589854,1.43739283772487,2.82452459763714e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14304004412141,THY1;Thy-1 membrane glycoprotein,1.20614197148825,1.13464089840782,1.28214879035911,1.84122326434061e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702772153870113,THY1;Thy-1 membrane glycoprotein,1.30214749420626,1.17214612884164,1.44656715996946,8.66218184132713e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.21954963181721,THY1;Thy-1 membrane glycoprotein,2.13579833428921,1.77907199296677,2.5640527998789,4.00198710432176e-16
primary,Circulatory system disorders,I95 (hypotension),4.80382588327152,THY1;Thy-1 membrane glycoprotein,1.25064226742233,1.20071935142823,1.30264085375388,5.26557536336998e-27
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102942604642128,THY1;Thy-1 membrane glycoprotein,2.49630640037532,1.92257618845495,3.24124769773761,6.60811021076491e-12
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.252312867956265,CHRDL1;Chordin-like protein 1,1.89847294149586,1.60287056181722,2.24859049473449,1.14169135892874e-13
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.512128853183213,CHRDL1;Chordin-like protein 1,1.37917574072119,1.22124827859407,1.55752581775068,2.20440861467681e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12924184899604,CHRDL1;Chordin-like protein 1,1.2297991524366,1.15832593983859,1.3056825400496,1.27803325091155e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.542807313201779,CHRDL1;Chordin-like protein 1,3.68070971084793,3.32534250925336,4.0740537065976,1.25224948984935e-139
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0644707537217207,CHRDL1;Chordin-like protein 1,2.86014049599157,2.11719833777167,3.86378711473046,7.49810959671767e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0566782629089629,CHRDL1;Chordin-like protein 1,3.10706798649112,2.26659742634788,4.25919105018708,1.85546522735015e-12
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96201159920531,CHRDL1;Chordin-like protein 1,1.23539461997087,1.17361994543347,1.30042086707147,6.65100721650561e-16
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01166249217282,CHRDL1;Chordin-like protein 1,1.27504593365145,1.17009306995706,1.38941266696054,2.9538715135194e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35090092739642,CHRDL1;Chordin-like protein 1,1.50661623463367,1.39822627949141,1.62340853676945,5.34591066974937e-27
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60685170998094,CHRDL1;Chordin-like protein 1,1.3738605155374,1.2822209148451,1.47204954645488,1.91268580061387e-19
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71203326011923,CHRDL1;Chordin-like protein 1,1.23393736464836,1.15461162065962,1.3187130569546,5.62567419378265e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.77817968520872,CHRDL1;Chordin-like protein 1,1.52766729168926,1.38732240966685,1.68220980057378,6.79264636078317e-18
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36560409287682,CHRDL1;Chordin-like protein 1,1.22959780664966,1.14098076936807,1.32509750094651,6.09998767621125e-08
primary,Circulatory system disorders,I50 (heart failure),4.41811407053999,CHRDL1;Chordin-like protein 1,1.34041832498099,1.28541764146499,1.39777238773316,9.4126635089935e-43
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22347656715824,CHRDL1;Chordin-like protein 1,1.27560903834955,1.22222376073737,1.33132612128027,6.41294647288986e-29
primary,Circulatory system disorders,I63 (cerebral infarction),2.07058823529411,CHRDL1;Chordin-like protein 1,1.22830768842169,1.15603821867224,1.30509506785051,2.99881028332861e-11
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.781963243758186,CHRDL1;Chordin-like protein 1,1.28858731189454,1.16683762295187,1.42304055655573,5.52827738646348e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71351266567328,CHRDL1;Chordin-like protein 1,1.24280812014459,1.17846274528075,1.3106668239473,1.11053510318076e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.780485896482923,CHRDL1;Chordin-like protein 1,1.42221070480346,1.29004655423398,1.56791495796723,1.46500733470261e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.80828244872397,CHRDL1;Chordin-like protein 1,1.54976653929002,1.40916449183323,1.70439742146668,1.74172754397903e-19
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14798081876907,CHRDL1;Chordin-like protein 1,1.33137299197973,1.25382026345963,1.41372260078337,9.0217124719456e-21
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405024653674571,CHRDL1;Chordin-like protein 1,1.53661465152538,1.34466970007433,1.75595879579344,2.79028715299467e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701135918527222,CHRDL1;Chordin-like protein 1,1.52593159367265,1.37727889377847,1.69062870206365,6.41057707580033e-16
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0488472059398202,CHRDL1;Chordin-like protein 1,2.5312992499047,1.78056890275701,3.5985554294736,2.28888842568017e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.222834691843077,CHRDL1;Chordin-like protein 1,1.93340940567224,1.62277373590925,2.30350778252361,1.61153623528893e-13
primary,Circulatory system disorders,I95 (hypotension),4.82914375490966,CHRDL1;Chordin-like protein 1,1.31997323359868,1.26815187556785,1.37391220324992,4.88544495850485e-42
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105520273571079,CHRDL1;Chordin-like protein 1,2.32974649159262,1.82367388830795,2.97625510234405,1.30090275211093e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.542796676595077,EPHA1;Ephrin type-A receptor 1,3.17518360354841,2.82188719717194,3.5727122353957,3.9179648624246e-82
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0644694942075136,EPHA1;Ephrin type-A receptor 1,2.38778670029143,1.68858792342831,3.3765048576878,8.49825294161881e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.056677155197686,EPHA1;Ephrin type-A receptor 1,2.58278467498329,1.7863773033228,3.73424845071664,4.55037593527827e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.810223692193279,EPHA1;Ephrin type-A receptor 1,1.36538412621116,1.23329252648304,1.51162337570126,1.98361474897292e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.69916374532422,EPHA1;Ephrin type-A receptor 1,1.31388885020298,1.17760700945892,1.46594228534772,1.02893625563086e-06
primary,Circulatory system disorders,I95 (hypotension),4.83101274523281,EPHA1;Ephrin type-A receptor 1,1.2054767275159,1.15596680225274,1.25710715718697,2.46783969495338e-18
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,HAVCR2;Hepatitis A virus cellular receptor 2,3.53290177616261,3.1785010038655,3.92681800157805,4.18160531526315e-121
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066585719321609,HAVCR2;Hepatitis A virus cellular receptor 2,2.8454390396537,2.0972072733817,3.86062142314141,1.84924093553049e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0548557098916599,HAVCR2;Hepatitis A virus cellular receptor 2,3.06737902001438,2.20225320639915,4.27235797640568,3.35870480518457e-11
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97159182359568,HAVCR2;Hepatitis A virus cellular receptor 2,1.27835744052764,1.21470638187731,1.34534383792959,4.34032970022788e-21
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01214177830956,HAVCR2;Hepatitis A virus cellular receptor 2,1.38022120581638,1.26705807624163,1.50349112854866,1.54765126010835e-13
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00589503669561,HAVCR2;Hepatitis A virus cellular receptor 2,1.2419583364557,1.1676890582194,1.32095141136622,5.67754289223747e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,HAVCR2;Hepatitis A virus cellular receptor 2,1.51691919975322,1.4081582226396,1.63408047589043,4.92668876257123e-28
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72606994711699,HAVCR2;Hepatitis A virus cellular receptor 2,1.20833601037484,1.13113812216546,1.29080249826025,1.92976769153257e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,HAVCR2;Hepatitis A virus cellular receptor 2,1.49507170565731,1.35708399613484,1.64708994537062,3.95185984469825e-16
primary,Circulatory system disorders,I50 (heart failure),4.43289393071009,HAVCR2;Hepatitis A virus cellular receptor 2,1.40373592101241,1.34669807229205,1.46318954224599,8.69593990215395e-58
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22577303155881,HAVCR2;Hepatitis A virus cellular receptor 2,1.24694353084662,1.19488761600036,1.30126728932452,3.53902518003791e-24
primary,Circulatory system disorders,I63 (cerebral infarction),2.08153156694708,HAVCR2;Hepatitis A virus cellular receptor 2,1.25804856538469,1.18461046765176,1.33603934464958,7.40641902885944e-14
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7258077195189,HAVCR2;Hepatitis A virus cellular receptor 2,1.27157601431126,1.20629359962181,1.34039139449852,4.08584377411146e-19
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772533871884865,HAVCR2;Hepatitis A virus cellular receptor 2,1.5394539687228601,1.39632291297787,1.69725677333644,4.5132650661825e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,HAVCR2;Hepatitis A virus cellular receptor 2,1.72042016509584,1.56487189469533,1.89142993397849,3.19262488222441e-29
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08680725846002,HAVCR2;Hepatitis A virus cellular receptor 2,1.33983011885368,1.23410422240334,1.45461356893467,3.04650128326401e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13543632426848,HAVCR2;Hepatitis A virus cellular receptor 2,1.47394213235508,1.38828713914612,1.56488189530278,5.90950039612065e-37
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406001765225066,HAVCR2;Hepatitis A virus cellular receptor 2,1.75539432194351,1.53770302047304,2.00390399478021,8.11745622108274e-17
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702842783100361,HAVCR2;Hepatitis A virus cellular receptor 2,1.6006286871397,1.44511537819337,1.77287726139728,1.87248447724853e-19
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0470072077718583,HAVCR2;Hepatitis A virus cellular receptor 2,3.14959551109745,2.20739022164206,4.4939729216277,2.51798977486985e-10
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.666298164861,HAVCR2;Hepatitis A virus cellular receptor 2,1.20770445803984,1.12795925228803,1.29308754284403,6.13839644244441e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,HAVCR2;Hepatitis A virus cellular receptor 2,2.28865090207823,1.92274864827967,2.72418496108163,1.21684638014822e-20
primary,Circulatory system disorders,I87 (other disorders of veins),0.466666666666666,HAVCR2;Hepatitis A virus cellular receptor 2,1.36754134071243,1.20475496980265,1.55232338976274,1.29407707640256e-06
primary,Circulatory system disorders,I95 (hypotension),4.81299212598425,HAVCR2;Hepatitis A virus cellular receptor 2,1.38496868328986,1.33097568300953,1.44115198961145,5.52549997578781e-58
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,HAVCR2;Hepatitis A virus cellular receptor 2,3.25105646993198,2.558834834183,4.13053942735668,4.86019383347247e-22
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.543270488339805,GCG;Pro-glucagon,1.53255742892914,1.35907603714507,1.72818312498521,3.27278703416238e-12
primary,Circulatory system disorders,I85 (oesophageal varices),0.209414549758718,VSNL1;Visinin-like protein 1,1.73281906634228,1.38993143856407,2.16029498532772,1.02550488065852e-06
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25186588719181,NPC2;NPC intracellular cholesterol transporter 2,1.77718503844631,1.4832847002528,2.12931924689787,4.52926506125242e-10
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519522501096769,NPC2;NPC intracellular cholesterol transporter 2,1.57241151869226,1.38343459057552,1.78720266282162,4.26108330681767e-12
primary,Circulatory system disorders,I08 (multiple valve diseases),2.05982985019419,NPC2;NPC intracellular cholesterol transporter 2,1.35484214906869,1.2690984613149,1.44637890979021,8.69587841310451e-20
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.38159111933395,NPC2;NPC intracellular cholesterol transporter 2,3.578467840206,3.14393458722461,4.07305932363337,5.17029378362063e-83
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0507731363951073,NPC2;NPC intracellular cholesterol transporter 2,2.92119117361053,2.02083394145192,4.22269128489056,1.18438371181345e-08
primary,Circulatory system disorders,I20 (angina pectoris),3.93809155881784,NPC2;NPC intracellular cholesterol transporter 2,1.22217053957713,1.16398060680842,1.28326951417679,7.58386784531384e-16
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.94277929155313,NPC2;NPC intracellular cholesterol transporter 2,1.39134416133811,1.3160436136419,1.47095320795074,2.76913791070208e-31
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.975429350715391,NPC2;NPC intracellular cholesterol transporter 2,1.37984643376792,1.25522059584998,1.51684587320906,2.62029046220722e-11
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.53273353751914,NPC2;NPC intracellular cholesterol transporter 2,1.30168053213797,1.25929503160499,1.34549264884139,6.21825776319198e-55
primary,Circulatory system disorders,I26 (pulmonary embolism),1.95603012146504,NPC2;NPC intracellular cholesterol transporter 2,1.2721009880221,1.18882841603453,1.36120646335543,3.22837574382149e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37392553462616,NPC2;NPC intracellular cholesterol transporter 2,1.91956645496786,1.77659396069943,2.07404474885598,2.98152582800603e-61
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.75622672926158,NPC2;NPC intracellular cholesterol transporter 2,1.42829314478468,1.28299469540939,1.59004656429072,7.38802599380869e-11
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60354590179151,NPC2;NPC intracellular cholesterol transporter 2,1.29168797862272,1.19890820578869,1.39164768917472,1.69537531555133e-11
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69515075725996,NPC2;NPC intracellular cholesterol transporter 2,1.24424867319982,1.15751013133307,1.33748700668093,3.07845314073729e-09
primary,Circulatory system disorders,I42 (cardiomyopathy),0.692129629629629,NPC2;NPC intracellular cholesterol transporter 2,1.46360922713218,1.30866970896482,1.63689275840344,2.52309323262393e-11
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.81941387698366,NPC2;NPC intracellular cholesterol transporter 2,1.2120701050396,1.14581980127197,1.2821509437172,1.99560724292393e-11
primary,Circulatory system disorders,I45 (other conduction disorders),1.73064019805187,NPC2;NPC intracellular cholesterol transporter 2,1.29211580628831,1.20309106576405,1.38772808174733,1.97373154742036e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.7576457544119,NPC2;NPC intracellular cholesterol transporter 2,1.63992479680034,1.47543243456019,1.82275601116381,4.63374059362296e-20
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.33407706967879,NPC2;NPC intracellular cholesterol transporter 2,1.24719401446351,1.14932823787771,1.35339310255344,1.1705063858051e-07
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.20956558652893,NPC2;NPC intracellular cholesterol transporter 2,1.20863733543494,1.16620132159129,1.25261752114462,2.71901108064451e-25
primary,Circulatory system disorders,I50 (heart failure),4.31552471004704,NPC2;NPC intracellular cholesterol transporter 2,1.54920246923061,1.48051881543285,1.62107246841611,7.88110319905624e-80
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.07622087156501,NPC2;NPC intracellular cholesterol transporter 2,1.41156973519527,1.34691532430119,1.47932767663254,4.49581693167194e-47
primary,Circulatory system disorders,I63 (cerebral infarction),2.04970238784538,NPC2;NPC intracellular cholesterol transporter 2,1.40248890408351,1.31369221308262,1.4972876496404,3.82946646923563e-24
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.745394027471754,NPC2;NPC intracellular cholesterol transporter 2,1.43288738780965,1.28446616755185,1.59845881348298,1.13992166089173e-10
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.582295445617764,NPC2;NPC intracellular cholesterol transporter 2,1.42359338140649,1.25986682172645,1.60859709981664,1.46402497468157e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.61938950391403,NPC2;NPC intracellular cholesterol transporter 2,1.28814785508299,1.21527524333436,1.36539019095149,1.56907393737934e-17
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.753356596492038,NPC2;NPC intracellular cholesterol transporter 2,1.75529949343773,1.58018533784069,1.94981957994434,9.33400318589984e-26
primary,Circulatory system disorders,I70 (atherosclerosis),0.783688189194812,NPC2;NPC intracellular cholesterol transporter 2,1.68370073322712,1.51772976703415,1.86782141369555,7.60817661669084e-23
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.05389664417121,NPC2;NPC intracellular cholesterol transporter 2,1.40203573551953,1.28010531862369,1.53558006132435,3.34754405656354e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.09991572244592,NPC2;NPC intracellular cholesterol transporter 2,1.53344255645835,1.43697140652299,1.6363903020501,4.77475731561415e-38
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406767125820467,NPC2;NPC intracellular cholesterol transporter 2,1.81042408227008,1.56979468984764,2.08793887433876,3.42703027294368e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.696307948551864,NPC2;NPC intracellular cholesterol transporter 2,1.7649545576741,1.58181663250683,1.96929563556169,2.86296088465197e-24
primary,Circulatory system disorders,I85 (oesophageal varices),0.207818597455376,NPC2;NPC intracellular cholesterol transporter 2,1.83391744577072,1.50364486435839,2.2367337378812,2.14832618618792e-09
primary,Circulatory system disorders,I95 (hypotension),4.53269618873089,NPC2;NPC intracellular cholesterol transporter 2,1.39362470923422,1.33326107569632,1.45672131707124,7.34301205903191e-49
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10848991274641,NPC2;NPC intracellular cholesterol transporter 2,2.20766442338301,1.69016285709285,2.88361691645156,6.21192295889345e-09
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249172668872883,XG;Glycoprotein Xg,1.66001900807965,1.34956761095422,2.04188592317901,1.60390193218068e-06
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14257888585897,XG;Glycoprotein Xg,1.29285055748241,1.20036312659832,1.3924641026914,1.18311982435201e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551968949308576,XG;Glycoprotein Xg,4.11330144509204,3.73641759605678,4.52820070113469,6.09577405216481e-183
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0661105601897762,XG;Glycoprotein Xg,2.87926731365141,2.15753441487739,3.84243245729757,6.83095681919318e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0564103561633177,XG;Glycoprotein Xg,3.36683122753262,2.51674731632978,4.50404871444134,2.92694785424889e-16
primary,Circulatory system disorders,I20 (angina pectoris),4.01337110943519,XG;Glycoprotein Xg,1.20901712809037,1.14243980613022,1.2794743391927,5.1029289364624e-11
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97660666839802,XG;Glycoprotein Xg,1.21423741391768,1.13850267880259,1.2950101258507,3.47195039403556e-09
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01466492687011,XG;Glycoprotein Xg,1.44459586958785,1.30353139159138,1.60092594615814,2.27980541399567e-12
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69582777979724,XG;Glycoprotein Xg,1.20502323077649,1.15966280459689,1.25215793845847,1.62539562437374e-21
primary,Circulatory system disorders,I26 (pulmonary embolism),1.98974681306593,XG;Glycoprotein Xg,1.24200831090512,1.14821419412564,1.34346418311966,6.31174016269034e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3522215067611,XG;Glycoprotein Xg,1.35234588800335,1.23211538672664,1.48430854812895,2.09974952111202e-10
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60899315738025,XG;Glycoprotein Xg,1.27024119688317,1.16433078064326,1.38578548732326,7.2366453803158e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.784245042520481,XG;Glycoprotein Xg,1.41469482158898,1.25834475186907,1.59047147870881,6.41159561485388e-09
primary,Circulatory system disorders,I50 (heart failure),4.42700156985871,XG;Glycoprotein Xg,1.34245418837782,1.27461332213485,1.41390586195559,8.87733752468689e-29
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21192157793736,XG;Glycoprotein Xg,1.25719870469406,1.19164571910469,1.32635779052849,5.41716571436556e-17
primary,Circulatory system disorders,I63 (cerebral infarction),2.06662373397342,XG;Glycoprotein Xg,1.21822703457329,1.12871158497563,1.31484174302798,3.9921619168963e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73381856498917,XG;Glycoprotein Xg,1.23783430989415,1.15805511380625,1.32310954848689,3.45095307298921e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.808368070435155,XG;Glycoprotein Xg,1.41026478647593,1.25454314090873,1.58531556478272,8.48113878166855e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15350635008282,XG;Glycoprotein Xg,1.27616609122047,1.18362490242179,1.37594257188125,2.16470906322845e-10
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406986933577395,XG;Glycoprotein Xg,1.57683977784325,1.34835888208527,1.84403701271538,1.18177391030134e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705625511675958,XG;Glycoprotein Xg,1.56434857051159,1.38497099663928,1.76695862657044,5.97286357424192e-13
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.048616377885382,XG;Glycoprotein Xg,2.9269726997658,2.1101892221082,4.05990566884575,1.24808367943279e-10
primary,Circulatory system disorders,I95 (hypotension),4.81393167070596,XG;Glycoprotein Xg,1.27762685828997,1.21457735357959,1.34394930402177,2.34206839653594e-21
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,MFGE8;Lactadherin,1.34934470851975,1.19665405135447,1.52151838733125,1.00819123320277e-06
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,MFGE8;Lactadherin,1.31397405621329,1.19053736847777,1.45020884359905,5.79663055327599e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,MFGE8;Lactadherin,1.44278844224523,1.30861091856689,1.59072376635531,1.83083249161671e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,CNTN4;Contactin-4,1.99064257629199,1.65569492273692,2.39335025561109,2.40662617148726e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,CNTN4;Contactin-4,2.74975538420125,2.11320921279553,3.57804358752594,5.09676596216581e-14
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544201233522795,AGR3;Anterior gradient protein 3,1.35822441919247,1.20448733678752,1.53158403293046,5.86386500761795e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248279637159837,DLL1;Delta-like protein 1,1.53573527818149,1.28878700505651,1.83000203710758,1.61559228731739e-06
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14185118535325,DLL1;Delta-like protein 1,1.22412549555137,1.15298191340498,1.29965892043665,3.59867088915207e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,DLL1;Delta-like protein 1,4.59829204807132,4.08118385383365,5.18092066337421,1.17633593486808e-138
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0663932825619996,DLL1;Delta-like protein 1,3.34176525610216,2.39962960279828,4.653799492167,9.32581129147527e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0566516897831607,DLL1;Delta-like protein 1,3.25120086253967,2.26725579801029,4.66215901084256,1.44638251414641e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96519209549603,DLL1;Delta-like protein 1,1.23081670728212,1.16878541739067,1.29614020194302,3.51297820172192e-15
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34833222278838,DLL1;Delta-like protein 1,1.55494225390162,1.44162044167622,1.67717198166068,2.83400846658723e-30
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60802638812534,DLL1;Delta-like protein 1,1.27973434546926,1.19404471183841,1.37157342496172,3.05233327351948e-12
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71710835816214,DLL1;Delta-like protein 1,1.21062437177605,1.13240158404772,1.29425054696531,2.04136717290799e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.773890951729529,DLL1;Delta-like protein 1,1.47202352632573,1.3327798954737,1.6258147871343,2.42289843864082e-14
primary,Circulatory system disorders,I50 (heart failure),4.4257901789233,DLL1;Delta-like protein 1,1.3967286527459,1.33898523302551,1.45696224370848,2.92110904841592e-54
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23942626696068,DLL1;Delta-like protein 1,1.2292793067832,1.17749197533284,1.28334429935987,5.45267271399499e-21
primary,Circulatory system disorders,I63 (cerebral infarction),2.06569457510191,DLL1;Delta-like protein 1,1.26116669300717,1.18651665772932,1.34051335663041,9.08245781697786e-14
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72775371832807,DLL1;Delta-like protein 1,1.24568684175124,1.18120135955974,1.31369278840869,5.47646510906623e-16
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78013491054844,DLL1;Delta-like protein 1,1.53521987927471,1.39041966280901,1.69509978948276,2.23476702482786e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.798106453316641,DLL1;Delta-like protein 1,1.5393407621198,1.39535987662876,1.69817838509771,7.35782161756846e-18
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15488215488215,DLL1;Delta-like protein 1,1.41605318227099,1.33314352243301,1.50411908491312,1.30055540693079e-29
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404810794954532,DLL1;Delta-like protein 1,1.58499789447672,1.3815026750288,1.81846794139813,5.04774369347637e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704721634954193,DLL1;Delta-like protein 1,1.50662016353878,1.35722739102997,1.67245690160956,1.43860414161734e-14
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0468713381767049,DLL1;Delta-like protein 1,3.64408846105351,2.46148883230469,5.39485718468603,1.04833353408308e-10
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.65935189081945,DLL1;Delta-like protein 1,1.22968963862304,1.1478022603595,1.31741908825242,4.0888097597723e-09
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.09013584875236,DLL1;Delta-like protein 1,1.21517355870542,1.14286792285455,1.2920537432607,4.7697454073023e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.21492350677009,DLL1;Delta-like protein 1,2.0103623571344,1.66572499255678,2.42630495732638,3.38653224978233e-13
primary,Circulatory system disorders,I95 (hypotension),4.84405974602053,DLL1;Delta-like protein 1,1.32292610086617,1.27090683108488,1.37707456246734,1.4764950007055e-42
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101564483681321,DLL1;Delta-like protein 1,2.10404972430017,1.60130445562747,2.76463681017668,9.31639612201086e-08
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0957554912842961,DLL1;Delta-like protein 1,1.99903010660046,1.50897944294235,2.64822783755294,1.38351669658798e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.547945205479452,CCL22;C-C motif chemokine 22,1.35091721746932,1.20080242109805,1.5197981752787,5.59418802725758e-07
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96844502277163,CCL22;C-C motif chemokine 22,1.26419709675298,1.20091326315519,1.33081576203073,3.6422867009557e-19
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01106221006304,CCL22;C-C motif chemokine 22,1.3199958384215,1.21046998797126,1.43943181637267,3.34345658173209e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36063880502145,CCL22;C-C motif chemokine 22,1.22025251022212,1.13169267946313,1.31574252950878,2.23986225263461e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77885015557185,CCL22;C-C motif chemokine 22,1.29419196686415,1.17232269552968,1.42873020669359,3.20925836427447e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.804996530187369,CCL22;C-C motif chemokine 22,1.43059926088965,1.2982693519833,1.57641728361799,4.79454998636437e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15178947791003,CCL22;C-C motif chemokine 22,1.21921632791767,1.14788789847411,1.29497702365976,1.16278425429706e-10
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406383189612449,CCL22;C-C motif chemokine 22,1.41941861176891,1.23858299454759,1.62665659411213,4.72287594564092e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700410722434968,CCL22;C-C motif chemokine 22,1.31536614509237,1.18500241612588,1.46007136534933,2.63849101317421e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,CCL7;C-C motif chemokine 7,1.53361483626895,1.36756738550531,1.71982345510177,2.59410620741964e-13
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96630662582621,CCL7;C-C motif chemokine 7,1.28704883593068,1.22375478046116,1.35361653537017,1.03963597535213e-22
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35063298615896,CCL7;C-C motif chemokine 7,1.29757697665633,1.20544247340627,1.39675351374576,4.14431103126461e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.787339734150124,CCL7;C-C motif chemokine 7,1.30596694480952,1.18579563502541,1.43831669687211,5.95685202921326e-08
primary,Circulatory system disorders,I50 (heart failure),4.40480668342802,CCL7;C-C motif chemokine 7,1.24837230052449,1.19809075238425,1.30076406784333,3.84404776639314e-26
primary,Circulatory system disorders,I63 (cerebral infarction),2.06544853114909,CCL7;C-C motif chemokine 7,1.25143791837841,1.17877467366469,1.32858034579794,1.99543271681431e-13
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.765336628532706,CCL7;C-C motif chemokine 7,1.29821086891749,1.17625717086704,1.4328086594645,2.15694267335464e-07
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.616811047596597,CCL7;C-C motif chemokine 7,1.32471007953064,1.18815566443791,1.4769586572987,4.06414312834001e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781802467195725,CCL7;C-C motif chemokine 7,1.28491005163751,1.16626474786063,1.41562526332691,3.9467602489239e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.801823755994025,CCL7;C-C motif chemokine 7,1.41848212813642,1.29017577990712,1.55954838028914,4.93982507482972e-13
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08672155953386,CCL7;C-C motif chemokine 7,1.31687991802557,1.21271778423975,1.42998869237016,5.85678168684258e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15077296512206,CCL7;C-C motif chemokine 7,1.26083470221701,1.1886390105323,1.33741542405103,1.31832217862033e-14
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.390978034500373,CCL7;C-C motif chemokine 7,1.58687248305357,1.38741240222378,1.81500776080452,1.60882842036477e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686372844022262,CCL7;C-C motif chemokine 7,1.42666266444729,1.28774620748642,1.58056482426045,1.05845897242395e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.397450832590968,ATRAID;All-trans retinoic acid-induced differentiation factor,4.19812668050119,3.6405623045521,4.84108391813507,1.14155732766483e-86
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0501504513540621,ATRAID;All-trans retinoic acid-induced differentiation factor,3.34752307276253,2.23546192166545,5.01279427489819,4.49524898733611e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37544341457832,ATRAID;All-trans retinoic acid-induced differentiation factor,1.37006881352616,1.26415175721794,1.48486013888708,1.72148282019051e-14
primary,Circulatory system disorders,I46 (cardiac arrest),0.759753593429158,ATRAID;All-trans retinoic acid-induced differentiation factor,1.38390379481171,1.24199319825045,1.54202914797932,3.95711976941332e-09
primary,Circulatory system disorders,I50 (heart failure),4.31792040487692,ATRAID;All-trans retinoic acid-induced differentiation factor,1.24359613528937,1.1878235137283,1.30198748368977,1.25224229148861e-20
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.748687514266149,ATRAID;All-trans retinoic acid-induced differentiation factor,1.41017325205579,1.26492962352658,1.57209426028737,5.72990925571614e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.771777600182669,ATRAID;All-trans retinoic acid-induced differentiation factor,1.34388071004042,1.20710801613523,1.4961505836081,6.77363142254835e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08550091327368,ATRAID;All-trans retinoic acid-induced differentiation factor,1.30267744197261,1.21982146564046,1.39116138354995,3.11603507621186e-15
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406337031456878,ATRAID;All-trans retinoic acid-induced differentiation factor,1.46170920578326,1.26083135842528,1.69459126154669,4.83532571676781e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.68546360188274,ATRAID;All-trans retinoic acid-induced differentiation factor,1.46509748070235,1.30774887048319,1.641378307723,4.44199198481458e-11
primary,Circulatory system disorders,I95 (hypotension),4.54545454545454,ATRAID;All-trans retinoic acid-induced differentiation factor,1.25128371346098,1.19697892934986,1.30805220808951,4.06052227647126e-23
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544410911888277,PRSS8;Prostasin,2.44412409775684,2.18586283299711,2.73289911656757,1.92833085766382e-55
primary,Circulatory system disorders,I20 (angina pectoris),3.99010717230008,PRSS8;Prostasin,1.26623090285119,1.20883572980038,1.32635118222399,1.99160137849372e-23
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96927707192922,PRSS8;Prostasin,1.28965830772801,1.22275670397489,1.36022034905647,8.01806213681311e-21
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0163282188651,PRSS8;Prostasin,1.3594759699322,1.24346087434983,1.48631529221975,1.50167465318863e-11
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72876510944136,PRSS8;Prostasin,1.27591135079824,1.23661206923471,1.31645955558501,1.31048254963089e-52
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35577833912219,PRSS8;Prostasin,1.61064039538665,1.49314380515926,1.73738287918931,6.03533158857487e-35
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71140939597315,PRSS8;Prostasin,1.22830911727891,1.14612674765885,1.31638432718925,5.88105586673228e-09
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.86250123383673,PRSS8;Prostasin,1.20253036752723,1.13957244236241,1.26896652732965,1.79298410370528e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.777375423128394,PRSS8;Prostasin,1.51696467707905,1.37126270339691,1.67814804982666,6.05645763372579e-16
primary,Circulatory system disorders,I50 (heart failure),4.41538339418955,PRSS8;Prostasin,1.37038796048574,1.31266248682245,1.43065196202127,1.0651309871214e-46
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22484496899379,PRSS8;Prostasin,1.25147771903753,1.19711316807854,1.30831112964971,4.17255443200875e-23
primary,Circulatory system disorders,I63 (cerebral infarction),2.07034025420383,PRSS8;Prostasin,1.28598081354671,1.20776727249083,1.36925936848717,3.95437071900189e-15
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.626181474480151,PRSS8;Prostasin,1.42155522505195,1.26963830224933,1.59164957003294,1.06058639561505e-09
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71358370665666,PRSS8;Prostasin,1.30530054220933,1.23580949506099,1.37869915411831,1.35617571487576e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.777742773883594,PRSS8;Prostasin,1.4952129007603,1.35173589305277,1.65391895716478,5.4692668669803e-15
primary,Circulatory system disorders,I70 (atherosclerosis),0.813568670711527,PRSS8;Prostasin,1.96289683999389,1.78441712275412,2.15922833026353,1.01765367848506e-43
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08539347975967,PRSS8;Prostasin,1.39747615890552,1.28131487460047,1.52416837845442,4.07662778712404e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14798564020741,PRSS8;Prostasin,1.51830810978237,1.4280891496854,1.61422661655174,1.02443643637398e-40
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405719462717138,PRSS8;Prostasin,1.84325345759959,1.60777040771648,2.11322667256853,1.80251768103496e-18
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697853214264592,PRSS8;Prostasin,1.79808256135961,1.62025232696477,1.99543049169517,2.38377967934591e-28
primary,Circulatory system disorders,I85 (oesophageal varices),0.222327155392909,PRSS8;Prostasin,1.97724963477269,1.64837111506467,2.371745101864,2.064010537225e-13
primary,Circulatory system disorders,I95 (hypotension),4.83928359625192,PRSS8;Prostasin,1.30950352802518,1.25684544648821,1.36436782637179,6.0870301298783e-38
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106213489113117,PRSS8;Prostasin,2.5363745001846,1.97344836288257,3.25987531581006,3.61845722899529e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.209597572660491,ADH4;All-trans-retinol dehydrogenase [NAD(+)] ADH4,1.95103753173881,1.61468137895009,2.35746042524413,4.42693845658699e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0997804829375374,ADH4;All-trans-retinol dehydrogenase [NAD(+)] ADH4,2.55132420943087,1.95641681339393,3.32713109858017,4.70243815059112e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.541915289054093,SMOC2;SPARC-related modular calcium-binding protein 2,3.52879269844189,3.1412112504092,3.96419626567766,3.92461787010266e-100
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.064365125804564,SMOC2;SPARC-related modular calcium-binding protein 2,2.45549007474691,1.72735063227627,3.49056606951603,5.56637945383091e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.0565853658536585,SMOC2;SPARC-related modular calcium-binding protein 2,2.73533505498136,1.8780037526131,3.98404840916808,1.56580648577991e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35066358689269,SMOC2;SPARC-related modular calcium-binding protein 2,1.28451315993461,1.18729453445989,1.38969228793409,4.50867103104653e-10
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60619729358697,SMOC2;SPARC-related modular calcium-binding protein 2,1.23637602033602,1.15034822230688,1.32883733292207,8.09679636694438e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.776903706884772,SMOC2;SPARC-related modular calcium-binding protein 2,1.40119601179029,1.26267847739619,1.55490910679471,2.1304405658197e-10
primary,Circulatory system disorders,I63 (cerebral infarction),2.07109858272649,SMOC2;SPARC-related modular calcium-binding protein 2,1.2118547757902,1.13697037236539,1.29167129883094,3.53947957762746e-09
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77920556184822,SMOC2;SPARC-related modular calcium-binding protein 2,1.32383050973377,1.1935465391241,1.46833588892821,1.11320790835882e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.808909730363423,SMOC2;SPARC-related modular calcium-binding protein 2,1.47929820726076,1.33621041125412,1.63770852821825,4.55569201100704e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15034619188921,SMOC2;SPARC-related modular calcium-binding protein 2,1.2391362257135,1.16351992285873,1.31966677639944,2.48431974092862e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699984357891443,SMOC2;SPARC-related modular calcium-binding protein 2,1.50284746752727,1.34793026553196,1.67556925488412,2.15277592185779e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.399990697890746,MXRA8;Matrix remodeling-associated protein 8,2.09550032138334,1.80317637577965,2.43521468886762,4.87570620958246e-22
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13076415678906,GPR37;Prosaposin receptor GPR37,1.26567716970759,1.19019830453843,1.34594268182918,5.90409910093645e-14
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550330198118871,GPR37;Prosaposin receptor GPR37,3.92962058614926,3.47701058370412,4.44114781342928,1.69125968415591e-106
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0658432929627486,GPR37;Prosaposin receptor GPR37,2.99199364798043,2.11718274790621,4.22827268850947,5.27396790320472e-10
primary,Circulatory system disorders,I20 (angina pectoris),4.00736216849326,GPR37;Prosaposin receptor GPR37,1.20263662747187,1.14832387550184,1.25951823226251,5.05131779802259e-15
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96136899272466,GPR37;Prosaposin receptor GPR37,1.26665886231931,1.2009568875317,1.33595526213234,3.37148645149599e-18
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00721437278922,GPR37;Prosaposin receptor GPR37,1.29401525661927,1.18315381307452,1.4152644109832,1.69760972961639e-08
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69682339045566,GPR37;Prosaposin receptor GPR37,1.2085552222198,1.17121789225917,1.24708283130593,2.70608306998006e-32
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34564168285308,GPR37;Prosaposin receptor GPR37,1.38672335224566,1.28328824338359,1.49849549824687,1.3801238896976e-16
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61293558288362,GPR37;Prosaposin receptor GPR37,1.23329007154225,1.14903167377961,1.32372713065559,6.33962901674931e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.77876954412029,GPR37;Prosaposin receptor GPR37,1.49000739663157,1.3456401856724,1.64986306566597,1.72819552850128e-14
primary,Circulatory system disorders,I50 (heart failure),4.39370142161008,GPR37;Prosaposin receptor GPR37,1.34646088965091,1.28914690482105,1.40632298815563,5.74680227434563e-41
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.1864620132375,GPR37;Prosaposin receptor GPR37,1.23452677640471,1.18084922630205,1.29064433266636,1.55466218105293e-20
primary,Circulatory system disorders,I63 (cerebral infarction),2.05679724425218,GPR37;Prosaposin receptor GPR37,1.24020628694353,1.16483065154882,1.32045944372179,1.70557255684507e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.767186782011068,GPR37;Prosaposin receptor GPR37,1.48720224582464,1.34243108315907,1.64758589676052,3.06278731126049e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.797521487107735,GPR37;Prosaposin receptor GPR37,1.7402393650997,1.57319455362394,1.92502131466603,5.30225459072936e-27
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16137453706514,GPR37;Prosaposin receptor GPR37,1.33906624956711,1.25900627462553,1.42421722343128,1.65765573749433e-20
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.397665960593101,GPR37;Prosaposin receptor GPR37,1.74887075878509,1.51655454010591,2.01677476810029,1.51129421020596e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.688041282476948,GPR37;Prosaposin receptor GPR37,1.61531622793866,1.44956715056973,1.80001769163743,3.92048726515535e-18
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0478917646119769,GPR37;Prosaposin receptor GPR37,3.71268633403572,2.48636695408616,5.54384773827632,1.43128083881744e-10
primary,Circulatory system disorders,I95 (hypotension),4.76314628374313,GPR37;Prosaposin receptor GPR37,1.27297530810359,1.22137848457105,1.32675182632724,2.86852625430322e-30
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0978395431492352,GPR37;Prosaposin receptor GPR37,2.02553757170058,1.52180766487394,2.69600590736316,1.31032557991102e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.795652258909545,CPM;Carboxypeptidase M,1.39877654559413,1.26949130771174,1.54122821686032,1.18268754149791e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.216724915555381,CPM;Carboxypeptidase M,2.11316111374879,1.76925203076123,2.52391960841143,1.51219347143077e-16
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101499063085571,CPM;Carboxypeptidase M,2.75086603956831,2.14673362072052,3.52501302192787,1.26176467622398e-15
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.251860591758939,PROS1;Vitamin K-dependent protein S,0.588508053149421,0.489748236627041,0.707183207043321,1.54445006709057e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.514704215132757,PROS1;Vitamin K-dependent protein S,0.696412994620816,0.612332867043398,0.792038260853897,3.55913385827437e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.04540295119182,PROS1;Vitamin K-dependent protein S,0.786457477168299,0.736831879908,0.839425356393582,5.06884654390733e-13
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3765016381507,PROS1;Vitamin K-dependent protein S,0.62546423385304,0.577820528188788,0.677036361196142,3.73996583920428e-31
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14185118535325,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.26849762810405,1.19491001706579,1.3466170753651,6.19214810787933e-15
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,NBL1;Neuroblastoma suppressor of tumorigenicity 1,5.044803686115,4.4989287017217,5.6569121048084,7.44242632565848e-169
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0663932825619996,NBL1;Neuroblastoma suppressor of tumorigenicity 1,3.33490898002937,2.39977768776307,4.63443674878379,7.29565434174109e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0566516897831607,NBL1;Neuroblastoma suppressor of tumorigenicity 1,3.7779022528504,2.64785557851254,5.39022805772128,2.30620118114539e-13
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96519209549603,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.2288780130314,1.16698466206161,1.29405400088477,5.42475703680331e-15
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0170552339227,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.2966548499354,1.18911195905131,1.4139238841752,4.08025728766522e-09
primary,Circulatory system disorders,I26 (pulmonary embolism),2.008008363414,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.24932556436675,1.17424300233616,1.32920899905304,1.93240908415887e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34833222278838,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.52851295247288,1.41712840492187,1.64865218830059,4.22583218291257e-28
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60802638812534,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.24691996767521,1.1636338505484,1.33616721879859,3.93203822281919e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.773890951729529,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.53303259450146,1.38810678859256,1.69308943311689,3.38836002645587e-17
primary,Circulatory system disorders,I50 (heart failure),4.4257901789233,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.37172112694443,1.31508635261459,1.43079490283263,7.23837687206378e-49
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23942626696068,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.26729706095704,1.21398343793973,1.32295201937515,3.34535604476253e-27
primary,Circulatory system disorders,I63 (cerebral infarction),2.06569457510191,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.30098733641828,1.22406224940473,1.3827467110793,2.64056171245387e-17
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72775371832807,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.25752360794323,1.1924879251954,1.32610619455577,2.7318344380937e-17
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78013491054844,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.51999933912317,1.37673423710627,1.67817283006707,1.13422023410398e-16
primary,Circulatory system disorders,I70 (atherosclerosis),0.798106453316641,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.48705555762332,1.34803384906448,1.6404144695573,2.30705973602139e-15
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15488215488215,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.38785789361509,1.30673277391535,1.4740194562492,1.47565448363466e-26
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404810794954532,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.60846684918614,1.40202068706507,1.84531200487966,1.1904953902899e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704721634954193,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.5950283481392,1.43700657569972,1.77042713261689,1.76814924612686e-18
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0468713381767049,NBL1;Neuroblastoma suppressor of tumorigenicity 1,3.69033684242034,2.50028952792049,5.44680360352169,4.91269483546508e-11
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.65935189081945,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.21727403193391,1.13644993486018,1.30384632298205,2.0363749712741e-08
primary,Circulatory system disorders,I95 (hypotension),4.84405974602053,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.33464666106643,1.28221874988877,1.38921826720306,2.9393256920449e-45
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12025316455696,ASGR1;Asialoglycoprotein receptor 1,1.24330083585305,1.17134040978594,1.31968209712442,8.13295862037853e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,ASGR1;Asialoglycoprotein receptor 1,3.13627983309763,2.82906783520673,3.47685236426157,1.03144008629902e-104
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0671299952614121,ASGR1;Asialoglycoprotein receptor 1,2.43832012845313,1.79836259305293,3.30601018492419,9.56172594929412e-09
primary,Circulatory system disorders,I15 (secondary hypertension),0.0572805562139527,ASGR1;Asialoglycoprotein receptor 1,2.725084706095,1.97505108954896,3.75994661337534,1.03540242259825e-09
primary,Circulatory system disorders,I20 (angina pectoris),3.98857450375675,ASGR1;Asialoglycoprotein receptor 1,1.22299070282164,1.16956644029789,1.2788553156563,1.01837945069613e-18
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9690922365539,ASGR1;Asialoglycoprotein receptor 1,1.31129403147613,1.24615424086267,1.37983885188608,1.90608692929293e-25
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02042834259497,ASGR1;Asialoglycoprotein receptor 1,1.36467523558684,1.25320266504366,1.48606330849058,8.6006118732984e-13
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68682726806765,ASGR1;Asialoglycoprotein receptor 1,1.23554878150621,1.1988055058961,1.27341823504586,6.53377073711879e-43
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34152382839591,ASGR1;Asialoglycoprotein receptor 1,1.35245791796995,1.25529317209232,1.45714360640614,2.06669322376673e-15
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71217946177321,ASGR1;Asialoglycoprotein receptor 1,1.22753678097809,1.14871273571186,1.31176968950401,1.41002801919835e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.782500444602525,ASGR1;Asialoglycoprotein receptor 1,1.46252451681126,1.32775766383268,1.61097014955249,1.28259610686888e-14
primary,Circulatory system disorders,I50 (heart failure),4.41132519077885,ASGR1;Asialoglycoprotein receptor 1,1.41601613116247,1.35866985651311,1.47578285784467,4.24071580913934e-61
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19838894357284,ASGR1;Asialoglycoprotein receptor 1,1.24119316201713,1.18917501974556,1.29548673648368,4.52399303082245e-23
primary,Circulatory system disorders,I63 (cerebral infarction),2.07280581812417,ASGR1;Asialoglycoprotein receptor 1,1.25615117616179,1.18268943667677,1.33417592855688,1.19566574080681e-13
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.782252888318356,ASGR1;Asialoglycoprotein receptor 1,1.30645185942132,1.18367836544121,1.44195966642443,1.10274193225758e-07
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620774188446482,ASGR1;Asialoglycoprotein receptor 1,1.37341676742502,1.23149448669854,1.53169473141616,1.18635691889133e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72257118513087,ASGR1;Asialoglycoprotein receptor 1,1.21490703778217,1.15244814367593,1.28075099825724,4.8645659164037e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769002668775328,ASGR1;Asialoglycoprotein receptor 1,1.46546556348716,1.32927109951637,1.61561424042702,1.60098699138674e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.79898742188118,ASGR1;Asialoglycoprotein receptor 1,1.79262755014928,1.63233869662368,1.96865610072286,2.64207440414044e-34
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08381788695067,ASGR1;Asialoglycoprotein receptor 1,1.24899495822307,1.1490892606524,1.3575867942417,1.72233701992625e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12868213949576,ASGR1;Asialoglycoprotein receptor 1,1.39193250215966,1.31152951042948,1.47726457937954,1.23935565453642e-27
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401415831207609,ASGR1;Asialoglycoprotein receptor 1,1.91351290572606,1.6795168148786,2.1801101411687,1.82212512874944e-22
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700643245917862,ASGR1;Asialoglycoprotein receptor 1,1.56146585485202,1.41062803437712,1.72843269554427,8.1549018039104e-18
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473914932269657,ASGR1;Asialoglycoprotein receptor 1,2.43362712551804,1.69360498582258,3.49700256886091,1.52141636510846e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.215321401762079,ASGR1;Asialoglycoprotein receptor 1,1.74838718754246,1.4599390777687,2.09382556033407,1.25267223186509e-09
primary,Circulatory system disorders,I95 (hypotension),4.82087922992954,ASGR1;Asialoglycoprotein receptor 1,1.27871594087296,1.22894433117133,1.33050327502154,6.68290277514406e-34
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100714878154745,ASGR1;Asialoglycoprotein receptor 1,1.95244127313569,1.50649426561567,2.53039590793652,4.2489152090613e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.546320143604152,CD5;T-cell surface glycoprotein CD5,2.39420235871277,2.13700288541624,2.68235713371499,3.11310755407102e-51
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544853084257637,CD5;T-cell surface glycoprotein CD5,2.67601162268906,1.88575776109572,3.79743270981212,3.54440222603288e-08
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02865826335989,CD5;T-cell surface glycoprotein CD5,1.29876909585636,1.19270980645574,1.41425949147182,1.8046894690868e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3528550512445,CD5;T-cell surface glycoprotein CD5,1.21301631111242,1.12502854372667,1.30788554586422,5.00032919014841e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.778694907335306,CD5;T-cell surface glycoprotein CD5,1.27743196093992,1.15847409858918,1.40860500620435,9.127794809515e-07
primary,Circulatory system disorders,I63 (cerebral infarction),2.07727299349876,CD5;T-cell surface glycoprotein CD5,1.22297583942988,1.15123782623339,1.29918412142758,6.73787856094351e-11
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.621323672626699,CD5;T-cell surface glycoprotein CD5,1.31344104404655,1.17684660192032,1.46588975434105,1.13669505335897e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.804754481683554,CD5;T-cell surface glycoprotein CD5,1.51762067507155,1.37880854394988,1.67040777598224,1.55103525378124e-17
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15645654532899,CD5;T-cell surface glycoprotein CD5,1.25601253838648,1.18286601969974,1.33368231930824,9.63909139230281e-14
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409093565542633,CD5;T-cell surface glycoprotein CD5,1.63261367733024,1.42903592282514,1.86519273366924,5.44419856038205e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.69805986155796,CD5;T-cell surface glycoprotein CD5,1.45028996660402,1.30764547703401,1.60849482843245,1.95541302219942e-12
primary,Circulatory system disorders,I95 (hypotension),4.82158568775051,CD5;T-cell surface glycoprotein CD5,1.20974717679299,1.16218715500315,1.2592534906778,1.34072007808173e-20
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545118271196339,BSG;Basigin,4.08293150092564,3.65078371215129,4.56623315858599,3.99455153657029e-134
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0659899462376026,BSG;Basigin,2.42847198890011,1.7505029366995,3.36901817028191,1.08300574501237e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.054365765101062,BSG;Basigin,3.08318142808672,2.16485581052423,4.39105813527458,4.34971306106543e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34982469809115,BSG;Basigin,1.37841690321278,1.27831128634385,1.48636187395098,7.24661866209778e-17
primary,Circulatory system disorders,I46 (cardiac arrest),0.775058275058275,BSG;Basigin,1.3999373555619,1.2680232399755,1.54557466906957,2.69033848712547e-11
primary,Circulatory system disorders,I50 (heart failure),4.42838396302172,BSG;Basigin,1.2122726934834,1.16225584397702,1.26444198235802,3.4145641234163e-19
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773446305725057,BSG;Basigin,1.35243129251502,1.22461373824819,1.49358964696112,2.51907620137754e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.802986409503626,BSG;Basigin,1.57247346637325,1.42681722196053,1.73299898851117,7.04223848082814e-20
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1537128907788,BSG;Basigin,1.25449038567596,1.18111456398552,1.33242462309755,1.6674178098225e-13
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406267008786253,BSG;Basigin,1.60540349274841,1.4011870371738,1.83938354134881,9.15045289699359e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700443614289049,BSG;Basigin,1.48586090555563,1.33874941298476,1.64913807561367,9.7434462083008e-14
primary,Circulatory system disorders,I85 (oesophageal varices),0.211666925586453,BSG;Basigin,1.93931490283812,1.60941647941509,2.33683595295165,3.3552328149694e-12
primary,Circulatory system disorders,I95 (hypotension),4.79739352673781,BSG;Basigin,1.26609578218225,1.21611803038789,1.31812742645416,1.62369624989532e-30
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104829942537661,BSG;Basigin,2.91107699635608,2.25567502429652,3.75691054226947,2.20391244058126e-16
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243399744822848,TFF3;Trefoil factor 3,1.66843624803783,1.40663817349605,1.97895917103403,4.15284801571224e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.504158819836785,TFF3;Trefoil factor 3,1.43797946435376,1.27402055172071,1.62303891967076,4.08327345607221e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12903859373465,TFF3;Trefoil factor 3,1.32984286521615,1.25261039666871,1.41183727268235,9.80766160723374e-21
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.205938885184168,TFF3;Trefoil factor 3,1.89806232952607,1.56606902899919,2.30043538315053,6.45899909631814e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550693283508703,TFF3;Trefoil factor 3,3.76372593061032,3.36781829766373,4.20617492653189,8.0790244217377e-121
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.062741407368194,TFF3;Trefoil factor 3,2.92200539391452,2.07853667035852,4.10775313412817,6.81992028653592e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0568817056665947,TFF3;Trefoil factor 3,2.82957707469873,1.96932290313682,4.06561382539527,1.85801284996163e-08
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.94710124491358,TFF3;Trefoil factor 3,1.26201809558284,1.1975870163561,1.32991561517142,3.21021936834715e-18
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.997584588496357,TFF3;Trefoil factor 3,1.33008573912731,1.21754184404513,1.45303266748694,2.55525009985372e-10
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.67706339834683,TFF3;Trefoil factor 3,1.28333857763393,1.24451318474349,1.32337521613556,4.92123027381709e-57
primary,Circulatory system disorders,I26 (pulmonary embolism),1.98649264225307,TFF3;Trefoil factor 3,1.27176571663433,1.19518181352884,1.35325690175205,3.28429725112185e-14
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3399445133109,TFF3;Trefoil factor 3,1.71812813628439,1.59545101528599,1.85023812352078,1.64395425722778e-46
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61067739137292,TFF3;Trefoil factor 3,1.3192408240917,1.23193213843761,1.41273719359038,2.18310601575957e-15
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70435535612367,TFF3;Trefoil factor 3,1.29129744350844,1.20702169086527,1.38145743380642,1.1360410246167e-13
primary,Circulatory system disorders,I42 (cardiomyopathy),0.674559471365638,TFF3;Trefoil factor 3,1.3722627827221,1.2332712227702,1.52691890484101,6.31851607510757e-09
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85185695447656,TFF3;Trefoil factor 3,1.28383406324359,1.21820760181122,1.35299590931297,1.03045684467557e-20
primary,Circulatory system disorders,I45 (other conduction disorders),1.75352375710157,TFF3;Trefoil factor 3,1.29328456648089,1.20954140723121,1.38282572212753,5.08199829467064e-14
primary,Circulatory system disorders,I46 (cardiac arrest),0.780974059102861,TFF3;Trefoil factor 3,1.73222368686425,1.56859953836882,1.91291583857909,1.94021569032767e-27
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.34281200631911,TFF3;Trefoil factor 3,1.238782160397,1.14830372823519,1.33638967041963,3.13718894743044e-08
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.36443429121077,TFF3;Trefoil factor 3,1.2241615353057,1.18456852257114,1.26507790471192,1.77493593849857e-33
primary,Circulatory system disorders,I50 (heart failure),4.40486791332739,TFF3;Trefoil factor 3,1.53519538942805,1.47219561246182,1.60089112056246,2.01535515800389e-89
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19509275882704,TFF3;Trefoil factor 3,1.34969583838578,1.29246057450593,1.40946570602533,6.53650806741126e-42
primary,Circulatory system disorders,I63 (cerebral infarction),2.06029359675705,TFF3;Trefoil factor 3,1.31004423918746,1.23236676392026,1.39261781384694,4.73633294390719e-18
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.776830531431758,TFF3;Trefoil factor 3,1.40203968862421,1.26860936823547,1.54950399839125,3.52410446511613e-11
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.616459871210931,TFF3;Trefoil factor 3,1.33901742691257,1.19712839957509,1.49772377817781,3.25046965684669e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7130715353742,TFF3;Trefoil factor 3,1.31268745371029,1.24488190052064,1.38418620305086,8.75789946974477e-24
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769547890614264,TFF3;Trefoil factor 3,1.614039210417,1.46188386472505,1.78203114188793,2.6277008020639e-21
primary,Circulatory system disorders,I70 (atherosclerosis),0.801319820881451,TFF3;Trefoil factor 3,1.74510817168557,1.58313128231546,1.92365760496476,3.92532254467973e-29
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08610260036137,TFF3;Trefoil factor 3,1.36590573788977,1.25298519074079,1.48900282189062,1.4145293992227e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14559844101095,TFF3;Trefoil factor 3,1.47078995865194,1.38555435024583,1.56126903436704,9.12173297470189e-37
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404492617027961,TFF3;Trefoil factor 3,1.80148575467081,1.56963234529231,2.06758667659685,5.58009062222663e-17
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70169231676396,TFF3;Trefoil factor 3,1.54493719465486,1.3924887152381,1.71407560385141,2.28227574027682e-16
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0490224915191089,TFF3;Trefoil factor 3,3.2720965731575,2.21765748613583,4.8278943213746,2.32828955642533e-09
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.68199102669858,TFF3;Trefoil factor 3,1.21434714301041,1.13451052768404,1.29980193903342,2.17865411564325e-08
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.528352287235087,TFF3;Trefoil factor 3,1.41294561045172,1.25680904686322,1.58847941385963,7.21935987888023e-09
primary,Circulatory system disorders,I95 (hypotension),4.79897516752069,TFF3;Trefoil factor 3,1.39754223364665,1.34312266320264,1.4541667327457,2.75778685513247e-61
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0981065437064652,TFF3;Trefoil factor 3,2.22913440917157,1.69398644569364,2.93334118864096,1.04647549524593e-08
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25298582102724,NPDC1;Neural proliferation differentiation and control protein 1,1.55695903897931,1.31111946427241,1.84889441055214,4.43361992966569e-07
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511503939168267,NPDC1;Neural proliferation differentiation and control protein 1,1.41838733438493,1.25685128370105,1.60068470823324,1.46407134378813e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.15062203210235,NPDC1;Neural proliferation differentiation and control protein 1,1.22643276875409,1.15588630739902,1.30128484665454,1.45085688653588e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,NPDC1;Neural proliferation differentiation and control protein 1,4.90530209990023,4.39099975671516,5.4798428659641,3.03104464368927e-174
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666000666000666,NPDC1;Neural proliferation differentiation and control protein 1,3.25501365333114,2.38791879140677,4.43696574669961,8.19271355389908e-14
primary,Circulatory system disorders,I15 (secondary hypertension),0.0568282024651682,NPDC1;Neural proliferation differentiation and control protein 1,2.80436583154708,1.98813506106588,3.95570093358368,4.21466333795996e-09
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02218995860228,NPDC1;Neural proliferation differentiation and control protein 1,1.25912748581709,1.15591582884317,1.37155490562555,1.28892433789373e-07
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99465716829919,NPDC1;Neural proliferation differentiation and control protein 1,1.21547473895686,1.14262738612036,1.29296642018925,6.08608438468993e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,NPDC1;Neural proliferation differentiation and control protein 1,1.51937644801173,1.41028434342667,1.63690733824897,3.67757899854469e-28
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60909126718399,NPDC1;Neural proliferation differentiation and control protein 1,1.26046926776067,1.17676412331377,1.35012849516103,4.04075916516381e-11
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71654410318927,NPDC1;Neural proliferation differentiation and control protein 1,1.20628962619432,1.12902186269337,1.2888454248288,2.80939334506121e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,NPDC1;Neural proliferation differentiation and control protein 1,1.59702345379886,1.44933029166908,1.75976720188912,3.22143709108146e-21
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,NPDC1;Neural proliferation differentiation and control protein 1,1.35988346401882,1.30425347180052,1.41788622817227,3.62157006037841e-47
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2193167776139,NPDC1;Neural proliferation differentiation and control protein 1,1.24583848402071,1.19369634854279,1.3002582525797,7.00906875557445e-24
primary,Circulatory system disorders,I63 (cerebral infarction),2.08398867568417,NPDC1;Neural proliferation differentiation and control protein 1,1.20572172110148,1.1352854136428,1.2805280956365,1.11932363565677e-09
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.611968695447502,NPDC1;Neural proliferation differentiation and control protein 1,1.31905498632822,1.18114783321059,1.47306375039265,8.88370428907417e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77276115011964,NPDC1;Neural proliferation differentiation and control protein 1,1.43837748054539,1.30388051719729,1.58674797978214,3.94237301187657e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,NPDC1;Neural proliferation differentiation and control protein 1,1.54820654292818,1.40575879897409,1.70508874019846,6.94140737404383e-19
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15754445217045,NPDC1;Neural proliferation differentiation and control protein 1,1.36683456748937,1.28763561580849,1.45090483048715,1.05491155624006e-24
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.413944637357032,NPDC1;Neural proliferation differentiation and control protein 1,1.46594412186536,1.2824406309172,1.67570499298253,2.07326890827794e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.710863247191893,NPDC1;Neural proliferation differentiation and control protein 1,1.41336812238918,1.27541293338054,1.56624525054107,4.04653718146459e-11
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0489763933783916,NPDC1;Neural proliferation differentiation and control protein 1,2.94009512171124,2.04096222106725,4.23533529209084,7.01133614940525e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,NPDC1;Neural proliferation differentiation and control protein 1,1.56378011861462,1.30331571917602,1.87629767936841,1.5111139285607e-06
primary,Circulatory system disorders,I95 (hypotension),4.80063010731515,NPDC1;Neural proliferation differentiation and control protein 1,1.31749946394902,1.26586784433837,1.37123700966842,1.21888258666379e-41
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0980142316664379,NPDC1;Neural proliferation differentiation and control protein 1,2.0637294479356,1.57600715525318,2.70238572209554,1.38858684454646e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.211023121780762,APOF;Apolipoprotein F,0.443515401451623,0.352321640989403,0.558313451232791,4.43486462853226e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.108878101891757,APOF;Apolipoprotein F,0.270198096853641,0.195571579022486,0.373300721445498,2.10563248835097e-15
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246362754607177,NFASC;Neurofascin,1.56616177858832,1.31421904789477,1.86640326103942,5.34481745796972e-07
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.515693763207382,NFASC;Neurofascin,1.35585820729894,1.2013893051092,1.53018798359687,8.09588183589525e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.1177475396471,NFASC;Neurofascin,1.23022818147987,1.15902608742438,1.30580441193566,9.6529714566087e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,NFASC;Neurofascin,1.57205615764058,1.39795739189811,1.76783682900387,4.21340067508096e-14
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,NFASC;Neurofascin,1.49902716956479,1.39071928239428,1.61576997136677,3.70242221131227e-26
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61513433475558,NFASC;Neurofascin,1.24864114378334,1.16599878530639,1.3371409349615,2.07539129478577e-10
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69610207733603,NFASC;Neurofascin,1.26221265384387,1.18089817543841,1.34912629781321,7.18495553993892e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.77379567139865,NFASC;Neurofascin,1.42094635134248,1.2879753753001,1.56764529207171,2.41160504213289e-12
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37587822014051,NFASC;Neurofascin,1.24135862208788,1.15269161972099,1.33684604127243,1.0765898069794e-08
primary,Circulatory system disorders,I50 (heart failure),4.42893177685223,NFASC;Neurofascin,1.27324369770206,1.22142391991038,1.32726196639162,4.43181732196637e-30
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22046561138599,NFASC;Neurofascin,1.22339720016657,1.17238028747832,1.27663414794755,1.73073229681809e-20
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,NFASC;Neurofascin,1.63351257557795,1.48333691789215,1.79889228292321,1.99301630739708e-23
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15212264150943,NFASC;Neurofascin,1.21663501356589,1.1462291614446,1.2913654668923,1.13920905685964e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699300699300699,NFASC;Neurofascin,1.37698231981916,1.24145996609613,1.52729879406174,1.43435077069748e-09
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0445727795972946,NFASC;Neurofascin,3.04345968122229,2.03888428772978,4.54299779883013,5.16562670254535e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.21132221791392,NFASC;Neurofascin,4.15857531830574,3.44751184868772,5.01629854719845,3.50125865047066e-50
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.269981548023696,NFASC;Neurofascin,1.56659280041959,1.32717845075622,1.84919593964782,1.12631956409607e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104659275912861,NFASC;Neurofascin,9.0459429367088,6.93352920946496,11.8019382542568,3.06925351591344e-59
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.400553144819035,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,2.18066864526927,1.88787740629642,2.51886892898906,3.03363640516806e-26
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96430141133955,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.20190849209701,1.13470489417951,1.27309226459226,3.73565790507197e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.38082610669151,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.39254434744658,1.28409574118909,1.51015200611889,1.197029825355e-15
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.746339834994515,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.32389968217835,1.18529291892362,1.47871495770312,6.60564102972619e-07
primary,Circulatory system disorders,I50 (heart failure),4.31055184669324,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.2068162054962,1.15130894582844,1.26499959817499,5.07998979998854e-15
primary,Circulatory system disorders,I63 (cerebral infarction),2.06089552238806,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.21297278840905,1.13367793071607,1.29781390777494,2.17686658538477e-08
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.740970170589917,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.37487905224887,1.23012615136328,1.53666549257395,2.03609238602526e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.765105470146585,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.477393679516,1.32534365046389,1.64688764571352,1.88025061823772e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11446088488739,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.28438915206865,1.20180562173845,1.37264750980723,1.56773305428081e-13
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402726146220569,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.48251152774408,1.27539675089511,1.72326017637381,2.92335787359824e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.691661896584621,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.49615237163852,1.33532928954566,1.67634450669558,3.81158092560345e-12
primary,Circulatory system disorders,I95 (hypotension),4.53164980749456,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.23189774947943,1.17727317218433,1.28905686549942,2.01399847898903e-19
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,LSP1;Lymphocyte-specific protein 1,1.48538219018848,1.32084611104271,1.67041431434232,3.95719355108157e-11
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13615569512289,REG1B;Lithostathine-1-beta,1.20704492287956,1.13787968057396,1.2804143273869,4.09872153821108e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,REG1B;Lithostathine-1-beta,2.96511868805243,2.64763997101068,3.32066630301008,6.13412224115254e-79
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0657932929543123,REG1B;Lithostathine-1-beta,2.30895464159993,1.65888032391341,3.21377706403137,7.04341090973685e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35161378024624,REG1B;Lithostathine-1-beta,1.4417139999138,1.33910922808928,1.55218051966771,2.67993291919968e-22
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60521451503064,REG1B;Lithostathine-1-beta,1.2166727086706,1.13654139077303,1.30245364756756,1.6811442183399e-08
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72480770724885,REG1B;Lithostathine-1-beta,1.21107332456143,1.13396818038139,1.29342129950329,1.15826213825874e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.782415028565895,REG1B;Lithostathine-1-beta,1.55504613243069,1.41147369829142,1.7132224829374,4.15122203624346e-19
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3583567196757,REG1B;Lithostathine-1-beta,1.20770855429771,1.1213296087533,1.30074149539805,6.21408734351426e-07
primary,Circulatory system disorders,I50 (heart failure),4.42925495557074,REG1B;Lithostathine-1-beta,1.31696606174064,1.26380932394216,1.37235861052726,3.38299211753474e-39
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21309603496476,REG1B;Lithostathine-1-beta,1.21772107752192,1.16715929972437,1.27047321046177,8.72384215132538e-20
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.774553746952897,REG1B;Lithostathine-1-beta,1.27621887929268,1.15638167788934,1.40847495165773,1.24728020657035e-06
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771153436282963,REG1B;Lithostathine-1-beta,1.44266915190229,1.30839094047683,1.5907281359591,1.94524291608878e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.804481836157096,REG1B;Lithostathine-1-beta,1.50573479485923,1.36836695083576,1.65689274435122,5.05374307854795e-17
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16089968793546,REG1B;Lithostathine-1-beta,1.33646350774657,1.26001065800742,1.41755523747939,4.92206400044617e-22
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406976744186046,REG1B;Lithostathine-1-beta,1.60353222654371,1.40201045386371,1.83402027743667,5.52855325335049e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704198029021494,REG1B;Lithostathine-1-beta,1.40745047706787,1.27049299469955,1.55917179682445,6.01496126966898e-11
primary,Circulatory system disorders,I95 (hypotension),4.80432583832568,REG1B;Lithostathine-1-beta,1.25717612283419,1.20857409967773,1.3077326448133,5.42127086474231e-30
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0948895214856987,REG1B;Lithostathine-1-beta,1.9879603664679,1.50836326272103,2.62004950420096,1.07223445747408e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,IDUA;Alpha-L-iduronidase,1.24070440853404,1.15144449179226,1.33688374935014,1.49769811563361e-08
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620429438307141,IDUA;Alpha-L-iduronidase,1.30867165146933,1.17252503586489,1.46062680025947,1.58951221212317e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,IDUA;Alpha-L-iduronidase,1.36797598639594,1.24203759650557,1.50668410088466,2.03427258719505e-10
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,IDUA;Alpha-L-iduronidase,1.45483481566158,1.27074308685198,1.66559579411476,5.60097180655532e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.211835584491303,IDUA;Alpha-L-iduronidase,2.35904442530676,1.95290825971442,2.84964261525768,5.42370707290373e-19
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10490936996095,IDUA;Alpha-L-iduronidase,3.0403432842699,2.32439272471556,3.97681819768055,4.79123126642746e-16
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13278968106169,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.21132468329966,1.14128054051081,1.28566766565062,2.81861164596758e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.543712950967691,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,4.31564833056898,3.83269521725924,4.85945775945664,7.70226885715801e-129
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645779926028844,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,2.84401719130214,2.03737152624064,3.97003378139229,8.16715378722793e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0567725768876881,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,2.77698671234978,1.9416797567532,3.97164113893959,2.21056352557753e-08
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96494331430409,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.2548808935864,1.19217460792971,1.32088541947963,3.93019097972677e-18
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00942786020894,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.2398447089016,1.13731618019602,1.35161613714696,1.05164390964721e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34922817078439,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.39261217913189,1.29214770595234,1.50088776424915,4.35554864803854e-18
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60953917594742,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.22305210158184,1.14178246194202,1.31010634078186,9.49870767992178e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.779475127301214,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.51785233434065,1.37633662504904,1.67391876880504,6.44583889885545e-17
primary,Circulatory system disorders,I50 (heart failure),4.42158063114656,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.34476700798874,1.28980302566397,1.40207323893046,5.32598298537673e-44
primary,Circulatory system disorders,I63 (cerebral infarction),2.07404497692232,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.24309148831199,1.17019898425691,1.32052451685811,1.69059176729081e-12
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.783284626548179,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.29583399667719,1.17355422089478,1.43085484849953,2.98239771902896e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71607847758204,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.230716752424,1.16730061207647,1.29757811229336,1.45847477496508e-14
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781785763269784,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.41434234957472,1.28232298310461,1.55995354380805,4.09756438850373e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.807668934151457,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.62755455657471,1.47805456283517,1.79217594616126,3.84175617668246e-23
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14949190219117,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.3911471918168,1.31040479591752,1.47686464161994,2.72559624484556e-27
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.403739490033906,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.74705377193412,1.52560161295628,2.00065132083515,7.15816762777531e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700343305541932,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.502981394955,1.35510940344858,1.66698944589427,1.25102838367274e-14
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0489284665818573,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,3.36437983999967,2.29814939897369,4.92528976264601,4.4048947622128e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.223205544895641,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.7108525385553,1.42579461137823,2.05290185930199,7.71576858504007e-09
primary,Circulatory system disorders,I95 (hypotension),4.8313170059998,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.29256115296884,1.24209235834419,1.34508059963538,1.4680311843969e-36
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10569583088667,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,2.07020893698455,1.59082376182957,2.69405395217489,6.14592084325097e-08
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.253144684942797,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.69826003221077,1.44015385592988,2.00262432040104,3.044375185386e-10
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51185503324116,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.37555550581165,1.22121928527251,1.54939655178024,1.51005775963764e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.1362235180931,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.30845155078623,1.23402143614579,1.38737092452958,2.31753329601845e-19
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544600200538702,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,3.29482763776285,3.00288907530129,3.61514824235615,5.34465582407259e-140
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0646830530401035,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.7675517753215,2.08664668429445,3.67064673034238,1.60692700139729e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0568649750970626,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.84561977371492,2.11167158627633,3.83466441902378,6.36538796332565e-12
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96983852132243,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.23255685203384,1.171930814547,1.29631918082366,4.4730264762589e-16
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01107271870582,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.28003910025733,1.17599053429575,1.39329361113337,1.14521515967793e-08
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72547423267931,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.22452683507185,1.18871619830189,1.26141628418382,8.38384023040368e-41
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99184255335999,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.20329248881643,1.13164364858179,1.27947770082622,3.45621767425175e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35143110061965,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.60451638460213,1.49306467146737,1.72428755274648,6.42464674333156e-38
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.74631262643125,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.30774420515802,1.18450087832154,1.44381058505231,1.07995557084664e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60823035534795,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.31617689881881,1.22992642345252,1.40847582095319,1.94748466526246e-15
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71178970565087,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.26717552793529,1.18691936899677,1.35285838325758,1.31074907260111e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.676313306071091,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.30667639412309,1.17781109097288,1.44964095859226,4.43426734580777e-07
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.86686867891857,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.24246523480031,1.18119118074431,1.30691786804119,3.98079258401422e-17
primary,Circulatory system disorders,I45 (other conduction disorders),1.76472900208308,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.20790396862408,1.13244249802294,1.28839389193273,9.53313491269629e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.780744257214037,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.58360707183677,1.44161029527351,1.73959034989802,8.73759308956928e-22
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36805116866708,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.20528303316344,1.11956231440472,1.29756706825566,7.03870675070786e-07
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.42707164609713,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.22596409189679,1.1874175808288,1.26576191803666,7.56896746744915e-36
primary,Circulatory system disorders,I50 (heart failure),4.42479626552733,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.45659923902375,1.39872487379884,1.51686824397582,7.19688073039035e-74
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22939639873177,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.34351813244234,1.28838882695646,1.40100638443549,2.12244812408745e-43
primary,Circulatory system disorders,I63 (cerebral infarction),2.07739067141423,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.31352448348795,1.2378265160859,1.39385167977979,2.15654754353414e-19
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.78258791668326,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.34452899072537,1.21999564066593,1.48177431676251,2.37670478882698e-09
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.622190818269249,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.35123751609857,1.21329223158829,1.50486649248719,4.27892599038386e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71854591234558,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.26995739797589,1.20538422072707,1.33798980021563,2.81457089707095e-19
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.783059229893629,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.57756085704805,1.43561439517242,1.73354228409731,2.63020475420004e-21
primary,Circulatory system disorders,I70 (atherosclerosis),0.807021677662582,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.6567121201791,1.51077206197345,1.81674993748763,7.35929957116507e-27
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.0916944826232,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.26612346558776,1.16728266650171,1.37333370580777,1.27202568449899e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1509223918575,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.43895674534603,1.35737963708302,1.52543655320077,2.39019160872818e-34
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404397330192383,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.69408240164614,1.48886181823223,1.92759002106366,1.23301150487158e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701485498703136,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.64686962974464,1.4915203848695,1.81839926888598,5.69784742861794e-23
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0490080765310123,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.76530862408144,2.00157165176047,3.82046367398008,6.9208415013188e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.22356886509384,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.7383043729064,1.46226033622419,2.06645972540571,3.68724233088877e-10
primary,Circulatory system disorders,I95 (hypotension),4.83724779319041,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.36545995326992,1.31313934570498,1.41986521847985,4.85365677130515e-55
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105867822063638,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.19636124858469,1.73265507140597,2.78416795927537,7.88745797277078e-11
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0980776775205963,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.95986373479389,1.51999143445888,2.52703125286208,2.11778435528079e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,LGALS1;Galectin-1,2.7542670022498,2.48456202584984,3.05324908002138,9.82795289200119e-83
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,LGALS1;Galectin-1,1.33577200687665,1.24145824107234,1.43725080338912,9.23686311036727e-15
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60909126718399,LGALS1;Galectin-1,1.23343421129814,1.1525035489011,1.32004795564515,1.36889611292075e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,LGALS1;Galectin-1,1.49882580569559,1.36352688483463,1.64755005625833,5.12783927948432e-17
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,LGALS1;Galectin-1,1.24923069100598,1.19917529473214,1.30137547546781,1.47861165124707e-26
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,LGALS1;Galectin-1,1.3787728974972,1.25436157673615,1.51552370395405,2.79575855059978e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15754445217045,LGALS1;Galectin-1,1.24667413410936,1.1754783112408,1.32218211241751,2.00213214256665e-13
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.413944637357032,LGALS1;Galectin-1,1.38040563146947,1.21078397761255,1.57378999278629,1.44101896868398e-06
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.710863247191893,LGALS1;Galectin-1,1.31852492993401,1.19190144963924,1.45860045004871,7.96872416784918e-08
primary,Circulatory system disorders,I95 (hypotension),4.80063010731515,LGALS1;Galectin-1,1.22331894554699,1.1760698691668,1.27246627242853,1.12804520422445e-23
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.507260406582768,"FABP4;Fatty acid-binding protein, adipocyte",1.38763327687665,1.21580645696131,1.58374394219614,1.19055417083943e-06
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13615569512289,"FABP4;Fatty acid-binding protein, adipocyte",1.23823318764349,1.16036187724406,1.32133040308363,1.13391821695435e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,"FABP4;Fatty acid-binding protein, adipocyte",3.91133598594556,3.54031883367595,4.32123486998714,1.78328672671439e-158
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0657932929543123,"FABP4;Fatty acid-binding protein, adipocyte",2.74564168762478,2.0507794593748,3.67594294079836,1.16737315684927e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0561395357841144,"FABP4;Fatty acid-binding protein, adipocyte",2.84546122887105,2.08466807882562,3.88390347952635,4.46228946760065e-11
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97029702970297,"FABP4;Fatty acid-binding protein, adipocyte",1.21469197147776,1.14869580796856,1.28447982079945,8.87251774189115e-12
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.102671393425156,"FABP4;Fatty acid-binding protein, adipocyte",2.02793395738263,1.56621754031373,2.62576304354362,8.15422636628587e-08
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0136641147398,"FABP4;Fatty acid-binding protein, adipocyte",1.34703525317532,1.22841766184161,1.47710671187911,2.38512189163556e-10
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69827360974335,"FABP4;Fatty acid-binding protein, adipocyte",1.24040592808085,1.20019075275811,1.28196860614224,1.40916159738856e-37
primary,Circulatory system disorders,I26 (pulmonary embolism),1.98999139885839,"FABP4;Fatty acid-binding protein, adipocyte",1.22697341508952,1.14643855890989,1.31316567262701,3.52030245906945e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35161378024624,"FABP4;Fatty acid-binding protein, adipocyte",1.70589477176908,1.577112681598,1.84519280474015,1.4290999343424e-40
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60521451503064,"FABP4;Fatty acid-binding protein, adipocyte",1.25398402940037,1.1627018212931,1.35243268497021,4.37886167419838e-09
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.855644268314,"FABP4;Fatty acid-binding protein, adipocyte",1.22452630873794,1.15793062217294,1.29495209132436,1.25251392217614e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.782415028565895,"FABP4;Fatty acid-binding protein, adipocyte",1.65225659851677,1.49331080085513,1.828120352293,2.24014813219912e-22
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3583567196757,"FABP4;Fatty acid-binding protein, adipocyte",1.24286685515814,1.14556609769586,1.3484320309039,1.72026254800568e-07
primary,Circulatory system disorders,I50 (heart failure),4.42925495557074,"FABP4;Fatty acid-binding protein, adipocyte",1.4674678024871,1.4030779151282,1.53481266301563,5.35547250806923e-63
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21309603496476,"FABP4;Fatty acid-binding protein, adipocyte",1.32693832288904,1.26693673462118,1.38978156101699,4.42856844892378e-33
primary,Circulatory system disorders,I63 (cerebral infarction),2.0683226194869,"FABP4;Fatty acid-binding protein, adipocyte",1.21942013746438,1.14159016606558,1.3025563077321,3.74194011326403e-09
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.621996589676019,"FABP4;Fatty acid-binding protein, adipocyte",1.37736761376131,1.22440744537013,1.54943646464436,9.77661345519652e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73036217108457,"FABP4;Fatty acid-binding protein, adipocyte",1.22237141123122,1.15386344426576,1.29494687991109,8.89767507524541e-12
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771153436282963,"FABP4;Fatty acid-binding protein, adipocyte",1.5559336899181,1.40208878476982,1.72665930554433,8.63035286519126e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.804481836157096,"FABP4;Fatty acid-binding protein, adipocyte",1.69320573754454,1.53202678464026,1.87134174049505,5.82302235213153e-25
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16089968793546,"FABP4;Fatty acid-binding protein, adipocyte",1.3953263640628,1.30830491426572,1.48813601555675,3.70375459043352e-24
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406976744186046,"FABP4;Fatty acid-binding protein, adipocyte",1.76320740699369,1.53567646382428,2.02445009304587,8.60549758493779e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704198029021494,"FABP4;Fatty acid-binding protein, adipocyte",1.6105502375459,1.44473310140876,1.79539879381864,8.18500630759453e-18
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0483830388419035,"FABP4;Fatty acid-binding protein, adipocyte",2.98115830938558,2.15823417284773,4.11785939516106,3.40942281689995e-11
primary,Circulatory system disorders,I95 (hypotension),4.80432583832568,"FABP4;Fatty acid-binding protein, adipocyte",1.36840359603064,1.31025693134029,1.42913069707186,1.68307713049108e-45
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104513431911434,"FABP4;Fatty acid-binding protein, adipocyte",1.92428293263971,1.47759541148996,2.50600724396852,1.19209563381056e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535211267605633,CALB2;Calretinin,2.60850679846751,2.31875234832594,2.93446935916364,2.46017779502875e-57
primary,Circulatory system disorders,I15 (secondary hypertension),0.0561921772461819,CALB2;Calretinin,2.61007838346048,1.82294176566079,3.73709643178768,1.61636129329132e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.32879663371519,CALB2;Calretinin,1.24255421513944,1.14761126711501,1.34535188160195,8.55951791668642e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.803842366511927,CALB2;Calretinin,1.28915400627876,1.16398899471957,1.42777814862842,1.09327962418028e-06
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249296708826018,RNASE6;Ribonuclease K6,1.72428940311529,1.43529809207591,2.07146791465145,5.84980555441524e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.514226945491943,RNASE6;Ribonuclease K6,1.57454450125994,1.38440871241988,1.79079368990275,4.71837830607382e-12
primary,Circulatory system disorders,I08 (multiple valve diseases),2.04343150042333,RNASE6;Ribonuclease K6,1.31430305653903,1.23101371722944,1.40322768158551,2.78910548082989e-16
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.196522017321359,RNASE6;Ribonuclease K6,1.69755864313875,1.38052397387424,2.08739971302923,5.24302628245015e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.393682764934767,RNASE6;Ribonuclease K6,3.84675731722598,3.3756749630694,4.38358017863681,7.5313491937758e-91
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0502558479532163,RNASE6;Ribonuclease K6,2.68174059899678,1.82386709390873,3.9431231937493,5.29475590159889e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.0434117028811661,RNASE6;Ribonuclease K6,2.7712710735574,1.83592109775473,4.18315545941942,1.22305266409059e-06
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96365767878077,RNASE6;Ribonuclease K6,1.34430745315442,1.27193610252019,1.42079663044852,1.07519963185505e-25
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.976982565322838,RNASE6;Ribonuclease K6,1.38898140890737,1.26415510563211,1.5261334196215,7.98616457150797e-12
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.54727169382341,RNASE6;Ribonuclease K6,1.26502725436765,1.22396200690299,1.30747028524373,2.63412268379227e-44
primary,Circulatory system disorders,I26 (pulmonary embolism),1.94974503334179,RNASE6;Ribonuclease K6,1.2162151058463,1.13687355436997,1.30109384460831,1.29334881040677e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37828230707487,RNASE6;Ribonuclease K6,1.75219054730332,1.62006942999146,1.89508650507361,1.14644373956993e-44
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60330768347306,RNASE6;Ribonuclease K6,1.29263077226651,1.20028253917869,1.39208416257864,1.14349941856956e-11
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70082061156191,RNASE6;Ribonuclease K6,1.28986516452961,1.20046341415301,1.3859249045427,3.77522620835116e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.685088442855833,RNASE6;Ribonuclease K6,1.47950868599908,1.32248733232087,1.65517347383985,7.76383558287096e-12
primary,Circulatory system disorders,I45 (other conduction disorders),1.733574552866,RNASE6;Ribonuclease K6,1.21413281175422,1.13072849814264,1.30368915880305,9.11269992502306e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.756761700084592,RNASE6;Ribonuclease K6,1.61034654901979,1.4484532210579,1.79033466199615,1.21242036735607e-18
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.33192243104598,RNASE6;Ribonuclease K6,1.26248091069955,1.16384182459388,1.36947995526536,1.96105118553588e-08
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.21055088702147,RNASE6;Ribonuclease K6,1.2049319590198,1.16287070177596,1.24851458003885,8.37486000540199e-25
primary,Circulatory system disorders,I50 (heart failure),4.3150542839361,RNASE6;Ribonuclease K6,1.51610267574423,1.44893871380629,1.58637994933588,1.93604853912886e-72
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08760480293564,RNASE6;Ribonuclease K6,1.33136855403289,1.27041023411283,1.39525184784539,5.1664801946021e-33
primary,Circulatory system disorders,I63 (cerebral infarction),2.04961254527947,RNASE6;Ribonuclease K6,1.37043392022568,1.28391212540057,1.46278634849652,2.77954597450103e-21
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.730943264879916,RNASE6;Ribonuclease K6,1.40678090209605,1.26018163328677,1.57043433599371,1.21203685382371e-09
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.601514077259108,RNASE6;Ribonuclease K6,1.3811302027166,1.22485160971514,1.55734835283404,1.36163563653528e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.59496137358732,RNASE6;Ribonuclease K6,1.29507118991157,1.22189243217132,1.37263260069345,2.96422846887604e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.747975662198636,RNASE6;Ribonuclease K6,1.61086305184834,1.44789992021483,1.79216790855624,1.92887344275533e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.759690632007688,RNASE6;Ribonuclease K6,1.74210285327238,1.56790134814141,1.93565899728153,5.33991874869287e-25
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.0728582866293,RNASE6;Ribonuclease K6,1.34913148743021,1.23294670978728,1.4762647533158,7.14589026649551e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06672845227062,RNASE6;Ribonuclease K6,1.46924895843885,1.37612186257497,1.56867829847158,1.09437088062452e-30
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402617010568696,RNASE6;Ribonuclease K6,1.74468910936463,1.50989000243841,2.01600122089669,4.44702101928976e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.689197234052296,RNASE6;Ribonuclease K6,1.68582018139328,1.50869240551564,1.88374361374315,2.94772504349116e-20
primary,Circulatory system disorders,I85 (oesophageal varices),0.207985738120814,RNASE6;Ribonuclease K6,1.90920463794951,1.56486666090528,2.32931178140075,1.85478420659509e-10
primary,Circulatory system disorders,I87 (other disorders of veins),0.425415122821462,RNASE6;Ribonuclease K6,1.42477496454805,1.23569735427179,1.64278388440766,1.09742557837567e-06
primary,Circulatory system disorders,I95 (hypotension),4.54587198089815,RNASE6;Ribonuclease K6,1.36692219227721,1.30800266268201,1.42849577684246,6.00034514112944e-44
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109669164686528,RNASE6;Ribonuclease K6,2.34974660722503,1.79983446748789,3.06767606571725,3.37891216847911e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.802646776688005,F9;Coagulation factor IX,1.46676556972091,1.3332894762449,1.61360400336914,3.57549402305472e-15
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407084841961053,F9;Coagulation factor IX,1.51397569286685,1.32474778582538,1.73023304746537,1.14211503734932e-09
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249490129299249,EFNA4;Ephrin-A4,1.65028514443294,1.38622127654731,1.96465102939364,1.79273967317127e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12382367508667,EFNA4;Ephrin-A4,1.302954322293,1.22698364478404,1.38362884721322,5.93938665027489e-18
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.533550191403693,EFNA4;Ephrin-A4,4.62372001137737,4.16384393645515,5.1343871359915,1.7421763480573e-180
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0672428455590056,EFNA4;Ephrin-A4,3.53196604407734,2.60962023209312,4.78030633848574,3.03865717144414e-16
primary,Circulatory system disorders,I15 (secondary hypertension),0.0573768870071028,EFNA4;Ephrin-A4,2.9928762804564,2.13264683410146,4.20008990091059,2.29156323331625e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96997521634908,EFNA4;Ephrin-A4,1.34653997849809,1.27896359417866,1.41768688487027,9.73797393621104e-30
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02016560358147,EFNA4;Ephrin-A4,1.44693365924788,1.32760837023134,1.57698389164242,3.99013773074955e-17
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69118764504138,EFNA4;Ephrin-A4,1.25208943981235,1.21451848480378,1.29082264692159,2.07872755413521e-47
primary,Circulatory system disorders,I26 (pulmonary embolism),2.003996003996,EFNA4;Ephrin-A4,1.22461113574931,1.15084535529322,1.30310508436567,1.63362835234217e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34378721714966,EFNA4;Ephrin-A4,1.65940577498557,1.5389629391413,1.78927474861216,1.24488497714507e-39
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61091444254405,EFNA4;Ephrin-A4,1.27652858288973,1.19111665916337,1.36806517682242,4.85882562643706e-12
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71308335152946,EFNA4;Ephrin-A4,1.27288886893194,1.19078780025662,1.36065054773124,1.31239368629242e-12
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85890130834441,EFNA4;Ephrin-A4,1.22831398220089,1.16650977209666,1.29339271299752,5.85167992027111e-15
primary,Circulatory system disorders,I45 (other conduction disorders),1.7369235039854,EFNA4;Ephrin-A4,1.20119321474963,1.12438344499225,1.28325007415107,5.41321265791218e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.783816951031234,EFNA4;Ephrin-A4,1.65122359120245,1.49767174597497,1.82051865201515,7.44054487621632e-24
primary,Circulatory system disorders,I50 (heart failure),4.41472906895519,EFNA4;Ephrin-A4,1.50967381883661,1.44734264316028,1.57468934536763,1.03703315539438e-81
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20347304666277,EFNA4;Ephrin-A4,1.34103379347386,1.28434589199888,1.40022376093719,1.86926857692303e-40
primary,Circulatory system disorders,I63 (cerebral infarction),2.07030707239127,EFNA4;Ephrin-A4,1.2646301779749,1.19003412494746,1.34390220710304,3.76981968990915e-14
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.783573093305473,EFNA4;Ephrin-A4,1.31271271078603,1.18816610132031,1.45031461438291,8.80296241709921e-08
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.615878170980454,EFNA4;Ephrin-A4,1.38985022690991,1.24402866972071,1.55276457870959,5.84741096174012e-09
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72319479179071,EFNA4;Ephrin-A4,1.23231199192703,1.16852756505587,1.29957811082922,1.32421507304245e-14
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.768316831683168,EFNA4;Ephrin-A4,1.56259982009,1.41516674081437,1.72539258260139,1.07093308805506e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.796370768042156,EFNA4;Ephrin-A4,1.750152239762,1.58827808233305,1.92852429081223,1.26588084492815e-29
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08366186580026,EFNA4;Ephrin-A4,1.2828492724811,1.18024382310058,1.39437480942024,4.7333489048925e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1322688704792,EFNA4;Ephrin-A4,1.44213506290671,1.35746294517601,1.53208862684297,1.91898262441538e-32
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.400110921839717,EFNA4;Ephrin-A4,1.88120530062181,1.64250999967169,2.15458863799609,6.98999892389921e-20
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701823949246629,EFNA4;Ephrin-A4,1.68572588183211,1.51975384955287,1.86982368856292,5.36233301764202e-23
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0474711711533516,EFNA4;Ephrin-A4,3.66089487159698,2.56449305094622,5.22604311832316,8.95912784663741e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.215683558580841,EFNA4;Ephrin-A4,2.07916389429156,1.73128591213686,2.49694315018715,4.6828921605602e-15
primary,Circulatory system disorders,I95 (hypotension),4.82504970178926,EFNA4;Ephrin-A4,1.35157655424162,1.29828430892258,1.40705635077085,8.87353328601331e-49
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100884220521037,EFNA4;Ephrin-A4,2.59364904633936,1.99887668780107,3.36539788403724,7.43068214303946e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.92126201270059,1.71174769797494,2.15642043848704,1.5028820263438e-28
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9594291374396,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.22113788003346,1.16034777368668,1.28511275314884,1.74327109283642e-14
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.25762261244408,1.16733549688012,1.35489295027673,1.63441100514929e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.34646198052545,1.22062438839338,1.48527252301324,2.80962849078374e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.39232565418691,1.26400375351852,1.53367481853654,1.95981365078878e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15586074736505,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.224105238195,1.15348571531064,1.29904827973782,2.56343896107674e-11
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.49390915638644,1.30491446665883,1.71027651586204,6.01203440586215e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.212665406427221,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.74428992074323,1.44913564228617,2.09956006796332,4.05148751765778e-09
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102358174875004,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",2.55378605756423,1.96453396837754,3.31978134905739,2.4663659865688e-12
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25327632679617,INHBB;Inhibin beta B chain,1.64261425241274,1.36137032543381,1.9819600382208,2.22400169949968e-07
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513153922957252,INHBB;Inhibin beta B chain,1.42992602118228,1.25204361333452,1.63308083223128,1.31848657346875e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.04560775471303,INHBB;Inhibin beta B chain,1.24793796736242,1.16704631747872,1.33443647185242,9.30896125424234e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.399990697890746,INHBB;Inhibin beta B chain,4.17266237446416,3.58912159820528,4.85107868732426,4.17484409410501e-77
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0487363364199679,INHBB;Inhibin beta B chain,3.81179416322846,2.52364896298697,5.75744683825805,2.02388204939592e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97956461677702,INHBB;Inhibin beta B chain,1.22561339761821,1.15817788651758,1.29697537650099,1.84594343147453e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.38176903718892,INHBB;Inhibin beta B chain,1.6234308860368,1.49651412805878,1.76111123331455,1.89223874476504e-31
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60085876971903,INHBB;Inhibin beta B chain,1.28089208441408,1.18736512432449,1.38178602209497,1.5599969247995e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.759528952686223,INHBB;Inhibin beta B chain,1.43472989640338,1.28550165185699,1.60128139287889,1.17966464920802e-10
primary,Circulatory system disorders,I50 (heart failure),4.33509766265398,INHBB;Inhibin beta B chain,1.40033537975648,1.33643247300096,1.46729387036999,2.51302436206411e-45
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08741209232076,INHBB;Inhibin beta B chain,1.22950730826803,1.17181163563297,1.29004370251704,3.5896434744867e-17
primary,Circulatory system disorders,I63 (cerebral infarction),2.04956213899757,INHBB;Inhibin beta B chain,1.24467598562246,1.1639886354825,1.33095655916182,1.5473167012187e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.743580806320436,INHBB;Inhibin beta B chain,1.44730384156338,1.29571264987,1.61663036168882,5.78820487089113e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.762471523548282,INHBB;Inhibin beta B chain,1.54267003234518,1.3829301654064,1.72086117450228,7.66186283109755e-15
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07371943850515,INHBB;Inhibin beta B chain,1.28461768953283,1.17039343814502,1.4099896278265,1.35261968697531e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.09991054192758,INHBB;Inhibin beta B chain,1.33022653764914,1.24454183273355,1.42181049678292,4.47213457172218e-17
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.399748994817207,INHBB;Inhibin beta B chain,1.65172435349733,1.42071383118755,1.92029758565504,6.65418603071928e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.683848157796799,INHBB;Inhibin beta B chain,1.53148098548603,1.36465672363561,1.71869889935159,4.37361742264272e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.211303580550782,INHBB;Inhibin beta B chain,1.72928240684864,1.40681540038041,2.12566456254857,1.97634356580076e-07
primary,Circulatory system disorders,I95 (hypotension),4.56697688521913,INHBB;Inhibin beta B chain,1.30359222032862,1.24623215525353,1.3635923850445,7.58573239216395e-31
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513808606294155,SORCS2;VPS10 domain-containing receptor SorCS2,1.39323691766438,1.23270079577205,1.5746798537006,1.10017215514801e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12406808271205,SORCS2;VPS10 domain-containing receptor SorCS2,1.24876046757402,1.17542155992147,1.32667526149502,6.29582156542699e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.543270488339805,SORCS2;VPS10 domain-containing receptor SorCS2,3.88825819576429,3.4714073671587,4.35516498004742,8.21188614700954e-122
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066198595787362,SORCS2;VPS10 domain-containing receptor SorCS2,3.03425510513966,2.19390978447121,4.19648251182996,1.96402190560619e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.056191049568533,SORCS2;VPS10 domain-containing receptor SorCS2,3.2701249264394,2.30377385556629,4.6418258496521,3.36552692017788e-11
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97178657543845,SORCS2;VPS10 domain-containing receptor SorCS2,1.28287189988339,1.21768503049174,1.35154844668314,7.81846639632083e-21
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00263216058188,SORCS2;VPS10 domain-containing receptor SorCS2,1.35593307455403,1.24191234214677,1.48042212020489,1.08880478574588e-11
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.74067591782306,SORCS2;VPS10 domain-containing receptor SorCS2,1.21525079809628,1.17843534170431,1.25321640484559,2.01854044650724e-35
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35088884862394,SORCS2;VPS10 domain-containing receptor SorCS2,1.47992332915868,1.37187423785799,1.59648238865379,3.90148463727945e-24
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59540137152077,SORCS2;VPS10 domain-containing receptor SorCS2,1.24713594934808,1.16285022975431,1.33753086713923,6.17749749069265e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.791005822124071,SORCS2;VPS10 domain-containing receptor SorCS2,1.50898507653907,1.36731300730538,1.66533628295183,2.8533307631912e-16
primary,Circulatory system disorders,I50 (heart failure),4.41331281885172,SORCS2;VPS10 domain-containing receptor SorCS2,1.33856425410419,1.2828207645744,1.39673001236456,3.71509517332427e-41
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20646583394562,SORCS2;VPS10 domain-containing receptor SorCS2,1.26843619488725,1.21433870865081,1.32494366607784,1.09933156197841e-26
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.630724730837216,SORCS2;VPS10 domain-containing receptor SorCS2,1.31246929546849,1.17493569285713,1.46610207011305,1.47674479100941e-06
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775318362591893,SORCS2;VPS10 domain-containing receptor SorCS2,1.41416301803141,1.2799491836081,1.5624503434818,9.67471096146315e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.803777755450617,SORCS2;VPS10 domain-containing receptor SorCS2,1.53732802000447,1.39374298313503,1.69570535578575,8.24595852363807e-18
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14250834215024,SORCS2;VPS10 domain-containing receptor SorCS2,1.32273505360895,1.24478819566372,1.40556283240859,1.78060984318066e-19
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407859840874387,SORCS2;VPS10 domain-containing receptor SorCS2,1.63607627389772,1.42663329130088,1.87626742648788,1.86994572813081e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.675648501910315,SORCS2;VPS10 domain-containing receptor SorCS2,1.46358158293017,1.31510933228343,1.62881594503866,2.97231118233519e-12
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0481502287135863,SORCS2;VPS10 domain-containing receptor SorCS2,3.23545849891719,2.21750544116456,4.72070620612227,1.11787228612633e-09
primary,Circulatory system disorders,I95 (hypotension),4.80175856088412,SORCS2;VPS10 domain-containing receptor SorCS2,1.29250207678787,1.24117737152236,1.3459491421858,2.27806130019237e-35
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,DLK1;Protein delta homolog 1,2.35306298387476,2.09527833666423,2.64256319038576,2.34850375576088e-47
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250226583126453,IL6;Interleukin-6,1.5007442082101,1.27606999069161,1.76497621204576,9.28553460340116e-07
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.506015082005946,IL6;Interleukin-6,1.36372268126581,1.21399501072424,1.53191696421334,1.71420762283668e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13307047806801,IL6;Interleukin-6,1.27242456690589,1.20146305611715,1.34757724777496,1.89099553063931e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,IL6;Interleukin-6,1.64079698992443,1.4729811370019,1.82773200179928,2.35541922028058e-19
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9594291374396,IL6;Interleukin-6,1.24706790871003,1.18697082226216,1.31020774880591,1.92155972111543e-18
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99980121260312,IL6;Interleukin-6,1.20956886065586,1.13902007723973,1.28448730439752,5.45991015972759e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,IL6;Interleukin-6,1.54362728376425,1.44017792473939,1.65450750928056,1.37490017677049e-34
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.74928522133491,IL6;Interleukin-6,1.32546889573278,1.20394007444917,1.45926515018523,9.32061199709465e-09
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60473307214373,IL6;Interleukin-6,1.20978730377504,1.13147205532659,1.29352317053277,2.44211780589479e-08
primary,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.18503208535097,IL6;Interleukin-6,1.68527785972572,1.40233795395825,2.02530456832111,2.6072039529563e-08
primary,Circulatory system disorders,"I38 (endocarditis, valve unspecified)",0.246145363605931,IL6;Interleukin-6,1.6115098831843,1.37185841513298,1.89302633198408,6.294110959609e-09
primary,Circulatory system disorders,I42 (cardiomyopathy),0.667232564107625,IL6;Interleukin-6,1.35826544683499,1.22733301393071,1.50316581003336,3.20455723361809e-09
primary,Circulatory system disorders,I45 (other conduction disorders),1.74424340482626,IL6;Interleukin-6,1.23156116185985,1.15553101262546,1.31259384545241,1.49089985653958e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,IL6;Interleukin-6,1.43001208884833,1.30314484186203,1.56923045586429,4.4869131176387e-14
primary,Circulatory system disorders,I50 (heart failure),4.39523336643495,IL6;Interleukin-6,1.36498398826562,1.31196313856637,1.42014758909879,1.83303378055165e-53
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20671151689892,IL6;Interleukin-6,1.22040329486645,1.17082822220012,1.27207746950459,4.7872586817875e-21
primary,Circulatory system disorders,I63 (cerebral infarction),2.07802469135802,IL6;Interleukin-6,1.23610186165643,1.16590150005001,1.31052907327501,1.19978646361689e-12
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.779719301051621,IL6;Interleukin-6,1.27970498179628,1.16313938714073,1.40795235595961,4.16493215178661e-07
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.626638027863716,IL6;Interleukin-6,1.33418068491447,1.20134213610289,1.48170787197495,7.12120721851252e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72922961470861,IL6;Interleukin-6,1.232272241334,1.17093287396831,1.29682487401357,1.0806141602297e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774430015567422,IL6;Interleukin-6,1.40418903573139,1.27894289591384,1.54170045775138,1.06795707284003e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,IL6;Interleukin-6,1.65157293871892,1.51076244075443,1.80550766839724,2.5906387810591e-28
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.09602002799187,IL6;Interleukin-6,1.38928036304688,1.28412710300225,1.50304430350793,2.66781219954739e-16
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15586074736505,IL6;Interleukin-6,1.36991926398357,1.29430347112539,1.44995268242736,1.6931771166763e-27
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,IL6;Interleukin-6,1.64711190336553,1.45386667883153,1.86604291969111,4.60377901434027e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,IL6;Interleukin-6,1.5179066829226,1.37784927032598,1.67220083334369,2.93243676853616e-17
primary,Circulatory system disorders,I85 (oesophageal varices),0.212665406427221,IL6;Interleukin-6,1.86410263631436,1.57602632436096,2.20483540471516,3.56509531771647e-13
primary,Circulatory system disorders,I95 (hypotension),4.82266136529978,IL6;Interleukin-6,1.26641442625055,1.21878117517234,1.31590931307971,1.43701043502967e-33
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102358174875004,IL6;Interleukin-6,2.14746847337961,1.69786186059012,2.7161343046816,1.81114696035086e-10
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245878511830384,SCARB2;Lysosome membrane protein 2,1.89533806873364,1.59538589792003,2.25168493683842,3.48705606852334e-13
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.501500473303659,SCARB2;Lysosome membrane protein 2,1.38415469557796,1.22292275338796,1.56664369518254,2.67789775389686e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13748462422617,SCARB2;Lysosome membrane protein 2,1.33655625159737,1.25854407082652,1.41940409962032,3.25743529571836e-21
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.209403000100674,SCARB2;Lysosome membrane protein 2,1.66569272188844,1.38241674233538,2.00701579978333,8.1006969896688e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.530948439455727,SCARB2;Lysosome membrane protein 2,4.38693502023352,3.95000573293455,4.87219517462664,5.84525559950502e-168
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066429132193973,SCARB2;Lysosome membrane protein 2,3.36984492709643,2.52265091030239,4.50155619483488,1.98060719389608e-16
primary,Circulatory system disorders,I15 (secondary hypertension),0.0563856780377784,SCARB2;Lysosome membrane protein 2,3.08116583701261,2.23340510109316,4.25072142556088,7.16906303829662e-12
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.98720360531701,SCARB2;Lysosome membrane protein 2,1.28503705377748,1.22026410865739,1.3532482172224,2.02525759765048e-21
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0322996895036,SCARB2;Lysosome membrane protein 2,1.36622467564527,1.25385151559514,1.48866898602108,1.03537335067012e-12
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68184003176792,SCARB2;Lysosome membrane protein 2,1.22081883065609,1.18382704666262,1.25896652005556,5.25333151471824e-37
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35763061133783,SCARB2;Lysosome membrane protein 2,1.64482950737575,1.52643825801363,1.77240323618106,5.80006146773967e-39
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60712478494079,SCARB2;Lysosome membrane protein 2,1.31465958096348,1.22605305752442,1.40966967392816,1.53660304675133e-14
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71313131313131,SCARB2;Lysosome membrane protein 2,1.26823405033848,1.18593733909722,1.35624164398292,3.87203366875365e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.682497375010096,SCARB2;Lysosome membrane protein 2,1.34076224247008,1.20580074813387,1.49082955340299,6.05339238806464e-08
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.87538644951403,SCARB2;Lysosome membrane protein 2,1.22570818804934,1.16374141294235,1.29097456320017,1.4840572155491e-14
primary,Circulatory system disorders,I45 (other conduction disorders),1.73558555831365,SCARB2;Lysosome membrane protein 2,1.21107919030729,1.13296390205398,1.29458035029741,1.8056118637502e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.783705375130953,SCARB2;Lysosome membrane protein 2,1.63860284227941,1.48728262347953,1.80531879572728,1.69410730923666e-23
primary,Circulatory system disorders,I50 (heart failure),4.43234678746267,SCARB2;Lysosome membrane protein 2,1.45670472866341,1.3964443421644,1.51956551538702,3.34048316599321e-68
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21880439902517,SCARB2;Lysosome membrane protein 2,1.31017984957393,1.25458350285667,1.36823992529868,2.68914113710871e-34
primary,Circulatory system disorders,I63 (cerebral infarction),2.0809341980322,SCARB2;Lysosome membrane protein 2,1.24732676559722,1.17347316124267,1.32582841394316,1.27596142984575e-12
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.610739337257115,SCARB2;Lysosome membrane protein 2,1.33089096427321,1.19004730911915,1.48840365018356,5.47936213775311e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73928326128237,SCARB2;Lysosome membrane protein 2,1.26366376786283,1.19804732811186,1.3328739864776,7.85505603432445e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.76183566116452,SCARB2;Lysosome membrane protein 2,1.5620554364018,1.41460558261478,1.72487456318549,1.18336221798854e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.798451488023227,SCARB2;Lysosome membrane protein 2,1.53752901613101,1.39525175682736,1.69431463811251,3.85591207356207e-18
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08686884981448,SCARB2;Lysosome membrane protein 2,1.26416099035003,1.16267781827178,1.37450201974114,4.01561329114595e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13552193707764,SCARB2;Lysosome membrane protein 2,1.32516873993017,1.24691630525763,1.40833204432697,1.23570555905261e-19
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405233765448277,SCARB2;Lysosome membrane protein 2,1.54453126243116,1.34874688957641,1.76873573467621,3.25696158963963e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698200016143353,SCARB2;Lysosome membrane protein 2,1.56291875461121,1.40866209107563,1.73406741687089,3.68219682435002e-17
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0483179319925107,SCARB2;Lysosome membrane protein 2,3.5545211352291,2.54559657605081,4.96332396879298,9.66953761696251e-14
primary,Circulatory system disorders,I85 (oesophageal varices),0.213490161326055,SCARB2;Lysosome membrane protein 2,2.0012559464723,1.67068807802333,2.3972310666329,5.00724773425862e-14
primary,Circulatory system disorders,I95 (hypotension),4.83822011776846,SCARB2;Lysosome membrane protein 2,1.36190856728721,1.30800494847457,1.41803358451619,8.37514771576031e-51
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102681807199806,SCARB2;Lysosome membrane protein 2,2.29157697359007,1.77862173486827,2.9524687138028,1.41882398698904e-10
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248285916038359,YAP1;Transcriptional coactivator YAP1,1.75641918461823,1.46636588961993,2.10384623233058,9.55341428411389e-10
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.521248264402613,YAP1;Transcriptional coactivator YAP1,1.41580699357893,1.24628729454506,1.60838472143674,9.10959418979475e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.04421148587055,YAP1;Transcriptional coactivator YAP1,1.29665782211576,1.21512610751237,1.38366009688987,4.48759173614189e-15
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.202548930359581,YAP1;Transcriptional coactivator YAP1,1.63259736477894,1.33828585313493,1.99163291552363,1.34479236298775e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.401231049811923,YAP1;Transcriptional coactivator YAP1,3.97288981375019,3.52120619984481,4.48251325721727,3.72297710108924e-111
primary,Circulatory system disorders,I15 (secondary hypertension),0.0432348791698903,YAP1;Transcriptional coactivator YAP1,2.91945106110436,2.00060856580482,4.26030091236495,2.75864292437523e-08
primary,Circulatory system disorders,I26 (pulmonary embolism),1.96024359416293,YAP1;Transcriptional coactivator YAP1,1.23194050303535,1.15219358607235,1.31720695321046,1.00280552088539e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37277295568752,YAP1;Transcriptional coactivator YAP1,1.76336469033223,1.63245528934356,1.90477194163206,4.33514334753829e-47
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.749977204340293,YAP1;Transcriptional coactivator YAP1,1.29985001177493,1.16792146353298,1.44668122460922,1.56556056894448e-06
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59227654366177,YAP1;Transcriptional coactivator YAP1,1.3049606177232,1.21188897046863,1.40518005799657,1.78198343090298e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.693747147421268,YAP1;Transcriptional coactivator YAP1,1.34520108377036,1.20401145297604,1.50294746059442,1.59177515872675e-07
primary,Circulatory system disorders,I45 (other conduction disorders),1.71521109413133,YAP1;Transcriptional coactivator YAP1,1.23109360071476,1.146919049459,1.32144588097629,8.74257297581724e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.762802559373363,YAP1;Transcriptional coactivator YAP1,1.53182403573933,1.3809926139432,1.6991292008208,7.40875802081661e-16
primary,Circulatory system disorders,I50 (heart failure),4.31178969119504,YAP1;Transcriptional coactivator YAP1,1.38094091655451,1.31992500149879,1.44477740238952,1.58536367664378e-44
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08540958197422,YAP1;Transcriptional coactivator YAP1,1.25875477811959,1.20149973248088,1.31873819744201,3.36759281115713e-22
primary,Circulatory system disorders,I63 (cerebral infarction),2.04123570107541,YAP1;Transcriptional coactivator YAP1,1.2302639912201,1.15264110931612,1.31311426935901,4.603484310885e-10
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.592228144503667,YAP1;Transcriptional coactivator YAP1,1.35745695536444,1.20451876506622,1.52981376389433,5.41219575654799e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.744891683181849,YAP1;Transcriptional coactivator YAP1,1.40162417620114,1.26003957698234,1.55911795724418,5.15721464433751e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.770247481883232,YAP1;Transcriptional coactivator YAP1,1.46000637419125,1.31530805452498,1.62062309688274,1.1881110987739e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.07910282444157,YAP1;Transcriptional coactivator YAP1,1.30948564808308,1.2268938203788,1.39763737827463,4.98770206551189e-16
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.400975098535073,YAP1;Transcriptional coactivator YAP1,1.42389785413187,1.23233434783521,1.64523946164687,1.6364248871734e-06
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686399708109094,YAP1;Transcriptional coactivator YAP1,1.48271811797672,1.32739011158075,1.65622223504314,3.03612381358895e-12
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.05505190473953,YAP1;Transcriptional coactivator YAP1,1.20527972979365,1.12817073939319,1.28765901855672,3.11061507769725e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.209414549758718,YAP1;Transcriptional coactivator YAP1,1.88068087621158,1.55339226466411,2.27692685138532,9.47909536131263e-11
primary,Circulatory system disorders,I87 (other disorders of veins),0.421402701532994,YAP1;Transcriptional coactivator YAP1,1.51142288618373,1.3127242564616,1.74019724983028,9.25945815244344e-09
primary,Circulatory system disorders,I95 (hypotension),4.54576635492648,YAP1;Transcriptional coactivator YAP1,1.31214367246446,1.2558098403622,1.37100455964889,6.99599801086613e-34
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106947004346144,YAP1;Transcriptional coactivator YAP1,2.32141411386437,1.80204221471507,2.9904757191833,7.14135338630092e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,CCL20;C-C motif chemokine 20,1.46991665464016,1.30933944582514,1.6501870301684,6.738395743396e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,CCL20;C-C motif chemokine 20,1.43674189978431,1.33490271798011,1.54635035107223,4.42982889839358e-22
primary,Circulatory system disorders,I46 (cardiac arrest),0.77379567139865,CCL20;C-C motif chemokine 20,1.41839938143337,1.28722984576469,1.56293517577305,1.66670865152517e-12
primary,Circulatory system disorders,I50 (heart failure),4.42893177685223,CCL20;C-C motif chemokine 20,1.27255096943217,1.22144106241353,1.32579951635399,9.97591936504068e-31
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772200772200772,CCL20;C-C motif chemokine 20,1.31820850021954,1.19587360100361,1.45305795578459,2.70395064263508e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,CCL20;C-C motif chemokine 20,1.53775829383079,1.39854686661639,1.6908268336881,6.20821860727171e-19
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15212264150943,CCL20;C-C motif chemokine 20,1.30476713787806,1.23014974699521,1.38391060783036,8.44599471855081e-19
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405604719764011,CCL20;C-C motif chemokine 20,1.47777096095922,1.29258072584225,1.6894937154748,1.08602865238341e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699300699300699,CCL20;C-C motif chemokine 20,1.34584540976128,1.2148877409538,1.49091953595108,1.29504921335631e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.21132221791392,CCL20;C-C motif chemokine 20,2.62750495609163,2.19549266280446,3.14452533194412,5.6126937949769e-26
primary,Circulatory system disorders,I95 (hypotension),4.80141802528292,CCL20;C-C motif chemokine 20,1.213707884824,1.16690622081441,1.26238664548026,4.76100768437168e-22
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104659275912861,CCL20;C-C motif chemokine 20,3.24583096730356,2.52386291749919,4.17432285852749,4.62498008878413e-20
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.390095772015884,CCER2;Coiled-coil domain-containing glutamate-rich protein 2,2.38343878495426,2.04649901049334,2.77585301165369,5.78023062947792e-29
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.509042999161576,ACE2;Angiotensin-converting enzyme 2,1.44079801961284,1.26400355996415,1.64232047999862,4.56304122071362e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34564168285308,ACE2;Angiotensin-converting enzyme 2,1.41236451271276,1.30178596880309,1.53233600958567,1.03852505399708e-16
primary,Circulatory system disorders,I42 (cardiomyopathy),0.678434197886647,ACE2;Angiotensin-converting enzyme 2,1.33876184682464,1.19152232487619,1.50419614059648,9.21624772919144e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.77876954412029,ACE2;Angiotensin-converting enzyme 2,1.35677539179654,1.21550468812871,1.5144651285703,5.3634657377202e-08
primary,Circulatory system disorders,I50 (heart failure),4.39370142161008,ACE2;Angiotensin-converting enzyme 2,1.27648656662254,1.21884713196001,1.3368517774231,3.98398212468505e-25
primary,Circulatory system disorders,I70 (atherosclerosis),0.797521487107735,ACE2;Angiotensin-converting enzyme 2,1.51140229673086,1.35822944992778,1.68184904449301,3.56398269320055e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.688041282476948,ACE2;Angiotensin-converting enzyme 2,1.33106571879091,1.18599037111613,1.49388729528471,1.19156121226643e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.209597572660491,ACE2;Angiotensin-converting enzyme 2,3.54390045620492,2.9288446482032,4.28811765458244,1.08556785807944e-38
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.267994640107197,ACE2;Angiotensin-converting enzyme 2,1.67408403374504,1.38786191355081,2.01933443426645,7.20035605133387e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0997804829375374,ACE2;Angiotensin-converting enzyme 2,6.52577233374549,4.99345977389822,8.52829630759854,6.10021097758517e-43
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24885778166618,ROBO2;Roundabout homolog 2,1.71302315032493,1.43015427251368,2.05184039928188,5.05234271012296e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34671603975833,ROBO2;Roundabout homolog 2,1.65634919049037,1.53189169953864,1.79091814497353,9.6520074123327e-37
primary,Circulatory system disorders,I85 (oesophageal varices),0.21954963181721,ROBO2;Roundabout homolog 2,1.99766706340815,1.65590796801841,2.40996104451464,4.8896187259354e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102942604642128,ROBO2;Roundabout homolog 2,2.69879267687643,2.07493750193786,3.51021749135072,1.3387363601392e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54862348979996,S100A11;Protein S100-A11,1.44707445662435,1.28933378259943,1.62411356258184,3.48795605465882e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36329409899734,S100A11;Protein S100-A11,1.24852765502919,1.15955775425882,1.34432398873403,3.984734413076e-09
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245862688787421,WFDC2;WAP four-disulfide core domain protein 2,1.64287820468882,1.38305088718343,1.95151806810099,1.58659568975563e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.52445747558382,WFDC2;WAP four-disulfide core domain protein 2,1.50549686233045,1.33632477622786,1.69608529513665,1.73107228867342e-11
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13535637506201,WFDC2;WAP four-disulfide core domain protein 2,1.38804665955299,1.30760349372864,1.47343865195886,5.05306469708692e-27
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.196118909991742,WFDC2;WAP four-disulfide core domain protein 2,1.88864865550048,1.56251385040762,2.2828557602822,4.88746103907718e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.525694889997309,WFDC2;WAP four-disulfide core domain protein 2,4.25989887452279,3.80050992374459,4.77481674440172,9.00690650497349e-137
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0660392933795608,WFDC2;WAP four-disulfide core domain protein 2,3.52720842004249,2.58979214805527,4.80393735372201,1.27347833112124e-15
primary,Circulatory system disorders,I15 (secondary hypertension),0.055742510890435,WFDC2;WAP four-disulfide core domain protein 2,3.17528465955797,2.25893801394983,4.46335074577576,2.91951719841344e-11
primary,Circulatory system disorders,I20 (angina pectoris),3.98252103748891,WFDC2;WAP four-disulfide core domain protein 2,1.21798868686517,1.16371450831837,1.27479414472136,2.2708055818357e-17
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.94360910228405,WFDC2;WAP four-disulfide core domain protein 2,1.47275547904032,1.39862151708321,1.55081891315865,7.3406769876945e-49
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.101235486136936,WFDC2;WAP four-disulfide core domain protein 2,2.08363167000199,1.60417517883542,2.70638830067617,3.75130574240414e-08
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00870212282188,WFDC2;WAP four-disulfide core domain protein 2,1.41476748854728,1.29741098602485,1.54273940039847,4.05718246528566e-15
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.65827777658685,WFDC2;WAP four-disulfide core domain protein 2,1.34330076465892,1.3026449608863,1.38522544401164,5.02902104337213e-79
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00542005420054,WFDC2;WAP four-disulfide core domain protein 2,1.37179757894841,1.28929613358989,1.45957825249116,1.69888949419862e-23
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35255494107168,WFDC2;WAP four-disulfide core domain protein 2,2.09641621921855,1.95022341686275,2.25356793801225,1.32949020997736e-89
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.748583481533562,WFDC2;WAP four-disulfide core domain protein 2,1.40522736197327,1.2706957763933,1.55400212664842,3.45514507676174e-11
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.6020253584843,WFDC2;WAP four-disulfide core domain protein 2,1.43294501201705,1.33755890957419,1.5351334380616,1.3782463108906e-24
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70702906507012,WFDC2;WAP four-disulfide core domain protein 2,1.28674060276438,1.20309424686437,1.37620255696318,1.96086270727853e-13
primary,Circulatory system disorders,I42 (cardiomyopathy),0.672780342393442,WFDC2;WAP four-disulfide core domain protein 2,1.43636607789215,1.29203732579504,1.59681726566973,2.05326233783427e-11
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.84447575048167,WFDC2;WAP four-disulfide core domain protein 2,1.26248891927372,1.19824382790758,1.33017857815485,2.1912773683748e-18
primary,Circulatory system disorders,I45 (other conduction disorders),1.72988184658679,WFDC2;WAP four-disulfide core domain protein 2,1.37302803619956,1.28482374249402,1.46728763318972,8.12396128831793e-21
primary,Circulatory system disorders,I46 (cardiac arrest),0.760063614019869,WFDC2;WAP four-disulfide core domain protein 2,1.77087216115431,1.60674459513249,1.95176521561148,1.09641882990323e-30
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35932823412038,WFDC2;WAP four-disulfide core domain protein 2,1.31328502543266,1.21793362164418,1.41610144212731,1.37541873657678e-12
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.34512153950033,WFDC2;WAP four-disulfide core domain protein 2,1.25870966650726,1.21778335270435,1.30101139996735,2.22661600263887e-42
primary,Circulatory system disorders,I50 (heart failure),4.43657571339304,WFDC2;WAP four-disulfide core domain protein 2,1.67875302271322,1.61086212862585,1.74950522529997,1.39742665402877e-133
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20796237191332,WFDC2;WAP four-disulfide core domain protein 2,1.4832629482702,1.42105784830071,1.5481910017541,1.01982397680501e-72
primary,Circulatory system disorders,I63 (cerebral infarction),2.05899411715966,WFDC2;WAP four-disulfide core domain protein 2,1.42647286919248,1.34242723253885,1.51578036948333,1.98870006606856e-30
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.775697603723348,WFDC2;WAP four-disulfide core domain protein 2,1.47087651044378,1.33156372160387,1.62476468371288,2.9533860016351e-14
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.630256442047403,WFDC2;WAP four-disulfide core domain protein 2,1.3946577935518,1.24976222254195,1.55635234129465,2.78946495514671e-09
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71719995857926,WFDC2;WAP four-disulfide core domain protein 2,1.37664945252147,1.30543979517582,1.45174348302475,4.10123218383595e-32
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.779054389155232,WFDC2;WAP four-disulfide core domain protein 2,1.75662201621465,1.59558894311814,1.93390717650614,1.57892085434011e-30
primary,Circulatory system disorders,I70 (atherosclerosis),0.804184238815843,WFDC2;WAP four-disulfide core domain protein 2,2.04226823456697,1.85997001201527,2.24243375698415,1.18547199263465e-50
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08318174301306,WFDC2;WAP four-disulfide core domain protein 2,1.56071200592449,1.43691861127777,1.69517044759467,4.70289609467745e-26
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14574305511942,WFDC2;WAP four-disulfide core domain protein 2,1.70061145884398,1.60281417321423,1.80437594219159,4.05908041619408e-69
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407125733652971,WFDC2;WAP four-disulfide core domain protein 2,2.22087710456235,1.95088281026956,2.528237517705,1.61788455259739e-33
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.707517894823948,WFDC2;WAP four-disulfide core domain protein 2,1.85770035208411,1.67959925541817,2.05468690641579,2.076189116526e-33
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0495356037151702,WFDC2;WAP four-disulfide core domain protein 2,3.64519026593028,2.55143524864414,5.20781865104901,1.19573782137069e-12
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.66239596789563,WFDC2;WAP four-disulfide core domain protein 2,1.21156193597537,1.13029349096806,1.298673606841,6.05168053135731e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.212678092091678,WFDC2;WAP four-disulfide core domain protein 2,1.69169804748903,1.40665422066278,2.03450303695087,2.34577377894493e-08
primary,Circulatory system disorders,I95 (hypotension),4.80833056754065,WFDC2;WAP four-disulfide core domain protein 2,1.49039340271472,1.43210413962646,1.55105514563692,1.43194591580576e-85
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0867445991160312,WFDC2;WAP four-disulfide core domain protein 2,2.37400517955762,1.79704882093408,3.13619781884218,1.15763194206976e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12989847418983,GFRA1;GDNF family receptor alpha-1,1.20082707690616,1.13168072136149,1.27419831531299,1.46541187865604e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544400866358367,GFRA1;GDNF family receptor alpha-1,4.15604234225521,3.74143609909822,4.61659306563631,1.60646414125042e-155
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0661388526854319,GFRA1;GDNF family receptor alpha-1,2.49849553302447,1.83310057872534,3.40542139421723,6.81612095176963e-09
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544884893066339,GFRA1;GDNF family receptor alpha-1,3.28310227187312,2.36170155973339,4.56398078036382,1.51316070925111e-12
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97767741161893,GFRA1;GDNF family receptor alpha-1,1.30636718748843,1.24170032502297,1.37440185377648,5.8769686357088e-25
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02873843156356,GFRA1;GDNF family receptor alpha-1,1.30605978727507,1.20010974272927,1.42136348635727,6.17440079264313e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35488657217601,GFRA1;GDNF family receptor alpha-1,1.38757391238118,1.2884389195904,1.49433654405045,4.67713617481881e-18
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60782396088019,GFRA1;GDNF family receptor alpha-1,1.2516942520066,1.16883614887699,1.34042611704956,1.32340444177027e-10
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71050319254876,GFRA1;GDNF family receptor alpha-1,1.22585992856898,1.14753330118311,1.30953285880402,1.49501463851743e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.776793536454784,GFRA1;GDNF family receptor alpha-1,1.39338228034248,1.26484787732216,1.53497840648065,1.84185253104162e-11
primary,Circulatory system disorders,I50 (heart failure),4.43078976815406,GFRA1;GDNF family receptor alpha-1,1.36902214502245,1.31341679971637,1.42698162073655,7.29797361800399e-50
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22744275337938,GFRA1;GDNF family receptor alpha-1,1.20484558440179,1.15461182549595,1.25726486616309,9.79459860943477e-18
primary,Circulatory system disorders,I63 (cerebral infarction),2.07739466593775,GFRA1;GDNF family receptor alpha-1,1.23730403858658,1.16519642790962,1.31387399345975,3.63964373372048e-12
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73862970915479,GFRA1;GDNF family receptor alpha-1,1.29088402348412,1.22505799913777,1.36024707667668,1.16231421478304e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775193798449612,GFRA1;GDNF family receptor alpha-1,1.44865942874902,1.3147804263455,1.59617081183407,6.8114289885327e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.804801527758832,GFRA1;GDNF family receptor alpha-1,1.72017778627497,1.56564158366137,1.88996744036012,1.40283717547994e-29
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15456859301935,GFRA1;GDNF family receptor alpha-1,1.40280585957855,1.3219418951378,1.48861632035861,5.49962051038967e-29
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409117475160724,GFRA1;GDNF family receptor alpha-1,1.77304103852595,1.55593138122434,2.02044547865824,8.45563967131677e-18
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.694200694200694,GFRA1;GDNF family receptor alpha-1,1.79887115769506,1.62599262181005,1.99013045851643,4.7135272242313e-30
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0447462111632069,GFRA1;GDNF family receptor alpha-1,4.19323314256666,2.9512645069444,5.95785438633024,1.25439195777977e-15
primary,Circulatory system disorders,I85 (oesophageal varices),0.210206703258203,GFRA1;GDNF family receptor alpha-1,1.70280895470106,1.41836777500309,2.04429231071877,1.14374252017972e-08
primary,Circulatory system disorders,I95 (hypotension),4.82782894350912,GFRA1;GDNF family receptor alpha-1,1.35396407659109,1.30140028515526,1.40865092901103,7.33168272809073e-51
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105066542143357,GFRA1;GDNF family receptor alpha-1,1.90595412998791,1.47740232387298,2.45881645569301,6.93005917898758e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.541915289054093,CXCL10;C-X-C motif chemokine 10,1.33303745023384,1.18792000379955,1.49588258303778,1.01690882753338e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35066358689269,CXCL10;C-X-C motif chemokine 10,1.33290801420087,1.23916415158255,1.43374368283002,1.13451216884134e-14
primary,Circulatory system disorders,I85 (oesophageal varices),0.222469410456062,CXCL10;C-X-C motif chemokine 10,1.87415513802962,1.57590588241265,2.22884978132411,1.21973575264937e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105347353635459,CXCL10;C-X-C motif chemokine 10,2.03568421198026,1.58567345956731,2.6134070579932,2.45020134054594e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.771777600182669,SMNDC1;Survival of motor neuron-related-splicing factor 30,1.34362413645341,1.20764691760747,1.49491195956247,5.76946959201452e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,MFAP5;Microfibrillar-associated protein 5,3.57499529316338,3.18790786561394,4.00908429129866,2.99229781240391e-105
primary,Circulatory system disorders,I15 (secondary hypertension),0.0561395357841144,MFAP5;Microfibrillar-associated protein 5,2.49935748817326,1.73402372840967,3.60248118370148,9.06322757156365e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.782415028565895,MFAP5;Microfibrillar-associated protein 5,1.37435519013377,1.24394565544828,1.51843625995617,4.06876551999123e-10
primary,Circulatory system disorders,I50 (heart failure),4.42925495557074,MFAP5;Microfibrillar-associated protein 5,1.21287425070559,1.16268691407807,1.26522792181857,3.52576443696161e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.804481836157096,MFAP5;Microfibrillar-associated protein 5,1.29426511221801,1.17295114299956,1.42812613355826,2.79538537313094e-07
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07968753028746,MFAP5;Microfibrillar-associated protein 5,1.23703421567717,1.13607638326264,1.34696370182556,9.72804834752463e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.401231049811923,CALCB;Calcitonin gene-related peptide 2,2.80045970684619,2.42501462944898,3.23403185878968,1.15160223273042e-44
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37277295568752,CALCB;Calcitonin gene-related peptide 2,1.31836084223269,1.21780091002096,1.42722451266896,8.63915058964667e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.762802559373363,CALCB;Calcitonin gene-related peptide 2,1.29693719040469,1.16705798957757,1.44127034892554,1.36907166231672e-06
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.400975098535073,CALCB;Calcitonin gene-related peptide 2,1.44456000194024,1.24934237283356,1.67028161741823,6.86319946097502e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686399708109094,CALCB;Calcitonin gene-related peptide 2,1.33096430079675,1.19024083438905,1.48832565545836,5.31705705449701e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.211303580550782,FUOM;Fucose mutarotase,3.13607664254853,2.58311257518323,3.80741311951564,7.49558378223338e-31
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.265208793765266,FUOM;Fucose mutarotase,1.69408306258575,1.40770604175466,2.03871926227059,2.41466798120521e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109096817622617,FUOM;Fucose mutarotase,4.23200435480282,3.25438897566827,5.50329447185777,5.04925200638423e-27
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.517660795952126,HAVCR1;Hepatitis A virus cellular receptor 1,1.42589799507909,1.26750217489268,1.60408805021792,3.51492726294561e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12977396726422,HAVCR1;Hepatitis A virus cellular receptor 1,1.33695141626126,1.26125884395661,1.41718656563449,1.58107265339408e-22
primary,Circulatory system disorders,I10 (essential (primary) hypertension),19.4751792235898,HAVCR1;Hepatitis A virus cellular receptor 1,1.25387161963393,1.22418558193973,1.28427753252269,1.83890332401515e-76
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.208199560251396,HAVCR1;Hepatitis A virus cellular receptor 1,1.59483854125701,1.33001903779272,1.91238613914879,4.69596017047786e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.546320143604152,HAVCR1;Hepatitis A virus cellular receptor 1,3.12125551787862,2.81260675916178,3.46377465536318,7.73011031048513e-102
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066134993191986,HAVCR1;Hepatitis A virus cellular receptor 1,2.31734668729344,1.70791948937765,3.1442323262361,6.73687375471586e-08
primary,Circulatory system disorders,I20 (angina pectoris),4.00236512661583,HAVCR1;Hepatitis A virus cellular receptor 1,1.21107023887776,1.1590583860442,1.26541608356864,1.22444709870355e-17
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97356167942287,HAVCR1;Hepatitis A virus cellular receptor 1,1.36835773401574,1.30189008602932,1.43821886988278,5.23822381745196e-35
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02865826335989,HAVCR1;Hepatitis A virus cellular receptor 1,1.4313783449061,1.31760142697861,1.5549800753968,2.12423881692096e-17
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72147041001817,HAVCR1;Hepatitis A virus cellular receptor 1,1.28138497211321,1.2441101180083,1.31977662024498,6.94925040422671e-61
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3528550512445,HAVCR1;Hepatitis A virus cellular receptor 1,1.52867899562836,1.42175274260412,1.64364688855467,1.84108136194533e-30
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60968549522766,HAVCR1;Hepatitis A virus cellular receptor 1,1.3765819401942,1.28694880732091,1.47245782216751,1.35664968007998e-20
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71036960384247,HAVCR1;Hepatitis A virus cellular receptor 1,1.33484950473977,1.25092429772078,1.42440530058497,2.84574601157359e-18
primary,Circulatory system disorders,I42 (cardiomyopathy),0.678971397354352,HAVCR1;Hepatitis A virus cellular receptor 1,1.30014064552865,1.17270789983856,1.44142091853253,6.13457801528534e-07
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.84877477301571,HAVCR1;Hepatitis A virus cellular receptor 1,1.22319856274353,1.16286649750928,1.28666078789142,5.86982700069385e-15
primary,Circulatory system disorders,I45 (other conduction disorders),1.74740619393088,HAVCR1;Hepatitis A virus cellular receptor 1,1.20693832263796,1.13153851300819,1.28736238131171,1.09937479525524e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.778694907335306,HAVCR1;Hepatitis A virus cellular receptor 1,1.55711043880927,1.41712173711125,1.7109277595242,3.16088552954603e-20
primary,Circulatory system disorders,I50 (heart failure),4.42865275514811,HAVCR1;Hepatitis A virus cellular receptor 1,1.4608183773429,1.40287374954264,1.52115636369878,3.12268438216509e-75
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22727542599299,HAVCR1;Hepatitis A virus cellular receptor 1,1.32024917762289,1.26622459529616,1.37657876611235,7.96895446012296e-39
primary,Circulatory system disorders,I63 (cerebral infarction),2.07727299349876,HAVCR1;Hepatitis A virus cellular receptor 1,1.35337448617067,1.27588851871409,1.43556625281316,8.3472263832686e-24
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.776618449134455,HAVCR1;Hepatitis A virus cellular receptor 1,1.37308432121613,1.2462671045707,1.51280616029659,1.430496845431e-10
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.621323672626699,HAVCR1;Hepatitis A virus cellular receptor 1,1.42216064105768,1.27810426141728,1.58245375594853,1.02580255775376e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73256040910332,HAVCR1;Hepatitis A virus cellular receptor 1,1.28771108789571,1.22277472518278,1.35609594452624,9.87917391904643e-22
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.777096114519427,HAVCR1;Hepatitis A virus cellular receptor 1,1.5020958015979,1.36571840854801,1.65209151685731,5.37897660403942e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.804754481683554,HAVCR1;Hepatitis A virus cellular receptor 1,1.9066313603805,1.74074885128685,2.08832143804033,6.70932858226407e-44
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15645654532899,HAVCR1;Hepatitis A virus cellular receptor 1,1.34263796202168,1.26641602842422,1.42344747429072,5.05231962832374e-23
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409093565542633,HAVCR1;Hepatitis A virus cellular receptor 1,1.6510981444504,1.45118388470144,1.87855247797796,2.63585824627745e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.69805986155796,HAVCR1;Hepatitis A virus cellular receptor 1,1.58463544467538,1.43381618342257,1.75131897767224,1.85629013198701e-19
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0447435997198661,HAVCR1;Hepatitis A virus cellular receptor 1,2.86386281567559,1.99957950973009,4.10171747964972,9.43467310484922e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.210194429847609,HAVCR1;Hepatitis A virus cellular receptor 1,2.72695672157749,2.30506820430485,3.22606200869413,1.29979554968277e-31
primary,Circulatory system disorders,I95 (hypotension),4.82158568775051,HAVCR1;Hepatitis A virus cellular receptor 1,1.34475869080278,1.29327034580048,1.39829691631126,5.08521956231964e-50
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103114846592346,HAVCR1;Hepatitis A virus cellular receptor 1,3.95833559775861,3.15163655793085,4.97151889708051,2.66278315786795e-32
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,IGSF8;Immunoglobulin superfamily member 8,2.95301698164881,2.62981128393402,3.3159448920081,7.00348210813817e-75
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666000666000666,IGSF8;Immunoglobulin superfamily member 8,2.24543238584396,1.61954760373605,3.11319444255041,1.22196048582652e-06
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9707155076985,IGSF8;Immunoglobulin superfamily member 8,1.21241905387664,1.15223312355026,1.27574874576932,1.21917385138251e-13
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,IGSF8;Immunoglobulin superfamily member 8,1.22819229445318,1.13972426463004,1.32352741708437,7.08933079138715e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,IGSF8;Immunoglobulin superfamily member 8,1.43671450873447,1.30358032458477,1.58344563866106,2.80669015679601e-13
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,IGSF8;Immunoglobulin superfamily member 8,1.25254584404731,1.20167487350227,1.30557035520575,1.84951728348295e-26
primary,Circulatory system disorders,I63 (cerebral infarction),2.08398867568417,IGSF8;Immunoglobulin superfamily member 8,1.21118714468191,1.14045020057455,1.28631158002661,4.36596276826621e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77276115011964,IGSF8;Immunoglobulin superfamily member 8,1.29477771623056,1.17339741169917,1.42871402112572,2.69213755697956e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,IGSF8;Immunoglobulin superfamily member 8,1.53057967272581,1.3900594160475,1.6853050362571,4.59315631780169e-18
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15754445217045,IGSF8;Immunoglobulin superfamily member 8,1.26821303715621,1.19485177122567,1.34607852316538,5.47101393213059e-15
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.413944637357032,IGSF8;Immunoglobulin superfamily member 8,1.6211885070272,1.41912953878291,1.85201710167427,1.12793728987117e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.710863247191893,IGSF8;Immunoglobulin superfamily member 8,1.41083868614223,1.27329779412322,1.56323666584701,4.81328218078591e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,IGSF8;Immunoglobulin superfamily member 8,1.96327973077897,1.63816305338284,2.35292042103379,2.80471574014183e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105795227459739,IGSF8;Immunoglobulin superfamily member 8,2.35329964234781,1.81612481666872,3.04936046016519,9.57523015617372e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551748512635237,CTSZ;Cathepsin Z,2.81135196259373,2.50542131531616,3.15463902588465,3.20774766752449e-69
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645944253053554,CTSZ;Cathepsin Z,2.46538856566661,1.75916826628835,3.45512188697209,1.60502225642125e-07
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97648975323291,CTSZ;Cathepsin Z,1.21302812291307,1.15228073597872,1.27697806709248,1.74089163466272e-13
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34556454781173,CTSZ;Cathepsin Z,1.26581230826052,1.1738660701259,1.36496048443753,8.99606240718847e-10
primary,Circulatory system disorders,I63 (cerebral infarction),2.07846295896116,CTSZ;Cathepsin Z,1.21418533775956,1.14275071985111,1.29008541304823,3.53672495115482e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772185638131075,CTSZ;Cathepsin Z,1.35332551246462,1.22537399689639,1.49463751256874,2.36040597625492e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.799984314033058,CTSZ;Cathepsin Z,1.48833229058069,1.35001258181272,1.64082397232982,1.34615956774519e-15
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407739203732381,CTSZ;Cathepsin Z,1.54927848937144,1.35182128356618,1.77557778295738,3.10133523653193e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704460273542513,CTSZ;Cathepsin Z,1.37611655124053,1.24011602309987,1.52703192872593,1.81765009226016e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.219341193059417,CTSZ;Cathepsin Z,2.16796980534461,1.80288377159103,2.60698618011195,1.96230835938691e-16
primary,Circulatory system disorders,I95 (hypotension),4.8165272995573,CTSZ;Cathepsin Z,1.2015689002147,1.15442940612666,1.25063326895604,2.41263213150643e-19
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103760841050138,CTSZ;Cathepsin Z,3.2585456323594,2.50607735752983,4.23694807595026,1.16544943881338e-18
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0979431929480901,CTSZ;Cathepsin Z,2.05703170958127,1.56100472035947,2.71067691150121,3.00482396589337e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12025316455696,SNCG;Gamma-synuclein,1.22712073848794,1.15363337234062,1.30528930848455,8.25547043350493e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,SNCG;Gamma-synuclein,3.58634814171698,3.16541847387777,4.06325201540903,2.04747597890535e-89
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0671299952614121,SNCG;Gamma-synuclein,2.4912008905237,1.76577568198603,3.51464908043465,2.01552287287475e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.0572805562139527,SNCG;Gamma-synuclein,3.07992913347073,2.13704551981493,4.43882143793702,1.61430431996112e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34152382839591,SNCG;Gamma-synuclein,1.36730307090802,1.26430548684048,1.47869142954246,4.91289307036972e-15
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.610181269482,SNCG;Gamma-synuclein,1.23693938774256,1.15213255593187,1.32798872931024,4.41478166428344e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.782500444602525,SNCG;Gamma-synuclein,1.28753950241355,1.16297729022383,1.42544311416112,1.12564384219802e-06
primary,Circulatory system disorders,I50 (heart failure),4.41132519077885,SNCG;Gamma-synuclein,1.27476134562851,1.22065285293537,1.33126833268021,5.33333962800448e-28
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620774188446482,SNCG;Gamma-synuclein,1.33461674606333,1.19042325503209,1.49627609452626,7.49753103418295e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769002668775328,SNCG;Gamma-synuclein,1.45418460982875,1.31158695548167,1.61228568996115,1.15280231937823e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.79898742188118,SNCG;Gamma-synuclein,1.44774512656381,1.3081861226719,1.6021924672373,8.41002501951052e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12868213949576,SNCG;Gamma-synuclein,1.20473727115873,1.13229231080648,1.28181731754871,3.94429570584632e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700643245917862,SNCG;Gamma-synuclein,1.36575509050366,1.22585934462729,1.52161581621241,1.57315429491715e-08
primary,Circulatory system disorders,I95 (hypotension),4.82087922992954,SNCG;Gamma-synuclein,1.20352795943826,1.15504199474872,1.25404925165924,1.04598846163413e-18
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,RTN4R;Reticulon-4 receptor,2.32192145502794,2.07982099073736,2.59220349603629,8.00762305369888e-51
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02719738531574,RTN4R;Reticulon-4 receptor,1.32008634474558,1.21079885293474,1.43923819663352,3.00983861363014e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,RTN4R;Reticulon-4 receptor,1.31351586122873,1.1910530762753,1.44857013685312,4.72614001819246e-08
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,RTN4R;Reticulon-4 receptor,1.40514551744603,1.22557535224238,1.61102613689655,1.08394557337234e-06
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0446792804693267,RTN4R;Reticulon-4 receptor,2.55419780916012,1.74586347478784,3.73679072993445,1.36224300636871e-06
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.247975512418148,COL6A3;Collagen alpha-3(VI) chain,1.93884008657588,1.64099529989925,2.29074445340845,7.2284793418951e-15
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.507260406582768,COL6A3;Collagen alpha-3(VI) chain,1.5556180938036,1.3802204608527,1.75330515841947,4.50459507672373e-13
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13615569512289,COL6A3;Collagen alpha-3(VI) chain,1.35250117024815,1.27484073439693,1.4348925055238,1.40430547850079e-23
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.209059233449477,COL6A3;Collagen alpha-3(VI) chain,1.69664229690424,1.41073720580905,2.04048994510896,1.96857661781634e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,COL6A3;Collagen alpha-3(VI) chain,4.40974580564334,4.00086324004527,4.8604155912535,2.88878939797512e-196
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0657932929543123,COL6A3;Collagen alpha-3(VI) chain,3.16084780063697,2.37142595031868,4.21305958022808,4.16995423851081e-15
primary,Circulatory system disorders,I15 (secondary hypertension),0.0561395357841144,COL6A3;Collagen alpha-3(VI) chain,3.12457501729837,2.28379399920824,4.27489039821884,1.05098565518212e-12
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97029702970297,COL6A3;Collagen alpha-3(VI) chain,1.26599409751368,1.20275937917591,1.3325533624503,1.84952892479794e-19
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.102671393425156,COL6A3;Collagen alpha-3(VI) chain,1.90086026995425,1.4652996421007,2.46589138635865,1.31599791174849e-06
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0136641147398,COL6A3;Collagen alpha-3(VI) chain,1.39946339535607,1.28494604626395,1.52418679417395,1.20140711203004e-14
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69827360974335,COL6A3;Collagen alpha-3(VI) chain,1.25488933310393,1.21738229962986,1.29355194240692,1.07872980196063e-48
primary,Circulatory system disorders,I26 (pulmonary embolism),1.98999139885839,COL6A3;Collagen alpha-3(VI) chain,1.27496757655342,1.19889300767066,1.35586938188986,1.00249150150036e-14
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35161378024624,COL6A3;Collagen alpha-3(VI) chain,1.76468136921852,1.64038795636202,1.89839258621067,1.87441019740178e-52
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60521451503064,COL6A3;Collagen alpha-3(VI) chain,1.35699977560185,1.26733527211863,1.45300808041513,2.08357165046382e-18
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72480770724885,COL6A3;Collagen alpha-3(VI) chain,1.2375213091141,1.15856311097553,1.32186065308256,2.36807359154301e-10
primary,Circulatory system disorders,I37 (pulmonary valve disorders),0.212901852246114,COL6A3;Collagen alpha-3(VI) chain,1.59654327290688,1.32811722483521,1.91922096528829,6.31570009538143e-07
primary,Circulatory system disorders,I42 (cardiomyopathy),0.671609922745448,COL6A3;Collagen alpha-3(VI) chain,1.3777884911426,1.24029244077735,1.53052704661753,2.30600268031291e-09
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.855644268314,COL6A3;Collagen alpha-3(VI) chain,1.21504088006304,1.15420947986352,1.27907833541529,1.06424298306965e-13
primary,Circulatory system disorders,I45 (other conduction disorders),1.75584959838578,COL6A3;Collagen alpha-3(VI) chain,1.26515836644856,1.18523801702664,1.35046772817009,1.61310358330165e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.782415028565895,COL6A3;Collagen alpha-3(VI) chain,1.70240192211259,1.54704512456523,1.87335990294862,1.19004661054847e-27
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3583567196757,COL6A3;Collagen alpha-3(VI) chain,1.21217315765001,1.12522067811284,1.30584497130958,4.05249690350339e-07
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.41172979922856,COL6A3;Collagen alpha-3(VI) chain,1.21482396846212,1.17597927453928,1.25495177194192,8.29922071818808e-32
primary,Circulatory system disorders,I50 (heart failure),4.42925495557074,COL6A3;Collagen alpha-3(VI) chain,1.48027997816973,1.41976637912797,1.54337280131681,9.37259462284587e-76
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21309603496476,COL6A3;Collagen alpha-3(VI) chain,1.36348491927693,1.30650283358299,1.42295223348057,5.58569844863591e-46
primary,Circulatory system disorders,I63 (cerebral infarction),2.0683226194869,COL6A3;Collagen alpha-3(VI) chain,1.29096592112994,1.21547131305293,1.37114960396132,9.83339993384858e-17
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.621996589676019,COL6A3;Collagen alpha-3(VI) chain,1.35688570137294,1.21661564257603,1.51332823790755,4.21108502216337e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73036217108457,COL6A3;Collagen alpha-3(VI) chain,1.30128225821117,1.23475078704787,1.37139861200957,7.94712274988799e-23
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771153436282963,COL6A3;Collagen alpha-3(VI) chain,1.52606485373331,1.38443794969621,1.68218007770669,1.8014904232404e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.804481836157096,COL6A3;Collagen alpha-3(VI) chain,1.66756437196751,1.51636510879601,1.83383996276682,5.3729033838125e-26
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07968753028746,COL6A3;Collagen alpha-3(VI) chain,1.30754340993582,1.20319591698281,1.42094046757892,2.62837766125297e-10
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16089968793546,COL6A3;Collagen alpha-3(VI) chain,1.42416446009352,1.34202821852128,1.51132769147604,1.89541950870057e-31
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406976744186046,COL6A3;Collagen alpha-3(VI) chain,1.71662419280757,1.50341208692034,1.96007378480547,1.39705376961937e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704198029021494,COL6A3;Collagen alpha-3(VI) chain,1.66980544405755,1.50890096075518,1.84786827865015,3.49705043455648e-23
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0483830388419035,COL6A3;Collagen alpha-3(VI) chain,3.61982276234223,2.63081309637141,4.98063387659261,2.77482432254994e-15
primary,Circulatory system disorders,I85 (oesophageal varices),0.218776015953224,COL6A3;Collagen alpha-3(VI) chain,1.83635163114827,1.53551843903238,2.19612296896019,2.77288232232253e-11
primary,Circulatory system disorders,I95 (hypotension),4.80432583832568,COL6A3;Collagen alpha-3(VI) chain,1.37841461077135,1.32458842737021,1.4344280834162,3.54787352629634e-56
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104513431911434,COL6A3;Collagen alpha-3(VI) chain,2.16378382264261,1.68182316962787,2.78386010829296,1.92860308077148e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,IL16;Pro-interleukin-16,2.02377876177948,1.8087754519742,2.26433882224543,8.84282714613968e-35
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02086365841824,IL16;Pro-interleukin-16,1.25471547392779,1.15269578953832,1.36576444088893,1.56999010540844e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,IL16;Pro-interleukin-16,1.20436195327899,1.11825304564739,1.29710151038868,8.97067686119263e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699300699300699,IL16;Pro-interleukin-16,1.30518818195336,1.17812434644401,1.44595618913448,3.45471341185067e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534323851898935,GFRA3;GDNF family receptor alpha-3,2.14876886970836,1.90774467783078,2.42024402378509,2.08838706675585e-36
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,LEPR;Leptin receptor,1.70886061289579,1.42986002374612,2.04230102654094,3.82189476769128e-09
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105795227459739,LEPR;Leptin receptor,1.95941612816126,1.52020063486418,2.5255295092292,2.05370769336365e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535211267605633,PLIN1;Perilipin-1,1.3533345239234,1.20210254108749,1.52359243162907,5.60096539942346e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.554640953276889,LGALS3;Galectin-3,2.40869279252704,2.14899773987519,2.69977062382051,1.55070703758953e-51
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482226535694,LGALS3;Galectin-3,1.27797183838691,1.18373072502704,1.37971582994326,3.48359982824229e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.780226441659007,LGALS3;Galectin-3,1.31927275873281,1.19330320731364,1.4585401273266,6.25165477837468e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.397450832590968,RBP7;Retinoid-binding protein 7,2.11449645125092,1.84170979814135,2.42768716703628,2.26177777543897e-26
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37544341457832,RBP7;Retinoid-binding protein 7,1.38462989319681,1.28051434824415,1.49721082295023,3.36412009209302e-16
primary,Circulatory system disorders,I50 (heart failure),4.31792040487692,RBP7;Retinoid-binding protein 7,1.21865469520818,1.16566993099824,1.27404784721619,2.80401719246147e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.748687514266149,RBP7;Retinoid-binding protein 7,1.31594668063483,1.18376608260725,1.46288670685658,3.70455072367035e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08550091327368,RBP7;Retinoid-binding protein 7,1.22341366505895,1.1471217892953,1.30477950102618,8.3589896588899e-10
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406337031456878,RBP7;Retinoid-binding protein 7,1.44923026124502,1.25772682678363,1.66989230521488,2.88083769497605e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.397450832590968,EFCAB14;EF-hand calcium-binding domain-containing protein 14,4.02212712991182,3.49863525808129,4.62394775557277,3.16349815964868e-85
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0501504513540621,EFCAB14;EF-hand calcium-binding domain-containing protein 14,2.70795769096901,1.81579411778481,4.03847263533609,1.03285902689119e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37544341457832,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.32893132455792,1.22688369602651,1.43946689577095,3.03746051961839e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.759753593429158,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.3416040273739,1.20517594598494,1.49347601257912,7.8387705803778e-08
primary,Circulatory system disorders,I50 (heart failure),4.31792040487692,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.2303360230577,1.17546556702539,1.28776781906428,5.33581486479741e-19
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.748687514266149,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.31234009943691,1.17802053886737,1.46197496543309,8.06154298769668e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.771777600182669,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.3483647607361,1.21220111743416,1.49982333941683,3.73419411723092e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08550091327368,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.20667669609731,1.13025769206199,1.28826254325058,1.82149188039603e-08
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406337031456878,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.61064858963576,1.39234257316607,1.86318290433131,1.41772289643485e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.68546360188274,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.40329302158399,1.25373538065359,1.57069133950717,3.79836026281508e-09
primary,Circulatory system disorders,I95 (hypotension),4.54545454545454,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.20960391863677,1.15732842421516,1.26424065059463,3.11302812469033e-17
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13362497514416,PI3;Elafin,1.22122728949622,1.14668581295639,1.300614410468,4.98524270056409e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.553553294438581,PI3;Elafin,3.04763049256293,2.7098090476123,3.42756683441712,3.8441909327892e-77
primary,Circulatory system disorders,I15 (secondary hypertension),0.0575876722665713,PI3;Elafin,2.63738188190042,1.81391516725537,3.83467943625025,3.81128224617541e-07
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96961044258617,PI3;Elafin,1.21000665049758,1.14570696491269,1.27791498095671,7.79012870831788e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35248187395426,PI3;Elafin,1.31528257079046,1.21556652390448,1.42317858134854,9.57067781556023e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.786713286713286,PI3;Elafin,1.4942153908349,1.34713793220615,1.6573504322245,3.04642457193009e-14
primary,Circulatory system disorders,I50 (heart failure),4.429707691383,PI3;Elafin,1.33994232702594,1.28215606552833,1.40033299223668,1.06979878719645e-38
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19502736765567,PI3;Elafin,1.20259254235818,1.14905441218462,1.25862518571761,2.02778107543179e-15
primary,Circulatory system disorders,I63 (cerebral infarction),2.05594071240736,PI3;Elafin,1.26680878840912,1.18801321383423,1.35083051914143,5.27376573199486e-13
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73726990198422,PI3;Elafin,1.21141212946484,1.14578685832975,1.2807961068377,1.4870649382557e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771172460397909,PI3;Elafin,1.53240171693501,1.38115364429092,1.70021274010464,8.24640684253768e-16
primary,Circulatory system disorders,I70 (atherosclerosis),0.807317558162656,PI3;Elafin,1.46867447804287,1.32593047082529,1.62678569496328,1.73396469093711e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15019126233138,PI3;Elafin,1.26564762425279,1.18813829445139,1.34821334878055,2.74445124927196e-13
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407530365982148,PI3;Elafin,1.53261782520115,1.32708244385689,1.76998603892134,6.18213681376172e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.71041948579161,PI3;Elafin,1.3247282479051,1.18792026750194,1.47729185098262,4.27403203448608e-07
primary,Circulatory system disorders,I95 (hypotension),4.82052714539396,PI3;Elafin,1.28166564933778,1.22901537981923,1.33657142430069,4.35872010507744e-31
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24756335282651,CKAP4;Cytoskeleton-associated protein 4,1.67143707340213,1.40598911375767,1.98700108201874,5.829030745301e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.514309091971713,CKAP4;Cytoskeleton-associated protein 4,1.39163207883766,1.23378849070632,1.56966924026122,7.43567888096844e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.118321727427,CKAP4;Cytoskeleton-associated protein 4,1.26895688865524,1.19576697646097,1.34662657270512,3.88714992649701e-15
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.546885681360964,CKAP4;Cytoskeleton-associated protein 4,4.30439473583798,3.85397426170958,4.80745661069645,1.04843313339026e-147
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066203243958954,CKAP4;Cytoskeleton-associated protein 4,3.14157690895666,2.28514511310204,4.31898412853618,1.80388714700367e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0545415587198317,CKAP4;Cytoskeleton-associated protein 4,3.24887128487801,2.28718388865508,4.61491735669387,4.70894331260222e-11
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96629662966296,CKAP4;Cytoskeleton-associated protein 4,1.23702845990191,1.17567031793037,1.30158887850557,2.50648823427741e-16
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0258410531448,CKAP4;Cytoskeleton-associated protein 4,1.34378157106528,1.23454156378624,1.46268782170168,8.46138595211337e-12
primary,Circulatory system disorders,I26 (pulmonary embolism),2.01010955293747,CKAP4;Cytoskeleton-associated protein 4,1.27544258612875,1.19964229216065,1.3560323782691,7.09804616055309e-15
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35219634203532,CKAP4;Cytoskeleton-associated protein 4,1.61978514553731,1.50387267566635,1.74463168335763,3.97588208685518e-37
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61902897415818,CKAP4;Cytoskeleton-associated protein 4,1.28527952577824,1.20053704638548,1.37600373462721,5.51726574501924e-13
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70044758907804,CKAP4;Cytoskeleton-associated protein 4,1.24711247484507,1.16726828965504,1.33241820984774,6.08767126201014e-11
primary,Circulatory system disorders,I45 (other conduction disorders),1.75503670154615,CKAP4;Cytoskeleton-associated protein 4,1.21110192127268,1.13492107913028,1.29239635308774,7.55187838481644e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.773668004832989,CKAP4;Cytoskeleton-associated protein 4,1.54774362705884,1.40441993280908,1.70569377373464,1.25058963319676e-18
primary,Circulatory system disorders,I50 (heart failure),4.43095181953941,CKAP4;Cytoskeleton-associated protein 4,1.45739136650674,1.39832030802025,1.51895784033597,3.36498355983842e-71
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21709418639199,CKAP4;Cytoskeleton-associated protein 4,1.27277904945771,1.21979525178837,1.32806428485715,1.02155496775419e-28
primary,Circulatory system disorders,I63 (cerebral infarction),2.06961246066954,CKAP4;Cytoskeleton-associated protein 4,1.34101557624136,1.26293035994153,1.42392869216097,9.12928121564613e-22
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.77536246217141,CKAP4;Cytoskeleton-associated protein 4,1.37152599258158,1.24260186331231,1.51382643456901,3.55291231107867e-10
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.621965723644446,CKAP4;Cytoskeleton-associated protein 4,1.33659003000149,1.19849926692604,1.49059157364478,1.84504205670146e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73381013796068,CKAP4;Cytoskeleton-associated protein 4,1.30033615347149,1.23399854176984,1.37023995960314,8.35822631125982e-23
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772050222256882,CKAP4;Cytoskeleton-associated protein 4,1.55880745284411,1.41381290142688,1.71867201989033,5.01974730174057e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.803604517349665,CKAP4;Cytoskeleton-associated protein 4,1.58266683876622,1.43812702903805,1.74173370776969,5.67360985024157e-21
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07661101575908,CKAP4;Cytoskeleton-associated protein 4,1.27408287531563,1.17318606363026,1.383657054491,8.6964385903275e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14883867909622,CKAP4;Cytoskeleton-associated protein 4,1.38019135316102,1.30042175928346,1.46485411962813,2.72935212589296e-26
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40758219899372,CKAP4;Cytoskeleton-associated protein 4,1.75355945924055,1.53479481010681,2.0035061083364,1.44250653108013e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.69879565107064,CKAP4;Cytoskeleton-associated protein 4,1.53783600882959,1.38737973504128,1.70460871693687,2.55289464157294e-16
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0447897801406009,CKAP4;Cytoskeleton-associated protein 4,3.61263341255341,2.46201868953606,5.30098338772427,5.19730127762541e-11
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.08814840122997,CKAP4;Cytoskeleton-associated protein 4,1.20337142681418,1.13237950902781,1.27881401891143,2.41330394613301e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.212351451392947,CKAP4;Cytoskeleton-associated protein 4,2.13015164962234,1.77450823276111,2.55707241398841,4.91387066733906e-16
primary,Circulatory system disorders,I87 (other disorders of veins),0.460056922297165,CKAP4;Cytoskeleton-associated protein 4,1.39634589791708,1.22956631306327,1.58574762980639,2.68403330653438e-07
primary,Circulatory system disorders,I95 (hypotension),4.79927971658413,CKAP4;Cytoskeleton-associated protein 4,1.37416137418061,1.32061680829292,1.42987691087384,2.27493535438227e-55
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105168854438515,CKAP4;Cytoskeleton-associated protein 4,2.80387849358893,2.17332463104677,3.61737703355617,2.15043395504593e-15
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0954812057912274,CKAP4;Cytoskeleton-associated protein 4,1.97431110268653,1.50158277561582,2.59586377353902,1.11005919858909e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.211835584491303,HAO1;Hydroxyacid oxidase 1,3.05154290119036,2.54053966073269,3.66532915101971,8.14561468726541e-33
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.264792352173828,HAO1;Hydroxyacid oxidase 1,1.54962880707555,1.30064420196925,1.84627697265911,9.51945267810076e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10490936996095,HAO1;Hydroxyacid oxidase 1,5.11822942999761,3.97824720215707,6.58487800453667,5.83492932974956e-37
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.401231049811923,ZHX2;Zinc fingers and homeoboxes protein 2,1.52978823829192,1.31975206792387,1.77325128779513,1.68106128721528e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.223942167917337,IL1R2;Interleukin-1 receptor type 2,2.64538050203984,2.18961728113355,3.19600966838813,6.53137980842845e-24
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106044538706256,IL1R2;Interleukin-1 receptor type 2,3.98263350649924,3.02536895597707,5.24278852526529,6.68453221397864e-23
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.386548125241592,CYTL1;Cytokine-like protein 1,3.62072122888612,3.07397691627489,4.26471069053867,1.51236053469847e-53
primary,Circulatory system disorders,I15 (secondary hypertension),0.043122035360069,CYTL1;Cytokine-like protein 1,3.85783004642407,2.4228035089982,6.14282281324838,1.28187178618382e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37382666545156,CYTL1;Cytokine-like protein 1,1.26107207567155,1.15884675468909,1.37231499644249,7.53264936225672e-08
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25137964217679,EFNA1;Ephrin-A1,1.53437760387259,1.28973455818753,1.82542571750138,1.35768163578145e-06
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516192345436702,EFNA1;Ephrin-A1,1.42819852520506,1.26551140186099,1.6117998023553,7.6411086369296e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14392391133469,EFNA1;Ephrin-A1,1.30575737035074,1.23054133200434,1.38557094010659,1.21500442004288e-18
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.206043956043956,EFNA1;Ephrin-A1,1.62896320458899,1.35022624221574,1.96524185276561,3.47121771094145e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.531234628627643,EFNA1;Ephrin-A1,5.12019645285607,4.55301146173736,5.75803771551151,1.10847245439415e-163
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666967455911489,EFNA1;Ephrin-A1,3.70571911782422,2.70867800649993,5.06976249936492,2.58264150757347e-16
primary,Circulatory system disorders,I15 (secondary hypertension),0.0549472114290199,EFNA1;Ephrin-A1,3.80018631180822,2.69001393796317,5.36852831899797,3.63481497097256e-14
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97057638049173,EFNA1;Ephrin-A1,1.26183258524501,1.19895997527274,1.32800219025152,4.73540386678506e-19
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.102120974076983,EFNA1;Ephrin-A1,2.06129298592127,1.58918216241737,2.67365747885378,5.02756134785364e-08
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00791795194215,EFNA1;Ephrin-A1,1.35591337990258,1.24447301134088,1.47733303739382,3.44548670639732e-12
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72532442398191,EFNA1;Ephrin-A1,1.20569083143347,1.16980230323329,1.2426803888014,7.11225261154193e-34
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00729203820393,EFNA1;Ephrin-A1,1.21261462420878,1.14003681571849,1.28981293110109,9.24070254814271e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3445940625246,EFNA1;Ephrin-A1,1.6121388829059,1.49565199932012,1.73769819380345,9.58363509563451e-36
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60170427647151,EFNA1;Ephrin-A1,1.26409736996558,1.17967228036901,1.35456447298571,3.02607607673253e-11
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72698987830333,EFNA1;Ephrin-A1,1.22211903245396,1.14412372376139,1.30543130822946,2.49991815227277e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.775513409510346,EFNA1;Ephrin-A1,1.5356941034769,1.39340740590699,1.69251029487576,5.26836920269241e-18
primary,Circulatory system disorders,I50 (heart failure),4.43036721765812,EFNA1;Ephrin-A1,1.46158740456869,1.40169479598522,1.52403914697589,1.0457133602869e-70
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22287858226231,EFNA1;Ephrin-A1,1.26064343979122,1.2078988408671,1.31569120568722,2.36168352900391e-26
primary,Circulatory system disorders,I63 (cerebral infarction),2.08304620897403,EFNA1;Ephrin-A1,1.26392011603206,1.19004965525009,1.34237596949245,2.48529231079194e-14
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.628572551022412,EFNA1;Ephrin-A1,1.34262334739048,1.20418999432444,1.49697096093986,1.11688309323004e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72643162266973,EFNA1;Ephrin-A1,1.26078804165168,1.19592565782876,1.32916831039299,8.00518333063194e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771859533349045,EFNA1;Ephrin-A1,1.55969334105839,1.41410112466621,1.72027535775851,6.10750018490288e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.803725829272127,EFNA1;Ephrin-A1,1.65488546363732,1.50358289965652,1.82141330443685,7.26131396674742e-25
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08665749656121,EFNA1;Ephrin-A1,1.22482297451846,1.12817648205165,1.32974879619905,1.32602550011774e-06
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13100401926061,EFNA1;Ephrin-A1,1.42730435075858,1.34400398588172,1.51576761013688,4.30744543945944e-31
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404715127701375,EFNA1;Ephrin-A1,1.92374585242124,1.68391415749292,2.19773560798243,5.93483582970371e-22
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702051090440699,EFNA1;Ephrin-A1,1.59284638822455,1.43704449839786,1.76554005064466,7.71915129120413e-19
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0470855976928057,EFNA1;Ephrin-A1,3.42680356908131,2.3618600720658,4.97192142750327,8.81499456242596e-11
primary,Circulatory system disorders,I95 (hypotension),4.81899203407208,EFNA1;Ephrin-A1,1.30188834673118,1.25078742457013,1.35507699714597,3.80104154959725e-38
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,"ST3GAL1;CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1",1.81389434516613,1.62203327892888,2.02844956276013,1.63343739418327e-25
primary,Circulatory system disorders,I08 (multiple valve diseases),2.1362235180931,"FABP1;Fatty acid-binding protein, liver",1.25449296243281,1.18200281419943,1.33142880362712,8.26649069482942e-14
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.207839061979176,"FABP1;Fatty acid-binding protein, liver",1.66786326495341,1.38302263453575,2.01136828936631,8.61510752034884e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544600200538702,"FABP1;Fatty acid-binding protein, liver",2.81567883520008,2.52285260202153,3.1424932620483,3.19286829680765e-76
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96983852132243,"FABP1;Fatty acid-binding protein, liver",1.22743669400572,1.16579300495113,1.2923399191736,6.43811906344047e-15
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72547423267931,"FABP1;Fatty acid-binding protein, liver",1.23913156617582,1.20227964807482,1.2771130583072,4.84664424294631e-44
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35143110061965,"FABP1;Fatty acid-binding protein, liver",1.44170208407507,1.338565887604,1.55278490097104,4.46845090289498e-22
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60823035534795,"FABP1;Fatty acid-binding protein, liver",1.25517737151236,1.17191055089018,1.34436048276888,8.60773196738766e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.780744257214037,"FABP1;Fatty acid-binding protein, liver",1.47254914005182,1.33555956829463,1.62358985802195,7.97826114905144e-15
primary,Circulatory system disorders,I50 (heart failure),4.42479626552733,"FABP1;Fatty acid-binding protein, liver",1.36169647000926,1.30635328620615,1.41938424774863,3.56904304134241e-48
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22939639873177,"FABP1;Fatty acid-binding protein, liver",1.24349685069614,1.19138879991962,1.29788396348492,1.90529061220719e-23
primary,Circulatory system disorders,I63 (cerebral infarction),2.07739067141423,"FABP1;Fatty acid-binding protein, liver",1.28443613341965,1.20920589070954,1.36434679446192,4.33780482886561e-16
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.78258791668326,"FABP1;Fatty acid-binding protein, liver",1.28666985357019,1.16528436802992,1.42069983731543,6.18046854368893e-07
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.622190818269249,"FABP1;Fatty acid-binding protein, liver",1.40480739190969,1.25901555937709,1.56748166745493,1.20141506266e-09
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71854591234558,"FABP1;Fatty acid-binding protein, liver",1.23930570581388,1.17549822753315,1.30657673188157,1.78648052313977e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.783059229893629,"FABP1;Fatty acid-binding protein, liver",1.43178873910313,1.29873664836509,1.57847166013463,5.48277521904452e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.807021677662582,"FABP1;Fatty acid-binding protein, liver",1.69833658089765,1.54448271360241,1.86751662327612,8.11543666469503e-28
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1509223918575,"FABP1;Fatty acid-binding protein, liver",1.34598809616549,1.26818384304135,1.42856571226648,1.36421649769446e-22
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404397330192383,"FABP1;Fatty acid-binding protein, liver",1.74275627179717,1.52415842777496,1.99270585494333,4.54579784542918e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701485498703136,"FABP1;Fatty acid-binding protein, liver",1.59736992040576,1.44219583024918,1.7692400775949,2.639935716976e-19
primary,Circulatory system disorders,I85 (oesophageal varices),0.22356886509384,"FABP1;Fatty acid-binding protein, liver",2.39563230808196,2.0129759131037,2.85102972080643,7.64404064543089e-23
primary,Circulatory system disorders,I95 (hypotension),4.83724779319041,"FABP1;Fatty acid-binding protein, liver",1.27423161181036,1.22461304288348,1.32586061366271,5.84091107078385e-33
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105867822063638,"FABP1;Fatty acid-binding protein, liver",3.63335576061197,2.8562381950336,4.62190937230882,7.97178375845528e-26
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246966397013067,ADM;Pro-adrenomedullin,1.96637451168343,1.6799030177695,2.30169758569288,3.86067756650364e-17
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516916380030704,ADM;Pro-adrenomedullin,1.6124156007343,1.43747768195489,1.80864308512648,3.54454070560809e-16
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13059890259563,ADM;Pro-adrenomedullin,1.4559243358849,1.37409505257584,1.54262666752807,4.14769365253677e-37
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.207900207900207,ADM;Pro-adrenomedullin,1.6089476929452,1.34381135662814,1.92639589319235,2.26184577276608e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,ADM;Pro-adrenomedullin,3.38266258591377,3.10194598888382,3.68878317389987,2.50766609171284e-167
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0660399347370056,ADM;Pro-adrenomedullin,2.93517743576334,2.26856684292318,3.79766926696018,2.56867765614367e-16
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544069640914037,ADM;Pro-adrenomedullin,2.98296797354891,2.24912813279196,3.95624322220042,3.30147493248609e-14
primary,Circulatory system disorders,I20 (angina pectoris),4.00081441514812,ADM;Pro-adrenomedullin,1.21001582808489,1.15752871066377,1.26488292750543,3.59464870981208e-17
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97515713858126,ADM;Pro-adrenomedullin,1.2897412476605,1.22584299191454,1.3569702620063,9.76406563960403e-23
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02719738531574,ADM;Pro-adrenomedullin,1.36607257490151,1.25648634499205,1.48521652251609,2.64215206012479e-13
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72309957443375,ADM;Pro-adrenomedullin,1.30610963728443,1.26750288194867,1.34589231227986,3.77884942691066e-68
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00521906331547,ADM;Pro-adrenomedullin,1.21463014522855,1.14270966897281,1.29107719113299,4.27509374206978e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,ADM;Pro-adrenomedullin,1.87583540392713,1.75003517456902,2.01067870735399,1.42184242401574e-70
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.751206601276662,ADM;Pro-adrenomedullin,1.36473001563791,1.23752975359853,1.50500463537725,4.68736365924173e-10
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60931213624467,ADM;Pro-adrenomedullin,1.44896493009219,1.35517119341296,1.54925029313053,1.76360039271513e-27
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70988496782998,ADM;Pro-adrenomedullin,1.26267842189813,1.18244121694855,1.34836030263019,3.33703473013631e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.678005727979426,ADM;Pro-adrenomedullin,1.42802717715849,1.28866835439119,1.58245650384319,1.04134779582101e-11
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.84672529100941,ADM;Pro-adrenomedullin,1.26215249090336,1.1993787196278,1.32821175182091,3.72758250049435e-19
primary,Circulatory system disorders,I45 (other conduction disorders),1.75073028237585,ADM;Pro-adrenomedullin,1.24720524408385,1.1687777365826,1.33089540652823,2.62001041420231e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.777574744372302,ADM;Pro-adrenomedullin,1.77997223811442,1.62475107670168,1.95002250737993,3.12321511379478e-35
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37326630020149,ADM;Pro-adrenomedullin,1.31700313941103,1.22406360392448,1.4169992994298,1.64830745881953e-13
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.39571544860722,ADM;Pro-adrenomedullin,1.30921176278921,1.2675796943439,1.3522111844122,5.06922229362423e-60
primary,Circulatory system disorders,I49 (other cardiac arrhythmias),1.98099659669899,ADM;Pro-adrenomedullin,1.2259204090212,1.15283137156089,1.3036432615638,8.3257291426762e-11
primary,Circulatory system disorders,I50 (heart failure),4.43006958737626,ADM;Pro-adrenomedullin,1.62384731160045,1.55941251503672,1.69094454864619,8.71079565244384e-122
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22702211331343,ADM;Pro-adrenomedullin,1.43231947093444,1.37353058813942,1.49362459382643,2.33784948875343e-63
primary,Circulatory system disorders,I63 (cerebral infarction),2.07622575299736,ADM;Pro-adrenomedullin,1.33163778001367,1.25505832553208,1.41288985626063,2.59465163329063e-21
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.775499733606961,ADM;Pro-adrenomedullin,1.29872185772724,1.17703576248372,1.43298828931022,1.91658759519692e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73646870797357,ADM;Pro-adrenomedullin,1.29891053073226,1.23324971053842,1.36806727172112,5.01075021721534e-23
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77792255780937,ADM;Pro-adrenomedullin,1.66224587878083,1.51464933887989,1.82422511309924,9.0122171108181e-27
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,ADM;Pro-adrenomedullin,1.75800987246168,1.60600717232903,1.92439907176176,2.20810274725884e-34
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08369975485427,ADM;Pro-adrenomedullin,1.35241619695058,1.2463952410219,1.46745551457232,4.23253786670371e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15331271301641,ADM;Pro-adrenomedullin,1.54547686778292,1.45871888379845,1.63739482321128,2.33763973367685e-49
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,ADM;Pro-adrenomedullin,1.93976721469382,1.71518850299308,2.19375120614146,4.87107193587971e-26
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697054070367413,ADM;Pro-adrenomedullin,1.6189625854752,1.46618919359921,1.78765459779062,1.62264872569211e-21
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0446792804693267,ADM;Pro-adrenomedullin,2.64446924469534,1.90664431899012,3.66781445101602,5.65918170548363e-09
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.6683941955031,ADM;Pro-adrenomedullin,1.22744136751844,1.14729740904773,1.31318374713845,2.70608523159631e-09
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.533156911581569,ADM;Pro-adrenomedullin,1.46202439438141,1.30313738507397,1.64028394415606,9.75451143137491e-11
primary,Circulatory system disorders,I95 (hypotension),4.82261749028642,ADM;Pro-adrenomedullin,1.39430422366465,1.34075495268547,1.44999223328257,3.8674175366355e-62
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0933017144190024,ADM;Pro-adrenomedullin,2.14106428759602,1.67116911048296,2.74308342277477,1.72284130804178e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,INHBC;Inhibin beta C chain,1.46775047985407,1.30232208010365,1.65419254117262,3.18704890269842e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,NOTCH1;Neurogenic locus notch homolog protein 1,1.88381414730215,1.67789454499015,2.11500523210566,7.96750185403397e-27
primary,Circulatory system disorders,I85 (oesophageal varices),0.218776015953224,NOTCH1;Neurogenic locus notch homolog protein 1,2.0114344851705,1.6755518782101,2.41464841569399,6.53667739120725e-14
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104513431911434,NOTCH1;Neurogenic locus notch homolog protein 1,2.95036514265906,2.27337982140376,3.82894859585876,4.11130096403904e-16
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.252834511910875,PLAUR;Urokinase plasminogen activator surface receptor,1.75363551704029,1.48395197844746,2.0723295438728,4.31373641158758e-11
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511281757703772,PLAUR;Urokinase plasminogen activator surface receptor,1.4817701993175,1.31626562002267,1.66808498997916,7.64515124846103e-11
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13649030574935,PLAUR;Urokinase plasminogen activator surface receptor,1.35713662022072,1.28048551511013,1.43837613484109,7.4219548555051e-25
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54622098201033,PLAUR;Urokinase plasminogen activator surface receptor,3.19235527779201,2.87183060524517,3.54865367094883,1.51137524793417e-102
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.065109304711546,PLAUR;Urokinase plasminogen activator surface receptor,2.64379030234108,1.9505146582863,3.58347840815189,3.71335860546921e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0572398547291962,PLAUR;Urokinase plasminogen activator surface receptor,2.63322979565904,1.90480461407621,3.64021543496175,4.6282287300701e-09
primary,Circulatory system disorders,I20 (angina pectoris),4.01397965092232,PLAUR;Urokinase plasminogen activator surface receptor,1.2375063187633,1.1846542843839,1.29271628792153,1.07855977642822e-21
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97533391434767,PLAUR;Urokinase plasminogen activator surface receptor,1.38983062901453,1.32270619313823,1.46036148266908,7.8925406037515e-39
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.102703877071359,PLAUR;Urokinase plasminogen activator surface receptor,1.95598415035549,1.52958249718266,2.50125377577789,8.92094349239737e-08
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01774633413699,PLAUR;Urokinase plasminogen activator surface receptor,1.42269867449728,1.30957875843026,1.54558975959756,7.40858155290136e-17
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.74393067136506,PLAUR;Urokinase plasminogen activator surface receptor,1.31929273335808,1.28126746424007,1.35844651087254,5.62131547319064e-77
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99701046337817,PLAUR;Urokinase plasminogen activator surface receptor,1.29288975656053,1.21651371652338,1.37406089213382,1.35642375577772e-16
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35630135630135,PLAUR;Urokinase plasminogen activator surface receptor,1.88357834465972,1.75460893408402,2.02202742249412,1.51718118645914e-68
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.745309689025957,PLAUR;Urokinase plasminogen activator surface receptor,1.44664374850098,1.3119524467101,1.59516310238599,1.30945107437418e-13
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61283923186795,PLAUR;Urokinase plasminogen activator surface receptor,1.3774969206883,1.28766089106905,1.47360052609067,1.30706291151933e-20
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71911825869957,PLAUR;Urokinase plasminogen activator surface receptor,1.27699935887034,1.19690470693887,1.36245379694922,1.37660215840572e-13
primary,Circulatory system disorders,I42 (cardiomyopathy),0.674846625766871,PLAUR;Urokinase plasminogen activator surface receptor,1.41419114457248,1.27657621520572,1.566640964766,3.25031137218058e-11
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.86200954663392,PLAUR;Urokinase plasminogen activator surface receptor,1.23095316818826,1.1707142722541,1.29429164586442,4.78624812078014e-16
primary,Circulatory system disorders,I45 (other conduction disorders),1.77038414368793,PLAUR;Urokinase plasminogen activator surface receptor,1.28842084733777,1.20939239973981,1.37261345466676,4.27196506888732e-15
primary,Circulatory system disorders,I46 (cardiac arrest),0.781928757602085,PLAUR;Urokinase plasminogen activator surface receptor,1.71671785011971,1.56544414238522,1.88260960396147,1.6168003672914e-30
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.365208060093,PLAUR;Urokinase plasminogen activator surface receptor,1.28552429036078,1.19477254441059,1.38316929765308,1.76668946052164e-11
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.43541654062556,PLAUR;Urokinase plasminogen activator surface receptor,1.26531532999142,1.22594049719547,1.30595480610509,3.2718962643941e-48
primary,Circulatory system disorders,I50 (heart failure),4.42028552655158,PLAUR;Urokinase plasminogen activator surface receptor,1.594945965697,1.53256339965378,1.65986779670441,2.17017897205672e-116
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22897055576741,PLAUR;Urokinase plasminogen activator surface receptor,1.39775116210864,1.34108595309554,1.45681065905316,1.21867174026198e-56
primary,Circulatory system disorders,I63 (cerebral infarction),2.07920792079207,PLAUR;Urokinase plasminogen activator surface receptor,1.3907381003768,1.31147281163496,1.4747941754343,3.19784781685849e-28
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.783739902583735,PLAUR;Urokinase plasminogen activator surface receptor,1.45293713904426,1.32010369586994,1.59913674707423,2.22234350059092e-14
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.622345154598439,PLAUR;Urokinase plasminogen activator surface receptor,1.53420878392114,1.38060597036572,1.70490106749088,1.83258558855696e-15
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72063045759657,PLAUR;Urokinase plasminogen activator surface receptor,1.40037022484766,1.33006501272251,1.47439166347654,1.38351543859709e-37
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.782299486369024,PLAUR;Urokinase plasminogen activator surface receptor,1.61953959206281,1.47461814709775,1.7787035209225,6.73374552184463e-24
primary,Circulatory system disorders,I70 (atherosclerosis),0.810340738398292,PLAUR;Urokinase plasminogen activator surface receptor,1.98100351818019,1.81047406000608,2.16759523139984,4.14704496735759e-50
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08699948614569,PLAUR;Urokinase plasminogen activator surface receptor,1.44201924511728,1.33283485729232,1.5601478997278,8.09794088431253e-20
primary,Circulatory system disorders,I72 (other aneurysm),0.339719533873197,PLAUR;Urokinase plasminogen activator surface receptor,1.46647354215723,1.27051656793202,1.69265376314418,1.68125831185257e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15107553776888,PLAUR;Urokinase plasminogen activator surface receptor,1.6820393593971,1.58782037790846,1.78184915997099,5.91318076027134e-70
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40706635576809,PLAUR;Urokinase plasminogen activator surface receptor,2.10728842351584,1.85976276324997,2.38775858277953,1.39921498349247e-31
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702149963409086,PLAUR;Urokinase plasminogen activator surface receptor,1.80384783698617,1.6349055184808,1.99024774350464,6.44011888097283e-32
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.049331070681558,PLAUR;Urokinase plasminogen activator surface receptor,2.64720212963318,1.87367136244578,3.74007910650193,3.37328150970835e-08
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.67868135428478,PLAUR;Urokinase plasminogen activator surface receptor,1.2177936512671,1.1383931507725,1.30273216775777,1.01675955750596e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.221094814142171,PLAUR;Urokinase plasminogen activator surface receptor,2.31686819040948,1.95836114378733,2.74100526798149,1.17104495347201e-22
primary,Circulatory system disorders,I87 (other disorders of veins),0.458271604938271,PLAUR;Urokinase plasminogen activator surface receptor,1.3771728091451,1.21402701986994,1.56224277977914,6.53652015138144e-07
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.537623781946119,PLAUR;Urokinase plasminogen activator surface receptor,1.37483185888315,1.22193949929884,1.54685452208124,1.2079957165616e-07
primary,Circulatory system disorders,I95 (hypotension),4.83547868858961,PLAUR;Urokinase plasminogen activator surface receptor,1.47670703316749,1.42066331322204,1.53496162075209,8.52810750117781e-87
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106565626665087,PLAUR;Urokinase plasminogen activator surface receptor,3.08251030733214,2.43614708279861,3.9003678644449,6.85332101067428e-21
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0987244797219918,PLAUR;Urokinase plasminogen activator surface receptor,2.13551713332485,1.6562299832962,2.75350251638838,4.89515913910837e-09
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08973335462238,GGH;Gamma-glutamyl hydrolase,1.23585912392799,1.13703444309843,1.34327309385107,6.35567373721907e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.219280759110118,GGH;Gamma-glutamyl hydrolase,1.65416934457578,1.37718961481553,1.98685510774838,7.32740086554957e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.221799124580446,GSTA1;Glutathione S-transferase A1,2.0619427195404,1.72203283455897,2.46894698715459,3.45341450409767e-15
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105957146220861,GSTA1;Glutathione S-transferase A1,2.84240460166568,2.20722151096057,3.66037748338825,5.70360929468264e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544400866358367,FGF21;Fibroblast growth factor 21,1.63905063672932,1.4632991468057,1.8359109930647,1.36137915909932e-17
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02873843156356,FGF21;Fibroblast growth factor 21,1.23061535527124,1.13097910950872,1.33902928877899,1.45573792766263e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35488657217601,FGF21;Fibroblast growth factor 21,1.3292726204125,1.23511842097559,1.43060428001926,3.11002392927966e-14
primary,Circulatory system disorders,I46 (cardiac arrest),0.776793536454784,FGF21;Fibroblast growth factor 21,1.3133169121796,1.19231081496975,1.44660376318126,3.26803632063559e-08
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775193798449612,FGF21;Fibroblast growth factor 21,1.34014853305781,1.21632554920895,1.47657680283461,3.23582912181908e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.804801527758832,FGF21;Fibroblast growth factor 21,1.52766547106794,1.39070346540791,1.67811603950286,9.42134732486907e-19
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15456859301935,FGF21;Fibroblast growth factor 21,1.24369677276135,1.17249384756163,1.31922369212746,4.15751876013484e-13
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409117475160724,FGF21;Fibroblast growth factor 21,1.56962923913872,1.37698460437565,1.78922548627644,1.49715596608869e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.694200694200694,FGF21;Fibroblast growth factor 21,1.32134306547131,1.19264416857346,1.46392993205799,9.85030800251249e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.210206703258203,FGF21;Fibroblast growth factor 21,1.61540218000775,1.34630323562019,1.93828859214742,2.49097605443674e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105066542143357,FGF21;Fibroblast growth factor 21,2.26106366082988,1.76928900068153,2.88952730523737,7.04441797187365e-11
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250226583126453,CD302;CD302 antigen,1.77759255556447,1.50030373746639,2.1061303885934,2.9664223393278e-11
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.506015082005946,CD302;CD302 antigen,1.45519358499106,1.2893159218844,1.6424123318854,1.23867481160129e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13307047806801,CD302;CD302 antigen,1.36243130976635,1.28391639055479,1.44574762615933,1.74643466807741e-24
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,CD302;CD302 antigen,4.077181743992,3.6791686163367,4.5182520039251,2.08802081563766e-158
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0629760100761616,CD302;CD302 antigen,3.33440649361074,2.45475262367284,4.52928191517652,1.28937344550855e-14
primary,Circulatory system disorders,I15 (secondary hypertension),0.0570944815230445,CD302;CD302 antigen,3.29662893742687,2.38624853562442,4.55432960516678,4.67128991130816e-13
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9594291374396,CD302;CD302 antigen,1.27515981703438,1.21124470886749,1.34244760540542,1.95885547298805e-20
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0131672317275,CD302;CD302 antigen,1.31588722883525,1.20739399525875,1.43412937766071,4.03207273274925e-10
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69094327284616,CD302;CD302 antigen,1.21120064244525,1.17494622621653,1.24857373344116,4.41656897731555e-35
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99980121260312,CD302;CD302 antigen,1.27608628491892,1.19977666008628,1.35724944544351,9.24639304630811e-15
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,CD302;CD302 antigen,1.68154505742594,1.56206987764704,1.8101583166131,1.90631687351698e-43
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.74928522133491,CD302;CD302 antigen,1.29775545199113,1.17409361465157,1.43444201736205,3.37422549861012e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60473307214373,CD302;CD302 antigen,1.37501640396373,1.28393130365415,1.47256329508313,8.47264128179704e-20
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69699124834548,CD302;CD302 antigen,1.21710891513535,1.13841488854915,1.30124274216921,8.34929083516299e-09
primary,Circulatory system disorders,I45 (other conduction disorders),1.74424340482626,CD302;CD302 antigen,1.23696311916039,1.15817221632858,1.32111419751836,2.40662643024191e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,CD302;CD302 antigen,1.55436038044264,1.41018636439358,1.71327439641551,6.64262446133245e-19
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.39861602832314,CD302;CD302 antigen,1.20481177618275,1.16624203657137,1.24465708704524,3.11418297336617e-29
primary,Circulatory system disorders,I50 (heart failure),4.39523336643495,CD302;CD302 antigen,1.45002394136119,1.3907689181749,1.51180358077015,3.14922857432782e-68
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20671151689892,CD302;CD302 antigen,1.30275287859641,1.24809304541573,1.35980652157702,1.14011204501237e-33
primary,Circulatory system disorders,I63 (cerebral infarction),2.07802469135802,CD302;CD302 antigen,1.28700891093585,1.21175510014337,1.36693622055504,2.2492859957009e-16
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.779719301051621,CD302;CD302 antigen,1.30287226935857,1.1796973473027,1.4389081692391,1.77619439792959e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72922961470861,CD302;CD302 antigen,1.29091018600516,1.22467284722087,1.36073002035892,2.07193534928019e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774430015567422,CD302;CD302 antigen,1.57542759493847,1.42915849457141,1.73666679820415,6.10110013241533e-20
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,CD302;CD302 antigen,1.69690844517887,1.54199296654319,1.86738742250854,2.5785964848279e-27
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15586074736505,CD302;CD302 antigen,1.4528227499876,1.36890604370703,1.54188371991239,8.58686965858723e-35
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,CD302;CD302 antigen,1.80844205074572,1.58328364304176,2.06562018453135,2.47510078357044e-18
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,CD302;CD302 antigen,1.64204565938222,1.48247961688948,1.81878652278092,1.93298034441902e-21
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0472375853720943,CD302;CD302 antigen,3.00466775713,2.09480336166627,4.30972591315468,2.2597294780819e-09
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.66999858645827,CD302;CD302 antigen,1.23801267749302,1.15641019592877,1.32537346611897,8.40630127496031e-10
primary,Circulatory system disorders,I95 (hypotension),4.82266136529978,CD302;CD302 antigen,1.33545425137389,1.28333995836172,1.38968481881395,4.93339920024973e-46
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0905939814085394,CD302;CD302 antigen,1.9976321923181,1.51278279427069,2.63787662769489,1.07009553703801e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.209820512235728,FTCD;Formimidoyltransferase-cyclodeaminase,2.54113471438518,2.07962005849822,3.10506989498678,7.51146356358525e-20
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107154256531849,FTCD;Formimidoyltransferase-cyclodeaminase,3.82384297541515,2.91979580912085,5.00780741411995,1.92544082508481e-22
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535523027490182,DKK4;Dickkopf-related protein 4,2.36169479135368,2.10188713690457,2.65361645236632,2.41691494084376e-47
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.252238331136663,CD80;T-lymphocyte activation antigen CD80,1.69998162362682,1.4146292173686,2.04289398606127,1.51535438082102e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519993641999137,CD80;T-lymphocyte activation antigen CD80,1.42412116161012,1.25225558367119,1.61957439790365,7.12083186789862e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.04378566394616,CD80;T-lymphocyte activation antigen CD80,1.24716336347051,1.16844252108675,1.33118782234698,3.14577475844016e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.393423236986332,CD80;T-lymphocyte activation antigen CD80,1.72971510887148,1.49438614573257,2.00210257998049,2.07514561278637e-13
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96981272710332,CD80;T-lymphocyte activation antigen CD80,1.23160230483792,1.16605355486843,1.30083582434875,8.30267800287338e-14
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36945723009615,CD80;T-lymphocyte activation antigen CD80,1.65531971662994,1.52962955559859,1.7913378793152,6.67391779310274e-36
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59527124175548,CD80;T-lymphocyte activation antigen CD80,1.21900343014363,1.13193772624833,1.31276600138331,1.62457635596888e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.76098314479124,CD80;T-lymphocyte activation antigen CD80,1.37162895326526,1.23350082485914,1.52522474855288,5.37785356295263e-09
primary,Circulatory system disorders,I50 (heart failure),4.32233089767963,CD80;T-lymphocyte activation antigen CD80,1.35045235530313,1.29100893469513,1.41263279821874,4.22593548044297e-39
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.07117634840407,CD80;T-lymphocyte activation antigen CD80,1.24446960111725,1.18781828861058,1.30382281781205,3.56246117810455e-20
primary,Circulatory system disorders,I63 (cerebral infarction),2.05229830076078,CD80;T-lymphocyte activation antigen CD80,1.23005118650513,1.15251002803539,1.31280933320974,4.58984263772524e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.62139017946615,CD80;T-lymphocyte activation antigen CD80,1.20475433769698,1.13717059372677,1.27635468434249,2.55057910664994e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.745403722473467,CD80;T-lymphocyte activation antigen CD80,1.36571763118935,1.22642407365996,1.52083173202501,1.35854099261481e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.768391379467127,CD80;T-lymphocyte activation antigen CD80,1.4108546299986,1.26933272137348,1.56815526258132,1.74722484988489e-10
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07497556873707,CD80;T-lymphocyte activation antigen CD80,1.24613511155634,1.13957204020776,1.36266305372887,1.40337198688104e-06
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.07383878838097,CD80;T-lymphocyte activation antigen CD80,1.36796499322698,1.28161133553985,1.46013707182625,4.60213268301164e-21
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.682454104961441,CD80;T-lymphocyte activation antigen CD80,1.49312081208071,1.33481014237081,1.67020738657919,2.38146086777906e-12
primary,Circulatory system disorders,I85 (oesophageal varices),0.20891048639811,CD80;T-lymphocyte activation antigen CD80,3.17954609788474,2.63423826605733,3.83773689678612,1.93627957902774e-33
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.263918276340636,CD80;T-lymphocyte activation antigen CD80,1.63019612029325,1.36341258085023,1.94918209494731,8.33457307513569e-08
primary,Circulatory system disorders,I95 (hypotension),4.54597294769736,CD80;T-lymphocyte activation antigen CD80,1.23597592120137,1.18282723955564,1.29151276425074,3.47735388761865e-21
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102149683335981,CD80;T-lymphocyte activation antigen CD80,4.32172747969095,3.36325280577142,5.55335250941148,2.61826747715208e-30
primary,Circulatory system disorders,I85 (oesophageal varices),0.224396555209638,LAMP2;Lysosome-associated membrane glycoprotein 2,1.82931715093254,1.51963986606208,2.20210150669951,1.74541001203404e-10
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105090842949819,LAMP2;Lysosome-associated membrane glycoprotein 2,2.24074985624711,1.71594572161394,2.92605987184081,3.10479843865855e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54686883045092,THOP1;Thimet oligopeptidase,0.70779945185441,0.627580879149077,0.798271713957684,1.79084248821964e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.222515408699761,THOP1;Thimet oligopeptidase,1.67252093185206,1.38630564790931,2.01782793837847,7.83214178158389e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106299212598425,THOP1;Thimet oligopeptidase,2.2315436942056,1.7084329388332,2.91482746905465,3.86798671992794e-09
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249847533985166,CD4;T-cell surface glycoprotein CD4,1.68901822242522,1.42403182429362,2.0033137651959,1.74635794090524e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51508896097513,CD4;T-cell surface glycoprotein CD4,1.40868981315971,1.24916249840623,1.58858994905129,2.2972278132537e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13180583441596,CD4;T-cell surface glycoprotein CD4,1.25635314994397,1.18372091385739,1.33344204609052,5.86280316622494e-14
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.540061101803488,CD4;T-cell surface glycoprotein CD4,2.48338918420255,2.21568425671572,2.7834389405988,4.53135558674225e-55
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0648457457260758,CD4;T-cell surface glycoprotein CD4,2.70002018450987,1.94706002739366,3.74416242652738,2.60888069662266e-09
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96516087360219,CD4;T-cell surface glycoprotein CD4,1.2397755256246,1.1778057340893,1.30500583368804,2.11691714041059e-16
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01554812044873,CD4;T-cell surface glycoprotein CD4,1.28769613094819,1.18138731194103,1.40357130036768,8.84145334171333e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35281705417184,CD4;T-cell surface glycoprotein CD4,1.47168944296883,1.36620678176374,1.58531625333451,2.35758371345566e-24
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61991307783484,CD4;T-cell surface glycoprotein CD4,1.28497857971856,1.20012149698647,1.3758356587076,6.32130693533583e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.788640431097213,CD4;T-cell surface glycoprotein CD4,1.49390786181924,1.35524206869837,1.64676167538749,6.69575279728766e-16
primary,Circulatory system disorders,I50 (heart failure),4.40394987309644,CD4;T-cell surface glycoprotein CD4,1.31099728744338,1.25744667150191,1.36682845216095,4.2425127479723e-37
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20423422162691,CD4;T-cell surface glycoprotein CD4,1.2435944474075,1.19143964349927,1.29803230743658,1.9986545438264e-23
primary,Circulatory system disorders,I63 (cerebral infarction),2.06492584411486,CD4;T-cell surface glycoprotein CD4,1.25616502876425,1.18238260737596,1.33455158224307,1.53057601954372e-13
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.617830509808551,CD4;T-cell surface glycoprotein CD4,1.35399712785017,1.21265446513045,1.51181418527932,7.13705560763809e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.799212598425196,CD4;T-cell surface glycoprotein CD4,1.43702900511696,1.3042698454856,1.5833014684002,2.28209030158847e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14830905358815,CD4;T-cell surface glycoprotein CD4,1.21036605628995,1.14013038473694,1.2849284694372,3.85896662266967e-10
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.38965639390719,CD4;T-cell surface glycoprotein CD4,1.57416446487413,1.37081369353522,1.80768092276779,1.28300788425759e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.683568741012154,CD4;T-cell surface glycoprotein CD4,1.39398971204474,1.25534752119686,1.54794372432735,5.14079858355206e-10
primary,Circulatory system disorders,I95 (hypotension),4.82172839506172,CD4;T-cell surface glycoprotein CD4,1.22748310717558,1.17966407827124,1.2772405349576,4.99657030007931e-24
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.254464488571818,SHISA5;Protein shisa-5,1.85797680665281,1.55567002060957,2.2190295938898,8.07177801337572e-12
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519911002134132,SHISA5;Protein shisa-5,1.58174004170499,1.39288884951771,1.79619612892959,1.56931665809467e-12
primary,Circulatory system disorders,I08 (multiple valve diseases),2.05032618825722,SHISA5;Protein shisa-5,1.32612392763919,1.24244669474669,1.41543671764182,2.10467969288639e-17
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.386548125241592,SHISA5;Protein shisa-5,4.51998440982422,3.98518300797208,5.12655479665166,6.65809024714048e-122
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0499217136762803,SHISA5;Protein shisa-5,3.29918236539025,2.30030364658982,4.73181194849572,8.73537810784575e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.043122035360069,SHISA5;Protein shisa-5,3.03884411408505,2.0468805707522,4.51153510452042,3.53088944479007e-08
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96056462695953,SHISA5;Protein shisa-5,1.31177352098319,1.24108179891664,1.38649182661023,7.8729647668152e-22
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.975,SHISA5;Protein shisa-5,1.32323209029628,1.20399357624467,1.45427949063578,6.13602405232949e-09
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.55609939759036,SHISA5;Protein shisa-5,1.24026201559232,1.20007115578838,1.28179888325919,1.41891547012699e-37
primary,Circulatory system disorders,I26 (pulmonary embolism),1.94608719570898,SHISA5;Protein shisa-5,1.23789783973552,1.1572953839623,1.32411403593033,5.21283082822902e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37382666545156,SHISA5;Protein shisa-5,1.79017282319924,1.65581140770446,1.93543704434554,1.8549063451272e-48
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.752631937970395,SHISA5;Protein shisa-5,1.33919077852164,1.20300263853432,1.49079634892774,9.41485201302088e-08
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59954363947518,SHISA5;Protein shisa-5,1.30002197572463,1.20743291950484,1.39971099848765,3.3959646603204e-12
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.68947380404836,SHISA5;Protein shisa-5,1.28750551439212,1.19821472203183,1.38345024402569,5.53325978750937e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.694191551347414,SHISA5;Protein shisa-5,1.43170824426166,1.28070892158662,1.6005108281337,2.77570040049369e-10
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.80182232346241,SHISA5;Protein shisa-5,1.20163864151639,1.13599977127838,1.27107017210087,1.46387636430289e-10
primary,Circulatory system disorders,I45 (other conduction disorders),1.72672672672672,SHISA5;Protein shisa-5,1.21578708967303,1.13199064524536,1.30578662785258,8.20570858929372e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.754031342266636,SHISA5;Protein shisa-5,1.57659234301282,1.41774298590009,1.75323979082752,4.38396890099688e-17
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3391530885075,SHISA5;Protein shisa-5,1.25503390562599,1.15750705129288,1.36077797756091,3.71530832725483e-08
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.20050090441074,SHISA5;Protein shisa-5,1.21946035222134,1.17678060110721,1.26368802242373,9.72669183919392e-28
primary,Circulatory system disorders,I50 (heart failure),4.32582211230191,SHISA5;Protein shisa-5,1.47206764890807,1.40661152460692,1.54056974868544,2.48035837498349e-62
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08907349717318,SHISA5;Protein shisa-5,1.33762759600015,1.27642209517373,1.40176795148442,4.32190929566945e-34
primary,Circulatory system disorders,I63 (cerebral infarction),2.05420177636073,SHISA5;Protein shisa-5,1.32201270917527,1.23860549749518,1.41103652999711,4.63530332336148e-17
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.737633119727075,SHISA5;Protein shisa-5,1.36212116326218,1.22068767173363,1.51994167416444,3.29239885240345e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.62097233291586,SHISA5;Protein shisa-5,1.2872212289339,1.21495302138119,1.3637881161318,1.08499052230584e-17
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.752084706096203,SHISA5;Protein shisa-5,1.69343544924372,1.52420226026006,1.88145871156627,1.06350771686071e-22
primary,Circulatory system disorders,I70 (atherosclerosis),0.772797527047913,SHISA5;Protein shisa-5,1.68550600380825,1.51861940629681,1.87073237513889,9.81771258107709e-23
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.06576375948734,SHISA5;Protein shisa-5,1.29499777096952,1.18240979510334,1.41830627060177,2.53902104872778e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08525133492911,SHISA5;Protein shisa-5,1.44249608500265,1.3516014377808,1.53950336029861,2.64856799352702e-28
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402217879380084,SHISA5;Protein shisa-5,1.76522913163569,1.52891016123112,2.03807520297085,9.22053119803572e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.689168903243415,SHISA5;Protein shisa-5,1.75017612623463,1.56806325215954,1.95343935815289,1.78599212338605e-23
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.63919158051597,SHISA5;Protein shisa-5,1.24065935648015,1.15223911445736,1.33586476930758,1.08757282152239e-08
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.03799573660661,SHISA5;Protein shisa-5,1.20291576154177,1.12581234516784,1.28529975317501,4.59796039060075e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.213413249784316,SHISA5;Protein shisa-5,1.78132580746613,1.46382631999059,2.16768997046403,8.18867412869339e-09
primary,Circulatory system disorders,I95 (hypotension),4.54078956371017,SHISA5;Protein shisa-5,1.38139344916689,1.32196467583983,1.44349383631519,5.12582925276417e-47
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10667029799596,SHISA5;Protein shisa-5,2.16157902656465,1.64906320997667,2.8333807096153,2.37006591325566e-08
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0794804251067308,SHISA5;Protein shisa-5,2.26602658262013,1.65901895842332,3.09512826666013,2.71726425663068e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.387391334424793,SERPINF1;Pigment epithelium-derived factor,2.87922506894732,2.50569558544764,3.30843740388908,2.57870668405455e-50
primary,Circulatory system disorders,I70 (atherosclerosis),0.769940064545873,SERPINF1;Pigment epithelium-derived factor,1.33776464029726,1.1991331664323,1.4924232628426,1.85429992936774e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25298582102724,NRCAM;Neuronal cell adhesion molecule,1.60404599445538,1.34884044006069,1.90753737500084,9.05964923676946e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,NRCAM;Neuronal cell adhesion molecule,1.3340315251505,1.2377445046765,1.4378089366355,4.69253526018153e-14
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0489763933783916,NRCAM;Neuronal cell adhesion molecule,2.69440383620737,1.81412160121724,4.00183318896472,9.06137125569155e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,NRCAM;Neuronal cell adhesion molecule,2.63428802510798,2.18691523004839,3.17317896179896,1.98133967516178e-24
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105795227459739,NRCAM;Neuronal cell adhesion molecule,4.34162838390603,3.31450827207786,5.68703876310485,1.55642624665431e-26
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,CDCP1;CUB domain-containing protein 1,1.37526076891847,1.22726030149038,1.541109233493,4.13212973721697e-08
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9690922365539,CDCP1;CUB domain-containing protein 1,1.27778389747914,1.2163193105829,1.34235449067607,1.925263047978e-22
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02042834259497,CDCP1;CUB domain-containing protein 1,1.24114383364344,1.14195859827013,1.34894383922906,3.70065491984548e-07
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68682726806765,CDCP1;CUB domain-containing protein 1,1.20971507758001,1.17489756372653,1.24556439140343,2.19507654492555e-37
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34152382839591,CDCP1;CUB domain-containing protein 1,1.46117653536051,1.35970367807168,1.57022217555227,5.30979816723318e-25
primary,Circulatory system disorders,I46 (cardiac arrest),0.782500444602525,CDCP1;CUB domain-containing protein 1,1.32967230632896,1.21021396228525,1.46092219831907,2.98365956200316e-09
primary,Circulatory system disorders,I50 (heart failure),4.41132519077885,CDCP1;CUB domain-containing protein 1,1.30491218098027,1.25356041877886,1.35836755417776,1.35174608295241e-38
primary,Circulatory system disorders,I63 (cerebral infarction),2.07280581812417,CDCP1;CUB domain-containing protein 1,1.20855098350159,1.13930710079909,1.28200331473246,3.12685069353638e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769002668775328,CDCP1;CUB domain-containing protein 1,1.27199901902388,1.15542208410881,1.40033804671968,9.31354590037159e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.79898742188118,CDCP1;CUB domain-containing protein 1,1.49300510219018,1.36177447236894,1.63688208318977,1.36309238487975e-17
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08381788695067,CDCP1;CUB domain-containing protein 1,1.2279940593508,1.1335837672662,1.33026729329192,4.8564693573987e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12868213949576,CDCP1;CUB domain-containing protein 1,1.28476089645386,1.21180342379582,1.36211082477932,4.44882493932078e-17
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401415831207609,CDCP1;CUB domain-containing protein 1,1.43824634335463,1.2629675639676,1.63785088642707,4.23183835351017e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700643245917862,CDCP1;CUB domain-containing protein 1,1.35454053236865,1.22559859790076,1.49704810120722,2.7512006539189e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.215321401762079,CDCP1;CUB domain-containing protein 1,2.48778544347055,2.1139166898486,2.92777688092677,5.38989613315446e-28
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100714878154745,CDCP1;CUB domain-containing protein 1,3.47078337043211,2.77059793479243,4.34791965055389,2.63577838583668e-27
primary,Circulatory system disorders,I70 (atherosclerosis),0.763856544014904,GLA;Alpha-galactosidase A,1.38236880039904,1.23896745027024,1.54236779981577,6.84557550977243e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.21169190685556,GLA;Alpha-galactosidase A,1.71245007570824,1.39539755618225,2.10154106175758,2.61348310066888e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109297241988744,GLA;Alpha-galactosidase A,2.07115847174382,1.5632581967099899,2.74407479462077,3.92700465810846e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.218638972396829,SSC5D;Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D,1.71146422497375,1.42469241303672,2.05595942433752,9.31417610416251e-09
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103428761001502,SSC5D;Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D,2.08836391282997,1.6030296032279,2.72063836103125,4.84429881414357e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535211267605633,PXN;Paxillin,1.46984028633403,1.30421161870444,1.656503006373,2.7166218845899e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.549977492024347,CD163;Scavenger receptor cysteine-rich type 1 protein M130,1.40544158545103,1.25167332901357,1.57810029528375,8.55700066374246e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.801344695489015,CD163;Scavenger receptor cysteine-rich type 1 protein M130,1.31018354200646,1.19010807884297,1.44237396944104,3.61393530727767e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.218638972396829,CD163;Scavenger receptor cysteine-rich type 1 protein M130,3.11282428552902,2.60971053174086,3.71293096101183,1.54594902168651e-36
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.271845419698036,CD163;Scavenger receptor cysteine-rich type 1 protein M130,1.65733055896886,1.40769446590548,1.95123632877625,1.31710105722834e-09
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103428761001502,CD163;Scavenger receptor cysteine-rich type 1 protein M130,5.37153351126641,4.18063258807761,6.90167615899626,1.80695048462127e-39
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,IFNLR1;Interferon lambda receptor 1,1.38958189808937,1.23381996413739,1.56500778689186,5.83184884163851e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.801823755994025,IFNLR1;Interferon lambda receptor 1,1.30393936183993,1.1824933021611,1.43785834240936,1.03498543377056e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.217869199968595,IFNLR1;Interferon lambda receptor 1,1.63544488766976,1.35842187258767,1.96896121490604,2.04785193734641e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.254307977132626,CD59;CD59 glycoprotein,1.69286702959206,1.42325921711857,2.0135466156908,2.71942645230301e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12519083969465,CD59;CD59 glycoprotein,1.26237167336765,1.1850771376239,1.34470760689569,4.92459960222544e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.552418615080416,CD59;CD59 glycoprotein,4.18487774444199,3.79410365995071,4.61589964470117,3.73820393802037e-180
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0690902440511267,CD59;CD59 glycoprotein,3.12058883585145,2.31205774999667,4.21186481282949,1.02360502654581e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.058952675231745,CD59;CD59 glycoprotein,3.11126490488089,2.24174355413675,4.31805381595979,1.14477508319523e-11
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.95008038081717,CD59;CD59 glycoprotein,1.20658197733687,1.14195418406578,1.27486731810098,2.29448678036093e-11
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00948426751333,CD59;CD59 glycoprotein,1.29596971836253,1.18232634804506,1.42053631274453,3.0809517663991e-08
primary,Circulatory system disorders,I26 (pulmonary embolism),1.97873475922656,CD59;CD59 glycoprotein,1.24021997910525,1.161511053011,1.32426255659339,1.23043463258325e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35603588907014,CD59;CD59 glycoprotein,1.42045528121977,1.31345827646095,1.53616848140902,1.57868278738921e-18
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59579902331378,CD59;CD59 glycoprotein,1.20528527695224,1.12038576872763,1.29661821792649,5.43887984191359e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.780948119826727,CD59;CD59 glycoprotein,1.54439470246294,1.39322048971919,1.71197237953078,1.34651640195188e-16
primary,Circulatory system disorders,I50 (heart failure),4.42434311734662,CD59;CD59 glycoprotein,1.32244597296062,1.26500558085752,1.38249457382965,5.83204679055877e-35
primary,Circulatory system disorders,I63 (cerebral infarction),2.08031653443739,CD59;CD59 glycoprotein,1.20864486141823,1.13354788413018,1.28871697568704,7.03890162256911e-09
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771140229510865,CD59;CD59 glycoprotein,1.40789523010784,1.26887738460955,1.56214383123421,1.12331387420006e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.806139690165502,CD59;CD59 glycoprotein,1.43311832932471,1.29400846217059,1.58718293263811,4.93695724199862e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.17234485459304,CD59;CD59 glycoprotein,1.2648810141067,1.1875554721488,1.34724146986804,2.85855510303594e-13
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409077032665106,CD59;CD59 glycoprotein,1.59942595806409,1.38743208249187,1.84381161976209,9.56746715817556e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.710982541202355,CD59;CD59 glycoprotein,1.46324691684584,1.31348933067738,1.63007912561778,4.84705084841796e-12
primary,Circulatory system disorders,I85 (oesophageal varices),0.219574675720733,CD59;CD59 glycoprotein,1.63672349359856,1.35067490296172,1.98335201803435,4.97931572710942e-07
primary,Circulatory system disorders,I95 (hypotension),4.82688183025227,CD59;CD59 glycoprotein,1.25334493216405,1.20157425434183,1.30734618630936,9.39368338291165e-26
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.533181183229385,FOLR1;Folate receptor alpha,3.70521541653288,3.32476748638947,4.12919740677009,4.15876294168498e-124
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666941289550599,FOLR1;Folate receptor alpha,2.25593658863205,1.65180610809182,3.08102135413942,3.1249614464345e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.0569084950646598,FOLR1;Folate receptor alpha,2.71877007550747,1.95748471594631,3.77612691596498,2.41468123531893e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35249532434294,FOLR1;Folate receptor alpha,1.48144115017375,1.37458762705873,1.59660092832652,7.84997509771178e-25
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60348704193128,FOLR1;Folate receptor alpha,1.30660032847154,1.21893306499529,1.4005727364271,4.45830829275435e-14
primary,Circulatory system disorders,I46 (cardiac arrest),0.769547890614264,FOLR1;Folate receptor alpha,1.44220624741825,1.30821663289691,1.58991928996222,1.83623939739696e-13
primary,Circulatory system disorders,I50 (heart failure),4.40617577197149,FOLR1;Folate receptor alpha,1.2934832349604,1.24020369695639,1.34905167855056,3.96573360516232e-33
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23285702881775,FOLR1;Folate receptor alpha,1.21412265448615,1.16294496261643,1.26755252184938,1.04647792285383e-18
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72632428495502,FOLR1;Folate receptor alpha,1.24024558868778,1.17593087433858,1.30807784184141,2.28228510559596e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781710335074832,FOLR1;Folate receptor alpha,1.29548541911663,1.17412630187217,1.42938836176971,2.4879957646004e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.797799174690509,FOLR1;Folate receptor alpha,1.43983889282357,1.3074732653652,1.58560491614208,1.27424981325868e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15470932314671,FOLR1;Folate receptor alpha,1.34498887662049,1.26654619485499,1.428289852815,4.16726736729372e-22
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406639819271191,FOLR1;Folate receptor alpha,1.47962831616242,1.29420436759778,1.69161842503536,9.74719160671725e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.707922836410831,FOLR1;Folate receptor alpha,1.33332388092905,1.20232869144173,1.47859115740136,4.97644978385099e-08
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.047083750220705,FOLR1;Folate receptor alpha,2.57386839765595,1.79891101304833,3.68267161654984,2.30869852273571e-07
primary,Circulatory system disorders,I95 (hypotension),4.84443392878268,FOLR1;Folate receptor alpha,1.31069497671703,1.25918426963037,1.36431288368584,6.19496712860791e-40
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0942266543648534,FOLR1;Folate receptor alpha,1.98243900982015,1.514641951818,2.59471515557819,6.24985084242736e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,CALB1;Calbindin,3.07033830252559,2.74569179378719,3.43337053098479,3.60095373686895e-86
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,PSPN;Persephin,1.58330195878364,1.35189548807324,1.85431870644153,1.19805716073509e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.211023121780762,SHBG;Sex hormone-binding globulin,2.10686679782651,1.69337596066523,2.62132438802306,2.30599822315419e-11
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.108878101891757,SHBG;Sex hormone-binding globulin,2.38456846986657,1.76003828435014,3.23070630794903,2.03930935689841e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37530422004867,APCS;Serum amyloid P-component,0.744925931568881,0.682995021168967,0.812472457813839,2.9424198061406e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.212795167490389,APCS;Serum amyloid P-component,0.521533516020572,0.420352846518148,0.647068791339889,3.30391875937791e-09
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.268231733877438,APCS;Serum amyloid P-component,0.534310205987013,0.440743081384131,0.647741072475434,1.75762737249318e-10
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107504746220178,APCS;Serum amyloid P-component,0.342720115446865,0.260475534502276,0.450933243140676,2.03210267801331e-14
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35696917405286,LDLR;Low-density lipoprotein receptor,0.776756888711732,0.720458394382207,0.837454693936217,4.67765821239655e-11
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511503939168267,REN;Renin,1.54339701832602,1.35657549314922,1.75594677053157,4.3210068274867e-11
primary,Circulatory system disorders,I08 (multiple valve diseases),2.15062203210235,REN;Renin,1.26762298135881,1.19018784503609,1.35009614622663,1.65735670512905e-13
primary,Circulatory system disorders,I10 (essential (primary) hypertension),19.5249509697101,REN;Renin,0.765718933123987,0.745048973356572,0.786962341419036,1.75769894379855e-81
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,REN;Renin,3.26195736149479,2.87377073530997,3.70257992312053,1.00399868893342e-74
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666000666000666,REN;Renin,2.67602165467714,1.861281315707,3.84739901264246,1.07373650552174e-07
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9707155076985,REN;Renin,1.21026373454942,1.14531038761402,1.27890074429251,1.19669549086683e-11
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02218995860228,REN;Renin,1.25726590030278,1.14723252097151,1.37785280243411,9.61715216453975e-07
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.70175581371691,REN;Renin,1.26771434818419,1.22670572369237,1.31009388605013,2.1858564427947e-45
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,REN;Renin,1.60875049812849,1.48501553173956,1.7427953512358,2.46877599910212e-31
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60909126718399,REN;Renin,1.27348709601114,1.18398505761479,1.3697549418183,7.91241604994027e-11
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71654410318927,REN;Renin,1.2974551794916,1.2086904191085,1.39273871636312,5.93504364330662e-13
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.86725663716814,REN;Renin,1.26493096944951,1.19705977257392,1.33665034456221,6.69119050393613e-17
primary,Circulatory system disorders,I45 (other conduction disorders),1.76368921360672,REN;Renin,1.29616887010263,1.20853123525323,1.39016162000239,3.79471427395137e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,REN;Renin,1.69339119599324,1.52285868308992,1.8830202529686,2.33106389133156e-22
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36916035353535,REN;Renin,1.21427804927305,1.1220896944043,1.31404039115531,1.43979024153031e-06
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,REN;Renin,1.4555789556087,1.39119857512632,1.52293866159153,1.7609618480166e-59
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2193167776139,REN;Renin,1.30198952898607,1.24347108672867,1.3632618817451,2.39098109919665e-29
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.611968695447502,REN;Renin,1.45401202040921,1.29122930770588,1.6373164261975,6.4432721508636e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77276115011964,REN;Renin,1.3935820684798,1.25409373332652,1.54858518943161,6.93075945327713e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,REN;Renin,1.97800894107427,1.78105583978338,2.19674155272167,3.27482732589269e-37
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15754445217045,REN;Renin,1.56568924917837,1.4689153787704,1.66883869583061,3.73715964372023e-43
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.413944637357032,REN;Renin,1.67910445716951,1.45170777068582,1.9421207456612,2.94562539126152e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.710863247191893,REN;Renin,1.67415047321274,1.49901898643417,1.86974269994113,6.21557415410131e-20
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0489763933783916,REN;Renin,4.18106272418447,2.75653895459696,6.34175166449654,1.69079067553732e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,REN;Renin,1.80422826793533,1.47908072396395,2.20085326654305,5.86099575463045e-09
primary,Circulatory system disorders,I95 (hypotension),4.80063010731515,REN;Renin,1.41486729779474,1.35603187741824,1.47625546545434,1.01487313918991e-57
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105795227459739,REN;Renin,2.18874368017613,1.63948942030961,2.92200659434951,1.07547068513066e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,NECTIN4;Nectin-4,5.64567490361845,4.98656964373272,6.39189811725721,1.99749191687764e-164
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0663932825619996,NECTIN4;Nectin-4,2.96694887330069,2.10185608177708,4.18810102799124,6.27038545815892e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0566516897831607,NECTIN4;Nectin-4,3.40946469440708,2.33869981244064,4.9704752361002,1.80186672177278e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96519209549603,NECTIN4;Nectin-4,1.20770068985811,1.1464668524116,1.27220508226269,1.17282353580651e-12
primary,Circulatory system disorders,I26 (pulmonary embolism),2.008008363414,NECTIN4;Nectin-4,1.22175722555703,1.14776527794561,1.30051914523203,3.30686913876127e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34833222278838,NECTIN4;Nectin-4,1.36313121265822,1.263163916498,1.47100996050817,1.56450094777732e-15
primary,Circulatory system disorders,I46 (cardiac arrest),0.773890951729529,NECTIN4;Nectin-4,1.42518995152982,1.28932822574951,1.57536797642107,4.16360438797608e-12
primary,Circulatory system disorders,I50 (heart failure),4.4257901789233,NECTIN4;Nectin-4,1.27842689804244,1.22529381777725,1.33386401687986,8.20912066290896e-30
primary,Circulatory system disorders,I63 (cerebral infarction),2.06569457510191,NECTIN4;Nectin-4,1.22397105374768,1.1511673262722,1.30137913596235,1.05195300518873e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72775371832807,NECTIN4;Nectin-4,1.21998991113718,1.15649765538159,1.28696792107668,3.05681548730552e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78013491054844,NECTIN4;Nectin-4,1.34917741493989,1.22112677860563,1.49065578519407,3.94662144836864e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.798106453316641,NECTIN4;Nectin-4,1.45299843461418,1.31604600458249,1.60420262182325,1.39133036445639e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15488215488215,NECTIN4;Nectin-4,1.32218930934387,1.24434847903384,1.40489951102811,1.85529415105544e-19
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404810794954532,NECTIN4;Nectin-4,1.56160378897942,1.35912840977734,1.79424282224693,3.16122026308454e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704721634954193,NECTIN4;Nectin-4,1.39777869954433,1.2581774485371,1.55286942646406,4.43252673994802e-10
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0468713381767049,NECTIN4;Nectin-4,2.92192988966271,1.93459743586745,4.41315289776353,3.4579718458477e-07
primary,Circulatory system disorders,I95 (hypotension),4.84405974602053,NECTIN4;Nectin-4,1.28686400434889,1.23598171955553,1.33984098590421,1.61885807683406e-34
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24885778166618,MSR1;Macrophage scavenger receptor types I and II,1.54098489911135,1.29974348528356,1.82700239406944,6.42397420518526e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.11847096585935,MSR1;Macrophage scavenger receptor types I and II,1.2373480258403,1.16667520785878,1.3123019386525,1.27138403943439e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535644721464744,MSR1;Macrophage scavenger receptor types I and II,1.70646994424833,1.52265312367413,1.91247738920091,3.91263085861871e-20
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96840089371209,MSR1;Macrophage scavenger receptor types I and II,1.22118683424972,1.1613853968124,1.28406753540896,6.17959764708894e-15
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01919747923676,MSR1;Macrophage scavenger receptor types I and II,1.2834273150754,1.17973206271651,1.39623709920094,6.42498773939901e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34671603975833,MSR1;Macrophage scavenger receptor types I and II,1.47431733876791,1.37023290613511,1.58630814196587,2.69445547758699e-25
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70951833297596,MSR1;Macrophage scavenger receptor types I and II,1.23555744422498,1.15735356130602,1.31904566505766,2.29147372353476e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.777423618129518,MSR1;Macrophage scavenger receptor types I and II,1.44546809509026,1.31364775845084,1.59051617945729,4.30250829888234e-14
primary,Circulatory system disorders,I50 (heart failure),4.42118878240931,MSR1;Macrophage scavenger receptor types I and II,1.32905189021656,1.27600749070631,1.38430137734573,1.18404515891265e-42
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21786716187917,MSR1;Macrophage scavenger receptor types I and II,1.21334647467556,1.16344725193364,1.26538583090966,1.78969431215415e-19
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620296731289011,MSR1;Macrophage scavenger receptor types I and II,1.3321482095165,1.19583882453974,1.48399501312482,1.91590122450951e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771877977174187,MSR1;Macrophage scavenger receptor types I and II,1.36210217165144,1.23653741867873,1.50041745441073,3.78508030321385e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.795642447232759,MSR1;Macrophage scavenger receptor types I and II,1.50262815844959,1.36725776699899,1.65140139413614,2.81541415153058e-17
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07181761593526,MSR1;Macrophage scavenger receptor types I and II,1.22402592320019,1.12778669089101,1.32847769242815,1.30975968361241e-06
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14304004412141,MSR1;Macrophage scavenger receptor types I and II,1.29899138147045,1.22457664606906,1.37792813095943,3.59485729440192e-18
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402598412945386,MSR1;Macrophage scavenger receptor types I and II,1.38969930193489,1.21638356246232,1.58770983873612,1.28443042428175e-06
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702772153870113,MSR1;Macrophage scavenger receptor types I and II,1.47747572976272,1.33569438533459,1.63430688636988,3.36594128127746e-14
primary,Circulatory system disorders,I85 (oesophageal varices),0.21954963181721,MSR1;Macrophage scavenger receptor types I and II,2.89367409302902,2.45021372705426,3.4173956599019,5.89621799084023e-36
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.268613138686131,MSR1;Macrophage scavenger receptor types I and II,1.54761683055224,1.31692460391354,1.81872056083615,1.14095030411543e-07
primary,Circulatory system disorders,I95 (hypotension),4.80382588327152,MSR1;Macrophage scavenger receptor types I and II,1.23844261262788,1.19074973252236,1.28804572689146,1.36057430102318e-26
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102942604642128,MSR1;Macrophage scavenger receptor types I and II,4.32966353776071,3.45041587036636,5.43296433082546,1.06848591989501e-36
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.251860591758939,B2M;Beta-2-microglobulin,1.65596365553734,1.38501000807017,1.97992477489856,3.15203261385192e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.514704215132757,B2M;Beta-2-microglobulin,1.55328333587676,1.36902762177692,1.76233779591744,8.17603353881192e-12
primary,Circulatory system disorders,I08 (multiple valve diseases),2.04540295119182,B2M;Beta-2-microglobulin,1.32750852041609,1.24459849763172,1.41594166723698,7.30732132568944e-18
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.390580648091377,B2M;Beta-2-microglobulin,3.54001289131508,3.11047144769338,4.02887198336769,9.01112676100048e-82
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.049857227031682,B2M;Beta-2-microglobulin,2.83444746655683,1.95063039622782,4.11871590651258,4.64707457806569e-08
primary,Circulatory system disorders,I15 (secondary hypertension),0.0430663221360895,B2M;Beta-2-microglobulin,2.75703328008596,1.84381503107415,4.12255696986768,7.78692051845242e-07
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96320416802344,B2M;Beta-2-microglobulin,1.24858962474825,1.18193640001662,1.31900164087261,2.16052194273051e-15
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3765016381507,B2M;Beta-2-microglobulin,1.63531169011874,1.51384643636433,1.76652285172433,8.46354216660843e-36
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59062941524998,B2M;Beta-2-microglobulin,1.2852809208307,1.1943497492436,1.38313508794022,2.02833737165214e-11
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69187038089823,B2M;Beta-2-microglobulin,1.24111452333742,1.15557542966622,1.33298547242735,3.0547560525824e-09
primary,Circulatory system disorders,I42 (cardiomyopathy),0.691050442135891,B2M;Beta-2-microglobulin,1.35645566678272,1.21399287011489,1.51563655869974,7.23617012818134e-08
primary,Circulatory system disorders,I45 (other conduction disorders),1.73126732403326,B2M;Beta-2-microglobulin,1.20061501558135,1.11848348798776,1.28877755561034,4.25654206805711e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.757575757575757,B2M;Beta-2-microglobulin,1.50473453029331,1.35471619706324,1.67136556834962,2.42924803455121e-14
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3464478879025,B2M;Beta-2-microglobulin,1.21777921563734,1.1239272256404,1.31946818637952,1.4713474362407e-06
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.2138208934485,B2M;Beta-2-microglobulin,1.20139172653127,1.15988401453819,1.24438483717913,1.48887019982238e-24
primary,Circulatory system disorders,I50 (heart failure),4.31521415993962,B2M;Beta-2-microglobulin,1.39811036796316,1.33696019167277,1.46205744432854,7.86489424644173e-49
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08563001198267,B2M;Beta-2-microglobulin,1.27531818407545,1.21753714206536,1.33584135911822,8.6413113802125e-25
primary,Circulatory system disorders,I63 (cerebral infarction),2.04926422089294,B2M;Beta-2-microglobulin,1.30667911429747,1.22491330646019,1.39390297969363,4.92838363526288e-16
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.736682167687278,B2M;Beta-2-microglobulin,1.33456870625875,1.19746437924035,1.48737086681028,1.80679395966478e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.746556536340738,B2M;Beta-2-microglobulin,1.48138678839935,1.33277623470318,1.64656808825292,3.1955887040676e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.765004994097884,B2M;Beta-2-microglobulin,1.53594065154074,1.38389936682716,1.70468586199594,7.08229388646833e-16
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.06663035584604,B2M;Beta-2-microglobulin,1.25457149890649,1.14618928680817,1.37320219616735,8.66430374463569e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08242351805456,B2M;Beta-2-microglobulin,1.4347914854565,1.34571224986077,1.52976730868837,2.4655781002156e-28
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.403967047182443,B2M;Beta-2-microglobulin,1.60590201678437,1.39212299005613,1.85250966037714,8.0902349840054e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.676903507177902,B2M;Beta-2-microglobulin,1.59585966828494,1.4293739562033,1.78173673152911,9.17645203255335e-17
primary,Circulatory system disorders,I95 (hypotension),4.56233059244242,B2M;Beta-2-microglobulin,1.28296495747222,1.22835081191458,1.34000732212334,3.01883418005952e-29
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35088884862394,BAIAP2;Brain-specific angiogenesis inhibitor 1-associated protein 2,1.20641145890257,1.11751431495254,1.3023802815745,1.54783598641536e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.803777755450617,BAIAP2;Brain-specific angiogenesis inhibitor 1-associated protein 2,1.47143419254577,1.33244402587718,1.62492272916867,2.35810543553025e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.675648501910315,BAIAP2;Brain-specific angiogenesis inhibitor 1-associated protein 2,1.35802074668258,1.2188263704604,1.51311162370376,2.91344626552956e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.210737581535373,BAIAP2;Brain-specific angiogenesis inhibitor 1-associated protein 2,2.37106906436771,1.95718755596985,2.87247304983794,1.13635369206216e-18
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102329500993198,BAIAP2;Brain-specific angiogenesis inhibitor 1-associated protein 2,3.51666721629655,2.68613042926956,4.60400141981856,5.77984356015963e-20
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13590323532304,RETN;Resistin,1.20320061389468,1.13394415815845,1.2766869575197,9.60741602903158e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.555336746750689,RETN;Resistin,3.18884828836792,2.854301719203,3.56260634179431,1.84802779501426e-93
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0647897278831428,RETN;Resistin,2.91734136606722,2.11209658871053,4.02958874686835,8.1931653597762e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0569576745556319,RETN;Resistin,2.59963560878945,1.83700070399,3.67888008088802,6.94648596656985e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35947197320461,RETN;Resistin,1.36605630366019,1.26831762722223,1.4713268858817,1.78978368220612e-16
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60083693570991,RETN;Resistin,1.20384288184572,1.12389433288518,1.28947859399755,1.21480396351343e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.780083313683879,RETN;Resistin,1.33071574331189,1.20724098152429,1.46681931494925,8.88997437834101e-09
primary,Circulatory system disorders,I50 (heart failure),4.42854878338749,RETN;Resistin,1.26520373026717,1.21390374337261,1.31867167213324,8.13387167863351e-29
primary,Circulatory system disorders,I63 (cerebral infarction),2.0591538749532,RETN;Resistin,1.20283725782538,1.13237640754123,1.2776824553899,2.01711247877243e-09
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.770622002044507,RETN;Resistin,1.36756459766324,1.23982932280738,1.50845999072437,3.92889324945755e-10
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07966725009341,RETN;Resistin,1.22899141885554,1.13140014844079,1.33500062705676,1.03696861402081e-06
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14867475157815,RETN;Resistin,1.23054193704506,1.15944585855434,1.30599755706976,8.35980622720896e-12
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.410956210551153,RETN;Resistin,1.44079686913003,1.26060622427329,1.646743906323,8.44150721571584e-08
primary,Circulatory system disorders,I95 (hypotension),4.79958950879201,RETN;Resistin,1.20766896825283,1.16060556714142,1.25664082455943,1.35436297646243e-20
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.543270488339805,CFC1;Cryptic protein,2.10943924479889,1.87674657001126,2.37098284797772,6.06400252778086e-36
primary,Circulatory system disorders,I70 (atherosclerosis),0.803777755450617,CFC1;Cryptic protein,1.27235386452819,1.15406925991594,1.40276187297263,1.30958296694305e-06
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0481502287135863,CFC1;Cryptic protein,2.78777186855701,1.89149338928011,4.10874922173304,2.21147868608265e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.219481402350199,PLTP;Phospholipid transfer protein,1.68604332698987,1.40474324916746,2.02367379389213,2.03215285808222e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104850297075841,PLTP;Phospholipid transfer protein,1.9808282579451,1.52683494534071,2.56981319391945,2.65730572430742e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246769649276207,VEGFD;Vascular endothelial growth factor D,1.61224284671129,1.35803540345771,1.91403478153333,4.87769042802194e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.11930315756727,VEGFD;Vascular endothelial growth factor D,1.27247864075998,1.1997465758108,1.34961993127266,1.02034138705451e-15
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.205805261625084,VEGFD;Vascular endothelial growth factor D,1.56666507057995,1.30505908272955,1.88071136077747,1.46316864963858e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545128884043298,VEGFD;Vascular endothelial growth factor D,1.79697173068773,1.60616310218822,2.01044800275363,1.40586207025047e-24
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0640503086060323,VEGFD;Vascular endothelial growth factor D,2.22999814573176,1.62465570738651,3.06088958254834,6.93149912757199e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34790315354798,VEGFD;Vascular endothelial growth factor D,1.53601833419581,1.42751740510758,1.65276606403821,1.60683458811984e-30
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61778194094803,VEGFD;Vascular endothelial growth factor D,1.3727665710897,1.28302193309101,1.46878865442412,4.12968197140403e-20
primary,Circulatory system disorders,I46 (cardiac arrest),0.775073330872783,VEGFD;Vascular endothelial growth factor D,1.28353199070618,1.16617489276347,1.41269922838265,3.35631614007295e-07
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37618265697083,VEGFD;Vascular endothelial growth factor D,1.23399466593012,1.14683848029578,1.32777445272962,1.84372080269032e-08
primary,Circulatory system disorders,I50 (heart failure),4.43042933249765,VEGFD;Vascular endothelial growth factor D,1.26010785575528,1.20949971593571,1.31283355193493,2.07990179624148e-28
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22309970384995,VEGFD;Vascular endothelial growth factor D,1.22542852555249,1.17499679979943,1.27802481802,2.51767914962521e-21
primary,Circulatory system disorders,I70 (atherosclerosis),0.803002022087416,VEGFD;Vascular endothelial growth factor D,1.37334916838301,1.2498828243619,1.50901180617567,4.0921518505438e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14977557287975,VEGFD;Vascular endothelial growth factor D,1.2743852242816,1.20137124176137,1.35183667080808,7.97741510076577e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698511528358789,VEGFD;Vascular endothelial growth factor D,1.30526649488254,1.17882286292031,1.44527280243132,2.98190932222678e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.805149847332698,PLAT;Tissue-type plasminogen activator,1.36684250132651,1.24071188350557,1.50579554227678,2.51186134494434e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.219494192144827,PLAT;Tissue-type plasminogen activator,1.97571233517471,1.65063199963066,2.36481495102174,1.13739412458953e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104856404978737,PLAT;Tissue-type plasminogen activator,2.51735969593702,1.95334092237384,3.24423645977111,9.81043480653644e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01139292812026,CA6;Carbonic anhydrase 6,0.776395228469362,0.709314049118846,0.84982040259715,4.02952286462366e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35049879736603,CA6;Carbonic anhydrase 6,0.720110128352572,0.66584346320444,0.778799561176649,2.14095701949391e-16
primary,Circulatory system disorders,I46 (cardiac arrest),0.776657032187026,CA6;Carbonic anhydrase 6,0.765144443411433,0.690305449986952,0.848097055143426,3.44591397274977e-07
primary,Circulatory system disorders,I50 (heart failure),4.43290180607045,CA6;Carbonic anhydrase 6,0.773369454073829,0.740490016868343,0.807708812907322,4.40883325897631e-31
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772998170767687,CA6;Carbonic anhydrase 6,0.716205112812255,0.645996956798653,0.794043622373121,2.28258562240535e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.80688012910082,CA6;Carbonic anhydrase 6,0.690356339940411,0.624233361028062,0.76348350769176,5.46185664379122e-13
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07842172586834,CA6;Carbonic anhydrase 6,0.719359630687235,0.659496892185638,0.784656128624807,1.0811829138032e-13
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40727988194786,CA6;Carbonic anhydrase 6,0.681159810112399,0.591328502932479,0.784637785277432,1.03115066221208e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697179769970064,CA6;Carbonic anhydrase 6,0.7413127605857,0.664842770966665,0.826578302428058,7.09601157581525e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.222104290740413,CA6;Carbonic anhydrase 6,0.620637918100443,0.512974078000887,0.75089842138843,9.24224070338043e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,CD300LG;CMRF35-like molecule 9,3.53704535927716,3.12625806463536,4.00180970826006,1.79091288100843e-89
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066585719321609,CD300LG;CMRF35-like molecule 9,2.65884697120258,1.90559445954789,3.70984874607077,8.71791457995513e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,CD300LG;CMRF35-like molecule 9,1.24455723165265,1.15133074296227,1.3453325313573,3.64523532570254e-08
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246362754607177,PGF;Placenta growth factor,1.55557957467674,1.30786940413845,1.85020599571676,5.94898619323047e-07
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.515693763207382,PGF;Placenta growth factor,1.4214599260805,1.25742441263212,1.60689445914547,1.89427583579847e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.1177475396471,PGF;Placenta growth factor,1.29600746480939,1.21823190388781,1.37874844968462,2.1832180432914e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,PGF;Placenta growth factor,3.55244138493825,3.24800808398592,3.88540898516948,2.94374073018512e-169
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0658825353149766,PGF;Placenta growth factor,2.82581039189048,2.1094440560088,3.78545444150091,3.31297718363884e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0542772403900207,PGF;Placenta growth factor,3.08954978267132,2.25969621262763,4.22415978141806,1.56986813824071e-12
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9698634499781,PGF;Placenta growth factor,1.34069401371747,1.27114941155524,1.4140434020409,3.91861078656081e-27
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02086365841824,PGF;Placenta growth factor,1.46627271630556,1.3425202421965,1.60143259744416,1.78145040143385e-17
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.70895041854475,PGF;Placenta growth factor,1.26203435124158,1.22281570397911,1.30251083505953,2.54988579411668e-47
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00822078684674,PGF;Placenta growth factor,1.21577634857787,1.1404164898583,1.29611606190034,2.17069371418663e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,PGF;Placenta growth factor,1.68477766044839,1.56396923083742,1.81491790834408,5.80871834635525e-43
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.753339546442994,PGF;Placenta growth factor,1.33233462317056,1.20168043369394,1.4771943507829,5.07182391646023e-08
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61513433475558,PGF;Placenta growth factor,1.31368047020282,1.22419483538595,1.40970728507299,3.46382660455006e-14
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69610207733603,PGF;Placenta growth factor,1.26607956365253,1.18105101645833,1.35722965321636,2.90414118006526e-11
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.8593658821241,PGF;Placenta growth factor,1.2134199981725,1.14970476275069,1.28066625421489,2.07651422124096e-12
primary,Circulatory system disorders,I45 (other conduction disorders),1.7523409876831,PGF;Placenta growth factor,1.22419398920222,1.14280890017607,1.31137491401052,8.25613277142194e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.77379567139865,PGF;Placenta growth factor,1.59588030757244,1.4434048766833,1.76446262392412,7.30778253482676e-20
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37587822014051,PGF;Placenta growth factor,1.25157926923934,1.15864943240346,1.35196257244116,1.19202258913539e-08
primary,Circulatory system disorders,I50 (heart failure),4.42893177685223,PGF;Placenta growth factor,1.42459080780602,1.36453699504614,1.48728761261383,2.38170784800067e-58
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22046561138599,PGF;Placenta growth factor,1.2845522160566,1.22851578713454,1.34314464092045,3.67474848107733e-28
primary,Circulatory system disorders,I63 (cerebral infarction),2.07125909214671,PGF;Placenta growth factor,1.30716197042089,1.22780665079988,1.3916461649735,5.17782733746693e-17
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73413192283758,PGF;Placenta growth factor,1.24269179716794,1.17656496153093,1.31253517930628,6.80048323118231e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772200772200772,PGF;Placenta growth factor,1.50139123570622,1.35771619345662,1.66027013120948,2.40263298866624e-15
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,PGF;Placenta growth factor,1.81366901039432,1.64815269304073,1.99580736248169,3.37103357647221e-34
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07917159993012,PGF;Placenta growth factor,1.39953327349364,1.28222154732439,1.52757796630624,5.25065291215108e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15212264150943,PGF;Placenta growth factor,1.39428330637405,1.31116458655501,1.48267117520397,3.01781041061495e-26
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405604719764011,PGF;Placenta growth factor,1.77153913720415,1.54614516807136,2.02979059111298,1.77889240835345e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699300699300699,PGF;Placenta growth factor,1.67081316646189,1.50625931780512,1.85334397883779,2.91326411810088e-22
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0445727795972946,PGF;Placenta growth factor,2.96003617239302,2.0798077184572,4.21280008921912,1.67410260040367e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.21132221791392,PGF;Placenta growth factor,2.18969246292369,1.83390774453849,2.61450070019275,4.57480394751288e-18
primary,Circulatory system disorders,I95 (hypotension),4.80141802528292,PGF;Placenta growth factor,1.35745663208855,1.30285753168666,1.41434382746031,3.2187879930687e-48
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104659275912861,PGF;Placenta growth factor,2.78748782840416,2.20742046307484,3.51998566810327,7.2011083644101e-18
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,FGFR2;Fibroblast growth factor receptor 2,2.65466882428117,2.35879434012434,2.98765621348696,5.62224221764943e-59
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34833222278838,FGFR2;Fibroblast growth factor receptor 2,1.30257902732761,1.20638042394167,1.4064486531454,1.44721439713049e-11
primary,Circulatory system disorders,I50 (heart failure),4.4257901789233,FGFR2;Fibroblast growth factor receptor 2,1.20918192929554,1.15852015009788,1.26205913467396,3.37505220996545e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78013491054844,FGFR2;Fibroblast growth factor receptor 2,1.3277820569797,1.20062208665937,1.46840976059557,3.39569074011789e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.798106453316641,FGFR2;Fibroblast growth factor receptor 2,1.4494133892144,1.31205681283489,1.60114954800995,2.74157579687213e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.21492350677009,FGFR2;Fibroblast growth factor receptor 2,3.69925235071944,3.09228689667649,4.4253552181756,2.01208728995032e-46
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.268159486386501,FGFR2;Fibroblast growth factor receptor 2,1.58412973996974,1.33374929973041,1.88151329006422,1.59786729468222e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101564483681321,FGFR2;Fibroblast growth factor receptor 2,5.08559968701541,3.97150053473672,6.51222981096382,5.0143549111968e-38
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,CLEC7A;C-type lectin domain family 7 member A,3.42553688954685,3.04123966592869,3.8583946911869,1.91693093955181e-91
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0658825353149766,CLEC7A;C-type lectin domain family 7 member A,3.29833087834856,2.37721919934092,4.57634978973909,9.16672566891742e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0542772403900207,CLEC7A;C-type lectin domain family 7 member A,3.63953756329178,2.53682753800476,5.22157437830014,2.3003090805874e-12
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9698634499781,CLEC7A;C-type lectin domain family 7 member A,1.21719406042353,1.15622297973796,1.2813803277514,6.5688189369573e-14
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02086365841824,CLEC7A;C-type lectin domain family 7 member A,1.28095143332747,1.17557925836934,1.39576856503892,1.57374373017257e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,CLEC7A;C-type lectin domain family 7 member A,1.42133522929717,1.31833119899446,1.5323871843298,5.18348412163661e-20
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61513433475558,CLEC7A;C-type lectin domain family 7 member A,1.21360349619302,1.13307577371806,1.29985432584,3.26738030398254e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.77379567139865,CLEC7A;C-type lectin domain family 7 member A,1.37319227459862,1.24424628384448,1.51550143046521,2.90949692403434e-10
primary,Circulatory system disorders,I50 (heart failure),4.42893177685223,CLEC7A;C-type lectin domain family 7 member A,1.2999831116547,1.24666185664723,1.35558498206755,1.19810052503717e-34
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.775560017322152,CLEC7A;C-type lectin domain family 7 member A,1.28065357297224,1.15908870070429,1.41496813226633,1.16685151097165e-06
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772200772200772,CLEC7A;C-type lectin domain family 7 member A,1.3682274894251,1.23945780856031,1.5103753027245,5.0743156909961e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,CLEC7A;C-type lectin domain family 7 member A,1.38033321983526,1.25252169890393,1.52118705763588,7.94134512869708e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15212264150943,CLEC7A;C-type lectin domain family 7 member A,1.33738703158735,1.259448416966,1.42014873190817,2.31776167652401e-21
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405604719764011,CLEC7A;C-type lectin domain family 7 member A,1.66387194751457,1.45232427972131,1.9062339564117,2.15936199293917e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699300699300699,CLEC7A;C-type lectin domain family 7 member A,1.52572479140517,1.3747233747031,1.69331240156669,1.93879144111463e-15
primary,Circulatory system disorders,I85 (oesophageal varices),0.21132221791392,CLEC7A;C-type lectin domain family 7 member A,1.61257334459286,1.33603743711724,1.94634725004582,6.41477601766037e-07
primary,Circulatory system disorders,I95 (hypotension),4.80141802528292,CLEC7A;C-type lectin domain family 7 member A,1.27296354975102,1.22301774496462,1.32494904973075,3.14935313662045e-32
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104659275912861,CLEC7A;C-type lectin domain family 7 member A,2.05147368485227,1.57353245219183,2.67458372007462,1.09741135626888e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25027808676307,PIGR;Polymeric immunoglobulin receptor,1.66440456535892,1.40021469686999,1.97844128002668,7.59648576979653e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516139278199071,PIGR;Polymeric immunoglobulin receptor,1.36705244285643,1.21169287268678,1.54233174399701,3.78211746549534e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14262998886945,PIGR;Polymeric immunoglobulin receptor,1.2279362993349,1.15728101172864,1.30290529261518,1.11317158107032e-11
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.206414734836456,PIGR;Polymeric immunoglobulin receptor,1.72653515517741,1.4303165936574,2.08410057974725,1.29462421229103e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.533354561375577,PIGR;Polymeric immunoglobulin receptor,2.04426063465396,1.81842824132856,2.29813937521262,5.00233694416275e-33
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97588716088135,PIGR;Polymeric immunoglobulin receptor,1.32900261351397,1.26314089237716,1.3982984458709,5.45151565078377e-28
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01945509826911,PIGR;Polymeric immunoglobulin receptor,1.31231215539214,1.20482534112521,1.42938825604515,4.5578851209326e-10
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.71473612628021,PIGR;Polymeric immunoglobulin receptor,1.28209953963842,1.24431604475458,1.32103032543092,1.32040569133904e-59
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35396133245724,PIGR;Polymeric immunoglobulin receptor,1.67559924758492,1.55578407029823,1.80464171867304,2.44395027175281e-42
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72681644359464,PIGR;Polymeric immunoglobulin receptor,1.26657912846096,1.18588407445409,1.35276518439748,1.98046033438059e-12
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.8422897661634,PIGR;Polymeric immunoglobulin receptor,1.21620105892717,1.15531265033048,1.28029846752952,8.06663891351144e-14
primary,Circulatory system disorders,I46 (cardiac arrest),0.782382493695268,PIGR;Polymeric immunoglobulin receptor,1.64831049053127,1.49605891329189,1.81605647281441,5.16634422958246e-24
primary,Circulatory system disorders,I50 (heart failure),4.41102857257273,PIGR;Polymeric immunoglobulin receptor,1.4312611065597,1.37320572418209,1.491770911726,1.33428080898001e-64
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22083165119095,PIGR;Polymeric immunoglobulin receptor,1.26727916307548,1.21455513056043,1.3222919542765,8.73083366991371e-28
primary,Circulatory system disorders,I63 (cerebral infarction),2.09677419354838,PIGR;Polymeric immunoglobulin receptor,1.34983995500514,1.27139248407165,1.43312779252327,9.22499949665491e-23
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.790099568670133,PIGR;Polymeric immunoglobulin receptor,1.40995783925827,1.27823618245308,1.55525335284337,6.62312422250162e-12
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.627806254221798,PIGR;Polymeric immunoglobulin receptor,1.46102800403629,1.31049685261832,1.62885002303776,8.25077393628043e-12
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72783386098002,PIGR;Polymeric immunoglobulin receptor,1.27401504387679,1.20867990789333,1.3428818675851,1.94829623409647e-19
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774716433920661,PIGR;Polymeric immunoglobulin receptor,1.56599242001755,1.42002744919689,1.72696116609532,2.59740781876632e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.804976943870249,PIGR;Polymeric immunoglobulin receptor,2.0557818553148,1.86896550386815,2.26127182545351,9.99560814526744e-50
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08319751957705,PIGR;Polymeric immunoglobulin receptor,1.3101361692758,1.20653155576075,1.42263728938478,1.30329188435309e-10
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13523847856711,PIGR;Polymeric immunoglobulin receptor,1.57121845506671,1.48024080145351,1.66778772150995,7.20458859578223e-50
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405357071891268,PIGR;Polymeric immunoglobulin receptor,1.9554876703904,1.71009134329571,2.23609811489913,1.09958177981297e-22
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.69617105917454,PIGR;Polymeric immunoglobulin receptor,1.92237176402115,1.7345969428197,2.1304737186372,1.19563910553692e-35
primary,Circulatory system disorders,I85 (oesophageal varices),0.216372875972685,PIGR;Polymeric immunoglobulin receptor,3.17499654589389,2.64633508870056,3.80926932098686,1.73894204072135e-35
primary,Circulatory system disorders,I95 (hypotension),4.82220848373651,PIGR;Polymeric immunoglobulin receptor,1.34924847822126,1.29678987658309,1.40382916990311,1.36106427239834e-49
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103193030501478,PIGR;Polymeric immunoglobulin receptor,5.00095678725351,3.84269010445724,6.50834912733858,4.82138276529002e-33
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0933206258438567,PIGR;Polymeric immunoglobulin receptor,2.02149411860889,1.52947270738213,2.67179561416612,7.57720570975293e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13441773893339,LCN2;Neutrophil gelatinase-associated lipocalin,1.24729678577454,1.17358659746908,1.32563653603286,1.15893327880095e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.559134556946639,LCN2;Neutrophil gelatinase-associated lipocalin,3.81017236379943,3.41496831053326,4.25111219834248,1.12049642072701e-126
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0626047620009289,LCN2;Neutrophil gelatinase-associated lipocalin,2.90403131390397,2.0643225699311,4.08531011333966,9.22509701326643e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0585894094591591,LCN2;Neutrophil gelatinase-associated lipocalin,2.98540770240906,2.09724733839964,4.24969386605797,1.2723017792747e-09
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96875648313348,LCN2;Neutrophil gelatinase-associated lipocalin,1.21508408804645,1.15285534799354,1.2806718063921,3.78589023897009e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00932462226177,LCN2;Neutrophil gelatinase-associated lipocalin,1.25673581208042,1.15015664136639,1.37319113289571,4.32571942962101e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34970817120622,LCN2;Neutrophil gelatinase-associated lipocalin,1.41480665725058,1.31069301196436,1.52719047033035,5.71422019246323e-19
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60808917585429,LCN2;Neutrophil gelatinase-associated lipocalin,1.24702011556092,1.16237701861095,1.33782683562677,7.47946002093066e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.782197429056512,LCN2;Neutrophil gelatinase-associated lipocalin,1.39088366513864,1.2578748742318,1.53795692209127,1.24681665745705e-10
primary,Circulatory system disorders,I50 (heart failure),4.4231553200163,LCN2;Neutrophil gelatinase-associated lipocalin,1.32573922274938,1.27023155085483,1.38367251667881,3.41893845701678e-38
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19328991432621,LCN2;Neutrophil gelatinase-associated lipocalin,1.20217572271556,1.15040074602123,1.25628088584359,2.44589873192688e-16
primary,Circulatory system disorders,I63 (cerebral infarction),2.07353656559104,LCN2;Neutrophil gelatinase-associated lipocalin,1.23335495729889,1.15931375886126,1.3121249006722,3.1375739771948e-11
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.78169881001231,LCN2;Neutrophil gelatinase-associated lipocalin,1.29934942674662,1.1740310289568,1.43804455857265,4.18055989367568e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778501233469486,LCN2;Neutrophil gelatinase-associated lipocalin,1.38469465394714,1.25226096774883,1.53113395214787,2.21390790009267e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.792960453120258,LCN2;Neutrophil gelatinase-associated lipocalin,1.40839953084186,1.27457623940748,1.55627351047883,1.78367300417971e-11
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07618238459359,LCN2;Neutrophil gelatinase-associated lipocalin,1.26546751485249,1.16101099747202,1.37932201730547,8.48920053581948e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15262985417008,LCN2;Neutrophil gelatinase-associated lipocalin,1.30679231581836,1.22945639061465,1.38899286686221,8.1919489363127e-18
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404514380486226,LCN2;Neutrophil gelatinase-associated lipocalin,1.60105071254575,1.39310809103469,1.84003194055057,3.34177232136848e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700489938049155,LCN2;Neutrophil gelatinase-associated lipocalin,1.36110519762644,1.22399854316484,1.51356990525128,1.26195187023458e-08
primary,Circulatory system disorders,I95 (hypotension),4.83363446273777,LCN2;Neutrophil gelatinase-associated lipocalin,1.22131058063787,1.17263087902862,1.27201113415469,5.76563953414142e-22
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246966397013067,XCL1;Lymphotactin,1.54498979366009,1.29967962656893,1.83660143139686,8.1686859902842e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13059890259563,XCL1;Lymphotactin,1.24000822244037,1.16879011911265,1.31556587155878,1.01708867793164e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,XCL1;Lymphotactin,1.85464849432204,1.65124694542257,2.08310516305648,1.96872445083289e-25
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02719738531574,XCL1;Lymphotactin,1.33942917807332,1.2302951661967,1.45824398271865,1.58925048725207e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,XCL1;Lymphotactin,1.42061030407888,1.31909356690613,1.52993971518528,1.67739310276299e-20
primary,Circulatory system disorders,I46 (cardiac arrest),0.777574744372302,XCL1;Lymphotactin,1.38370283620539,1.25498520267475,1.52562240163643,7.07140383804877e-11
primary,Circulatory system disorders,I50 (heart failure),4.43006958737626,XCL1;Lymphotactin,1.25478733609382,1.20411941581171,1.30758730251023,3.73030119467073e-27
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22702211331343,XCL1;Lymphotactin,1.21244378025325,1.16216538995028,1.26489734850706,4.89217326458396e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,XCL1;Lymphotactin,1.39956533690813,1.27126539752076,1.54081369326562,7.25477938947311e-12
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08369975485427,XCL1;Lymphotactin,1.28080302881214,1.17905635022157,1.39132993796783,4.62285111710964e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15331271301641,XCL1;Lymphotactin,1.25147263337235,1.17945891558917,1.32788326187486,1.18419584182332e-13
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,XCL1;Lymphotactin,1.40387804873317,1.22690019585132,1.60638459622,8.04083001923843e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.211835584491303,XCL1;Lymphotactin,1.82732756548511,1.51681512313013,2.20140607821148,2.23440570669018e-10
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10490936996095,XCL1;Lymphotactin,2.30955943334323,1.77460490793167,3.00577596303486,4.76400942892132e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,SPINK5;Serine protease inhibitor Kazal-type 5,2.87219752534999,2.5390804215713,3.24901824870968,3.7348203739618e-63
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13307047806801,ADGRG1;Adhesion G-protein coupled receptor G1,1.23203606746266,1.16019609412605,1.3083244110318,9.93834484078462e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,ADGRG1;Adhesion G-protein coupled receptor G1,1.4054684753313,1.24724235648864,1.58376728057188,2.32958349109111e-08
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0131672317275,ADGRG1;Adhesion G-protein coupled receptor G1,1.25820443333832,1.15415209921459,1.37163758325225,1.83605756861073e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,ADGRG1;Adhesion G-protein coupled receptor G1,1.46078123118077,1.3524309841961,1.57781197732498,5.5310162386759e-22
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60473307214373,ADGRG1;Adhesion G-protein coupled receptor G1,1.20187112686873,1.12092658461471,1.28866085025294,2.35453696668548e-07
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69699124834548,ADGRG1;Adhesion G-protein coupled receptor G1,1.26476049868239,1.18258597710835,1.35264509303476,7.2448742287768e-12
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.82903315026275,ADGRG1;Adhesion G-protein coupled receptor G1,1.24247427725857,1.17990308872007,1.30836366512425,1.79709899495367e-16
primary,Circulatory system disorders,I45 (other conduction disorders),1.74424340482626,ADGRG1;Adhesion G-protein coupled receptor G1,1.23053106524694,1.15247331729713,1.31387571392023,5.50235213839744e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,ADGRG1;Adhesion G-protein coupled receptor G1,1.35277873918899,1.22518647625351,1.49365860027914,2.25931323568881e-09
primary,Circulatory system disorders,I50 (heart failure),4.39523336643495,ADGRG1;Adhesion G-protein coupled receptor G1,1.32611891459059,1.27143516817575,1.38315457968506,2.0142619240761e-39
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20671151689892,ADGRG1;Adhesion G-protein coupled receptor G1,1.24338591463201,1.1911255970574,1.29793913968821,2.70067325437356e-23
primary,Circulatory system disorders,I63 (cerebral infarction),2.07802469135802,ADGRG1;Adhesion G-protein coupled receptor G1,1.20157539355114,1.13093511768998,1.27662799023928,2.84499088051705e-09
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.626638027863716,ADGRG1;Adhesion G-protein coupled receptor G1,1.3734403000041,1.22891836196772,1.53495815186209,2.22264799463374e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72922961470861,ADGRG1;Adhesion G-protein coupled receptor G1,1.233022814857,1.16908766897093,1.30045445034599,1.25230238379388e-14
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774430015567422,ADGRG1;Adhesion G-protein coupled receptor G1,1.36035031255802,1.23063539745557,1.50373780626078,1.75606901721123e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,ADGRG1;Adhesion G-protein coupled receptor G1,1.41896091219407,1.2855769340301,1.56618403538305,3.71763896513232e-12
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.09602002799187,ADGRG1;Adhesion G-protein coupled receptor G1,1.28391207799346,1.18316663502711,1.39323589358967,2.04671688571825e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15586074736505,ADGRG1;Adhesion G-protein coupled receptor G1,1.21198639562176,1.14111165462233,1.28726318517744,4.01260785777826e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,ADGRG1;Adhesion G-protein coupled receptor G1,1.30759776726672,1.17727002943631,1.45235322246297,5.54388893399365e-07
primary,Circulatory system disorders,I81 (portal vein thrombosis),0.0747898994272668,ADGRG1;Adhesion G-protein coupled receptor G1,2.34850694475761,1.68502966762045,3.27322715769363,4.6469220738227e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.212665406427221,ADGRG1;Adhesion G-protein coupled receptor G1,3.60947753215959,2.95709657138232,4.40578376142607,1.65125408324906e-36
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.270254275738267,ADGRG1;Adhesion G-protein coupled receptor G1,1.65465375395459,1.39699909419878,1.95982879075972,5.50269162907266e-09
primary,Circulatory system disorders,I95 (hypotension),4.82266136529978,ADGRG1;Adhesion G-protein coupled receptor G1,1.22303953377697,1.17482959777385,1.27322779747446,9.95372539306497e-23
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102358174875004,ADGRG1;Adhesion G-protein coupled receptor G1,7.4427518291283,5.7234578083984,9.67851194931648,1.02921567688076e-50
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545490350531705,AGER;Advanced glycosylation end product-specific receptor,2.55162632272715,2.27707860433248,2.85927630185728,1.62517929206692e-58
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0647884558751349,AGER;Advanced glycosylation end product-specific receptor,2.34520471166528,1.69861767954416,3.23791822365405,2.22736228464992e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248892721357739,MMP12;Macrophage metalloelastase,1.55178593713058,1.30708189472201,1.84230200448791,5.20778484031982e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12761785238057,MMP12;Macrophage metalloelastase,1.3012789469748,1.22666944368507,1.38042641117144,2.29651237390586e-18
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545847241311604,MMP12;Macrophage metalloelastase,2.06320054374216,1.84283260419621,2.30992032266253,3.19941826114517e-36
primary,Circulatory system disorders,I20 (angina pectoris),4.00952107358312,MMP12;Macrophage metalloelastase,1.3137244735492,1.25702227650944,1.37298441296887,8.1245462862534e-34
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97642989300941,MMP12;Macrophage metalloelastase,1.50049698142031,1.4268994567067,1.57789056591831,2.47507592400122e-56
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.101898845799611,MMP12;Macrophage metalloelastase,1.99754044141391,1.54122031031945,2.58896654058306,1.70316762845839e-07
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.03319152273217,MMP12;Macrophage metalloelastase,1.49631536187813,1.37608049927882,1.62705573065375,4.11996009232541e-21
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.74204760259354,MMP12;Macrophage metalloelastase,1.35517041524203,1.31549645994695,1.39604089426536,2.10338425854054e-89
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36141288332711,MMP12;Macrophage metalloelastase,1.47802521660037,1.37322798099521,1.59082000304376,2.17193154468008e-25
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.745302632095084,MMP12;Macrophage metalloelastase,1.29294327742226,1.17027315652514,1.42847189932575,4.38298138945352e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60417281763605,MMP12;Macrophage metalloelastase,1.24014645821601,1.15809365341111,1.32801283669564,7.16527528182104e-10
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71536360599689,MMP12;Macrophage metalloelastase,1.36291885965515,1.27639800637343,1.45530454351104,2.1863871067178e-20
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.84726179481637,MMP12;Macrophage metalloelastase,1.23784690757011,1.17627681522684,1.30263977555775,2.46492124562084e-16
primary,Circulatory system disorders,I45 (other conduction disorders),1.74867034325751,MMP12;Macrophage metalloelastase,1.21808255844711,1.14144483292491,1.29986581602114,2.67933845247524e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.779719457722749,MMP12;Macrophage metalloelastase,1.65683106434393,1.50561373421598,1.82323600893857,4.64673202333247e-25
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37207743563458,MMP12;Macrophage metalloelastase,1.21946079516613,1.13266943229465,1.31290258971195,1.38640799314315e-07
primary,Circulatory system disorders,I50 (heart failure),4.42899192034926,MMP12;Macrophage metalloelastase,1.43421455482994,1.3766439237106,1.49419276390781,1.07905202996778e-66
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2298960449277,MMP12;Macrophage metalloelastase,1.30663344820508,1.25260648495553,1.36299068260765,2.20095675617537e-35
primary,Circulatory system disorders,I63 (cerebral infarction),2.0746969488595,MMP12;Macrophage metalloelastase,1.30236893684088,1.22670077896793,1.38270463076994,5.12490520075002e-18
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.77551750879914,MMP12;Macrophage metalloelastase,1.30677361466904,1.18424096295717,1.44198464114178,1.0030517613941e-07
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.623297203002802,MMP12;Macrophage metalloelastase,1.50262856832317,1.34884164963777,1.67394935865696,1.44474487322041e-13
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7361473944727,MMP12;Macrophage metalloelastase,1.26390396938555,1.19963797296109,1.33161276971379,1.41529170046788e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.770255968013798,MMP12;Macrophage metalloelastase,1.48266951409472,1.34527892141769,1.63409152780691,2.05349606378866e-15
primary,Circulatory system disorders,I70 (atherosclerosis),0.803984626245195,MMP12;Macrophage metalloelastase,1.9501984820839,1.77601877471456,2.14146053728155,1.72550037397156e-44
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07843137254901,MMP12;Macrophage metalloelastase,1.95533836982644,1.80368325860022,2.11974476243832,1.38096256429912e-59
primary,Circulatory system disorders,I72 (other aneurysm),0.32725206247183,MMP12;Macrophage metalloelastase,1.70010703250597,1.46646170862609,1.97097810667297,1.98389747471175e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15034548487014,MMP12;Macrophage metalloelastase,1.58317499635191,1.49253225054527,1.67932255276774,1.15633534696726e-52
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405810739281303,MMP12;Macrophage metalloelastase,2.11254329782942,1.85471733942795,2.40620987917247,2.02514637883469e-29
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.692672972018366,MMP12;Macrophage metalloelastase,1.79636687563272,1.62253250198101,1.98882546138866,1.64293598451069e-29
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0450274079874706,MMP12;Macrophage metalloelastase,2.63285740224757,1.80044181530738,3.85013169636162,5.95670623344378e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.207611101318134,MMP12;Macrophage metalloelastase,1.57872634257781,1.31096700473647,1.90117436651285,1.46915989968729e-06
primary,Circulatory system disorders,I95 (hypotension),4.83433023768298,MMP12;Macrophage metalloelastase,1.36502877386969,1.31234221487728,1.41983053838319,3.78185864333789e-54
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,KYNU;Kynureninase,0.71089892456431,0.630853060827947,0.801101416997839,2.1614031279865e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.21132221791392,KYNU;Kynureninase,2.08077565604922,1.72507756774951,2.50981602900059,1.84892927756944e-14
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104659275912861,KYNU;Kynureninase,3.42749498025571,2.64565247726352,4.44038736781829,1.11032704599807e-20
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.390095772015884,AHNAK;Neuroblast differentiation-associated protein AHNAK,2.14955791728244,1.86664625740648,2.47534808559362,2.19534247138107e-26
primary,Circulatory system disorders,I70 (atherosclerosis),0.754214729370008,AHNAK;Neuroblast differentiation-associated protein AHNAK,1.34928284666694,1.21251667097526,1.50147560350269,3.93331642024365e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53554427165979,EPHB6;Ephrin type-B receptor 6,4.06826009018601,3.61077667421536,4.58370640299897,1.31998785713844e-117
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0672428455590056,EPHB6;Ephrin type-B receptor 6,3.06757731326975,2.22416423603003,4.23081642104068,8.30779991047306e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0573768870071028,EPHB6;Ephrin type-B receptor 6,3.22940349786384,2.28020923060631,4.57372367940204,4.05921757855217e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.781837615296306,EPHB6;Ephrin type-B receptor 6,1.31403922440888,1.19096327974705,1.44983402313782,5.24061296548383e-08
primary,Circulatory system disorders,I50 (heart failure),4.41264519219255,EPHB6;Ephrin type-B receptor 6,1.21171777406551,1.16155436444287,1.26404756327571,5.46899465890636e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.796370768042156,EPHB6;Ephrin type-B receptor 6,1.29043375344296,1.16999886450356,1.42326571635729,3.38322717280766e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701823949246629,EPHB6;Ephrin type-B receptor 6,1.29821501000887,1.16945367032987,1.44115346761616,9.72046988784205e-07
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0474711711533516,EPHB6;Ephrin type-B receptor 6,2.60542956519771,1.77567969930128,3.82290974091639,9.8248616660047e-07
primary,Circulatory system disorders,I95 (hypotension),4.82306163021868,EPHB6;Ephrin type-B receptor 6,1.24737708982831,1.19808847193854,1.298693410939,6.18186814981279e-27
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.552153203071838,CXCL16;C-X-C motif chemokine 16,2.64893738846639,2.36146953468647,2.97139945485123,4.91976958605178e-62
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9731559662259,CXCL16;C-X-C motif chemokine 16,1.27646865552519,1.21274929817425,1.34353590720791,9.38033083131722e-21
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01531711673234,CXCL16;C-X-C motif chemokine 16,1.24710291630833,1.14409255204019,1.35938799801759,5.1595815960897e-07
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99122841367427,CXCL16;C-X-C motif chemokine 16,1.21673566844404,1.14347732669659,1.29468739982878,5.95247245814095e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35376954796545,CXCL16;C-X-C motif chemokine 16,1.32904590163893,1.23313085816647,1.43242138250407,9.82624991916207e-14
primary,Circulatory system disorders,I46 (cardiac arrest),0.781750111540028,CXCL16;C-X-C motif chemokine 16,1.38759786361295,1.25816643362626,1.53034430075663,5.49729768413451e-11
primary,Circulatory system disorders,I50 (heart failure),4.43253393842181,CXCL16;C-X-C motif chemokine 16,1.2742869436856,1.22230803812787,1.32847626309868,3.84208662835339e-30
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772410580860519,CXCL16;C-X-C motif chemokine 16,1.34408755556686,1.21757154317894,1.48374965491799,4.54782511997196e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.805793949749524,CXCL16;C-X-C motif chemokine 16,1.65372855529383,1.50188578113827,1.82092284842161,1.35511346281471e-24
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16053630054848,CXCL16;C-X-C motif chemokine 16,1.37106912623849,1.29151493394348,1.45552366412407,4.27637252353905e-25
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407640344747263,CXCL16;C-X-C motif chemokine 16,1.66883272107402,1.45849126641605,1.90950930941871,9.29873493235012e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703404321467433,CXCL16;C-X-C motif chemokine 16,1.65847214401652,1.49611433077565,1.83844897137826,6.31870484959258e-22
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,CXCL17;C-X-C motif chemokine 17,1.31568732082578,1.17816004707097,1.46926822929131,1.11289106778672e-06
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9698634499781,CXCL17;C-X-C motif chemokine 17,1.35973435405454,1.29631606059428,1.42625519331183,1.86697889435497e-36
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02086365841824,CXCL17;C-X-C motif chemokine 17,1.27437278284376,1.1750340399187,1.38210973851047,4.76053155747345e-09
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.70895041854475,CXCL17;C-X-C motif chemokine 17,1.26216785376218,1.22670239591612,1.29865866111798,1.06613749015967e-57
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,CXCL17;C-X-C motif chemokine 17,1.4557714396791,1.35910036234118,1.55931860759327,8.96406156151233e-27
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.753339546442994,CXCL17;C-X-C motif chemokine 17,1.29940679722281,1.18252236171126,1.42784447832803,5.15140662484697e-08
primary,Circulatory system disorders,I42 (cardiomyopathy),0.680272108843537,CXCL17;C-X-C motif chemokine 17,1.30271751623374,1.17992616630885,1.43828739082136,1.64542239128167e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.77379567139865,CXCL17;C-X-C motif chemokine 17,1.38826403280179,1.26701634101064,1.52111457633908,1.98470647076728e-12
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37587822014051,CXCL17;C-X-C motif chemokine 17,1.23331577359711,1.14916772195811,1.32362558427209,6.02227265629487e-09
primary,Circulatory system disorders,I50 (heart failure),4.42893177685223,CXCL17;C-X-C motif chemokine 17,1.29042704208677,1.24093242875973,1.3418957489999,2.18394011533106e-37
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22046561138599,CXCL17;C-X-C motif chemokine 17,1.25158905007425,1.20199671171777,1.30322748389812,1.4488593481964e-27
primary,Circulatory system disorders,I63 (cerebral infarction),2.07125909214671,CXCL17;C-X-C motif chemokine 17,1.23623013487426,1.16713500871999,1.30941573592869,4.94698372138712e-13
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.618948757251789,CXCL17;C-X-C motif chemokine 17,1.33309420435294,1.2022528060037,1.47817509662267,4.90715253712113e-08
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772200772200772,CXCL17;C-X-C motif chemokine 17,1.33367261104605,1.21593008899204,1.46281652996091,1.02265455871197e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,CXCL17;C-X-C motif chemokine 17,1.73785382285576,1.59543782908782,1.89298251210523,8.85899727078441e-37
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07917159993012,CXCL17;C-X-C motif chemokine 17,1.47798597508725,1.36949724115484,1.59506896173996,9.76512071368532e-24
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15212264150943,CXCL17;C-X-C motif chemokine 17,1.42658697234177,1.34987385933062,1.50765967915287,2.16201718603579e-36
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405604719764011,CXCL17;C-X-C motif chemokine 17,1.77793923591642,1.57738985763272,2.00398646619617,4.35123448604026e-21
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699300699300699,CXCL17;C-X-C motif chemokine 17,1.58904959422982,1.44698751715962,1.74505901604361,3.24304542070575e-22
primary,Circulatory system disorders,I95 (hypotension),4.80141802528292,CXCL17;C-X-C motif chemokine 17,1.23207118845261,1.18624553875251,1.27966712103415,3.77136149042033e-27
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54903967254408,NECTIN2;Nectin-2,4.69772845280068,4.18966291541351,5.26740529293273,1.20493377858385e-154
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666993624325649,NECTIN2;Nectin-2,3.0967728686691,2.24212215901293,4.27719879649508,6.86920434547609e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0569129624178196,NECTIN2;Nectin-2,3.16475726577986,2.22965326228011,4.49203861458892,1.13884875167842e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97117516629711,NECTIN2;Nectin-2,1.2572553083112,1.19460042246705,1.32319634293474,1.67229399871357e-18
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02175151789047,NECTIN2;Nectin-2,1.28810328866356,1.18255287624491,1.40307475090209,6.47911204367573e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35848165065364,NECTIN2;Nectin-2,1.48919612485879,1.38200829277878,1.60469738849058,1.48035684474107e-25
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60755848356937,NECTIN2;Nectin-2,1.27199245285974,1.18738978060062,1.36262314748382,7.33162468448811e-12
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71517466818951,NECTIN2;Nectin-2,1.2058177530306,1.12855185102631,1.28837363759714,3.03802450541856e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.783382090196925,NECTIN2;Nectin-2,1.57648806605889,1.43031674366542,1.73759737724742,4.7755685646783e-20
primary,Circulatory system disorders,I50 (heart failure),4.43476539299148,NECTIN2;Nectin-2,1.39008625120191,1.33322237070198,1.44937545922152,6.8861040688749e-54
primary,Circulatory system disorders,I63 (cerebral infarction),2.08710719067496,NECTIN2;Nectin-2,1.28654740787261,1.21145290784185,1.36629680112982,2.18976966547973e-16
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.775363763205102,NECTIN2;Nectin-2,1.29533846672109,1.17268154287912,1.43082472266752,3.42532615619103e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72478491130667,NECTIN2;Nectin-2,1.21201292854172,1.14972210891485,1.27767860386607,9.14937334152138e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773914751522294,NECTIN2;Nectin-2,1.53775887393456,1.39379616955083,1.69659122763017,9.44333307940293e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.801807998427827,NECTIN2;Nectin-2,1.70499302029413,1.54806987442292,1.87782298931135,2.45334015507035e-27
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15678471945881,NECTIN2;Nectin-2,1.44757777255892,1.36362178780723,1.53670279130425,6.97690779383023e-34
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.414554599394868,NECTIN2;Nectin-2,1.79068492645347,1.56730300948241,2.04590464411002,1.03561886419623e-17
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.711925739458779,NECTIN2;Nectin-2,1.57949539559031,1.42543928516925,1.75020131032433,2.54880692718485e-18
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0490494221978065,NECTIN2;Nectin-2,3.89802322301567,2.69401630193134,5.64012364597663,5.28847016742591e-13
primary,Circulatory system disorders,I85 (oesophageal varices),0.221790417868849,NECTIN2;Nectin-2,2.11480957772946,1.76425615440699,2.53501711692175,5.5120192726743e-16
primary,Circulatory system disorders,I95 (hypotension),4.79204874874282,NECTIN2;Nectin-2,1.35051857059053,1.29749444322374,1.40570961134773,6.07863258416885e-49
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105952988266687,NECTIN2;Nectin-2,2.57052179643064,1.98375759677203,3.33084158905143,9.24685900846822e-13
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248279637159837,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.63943000606751,1.38234757044778,1.94432341203731,1.3426214330354e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51775003419104,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.46678982272662,1.30226124594898,1.6521050524594,2.7768441037284e-10
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14185118535325,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.3218882756715,1.24618750001883,1.40218756273143,1.78141359690911e-20
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.203152774793428,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.65393886031771,1.37135779620671,1.99474838822931,1.41279422175598e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,3.92185833657418,3.51046233782327,4.38146640869353,4.65043769193568e-129
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0663932825619996,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,2.98866385937716,2.18675936952938,4.08463399714141,6.47906840200941e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0566516897831607,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,2.84700450945493,2.02478520994876,4.0031083973899,1.77582061167486e-09
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96519209549603,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.25377091411569,1.19154823690073,1.3192428610118,3.09261987742221e-18
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0170552339227,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.2961450594613,1.19015386044251,1.41157548700577,2.53238009511677e-09
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72227403592717,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.22286199466252,1.18677018102145,1.26005142520764,1.43983323236403e-39
primary,Circulatory system disorders,I26 (pulmonary embolism),2.008008363414,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.24579191477961,1.17160964343646,1.32467115103121,2.27993902055862e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34833222278838,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.60405578995014,1.49016530668112,1.72665070494971,2.88527222505007e-36
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60802638812534,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.40765775875915,1.31498414655811,1.50686255114275,7.53159264091892e-23
primary,Circulatory system disorders,I42 (cardiomyopathy),0.675741847027715,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.36377715343756,1.22829896786393,1.51419823096708,6.17399139790617e-09
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85030973104367,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.22131791990156,1.16025040789774,1.28559960101659,2.1836786204947e-14
primary,Circulatory system disorders,I45 (other conduction disorders),1.74834074045069,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.21283999053141,1.13604753810381,1.29482331794623,7.3778101461382e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.773890951729529,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.60206120102845,1.45479082410164,1.76423995073356,9.77844238532915e-22
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36676499508357,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.20251214719968,1.11632388922592,1.29535476049472,1.17420465970246e-06
primary,Circulatory system disorders,I50 (heart failure),4.4257901789233,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.44914860285808,1.39066701971326,1.51008950625616,9.96496865213208e-70
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23942626696068,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.35449913946432,1.29846996440793,1.4129459818858,5.20584196094059e-45
primary,Circulatory system disorders,I63 (cerebral infarction),2.06569457510191,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.26794531766989,1.19389527365049,1.3465882343979,1.05775328611983e-14
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.621798130694927,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.30650609098407,1.17144294781123,1.45714152700976,1.56988809681462e-06
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72775371832807,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.22210468783287,1.15951895115108,1.28806852750479,7.54011928398087e-14
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78013491054844,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.42023269876363,1.28897250276006,1.56485954069488,1.33704461281634e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.798106453316641,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.56323742617933,1.42098238458672,1.71973366954757,4.41144441438737e-20
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15488215488215,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.39973469692891,1.31935670496292,1.4850094856203,7.56858823998532e-29
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404810794954532,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.60582575424008,1.40542568604783,1.83480092798941,3.30265087407609e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704721634954193,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.55096201774347,1.40112657472097,1.71682075258755,2.53008261058713e-17
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0468713381767049,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,2.54251906951815,1.7437444237547,3.70719649668845,1.23600089794098e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.21492350677009,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.98048086922127,1.6546134905602,2.37052610517727,9.32694553324904e-14
primary,Circulatory system disorders,I95 (hypotension),4.84405974602053,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.29341765850512,1.243220293268,1.34564183708369,3.55841155524989e-37
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101564483681321,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,2.41456714845914,1.86701981568375,3.12269557368513,1.84061761338714e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.218776015953224,ADAMTS13;A disintegrin and metalloproteinase with thrombospondin motifs 13,1.64340376665873,1.36836947535518,1.97371834793894,1.05988297504178e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104513431911434,ADAMTS13;A disintegrin and metalloproteinase with thrombospondin motifs 13,1.97412860558218,1.51740387346498,2.56832331822026,4.06040585188486e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.20891048639811,TCTN3;Tectonic-3,2.30625794044975,1.87260013845847,2.84034246214784,3.75798044120833e-15
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102149683335981,TCTN3;Tectonic-3,2.96365327210519,2.20829556934927,3.97738456716098,4.56294816397707e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.546437423157237,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,2.38070922014478,2.12709942907179,2.66455639704424,1.79897187438343e-51
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35507175632139,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,1.25700496059462,1.16706997423765,1.35387038124393,1.55102408465408e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.778861693634752,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,1.30939703483,1.18759257988419,1.44369426338853,6.26056769800043e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.802978035042585,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,1.34314914042275,1.22013486097492,1.47856574803287,1.74775223632024e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.212186100837064,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,2.24231072372879,1.87067074271892,2.68778319291041,2.45850107423005e-18
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105082898731221,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,3.51403073367551,2.74417957160827,4.49985566723646,2.25415099331928e-23
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.403967047182443,CFI;Complement factor I,1.4752862723588,1.27277385193344,1.71002066243277,2.44775106453535e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.676903507177902,CFI;Complement factor I,1.35233813432611,1.20582066118716,1.51665872746956,2.48512596672118e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,TGFBR2;TGF-beta receptor type-2,4.63074839763157,4.16177067929503,5.15257383806638,3.77683396989484e-174
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0663932825619996,TGFBR2;TGF-beta receptor type-2,2.7393309202346,2.01105503327615,3.7313418908924,1.65094074454078e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0566516897831607,TGFBR2;TGF-beta receptor type-2,2.85162033123456,2.04040227258798,3.98536044718097,8.48569178564921e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96519209549603,TGFBR2;TGF-beta receptor type-2,1.20935415424776,1.14916528217698,1.27269548869913,2.92282076451236e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0170552339227,TGFBR2;TGF-beta receptor type-2,1.25124328869029,1.14883688562631,1.36277811678981,2.67816715552871e-07
primary,Circulatory system disorders,I26 (pulmonary embolism),2.008008363414,TGFBR2;TGF-beta receptor type-2,1.21673241008482,1.14414821536515,1.29392131007986,4.0806389778473e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34833222278838,TGFBR2;TGF-beta receptor type-2,1.37453179143286,1.27551561274167,1.48123443318625,7.45450959909104e-17
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60802638812534,TGFBR2;TGF-beta receptor type-2,1.22812311307105,1.14661240689795,1.31542827531392,4.50430318665779e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.773890951729529,TGFBR2;TGF-beta receptor type-2,1.42350010373139,1.29144358238664,1.56906006035392,1.17047370416472e-12
primary,Circulatory system disorders,I50 (heart failure),4.4257901789233,TGFBR2;TGF-beta receptor type-2,1.316705807049,1.26303751572861,1.37265454171124,2.1014542158813e-38
primary,Circulatory system disorders,I63 (cerebral infarction),2.06569457510191,TGFBR2;TGF-beta receptor type-2,1.25486564032519,1.18145031271717,1.3328429967124,1.5713214138061e-13
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72775371832807,TGFBR2;TGF-beta receptor type-2,1.23415147930355,1.17086304399805,1.30086083225092,4.76701626036548e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78013491054844,TGFBR2;TGF-beta receptor type-2,1.44892228950187,1.31450316973615,1.59708690655856,8.33507097260942e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.798106453316641,TGFBR2;TGF-beta receptor type-2,1.46682400345777,1.33220136950842,1.6150506270038,6.20073363962366e-15
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15488215488215,TGFBR2;TGF-beta receptor type-2,1.35276015618847,1.27449345518478,1.43583321885771,2.88830331354684e-23
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404810794954532,TGFBR2;TGF-beta receptor type-2,1.65775062762422,1.45065527555492,1.89441088430692,1.13754282270599e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704721634954193,TGFBR2;TGF-beta receptor type-2,1.49829224467518,1.35231989497818,1.66002116717363,1.0668201497485e-14
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0468713381767049,TGFBR2;TGF-beta receptor type-2,3.01941111243651,2.10627796626145,4.32841420360441,1.80991616489578e-09
primary,Circulatory system disorders,I95 (hypotension),4.84405974602053,TGFBR2;TGF-beta receptor type-2,1.33894791397031,1.28676601630232,1.39324593097138,5.87116422165901e-47
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101564483681321,TGFBR2;TGF-beta receptor type-2,1.91903069688148,1.47683783663705,2.49362436701874,1.07347546418145e-06
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02175477885307,SIT1;Signaling threshold-regulating transmembrane adapter 1,1.2988394414512,1.19113649397187,1.41628092431623,3.2149837873187e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.809951402915825,SIT1;Signaling threshold-regulating transmembrane adapter 1,1.43639855921785,1.30350301297092,1.5828431544785,2.65154983159446e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1566999453231,SIT1;Signaling threshold-regulating transmembrane adapter 1,1.22204483125567,1.15066164380435,1.2978563921373,6.58250288871107e-11
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401879436169149,SIT1;Signaling threshold-regulating transmembrane adapter 1,1.56538257911147,1.36414259505671,1.79630973174312,1.73719372237883e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.694444444444444,SIT1;Signaling threshold-regulating transmembrane adapter 1,1.34978579467035,1.21519122619106,1.49928805625478,2.18699806517366e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534430007549568,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,2.1516119937514,1.92167102587235,2.40906695752116,2.74344378622307e-40
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97277499694787,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.22109403682714,1.15998671817648,1.28542044784684,2.42561013721341e-14
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01984126984126,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.28705356694133,1.18075821180786,1.40291794510591,9.58058690666702e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34200167004652,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.47725975797191,1.37194556469008,1.59065814904705,4.63228248162931e-25
primary,Circulatory system disorders,I46 (cardiac arrest),0.78112609040444,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.37344717086214,1.24516014687622,1.5149514188047,2.26065068592895e-10
primary,Circulatory system disorders,I50 (heart failure),4.40779610194902,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.26994565103668,1.21817637069476,1.32391498914657,2.21394153800824e-29
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19219606578523,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.20173805673778,1.15112728548639,1.25457399474435,5.71325569502151e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.79766652776951,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.48037220083406,1.34466534690774,1.62977491614696,1.27673916243243e-15
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12774507243173,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.26371266354519,1.1901649855294,1.34180530886155,2.00251803574328e-14
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402745813824299,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.52559563313483,1.33237087167052,1.74684247856748,9.77458942434709e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702966758012629,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.4103880945034,1.27266902591887,1.56301012801088,5.40474886618869e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.216034089782974,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.60311998095505,1.33416285309667,1.92629682903569,4.73222325012112e-07
primary,Circulatory system disorders,I95 (hypotension),4.82297184276554,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.20120468521835,1.15435484085103,1.24995594485207,1.69062500200806e-19
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101048126646985,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,2.04200685805807,1.57032251298228,2.65537300387875,9.9564841898746e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539771042173319,OSM;Oncostatin-M,1.39931921014656,1.24269812230273,1.57567973809827,2.89409352309436e-08
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96219806029682,OSM;Oncostatin-M,1.26283170459705,1.19939875979424,1.32961944567049,7.00939596209393e-19
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3531424954005,OSM;Oncostatin-M,1.2999511313882,1.20603392488662,1.40118193122662,7.06622702171205e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.785211198137589,OSM;Oncostatin-M,1.3396061948827,1.21382238912831,1.47842449887322,6.1824350761528e-09
primary,Circulatory system disorders,I50 (heart failure),4.41000954805856,OSM;Oncostatin-M,1.22543988556397,1.17520459969989,1.27782252853207,1.74138141430719e-21
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.619781694727907,OSM;Oncostatin-M,1.36003615997924,1.21749227764435,1.51926906676562,5.21978537854815e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.799731448205047,OSM;Oncostatin-M,1.42292305115598,1.29083372272829,1.56852890799262,1.28630271693189e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13914434226309,OSM;Oncostatin-M,1.28072368065598,1.2060965779249,1.35996832775619,6.60816191478652e-16
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.392861373238046,OSM;Oncostatin-M,1.69415659238239,1.47518606471661,1.94563020093609,8.28395372721744e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.68176428740811,OSM;Oncostatin-M,1.34907162078928,1.21394780282453,1.49923599168299,2.69054975417383e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,CCL27;C-C motif chemokine 27,1.85919732677562,1.65817052341508,2.0845954327849,2.35756009172838e-26
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.541915289054093,PON3;Serum paraoxonase/lactonase 3,0.704077756782735,0.624945743577358,0.793229640638148,8.02104789595202e-09
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01000234429944,PON3;Serum paraoxonase/lactonase 3,0.782446693051508,0.716539108906813,0.854416485935119,4.64231772478208e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35066358689269,PON3;Serum paraoxonase/lactonase 3,0.758112924288366,0.703008947817511,0.817536117793836,6.36571517052645e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.808909730363423,PON3;Serum paraoxonase/lactonase 3,0.734184155396677,0.665700608401311,0.809712905821147,6.21607325317738e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699984357891443,PON3;Serum paraoxonase/lactonase 3,0.753945780014807,0.678686888826648,0.837550052255874,1.40977499210488e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.38532698296391,"GSR;Glutathione reductase, mitochondrial",1.23991956137901,1.14511775470861,1.34256980329637,1.1638996656507e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.209945003537116,"GSR;Glutathione reductase, mitochondrial",2.06943777876198,1.69645930845116,2.52441818016682,7.35874193469042e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109499041883383,"GSR;Glutathione reductase, mitochondrial",2.4744445296462,1.88708327024966,3.24462403266705,5.63877194971701e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535211267605633,MUC13;Mucin-13,2.19301106453293,1.94163151179145,2.47693627753628,1.24027212521198e-36
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.32879663371519,MUC13;Mucin-13,1.20710907834969,1.1182006222092,1.30308667165242,1.42111732486607e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.803842366511927,MUC13;Mucin-13,1.38415084511821,1.25461330750644,1.52706300067012,8.90555672743032e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.695799062883343,MUC13;Mucin-13,1.38312047695641,1.24441870950725,1.53728181612894,1.79131576296305e-09
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0461448949702064,MUC13;Mucin-13,2.990157882137,1.98090975643937,4.51360498934454,1.85220489523516e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.212736066791097,MUC13;Mucin-13,2.61077754955524,2.1517667878721,3.16770360602238,2.30440887666969e-22
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102327447833065,MUC13;Mucin-13,3.96928696680944,3.0094793883869,5.23520416377671,1.65833926421346e-22
primary,Circulatory system disorders,I70 (atherosclerosis),0.802969620005861,ACP5;Tartrate-resistant acid phosphatase type 5,1.3102922473144,1.18889873468387,1.4440807474059,5.0906719037008e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.220500712236813,ACP5;Tartrate-resistant acid phosphatase type 5,2.17396102201594,1.80785355978861,2.61420871157131,1.53969565239223e-16
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105337078651685,ACP5;Tartrate-resistant acid phosphatase type 5,3.41817248000713,2.62283135241506,4.45469095537529,9.40036105805006e-20
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.393553223388305,HS6ST2;Heparan-sulfate 6-O-sulfotransferase 2,3.3726243729834,2.8739669392196,3.95780306517038,3.70719157784285e-50
primary,Circulatory system disorders,I15 (secondary hypertension),0.042087542087542,HS6ST2;Heparan-sulfate 6-O-sulfotransferase 2,3.30660126997708,2.05643707454432,5.31677438320684,8.00612604096456e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249342286095731,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.72123060367214,1.45276397690873,2.03930909501322,3.45991850767479e-10
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14132762312633,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.34661977867897,1.26911125405875,1.42886198710319,7.62436754862105e-23
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.205983325159391,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.59769551766055,1.3238803180544,1.92814330143076,1.03405089031746e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.529100529100529,VSIG4;V-set and immunoglobulin domain-containing protein 4,4.19206667102208,3.78533951397374,4.64249584731334,9.1704907454328e-167
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666771258236586,VSIG4;V-set and immunoglobulin domain-containing protein 4,2.79919303896845,2.06494564125777,3.79452200235005,3.32523016444403e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0549310419241559,VSIG4;V-set and immunoglobulin domain-containing protein 4,2.90353669130545,2.07648028288222,4.06000740158975,4.61634696572754e-10
primary,Circulatory system disorders,I20 (angina pectoris),3.99259868421052,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.20199859349366,1.14944909111708,1.25695050779206,7.22173826181323e-16
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97548298716734,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.29828747751478,1.23351605369256,1.36646002232882,1.56451800687677e-23
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01353342106813,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.36382343260973,1.25161645127934,1.48608973095086,1.40572929967813e-12
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72079998370705,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.25250039472457,1.21522825787865,1.29091570132157,2.54259093661884e-48
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00273370178879,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.22584092034672,1.15245982814427,1.30389443978813,1.01001897360665e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35206943378402,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.71542899901835,1.59378235207091,1.84636041856622,6.87438276646985e-47
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59534608558469,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.33301098459473,1.24423780679135,1.42811790105667,2.96758819024836e-16
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72647991023091,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.26085527091924,1.18017513266638,1.34705093354498,6.41669571873841e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.674692159408316,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.30508597161075,1.17423334799107,1.45052037247039,7.83145530217792e-07
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.83689339501919,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.24413566581169,1.18152269120674,1.31006671853571,1.1204394521707e-16
primary,Circulatory system disorders,I45 (other conduction disorders),1.75586928310197,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.21307867851087,1.13613044748906,1.29523848560695,7.60206926887546e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.781173330192938,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.57860717375769,1.43279750344848,1.73925527022587,2.63159582730366e-20
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37668134863418,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.23962557383126,1.15088026092341,1.33521410999224,1.44625430360497e-08
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.41156428499849,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.22501534423621,1.18583564918527,1.26548952601077,1.96471092096766e-34
primary,Circulatory system disorders,I50 (heart failure),4.43481358347185,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.52220732077412,1.460329420535,1.58670714623378,1.24966225692248e-87
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21770879055105,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.32404981576885,1.26862057420206,1.38190090109504,7.12422995321891e-38
primary,Circulatory system disorders,I63 (cerebral infarction),2.08439948037633,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.33903213915035,1.26091383357691,1.42199016453903,1.74424188330773e-21
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.782946508616396,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.32600069842819,1.20101920467154,1.46398812391424,2.31800950223388e-08
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.626423690205011,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.37950447212839,1.2368916969,1.53856040378617,7.53615962503537e-09
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72759475735033,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.28835466365962,1.222159222324,1.35813542871867,4.75049622179283e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773595649015334,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.7040765785342,1.54705595682434,1.87703422923993,3.19003347581243e-27
primary,Circulatory system disorders,I70 (atherosclerosis),0.805453509616329,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.71550640953495,1.56003633468657,1.88647031849216,8.4818153578767e-29
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08830173853256,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.31943333890405,1.21434160384014,1.43361993882625,5.9162622173752e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13434646828317,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.47845756049408,1.39246308642844,1.56976280339941,1.90451144742333e-37
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406551967947207,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.79817730540905,1.5749035275568,2.05310456488994,4.15538933325085e-18
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701830263235496,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.64046724209026,1.48098121585771,1.81712822793139,2.41139271427607e-21
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0470717451849527,VSIG4;V-set and immunoglobulin domain-containing protein 4,3.40142377331083,2.39922097471337,4.82226681392959,6.24179558417813e-12
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.66653248530714,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.23103423784635,1.14963132995609,1.3182011095747,2.60394215058755e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.221712088213942,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.80553847779899,1.50950616318037,2.15962628992801,1.00057975952727e-10
primary,Circulatory system disorders,I87 (other disorders of veins),0.467308069899862,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.41761322598694,1.2496198229243,1.60819092465281,5.87471765931286e-08
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.542218380417272,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.41531714645415,1.25873927365039,1.59137215067422,6.36975782823886e-09
primary,Circulatory system disorders,I95 (hypotension),4.81371969248965,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.39116763165225,1.33679842805575,1.44774809630178,3.03729467591962e-59
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10395825977796,VSIG4;V-set and immunoglobulin domain-containing protein 4,2.46845876494065,1.92317094529779,3.16835520477813,1.2947308230975e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.401231049811923,KIAA0319;Dyslexia-associated protein KIAA0319,2.43713955084323,2.11625144194517,2.80668406057878,3.93301972437199e-35
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250226583126453,RBP5;Retinol-binding protein 5,1.61964703163559,1.36912162195103,1.91601422768254,1.8619865577393e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13307047806801,RBP5;Retinol-binding protein 5,1.22194501253044,1.15090709455304,1.29736763350814,5.40389969782244e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,RBP5;Retinol-binding protein 5,2.28618638886516,2.04902344949466,2.55079960452445,1.51690561518103e-49
primary,Circulatory system disorders,I15 (secondary hypertension),0.0570944815230445,RBP5;Retinol-binding protein 5,2.33929701277711,1.66395801001018,3.28873113448002,1.00999755149022e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,RBP5;Retinol-binding protein 5,1.35858953220964,1.26105607006071,1.46366649417955,7.48414830730364e-16
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,RBP5;Retinol-binding protein 5,1.38983918375793,1.25908962888626,1.53416636305517,6.55984577920743e-11
primary,Circulatory system disorders,I50 (heart failure),4.39523336643495,RBP5;Retinol-binding protein 5,1.2465222021298,1.19524524009485,1.29999898621576,8.52313535912927e-25
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.626638027863716,RBP5;Retinol-binding protein 5,1.36037670712175,1.21896330122988,1.51819565315231,3.89390039217265e-08
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774430015567422,RBP5;Retinol-binding protein 5,1.32741238954623,1.20238927453004,1.46543527062776,2.00238124868025e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,RBP5;Retinol-binding protein 5,1.63097794460371,1.4822131014815,1.79467382465108,1.19002811883092e-23
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,RBP5;Retinol-binding protein 5,1.46643257786691,1.28003538178249,1.67997270703162,3.4010477563367e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,RBP5;Retinol-binding protein 5,1.38194975324175,1.24610735497887,1.53260079306514,8.9151420986524e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.212665406427221,RBP5;Retinol-binding protein 5,2.56299650620097,2.16006115988848,3.04109495267139,4.0522075063012e-27
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102358174875004,RBP5;Retinol-binding protein 5,3.24558043753392,2.56355523710906,4.10905613579909,1.35153687629557e-22
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34734942830806,PROC;Vitamin K-dependent protein C,0.735751209461851,0.682262422301743,0.793433471534746,1.60660920231345e-15
primary,Circulatory system disorders,I85 (oesophageal varices),0.218993801693291,PROC;Vitamin K-dependent protein C,0.440156231059746,0.365310603816442,0.530336392419827,6.157741550172e-18
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103596559812353,PROC;Vitamin K-dependent protein C,0.271755510197004,0.207361286025723,0.356146794504703,3.65115774854836e-21
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.253363448885397,FAM3C;Protein FAM3C,1.56944609989274,1.31996797002599,1.8660763870051,3.34381702761632e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14990370632394,FAM3C;Protein FAM3C,1.22647390263929,1.15523288668848,1.30210821661008,2.28979897150963e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54903967254408,FAM3C;Protein FAM3C,5.10894821893511,4.53939551544817,5.74996204118671,4.39567240980327e-161
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666993624325649,FAM3C;Protein FAM3C,3.25652534914815,2.3448018001093,4.52275213587354,1.85248402328704e-12
primary,Circulatory system disorders,I15 (secondary hypertension),0.0569129624178196,FAM3C;Protein FAM3C,3.17170918970027,2.21659575965301,4.53837337738293,2.71742231541194e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97117516629711,FAM3C;Protein FAM3C,1.23700162708519,1.17452084331319,1.30280619039077,8.77240724097187e-16
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02175151789047,FAM3C;Protein FAM3C,1.2488175341368,1.1450831266568,1.36194936180815,5.11636683498788e-07
primary,Circulatory system disorders,I26 (pulmonary embolism),1.98767364895662,FAM3C;Protein FAM3C,1.21015247973072,1.13686045129592,1.28816955724782,2.17717821609438e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35848165065364,FAM3C;Protein FAM3C,1.37496389422114,1.27511522479994,1.48263127413318,1.24978394168939e-16
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60755848356937,FAM3C;Protein FAM3C,1.28647906406115,1.20027414476833,1.37887530901293,1.09107833419689e-12
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71517466818951,FAM3C;Protein FAM3C,1.20571883283474,1.12758097666438,1.2892713995166,4.43829626584745e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.783382090196925,FAM3C;Protein FAM3C,1.54674206042979,1.40117859332788,1.70742759909033,5.19621793621927e-18
primary,Circulatory system disorders,I50 (heart failure),4.43476539299148,FAM3C;Protein FAM3C,1.34998977491958,1.29416609658049,1.40822140002187,4.29124350032518e-44
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21947665715255,FAM3C;Protein FAM3C,1.2370261349164,1.18468372748552,1.29168116600547,5.26832782844598e-22
primary,Circulatory system disorders,I63 (cerebral infarction),2.08710719067496,FAM3C;Protein FAM3C,1.23889449881228,1.16584188252563,1.31652465243597,4.9028410231563e-12
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.775363763205102,FAM3C;Protein FAM3C,1.31740466574362,1.19126007211583,1.45690692901383,7.96547874718935e-08
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773914751522294,FAM3C;Protein FAM3C,1.365064090685,1.23570683231321,1.50796282981574,8.98335526379324e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.801807998427827,FAM3C;Protein FAM3C,1.5834915983885,1.43564231536127,1.746567104729,3.90626974823838e-20
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15678471945881,FAM3C;Protein FAM3C,1.3562518162065,1.27691121931811,1.44052222357769,3.8506791205748e-23
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.414554599394868,FAM3C;Protein FAM3C,1.64505269407761,1.43620642796949,1.88426838481571,6.67426627418296e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.711925739458779,FAM3C;Protein FAM3C,1.494599855177,1.34716041442472,1.65817574742872,3.36120059496329e-14
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0490494221978065,FAM3C;Protein FAM3C,3.79995456122664,2.59966235593524,5.55443464972296,5.47333963329301e-12
primary,Circulatory system disorders,I95 (hypotension),4.79204874874282,FAM3C;Protein FAM3C,1.257602889819,1.20778350753195,1.30947725202255,1.07124114335206e-28
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544600200538702,PRELP;Prolargin,3.10583121605719,2.75449124404411,3.50198519000295,1.97387837016313e-76
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0646830530401035,PRELP;Prolargin,3.36622419037518,2.40270331407088,4.71613171443471,1.72373851659218e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.780744257214037,PRELP;Prolargin,1.40568198010764,1.27177331627241,1.55369027162077,2.61505585472305e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534430007549568,SFRP1;Secreted frizzled-related protein 1,2.03585584805487,1.81444118738779,2.2842895448302,1.03494617557173e-33
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34401654174205,SFRP1;Secreted frizzled-related protein 1,1.39498671029421,1.2944511221476,1.50333055346957,2.71620623661685e-18
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61354581673306,SFRP1;Secreted frizzled-related protein 1,1.22860645019038,1.14702602520703,1.31598915480314,4.28120962672719e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.78312416978925,SFRP1;Secreted frizzled-related protein 1,1.41057141757365,1.27913201749232,1.55551709820889,5.4661020569963e-12
primary,Circulatory system disorders,I50 (heart failure),4.41596865441896,SFRP1;Secreted frizzled-related protein 1,1.23781733420857,1.18703938094593,1.29076741468023,1.81068443321093e-23
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.76561477279489,SFRP1;Secreted frizzled-related protein 1,1.27646110340717,1.15568535036676,1.40985861592376,1.48619667412658e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.797682355742519,SFRP1;Secreted frizzled-related protein 1,1.3630597558238,1.23695830317882,1.50201659439272,4.01487510097235e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.214056368176953,SFRP1;Secreted frizzled-related protein 1,1.63165161762621,1.35638914290406,1.96277522216242,2.06385020508648e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101050128789379,SFRP1;Secreted frizzled-related protein 1,2.17972308145647,1.67882609959352,2.8300684108881,4.94445915080252e-09
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246966397013067,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.54504005217087,1.29416360516592,1.84454944744495,1.49145806167514e-06
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13059890259563,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.23296266020424,1.16025544967795,1.31022605571892,1.44655899349237e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,5.39868480224052,4.78278462124493,6.09389715448996,6.83011797719897e-164
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0660399347370056,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,3.53237535808683,2.53178750397747,4.92840558333449,1.11361414678164e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544069640914037,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,3.59652158682352,2.48361317157512,5.20812486925417,1.23879134228204e-11
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00521906331547,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.23881000583249,1.16335929670669,1.31915413827446,2.39956302140299e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.44708402029749,1.3404431038264,1.56220891123444,3.02600922842757e-21
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60931213624467,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.29956584704048,1.21160913340522,1.39390777457039,2.33191337127888e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.777574744372302,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.41154818814575,1.27627992297622,1.56115304455406,1.99649069643111e-11
primary,Circulatory system disorders,I50 (heart failure),4.43006958737626,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.31577060778548,1.26059249651502,1.37336395155319,3.73872678539794e-36
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22702211331343,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.25234917936036,1.19870410917075,1.30839500344214,7.2107866941172e-24
primary,Circulatory system disorders,I63 (cerebral infarction),2.07622575299736,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.20546269083188,1.13344666329111,1.28205441513081,2.75590125756364e-09
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77792255780937,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.40998498862015,1.27509837563683,1.55914061700631,2.1301836233656e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.39922378574014,1.26699365927417,1.5452541441309,3.30651548423783e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15331271301641,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.26604165164313,1.19110264948158,1.34569549013505,3.52308012621584e-14
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.54017148019942,1.34025057091589,1.76991395482012,1.14135334698723e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697054070367413,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.42435976307865,1.28063366960474,1.58421630075027,7.13385176321491e-11
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0446792804693267,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,3.73512688467231,2.4941229899339,5.59361863905982,1.59980003980644e-10
primary,Circulatory system disorders,I95 (hypotension),4.82261749028642,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.23903629653624,1.18966034277059,1.29046156196053,5.14767267476972e-25
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.253675295621604,NPPB;Natriuretic peptides B,2.40629673449578,2.01033974072026,2.88024151199962,1.0418970768987e-21
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.509042999161576,NPPB;Natriuretic peptides B,2.00446892712832,1.76757626282183,2.27311022688696,2.30890460439486e-27
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13076415678906,NPPB;Natriuretic peptides B,1.80839795768652,1.70072236528872,1.92289067287569,8.56969761306511e-80
primary,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0339280724863289,NPPB;Natriuretic peptides B,4.46590977658701,2.70221536097512,7.38074041789858,5.28210690568313e-09
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.207576543850544,NPPB;Natriuretic peptides B,1.85958533322437,1.5356508377626,2.25185147984648,2.11793552460514e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550330198118871,NPPB;Natriuretic peptides B,1.78232548091831,1.58115244692345,2.00909414276389,3.14814439735499e-21
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0658432929627486,NPPB;Natriuretic peptides B,3.08917540587073,2.21216517176708,4.31387529739184,3.59061954884921e-11
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.0978766753890098,NPPB;Natriuretic peptides B,2.87843101716607,2.19234517071543,3.77922474583686,2.7284294460825e-14
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00721437278922,NPPB;Natriuretic peptides B,1.33724316690152,1.22502442646176,1.45974173967266,8.11494581376596e-11
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69682339045566,NPPB;Natriuretic peptides B,1.29019807627747,1.24995325695328,1.331738660442,5.97429805483341e-56
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34564168285308,NPPB;Natriuretic peptides B,2.25914849393579,2.08934018524129,2.4427577441454,7.04774472113703e-93
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.749700119952019,NPPB;Natriuretic peptides B,1.44083305205797,1.30061175473641,1.59617186015931,2.72263084029785e-12
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61293558288362,NPPB;Natriuretic peptides B,1.85594601182026,1.72807556265417,1.99327834571137,1.18437950943126e-64
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69437212096935,NPPB;Natriuretic peptides B,1.37829959817839,1.28754654310313,1.47544940609307,2.63991301989698e-20
primary,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.187594795242276,NPPB;Natriuretic peptides B,2.0978710680267,1.70900724165454,2.57521613179515,1.40601724012946e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.678434197886647,NPPB;Natriuretic peptides B,2.22017272364882,1.99203324135079,2.47444009493122,4.03748405158149e-47
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.83024536805207,NPPB;Natriuretic peptides B,1.55921345758819,1.4787284692768,1.64407912394703,1.23862100365222e-60
primary,Circulatory system disorders,I45 (other conduction disorders),1.74252275682704,NPPB;Natriuretic peptides B,1.44704601599865,1.35352805536199,1.5470253195879,2.21121995245795e-27
primary,Circulatory system disorders,I46 (cardiac arrest),0.77876954412029,NPPB;Natriuretic peptides B,1.71523865527098,1.55275011167095,1.89473091801603,2.26689664675172e-26
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35648399348887,NPPB;Natriuretic peptides B,1.60232711514156,1.48354842879696,1.73061568741633,3.66837221487587e-33
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.37432446211889,NPPB;Natriuretic peptides B,1.71542130122787,1.65680642759154,1.77610986516029,2.72381495243941e-203
primary,Circulatory system disorders,I49 (other cardiac arrhythmias),1.98836081474296,NPPB;Natriuretic peptides B,1.42682308311417,1.33891507342559,1.52050279432498,6.25122049671873e-28
primary,Circulatory system disorders,I50 (heart failure),4.39370142161008,NPPB;Natriuretic peptides B,1.83607184609055,1.75640716727848,1.9193498448483,8.87891177638921e-159
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.1864620132375,NPPB;Natriuretic peptides B,1.71138116389003,1.63603921468459,1.7901927177719,5.36584687213326e-121
primary,Circulatory system disorders,I63 (cerebral infarction),2.05679724425218,NPPB;Natriuretic peptides B,1.34645475405865,1.2656696298655,1.43239622880088,4.3807612655944e-21
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.768373035985808,NPPB;Natriuretic peptides B,1.44273214259748,1.30278721107573,1.59770990810174,1.90991616251816e-12
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73322520574277,NPPB;Natriuretic peptides B,1.24083067260907,1.17597713381554,1.30926079582172,3.31718310044729e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.767186782011068,NPPB;Natriuretic peptides B,1.48151486516616,1.33932013703027,1.63880631301126,2.25836062888871e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.797521487107735,NPPB;Natriuretic peptides B,1.48987405321906,1.34962716915984,1.64469473138808,2.69953120244679e-15
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08526202182515,NPPB;Natriuretic peptides B,1.32430794840026,1.21781049561132,1.44011859687227,5.13928136400713e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16137453706514,NPPB;Natriuretic peptides B,1.36467994106841,1.28403404053058,1.4503909419605,1.45972392069193e-23
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.397665960593101,NPPB;Natriuretic peptides B,1.42042676922229,1.23599618571986,1.63237737303226,7.58276784020762e-07
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.688041282476948,NPPB;Natriuretic peptides B,1.37902200505487,1.23955598277103,1.5341797521515,3.47000173253734e-09
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.10877489239893,NPPB;Natriuretic peptides B,1.22215149383221,1.14851573705498,1.30050832190276,2.4947677141842e-10
primary,Circulatory system disorders,I87 (other disorders of veins),0.455471652882656,NPPB;Natriuretic peptides B,1.48954675137282,1.30546262214543,1.69958870279945,3.2109282239746e-09
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.525705604861277,NPPB;Natriuretic peptides B,1.40455254396737,1.24118059953002,1.5894285243519,7.26066096304418e-08
primary,Circulatory system disorders,I95 (hypotension),4.76314628374313,NPPB;Natriuretic peptides B,1.31530719694487,1.26242351865997,1.37040620422801,3.76310095587327e-39
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.386548125241592,PRAP1;Proline-rich acidic protein 1,3.1006322020083,2.69027823823711,3.573578344235,5.05136228108286e-55
primary,Circulatory system disorders,I20 (angina pectoris),3.95421188875958,PRAP1;Proline-rich acidic protein 1,1.20466553475224,1.14573734481223,1.26662455159627,3.42251756836312e-13
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96056462695953,PRAP1;Proline-rich acidic protein 1,1.2784524959803,1.20709761904855,1.35402535692727,5.14640543209878e-17
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.975,PRAP1;Proline-rich acidic protein 1,1.3030357050445,1.18141623301558,1.43717514722724,1.19168327574997e-07
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.55609939759036,PRAP1;Proline-rich acidic protein 1,1.23833195622892,1.196828082821,1.28127511029259,1.02498973338843e-34
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37382666545156,PRAP1;Proline-rich acidic protein 1,1.3610550175821,1.25349270900039,1.4778472563775,2.15471396210364e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.754031342266636,PRAP1;Proline-rich acidic protein 1,1.40733915615979,1.25920834889403,1.57289578186177,1.72571361483671e-09
primary,Circulatory system disorders,I50 (heart failure),4.32582211230191,PRAP1;Proline-rich acidic protein 1,1.3462430032842,1.28442660635989,1.41103447633179,2.70808766189966e-35
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08907349717318,PRAP1;Proline-rich acidic protein 1,1.21269558043503,1.15538343322422,1.27285066456484,5.84949919667264e-15
primary,Circulatory system disorders,I63 (cerebral infarction),2.05420177636073,PRAP1;Proline-rich acidic protein 1,1.24744090930544,1.16594900080668,1.33462854818879,1.41553655966241e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.752084706096203,PRAP1;Proline-rich acidic protein 1,1.44211517792324,1.29069661413791,1.61129746806197,9.88561013884274e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.772797527047913,PRAP1;Proline-rich acidic protein 1,1.84660166479767,1.65843059287549,2.05612325477014,4.81538949127233e-29
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08525133492911,PRAP1;Proline-rich acidic protein 1,1.40069919091585,1.30949241749196,1.49825855974791,1.03089020261082e-22
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402217879380084,PRAP1;Proline-rich acidic protein 1,1.95635221026805,1.68775593313361,2.26769398079652,5.27731528427335e-19
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.689168903243415,PRAP1;Proline-rich acidic protein 1,1.54947617211136,1.3808949316434,1.73863800418442,9.228856939795e-14
primary,Circulatory system disorders,I95 (hypotension),4.54078956371017,PRAP1;Proline-rich acidic protein 1,1.25466470907205,1.19870247594763,1.31323957677352,1.93676847896138e-22
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.549645390070922,ANG;Angiogenin,2.36025368560122,2.09929554223187,2.65365087874743,8.52943090791079e-47
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34999310222502,ANG;Angiogenin,1.26033253645204,1.1664592751669,1.36176044569782,4.66191568743081e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.782263453752112,ANG;Angiogenin,1.30435582824621,1.17715309190825,1.44530404615585,3.86844667273508e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772785370170091,ANG;Angiogenin,1.29047728598053,1.16467456616354,1.42986862941234,1.09976547353854e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.804595439970098,ANG;Angiogenin,1.49686167421561,1.35409804607599,1.65467698460133,3.08606504633925e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702852755300927,ANG;Angiogenin,1.34329168472559,1.20656140100192,1.49551655535683,7.11116794856389e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104105283834217,ANG;Angiogenin,0.407464103923179,0.306911084028917,0.540961225011593,5.32482176735269e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535211267605633,GPKOW;G-patch domain and KOW motifs-containing protein,1.46012297799231,1.29436608359639,1.64710674814462,7.42491827594062e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.32879663371519,GPKOW;G-patch domain and KOW motifs-containing protein,1.28184082513954,1.18739893808286,1.38379431570602,2.03308155348483e-10
primary,Circulatory system disorders,I50 (heart failure),4.42914979757085,GPKOW;G-patch domain and KOW motifs-containing protein,1.20598883611818,1.15630890510751,1.25780322750905,2.62441079459271e-18
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.695799062883343,GPKOW;G-patch domain and KOW motifs-containing protein,1.30713221110775,1.17608814684026,1.45277768669453,6.72528465125697e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551252935810089,CCL16;C-C motif chemokine 16,2.63621401844101,2.35445828776818,2.95168718304732,2.12670066208113e-63
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35161378024624,CCL16;C-C motif chemokine 16,1.2859263121854,1.19077080108819,1.38868578139436,1.44292263206634e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.782415028565895,CCL16;C-C motif chemokine 16,1.39342090107411,1.25979699792612,1.54121799841282,1.1178506769925e-10
primary,Circulatory system disorders,I50 (heart failure),4.42925495557074,CCL16;C-C motif chemokine 16,1.24666145998066,1.19445559545044,1.30114907722042,5.46216365325017e-24
primary,Circulatory system disorders,I70 (atherosclerosis),0.804481836157096,CCL16;C-C motif chemokine 16,1.60446688379861,1.4529304141354,1.77180817206468,9.59508665019584e-21
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.16089968793546,CCL16;C-C motif chemokine 16,1.2352830481216,1.16197948889583,1.31321096762784,1.29000138880477e-11
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406976744186046,CCL16;C-C motif chemokine 16,1.41315777696313,1.22878769357424,1.62519116445783,1.24425252123442e-06
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704198029021494,CCL16;C-C motif chemokine 16,1.33672071339791,1.20193657726896,1.48661942686447,8.70754984554594e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13307047806801,AREG;Amphiregulin,1.24816253235276,1.17495561731644,1.32593068555854,6.56506398619621e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,AREG;Amphiregulin,2.78562689776272,2.46692514833839,3.14550168608307,2.38008421954531e-61
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0629760100761616,AREG;Amphiregulin,2.45782054871532,1.71396691927533,3.52450317549967,1.01013342553594e-06
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9594291374396,AREG;Amphiregulin,1.23078028447887,1.16719129133213,1.29783362839607,1.69376235325663e-14
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0131672317275,AREG;Amphiregulin,1.2575146967218,1.15017481655299,1.3748720539809,4.81743773978725e-07
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69094327284616,AREG;Amphiregulin,1.27190676000505,1.23289076151054,1.31215745680864,1.01613436346755e-51
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99980121260312,AREG;Amphiregulin,1.23856636717704,1.1637694829643,1.31817053837386,1.67251299715209e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,AREG;Amphiregulin,1.81977692416343,1.68723780895064,1.96272750417875,2.6380072951746e-54
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.74928522133491,AREG;Amphiregulin,1.31259040014004,1.18538985045991,1.4534404507271,1.69359246733317e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60473307214373,AREG;Amphiregulin,1.27263904790404,1.18760636401289,1.36376007684692,8.30628547065878e-12
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69699124834548,AREG;Amphiregulin,1.28529262523079,1.20022302666908,1.37639180032841,6.79106536089742e-13
primary,Circulatory system disorders,I42 (cardiomyopathy),0.667232564107625,AREG;Amphiregulin,1.32758649287392,1.19064170215533,1.48028234931699,3.37313750709477e-07
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.82903315026275,AREG;Amphiregulin,1.27855065575934,1.211978743333,1.34877924908744,2.12241972715842e-19
primary,Circulatory system disorders,I45 (other conduction disorders),1.74424340482626,AREG;Amphiregulin,1.3304798648816,1.24270929346139,1.42444953149485,2.3944563433962e-16
primary,Circulatory system disorders,I46 (cardiac arrest),0.776033562466762,AREG;Amphiregulin,1.65769346713626,1.49628311305324,1.8365158351476,4.04581310636868e-22
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36367240149052,AREG;Amphiregulin,1.20488785850876,1.11676070553894,1.29996940649985,1.51219145002278e-06
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.39861602832314,AREG;Amphiregulin,1.21567779103861,1.1759991457293,1.25669520848844,8.75483556310731e-31
primary,Circulatory system disorders,I50 (heart failure),4.39523336643495,AREG;Amphiregulin,1.56282548529702,1.49724375288027,1.63127980517223,1.26931496269154e-92
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20671151689892,AREG;Amphiregulin,1.4096457427556,1.34906545960006,1.47294640592019,5.66198792768445e-53
primary,Circulatory system disorders,I63 (cerebral infarction),2.07802469135802,AREG;Amphiregulin,1.33039098307627,1.25097488508183,1.41484868238172,9.86015163534029e-20
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.779719301051621,AREG;Amphiregulin,1.37545515949651,1.24282416144132,1.52224019654682,7.18773865635718e-10
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.626638027863716,AREG;Amphiregulin,1.43304024430596,1.28042567498362,1.60384501960783,3.78882222309975e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72922961470861,AREG;Amphiregulin,1.34246086548142,1.27263438902376,1.41611855760994,3.21633732533797e-27
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774430015567422,AREG;Amphiregulin,1.6349938585847,1.47805119430491,1.80860103351618,1.31438254153445e-21
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,AREG;Amphiregulin,1.67147416269198,1.51191295203586,1.8478748216191,1.06625117713067e-23
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.09602002799187,AREG;Amphiregulin,1.29695684825487,1.18765773286975,1.41631466682808,7.08945941920264e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15586074736505,AREG;Amphiregulin,1.46519841959692,1.37929611751122,1.55645070085673,2.88990284478145e-35
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406023336486912,AREG;Amphiregulin,1.71232029738218,1.48578307870165,1.97339762638108,1.0979921862747e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702335858585858,AREG;Amphiregulin,1.49527043257569,1.34493976406393,1.66240431450937,9.93919092927279e-14
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0472375853720943,AREG;Amphiregulin,2.94612286185362,1.9305242585546,4.49600147663259,5.44283974473048e-07
primary,Circulatory system disorders,I81 (portal vein thrombosis),0.0747898994272668,AREG;Amphiregulin,2.44040033883315,1.74876828250236,3.40557057979976,1.54493371973661e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.212665406427221,AREG;Amphiregulin,2.56427155233007,2.10932073391459,3.11734886419389,3.39114072693177e-21
primary,Circulatory system disorders,I95 (hypotension),4.82266136529978,AREG;Amphiregulin,1.38419358593991,1.32974099293769,1.44087600031368,9.07684725616326e-57
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102358174875004,AREG;Amphiregulin,4.15994146612058,3.14208257698686,5.50752966465457,2.36355383441101e-23
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25298582102724,SEMA3F;Semaphorin-3F,1.59237075569697,1.34263525996249,1.88855804641223,9.03571189028082e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,SEMA3F;Semaphorin-3F,2.8222744788855,2.52028968857041,3.16044352769882,3.40332623459831e-72
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666000666000666,SEMA3F;Semaphorin-3F,2.41639714407465,1.75345333510775,3.32998605721854,6.959387952398e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,SEMA3F;Semaphorin-3F,1.25275875702915,1.16276479928199,1.34971793460064,3.12801957325806e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,SEMA3F;Semaphorin-3F,1.41849027949313,1.28692851100636,1.56350151217263,1.92902299597628e-12
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,SEMA3F;Semaphorin-3F,1.20154226096463,1.15260215600606,1.2525603889955,4.97809864151391e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77276115011964,SEMA3F;Semaphorin-3F,1.29863873573933,1.17696603288726,1.4328897511388,1.92717975147924e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,SEMA3F;Semaphorin-3F,1.35966780345321,1.23449971410129,1.49752690472927,4.50660510845188e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.710863247191893,SEMA3F;Semaphorin-3F,1.29405508616614,1.16769124970624,1.4340936154602,8.7844887080814e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,SEMA3F;Semaphorin-3F,1.66350797354384,1.38761531257321,1.99425500206703,3.78592418448189e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105795227459739,SEMA3F;Semaphorin-3F,1.9553094065218,1.50861736381648,2.5342641327955,4.03319319115419e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545871102699472,CCL18;C-C motif chemokine 18,1.49217596883801,1.32931033564068,1.67499571941906,1.14226363659718e-11
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35724962630792,CCL18;C-C motif chemokine 18,1.3202142030932,1.22605978850389,1.42159914091619,1.85562723149653e-13
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25298582102724,COL4A1;Collagen alpha-1(IV) chain,1.76738345293848,1.49702325204391,2.08657030908235,1.77748213851371e-11
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511503939168267,COL4A1;Collagen alpha-1(IV) chain,1.5537643058492,1.38058121425453,1.74867185878278,2.69651209897855e-13
primary,Circulatory system disorders,I08 (multiple valve diseases),2.15062203210235,COL4A1;Collagen alpha-1(IV) chain,1.34125304795672,1.26506909676772,1.42202488642682,7.52644607950903e-23
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,COL4A1;Collagen alpha-1(IV) chain,1.42979349533971,1.27454676332155,1.60395012419015,1.08309925836606e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,COL4A1;Collagen alpha-1(IV) chain,1.80310243972114,1.67757988891135,1.93801703848403,1.04309310425522e-57
primary,Circulatory system disorders,I33 (acute and subacute endocarditis),0.127383542046367,COL4A1;Collagen alpha-1(IV) chain,1.82425400866225,1.44713440312433,2.29965004006221,3.6214642429265e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60909126718399,COL4A1;Collagen alpha-1(IV) chain,1.35137617688602,1.26289725819148,1.4460539522196,2.88674963460158e-18
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71654410318927,COL4A1;Collagen alpha-1(IV) chain,1.26238764320888,1.18208498307753,1.34814550945189,3.69567326768791e-12
primary,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.18808777429467,COL4A1;Collagen alpha-1(IV) chain,2.14683877106013,1.77893411303138,2.59083047267736,1.6431326483581e-15
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.86725663716814,COL4A1;Collagen alpha-1(IV) chain,1.21880929416747,1.15816606299176,1.28262789164422,2.98454408120348e-14
primary,Circulatory system disorders,I45 (other conduction disorders),1.76368921360672,COL4A1;Collagen alpha-1(IV) chain,1.21127950459083,1.13502536870822,1.29265660371242,7.57183546373095e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,COL4A1;Collagen alpha-1(IV) chain,1.45323393628491,1.31997463386469,1.59994655911442,2.59152730963128e-14
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36916035353535,COL4A1;Collagen alpha-1(IV) chain,1.28670215829671,1.19539876535159,1.38497921543232,1.91054889732511e-11
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.41474940429707,COL4A1;Collagen alpha-1(IV) chain,1.25502320997509,1.21498263041685,1.29638335408613,6.63282998377085e-43
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,COL4A1;Collagen alpha-1(IV) chain,1.43666707301823,1.37874461348347,1.49702291382299,1.00101994057315e-66
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2193167776139,COL4A1;Collagen alpha-1(IV) chain,1.32377808108788,1.26882510984644,1.38111107225865,1.90058047161713e-38
primary,Circulatory system disorders,I63 (cerebral infarction),2.08398867568417,COL4A1;Collagen alpha-1(IV) chain,1.22213062413443,1.15119244289234,1.29744012104056,4.86953106365094e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77276115011964,COL4A1;Collagen alpha-1(IV) chain,1.34305830596374,1.21860817548723,1.48021788258312,2.76483184425249e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,COL4A1;Collagen alpha-1(IV) chain,1.44632808786565,1.31527832199352,1.5904351974558,2.63451185794946e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15754445217045,COL4A1;Collagen alpha-1(IV) chain,1.30704184237876,1.23232773355699,1.38628575111091,4.83243756529114e-19
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0489763933783916,COL4A1;Collagen alpha-1(IV) chain,2.90869574159158,2.04965987290857,4.12776335673054,2.25189474554408e-09
primary,Circulatory system disorders,I81 (portal vein thrombosis),0.0744412012459106,COL4A1;Collagen alpha-1(IV) chain,2.7233656801842,2.04256180791967,3.63108748986109,8.72434244929351e-12
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.09281164695177,COL4A1;Collagen alpha-1(IV) chain,1.23336369252275,1.1610343916992,1.31019891306325,1.0291520152031e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,COL4A1;Collagen alpha-1(IV) chain,3.69111875383935,3.13426919315029,4.34690092501294,3.23564221837744e-55
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.268991380495179,COL4A1;Collagen alpha-1(IV) chain,1.74508544730996,1.48691514844173,2.04808137276998,9.33105317839151e-12
primary,Circulatory system disorders,I95 (hypotension),4.80063010731515,COL4A1;Collagen alpha-1(IV) chain,1.221394197858,1.17414094992228,1.27054915055976,2.94555577354791e-23
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105795227459739,COL4A1;Collagen alpha-1(IV) chain,5.64084248048446,4.46745196462503,7.12242776007303,6.82136351830528e-48
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.254464488571818,ADAMTSL2;ADAMTS-like protein 2,1.74246440429066,1.44222446755653,2.10520780122668,8.65895940962083e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519911002134132,ADAMTSL2;ADAMTS-like protein 2,1.42349992750313,1.24910363359757,1.62224493556653,1.18600687017409e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.05032618825722,ADAMTSL2;ADAMTS-like protein 2,1.26193498801638,1.1819464362582,1.34733678712326,3.32537344986654e-12
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.202024787760475,ADAMTSL2;ADAMTS-like protein 2,1.79398917853495,1.46025706955839,2.20399355688365,2.61823610543792e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.386548125241592,ADAMTSL2;ADAMTS-like protein 2,1.82730395444545,1.57243586530471,2.12348230894933,3.67113537052402e-15
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.55609939759036,ADAMTSL2;ADAMTS-like protein 2,1.21531689188019,1.1764218420293,1.25549789618114,7.04657713627299e-32
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37382666545156,ADAMTSL2;ADAMTS-like protein 2,1.66435670247662,1.53515913627932,1.80442741577434,4.47985763258283e-35
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59954363947518,ADAMTSL2;ADAMTS-like protein 2,1.20292213455165,1.11638776527802,1.29616402723111,1.23197402906325e-06
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.80182232346241,ADAMTSL2;ADAMTS-like protein 2,1.20846844050502,1.1430792698281,1.27759815985137,2.5307907035355e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.754031342266636,ADAMTSL2;ADAMTS-like protein 2,1.41927943062764,1.2755479959291,1.57920682611042,1.29768286132249e-10
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3391530885075,ADAMTSL2;ADAMTS-like protein 2,1.25857658692872,1.16044410223629,1.36500760537503,2.81394359394409e-08
primary,Circulatory system disorders,I50 (heart failure),4.32582211230191,ADAMTSL2;ADAMTS-like protein 2,1.39074877163697,1.32908419684836,1.45527435387182,4.19412999051134e-46
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08907349717318,ADAMTSL2;ADAMTS-like protein 2,1.26073525514704,1.20330410971017,1.32090746698563,2.03668309974162e-22
primary,Circulatory system disorders,I63 (cerebral infarction),2.05420177636073,ADAMTSL2;ADAMTS-like protein 2,1.20508325927596,1.12902290380983,1.28626767170685,2.04514979249367e-08
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.752084706096203,ADAMTSL2;ADAMTS-like protein 2,1.47200110905126,1.32143986693131,1.63971688706496,2.1745371469033e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.772797527047913,ADAMTSL2;ADAMTS-like protein 2,1.71787995906429,1.54474210349078,1.9104234597386,1.81170361558036e-23
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08525133492911,ADAMTSL2;ADAMTS-like protein 2,1.35081103707018,1.26502356430716,1.44241618050015,2.6506088305348e-19
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402217879380084,ADAMTSL2;ADAMTS-like protein 2,1.55519808640964,1.3433665304178,1.80043274356403,3.39856243981679e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.689168903243415,ADAMTSL2;ADAMTS-like protein 2,1.46942956787756,1.31247425074051,1.64515475540537,2.42347346141583e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.213413249784316,ADAMTSL2;ADAMTS-like protein 2,3.8870669631844,3.19408602558854,4.73039531660565,7.7278973720713e-42
primary,Circulatory system disorders,I95 (hypotension),4.54078956371017,ADAMTSL2;ADAMTS-like protein 2,1.23441280058055,1.18101157895744,1.29022863906402,1.02557979687668e-20
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10667029799596,ADAMTSL2;ADAMTS-like protein 2,6.29504583427662,4.81588422389767,8.22852049868661,2.59589055372074e-41
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.512319123973406,F7;Coagulation factor VII,0.689288013320785,0.610640962728043,0.778064352553621,1.74668988422797e-09
primary,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0332336324360252,F7;Coagulation factor VII,0.310612111116739,0.196823915870705,0.490183741877057,5.09055158965109e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550893977415307,F7;Coagulation factor VII,1.47064815887132,1.30545841585099,1.65674063679901,2.22859898084694e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34740227901229,F7;Coagulation factor VII,0.703904155018297,0.652763269797863,0.759051684396175,7.26950117335239e-20
primary,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.187657603065074,F7;Coagulation factor VII,0.556841120840432,0.457181416964099,0.678225366021774,5.91905934334752e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.390580648091377,ADIPOQ;Adiponectin,1.67719640416047,1.42207905154112,1.97808115876564,8.12061143876059e-10
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59062941524998,ADIPOQ;Adiponectin,1.33150592578574,1.22513965491135,1.44710688556631,1.58193445392446e-11
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.2138208934485,ADIPOQ;Adiponectin,1.22893967056943,1.18083145707574,1.27900785912281,4.58698109566022e-24
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.04683150483052,ADIPOQ;Adiponectin,1.25376941644828,1.16370674886299,1.35080229719123,2.74432886639057e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12025316455696,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.26626087462061,1.192774466708,1.34427475381855,1.00209413810674e-14
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,3.36270724216199,3.0076394455298,3.75969267635962,1.12348650667824e-100
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0671299952614121,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,2.70766548199062,1.97171351426024,3.71831521635341,7.50361385966226e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0572805562139527,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,2.58172492832655,1.82777781176274,3.64667059784175,7.33876329890341e-08
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9690922365539,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.26557588824271,1.20230873248626,1.33217224962609,2.2283225358416e-19
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02042834259497,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.36278450379597,1.25078935475197,1.48480765104905,1.50082432134423e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34152382839591,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.56319341877378,1.45090324048356,1.68417410363164,7.43180095192201e-32
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.735919602761676,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.28423033146577,1.16060306522963,1.42102635575098,1.27282947005454e-06
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.610181269482,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.24870411663264,1.16576334904368,1.33754588542729,2.39262649373958e-10
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71217946177321,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.27215097258912,1.19035242856966,1.35957054248554,1.25886403952806e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.782500444602525,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.55394249423458,1.41008158209098,1.71248054442865,5.94342311304667e-19
primary,Circulatory system disorders,I50 (heart failure),4.41132519077885,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.4107382886438,1.35315435301116,1.47077272789826,6.5780910840064e-59
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19838894357284,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.27956790501167,1.22583252140837,1.33565882364979,2.01570536478313e-29
primary,Circulatory system disorders,I63 (cerebral infarction),2.07280581812417,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.21063186247865,1.13946659091271,1.28624175393731,6.25490073458138e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769002668775328,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.38370058745829,1.25367791002311,1.52720830480066,1.11586846894425e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.79898742188118,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.57076683163186,1.42650593292256,1.72961666854052,4.0350842835661e-20
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08381788695067,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.27343536384241,1.17131052361038,1.38446431855321,1.45055516426795e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12868213949576,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.34204075666192,1.26379364864988,1.42513249252818,8.12441929808517e-22
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401415831207609,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.50843789019976,1.31678698523297,1.72798250142769,3.03976633091657e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700643245917862,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.58181296433568,1.42710729106267,1.75328951776096,2.48750490270088e-18
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473914932269657,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,2.98287051345041,2.05272906337585,4.33448167064937,9.94451074041797e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.215321401762079,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.9212306542537,1.60035972291325,2.30643596811152,2.49767425313179e-12
primary,Circulatory system disorders,I95 (hypotension),4.82087922992954,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.30152020984707,1.2507187695849,1.35438509266361,1.74041345792172e-38
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100714878154745,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.98764351283508,1.5232867018246,2.59355427273354,4.18969790556439e-07
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24827695791209,HNMT;Histamine N-methyltransferase,1.57565615166477,1.32121555579007,1.87909709161304,4.19566834466528e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.533216609299456,HNMT;Histamine N-methyltransferase,2.36724739920651,2.10954279069433,2.65643355222272,1.27253068261742e-48
primary,Circulatory system disorders,I15 (secondary hypertension),0.0575545279536388,HNMT;Histamine N-methyltransferase,2.47545370929221,1.74986681263558,3.50190712950263,3.03155064228199e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3439789741956,HNMT;Histamine N-methyltransferase,1.24577197579994,1.1545415367523,1.3442113308925,1.48409884879396e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.782273756105309,HNMT;Histamine N-methyltransferase,1.37785965790268,1.24797284098489,1.52126486613075,2.22334593000037e-10
primary,Circulatory system disorders,I50 (heart failure),4.41432603951872,HNMT;Histamine N-methyltransferase,1.23782812531524,1.18680367286333,1.29104628074225,2.95665864727438e-23
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.613813789952523,HNMT;Histamine N-methyltransferase,1.44034471157475,1.28794800136856,1.61077379362902,1.60646079306341e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.792878008067881,HNMT;Histamine N-methyltransferase,1.35592912909369,1.22870532026905,1.49632607004761,1.38578085328311e-09
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401351082853169,HNMT;Histamine N-methyltransferase,1.48126246171454,1.29028733632214,1.70050377053132,2.41993287284149e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702012568610293,HNMT;Histamine N-methyltransferase,1.30988615866948,1.17945091924655,1.45474620492896,4.55858448051213e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.216351402314364,HNMT;Histamine N-methyltransferase,2.4598766167657,2.05594943535528,2.9431623490609,7.93574781325928e-23
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101196499791654,HNMT;Histamine N-methyltransferase,3.60198752359771,2.82409108159796,4.59415569302823,5.52534559478337e-25
primary,Circulatory system disorders,I85 (oesophageal varices),0.20891048639811,UPB1;Beta-ureidopropionase,2.18109081802003,1.78397183468225,2.66661001253902,2.8540462636602e-14
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102149683335981,UPB1;Beta-ureidopropionase,3.15477227212555,2.39082237208058,4.16283041567454,4.61637132852367e-16
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249070925911283,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.72811603179503,1.45392652770367,2.05401370870075,5.43712624204789e-10
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.50768440598949,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.40189805485712,1.24114198066005,1.58347569161025,5.43636609165566e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12025316455696,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.33690474184988,1.25959147153176,1.41896347282122,1.25568050111226e-21
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.209345499071769,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.71196315155319,1.42378986979532,2.05846234367243,1.08394948886995e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,3.53133524138029,3.1729658655969,3.93018050468957,3.79053234831562e-118
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0671299952614121,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.83427869239872,2.0897644595294,3.84403881956839,2.07793465844819e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0572805562139527,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.61894243477958,1.87598319728783,3.65614120990277,1.55101398366167e-08
primary,Circulatory system disorders,I20 (angina pectoris),3.98857450375675,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.24020684723597,1.18616387794729,1.29671207539448,2.79012566276657e-21
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9690922365539,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.24596470761445,1.18398125934702,1.31119309563815,2.995099688381e-17
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02042834259497,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.42143038709914,1.30575883718468,1.54734878128421,4.64916364888391e-16
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68682726806765,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.28721341352742,1.24913116481406,1.32645667535767,5.30301267934785e-61
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00259299890296,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.26118991052045,1.18559193409854,1.34160830944585,1.86750422965944e-13
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34152382839591,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.66206262803357,1.54307360169779,1.79022710029284,5.63895475977316e-41
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.610181269482,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.27415666596976,1.1893141785831,1.36505158911778,5.52549366116089e-12
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71217946177321,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.41257445719145,1.32259531762405,1.50867508036718,8.15499895847725e-25
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85606691243508,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.27442078834286,1.21094605674572,1.3412227049363,1.36887796944218e-20
primary,Circulatory system disorders,I46 (cardiac arrest),0.782500444602525,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.64940884273117,1.49882999880735,1.81511547850295,1.24310524392782e-24
primary,Circulatory system disorders,I50 (heart failure),4.41132519077885,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.5087685298379,1.44750456977763,1.5726254162907,3.10361148960394e-84
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19838894357284,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.35025613751207,1.29392072489958,1.40904431145155,2.20386036020369e-43
primary,Circulatory system disorders,I63 (cerebral infarction),2.07280581812417,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.29639946269163,1.22062623259562,1.37687649338265,2.96629183211272e-17
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.782252888318356,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.3680589322716,1.23955631995803,1.5098831832276,4.75103090938887e-10
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620774188446482,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.38618225138458,1.24268600959306,1.5462483839203,4.71552822584669e-09
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72257118513087,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.26311009211959,1.19818127812841,1.33155736443027,4.13297446594744e-18
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769002668775328,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.5594837620418,1.41428901867106,1.71958459124378,5.02663400336538e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.79898742188118,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.88592010202318,1.71625205811159,2.07236146602417,1.00580043310122e-39
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08381788695067,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.29394451617797,1.19202138299404,1.40458253084492,7.45725791625263e-10
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12868213949576,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.51292371622547,1.4251153939921,1.60614233820434,5.83664567676386e-42
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401415831207609,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.80702094890977,1.58256050857041,2.0633174479682,2.26416649810856e-18
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700643245917862,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.80052754409,1.62679601336324,1.99281250408554,6.65413694339814e-30
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473914932269657,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.75396676394079,1.91831751249757,3.9536379600768,3.99571803734409e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.215321401762079,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.47846946910978,2.0808215440651,2.95210847217042,2.6317258243428e-24
primary,Circulatory system disorders,I95 (hypotension),4.82087922992954,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.38402300847693,1.32989038897082,1.44035907310822,2.23449083604734e-57
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100714878154745,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.91631200008805,2.27464926417201,3.73898333066896,3.11926689396843e-17
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544137796046193,SORD;Sorbitol dehydrogenase,0.742359744267965,0.660732289671602,0.834071527189183,5.36483874628263e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.208902772354549,SORD;Sorbitol dehydrogenase,1.79095401609396,1.47827116704033,2.16977531543479,2.63833281558434e-09
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10344087280676,SORD;Sorbitol dehydrogenase,2.48893044123107,1.90370148900772,3.25406833847445,2.60486847599486e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.534642878358844,CRIP2;Cysteine-rich protein 2,2.15849034082418,1.92763643313817,2.41699133266865,1.51298736208372e-40
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9690922365539,CRIP2;Cysteine-rich protein 2,1.2267515470941,1.16459585489995,1.2922245532353,1.3219874074392e-14
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02042834259497,CRIP2;Cysteine-rich protein 2,1.2941823024965,1.18625747305309,1.41192605327442,6.45459896155005e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34152382839591,CRIP2;Cysteine-rich protein 2,1.30544993461224,1.21052670227188,1.40781655504229,4.50885616562198e-12
primary,Circulatory system disorders,I50 (heart failure),4.41132519077885,CRIP2;Cysteine-rich protein 2,1.20099023249955,1.15127997515296,1.25284689188456,2.03691099591304e-17
primary,Circulatory system disorders,I63 (cerebral infarction),2.07280581812417,CRIP2;Cysteine-rich protein 2,1.24307882356634,1.16926738821948,1.32154969613248,3.23989841072953e-12
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769002668775328,CRIP2;Cysteine-rich protein 2,1.32084416006673,1.19536094536819,1.45949999616644,4.66335998872813e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.79898742188118,CRIP2;Cysteine-rich protein 2,1.49456062150701,1.35626294011152,1.64696047152608,5.0182422051044e-16
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12868213949576,CRIP2;Cysteine-rich protein 2,1.22986606935121,1.15746098733243,1.306800458154,2.33415477920092e-11
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401415831207609,CRIP2;Cysteine-rich protein 2,1.49408597674234,1.30218183758737,1.71427126493641,1.03794292597781e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700643245917862,CRIP2;Cysteine-rich protein 2,1.44258801672975,1.30048239608685,1.60022172716384,4.34190506250239e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.393423236986332,HEPH;Hephaestin,1.52567663867173,1.31401886184778,1.77142754443834,2.95871455157103e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36945723009615,HEPH;Hephaestin,1.47488337879867,1.36127619985063,1.59797180123716,2.06992457952505e-21
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59527124175548,HEPH;Hephaestin,1.20824740971642,1.12176918447599,1.3013923214234,5.9577751850188e-07
primary,Circulatory system disorders,I50 (heart failure),4.32233089767963,HEPH;Hephaestin,1.22653627195594,1.1720096468535,1.28359969601139,1.35749982574125e-18
primary,Circulatory system disorders,I63 (cerebral infarction),2.05229830076078,HEPH;Hephaestin,1.21340352600139,1.13655832965069,1.29544439427504,6.84516626537042e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.768391379467127,HEPH;Hephaestin,1.42156001150863,1.27750238348674,1.58186230604507,1.10085048681262e-10
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.07383878838097,HEPH;Hephaestin,1.33633533423027,1.25159067732108,1.42681801476394,4.18842035692501e-18
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.682454104961441,HEPH;Hephaestin,1.33369833093669,1.19077168067275,1.49378026603587,6.39359963577997e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102149683335981,HEPH;Hephaestin,2.49082950047473,1.85730152826248,3.3404546897882,1.0975129093715e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3765016381507,CFP;Properdin,0.679982590727263,0.628348286141098,0.735859926557247,1.04739886074303e-21
primary,Circulatory system disorders,I42 (cardiomyopathy),0.691050442135891,CFP;Properdin,0.760544604740262,0.680126184933854,0.850471733941219,1.583004865931e-06
primary,Circulatory system disorders,I45 (other conduction disorders),1.73126732403326,CFP;Properdin,0.797345880150734,0.742916076057082,0.855763488074661,3.43654445514218e-10
primary,Circulatory system disorders,I50 (heart failure),4.31521415993962,CFP;Properdin,0.792454483693112,0.75744437666153,0.829082805384581,6.10190094104976e-24
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250960708964002,THBS2;Thrombospondin-2,1.91437937678616,1.60687767346396,2.28072644158644,3.62431813584052e-13
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519251494072695,THBS2;Thrombospondin-2,1.45780909396612,1.29168390759528,1.64529986164091,1.02022197302252e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14427245796794,THBS2;Thrombospondin-2,1.31241939977559,1.2368288456021,1.39262977818797,2.64528529909761e-19
primary,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0333019902836546,THBS2;Thrombospondin-2,3.61983673341989,2.21991061410428,5.90258810123445,2.51548485735223e-07
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.205700852189244,THBS2;Thrombospondin-2,1.60240323071666,1.32829552707182,1.93307593188361,8.39870606402111e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,THBS2;Thrombospondin-2,1.85228389105806,1.64722227606772,2.08287349128354,7.25450579379575e-25
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01214177830956,THBS2;Thrombospondin-2,1.27121022093762,1.16716446500143,1.38453103591899,3.63135505411501e-08
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,THBS2;Thrombospondin-2,1.84473650733636,1.7115826808708,1.98824913311706,9.32172549458905e-58
primary,Circulatory system disorders,I33 (acute and subacute endocarditis),0.121475734242442,THBS2;Thrombospondin-2,1.92658493209927,1.51188457205153,2.45503497370526,1.14329277360318e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60299330445057,THBS2;Thrombospondin-2,1.26765943237273,1.18300554705129,1.3583710072104,1.74589222941239e-11
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72606994711699,THBS2;Thrombospondin-2,1.239764065415,1.16072483668207,1.3241854480239,1.61220573147082e-10
primary,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.186088421382539,THBS2;Thrombospondin-2,1.80600031584693,1.47821878542235,2.20646441041358,7.25938894437641e-09
primary,Circulatory system disorders,I42 (cardiomyopathy),0.673764437809381,THBS2;Thrombospondin-2,1.29797564551748,1.16811119588786,1.44227774058443,1.24089570936002e-06
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.83692126216455,THBS2;Thrombospondin-2,1.23685261584072,1.17507919863213,1.30187343550361,4.22853142461101e-16
primary,Circulatory system disorders,I45 (other conduction disorders),1.75541941564561,THBS2;Thrombospondin-2,1.21024159725236,1.13410966343646,1.29148421086706,8.59662958829246e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,THBS2;Thrombospondin-2,1.55865242098159,1.41502796516219,1.71685466947878,2.29502517156871e-19
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37675299315568,THBS2;Thrombospondin-2,1.24254771561358,1.15375146311153,1.33817800014983,9.43718334917599e-09
primary,Circulatory system disorders,I50 (heart failure),4.43289393071009,THBS2;Thrombospondin-2,1.44235169651355,1.3836717874299,1.50352015220295,6.18788449193946e-67
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22577303155881,THBS2;Thrombospondin-2,1.30700432104191,1.25250965625743,1.36386996035351,6.93428068406985e-35
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772533871884865,THBS2;Thrombospondin-2,1.35332414553356,1.22677218256677,1.49293101760111,1.5389319214502e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,THBS2;Thrombospondin-2,1.71818996291115,1.56195233758541,1.89005559107669,9.18182339570842e-29
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13543632426848,THBS2;Thrombospondin-2,1.31385691307128,1.23753231505025,1.39488881787712,3.91107295184611e-19
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406001765225066,THBS2;Thrombospondin-2,1.47488602463632,1.29010582001222,1.68613206135829,1.27256889777336e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702842783100361,THBS2;Thrombospondin-2,1.45373324824516,1.31166513016033,1.61118894484533,9.99464725666487e-13
primary,Circulatory system disorders,I81 (portal vein thrombosis),0.0783407430619479,THBS2;Thrombospondin-2,2.64966682106972,1.95950559226478,3.58291106205173,2.46056254127069e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,THBS2;Thrombospondin-2,4.66176135663442,3.86943340632256,5.61633103975905,5.34438750907443e-59
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.268917460005888,THBS2;Thrombospondin-2,1.73915855851687,1.47817695769241,2.04621813100396,2.54103573581833e-11
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.541473750294279,THBS2;Thrombospondin-2,1.37094450620931,1.21623249874769,1.54533680117965,2.41501031775856e-07
primary,Circulatory system disorders,I95 (hypotension),4.81299212598425,THBS2;Thrombospondin-2,1.2126559338957,1.16525613634744,1.26198384041292,2.59238864085894e-21
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,THBS2;Thrombospondin-2,9.73226215147339,7.27600756207897,13.0177059021552,4.60858154898488e-53
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.538603157193779,DCXR;L-xylulose reductase,0.733635566260893,0.647596523093262,0.831105672884274,1.13520388435786e-06
primary,Circulatory system disorders,I85 (oesophageal varices),0.21492350677009,DCXR;L-xylulose reductase,2.17236936377764,1.79889630286094,2.62338003873505,7.59760383255149e-16
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101564483681321,DCXR;L-xylulose reductase,3.18024305505007,2.44001649357486,4.14503177164032,1.14358556118225e-17
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.399990697890746,PENK;Proenkephalin-A,4.4637457274002,3.81558901803744,5.2220052591335,6.1531055109048e-78
primary,Circulatory system disorders,I15 (secondary hypertension),0.0417827298050139,PENK;Proenkephalin-A,3.29290730815931,2.07961983949486,5.21404842087043,3.72570204941227e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.38176903718892,PENK;Proenkephalin-A,1.27048256325101,1.17148631906374,1.37784446754348,7.29942210143799e-09
primary,Circulatory system disorders,I50 (heart failure),4.33509766265398,PENK;Proenkephalin-A,1.20133047450013,1.14705647850355,1.25817249281875,7.45161178925668e-15
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.09991054192758,PENK;Proenkephalin-A,1.21311226394693,1.13542906526496,1.29611035154806,1.05557946168466e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.683848157796799,PENK;Proenkephalin-A,1.35219805425946,1.20530780463184,1.51698974396134,2.7093860269728e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,ITGA5;Integrin alpha-5,1.30263626861294,1.20868793165733,1.40388697848511,4.4317773570662e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,ITGA5;Integrin alpha-5,1.36092664202861,1.23562353068562,1.49893659273029,4.02214049886115e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,ITGA5;Integrin alpha-5,3.43830670266986,2.88661860861679,4.09543295617058,1.4631205314577e-43
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.268917460005888,ITGA5;Integrin alpha-5,1.79416906171004,1.52061979172887,2.11692800495357,4.33744296431813e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,ITGA5;Integrin alpha-5,5.78475374983169,4.54850135628276,7.3570113153796,1.93465719424644e-46
primary,Circulatory system disorders,I70 (atherosclerosis),0.803604517349665,PRCP;Lysosomal Pro-X carboxypeptidase,1.3373627779305,1.21321612461934,1.47421317892158,4.96891292340908e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.220131299553893,PRCP;Lysosomal Pro-X carboxypeptidase,2.59729883845129,2.16671385513637,3.11345277099168,5.68164272284076e-25
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105160662122687,PRCP;Lysosomal Pro-X carboxypeptidase,4.92595354684516,3.83842683001963,6.32160502732636,5.24108275918675e-36
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25298582102724,CCDC80;Coiled-coil domain-containing protein 80,1.6252945742607,1.37046897258066,1.92750256005216,2.37762729918271e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,CCDC80;Coiled-coil domain-containing protein 80,2.69565694459514,2.41013972151952,3.01499796798612,1.65589590760509e-67
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666000666000666,CCDC80;Coiled-coil domain-containing protein 80,2.41359813451124,1.7485782813345,3.33153855169138,8.41571002826931e-08
primary,Circulatory system disorders,I15 (secondary hypertension),0.0568282024651682,CCDC80;Coiled-coil domain-containing protein 80,2.43587375215027,1.71740754757167,3.45490559000063,5.94792762653867e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,CCDC80;Coiled-coil domain-containing protein 80,1.29425088661679,1.20119184282581,1.39451942461388,1.24383353397812e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,CCDC80;Coiled-coil domain-containing protein 80,1.39415460768277,1.26416886253052,1.53750588843994,2.84762243789246e-11
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,CCDC80;Coiled-coil domain-containing protein 80,1.22816618566866,1.17806001422662,1.28040351204871,4.01510775908841e-22
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72464565845603,CCDC80;Coiled-coil domain-containing protein 80,1.21645251023584,1.15390353970044,1.28239203603036,3.46496722296289e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77276115011964,CCDC80;Coiled-coil domain-containing protein 80,1.33319483866425,1.20801412587442,1.47134742861919,1.08781324727826e-08
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,CCDC80;Coiled-coil domain-containing protein 80,1.42498183613921,1.29351600078497,1.56980913424684,7.43269517484168e-13
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15754445217045,CCDC80;Coiled-coil domain-containing protein 80,1.25198812003069,1.17944087450787,1.32899773661993,1.59508240477199e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.710863247191893,CCDC80;Coiled-coil domain-containing protein 80,1.38768073817581,1.252205616879,1.53781280418121,4.07783370378486e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.221460068593826,CCDC80;Coiled-coil domain-containing protein 80,1.65355876721107,1.37810830274949,1.98406510661421,6.31702667406828e-08
primary,Circulatory system disorders,I95 (hypotension),4.80063010731515,CCDC80;Coiled-coil domain-containing protein 80,1.2440752846536,1.19546032403616,1.29466723634998,6.72711770919491e-27
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105795227459739,CCDC80;Coiled-coil domain-containing protein 80,1.92445221361753,1.48268131011952,2.49785054766682,8.65602525933027e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.551018015553558,RARRES2;Retinoic acid receptor responder protein 2,2.49249288935823,2.24717761266782,2.76458824103624,7.05560017893666e-67
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96801825241164,RARRES2;Retinoic acid receptor responder protein 2,1.31595418514063,1.25176052632554,1.38343986806528,5.3021446193312e-27
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0067310506292,RARRES2;Retinoic acid receptor responder protein 2,1.30263174837493,1.19700876900965,1.41757480463424,8.89960523467287e-10
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.70638211793264,RARRES2;Retinoic acid receptor responder protein 2,1.20894664335807,1.17361925716069,1.24533742742314,4.50561551457758e-36
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34490577840331,RARRES2;Retinoic acid receptor responder protein 2,1.28975768081846,1.19791992741746,1.38863611595177,1.4627503405334e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.781737367436057,RARRES2;Retinoic acid receptor responder protein 2,1.35970111801431,1.2360018847954,1.49578018696581,2.72287721906071e-10
primary,Circulatory system disorders,I50 (heart failure),4.42142098847953,RARRES2;Retinoic acid receptor responder protein 2,1.25138231579205,1.20117224084677,1.30369121681762,7.13555255976363e-27
primary,Circulatory system disorders,I63 (cerebral infarction),2.07233626588465,RARRES2;Retinoic acid receptor responder protein 2,1.2521173925633,1.17979883240663,1.32886888992882,1.28982066838818e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.770385973124256,RARRES2;Retinoic acid receptor responder protein 2,1.28638583785199,1.16735577886349,1.41755286073731,3.70421364536275e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.801966867646198,RARRES2;Retinoic acid receptor responder protein 2,1.5730277930941,1.43331668037027,1.7263571070751,1.35031922598087e-21
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08880173271673,RARRES2;Retinoic acid receptor responder protein 2,1.22173201427418,1.12643088327109,1.32509605060537,1.34432625015133e-06
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14947547266728,RARRES2;Retinoic acid receptor responder protein 2,1.29033790197816,1.21662752694148,1.36851408044912,2.00411156573948e-17
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405758651632788,RARRES2;Retinoic acid receptor responder protein 2,1.58827459103777,1.39471301450655,1.80869910174938,3.00793778082529e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701034954110525,RARRES2;Retinoic acid receptor responder protein 2,1.39215300536946,1.25820386769294,1.54036244850601,1.4569737532156e-10
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.247756535310183,CD300E;CMRF35-like molecule 2,1.63472677776845,1.37487622781945,1.94368888186505,2.6296545847163e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516619553562725,CD300E;CMRF35-like molecule 2,1.40793368773094,1.2479544610172,1.58842115715657,2.70847583127567e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12961155572906,CD300E;CMRF35-like molecule 2,1.3327081980553,1.25576880774548,1.41436156895195,2.89344936951498e-21
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.547259792041279,CD300E;CMRF35-like molecule 2,3.59263035531645,3.22622350088919,4.00065056447078,4.30835258056571e-120
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0662509742790335,CD300E;CMRF35-like molecule 2,3.27004402504737,2.41911189645804,4.4202948782173,1.31312292256404e-14
primary,Circulatory system disorders,I15 (secondary hypertension),0.0545808966861598,CD300E;CMRF35-like molecule 2,3.01827806995593,2.15539848080162,4.2265978141493,1.27367800551328e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97650026021858,CD300E;CMRF35-like molecule 2,1.29749287524925,1.23326642859405,1.36506412749902,8.77921600990364e-24
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.101437684099643,CD300E;CMRF35-like molecule 2,2.1737557720577,1.68674563562796,2.80137921020617,1.97825552205452e-09
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02853351028533,CD300E;CMRF35-like molecule 2,1.31076770994298,1.2041383192329,1.42683939376972,4.07770853284642e-10
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72230652503793,CD300E;CMRF35-like molecule 2,1.23846628965853,1.20178249944355,1.27626983362693,3.55487756435736e-44
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00574757893079,CD300E;CMRF35-like molecule 2,1.21507259979065,1.14213476549809,1.29266831494981,6.92991206741866e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35121922603101,CD300E;CMRF35-like molecule 2,1.62052463894618,1.50492291594926,1.74500639042711,1.99666843012331e-37
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.751659508004685,CD300E;CMRF35-like molecule 2,1.31074455387031,1.18603645407276,1.44856532832613,1.12844674084053e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.6066145496581,CD300E;CMRF35-like molecule 2,1.29860838926348,1.21200025118052,1.39140544486101,1.17267182512623e-13
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70549003500948,CD300E;CMRF35-like molecule 2,1.26250696781215,1.18152216763298,1.34904269038595,5.52728679049608e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.774211162681851,CD300E;CMRF35-like molecule 2,1.54136094647265,1.39962982999931,1.69744422159981,1.47588218728827e-18
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37376116180943,CD300E;CMRF35-like molecule 2,1.24162914552062,1.15262409455126,1.33750712161405,1.17934101428629e-08
primary,Circulatory system disorders,I50 (heart failure),4.43238353686114,CD300E;CMRF35-like molecule 2,1.44856516402766,1.38980025561107,1.50981482839912,7.34367256795205e-69
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22250416303227,CD300E;CMRF35-like molecule 2,1.28709737078397,1.2333280593555,1.34321085887296,4.51790437072758e-31
primary,Circulatory system disorders,I63 (cerebral infarction),2.08284440272236,CD300E;CMRF35-like molecule 2,1.26780783897946,1.19376691074617,1.34644100293673,1.08651194782556e-14
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.77600712659606,CD300E;CMRF35-like molecule 2,1.30399577120868,1.18068002834534,1.4401911868647,1.63367222615583e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73937782296697,CD300E;CMRF35-like molecule 2,1.23646313551807,1.17290124907206,1.30346956890421,3.20105198911853e-15
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778460637986537,CD300E;CMRF35-like molecule 2,1.52655844560113,1.38548546141491,1.68199577168877,1.22615687926552e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.806168260784696,CD300E;CMRF35-like molecule 2,1.65606981621373,1.50647484496751,1.8205197686081,1.57585689589727e-25
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08716867705039,CD300E;CMRF35-like molecule 2,1.22891384186105,1.13205533440503,1.33405955064149,8.6022497048323e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15230151985295,CD300E;CMRF35-like molecule 2,1.41955986794414,1.3373248424022,1.50685170482425,1.22117792215265e-30
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409812071892746,CD300E;CMRF35-like molecule 2,1.61107850801444,1.41167102917066,1.83865355692034,1.50293868235791e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699287039749975,CD300E;CMRF35-like molecule 2,1.5954040107328,1.44044156634428,1.76703728699117,3.23425517273734e-19
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0448220758467474,CD300E;CMRF35-like molecule 2,3.18277967602981,2.20644450513771,4.59113584890101,5.88124116109552e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.212512916496071,CD300E;CMRF35-like molecule 2,1.84933475158546,1.54259993355124,2.21706156537188,3.04110810121094e-11
primary,Circulatory system disorders,I95 (hypotension),4.81842754730285,CD300E;CMRF35-like molecule 2,1.33206561595306,1.27989585565188,1.38636186481021,6.11102442386357e-45
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105244693913348,CD300E;CMRF35-like molecule 2,2.29273224094655,1.7845149163327,2.94568629298908,8.60859972403463e-11
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,CTSO;Cathepsin O,1.71679991819295,1.52697533455674,1.93022237648843,1.56175144080259e-19
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,CTSO;Cathepsin O,1.2467193235797,1.15695046568577,1.34345343027778,7.30830472328295e-09
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772200772200772,CTSO;Cathepsin O,1.35718222917915,1.22986110358515,1.49768424892069,1.22823142775614e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,CTSO;Cathepsin O,1.40981918433677,1.28009788877528,1.55268604842838,3.07886546952608e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15212264150943,CTSO;Cathepsin O,1.21238516917742,1.14232657639349,1.28674043729421,2.27384603545181e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.21132221791392,CTSO;Cathepsin O,1.64833959914926,1.36615602349013,1.98880902869522,1.82131150199776e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104659275912861,CTSO;Cathepsin O,2.21862082808342,1.70149257257463,2.89291793460924,3.97088008161132e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.54480852743782,IGSF3;Immunoglobulin superfamily member 3,1.33598169281196,1.18756537261728,1.5029463848336,1.4278224686958e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35482087135126,IGSF3;Immunoglobulin superfamily member 3,1.3274629734629,1.23157811304413,1.4308129766608,1.30867184369898e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,IGSF3;Immunoglobulin superfamily member 3,1.47468598449094,1.33838447193855,1.62486848768062,4.14972238375014e-15
primary,Circulatory system disorders,I85 (oesophageal varices),0.212665406427221,IGSF3;Immunoglobulin superfamily member 3,3.30540640953202,2.81075065560469,3.88711517700414,2.33454281119894e-47
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.270254275738267,IGSF3;Immunoglobulin superfamily member 3,1.76265904056243,1.49573504750113,2.07721741792917,1.32739274458892e-11
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102358174875004,IGSF3;Immunoglobulin superfamily member 3,4.91886091291351,4.01713600391348,6.02299565088596,1.2285641704243e-53
primary,Circulatory system disorders,I85 (oesophageal varices),0.211706681555927,PCBD1;Pterin-4-alpha-carbinolamine dehydratase,2.17241622054259,1.77999799125045,2.6513469444767,2.30132666702782e-14
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109304867555059,PCBD1;Pterin-4-alpha-carbinolamine dehydratase,3.00330873801349,2.29695173343927,3.92688415891201,9.08771835466969e-16
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249490129299249,ACVRL1;Serine/threonine-protein kinase receptor R3,2.03873297376473,1.71880384293098,2.41821203472983,2.8643670499351e-16
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.508538298672259,ACVRL1;Serine/threonine-protein kinase receptor R3,1.36533125733643,1.20818169931064,1.54292143584323,6.00047082493763e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12382367508667,ACVRL1;Serine/threonine-protein kinase receptor R3,1.35492339982525,1.2758444156485,1.43890383253423,4.17937888176462e-23
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.209697521217036,ACVRL1;Serine/threonine-protein kinase receptor R3,1.7396702290789,1.44087736727956,2.10042337722155,8.46720662146786e-09
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.533550191403693,ACVRL1;Serine/threonine-protein kinase receptor R3,4.27123225052648,3.79495253303061,4.80728672602618,5.29452212668753e-128
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0672428455590056,ACVRL1;Serine/threonine-protein kinase receptor R3,3.24152593976058,2.35440375357509,4.46290930439837,5.65218990623911e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0573768870071028,ACVRL1;Serine/threonine-protein kinase receptor R3,2.97207727710005,2.09279868693414,4.22078023854018,1.15367257111747e-09
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96997521634908,ACVRL1;Serine/threonine-protein kinase receptor R3,1.30614378085146,1.24000203668441,1.37581352754757,7.25692571172823e-24
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02016560358147,ACVRL1;Serine/threonine-protein kinase receptor R3,1.3409920862481,1.22968196405022,1.46237793832242,3.21412588534299e-11
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69118764504138,ACVRL1;Serine/threonine-protein kinase receptor R3,1.21899007805442,1.18208660352034,1.25704563943952,1.533851720449e-36
primary,Circulatory system disorders,I26 (pulmonary embolism),2.003996003996,ACVRL1;Serine/threonine-protein kinase receptor R3,1.25997580401815,1.18391907729777,1.34091852826178,3.47470610474566e-13
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34378721714966,ACVRL1;Serine/threonine-protein kinase receptor R3,1.81282427746942,1.68196616877911,1.95386323576769,1.31627802241945e-54
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.733195941661382,ACVRL1;Serine/threonine-protein kinase receptor R3,1.31910210804077,1.19096503075553,1.46102557716052,1.08455916641122e-07
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61091444254405,ACVRL1;Serine/threonine-protein kinase receptor R3,1.35033093163551,1.26000204695107,1.44713544660014,1.85723691265788e-17
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71308335152946,ACVRL1;Serine/threonine-protein kinase receptor R3,1.25165560166321,1.17039969345778,1.33855276443766,5.58431481139518e-11
primary,Circulatory system disorders,I42 (cardiomyopathy),0.676466503997302,ACVRL1;Serine/threonine-protein kinase receptor R3,1.35782519911986,1.22063769361543,1.51043121231497,1.81529149998684e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.783816951031234,ACVRL1;Serine/threonine-protein kinase receptor R3,1.68459580368054,1.52744242017935,1.85791816718359,1.66843819827027e-25
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.34833323225584,ACVRL1;Serine/threonine-protein kinase receptor R3,1.20491673245947,1.16577787924124,1.24536960085891,1.8731576227594e-28
primary,Circulatory system disorders,I50 (heart failure),4.41472906895519,ACVRL1;Serine/threonine-protein kinase receptor R3,1.51140282099694,1.44888138367116,1.57662215351919,7.63822648112591e-82
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20347304666277,ACVRL1;Serine/threonine-protein kinase receptor R3,1.33471816427161,1.27810863648865,1.39383502088744,5.78550073311738e-39
primary,Circulatory system disorders,I63 (cerebral infarction),2.07030707239127,ACVRL1;Serine/threonine-protein kinase receptor R3,1.25662231026316,1.18212621176662,1.33581305865067,2.37190587754794e-13
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.615878170980454,ACVRL1;Serine/threonine-protein kinase receptor R3,1.44283300794601,1.29109082454624,1.61240948292709,1.00447913621448e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72319479179071,ACVRL1;Serine/threonine-protein kinase receptor R3,1.2275436311328,1.16379759049254,1.29478130788787,4.87934089425292e-14
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.768316831683168,ACVRL1;Serine/threonine-protein kinase receptor R3,1.49769576282698,1.35602039998329,1.65417319534244,1.62904832402074e-15
primary,Circulatory system disorders,I70 (atherosclerosis),0.796370768042156,ACVRL1;Serine/threonine-protein kinase receptor R3,1.85646192505282,1.68491524572598,2.04547432751484,6.89651664634278e-36
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08366186580026,ACVRL1;Serine/threonine-protein kinase receptor R3,1.27842891833645,1.17491372866188,1.39106426230998,1.18666596566302e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1322688704792,ACVRL1;Serine/threonine-protein kinase receptor R3,1.49472852208656,1.40698513285674,1.58794382581905,9.12213979245345e-39
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.400110921839717,ACVRL1;Serine/threonine-protein kinase receptor R3,2.12560543505578,1.85667297496641,2.43349180305726,8.68756708125038e-28
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701823949246629,ACVRL1;Serine/threonine-protein kinase receptor R3,1.69481532533712,1.5279015677346,1.87996337437917,1.99319686198885e-23
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0474711711533516,ACVRL1;Serine/threonine-protein kinase receptor R3,2.9729012248021,2.0276415986393,4.35882835426187,2.39849888291626e-08
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.536931367887145,ACVRL1;Serine/threonine-protein kinase receptor R3,1.36599403231518,1.21290518816879,1.53840523935577,2.70857553495226e-07
primary,Circulatory system disorders,I95 (hypotension),4.82504970178926,ACVRL1;Serine/threonine-protein kinase receptor R3,1.35000056899567,1.29682757012085,1.40535378664012,1.61865488277079e-48
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100884220521037,ACVRL1;Serine/threonine-protein kinase receptor R3,1.95758023769581,1.49404119541478,2.56493622717899,1.10490597839248e-06
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.253795287324206,GM2A;Ganglioside GM2 activator,1.70957214017362,1.42434209210678,2.05192061559794,8.51396566981174e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.523511482351846,GM2A;Ganglioside GM2 activator,1.40468025191988,1.23416980570911,1.59874808231919,2.65389808791525e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.06625046589638,GM2A;Ganglioside GM2 activator,1.23240433625683,1.15406560668692,1.31606075012048,4.48362381785934e-10
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.382177479492915,GM2A;Ganglioside GM2 activator,3.94101548336331,3.4688628388926,4.47743360330374,1.71333520874791e-98
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0511627906976744,GM2A;Ganglioside GM2 activator,2.66438692816895,1.81459780919218,3.91213836313285,5.72042354446785e-07
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.94405577708268,GM2A;Ganglioside GM2 activator,1.2256882899143,1.15902635669175,1.29618431484262,9.86616837631887e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.975916523035356,GM2A;Ganglioside GM2 activator,1.27784071929903,1.16163416576798,1.40567224348049,4.65677690645539e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37501167242506,GM2A;Ganglioside GM2 activator,1.48602792073391,1.37173560158892,1.60984301832135,2.99123864631862e-22
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69641815424104,GM2A;Ganglioside GM2 activator,1.22637308725124,1.14063690447377,1.31855364598079,3.41826615121824e-08
primary,Circulatory system disorders,I42 (cardiomyopathy),0.690443423293135,GM2A;Ganglioside GM2 activator,1.33964015235779,1.19630454431255,1.50014956169918,4.09900171676923e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.758810111261114,GM2A;Ganglioside GM2 activator,1.4286541845138,1.28287338825006,1.59100094960498,8.24021560607527e-11
primary,Circulatory system disorders,I50 (heart failure),4.32497125290404,GM2A;Ganglioside GM2 activator,1.35543281864682,1.29482074804829,1.41888221101964,8.35085695024129e-39
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.06015748776277,GM2A;Ganglioside GM2 activator,1.22204084876516,1.16547318692552,1.28135409102818,1.11040807025966e-16
primary,Circulatory system disorders,I63 (cerebral infarction),2.05134189031505,GM2A;Ganglioside GM2 activator,1.23510107943331,1.15628065905031,1.31929446754757,3.47883422006541e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.752159839787625,GM2A;Ganglioside GM2 activator,1.46875579648955,1.31857187057481,1.63604551095212,2.84969976146081e-12
primary,Circulatory system disorders,I70 (atherosclerosis),0.787364890048453,GM2A;Ganglioside GM2 activator,1.49938782612632,1.34926215848641,1.66621722768672,5.26558626150605e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.10417059822608,GM2A;Ganglioside GM2 activator,1.32524092340063,1.24112342527728,1.41505950922115,3.88749560630356e-17
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409893334575434,GM2A;Ganglioside GM2 activator,1.615932929491,1.39730731015045,1.86876516972648,9.75716994704778e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699317000396279,GM2A;Ganglioside GM2 activator,1.60551217467309,1.4363482975195,1.79459908677791,7.79600088978674e-17
primary,Circulatory system disorders,I87 (other disorders of veins),0.42845500058214,GM2A;Ganglioside GM2 activator,1.45037805745205,1.2575598053158,1.67276061197751,3.24375512604139e-07
primary,Circulatory system disorders,I95 (hypotension),4.51836095462939,GM2A;Ganglioside GM2 activator,1.29133006117711,1.23500486257558,1.35022409824529,2.70846135048601e-29
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106996650539635,GM2A;Ganglioside GM2 activator,2.00199381814306,1.51535089069898,2.64491826446501,1.033521686781e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544105846202023,SCG2;Secretogranin-2,4.12128800725185,3.66541137591354,4.63386318663474,6.10660089138437e-124
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0663414634146341,SCG2;Secretogranin-2,2.79948437217503,2.02014933295412,3.87947198863352,6.24480949411638e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.054655475307437,SCG2;Secretogranin-2,2.97803305971416,2.07984646780201,4.26410364517097,2.549122229428e-09
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.03187476792589,SCG2;Secretogranin-2,1.2415501954134,1.14076195865007,1.35124324232825,5.47953879324044e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35317732301968,SCG2;Secretogranin-2,1.24787357050408,1.15831624486379,1.34435518354119,5.61650156559324e-09
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60885261340448,SCG2;Secretogranin-2,1.20450243497451,1.12483714593011,1.28980992591585,9.85219763863119e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.779175128886111,SCG2;Secretogranin-2,1.41668966488398,1.28564021661313,1.56109740552169,2.01625822935366e-12
primary,Circulatory system disorders,I50 (heart failure),4.4305293005671,SCG2;Secretogranin-2,1.26328215900228,1.2118267193732,1.31692245082607,3.21962697861035e-28
primary,Circulatory system disorders,I70 (atherosclerosis),0.80140734949179,SCG2;Secretogranin-2,1.40331135429403,1.27474762579363,1.54484128249661,4.79481397181645e-12
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15326155794806,SCG2;Secretogranin-2,1.23610749225037,1.16474547903189,1.31184173701837,2.81897195173378e-12
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408418501944384,SCG2;Secretogranin-2,1.54792827343076,1.35415548782286,1.76942896235543,1.52287217523035e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.694362946446035,SCG2;Secretogranin-2,1.33686688986637,1.20548177359448,1.48257163266095,3.78503088815603e-08
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.044883303411131,SCG2;Secretogranin-2,3.69544262792534,2.49213858303319,5.47974992613236,7.87957815142757e-11
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.514704215132757,CFD;Complement factor D,1.58001171076807,1.38669791725598,1.80027457681933,6.43120202401794e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.390580648091377,CFD;Complement factor D,3.45983702265879,3.03433165504898,3.94501115375512,1.01911609671571e-76
primary,Circulatory system disorders,I15 (secondary hypertension),0.0430663221360895,CFD;Complement factor D,2.79254228088318,1.85033995580966,4.2145187245378,1.00650964898189e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3765016381507,CFD;Complement factor D,1.44844854910674,1.33624421140602,1.57007467759344,2.1376486681652e-19
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59062941524998,CFD;Complement factor D,1.22238903571432,1.13393086931533,1.31774784078047,1.61016018991031e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.757575757575757,CFD;Complement factor D,1.39905609546409,1.25522447277217,1.55936886247318,1.30449039017511e-09
primary,Circulatory system disorders,I50 (heart failure),4.31521415993962,CFD;Complement factor D,1.26833027029015,1.21116466389611,1.32819402884452,5.42077107713126e-24
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.746556536340738,CFD;Complement factor D,1.37438574527998,1.23215646616843,1.53303271840362,1.15956502361547e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.676903507177902,CFD;Complement factor D,1.32797174614315,1.18378880058898,1.48971586627369,1.31697665785906e-06
primary,Circulatory system disorders,I95 (hypotension),4.56233059244242,CFD;Complement factor D,1.20830151627775,1.15571959231826,1.26327576684108,7.73370932803297e-17
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246362754607177,HGF;Hepatocyte growth factor,1.58125489050429,1.3331291043469,1.87556255473746,1.42850788582565e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,HGF;Hepatocyte growth factor,1.57588239190397,1.40427589117469,1.76845969422403,1.06073476575101e-14
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9698634499781,HGF;Hepatocyte growth factor,1.33981688123887,1.27371336686657,1.40935105334472,9.11910275342242e-30
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02086365841824,HGF;Hepatocyte growth factor,1.3047590463717,1.1981965738303,1.42079872891533,9.38689169880474e-10
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.70895041854475,HGF;Hepatocyte growth factor,1.25668957395696,1.2197294681308,1.29476964077313,7.20755931290236e-51
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,HGF;Hepatocyte growth factor,1.55848725789869,1.44811462895135,1.67727228526893,2.43205255333055e-32
primary,Circulatory system disorders,I46 (cardiac arrest),0.77379567139865,HGF;Hepatocyte growth factor,1.51071949674972,1.37100967928358,1.66466614521082,7.86040098244079e-17
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37587822014051,HGF;Hepatocyte growth factor,1.20126832255446,1.11563224556323,1.29347783600885,1.17507594760449e-06
primary,Circulatory system disorders,I50 (heart failure),4.42893177685223,HGF;Hepatocyte growth factor,1.34288045774891,1.28863576928059,1.39940855809913,1.28240518671184e-44
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22046561138599,HGF;Hepatocyte growth factor,1.20899295413708,1.15865832097088,1.26151423305562,2.18610809660912e-18
primary,Circulatory system disorders,I63 (cerebral infarction),2.07125909214671,HGF;Hepatocyte growth factor,1.2915329660103,1.21639877764694,1.37130802245472,5.96110998248289e-17
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.775560017322152,HGF;Hepatocyte growth factor,1.3129220788047,1.18966149082448,1.4489536715341,6.21108597566555e-08
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.618948757251789,HGF;Hepatocyte growth factor,1.40446186923288,1.25954358543118,1.56605389836816,9.79161010341523e-10
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772200772200772,HGF;Hepatocyte growth factor,1.47380184424402,1.33739018344129,1.6241272763854,5.01143899818517e-15
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,HGF;Hepatocyte growth factor,1.66161167945061,1.5120871177101,1.8259221581544,4.84911615505262e-26
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07917159993012,HGF;Hepatocyte growth factor,1.2953698646081,1.19212271494672,1.40755902483563,1.01679474291129e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15212264150943,HGF;Hepatocyte growth factor,1.31863046912234,1.2428195011235,1.39906584385419,5.4051227870584e-20
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405604719764011,HGF;Hepatocyte growth factor,1.70740489044283,1.4953899327775,1.94947912648671,2.61111562043273e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699300699300699,HGF;Hepatocyte growth factor,1.51707021078821,1.37007248263637,1.67983960967693,1.10064395361434e-15
primary,Circulatory system disorders,I85 (oesophageal varices),0.21132221791392,HGF;Hepatocyte growth factor,2.94357906883495,2.48503724648115,3.48673153561482,7.86557845142758e-36
primary,Circulatory system disorders,I95 (hypotension),4.80141802528292,HGF;Hepatocyte growth factor,1.24189725284247,1.19377157074812,1.29196307267657,6.3650631509417e-27
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104659275912861,HGF;Hepatocyte growth factor,4.3220440136698,3.46514236463536,5.39085050205858,1.53318004428201e-38
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13225901542694,TGFA;Protransforming growth factor alpha,1.23896765463464,1.16728821549089,1.31504869907843,1.82579669748588e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,TGFA;Protransforming growth factor alpha,2.43856634612848,2.17455378569659,2.73463266973896,1.7175425342369e-52
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96630662582621,TGFA;Protransforming growth factor alpha,1.29502080880658,1.23043051366054,1.36300171088306,4.00865692465889e-23
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01780170550556,TGFA;Protransforming growth factor alpha,1.31518105080043,1.20674117989095,1.43336551798194,4.36839249962458e-10
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.71982890314696,TGFA;Protransforming growth factor alpha,1.24830946683389,1.2113082962618,1.28644089188201,2.61568462394926e-47
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35063298615896,TGFA;Protransforming growth factor alpha,1.50802398851051,1.39951727703358,1.62494339101223,4.16772003591056e-27
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.7092670631326,TGFA;Protransforming growth factor alpha,1.24823909881828,1.16781481157307,1.33420199194072,6.78077511687575e-11
primary,Circulatory system disorders,I45 (other conduction disorders),1.73485444531864,TGFA;Protransforming growth factor alpha,1.25686700273371,1.17656848329096,1.34264574055412,1.14327095031367e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.787339734150124,TGFA;Protransforming growth factor alpha,1.51318868706072,1.37289582572941,1.66781773222453,7.17605275537317e-17
primary,Circulatory system disorders,I50 (heart failure),4.40480668342802,TGFA;Protransforming growth factor alpha,1.36051417382447,1.30503214259036,1.41835496365876,1.34936188408176e-47
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20325722497205,TGFA;Protransforming growth factor alpha,1.22494776107964,1.17357316865004,1.27857133876028,1.66880936312845e-20
primary,Circulatory system disorders,I63 (cerebral infarction),2.06544853114909,TGFA;Protransforming growth factor alpha,1.23100807229367,1.15858218082478,1.30796148873392,1.84431353392571e-11
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.765336628532706,TGFA;Protransforming growth factor alpha,1.29468745456774,1.17121111894905,1.43118143082451,4.41067375905494e-07
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.616811047596597,TGFA;Protransforming growth factor alpha,1.44032624378743,1.29009522161119,1.60805160254135,8.46323254638623e-11
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71488758514785,TGFA;Protransforming growth factor alpha,1.21726853025472,1.15449356860947,1.28345684639297,3.39073335938174e-13
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781802467195725,TGFA;Protransforming growth factor alpha,1.35047274558057,1.22428170695448,1.48967074015403,1.93903034842926e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.801823755994025,TGFA;Protransforming growth factor alpha,1.64934881863896,1.49835050624931,1.81556419155578,1.71209730733066e-24
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08672155953386,TGFA;Protransforming growth factor alpha,1.27835137651951,1.17615967722903,1.38942209420015,7.60953025276249e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15077296512206,TGFA;Protransforming growth factor alpha,1.38481314170785,1.30456199313291,1.47000100228383,1.14898582651357e-26
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.390978034500373,TGFA;Protransforming growth factor alpha,1.70548441047168,1.48690338241857,1.95619776560782,2.36833514291501e-14
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686372844022262,TGFA;Protransforming growth factor alpha,1.50448177573187,1.35515229609406,1.67026644904287,1.88598906323923e-14
primary,Circulatory system disorders,I85 (oesophageal varices),0.217869199968595,TGFA;Protransforming growth factor alpha,1.61976569768828,1.34726022665952,1.94738986833509,2.87535272922359e-07
primary,Circulatory system disorders,I95 (hypotension),4.8255733696188,TGFA;Protransforming growth factor alpha,1.26289779980893,1.21367258609723,1.31411953358109,1.22412386411791e-30
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550567340897878,IGFBP6;Insulin-like growth factor-binding protein 6,4.99523651487527,4.48402851730806,5.56472550146116,1.91022211086164e-187
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0649171814140142,IGFBP6;Insulin-like growth factor-binding protein 6,2.97899471693864,2.11297863506263,4.19995232147026,4.70409903358583e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0570708859763057,IGFBP6;Insulin-like growth factor-binding protein 6,3.76654600395825,2.65280276858441,5.34787921964672,1.21739516127691e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00882723833543,IGFBP6;Insulin-like growth factor-binding protein 6,1.27734990565457,1.15802242235105,1.40897339290129,9.98282069525822e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.783572539523162,IGFBP6;Insulin-like growth factor-binding protein 6,1.3556234167361,1.21283874260038,1.51521779726718,8.41144217829913e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.704030922142462,IGFBP6;Insulin-like growth factor-binding protein 6,1.33596349773015,1.18865266434217,1.50153070010163,1.17874058793404e-06
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24885778166618,STC1;Stanniocalcin-1,1.54318412874914,1.29837240374121,1.83415578485901,8.53665797439221e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.535644721464744,STC1;Stanniocalcin-1,2.03000627672532,1.8087176720248,2.27836856314394,2.68264899755911e-33
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96840089371209,STC1;Stanniocalcin-1,1.20354568704993,1.14372311069273,1.26649729053664,1.0600011118475e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34671603975833,STC1;Stanniocalcin-1,1.28667665591875,1.19367197869314,1.38692777114429,4.5604248868658e-11
primary,Circulatory system disorders,I46 (cardiac arrest),0.777423618129518,STC1;Stanniocalcin-1,1.34807352714873,1.22213027836496,1.48699550839253,2.39470008471588e-09
primary,Circulatory system disorders,I50 (heart failure),4.42118878240931,STC1;Stanniocalcin-1,1.20510659130544,1.15606102159659,1.25623290577008,1.35900479729511e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.795642447232759,STC1;Stanniocalcin-1,1.34710767483306,1.22245911789787,1.48446607418225,1.80320388911289e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.21954963181721,STC1;Stanniocalcin-1,2.03092482742841,1.6961740337475,2.43174083118827,1.26245038440236e-14
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102942604642128,STC1;Stanniocalcin-1,2.62716922672182,2.03289037494416,3.39517478704366,1.55740566268119e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545479608514995,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.722996908591479,0.642638329000722,0.813403910478934,6.83273144192076e-08
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0647871839170724,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.437078645046219,0.312587171754774,0.611150294117981,1.30549002861524e-06
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34964731843795,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.711247286423639,0.659645044962407,0.766886231175768,7.53109413770751e-19
primary,Circulatory system disorders,I50 (heart failure),4.41406636948984,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.782608814581222,0.75058266804646,0.81600146490768,1.3471142391725e-30
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.782355716307595,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.764669157882012,0.69295700723702,0.84380259512404,9.28230945775499e-08
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.09345500314663,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.784035350702691,0.721786302918687,0.851652945845305,8.19395970780631e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37793011432909,TTR;Transthyretin,0.71479626174446,0.657341563899756,0.777272766341869,4.04640588789535e-15
primary,Circulatory system disorders,I85 (oesophageal varices),0.210917260826703,TTR;Transthyretin,0.390184035836497,0.317880855626382,0.478932842689322,2.24543625334027e-19
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.268761629108951,TTR;Transthyretin,0.559624406028549,0.464772390907077,0.673834078680075,9.00256860044121e-10
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107714167850758,TTR;Transthyretin,0.273899917040121,0.208580012432472,0.359675712354623,1.20445600256422e-20
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545118271196339,LAMP3;Lysosome-associated membrane glycoprotein 3,1.88902690386031,1.69189575819706,2.10912677463692,1.15185615869727e-29
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96674375947045,LAMP3;Lysosome-associated membrane glycoprotein 3,1.35201032847642,1.28592500750711,1.42149185810651,4.12983887721541e-32
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00756758876232,LAMP3;Lysosome-associated membrane glycoprotein 3,1.26470229748149,1.19046678788921,1.34356700877892,2.76453406898738e-14
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34982469809115,LAMP3;Lysosome-associated membrane glycoprotein 3,1.58438905171709,1.47472052950256,1.70221314274898,2.91659833380712e-36
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.752625437572928,LAMP3;Lysosome-associated membrane glycoprotein 3,1.29001363872667,1.1692885360753,1.42320320156945,3.78181022154139e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.775058275058275,LAMP3;Lysosome-associated membrane glycoprotein 3,1.37541471289363,1.24910884907602,1.51449221886757,8.82333767999314e-11
primary,Circulatory system disorders,I50 (heart failure),4.42838396302172,LAMP3;Lysosome-associated membrane glycoprotein 3,1.33204817817794,1.27902923649561,1.38726488680485,1.55182258814919e-43
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21931764334228,LAMP3;Lysosome-associated membrane glycoprotein 3,1.23894633899094,1.18791713360896,1.29216759946518,1.78279185487944e-23
primary,Circulatory system disorders,I63 (cerebral infarction),2.07265997857212,LAMP3;Lysosome-associated membrane glycoprotein 3,1.23822213522773,1.16666404535904,1.3141692865799,1.98833128663277e-12
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773446305725057,LAMP3;Lysosome-associated membrane glycoprotein 3,1.37790413700924,1.25137408283926,1.51722801105116,6.89688400272655e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.802986409503626,LAMP3;Lysosome-associated membrane glycoprotein 3,1.80258807665991,1.6448614828999,1.97543915271692,1.81074740792282e-36
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08093395804576,LAMP3;Lysosome-associated membrane glycoprotein 3,1.36592781437895,1.2585257469431,1.48249552988956,8.44460786664813e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1537128907788,LAMP3;Lysosome-associated membrane glycoprotein 3,1.46412769046115,1.38157648019334,1.55161145597609,6.13817891197149e-38
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406267008786253,LAMP3;Lysosome-associated membrane glycoprotein 3,1.93157438330595,1.70031362550822,2.19428906660004,4.58276001715169e-24
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700443614289049,LAMP3;Lysosome-associated membrane glycoprotein 3,1.60102790303079,1.44925088912148,1.76870020610235,2.01349434578593e-20
primary,Circulatory system disorders,I95 (hypotension),4.79739352673781,LAMP3;Lysosome-associated membrane glycoprotein 3,1.2694800241293,1.22086730039605,1.32002841843706,4.67630623200613e-33
primary,Circulatory system disorders,I85 (oesophageal varices),0.210737581535373,GSTA3;Glutathione S-transferase A3,1.78256753534731,1.4724629033789,2.15798103353406,3.06479239725342e-09
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102329500993198,GSTA3;Glutathione S-transferase A3,2.10218750354248,1.60189960611261,2.75871988680639,8.42007228285992e-08
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.552767759134389,CES1;Liver carboxylesterase 1,0.727414467531644,0.64954139325164,0.814623691533317,3.61011580604125e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.220931823958394,CES1;Liver carboxylesterase 1,1.98601227396999,1.65003046269772,2.39040723279181,3.98754352259961e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105542959893675,CES1;Liver carboxylesterase 1,3.47569440809864,2.69622792364786,4.48050089257438,6.8915323175977e-22
primary,Circulatory system disorders,I85 (oesophageal varices),0.213744152282626,PTS;6-pyruvoyl tetrahydrobiopterin synthase,2.99769687071202,2.49323616011285,3.60422597443393,1.66035769238401e-31
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102812216510432,PTS;6-pyruvoyl tetrahydrobiopterin synthase,4.57368204376899,3.5569930184786,5.88096949553253,2.08716281939475e-32
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13059890259563,RSPO3;R-spondin-3,1.23629535355691,1.16491200125817,1.31205292723881,2.74073071383242e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,RSPO3;R-spondin-3,3.68327472677333,3.31432358365936,4.09329758258194,1.71706285021584e-129
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0660399347370056,RSPO3;R-spondin-3,2.70258698384755,1.9809386557173,3.68712902046803,3.54314863477734e-10
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544069640914037,RSPO3;R-spondin-3,3.52490076460434,2.54747010666839,4.87735866567546,2.88111823565153e-14
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97515713858126,RSPO3;R-spondin-3,1.22925847900904,1.16781592796189,1.29393372023347,3.0256819867548e-15
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00521906331547,RSPO3;R-spondin-3,1.25006898295304,1.17555188546296,1.32930964720952,1.097369534363e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,RSPO3;R-spondin-3,1.38883719561864,1.28923041323554,1.49613966295833,5.12682809769128e-18
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60931213624467,RSPO3;R-spondin-3,1.29601568302798,1.21028612372168,1.38781782070629,1.12074252195245e-13
primary,Circulatory system disorders,I45 (other conduction disorders),1.75073028237585,RSPO3;R-spondin-3,1.20373673938942,1.12712899877177,1.2855512894574,3.25792004223804e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.777574744372302,RSPO3;R-spondin-3,1.54882314610009,1.4051438394558,1.70719400429811,1.27794460019388e-18
primary,Circulatory system disorders,I50 (heart failure),4.43006958737626,RSPO3;R-spondin-3,1.30987236800804,1.25633453868108,1.3656916749835,7.87161931071855e-37
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22702211331343,RSPO3;R-spondin-3,1.24434922539805,1.192279795416,1.29869263968234,1.19763376453529e-23
primary,Circulatory system disorders,I63 (cerebral infarction),2.07622575299736,RSPO3;R-spondin-3,1.22744277182877,1.15554194880496,1.30381745091368,2.85153669849004e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77792255780937,RSPO3;R-spondin-3,1.34528957698542,1.21970436341459,1.48380550257196,2.99213234667516e-09
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,RSPO3;R-spondin-3,1.34072525425237,1.21717805318448,1.47681286454944,2.77400936496551e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15331271301641,RSPO3;R-spondin-3,1.24191372193558,1.16999993567251,1.31824767310381,1.08897971421981e-12
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,RSPO3;R-spondin-3,1.54826926957634,1.35376004274809,1.77072572348075,1.74965475654636e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697054070367413,RSPO3;R-spondin-3,1.29346856168823,1.16598707872541,1.43488804516146,1.16919588214291e-06
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0446792804693267,RSPO3;R-spondin-3,2.96028174227133,2.04379888563508,4.28773498959115,9.37802825033424e-09
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.6683941955031,RSPO3;R-spondin-3,1.22917195406591,1.14840925227695,1.31561435060421,2.67167795329119e-09
primary,Circulatory system disorders,I95 (hypotension),4.82261749028642,RSPO3;R-spondin-3,1.25579275857585,1.20685425054317,1.30671574614894,2.88487241554555e-29
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545305292783988,DPY30;Protein dpy-30 homolog,2.09966758855084,1.8781150893331,2.34735560533533,7.44888020655483e-39
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35711212796746,DPY30;Protein dpy-30 homolog,1.37398292343843,1.27699062036849,1.47834216147623,1.79946705085179e-17
primary,Circulatory system disorders,I46 (cardiac arrest),0.778081123244929,DPY30;Protein dpy-30 homolog,1.3288833569271,1.2062280029073,1.46401092667515,8.67742726623138e-09
primary,Circulatory system disorders,I50 (heart failure),4.43220922229869,DPY30;Protein dpy-30 homolog,1.20098904747304,1.15272721577708,1.25127148245378,2.09743371985046e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.80418488444722,DPY30;Protein dpy-30 homolog,1.45012573919329,1.31927134295323,1.59395917352646,1.33536345628103e-14
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15221644696535,DPY30;Protein dpy-30 homolog,1.22702333271609,1.15684883777502,1.30145461521612,9.82811176877264e-12
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405893257878817,DPY30;Protein dpy-30 homolog,1.54719954908465,1.35497845726475,1.76668967086022,1.13215186612115e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.691433259111684,DPY30;Protein dpy-30 homolog,1.34789108829618,1.21647017625255,1.49351001066472,1.17236192540794e-08
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25298582102724,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.99990600471596,2.53194233088778,3.55436059002789,6.21794436877654e-37
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511503939168267,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.23730553000802,1.98534620446443,2.52124089156269,7.69290406197281e-40
primary,Circulatory system disorders,I08 (multiple valve diseases),2.15062203210235,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.01197499411557,1.8981518860862,2.13262353061377,2.0544141086125e-122
primary,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0333091678586123,NTproBNP;N-terminal prohormone of brain natriuretic peptide,4.85061136844344,3.04271312290313,7.73271409340873,3.21114233215093e-11
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.211615330355043,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.09651594651913,1.75489690090405,2.50463666084581,3.42543642682565e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.72927883377031,2.43635853733856,3.05741656587366,2.64659844154626e-67
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0666000666000666,NTproBNP;N-terminal prohormone of brain natriuretic peptide,3.87952592315006,2.85003759633972,5.28088520927683,6.9059892616476e-18
primary,Circulatory system disorders,I15 (secondary hypertension),0.0568282024651682,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.89714957937911,2.07551698654634,4.04404094965434,4.07425526935412e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9707155076985,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.21218894693554,1.15073248917226,1.27692757169796,4.20297255707669e-13
primary,Circulatory system disorders,I22 (subsequent myocardial infarction),0.103933796132878,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.84793486297783,2.23572646549592,3.62778412696629,2.34244344831312e-17
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02218995860228,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.45465258725269,1.3373197358301,1.58227990876654,2.45734364612116e-18
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.70175581371691,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.39379198974629,1.35117526627727,1.43775286535054,1.64292258042384e-97
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.64740006580524,2.45838442155776,2.85094838991231,2.45564775238844e-146
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.749769377220357,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.44053100328586,1.30401275547459,1.59134146711052,6.70518251739038e-13
primary,Circulatory system disorders,I33 (acute and subacute endocarditis),0.127383542046367,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.95603614024015,1.55404684602163,2.46200903899412,1.09145539707236e-08
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60909126718399,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.17733643888352,2.03343208960669,2.3314247829181,3.4167640067127e-110
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71654410318927,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.52306639951661,1.42662538120666,1.62602690790096,1.9568698341667e-36
primary,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.18808777429467,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.10325572906534,1.73106616222784,2.55546827635576,7.29293081450959e-14
primary,Circulatory system disorders,I37 (pulmonary valve disorders),0.21159460041927,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.88354749265134,1.57007006534702,2.25961327164658,9.28882934010497e-12
primary,Circulatory system disorders,"I38 (endocarditis, valve unspecified)",0.250877089825758,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.82927153786623,1.54454186746635,2.16648990210709,2.63367121162876e-12
primary,Circulatory system disorders,I42 (cardiomyopathy),0.683787554280549,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.66184307790892,2.40425000064696,2.9470348630571,2.7925641119991e-79
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.86725663716814,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.65362316418273,1.5721273633381,1.73934353722817,9.81460799977637e-85
primary,Circulatory system disorders,I45 (other conduction disorders),1.76368921360672,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.54261756465721,1.4473135002558,1.64419730097753,1.70942116120783e-40
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.92942451928542,1.75610256891873,2.11985281583632,1.24223516971665e-42
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36916035353535,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.82785531057287,1.69826904608811,1.967329643136,3.75062035407722e-58
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.41474940429707,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.91827538875038,1.85518678993445,1.98350941643748,0.0
primary,Circulatory system disorders,I49 (other cardiac arrhythmias),1.99555661350472,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.55878276622871,1.46574510517925,1.65772596047283,2.23325572529705e-45
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.18901241291443,2.09731856573181,2.28471507485154,5.29901821192655e-282
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2193167776139,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.90803716360791,1.82773992318895,1.99186206501251,1.18754240058845e-190
primary,Circulatory system disorders,I63 (cerebral infarction),2.08398867568417,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.45009225316142,1.36593784426781,1.5394313522413,3.82615962181715e-34
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.774190980376547,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.50887818042116,1.36729811483837,1.6651184834115,2.7700809885691e-16
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.611968695447502,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.3331681542932,1.19456862767694,1.48784865636217,2.83251598987646e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72464565845603,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.29207993727494,1.22558294852998,1.36218488215005,1.98790857151297e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77276115011964,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.55678029612285,1.41282841516828,1.71539931132237,3.85364176661108e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.60065440542119,1.45579248295188,1.7599311410093,2.4953959601082e-22
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08706316347153,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.38964323441225,1.28262841429536,1.5055867291141,8.42537699590166e-16
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15754445217045,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.49709745951496,1.41073435675091,1.58874758565328,2.00231850946178e-40
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.413944637357032,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.54307893725564,1.35393501427101,1.75864615472997,7.94142967476761e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.710863247191893,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.4877960506358,1.3439467268131,1.64704228532662,1.89142303171727e-14
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0489763933783916,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.72058594571673,1.90503197862574,3.88528275172093,3.69602381310812e-08
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.09281164695177,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.30703122571508,1.22865478116529,1.39040733913396,2.12810010259246e-17
primary,Circulatory system disorders,I87 (other disorders of veins),0.455000098060365,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.55016156488767,1.3632852866721,1.7626544500608,2.26046677360794e-11
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.531789638932496,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.47837790494212,1.30976896273864,1.66869218312451,2.4900215374635e-10
primary,Circulatory system disorders,I95 (hypotension),4.80063010731515,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.4278164069874,1.3716754940617,1.48625509523809,8.02946790668001e-68
primary,Circulatory system disorders,I08 (multiple valve diseases),2.1177475396471,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.27144321902465,1.19779957727116,1.349614651632,3.05361386515435e-15
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.205466175615429,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.63844173111334,1.35557773484554,1.98033003733244,3.28633965258696e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544228264883671,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,4.4587756958196,3.98658582071388,4.98689394878536,5.24624855924878e-151
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0658825353149766,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,2.9126357696648,2.11088778732312,4.01890009392163,7.6053170047704e-11
primary,Circulatory system disorders,I15 (secondary hypertension),0.0542772403900207,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,2.6700691336029,1.86408649102584,3.82453776288866,8.46920575237011e-08
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.9698634499781,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.21275842186513,1.15238828069987,1.27629117237427,1.31808004486381e-13
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02086365841824,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.34077371808763,1.23084633053393,1.46051876543737,1.83306944429181e-11
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00822078684674,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.21086750267664,1.13861842698281,1.28770101931654,1.08986542092289e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34761978842563,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.47609282735007,1.36933117411063,1.59117828918886,2.81886064097441e-24
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61513433475558,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.21184590703826,1.13152983587691,1.29786281885114,3.97823099004537e-08
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69610207733603,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.23383767440172,1.15442827203486,1.31870939377607,5.98124171533685e-10
primary,Circulatory system disorders,I46 (cardiac arrest),0.77379567139865,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.51321024819655,1.37187721397006,1.66910364275286,1.23167502196284e-16
primary,Circulatory system disorders,I50 (heart failure),4.42893177685223,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.374489623369,1.31825734459305,1.43312057581008,2.27780091782381e-50
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22046561138599,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.23966317235772,1.18780313731536,1.29378744054621,6.62508687179393e-23
primary,Circulatory system disorders,I63 (cerebral infarction),2.07125909214671,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.26036614302397,1.18656766615502,1.33875450999656,5.61643515838379e-14
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.775560017322152,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.30960502215842,1.18552139306848,1.44667597235294,1.0914541756931e-07
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.618948757251789,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.37073815239194,1.22803210036573,1.53002766121773,1.8865108653269e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73413192283758,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.25248745367482,1.18823910960712,1.3202097195164,5.32125208174607e-17
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772200772200772,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.53066166545222,1.38706379348876,1.68912572376503,2.46057642724958e-17
primary,Circulatory system disorders,I70 (atherosclerosis),0.803618223110817,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.71075367594804,1.55332753436236,1.88413459172416,1.13379506626673e-27
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15212264150943,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.36645237247213,1.28705684998729,1.450745618776,1.56711282795199e-24
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405604719764011,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.78336441132001,1.55812010117004,2.04117039577021,4.56140913331858e-17
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699300699300699,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.54966664275416,1.3969827624068,1.71903817877293,1.26218344418119e-16
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0445727795972946,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,3.38485658121626,2.30546012962201,4.96961709647154,4.8789790146168e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.21132221791392,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,2.05200574484568,1.7049481670186,2.4697100230577,2.87537351278501e-14
primary,Circulatory system disorders,I95 (hypotension),4.80141802528292,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.31758695552112,1.26592202713192,1.37136043780879,1.29967650387512e-41
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104659275912861,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,2.61605521274775,2.02086634136202,3.38654008732322,2.84450133601605e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.809951402915825,MVK;Mevalonate kinase,1.306045702287,1.1840030183651,1.440668097973,9.58720060666038e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.207721652985,MVK;Mevalonate kinase,2.17442747786921,1.79577005642828,2.6329288872968,1.76203415971159e-15
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0998382620155348,MVK;Mevalonate kinase,3.28707328788295,2.50388935867373,4.31522693384376,1.03461928335833e-17
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246966397013067,SMOC1;SPARC-related modular calcium-binding protein 1,1.54796960289595,1.30357504443776,1.83818331112908,6.23280013780663e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,SMOC1;SPARC-related modular calcium-binding protein 1,2.24886864324628,2.0069460167682,2.5199532684593,2.88052127296054e-44
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0660399347370056,SMOC1;SPARC-related modular calcium-binding protein 1,2.34692996378282,1.69532842464033,3.24897534592459,2.73076686125001e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.0544069640914037,SMOC1;SPARC-related modular calcium-binding protein 1,2.76440488943723,1.94223404541093,3.93461046097954,1.64279734499971e-08
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02719738531574,SMOC1;SPARC-related modular calcium-binding protein 1,1.26059630250329,1.15694610380681,1.37353246850151,1.22232974365703e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,SMOC1;SPARC-related modular calcium-binding protein 1,1.26504203717946,1.17394554988433,1.36320748095075,7.01461529438564e-10
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60931213624467,SMOC1;SPARC-related modular calcium-binding protein 1,1.2355499003107,1.15360317897081,1.32331774390542,1.53231204545602e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.777574744372302,SMOC1;SPARC-related modular calcium-binding protein 1,1.29658737667826,1.17483413568866,1.43095844280688,2.43607029418618e-07
primary,Circulatory system disorders,I50 (heart failure),4.43006958737626,SMOC1;SPARC-related modular calcium-binding protein 1,1.21076867338477,1.16127732247424,1.26236924813662,2.6641053027816e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,SMOC1;SPARC-related modular calcium-binding protein 1,1.36226905751579,1.23665488702009,1.50064258391177,3.76810683600827e-10
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408504678351197,SMOC1;SPARC-related modular calcium-binding protein 1,1.44759722996909,1.26420588712867,1.65759213870905,8.69385424190466e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697054070367413,SMOC1;SPARC-related modular calcium-binding protein 1,1.32464859011801,1.19398637060582,1.46960964588843,1.11983749364792e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.211835584491303,SMOC1;SPARC-related modular calcium-binding protein 1,1.94251902421907,1.6153603082667,2.33593715293271,1.70916870034661e-12
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10490936996095,SMOC1;SPARC-related modular calcium-binding protein 1,2.02710821928089,1.56040060877256,2.63340562005323,1.20518017283372e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3445940625246,GGT1;Glutathione hydrolase 1 proenzyme,1.23296335508785,1.13911798512416,1.3345401045738,2.16312255724072e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.803725829272127,GGT1;Glutathione hydrolase 1 proenzyme,1.36680278489316,1.2340453951099,1.51384208408746,2.04840149557856e-09
primary,Circulatory system disorders,I81 (portal vein thrombosis),0.0784713775650331,GGT1;Glutathione hydrolase 1 proenzyme,2.17502157502383,1.59485403343693,2.96623938782935,9.16637065303207e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.219814727586748,GGT1;Glutathione hydrolase 1 proenzyme,3.40690089124712,2.87408587536952,4.03849230193517,2.59509382055601e-45
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102026801655973,GGT1;Glutathione hydrolase 1 proenzyme,4.74135995617066,3.74718286312649,5.99930535955268,1.99549526654397e-38
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519911002134132,CKB;Creatine kinase B-type,1.38987740081596,1.22480702557143,1.57719473269486,3.33377425423102e-07
primary,Circulatory system disorders,I08 (multiple valve diseases),2.05032618825722,CKB;Creatine kinase B-type,1.2732578597813,1.19374530764152,1.35806655499893,2.09200391019048e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.386548125241592,CKB;Creatine kinase B-type,2.95645156266276,2.58913749755213,3.37587549932547,1.00995172626554e-57
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0499217136762803,CKB;Creatine kinase B-type,2.56844648204451,1.78800343940029,3.68954398283456,3.31775821264184e-07
primary,Circulatory system disorders,I15 (secondary hypertension),0.043122035360069,CKB;Creatine kinase B-type,2.76113458526356,1.88047520912459,4.05422212478284,2.19133450423258e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37382666545156,CKB;Creatine kinase B-type,1.55077585777122,1.43516751018178,1.67569690923498,1.25703403047584e-28
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59954363947518,CKB;Creatine kinase B-type,1.33303073551055,1.23955076988859,1.43356043575006,9.25956600079349e-15
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.68947380404836,CKB;Creatine kinase B-type,1.21324580985997,1.1295647999214,1.30312612011741,1.1504731882786e-07
primary,Circulatory system disorders,I46 (cardiac arrest),0.754031342266636,CKB;Creatine kinase B-type,1.44003150110116,1.29675236209377,1.59914165941092,9.11592390013961e-12
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.20050090441074,CKB;Creatine kinase B-type,1.23504916232133,1.19220919519377,1.27942850927492,9.99478115867245e-32
primary,Circulatory system disorders,I50 (heart failure),4.32582211230191,CKB;Creatine kinase B-type,1.35958631451,1.29982369086561,1.42209667325874,6.59921021374533e-41
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08907349717318,CKB;Creatine kinase B-type,1.28498115027373,1.22693025151323,1.34577866551283,2.14220567583683e-26
primary,Circulatory system disorders,I63 (cerebral infarction),2.05420177636073,CKB;Creatine kinase B-type,1.23555370795152,1.15809827571581,1.31818948118991,1.51737725143599e-10
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.62097233291586,CKB;Creatine kinase B-type,1.22140973222975,1.1533319593058,1.29350593465172,8.18791329938302e-12
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.752084706096203,CKB;Creatine kinase B-type,1.3981554028684,1.25841277214492,1.55341599659558,4.42880581838168e-10
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08525133492911,CKB;Creatine kinase B-type,1.30208624130309,1.22083763633642,1.38874206473399,9.75976278841426e-16
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.689168903243415,CKB;Creatine kinase B-type,1.45886633936216,1.30743755916835,1.62783375863682,1.43596559634676e-11
primary,Circulatory system disorders,I83 (varicose veins of lower extremities),2.03799573660661,CKB;Creatine kinase B-type,1.30255481397095,1.22000109399235,1.39069469015536,2.52422903661671e-15
primary,Circulatory system disorders,I87 (other disorders of veins),0.427136820102694,CKB;Creatine kinase B-type,1.58361358758136,1.38101899020639,1.81592868205057,4.63730149758144e-11
primary,Circulatory system disorders,I95 (hypotension),4.54078956371017,CKB;Creatine kinase B-type,1.31761175248569,1.26163407014334,1.3760731192771,1.35619424434197e-35
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.253139717425431,LGALS9;Galectin-9,1.63726945793848,1.38863974507974,1.93041520480478,4.43827217254619e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511844995293379,LGALS9;Galectin-9,1.39275062749786,1.23710441392746,1.56797945958136,4.27788891982587e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13033319589248,LGALS9;Galectin-9,1.32527430878536,1.24979505088891,1.40531200877881,4.83210696287895e-21
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544589493551431,LGALS9;Galectin-9,2.7963751870383,2.5314075075748,3.08907758363059,3.83832104192726e-91
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.064681785217272,LGALS9;Galectin-9,2.4412582126345,1.81439531566128,3.28469854904983,3.75550211193393e-09
primary,Circulatory system disorders,I15 (secondary hypertension),0.0568638600756877,LGALS9;Galectin-9,2.30068339248298,1.66748784729169,3.17432242822283,3.90849018748806e-07
primary,Circulatory system disorders,I20 (angina pectoris),4.00410888546481,LGALS9;Galectin-9,1.20106114974049,1.14900657234281,1.25547400697163,5.31200891313306e-16
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96160583059856,LGALS9;Galectin-9,1.29975399313192,1.23543392221614,1.36742274295979,4.29532773627046e-24
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01497928814025,LGALS9;Galectin-9,1.31705835750528,1.20987266630689,1.43373990121577,2.03259858042346e-10
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72750956606692,LGALS9;Galectin-9,1.24412524091316,1.20744387232248,1.28192096589962,2.02290872333334e-46
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35331838388606,LGALS9;Galectin-9,1.65657689068927,1.54224657758435,1.77938277487644,1.59397197403993e-43
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61010602656576,LGALS9;Galectin-9,1.34874529744658,1.26083168431644,1.44278883534759,3.33447058866688e-18
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.7176248376815,LGALS9;Galectin-9,1.23171587914206,1.1532191876108,1.31555564044491,5.53995079536267e-10
primary,Circulatory system disorders,I42 (cardiomyopathy),0.674347279018559,LGALS9;Galectin-9,1.29235987056297,1.1641687071199,1.43466666371192,1.49444468755348e-06
primary,Circulatory system disorders,I46 (cardiac arrest),0.776805680881949,LGALS9;Galectin-9,1.50625955032699,1.36934355406859,1.65686531054253,3.61610945477196e-17
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36418376009318,LGALS9;Galectin-9,1.24963871509998,1.1606527098057,1.34544718250659,3.36432609296299e-09
primary,Circulatory system disorders,I50 (heart failure),4.42075281365587,LGALS9;Galectin-9,1.41158783006783,1.35506344564011,1.47047004212731,2.14330372887132e-61
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22133599202392,LGALS9;Galectin-9,1.30649127171858,1.25250248751209,1.36280722800588,2.13241340755385e-35
primary,Circulatory system disorders,I63 (cerebral infarction),2.06755454134125,LGALS9;Galectin-9,1.29692027203599,1.22170029678845,1.3767715342621,1.48093142915459e-17
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.622178606476938,LGALS9;Galectin-9,1.34801876054115,1.20991900148527,1.50188118092219,6.11340582407508e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71259122292818,LGALS9;Galectin-9,1.25248853805943,1.18855424815529,1.31986195868217,3.71149672362886e-17
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.779118830340496,LGALS9;Galectin-9,1.48744303406877,1.35220067096255,1.63621186345425,3.24509145172466e-16
primary,Circulatory system disorders,I70 (atherosclerosis),0.80893758221908,LGALS9;Galectin-9,1.59175018736622,1.45082882247572,1.74635947379161,8.51969010442789e-23
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08379800518338,LGALS9;Galectin-9,1.2413087004254,1.14251410502686,1.3486461856115,3.24635639239903e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14309854674857,LGALS9;Galectin-9,1.4422126549651,1.36004710186379,1.52934213770326,2.02030189959384e-34
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40635244694843,LGALS9;Galectin-9,1.55225250869693,1.36149361543395,1.76973863369011,4.9496188060257e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699493064015404,LGALS9;Galectin-9,1.60643298816538,1.45413756351313,1.77467868942969,1.08337951935734e-20
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0490071158332189,LGALS9;Galectin-9,2.54251858327399,1.81755317402536,3.55665013749049,5.07238321783628e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.223564480702855,LGALS9;Galectin-9,2.08689433859886,1.76681159996017,2.46496456134551,4.71598293074929e-18
primary,Circulatory system disorders,I95 (hypotension),4.83124150296534,LGALS9;Galectin-9,1.29555987569464,1.24565201412781,1.34746732833339,3.5041488397361e-38
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10586574654956,LGALS9;Galectin-9,2.4055730106884,1.90355091614594,3.03999302601727,1.97953415689836e-13
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,DSG2;Desmoglein-2,2.36645517121128,2.10986961382929,2.65424462281759,5.50567527988408e-49
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.541473750294279,DSG2;Desmoglein-2,1.34398436227513,1.19165656253828,1.51578401262911,1.45830624599267e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550184704865204,LEP;Leptin,2.55529884709087,2.17643088502607,3.00011925160017,2.14945468857477e-30
primary,Circulatory system disorders,I20 (angina pectoris),4.01667453847259,LEP;Leptin,1.31284760900151,1.23019895631872,1.40104885929885,2.30923422208167e-16
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.70175581371691,LEP;Leptin,1.27211060824956,1.2173629798815,1.3293203640697,7.91886103565964e-27
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35841786584886,LEP;Leptin,1.32852942421261,1.19090344964387,1.48206005409296,3.55866387238689e-07
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.86725663716814,LEP;Leptin,1.23156811303977,1.14256653195001,1.32750257831173,5.25805877682475e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.782214903252367,LEP;Leptin,1.53306318622859,1.33003731285565,1.76708029936635,3.74984993205273e-09
primary,Circulatory system disorders,I50 (heart failure),4.43996362629976,LEP;Leptin,1.30700451150658,1.23002344735995,1.38880343847515,5.40786126053537e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.80061223288397,LEP;Leptin,1.53196718787885,1.33040516468538,1.76406671218271,3.09704034707938e-09
primary,Circulatory system disorders,I95 (hypotension),4.80063010731515,LEP;Leptin,1.35688283336141,1.27970481513054,1.43871539881882,1.70929781536042e-24
primary,Circulatory system disorders,I85 (oesophageal varices),0.220500712236813,GUSB;Beta-glucuronidase,2.04976003762071,1.69307901352505,2.48158306745481,1.86300896311851e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105337078651685,GUSB;Beta-glucuronidase,3.33735935755715,2.56671767111092,4.33938161833496,2.32540774797705e-19
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249435333398801,CCL3;C-C motif chemokine 3,1.62018366190899,1.37502061539359,1.9090587216872,8.1977266115015e-09
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51620247698679,CCL3;C-C motif chemokine 3,1.3776503537318,1.22545820081014,1.54874356047612,8.14080147065566e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13225901542694,CCL3;C-C motif chemokine 3,1.23069752084956,1.16055146775926,1.30508334175787,4.12862888054729e-12
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.539168421259765,CCL3;C-C motif chemokine 3,2.18757916223924,1.96735179535724,2.43245900522553,2.18538938037385e-47
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96630662582621,CCL3;C-C motif chemokine 3,1.22988545616874,1.16938081581434,1.29352065198882,9.03232481865456e-16
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01780170550556,CCL3;C-C motif chemokine 3,1.24865776975036,1.14700313165623,1.35932168180447,2.96610633270915e-07
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35063298615896,CCL3;C-C motif chemokine 3,1.50267569518416,1.39851451328407,1.6145947885766,1.10695392421978e-28
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61923357592252,CCL3;C-C motif chemokine 3,1.20415622569663,1.12556679918645,1.28823293022857,6.85290322183233e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.787339734150124,CCL3;C-C motif chemokine 3,1.44646371113045,1.31550801942017,1.59045573020486,2.4680679109568e-14
primary,Circulatory system disorders,I50 (heart failure),4.40480668342802,CCL3;C-C motif chemokine 3,1.29064827347538,1.23901890228769,1.34442901778928,1.6948206808824e-34
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20325722497205,CCL3;C-C motif chemokine 3,1.23381905377567,1.18279895489136,1.28703990747076,1.81585003611439e-22
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781802467195725,CCL3;C-C motif chemokine 3,1.36546196753953,1.24071822666371,1.50274763820512,1.85794151708965e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.801823755994025,CCL3;C-C motif chemokine 3,1.50616830057261,1.37179686333181,1.65370180548449,8.67514151521e-18
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15077296512206,CCL3;C-C motif chemokine 3,1.28169013948582,1.20874544083406,1.35903686430591,1.03053647317131e-16
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.390978034500373,CCL3;C-C motif chemokine 3,1.58227398817355,1.38522692758079,1.80735078405022,1.35991549885413e-11
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686372844022262,CCL3;C-C motif chemokine 3,1.48333918063435,1.34082722162488,1.64099825042228,1.99643017626145e-14
primary,Circulatory system disorders,I85 (oesophageal varices),0.217869199968595,CCL3;C-C motif chemokine 3,1.84317946119937,1.54994941130442,2.19188478114784,4.61392817419949e-12
primary,Circulatory system disorders,I95 (hypotension),4.8255733696188,CCL3;C-C motif chemokine 3,1.23042799604294,1.18327163572349,1.27946365630625,2.47823306583364e-25
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103994976846401,CCL3;C-C motif chemokine 3,2.04942374115388,1.60268232649318,2.62069257355291,1.06637134984381e-08
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.747880248232593,C1RL;Complement C1r subcomponent-like protein,1.31687141708917,1.1785342579957,1.47144668674771,1.16857152748718e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.766361941147041,C1RL;Complement C1r subcomponent-like protein,1.3795617304639,1.23619393091256,1.53955663473902,9.06492688576682e-09
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08616362338529,C1RL;Complement C1r subcomponent-like protein,1.22911909841469,1.14952545103579,1.31422384491485,1.54585372881656e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.678104946980385,C1RL;Complement C1r subcomponent-like protein,1.40243551578638,1.24795575653669,1.57603774463713,1.34668202484573e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,ALDH1A1;Retinal dehydrogenase 1,2.35095566361055,1.95969205603046,2.82033726434446,3.45325668342557e-20
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,ALDH1A1;Retinal dehydrogenase 1,3.67247780085501,2.8512130234711,4.73030008166612,7.28622810789275e-24
primary,Circulatory system disorders,I70 (atherosclerosis),0.770138069798099,CFB;Complement factor B,1.32498798688685,1.18919272454076,1.47628986384226,3.38259680234635e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.0933336455382,CFB;Complement factor B,1.22709479827601,1.14839773327089,1.31118479280458,1.43481450445162e-09
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.252312867956265,ANGPTL4;Angiopoietin-related protein 4,1.88334992542506,1.59055408782171,2.23004484333901,2.08717472934714e-13
primary,Circulatory system disorders,I08 (multiple valve diseases),2.12924184899604,ANGPTL4;Angiopoietin-related protein 4,1.33017191130523,1.25378754116551,1.41120983861479,3.21316089469703e-21
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.542807313201779,ANGPTL4;Angiopoietin-related protein 4,2.97845929522407,2.6541155860533,3.34243912357197,7.64454429767732e-77
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0644707537217207,ANGPTL4;Angiopoietin-related protein 4,2.93298488342865,2.10821313290178,4.08042251144716,1.68828195910421e-10
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35090092739642,ANGPTL4;Angiopoietin-related protein 4,1.54258111193803,1.43256584337067,1.66104510862073,1.62278009379484e-30
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60685170998094,ANGPTL4;Angiopoietin-related protein 4,1.28219012947078,1.1975201883725,1.37284660757712,9.9421505019553e-13
primary,Circulatory system disorders,I46 (cardiac arrest),0.77817968520872,ANGPTL4;Angiopoietin-related protein 4,1.55156964265321,1.40751494901173,1.71036787757979,9.9612352632933e-19
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36560409287682,ANGPTL4;Angiopoietin-related protein 4,1.20670860358322,1.120346404836,1.29972805524816,7.07483203540735e-07
primary,Circulatory system disorders,I50 (heart failure),4.41811407053999,ANGPTL4;Angiopoietin-related protein 4,1.42277298649488,1.36500001216103,1.4829911744065,2.10441386523759e-62
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22347656715824,ANGPTL4;Angiopoietin-related protein 4,1.26095810176568,1.20838493670183,1.31581856585229,1.38656850508667e-26
primary,Circulatory system disorders,I63 (cerebral infarction),2.07058823529411,ANGPTL4;Angiopoietin-related protein 4,1.23576294359661,1.16355554253917,1.31245135873276,5.53507054789338e-12
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.781963243758186,ANGPTL4;Angiopoietin-related protein 4,1.29074903352066,1.16945565915268,1.42462269047603,3.99984574542147e-07
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71351266567328,ANGPTL4;Angiopoietin-related protein 4,1.20063015159859,1.13904594437893,1.26554400025861,1.00361019784602e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.780485896482923,ANGPTL4;Angiopoietin-related protein 4,1.4382129335542,1.30470132356785,1.58538694249667,2.65904188903849e-13
primary,Circulatory system disorders,I70 (atherosclerosis),0.80828244872397,ANGPTL4;Angiopoietin-related protein 4,1.36688518482093,1.24161031566866,1.50479992386078,1.8600329984833e-10
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14798081876907,ANGPTL4;Angiopoietin-related protein 4,1.32204207156331,1.24575992218924,1.40299523836978,3.35945144237212e-20
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405024653674571,ANGPTL4;Angiopoietin-related protein 4,1.48447735707439,1.29657202706189,1.69961481327052,1.0573763535159e-08
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701135918527222,ANGPTL4;Angiopoietin-related protein 4,1.40425441016336,1.26686111669197,1.55654824548752,1.02892842218204e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.222834691843077,ANGPTL4;Angiopoietin-related protein 4,1.62399555156089,1.35451999846538,1.94708203236392,1.62467136651167e-07
primary,Circulatory system disorders,I87 (other disorders of veins),0.453789731051344,ANGPTL4;Angiopoietin-related protein 4,1.39703968379525,1.22978856489048,1.58703693774591,2.75810239891344e-07
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.538223666183896,ANGPTL4;Angiopoietin-related protein 4,1.42074568526556,1.26415798178366,1.59672946837917,3.76401011874049e-09
primary,Circulatory system disorders,I95 (hypotension),4.82914375490966,ANGPTL4;Angiopoietin-related protein 4,1.26144804110948,1.21260727396924,1.31225599134853,9.50505879512508e-31
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105520273571079,ANGPTL4;Angiopoietin-related protein 4,2.09320997337346,1.61197763291543,2.71810718905925,2.98725490768582e-08
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.517335269558903,RNASE1;Ribonuclease pancreatic,1.48320502559812,1.30163253940189,1.6901061408394,3.28620247060419e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.04229991594538,RNASE1;Ribonuclease pancreatic,1.35105712858926,1.26469612896713,1.44331537268373,4.34660943581861e-19
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.397664007998727,RNASE1;Ribonuclease pancreatic,4.4477110895791,3.90458741587546,5.06638264927397,1.04039668163567e-111
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0498934095341769,RNASE1;Ribonuclease pancreatic,2.66687468044601,1.79583481430035,3.96039797456254,1.16314197013894e-06
primary,Circulatory system disorders,I15 (secondary hypertension),0.0430985596007712,RNASE1;Ribonuclease pancreatic,3.25941898584764,2.16665098804098,4.90333338592285,1.42071774635612e-08
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96787709497206,RNASE1;Ribonuclease pancreatic,1.24497537973693,1.17729081130369,1.31655125587428,1.55835534801196e-14
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.972196983463565,RNASE1;Ribonuclease pancreatic,1.27985594544978,1.16318322766746,1.40823148248784,4.20513333008821e-07
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.56847253574116,RNASE1;Ribonuclease pancreatic,1.21434272268362,1.17467967385158,1.25534499400982,2.0424812528404e-30
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3798128372686,RNASE1;Ribonuclease pancreatic,1.70564987794542,1.5740157649966,1.84829248272587,8.26424885980218e-39
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59635119726339,RNASE1;Ribonuclease pancreatic,1.25482646469647,1.16432767427094,1.35235938413005,2.78660915487148e-09
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69310242814555,RNASE1;Ribonuclease pancreatic,1.31905661066111,1.22677594029684,1.41827882743428,7.24505500648675e-14
primary,Circulatory system disorders,I42 (cardiomyopathy),0.686988171064604,RNASE1;Ribonuclease pancreatic,1.39537670047543,1.24524521405937,1.56360860836593,9.66866309637421e-09
primary,Circulatory system disorders,I45 (other conduction disorders),1.73021394629743,RNASE1;Ribonuclease pancreatic,1.23541435582231,1.14985672199013,1.32733809472391,7.77045970823333e-09
primary,Circulatory system disorders,I46 (cardiac arrest),0.760395859814781,RNASE1;Ribonuclease pancreatic,1.50771881873769,1.35343983304499,1.67958410922594,8.98587246336957e-14
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.33835788512047,RNASE1;Ribonuclease pancreatic,1.2703652011256,1.17070377904149,1.37851074979206,9.41722701478288e-09
primary,Circulatory system disorders,I50 (heart failure),4.33648367239524,RNASE1;Ribonuclease pancreatic,1.47876282217734,1.41209404244669,1.54857921535098,4.93168111811318e-62
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08163265306122,RNASE1;Ribonuclease pancreatic,1.34120982865579,1.27914582917044,1.40628516581998,6.15154540219807e-34
primary,Circulatory system disorders,I63 (cerebral infarction),2.05075679981791,RNASE1;Ribonuclease pancreatic,1.3126461527899,1.22896527489212,1.40202490471944,5.75454489787044e-16
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.60804260258073,RNASE1;Ribonuclease pancreatic,1.22500882603381,1.15539529646146,1.29881662878206,1.05449504669811e-11
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.749386865292033,RNASE1;Ribonuclease pancreatic,1.52332701572697,1.3666047008689,1.69802225571757,2.99733761222746e-14
primary,Circulatory system disorders,I70 (atherosclerosis),0.761017719218537,RNASE1;Ribonuclease pancreatic,1.55729757777558,1.39784757617836,1.73493575914477,9.18829045276501e-16
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07646537823904,RNASE1;Ribonuclease pancreatic,1.3448069250529,1.22773514367939,1.47304219072066,1.82838383671025e-10
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06790265446013,RNASE1;Ribonuclease pancreatic,1.36294722455625,1.27553946740012,1.45634469524641,5.3556886878004e-20
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401989507392518,RNASE1;Ribonuclease pancreatic,1.68622445323993,1.45452800962696,1.95482856836393,4.26135186611204e-12
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686488452445899,RNASE1;Ribonuclease pancreatic,1.63275957493427,1.45750192691857,1.82909111837386,2.61351018463395e-17
primary,Circulatory system disorders,I95 (hypotension),4.5563330522189,RNASE1;Ribonuclease pancreatic,1.30887922538848,1.25190306646657,1.36844846261848,2.05854991759272e-32
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.98562080247976,CTSD;Cathepsin D,1.21453381889447,1.15140999603126,1.28111828308145,9.51843243531205e-13
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36024387680016,CTSD;Cathepsin D,1.23812164444229,1.14582260092593,1.33785562023101,6.52775187830358e-08
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.621039822080483,CTSD;Cathepsin D,1.32482017799366,1.18146934398566,1.48556415192138,1.47917659975999e-06
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769956991503199,CTSD;Cathepsin D,1.39351118688331,1.25789721198626,1.54374571265856,2.12294345309719e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.803878767525816,CTSD;Cathepsin D,1.55160833179883,1.40457067726513,1.7140386413272,5.24156110761778e-18
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14998937752283,CTSD;Cathepsin D,1.24898940806106,1.17385863653832,1.32892879337588,2.15355023960806e-12
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.413387892141433,CTSD;Cathepsin D,1.54874795746171,1.34741142962972,1.78016913245347,7.43150772253383e-10
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705748913020647,CTSD;Cathepsin D,1.33767146131956,1.20154074968437,1.48922534578943,1.07881052884354e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.224304551076452,CTSD;Cathepsin D,2.82882544548512,2.37419494250191,3.37051236095693,2.80966135830003e-31
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.111069198206127,CTSD;Cathepsin D,4.57313751257568,3.62480907769667,5.76956917196204,1.25334879587607e-37
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.25354271899998,FSTL3;Follistatin-related protein 3,1.93800489772161,1.6482133067868,2.27874812569922,1.17796481594552e-15
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.514623558759403,FSTL3;Follistatin-related protein 3,1.41742331261292,1.25834414134852,1.59661318483631,9.28035077372297e-09
primary,Circulatory system disorders,I08 (multiple valve diseases),2.13176007866273,FSTL3;Follistatin-related protein 3,1.2904311523287,1.21644526467437,1.36891696425497,2.58346795100642e-17
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.204237937196834,FSTL3;Follistatin-related protein 3,1.60203354194104,1.33359634470185,1.92450397730952,4.73940560211783e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545458125750743,FSTL3;Follistatin-related protein 3,3.92363941261497,3.58331570948973,4.29628519738158,1.17874819574072e-191
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0647846401507715,FSTL3;Follistatin-related protein 3,2.88930304123894,2.18285909304504,3.82437514666474,1.1988376431161e-13
primary,Circulatory system disorders,I15 (secondary hypertension),0.0569543187085117,FSTL3;Follistatin-related protein 3,2.63069169060769,1.93123288455325,3.58348225446318,8.60077711106219e-10
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96638367379862,FSTL3;Follistatin-related protein 3,1.23375181021359,1.17255502890514,1.29814251074134,5.8389289634107e-16
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00873053327041,FSTL3;Follistatin-related protein 3,1.29426129337324,1.18867851066899,1.40922232587633,2.83560052303348e-09
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.7330547344817,FSTL3;Follistatin-related protein 3,1.21245211472585,1.17663719139105,1.24935718610532,2.32255340906596e-36
primary,Circulatory system disorders,I26 (pulmonary embolism),1.9849689662694,FSTL3;Follistatin-related protein 3,1.2454397374879,1.17107631525766,1.32452524186919,2.79777747391961e-12
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35159097625849,FSTL3;Follistatin-related protein 3,1.66490993059161,1.54864125419675,1.78990781077977,2.49622403274894e-43
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60876431109356,FSTL3;Follistatin-related protein 3,1.29843843527,1.21273045246481,1.39020370665205,6.59248690869738e-14
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70857638341478,FSTL3;Follistatin-related protein 3,1.21517218457634,1.13755086316824,1.29809003357913,7.17859573259854e-09
primary,Circulatory system disorders,I42 (cardiomyopathy),0.669515389008132,FSTL3;Follistatin-related protein 3,1.33301863992874,1.20062130641024,1.48001595916231,7.21526436599651e-08
primary,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85759331520239,FSTL3;Follistatin-related protein 3,1.22448486614112,1.16361182224998,1.28854241486601,7.01026247147256e-15
primary,Circulatory system disorders,I46 (cardiac arrest),0.776077175472031,FSTL3;Follistatin-related protein 3,1.6533296006287,1.5050141415518,1.81626118509199,1.0148504352692e-25
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36631470716178,FSTL3;Follistatin-related protein 3,1.23158859109933,1.14374873133716,1.32617454880385,3.43588855940135e-08
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.41476531615596,FSTL3;Follistatin-related protein 3,1.2172306590398,1.17857706201512,1.2571519716947,7.38609592171579e-33
primary,Circulatory system disorders,I50 (heart failure),4.41397892067517,FSTL3;Follistatin-related protein 3,1.48964739736441,1.42977058755448,1.55203176494915,7.95820565812054e-81
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22417064451057,FSTL3;Follistatin-related protein 3,1.33457887083698,1.27938239677054,1.39215668980628,6.68968603993672e-41
primary,Circulatory system disorders,I63 (cerebral infarction),2.07479508196721,FSTL3;Follistatin-related protein 3,1.27507079531036,1.20104813629714,1.35365559790617,1.6721963163788e-15
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.785784088869388,FSTL3;Follistatin-related protein 3,1.32386912812594,1.20047115779594,1.4599513341268,1.90972147336865e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72075337877773,FSTL3;Follistatin-related protein 3,1.2891432258586,1.2233855284213,1.35843543851763,1.94773166270379e-21
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78429060030664,FSTL3;Follistatin-related protein 3,1.48331812619358,1.34825072267184,1.63191654674898,5.76641128328279e-16
primary,Circulatory system disorders,I70 (atherosclerosis),0.810258023914411,FSTL3;Follistatin-related protein 3,1.74616162744949,1.59311615161573,1.91390968328624,1.04406167799937e-32
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08751229105211,FSTL3;Follistatin-related protein 3,1.24220954690998,1.1446079765472,1.34813367550447,2.04777533522554e-07
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15244315240332,FSTL3;Follistatin-related protein 3,1.41349226605755,1.33263571725242,1.49925471780377,1.11205128166378e-30
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.403067243413291,FSTL3;Follistatin-related protein 3,1.76819859948067,1.55459579937485,2.01115060806332,4.0698218958901e-18
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698653861292608,FSTL3;Follistatin-related protein 3,1.62899152205216,1.47390897473259,1.80039162825455,1.18049162941343e-21
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0490850545825807,FSTL3;Follistatin-related protein 3,2.69360473851325,1.94061687831465,3.73876295131585,3.15596644774817e-09
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.66827852998065,FSTL3;Follistatin-related protein 3,1.22071515627957,1.14058757391393,1.30647179300509,8.54192315556395e-09
primary,Circulatory system disorders,I85 (oesophageal varices),0.22392017442203,FSTL3;Follistatin-related protein 3,2.60979263007231,2.23160056095098,3.05207737045794,3.16056907382951e-33
primary,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.532981945482437,FSTL3;Follistatin-related protein 3,1.3876960270409,1.23355885902522,1.56109313258616,4.92253568533761e-08
primary,Circulatory system disorders,I95 (hypotension),4.83107041364067,FSTL3;Follistatin-related protein 3,1.37642414855773,1.32318534824727,1.43180502961466,9.57086130391067e-57
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106034127280224,FSTL3;Follistatin-related protein 3,3.53582962714647,2.88064996108671,4.34002441153606,1.36702291434258e-33
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0962671905697446,FSTL3;Follistatin-related protein 3,2.21068237785271,1.72069568707016,2.8401980736465,5.46426151721893e-10
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250960708964002,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.76984618601318,1.49569374731768,2.09424925908986,2.96455387237916e-11
primary,Circulatory system disorders,I08 (multiple valve diseases),2.14427245796794,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.27798403716451,1.20460359462982,1.35583457207696,4.29670710153719e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.53035808992516,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,4.4889261239372,4.04533081986321,4.98116437034617,5.21517756556638e-176
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.066585719321609,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,3.23537767772146,2.40877173508361,4.34564577665761,6.18086019165208e-15
primary,Circulatory system disorders,I15 (secondary hypertension),0.0548557098916599,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,3.33142233605088,2.40593773376881,4.61291022845944,4.25972353039253e-13
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97159182359568,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.30062315024436,1.23594672497147,1.36868405795615,5.52338483027927e-24
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01214177830956,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.35080982259078,1.24017967063043,1.47130873051659,5.29610990888475e-12
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.7253645737995,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.22434060247211,1.18789372663475,1.26190573891521,2.31125458743278e-39
primary,Circulatory system disorders,I26 (pulmonary embolism),2.00589503669561,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.20711180810289,1.13507764229462,1.28371739779473,2.02355031679982e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3502093119239,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.62068104227371,1.50564045047467,1.74451147347784,8.245270491762e-38
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.749578117028374,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.28150646612789,1.15989074018428,1.41587372485332,1.08512849898959e-06
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60299330445057,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.27429933672583,1.18973561884338,1.364873652483,4.55186113198786e-12
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72606994711699,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.26606431856349,1.18539428540028,1.35222421643307,2.17078093166422e-12
primary,Circulatory system disorders,I46 (cardiac arrest),0.78010153080225,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.60881618593392,1.46151944681261,1.77095797511809,2.85131078441149e-22
primary,Circulatory system disorders,I50 (heart failure),4.43289393071009,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.45567079854948,1.39651746919473,1.51732972948167,2.10052389729825e-70
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22577303155881,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.27115236207278,1.21805846880901,1.32656056255094,3.00825446064388e-28
primary,Circulatory system disorders,I63 (cerebral infarction),2.08153156694708,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.29362158414342,1.21828349522319,1.37361854570242,4.12310533528051e-17
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.7818561623396,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.30080243071981,1.17843797713381,1.43587273713127,1.81461233517662e-07
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.62752480684002,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.35088118673626,1.21195988738039,1.50572638556741,5.57213383444745e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7258077195189,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.28321160144359,1.21754064496426,1.35242467747576,1.35720770917269e-20
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772533871884865,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.55106100166196,1.40767011828576,1.70905825137947,7.39218549653227e-19
primary,Circulatory system disorders,I70 (atherosclerosis),0.804347399603711,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.78850763874302,1.62798594052161,1.96485700166259,8.5517083688212e-34
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08680725846002,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.32072314647929,1.21610979686542,1.43433564480954,3.92299171524753e-11
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13543632426848,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.49772301372497,1.41124382137985,1.58950153889649,1.97358505092411e-40
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406001765225066,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.86439565999856,1.63543922292723,2.12540529069611,1.1823106280607e-20
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702842783100361,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.64992547287026,1.49068954172377,1.82617103684665,4.04694594027705e-22
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0470072077718583,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,3.29444472298136,2.32339403665759,4.67134109046491,2.20835364437178e-11
primary,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.666298164861,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.2149123947436,1.13493250243839,1.30052855454437,2.10806727983259e-08
primary,Circulatory system disorders,I85 (oesophageal varices),0.221407998119011,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,2.08024255735973,1.74675340582737,2.47740126512064,2.09427748226779e-16
primary,Circulatory system disorders,I87 (other disorders of veins),0.466666666666666,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.39342073999754,1.22873891812775,1.58017405488691,2.34164472308798e-07
primary,Circulatory system disorders,I95 (hypotension),4.81299212598425,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.39442091658371,1.34014229513224,1.45089793797925,1.5469843834647e-60
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103815717307842,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,2.63564651544883,2.06202149467023,3.36884584974149,1.00254241841897e-14
primary,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.096031357177854,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.94333815204214,1.48682330659908,2.54002150519215,1.15464481999338e-06
primary,Circulatory system disorders,I70 (atherosclerosis),0.795642447232759,NTRK3;NT-3 growth factor receptor,0.725092803427383,0.657715019073262,0.799372917351028,1.04624136021984e-10
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14304004412141,NTRK3;NT-3 growth factor receptor,0.789157550146828,0.743323484931148,0.837817789399495,8.74092307449057e-15
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702772153870113,NTRK3;NT-3 growth factor receptor,0.760916855277865,0.685903310606921,0.844134226635578,2.47201925695577e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.545532478665783,ANGPTL7;Angiopoietin-related protein 7,1.69188255709358,1.50434202643705,1.90280304391754,1.74966385395428e-18
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35285288212245,ANGPTL7;Angiopoietin-related protein 7,1.21176045524957,1.12412428478846,1.30622869799753,5.3096007716745e-07
primary,Circulatory system disorders,I70 (atherosclerosis),0.803595750476709,ANGPTL7;Angiopoietin-related protein 7,1.29796395947735,1.17747263258304,1.43078522038031,1.54980826423425e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.211835584491303,ANGPTL7;Angiopoietin-related protein 7,1.65601496146934,1.37114682504515,2.00006702602399,1.62914087993374e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10490936996095,ANGPTL7;Angiopoietin-related protein 7,2.97540024133108,2.29056357908291,3.8649905538346,3.08500714501548e-16
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544400866358367,VWA1;von Willebrand factor A domain-containing protein 1,1.41459743287201,1.25963709544827,1.58862096418012,4.64824579893568e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35488657217601,VWA1;von Willebrand factor A domain-containing protein 1,1.2898261048387,1.19813368782042,1.38853568481978,1.33827731176196e-11
primary,Circulatory system disorders,I50 (heart failure),4.43078976815406,VWA1;von Willebrand factor A domain-containing protein 1,1.2013791814016,1.15305390437155,1.25172980381331,1.97691251098296e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.804801527758832,VWA1;von Willebrand factor A domain-containing protein 1,1.51526198606151,1.37816099403424,1.66600193761255,8.7958645608683e-18
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.15456859301935,VWA1;von Willebrand factor A domain-containing protein 1,1.27162831184989,1.1988773896832,1.34879394457969,1.30118115453624e-15
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409117475160724,VWA1;von Willebrand factor A domain-containing protein 1,1.50715045098812,1.31932287942592,1.72171840368758,1.53533170515896e-09
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.694200694200694,VWA1;von Willebrand factor A domain-containing protein 1,1.32205226515177,1.19274679056018,1.46537572402275,1.05867648138089e-07
primary,Circulatory system disorders,I85 (oesophageal varices),0.210206703258203,VWA1;von Willebrand factor A domain-containing protein 1,1.94778585799929,1.6221333408245,2.33881497478725,9.17707454705842e-13
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105066542143357,VWA1;von Willebrand factor A domain-containing protein 1,2.35496127103666,1.82271347560002,3.04262993735589,5.65528139233522e-11
primary,Circulatory system disorders,I70 (atherosclerosis),0.796451453918186,CES2;Cocaine esterase,1.28588964123208,1.16564984582285,1.41853248242034,5.16420437783349e-07
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102358174875004,CES2;Cocaine esterase,2.13878580029435,1.6374003417584,2.79369961204986,2.43314742543197e-08
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24420505346909,ICAM1;Intercellular adhesion molecule 1,1.55074175097457,1.30166841709472,1.84747509168511,9.04768077810837e-07
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.550545612407995,ICAM1;Intercellular adhesion molecule 1,1.36579769351471,1.2161037419234,1.53391793422145,1.41504616823946e-07
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.97113752122241,ICAM1;Intercellular adhesion molecule 1,1.21652146390997,1.15606958822782,1.28013442030101,4.81877056974172e-14
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35223167578024,ICAM1;Intercellular adhesion molecule 1,1.5002007617624,1.39273952707408,1.61595350878038,1.06796754091288e-26
primary,Circulatory system disorders,I46 (cardiac arrest),0.783557113044847,ICAM1;Intercellular adhesion molecule 1,1.28647073507993,1.16729998409019,1.41780773989047,3.79542581578608e-07
primary,Circulatory system disorders,I50 (heart failure),4.42344345616264,ICAM1;Intercellular adhesion molecule 1,1.25119892174075,1.20049818051454,1.30404091166071,2.44990554499286e-26
primary,Circulatory system disorders,I63 (cerebral infarction),2.07313220660243,ICAM1;Intercellular adhesion molecule 1,1.22133400654521,1.14996226718297,1.29713539140536,7.61075040746784e-11
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.626391159611558,ICAM1;Intercellular adhesion molecule 1,1.3249169072278,1.18816861666166,1.47740378464982,4.14915184399898e-07
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772094305804494,ICAM1;Intercellular adhesion molecule 1,1.35961542605133,1.23252135727542,1.49981507082611,8.50710209610565e-10
primary,Circulatory system disorders,I70 (atherosclerosis),0.805927210388382,ICAM1;Intercellular adhesion molecule 1,1.54165602016304,1.40116647285256,1.696231911449,6.76073557770979e-19
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14875703283987,ICAM1;Intercellular adhesion molecule 1,1.33865428847073,1.26117744932824,1.42089069622643,8.94466788167251e-22
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409763401036228,ICAM1;Intercellular adhesion molecule 1,1.64684370857761,1.44147321443344,1.88147387917132,2.12420683690994e-13
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702045001873434,ICAM1;Intercellular adhesion molecule 1,1.39464214286235,1.2581541543185,1.54593672005259,2.44886504990845e-10
primary,Circulatory system disorders,I85 (oesophageal varices),0.220433387785628,ICAM1;Intercellular adhesion molecule 1,3.48761305902936,2.9190896926616,4.16686232015762,4.4740613456328e-43
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.272098113058737,ICAM1;Intercellular adhesion molecule 1,1.57925272666254,1.34168001571916,1.85889269084345,3.93934412737447e-08
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104277338370125,ICAM1;Intercellular adhesion molecule 1,5.43114733611743,4.19699973142802,7.0282018761481,7.01063683991727e-38
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.401231049811923,PRND;Prion-like protein doppel,2.16241233947618,1.86122094180107,2.51234392483996,6.9327907429642e-24
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.393423236986332,FCAMR;High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor,1.64901357207119,1.41967066263044,1.91540603919828,5.89653162351251e-11
primary,Circulatory system disorders,I85 (oesophageal varices),0.20891048639811,FCAMR;High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor,3.09765647592157,2.56298460475287,3.74386784260222,1.34068807285802e-31
primary,Circulatory system disorders,I86 (varicose veins of other sites),0.263918276340636,FCAMR;High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor,1.71472146986308,1.4294384622664,2.05694039780316,6.31487491299003e-09
primary,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102149683335981,FCAMR;High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor,3.84315313649233,2.97074644681016,4.97175585159409,1.20662311762652e-24
primary,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.253144684942797,COLEC12;Collectin-12,1.89590141056753,1.60186659697251,2.24390855354955,1.0089696873156e-13
primary,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51185503324116,COLEC12;Collectin-12,1.41355525729104,1.25214153420184,1.59577684378054,2.21141840346855e-08
primary,Circulatory system disorders,I08 (multiple valve diseases),2.1362235180931,COLEC12;Collectin-12,1.32755718091644,1.25081892130778,1.40900336457984,1.09111055878494e-20
primary,Circulatory system disorders,I11 (hypertensive heart disease),0.207839061979176,COLEC12;Collectin-12,1.57555300790455,1.3092101699359,1.89608004713149,1.49771721054844e-06
primary,Circulatory system disorders,I12 (hypertensive renal disease),0.544600200538702,COLEC12;Collectin-12,4.45888669508989,4.03230736546689,4.93059401421588,1.24892647751438e-186
primary,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0646830530401035,COLEC12;Collectin-12,3.22137552597959,2.40622278402214,4.31267642725671,3.88089568459378e-15
primary,Circulatory system disorders,I15 (secondary hypertension),0.0568649750970626,COLEC12;Collectin-12,3.17407888997689,2.31931999646582,4.34384941066731,5.37652812597091e-13
primary,Circulatory system disorders,I21 (acute myocardial infarction),2.96983852132243,COLEC12;Collectin-12,1.25950524672428,1.19656843335875,1.32575239518322,1.12925444473155e-18
primary,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01107271870582,COLEC12;Collectin-12,1.34089896434313,1.23081732589956,1.46082606633959,1.92371027189581e-11
primary,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.72547423267931,COLEC12;Collectin-12,1.23766072227967,1.20072867331305,1.27572872832901,2.73507349689074e-43
primary,Circulatory system disorders,I26 (pulmonary embolism),1.99184255335999,COLEC12;Collectin-12,1.21322180296005,1.14005751115872,1.29108148384693,1.12704770883326e-09
primary,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35143110061965,COLEC12;Collectin-12,1.60713003801399,1.49216480403432,1.73095287605206,5.20158388916861e-36
primary,Circulatory system disorders,I31 (other diseases of pericardium),0.74631262643125,COLEC12;Collectin-12,1.31841107974707,1.19240241959184,1.45773586722076,6.92065488013022e-08
primary,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60823035534795,COLEC12;Collectin-12,1.35209435195167,1.26190430508961,1.44873040626466,1.08534826243162e-17
primary,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71178970565087,COLEC12;Collectin-12,1.2360060786608,1.15663359699055,1.320825394024,3.92428993750487e-10
primary,Circulatory system disorders,I42 (cardiomyopathy),0.676313306071091,COLEC12;Collectin-12,1.34745478125792,1.21291227688093,1.49692143623432,2.75391898589839e-08
primary,Circulatory system disorders,I46 (cardiac arrest),0.780744257214037,COLEC12;Collectin-12,1.62076226744735,1.47290881270756,1.78345753988139,4.40800770849332e-23
primary,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36805116866708,COLEC12;Collectin-12,1.23402674257745,1.14529227069805,1.32963614647303,3.33133734482985e-08
primary,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.42707164609713,COLEC12;Collectin-12,1.2046170598589,1.16604702243143,1.24446290157088,3.55325948306665e-29
primary,Circulatory system disorders,I50 (heart failure),4.42479626552733,COLEC12;Collectin-12,1.43373735041633,1.37517043031303,1.49479856799344,2.65246245436695e-64
primary,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22939639873177,COLEC12;Collectin-12,1.33707078528025,1.28118453612666,1.39539483535664,1.45798313055791e-40
primary,Circulatory system disorders,I63 (cerebral infarction),2.07739067141423,COLEC12;Collectin-12,1.30251998297448,1.22625296252149,1.38353044428881,9.05610147862423e-18
primary,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.78258791668326,COLEC12;Collectin-12,1.3191820228563,1.19464777568395,1.45669815392317,4.36772263686326e-08
primary,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.622190818269249,COLEC12;Collectin-12,1.35466937089772,1.21445894842948,1.51106721789286,5.1678443864805e-08
primary,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71854591234558,COLEC12;Collectin-12,1.27980836633645,1.21372613720991,1.34948849195088,7.45496664486175e-20
primary,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.783059229893629,COLEC12;Collectin-12,1.53068512115079,1.38951852333463,1.68619338336675,6.49780187275435e-18
primary,Circulatory system disorders,I70 (atherosclerosis),0.807021677662582,COLEC12;Collectin-12,1.67636101150878,1.52513586581035,1.84258091616881,9.11158904267008e-27
primary,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.0916944826232,COLEC12;Collectin-12,1.27092903978698,1.17081156280505,1.37960768025214,1.0228360579924e-08
primary,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1509223918575,COLEC12;Collectin-12,1.45892180654281,1.37429211000334,1.54876304834564,3.04754428798078e-35
primary,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404397330192383,COLEC12;Collectin-12,1.7921426892178,1.57181607946574,2.04335320173624,2.86282857203113e-18
primary,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701485498703136,COLEC12;Collectin-12,1.66587742026012,1.50474742459353,1.84426139162999,8.1236974337503e-23
primary,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0490080765310123,COLEC12;Collectin-12,2.871301273019,2.04304684969721,4.03533134918683,1.24353039297032e-09
primary,Circulatory system disorders,I95 (hypotension),4.83724779319041,COLEC12;Collectin-12,1.33580779006371,1.28336070283166,1.39039823181258,1.44799945239687e-45
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.535105256968128,CDH3;Cadherin-3,3.68465907193708,3.26933555443617,4.15274365397763,2.33313283093907e-101
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0644896523421469,CDH3;Cadherin-3,2.68467919106466,1.91263709634901,3.76835855201901,1.14062785871295e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.05473988778323,CDH3;Cadherin-3,3.80910057150398,2.63052611508277,5.5157206311846,1.43702750460698e-12
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33958341505511,CDH3;Cadherin-3,1.25752381507438,1.16622790568926,1.35596664919847,2.5409406195518e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.796758153557026,CDH3;Cadherin-3,1.27847169146781,1.15954281301807,1.40959854826773,8.16616490445568e-07
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.403186346466247,CDH3;Cadherin-3,1.43867709602126,1.25473278765722,1.64958771060793,1.87721976441265e-07
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0469070653767223,CDH3;Cadherin-3,2.52073714214998,1.69020502193899,3.75937573095425,5.79864502855732e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,COL1A1;Collagen alpha-1(I) chain,1.62795455394506,1.44624845575214,1.83249013623469,7.00930776895829e-16
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103231335579751,COL1A1;Collagen alpha-1(I) chain,2.22237505957331,1.69893675416455,2.9070834410444,5.61798488268191e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,CHRDL2;Chordin-like protein 2,1.73607584749087,1.53504385444025,1.96343533738335,1.56204724581537e-18
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222866497051456,CHRDL2;Chordin-like protein 2,2.80612410587875,2.29746383997198,3.42740214692121,4.90873306192901e-24
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104495268138801,CHRDL2;Chordin-like protein 2,4.24351017334175,3.12764546258759,5.75748715980006,1.61883738718357e-20
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212294838724404,CSF1R;Macrophage colony-stimulating factor 1 receptor,2.95967706364034,2.44582027086574,3.58149305792532,6.98661952692618e-29
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.267599835323178,CSF1R;Macrophage colony-stimulating factor 1 receptor,1.73479341052194,1.45353823047409,2.07047060345207,1.03448348531195e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107252065172744,CSF1R;Macrophage colony-stimulating factor 1 receptor,4.12224565436263,3.19504792408332,5.31851466352792,1.21311117324885e-27
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.554382259767687,CST6;Cystatin-M,3.28421165587767,2.9003431552556,3.71888622250018,1.91675076166658e-78
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0668056764580845,CST6;Cystatin-M,3.24841481809954,2.30551132490198,4.576945129904,1.64022817214833e-11
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0587317982056423,CST6;Cystatin-M,3.11292107374621,2.15224445157306,4.5024056650678,1.63174312939574e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.535785685725709,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,3.9568666206476,3.53277169834878,4.43187241929988,5.48694852727172e-125
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0657829163759593,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,2.31847474738374,1.67972315041876,3.2001256593481,3.1535710692366e-07
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0578322863695283,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,2.79877047241938,1.99545425847739,3.92548018778621,2.48444442455584e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33247969268936,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.33284879015662,1.23593656730383,1.43736009146272,8.66794448566562e-14
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782044887780548,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.29112415034417,1.17117194925428,1.42336193473844,2.80741388326519e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.40318622520819,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.22936251653848,1.17879529955303,1.28209893409219,5.65299197666642e-22
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.798690148157022,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.29827702700371,1.17827450175609,1.4305013274356,1.32614250046976e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.10856160921863,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.21738250696465,1.14582195453177,1.29341226392292,1.96681072625447e-10
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51628043414491,KLK4;Kallikrein-4,1.32377774526766,1.17515764623246,1.49119356410102,3.90533179819808e-06
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13036752755967,KLK4;Kallikrein-4,1.24885098535182,1.17739832634751,1.32463988500174,1.4392771088592e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,KLK4;Kallikrein-4,2.19209298974979,1.96200000332551,2.44917006501807,9.37318776266254e-44
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645035183737294,KLK4;Kallikrein-4,2.21705053422095,1.61495957683039,3.04361368656451,8.44887555760243e-07
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547516621040281,KLK4;Kallikrein-4,2.61704185847657,1.8661276063289,3.67011776996959,2.46589211351295e-08
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97749312345654,KLK4;Kallikrein-4,1.24361993268371,1.18232649039762,1.3080909118835,2.79629089285653e-17
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02392419436939,KLK4;Kallikrein-4,1.26889605436842,1.16604009158969,1.38082490336732,3.3596647097315e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,KLK4;Kallikrein-4,1.48128058574783,1.37684758093902,1.59363476690497,6.07646925279541e-26
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60963817535032,KLK4;Kallikrein-4,1.21484828053704,1.13469360652359,1.3006650749055,2.29136309849089e-08
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70898245889416,KLK4;Kallikrein-4,1.23771242863368,1.15892256568543,1.32185885524478,2.08488888879188e-10
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.8490699317165,KLK4;Kallikrein-4,1.23871582593435,1.17723638258375,1.30340594303802,1.68912171607836e-16
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.74613439943559,KLK4;Kallikrein-4,1.32270017511649,1.24009117727082,1.41081219294178,1.89955644027636e-17
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778575480741016,KLK4;Kallikrein-4,1.38570202286835,1.25904614806268,1.52509905942372,2.55481370277578e-11
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36819103490363,KLK4;Kallikrein-4,1.20788374877662,1.12182162949554,1.30054824421128,5.49730764418707e-07
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.38816854134617,KLK4;Kallikrein-4,1.2046481439528,1.16652100633731,1.24402144740231,7.72449746267468e-30
sensitivity,Circulatory system disorders,I50 (heart failure),4.41849455578349,KLK4;Kallikrein-4,1.38648044083641,1.33095285261412,1.44432464985239,2.45505062393696e-55
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23386695833747,KLK4;Kallikrein-4,1.2686501196766,1.21633967242267,1.32321025339061,1.64078431351619e-28
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06780193047163,KLK4;Kallikrein-4,1.21374968024119,1.14312646415811,1.28873605193855,2.39760229283527e-10
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.618492131840601,KLK4;Kallikrein-4,1.33618792009271,1.19917821895455,1.48885138971102,1.51558024793523e-07
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778925943322373,KLK4;Kallikrein-4,1.33557677132299,1.21261705317665,1.47100464027342,4.30302259424128e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80476199800278,KLK4;Kallikrein-4,1.4483150960594,1.3179946193227,1.59152138159067,1.36710960064457e-14
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07882680032893,KLK4;Kallikrein-4,1.33111155420551,1.22687612206095,1.44420283179281,6.21570925366301e-12
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13499851323223,KLK4;Kallikrein-4,1.40720056892936,1.32667526107224,1.49261352743901,6.455319707412e-30
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409130060292851,KLK4;Kallikrein-4,1.68648647113713,1.48113186026162,1.92031289964026,3.03566399915419e-15
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697505828875957,KLK4;Kallikrein-4,1.50077480342969,1.35656746445195,1.66031183087483,3.36833611182037e-15
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0430073894514602,KLK4;Kallikrein-4,3.61990341643868,2.50805424607291,5.22464805729863,6.35769065953044e-12
sensitivity,Circulatory system disorders,I95 (hypotension),4.80223213408523,KLK4;Kallikrein-4,1.26253564679098,1.2136969800075,1.31333956141842,5.10148096241237e-31
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.541036954221485,ACAN;Aggrecan core protein,1.64445982685325,1.45947628265302,1.85288939208964,3.09498480625355e-16
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,NPTXR;Neuronal pentraxin receptor,1.72669033913567,1.54458718460068,1.93026302237205,7.56968442045408e-22
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,CCN5;CCN family member 5,2.4602148697839,2.19065206987744,2.76294774908935,3.30957174192202e-52
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.065040009460365,CCN5;CCN family member 5,2.24070142129846,1.59683331234264,3.14418719887753,3.04515541081798e-06
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.055206135767661,CCN5;CCN family member 5,2.39001931306786,1.65478565279136,3.45192279568159,3.39725847221123e-06
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781126716111724,CCN5;CCN family member 5,1.26966930335791,1.14520571593609,1.40765987931843,5.74233153446751e-06
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0453362769060947,CCN5;CCN family member 5,2.55742903049767,1.70792395497062,3.8294698232889,5.1498620870749e-06
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249165638001188,SRPX;Sushi repeat-containing protein SRPX,1.90652318026387,1.58470551143706,2.29369470267526,7.88036437004432e-12
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518513442518102,SRPX;Sushi repeat-containing protein SRPX,1.56885690984451,1.37734700102764,1.78699485440523,1.20244824193425e-11
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04221647952066,SRPX;Sushi repeat-containing protein SRPX,1.27308690445978,1.1913850524634,1.36039164076785,9.70836835439499e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.395745167562621,SRPX;Sushi repeat-containing protein SRPX,1.83134854397478,1.58275215943889,2.11899094214949,4.33761593594555e-16
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36386558474304,SRPX;Sushi repeat-containing protein SRPX,1.59190530032447,1.46840327069451,1.72579463406029,1.57455326563941e-29
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59786950732356,SRPX;Sushi repeat-containing protein SRPX,1.20267351959277,1.11519500609413,1.29701405299116,1.67050340274683e-06
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.67686069685932,SRPX;Sushi repeat-containing protein SRPX,1.27178252265921,1.18227784173862,1.3680631809549,1.06759348900554e-10
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.684758960265659,SRPX;Sushi repeat-containing protein SRPX,1.29778606987183,1.15767717552029,1.45485176590481,7.75434212371659e-06
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.760916756163882,SRPX;Sushi repeat-containing protein SRPX,1.32313375474623,1.18813188235382,1.47347525889178,3.40824006737479e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.31566820276497,SRPX;Sushi repeat-containing protein SRPX,1.26119409326954,1.20422352642422,1.32085987858176,7.59843919324015e-23
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.07689450222882,SRPX;Sushi repeat-containing protein SRPX,1.22200326985374,1.16534153339068,1.28142003759906,1.26623037084365e-16
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.745228026060121,SRPX;Sushi repeat-containing protein SRPX,1.32933375945215,1.1918124865841,1.48272338468615,3.2320787472125e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.768368817032175,SRPX;Sushi repeat-containing protein SRPX,1.34084272475516,1.20427710651722,1.49289495150187,8.72182088753133e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.21015121750651,SRPX;Sushi repeat-containing protein SRPX,2.79587092250889,2.32143701049527,3.3672652671558,2.31163995226738e-27
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.265482674966814,SRPX;Sushi repeat-containing protein SRPX,1.852536584236,1.5533964261901,2.20928266479275,6.80481236487142e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100472678281917,SRPX;Sushi repeat-containing protein SRPX,3.01555786634774,2.31766818606705,3.9235941106492,2.05554391015089e-16
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.2426614481409,ANGPT2;Angiopoietin-2,2.4960386403887,2.10050410026913,2.96605414553354,2.71575648816727e-25
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51628043414491,ANGPT2;Angiopoietin-2,1.97167211916862,1.74944808386458,2.22212421240835,9.2706877842811e-29
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13036752755967,ANGPT2;Angiopoietin-2,1.52542217613579,1.43712809139973,1.61914086111871,8.27940300511647e-44
sensitivity,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0312829937825049,ANGPT2;Angiopoietin-2,4.4579128545347,2.8073422998228,7.07893263314564,2.37516485189729e-10
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.20530668908746,ANGPT2;Angiopoietin-2,2.05397299213767,1.70229288813752,2.47830739459106,5.8272509132568e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,ANGPT2;Angiopoietin-2,2.15120745382609,1.91606085858586,2.41521217275551,1.80815715114426e-38
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645035183737294,ANGPT2;Angiopoietin-2,2.84689761701379,2.047612394556,3.95818371841619,4.90107317906234e-10
sensitivity,Circulatory system disorders,I22 (subsequent myocardial infarction),0.101755278555075,ANGPT2;Angiopoietin-2,1.99710474376525,1.53026812740761,2.60635851073129,3.54791086161046e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,ANGPT2;Angiopoietin-2,2.16551424548482,2.00988452969138,2.33319470751774,1.15425275091178e-91
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.748124791915552,ANGPT2;Angiopoietin-2,1.29974957078769,1.17514405728566,1.43756753590264,3.42074590426361e-07
sensitivity,Circulatory system disorders,I33 (acute and subacute endocarditis),0.127112015018773,ANGPT2;Angiopoietin-2,1.78961887997004,1.40715672643859,2.27603341928451,2.0912097108763e-06
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60963817535032,ANGPT2;Angiopoietin-2,1.495844474529,1.39620951969304,1.60258948275245,2.34631229883082e-30
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70898245889416,ANGPT2;Angiopoietin-2,1.33709350135714,1.25077991481234,1.42936339974705,1.4350991942524e-17
sensitivity,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.185731881366204,ANGPT2;Angiopoietin-2,1.83611574027974,1.50440074722975,2.24097270485346,2.27189756571144e-09
sensitivity,Circulatory system disorders,I37 (pulmonary valve disorders),0.21505376344086,ANGPT2;Angiopoietin-2,1.57159677675765,1.30459237208265,1.89324763931592,1.94806699125926e-06
sensitivity,Circulatory system disorders,"I38 (endocarditis, valve unspecified)",0.250342264815177,ANGPT2;Angiopoietin-2,1.72714486418804,1.45368233253684,2.05205037931872,5.1738566304218e-10
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.676417535879538,ANGPT2;Angiopoietin-2,1.44881069779673,1.3032080987203,1.61068093431236,6.85300842813507e-12
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.8490699317165,ANGPT2;Angiopoietin-2,1.28061585656664,1.2159247231971,1.34874876775087,8.58915722937398e-21
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.74613439943559,ANGPT2;Angiopoietin-2,1.31663415957539,1.23255873913086,1.40644454103924,3.07000137714602e-16
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778575480741016,ANGPT2;Angiopoietin-2,1.60844399955826,1.45849388472327,1.77381072818543,1.75725100907755e-21
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36819103490363,ANGPT2;Angiopoietin-2,1.36509863820923,1.26680267674864,1.47102175125136,3.27976270455837e-16
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.38816854134617,ANGPT2;Angiopoietin-2,1.32647241403494,1.28313180683709,1.37127694584464,2.19933510035683e-62
sensitivity,Circulatory system disorders,I50 (heart failure),4.41849455578349,ANGPT2;Angiopoietin-2,1.54009134812504,1.47660342503244,1.60630899289529,6.58087491755733e-90
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23386695833747,ANGPT2;Angiopoietin-2,1.45243665416972,1.39117891597749,1.51639175245369,1.2226608935261e-64
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.618492131840601,ANGPT2;Angiopoietin-2,1.30452006037859,1.16800343738144,1.45699279083062,2.43496905195082e-06
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73026831947277,ANGPT2;Angiopoietin-2,1.21150495631343,1.14913309062094,1.27726219978479,1.12248371901084e-12
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778925943322373,ANGPT2;Angiopoietin-2,1.36035907007218,1.23284609575269,1.50106068056923,8.87726176386056e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80476199800278,ANGPT2;Angiopoietin-2,1.63075009981637,1.48120312669153,1.79539581042549,2.16571400786402e-23
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13499851323223,ANGPT2;Angiopoietin-2,1.41413491855311,1.33183969134812,1.50151522053453,9.58575865554895e-30
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409130060292851,ANGPT2;Angiopoietin-2,1.45394772748349,1.26980765758006,1.66479071191229,6.05417001995094e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697505828875957,ANGPT2;Angiopoietin-2,1.41827551776203,1.27826750035254,1.57361854520152,4.41125158131417e-11
sensitivity,Circulatory system disorders,I83 (varicose veins of lower extremities),2.0820303831178,ANGPT2;Angiopoietin-2,1.20612650340883,1.1341558946074,1.28266418147815,2.36816412094383e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213177915550253,ANGPT2;Angiopoietin-2,1.83835778904434,1.52673098742938,2.21359190870311,1.32035724160299e-10
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.457943559434811,ANGPT2;Angiopoietin-2,1.42938953949664,1.2573721131327,1.62494017028258,4.74221907254086e-08
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.52870682227618,ANGPT2;Angiopoietin-2,1.44987001417835,1.28651902968467,1.63396188436387,1.12234934421782e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.80223213408523,ANGPT2;Angiopoietin-2,1.25848695826131,1.20914825724098,1.30983890075454,1.90777547138298e-29
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103618839077987,ANGPT2;Angiopoietin-2,2.45642711589786,1.89039516250845,3.191943301268,1.75548365959703e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54854743846169,SOST;Sclerostin,1.49927846543657,1.32931110847817,1.69097805817272,4.1997616228898e-11
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243707473045953,GDF15;Growth/differentiation factor 15,1.64120522394995,1.4087685085077,1.91199233291627,2.03831484901172e-10
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.50659548350642,GDF15;Growth/differentiation factor 15,1.41949538453871,1.26663671042016,1.59080115880922,1.68085713752804e-09
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13608520931684,GDF15;Growth/differentiation factor 15,1.30074943846765,1.22833210952376,1.37743619055101,2.32863729931257e-19
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.206494847369138,GDF15;Growth/differentiation factor 15,1.58210702269308,1.33128827657159,1.88018078075532,1.89739280287979e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,GDF15;Growth/differentiation factor 15,2.48646340032681,2.31010657053624,2.6762835619872,4.39258115598488e-130
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0642648490749756,GDF15;Growth/differentiation factor 15,2.10250689703002,1.6215022750177,2.72619737891552,2.06151090115403e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0564971751412429,GDF15;Growth/differentiation factor 15,2.27786912191892,1.75294717599188,2.95997951772604,7.28165031718981e-10
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97277292095944,GDF15;Growth/differentiation factor 15,1.28341426113312,1.22136343675614,1.34861754995271,5.68573148949763e-23
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01037684325505,GDF15;Growth/differentiation factor 15,1.32112190418065,1.21579206668394,1.43557696544802,5.05542247925913e-11
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68940971871145,GDF15;Growth/differentiation factor 15,1.24989001204488,1.21375084065323,1.28710521952658,3.27398951377804e-50
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.98886550075738,GDF15;Growth/differentiation factor 15,1.26858452835505,1.19476053926216,1.34697008538268,7.42511741597689e-15
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34461664744855,GDF15;Growth/differentiation factor 15,1.73262140809218,1.62549969831867,1.84680252286999,6.34809906088949e-64
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.749297533562285,GDF15;Growth/differentiation factor 15,1.31424894619521,1.19343259256092,1.44729606292117,2.79060459357317e-08
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60560787922695,GDF15;Growth/differentiation factor 15,1.30077855575853,1.21756499679931,1.38967928247706,6.3867569343245e-15
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72410422816036,GDF15;Growth/differentiation factor 15,1.25511368201873,1.17688492911031,1.33854238067395,4.50761700635105e-12
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.670026566651039,GDF15;Growth/differentiation factor 15,1.33805378985501,1.2086481229991,1.48131446239518,2.00502024283817e-08
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85820414068151,GDF15;Growth/differentiation factor 15,1.22347315993553,1.16332627694277,1.28672978746467,4.43785971441837e-15
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.75140581068416,GDF15;Growth/differentiation factor 15,1.28275678607138,1.20355033206578,1.36717586990142,1.89646782965704e-14
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783488276910483,GDF15;Growth/differentiation factor 15,1.62106689760817,1.48481531525101,1.76982137746654,4.06816250530674e-27
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35328613175907,GDF15;Growth/differentiation factor 15,1.27005043549994,1.18112157509868,1.3656749167238,1.08612388277876e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.41797849969538,GDF15;Growth/differentiation factor 15,1.46881696604465,1.41288923361097,1.52695853887061,6.30528258448884e-84
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22007806153785,GDF15;Growth/differentiation factor 15,1.35238554514683,1.29830647948013,1.40871719553801,1.24735835890717e-47
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06000195446105,GDF15;Growth/differentiation factor 15,1.2328417293364,1.16206710009181,1.30792682236084,3.93962381509507e-12
sensitivity,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.769535113748763,GDF15;Growth/differentiation factor 15,1.24941719218593,1.1337492525776,1.3768858648248,7.03722170641411e-06
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620112712310602,GDF15;Growth/differentiation factor 15,1.30909294115245,1.17724671127207,1.45570534380462,6.60152247902649e-07
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72235142371357,GDF15;Growth/differentiation factor 15,1.23023098794246,1.16863292316539,1.29507585632147,2.65861879268125e-15
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772140545178021,GDF15;Growth/differentiation factor 15,1.48675524024901,1.35704266342591,1.62886636064008,1.6667430443294e-17
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805696449473273,GDF15;Growth/differentiation factor 15,1.54289031549126,1.41238830953972,1.68545045973406,6.74293457071481e-22
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07487027427724,GDF15;Growth/differentiation factor 15,1.22336351327796,1.12689262394585,1.32809307099672,1.50537001920144e-06
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14282892917802,GDF15;Growth/differentiation factor 15,1.3647450404274,1.28904986406648,1.44488516487298,1.24829634575586e-26
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407613995397277,GDF15;Growth/differentiation factor 15,1.50252343841999,1.32471944795667,1.70419230010071,2.35780912641105e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70473401659346,GDF15;Growth/differentiation factor 15,1.47705324046073,1.34200663795718,1.62568963032592,1.54784307907211e-15
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220169901020964,GDF15;Growth/differentiation factor 15,2.44474552159478,2.16935126791381,2.75510045503391,1.1579273233381e-48
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.273277376537185,GDF15;Growth/differentiation factor 15,1.45905765890709,1.24779748790052,1.70608554084953,2.20084947747729e-06
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.454306159455612,GDF15;Growth/differentiation factor 15,1.32973998230505,1.1758261514936,1.50380089632687,5.60790543758084e-06
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.534550704280307,GDF15;Growth/differentiation factor 15,1.31779596712197,1.17660360251656,1.47593140735646,1.81857686379938e-06
sensitivity,Circulatory system disorders,I95 (hypotension),4.78418322403836,GDF15;Growth/differentiation factor 15,1.36270163329333,1.31190856504315,1.41546125306319,2.14928844245029e-57
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103231335579751,GDF15;Growth/differentiation factor 15,2.8217152053777,2.41391044357101,3.29841428933919,8.82269700132251e-39
sensitivity,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.095492370354491,GDF15;Growth/differentiation factor 15,1.73914888751322,1.36560988966802,2.21486302627301,7.26504345941912e-06
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511574668878039,COL5A1;Collagen alpha-1(V) chain,1.3701194621103,1.19928020825543,1.56529502240696,3.5802651955172e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.402386244005146,COL5A1;Collagen alpha-1(V) chain,1.50791526581392,1.29903945979162,1.7503767354684,6.70000033324487e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37606076234235,COL5A1;Collagen alpha-1(V) chain,1.49148876400783,1.37500495275777,1.61784052391954,5.65491473804248e-22
sensitivity,Circulatory system disorders,I50 (heart failure),4.32815776453125,COL5A1;Collagen alpha-1(V) chain,1.21868289525808,1.16370068305646,1.27626289201255,4.60433070688695e-17
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.76237693225135,COL5A1;Collagen alpha-1(V) chain,1.31281039738044,1.17756384369974,1.46359040207559,9.27280724039323e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212577088394692,COL5A1;Collagen alpha-1(V) chain,3.19553690134744,2.61220358414369,3.90913485834628,1.36054270069861e-29
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.266803969294139,COL5A1;Collagen alpha-1(V) chain,1.92097011999147,1.603929930102,2.30067793651397,1.30529074478501e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107418910398617,COL5A1;Collagen alpha-1(V) chain,5.33456285739557,4.03413144965915,7.05419772127377,7.60558094505764e-32
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.398835583468952,VGF;Neurosecretory protein VGF,3.25076184341068,2.80754520006607,3.76394743789918,5.55659165056541e-56
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0434732868092895,VGF;Neurosecretory protein VGF,2.77308209287798,1.80130967681939,4.26910730164892,3.59609267840586e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.219246266887888,DPP10;Inactive dipeptidyl peptidase 10,3.38107215275662,2.85107631490858,4.00959063858408,1.47532062662985e-44
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102677513624516,DPP10;Inactive dipeptidyl peptidase 10,4.75154309057639,3.73232511472816,6.04908764579813,1.09812938746482e-36
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223880597014925,NELL2;Protein kinase C-binding protein NELL2,2.5802959121278,2.15713026071281,3.08647424562268,3.33076574121982e-25
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104052143866813,NELL2;Protein kinase C-binding protein NELL2,3.87136983816169,2.99684534225421,5.00109372095744,3.7139865996605e-25
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.392451766032947,PRRT3;Proline-rich transmembrane protein 3,3.76126550422597,3.2636409256908,4.33476553192989,8.84764944101966e-75
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0445695519587145,PRRT3;Proline-rich transmembrane protein 3,2.87236218711109,1.90388169324392,4.33349643689679,4.93667555841655e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250298252590703,C7;Complement component C7,1.63222210646244,1.34828692728258,1.97595107607709,5.04062039079163e-07
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518934081346423,C7;Complement component C7,1.56906088477342,1.37484356835913,1.79071431600345,2.35975211658933e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.388594971674703,C7;Complement component C7,1.85941986312091,1.59976153509166,2.16122350208307,6.34258611673576e-16
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.372208669544,C7;Complement component C7,1.67131537673149,1.54041827528683,1.81333546434263,5.31287177675751e-35
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60460472218959,C7;Complement component C7,1.30834864744865,1.21308020602844,1.41109893210193,3.22404249987506e-12
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70190820010314,C7;Complement component C7,1.20088023424768,1.11628549938967,1.29188575664131,9.03519797513251e-07
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.693695805015233,C7;Complement component C7,1.30405937030065,1.16321500116269,1.46195745375457,5.29890335442585e-06
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.71460695212217,C7;Complement component C7,1.20656609829916,1.12207680257114,1.29741720551481,3.98639569561369e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.764626104849647,C7;Complement component C7,1.51621533505498,1.3611587920863,1.68893515996931,3.97615814179716e-14
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3386975343497,C7;Complement component C7,1.21305426092789,1.11687972904036,1.31751038334238,4.58809906161585e-06
sensitivity,Circulatory system disorders,I50 (heart failure),4.3261976612599,C7;Complement component C7,1.3250016631689,1.26501722867286,1.38783043235086,1.10709427668693e-32
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.10766891570844,C7;Complement component C7,1.25076582142318,1.19266976490772,1.31169179103105,2.95090018480138e-20
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.774613278416138,C7;Complement component C7,1.3788469619602,1.23785537093721,1.53589747974144,5.31121968653365e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06872037914691,C7;Complement component C7,1.20793428906319,1.12982630331134,1.29144209372554,3.04458433505396e-08
sensitivity,Circulatory system disorders,I81 (portal vein thrombosis),0.0747681020584593,C7;Complement component C7,2.23603423315788,1.60249373079422,3.12004284058942,2.19837394082337e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.217391304347826,C7;Complement component C7,4.46479605996982,3.66953568736417,5.43240495678103,1.56033540081381e-50
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.274017518384936,C7;Complement component C7,1.76161046841269,1.47435866146785,2.10482803372389,4.53011364497872e-10
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.505582473140931,C7;Complement component C7,1.39210254965335,1.21631010841028,1.59330214831829,1.56234345625553e-06
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107489192662694,C7;Complement component C7,7.76276583542353,5.87882200752595,10.2504435988152,2.53504148287054e-47
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.548569165263887,CLC;Galectin-10,1.79199237755095,1.59411524889853,2.01443194487948,1.49897708655051e-22
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3533328049457,CLC;Galectin-10,1.21865239255033,1.13054282583063,1.31362883381043,2.41250635249191e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.53896116715693,KLK6;Kallikrein-6,3.23961291801225,2.86601471797456,3.66191136170049,7.25870479749046e-79
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.057105724356576,KLK6;Kallikrein-6,2.74013866261989,1.89756486188643,3.95683965338607,7.57932128336837e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34111707163142,PLA2G15;Phospholipase A2 group XV,1.32500090567052,1.22883594758569,1.42869144044573,2.47277192781851e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781111657648794,PLA2G15;Phospholipase A2 group XV,1.34081656028766,1.21524485127822,1.4793636413688,5.04769999789899e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.799212598425196,PLA2G15;Phospholipase A2 group XV,1.32083622092513,1.19873548182841,1.45537389103287,1.87996656881971e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216284236811577,PLA2G15;Phospholipase A2 group XV,3.42676663097623,2.85679972081344,4.11044899564348,3.47830221044466e-40
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.269855026788528,PLA2G15;Phospholipase A2 group XV,1.59323690394261,1.3491020150489,1.88155069354977,4.05446754015186e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100241759537708,PLA2G15;Phospholipase A2 group XV,5.30532609414997,4.0876164198608,6.88579408491248,4.33474371330493e-36
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543533372543452,GFAP;Glial fibrillary acidic protein,1.48055769563836,1.3121871681746,1.67053233203259,1.87826257214749e-10
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.777438098515984,GFAP;Glial fibrillary acidic protein,1.26550744761048,1.14378779815778,1.40018026292729,5.02551087070663e-06
sensitivity,Circulatory system disorders,I81 (portal vein thrombosis),0.0752639188734179,CDHR2;Cadherin-related family member 2,2.45218562660836,1.81467196462446,3.31366465375965,5.24407999961371e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214013950538998,CDHR2;Cadherin-related family member 2,3.20987565894948,2.73858020529853,3.76227861648231,5.58594211878648e-47
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.27196569658951,CDHR2;Cadherin-related family member 2,1.80465466331402,1.51586966757994,2.14845545331113,3.23349234643458e-11
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101026108315835,CDHR2;Cadherin-related family member 2,4.68559348159601,3.83364833871357,5.7268649430016,2.03929178287502e-51
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13747020436872,SPP1;Osteopontin,1.20039992278175,1.13069852062326,1.27439803655191,2.16856029101605e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.551707946942129,SPP1;Osteopontin,3.12173388178499,2.78779065151888,3.49567942749749,1.4281179337706e-86
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.064365125804564,SPP1;Osteopontin,2.70084666472071,1.95238152119587,3.7362434683693,1.96346598248238e-09
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01000234429944,SPP1;Osteopontin,1.22355408940884,1.12138869510673,1.33502737832273,5.75212235713689e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34672225810871,SPP1;Osteopontin,1.40918065690046,1.30738956150157,1.51889703134977,3.05643546568853e-19
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72484679992951,SPP1;Osteopontin,1.22261913822901,1.14375291899776,1.30692349049801,3.46433508350496e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782759764976868,SPP1;Osteopontin,1.27448213319528,1.1544787797482,1.40695934505462,1.53206644633756e-06
sensitivity,Circulatory system disorders,I50 (heart failure),4.41706198452847,SPP1;Osteopontin,1.24234833361932,1.19110545892953,1.29579574207796,5.67194933864689e-24
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80695584212583,SPP1;Osteopontin,1.31126685588474,1.18970386223447,1.44525105946321,4.77838222443984e-08
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07655034973232,SPP1;Osteopontin,1.34137818990333,1.23272781249393,1.45960481309185,9.43699344283686e-12
sensitivity,Circulatory system disorders,I72 (other aneurysm),0.33778506716651,SPP1;Osteopontin,1.44512127312496,1.24454904596972,1.67801783368939,1.36776769020408e-06
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705836347639065,SPP1;Osteopontin,1.37724421931278,1.24163448166832,1.52766507988876,1.42813639696494e-09
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0448657927590511,SPP1;Osteopontin,2.6649861374014,1.8143174356065,3.91450303742878,5.83388475422844e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220513621106861,SPP1;Osteopontin,1.73893810087344,1.44852081247512,2.08758182321337,2.94969551282075e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.78580531320458,SPP1;Osteopontin,1.21907840622753,1.17112668820731,1.26899350471226,3.83942074115091e-22
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103392442597686,SPP1;Osteopontin,2.14561828408399,1.65177405168191,2.78711111626184,1.06367094421936e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,PODXL2;Podocalyxin-like protein 2,2.39490040898698,2.13218591598097,2.68998492391184,4.04257321588515e-49
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0570103011716599,PODXL2;Podocalyxin-like protein 2,2.32595885734583,1.63811430344136,3.30262948971264,2.36837856569443e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,SEZ6L;Seizure 6-like protein,2.70334704387627,2.40649144227341,3.03682161974805,5.04976812457431e-63
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216284236811577,SEZ6L;Seizure 6-like protein,1.61305250014741,1.33797458936479,1.94468444237577,5.38465418946483e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100241759537708,SEZ6L;Seizure 6-like protein,2.05405313154417,1.57438450878869,2.67986266611105,1.12803929875077e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.2426614481409,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.65079138442048,1.39942465964781,1.94730897164746,2.72748427836039e-09
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51628043414491,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.42203746709724,1.26523638750381,1.59827094588856,3.49115384796121e-09
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13036752755967,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.36758391425987,1.2906215674384,1.44913567983716,3.2150019218993e-26
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.20530668908746,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.53598442237904,1.28280764823006,1.83912853111395,3.01210544698225e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,EDA2R;Tumor necrosis factor receptor superfamily member 27,3.56372231324993,3.25864340225184,3.89736315338438,1.8245148913025e-170
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645035183737294,EDA2R;Tumor necrosis factor receptor superfamily member 27,2.43333544668267,1.84243572574154,3.21374651682854,3.71449415181286e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547516621040281,EDA2R;Tumor necrosis factor receptor superfamily member 27,2.55601156677642,1.89739170818214,3.44325059571079,6.70510032397457e-10
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97749312345654,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.32704733428393,1.26261033597,1.39477285846639,7.85229655165106e-29
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02392419436939,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.32443536925524,1.21883479017692,1.43918524600011,3.403687043068e-11
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.71585697471488,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.23143116577146,1.19529581203004,1.26865893845794,1.02105136319421e-42
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00406736825478,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.28577863952001,1.21020039137934,1.36607682630283,4.19924988248939e-16
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.81770412083248,1.6965893732207,1.94746490992053,1.05112205657141e-64
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60963817535032,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.39375302195658,1.30364569287995,1.49008852391613,2.11763000931101e-22
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70898245889416,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.29380513047593,1.21260757496314,1.38043976485693,6.73601242993303e-15
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.676417535879538,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.41040787150785,1.27398710339341,1.56143681416609,3.4619499073925e-11
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.8490699317165,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.24179718069357,1.18066037012246,1.30609977009608,4.19536378035494e-17
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.74613439943559,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.30159944213408,1.22103960946826,1.38747432485137,6.15762813668086e-16
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778575480741016,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.54764651213161,1.41072167945251,1.69786128716948,2.45317823964709e-20
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36819103490363,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.24086468608037,1.15327571895531,1.33510585877601,7.5502004031876e-09
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.38816854134617,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.24056326012355,1.20152454084287,1.28087038595879,7.30899285194847e-40
sensitivity,Circulatory system disorders,I49 (other cardiac arrhythmias),1.98162885536682,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.20520217843795,1.13378476991911,1.2811181887857,2.11596183416876e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.41849455578349,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.48250036821754,1.42394009312329,1.54346896500711,1.01187490223747e-81
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23386695833747,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.41089382125321,1.35375984330893,1.47043907727747,7.01446310315699e-60
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06780193047163,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.26573014875274,1.1928757543521,1.3430340952246,6.65114155931547e-15
sensitivity,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.770437441671134,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.29802507227587,1.17733528747843,1.43108688423444,1.61724994027842e-07
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.618492131840601,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.41879445761919,1.27619043938894,1.57733332803746,9.64521289811518e-11
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73026831947277,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.2893491931787,1.22441627537905,1.35772561618059,5.45030674033646e-22
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778925943322373,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.49875021688124,1.3648680112167,1.64576515395004,2.34540924130743e-17
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80476199800278,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.63339524140834,1.49182291823196,1.78840261940565,2.75650847871184e-26
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07882680032893,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.2571785878515,1.1595628994567,1.36301187498567,2.859160934997e-08
sensitivity,Circulatory system disorders,I72 (other aneurysm),0.33459867725903,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.4196593346286699,1.2293760974575,1.63939467390531,1.81994187999345e-06
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13499851323223,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.43655988497919,1.35527424688786,1.52272081305341,3.54172817409175e-34
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409130060292851,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.59914499440673,1.40896465945977,1.81499563950498,3.66723769739215e-13
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697505828875957,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.62155471946964,1.47087168106872,1.78767443963823,2.62559013106799e-22
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0430073894514602,EDA2R;Tumor necrosis factor receptor superfamily member 27,3.31169936071582,2.44231292198695,4.49055997576391,1.28555250672137e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213177915550253,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.84224368578309,1.55601662870282,2.18112180500087,1.32263199436036e-12
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.457943559434811,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.40193701062606,1.23815787497994,1.58738026989891,9.80537617819121e-08
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.52870682227618,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.31282700471419,1.16717895670861,1.47664994678027,5.71787598330368e-06
sensitivity,Circulatory system disorders,I95 (hypotension),4.80223213408523,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.3596479663395,1.30748176573212,1.4138955057136,1.87227759523047e-53
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103618839077987,EDA2R;Tumor necrosis factor receptor superfamily member 27,2.25278747099528,1.79673355707349,2.82459876674176,1.9601620366675e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.541402527857621,CRLF1;Cytokine receptor-like factor 1,1.51232038632463,1.34193331302133,1.70434173494336,1.18171624693428e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34349821720544,CRLF1;Cytokine receptor-like factor 1,1.22296471336058,1.13364850721982,1.31931783140885,1.97231086055604e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.777889091873416,CRLF1;Cytokine receptor-like factor 1,1.26258499773044,1.14227552982707,1.39556598637399,5.0298455495863e-06
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.81009870620158,CRLF1;Cytokine receptor-like factor 1,1.32311955786075,1.19960868726666,1.45934702122116,2.14447460035583e-08
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13189481856002,CRLF1;Cytokine receptor-like factor 1,1.20152785440981,1.13083036084569,1.2766452289475,2.95959213578421e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223880597014925,CRLF1;Cytokine receptor-like factor 1,1.64909433659475,1.36984347821145,1.98527216740094,1.26073103958533e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104052143866813,CRLF1;Cytokine receptor-like factor 1,2.06872189407332,1.57762220619114,2.71269652406237,1.46285095623239e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.398835583468952,VWC2L;von Willebrand factor C domain-containing protein 2-like,2.13990068244912,1.87548383605487,2.44159658575284,1.23808981778636e-29
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34334568365992,ITGA11;Integrin alpha-11,0.798495023421482,0.740253205631732,0.861319204804727,5.76607293469905e-09
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.782763391974698,ITGA11;Integrin alpha-11,0.715493930306329,0.647936933502234,0.79009474199611,3.69356347530548e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.401366941125203,PTPRR;Receptor-type tyrosine-protein phosphatase R,3.04075275718079,2.64630124117112,3.49400029990942,1.8353647630607e-55
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.553871032949262,CHI3L1;Chitinase-3-like protein 1,2.0316929230295,1.80803690933254,2.28301541422182,1.01554461303111e-32
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3488644866428,CHI3L1;Chitinase-3-like protein 1,1.37806379727545,1.27744288306775,1.48661036398019,1.13505329427945e-16
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.73160173160173,CHI3L1;Chitinase-3-like protein 1,1.21148016834211,1.13307438671008,1.2953114248286,1.91275659103095e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776491468678149,CHI3L1;Chitinase-3-like protein 1,1.36112273979073,1.2321679708051,1.50357350350935,1.27107457956795e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.41361916771752,CHI3L1;Chitinase-3-like protein 1,1.29246089799701,1.23916910082523,1.34804456610385,7.18270640559594e-33
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22321538398458,CHI3L1;Chitinase-3-like protein 1,1.20542834473168,1.15456703091532,1.25853021554807,1.98961517417387e-17
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.768765133171912,CHI3L1;Chitinase-3-like protein 1,1.3255300280701,1.19905776589703,1.46534212553226,3.62521829043114e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.795332969983245,CHI3L1;Chitinase-3-like protein 1,1.54571172306243,1.40122670052411,1.70509506414556,3.39502980916899e-18
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11705084191597,CHI3L1;Chitinase-3-like protein 1,1.26922606172369,1.19411030597622,1.3490669896209,1.86779785515935e-14
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698961658114823,CHI3L1;Chitinase-3-like protein 1,1.43719009404552,1.29371815498261,1.59657291541243,1.38780453232996e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223808371642874,CHI3L1;Chitinase-3-like protein 1,2.4795508459455,2.06778374318674,2.97331498900066,1.11860500011919e-22
sensitivity,Circulatory system disorders,I95 (hypotension),4.79711524826286,CHI3L1;Chitinase-3-like protein 1,1.23383318596277,1.18495347472142,1.28472920098484,2.23348387138914e-24
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10481123898978,CHI3L1;Chitinase-3-like protein 1,3.83280224961775,2.95952961976784,4.96375268101804,2.32217334022814e-24
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34056127441387,FLT3LG;Fms-related tyrosine kinase 3 ligand,1.23499880759703,1.14581039620169,1.33112953052454,3.41005568165031e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212666328481679,FLT3LG;Fms-related tyrosine kinase 3 ligand,1.74930194904328,1.45481104973886,2.10340532502546,2.75188753452585e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103374292958845,FLT3LG;Fms-related tyrosine kinase 3 ligand,1.94022063299172,1.49164652569489,2.52369179952542,7.77621510401394e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,COL9A1;Collagen alpha-1(IX) chain,1.53875001421415,1.36473508127129,1.73495328048459,1.94372053295363e-12
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246645619573796,TIMP4;Metalloproteinase inhibitor 4,1.60111770284955,1.34031298835307,1.91267108552628,2.11675877210121e-07
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.203071705999487,TIMP4;Metalloproteinase inhibitor 4,1.65026467911925,1.36130251223107,2.00056452307957,3.38741501461296e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,TIMP4;Metalloproteinase inhibitor 4,2.40643896583731,2.14129608156509,2.70441278352665,3.3746831888756e-49
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,TIMP4;Metalloproteinase inhibitor 4,1.44099629221453,1.33499336008375,1.55541621124299,7.16742688803821e-21
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60328187241126,TIMP4;Metalloproteinase inhibitor 4,1.20597405509748,1.12362891745327,1.29435385559908,2.09987818489537e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781126716111724,TIMP4;Metalloproteinase inhibitor 4,1.33825513876834,1.21134634834192,1.47845974761163,9.9460028672963e-09
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.40442331708496,TIMP4;Metalloproteinase inhibitor 4,1.21221979018205,1.17273418239037,1.25303486653198,4.6602983744393e-30
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,TIMP4;Metalloproteinase inhibitor 4,1.31879836556109,1.26387394345937,1.37610964923143,3.13116751619775e-37
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23266631912419,TIMP4;Metalloproteinase inhibitor 4,1.24701175436392,1.1938667480458,1.30252251188601,2.95460712106811e-23
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773495925333964,TIMP4;Metalloproteinase inhibitor 4,1.32675672837097,1.19973625518808,1.46722532445406,3.65938051517065e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805528134254689,TIMP4;Metalloproteinase inhibitor 4,1.27822639799536,1.15811270862147,1.4107976817533,1.08554625228508e-06
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11685689727547,TIMP4;Metalloproteinase inhibitor 4,1.24192225286927,1.16754570961918,1.32103682919186,6.14956566273232e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703334913861229,TIMP4;Metalloproteinase inhibitor 4,1.27387968657982,1.14591327674876,1.41613635936299,7.40938295829837e-06
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.463730365458994,TIMP4;Metalloproteinase inhibitor 4,1.39456792078268,1.22435945256673,1.58843849459327,5.50458290166919e-07
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.537039962091296,TIMP4;Metalloproteinase inhibitor 4,1.33773750787437,1.18409715171382,1.51131318691529,2.94379920422773e-06
sensitivity,Circulatory system disorders,I95 (hypotension),4.79237657500594,TIMP4;Metalloproteinase inhibitor 4,1.2611904736954,1.2106830206954,1.31380500407647,9.15564964392625e-29
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.392451766032947,FSHB;Follitropin subunit beta,1.76439280258394,1.44228870618348,2.15843190649929,3.3723915347814e-08
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24882990698501,ESM1;Endothelial cell-specific molecule 1,1.55567685537604,1.31157644440914,1.84520733707059,3.88411202597731e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13594151353487,ESM1;Endothelial cell-specific molecule 1,1.2324475356779,1.16178573670599,1.3074071063268,3.98139895695984e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54409116989494,ESM1;Endothelial cell-specific molecule 1,1.35559036130019,1.20669267487179,1.52286101168653,2.97800577105554e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34420842159444,ESM1;Endothelial cell-specific molecule 1,1.32597714740224,1.23096442734369,1.42832348066065,1.02479803822631e-13
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60848869496231,ESM1;Endothelial cell-specific molecule 1,1.26748320091869,1.1839671671181,1.35689038448719,9.37858559684452e-12
sensitivity,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.187432179145703,ESM1;Endothelial cell-specific molecule 1,1.58999156430395,1.30750039893243,1.93351617836742,3.37758088495051e-06
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36284170375079,ESM1;Endothelial cell-specific molecule 1,1.23984129188712,1.15139230087443,1.3350848602174,1.2470430763114e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.41290630784848,ESM1;Endothelial cell-specific molecule 1,1.20337535479,1.15449017104292,1.25433050955105,2.14600618732307e-18
sensitivity,Circulatory system disorders,I81 (portal vein thrombosis),0.0769367343315381,ESM1;Endothelial cell-specific molecule 1,2.09341730981359,1.55758811161869,2.81357824981913,9.70204771283758e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.224989638635062,ESM1;Endothelial cell-specific molecule 1,2.47195964161839,2.08208192104626,2.9348434410878,4.93591801526672e-25
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.272851296043656,ESM1;Endothelial cell-specific molecule 1,1.73656590945148,1.4793138554027,2.03855398694155,1.51138526622712e-11
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104567426260234,ESM1;Endothelial cell-specific molecule 1,3.20346641457573,2.51420946571689,4.08167943413122,4.57791778677778e-21
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.401569563321783,GSN;Gelsolin,1.57656279012261,1.35923670846958,1.82863677511902,1.79135474189128e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54854743846169,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,2.24049212370163,1.99817376692179,2.51219640627256,2.11955820380264e-43
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35127102692635,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.3189417467039,1.22360888508731,1.42170210792006,4.76182794597854e-13
sensitivity,Circulatory system disorders,I50 (heart failure),4.42483165318563,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.22673575054377,1.17664033943633,1.27896397159313,7.50111532301945e-22
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802926925739147,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.34647344621836,1.22228035665481,1.4832855093352,1.68846551631546e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13818094456345,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.20897580663211,1.13850457488884,1.28380907135527,5.89639574742953e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.712433951435752,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.33415284573516,1.2036744321624,1.47877513073492,4.01202559867813e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223196650075057,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.7330017583403,1.44480489104284,2.07868558102875,3.1174738922531e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104650014808964,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,2.06354332459284,1.58819058439589,2.68117132434165,5.86742566398905e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.02575736743205,OCLN;Occludin,1.24067567386048,1.16166557751335,1.32505960192443,1.33129299412235e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.398835583468952,OCLN;Occludin,2.94087821572832,2.5624124506499,3.37524299710291,3.69256813377971e-53
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0434732868092895,OCLN;Occludin,2.61470988884034,1.7194744321163,3.97604504905896,6.97135232421625e-06
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96506714245469,OCLN;Occludin,1.2217635672053,1.15581748697574,1.2914722531634,1.49492994356856e-12
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35966926963711,OCLN;Occludin,1.67059621187471,1.54384573769201,1.80775296066976,3.22626622578224e-37
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.751827996424232,OCLN;Occludin,1.30210659978355,1.16931779142613,1.44997502785965,1.50787571987202e-06
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59646660992385,OCLN;Occludin,1.2748286619402,1.18386712441934,1.37277916058473,1.28531421622384e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.76241500103029,OCLN;Occludin,1.44918569214846,1.30236300711176,1.61256052180511,9.95495577888895e-12
sensitivity,Circulatory system disorders,I50 (heart failure),4.29653229902571,OCLN;Occludin,1.31882692311025,1.26000739029957,1.38039226318103,1.36106250228288e-32
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.744422557148747,OCLN;Occludin,1.32141735751647,1.18585018037444,1.4724826640364,4.50118868726465e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.749278218230145,OCLN;Occludin,1.49024936624815,1.338866481733,1.65874880273976,2.8900912402936e-13
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.05767044795508,OCLN;Occludin,1.25040380556628,1.1708257733921,1.33539055298113,2.7261014146004e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.396316319985338,OCLN;Occludin,1.48097862099639,1.27747266778041,1.71690379854403,1.92001717476816e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.678696718868227,OCLN;Occludin,1.55289377255503,1.3883208097136,1.73697538203556,1.35821368154933e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.205992080748895,OCLN;Occludin,2.61755991109097,2.1571958244319,3.17616964141629,1.84608630224849e-22
sensitivity,Circulatory system disorders,I95 (hypotension),4.5225668498379,OCLN;Occludin,1.23294729952686,1.17967552516986,1.28862472008283,1.50724472944443e-20
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100672676520386,OCLN;Occludin,3.76164791137263,2.89192245362795,4.89293721945508,5.30637690332327e-23
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775347518293045,OMG;Oligodendrocyte-myelin glycoprotein,0.798049283552077,0.722648792112889,0.881316990949169,8.39212675919199e-06
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,OMG;Oligodendrocyte-myelin glycoprotein,0.78708666028159,0.713842544810898,0.867846019120839,1.55420984179979e-06
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406608881924747,OMG;Oligodendrocyte-myelin glycoprotein,0.719755631229807,0.627761226986735,0.825231228716781,2.44009467336013e-06
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702771380925911,OMG;Oligodendrocyte-myelin glycoprotein,0.748530320527117,0.674240494044657,0.831005621432341,5.59895458584801e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.541402527857621,OMD;Osteomodulin,1.33895515502101,1.18627559035575,1.51128533852719,2.29807817179142e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223880597014925,OMD;Osteomodulin,1.79964781181915,1.49620973763466,2.16462449422735,4.46687399666108e-10
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104052143866813,OMD;Osteomodulin,2.18818335966702,1.67812541708599,2.85327089785584,7.33523611283399e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534002829417976,PAEP;Glycodelin,1.48982733850331,1.30980562419915,1.69459151613353,1.30054602450922e-09
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.73292964704007,PAEP;Glycodelin,1.2070246210045,1.12604282412215,1.29383039836592,1.09533878003551e-07
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07869283127015,PAEP;Glycodelin,1.22945461425298,1.1240480831706,1.34474554170698,6.27428369818137e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,SUSD2;Sushi domain-containing protein 2,1.20081377741929,1.1137378354698,1.29469762283127,1.89175510302029e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,SUSD2;Sushi domain-containing protein 2,2.11589771366275,1.76816485220665,2.5320168134187,2.79420431358488e-16
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102507490932029,SUSD2;Sushi domain-containing protein 2,3.07430405104587,2.39017563730498,3.95424723219664,2.23214239532223e-18
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.239812867336308,TFRC;Transferrin receptor protein 1,1.5241430077828,1.27634443503127,1.82005095522376,3.23580537923393e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.551463347382518,TFRC;Transferrin receptor protein 1,1.52333934309331,1.35304815809434,1.71506294165043,3.42608789992396e-12
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33793103448275,TFRC;Transferrin receptor protein 1,1.3369577788646,1.23935049532567,1.4422523000621,6.00913070650194e-14
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782063626181446,TFRC;Transferrin receptor protein 1,1.28395950689251,1.16239343543187,1.4182392682966,8.43038259605121e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.41080309905482,TFRC;Transferrin receptor protein 1,1.20221774548665,1.15268307715242,1.25388108510584,9.57864510343567e-18
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07977342459287,TFRC;Transferrin receptor protein 1,1.22685302552877,1.12671823245447,1.3358870948331,2.52109286644787e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,MOG;Myelin-oligodendrocyte glycoprotein,3.33074527147558,2.97670358969869,3.72689578560956,9.10128630298744e-98
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547516621040281,MOG;Myelin-oligodendrocyte glycoprotein,3.18110201602111,2.2736774565226,4.45067967195767,1.4401706389747e-11
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24408818417918,IGFBP2;Insulin-like growth factor-binding protein 2,1.57666190647202,1.33578098589506,1.86098079967375,7.34434783495393e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.503473577394426,IGFBP2;Insulin-like growth factor-binding protein 2,1.3354469575368,1.18596093592779,1.50377514331794,1.78971540329416e-06
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13747020436872,IGFBP2;Insulin-like growth factor-binding protein 2,1.32381456043106,1.24925965872345,1.40281884408245,2.42633158146341e-21
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.551707946942129,IGFBP2;Insulin-like growth factor-binding protein 2,2.90996829891148,2.62579326211993,3.22489802332466,2.89861581578609e-92
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.064365125804564,IGFBP2;Insulin-like growth factor-binding protein 2,2.75913308726425,2.09300754853623,3.63726131736146,6.06366040537434e-13
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0565853658536585,IGFBP2;Insulin-like growth factor-binding protein 2,3.06200855604453,2.30147777019334,4.07385920416788,1.56722550619562e-14
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34672225810871,IGFBP2;Insulin-like growth factor-binding protein 2,1.52781732882198,1.42201411883044,1.64149269640766,5.49797204765445e-31
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60417320363978,IGFBP2;Insulin-like growth factor-binding protein 2,1.37995348241877,1.29106600081308,1.47496070103343,2.53813545339461e-21
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72484679992951,IGFBP2;Insulin-like growth factor-binding protein 2,1.26949085629551,1.18960324606545,1.35474330584437,6.22368265235921e-13
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.75212170988306,IGFBP2;Insulin-like growth factor-binding protein 2,1.22119439186419,1.14431322027969,1.30324085774002,1.70979295014729e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782759764976868,IGFBP2;Insulin-like growth factor-binding protein 2,1.41453658412284,1.28670444386024,1.55506865416503,7.16420672755151e-13
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35342185903983,IGFBP2;Insulin-like growth factor-binding protein 2,1.20125706822422,1.11564488319768,1.29343894790486,1.16849358912881e-06
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.40260775948004,IGFBP2;Insulin-like growth factor-binding protein 2,1.26746213228856,1.22745846120702,1.30876954907766,1.50870409858257e-47
sensitivity,Circulatory system disorders,I50 (heart failure),4.41706198452847,IGFBP2;Insulin-like growth factor-binding protein 2,1.39669766230591,1.34084025245414,1.45488200874064,6.2412410926828e-58
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21875620113505,IGFBP2;Insulin-like growth factor-binding protein 2,1.2997888229905,1.24633945487231,1.35553037157451,1.93611879268311e-34
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.0612300826058,IGFBP2;Insulin-like growth factor-binding protein 2,1.21924718108777,1.14846653099911,1.29439008318094,8.22007169644777e-11
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72074223414042,IGFBP2;Insulin-like growth factor-binding protein 2,1.23320376593968,1.17076370378122,1.29897392908245,2.63771371657183e-15
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773346873413271,IGFBP2;Insulin-like growth factor-binding protein 2,1.39717156238864,1.26993923382386,1.53715100908384,6.63264115283694e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80695584212583,IGFBP2;Insulin-like growth factor-binding protein 2,1.32632343308336,1.20647319862094,1.4580795090656,5.08545194968402e-09
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07655034973232,IGFBP2;Insulin-like growth factor-binding protein 2,1.23733387584986,1.13888190593637,1.34429664071877,4.79955066685567e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14415697444418,IGFBP2;Insulin-like growth factor-binding protein 2,1.31370135239417,1.23896404782451,1.39294699173283,6.8480817653963e-20
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408250966910184,IGFBP2;Insulin-like growth factor-binding protein 2,1.39710449133315,1.2246951412442,1.59378517474992,6.48428742897133e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705836347639065,IGFBP2;Insulin-like growth factor-binding protein 2,1.4092181295577,1.27509729990059,1.55744642924813,1.78608367871349e-11
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0448657927590511,IGFBP2;Insulin-like growth factor-binding protein 2,2.94035438031181,2.1358414173198,4.04790534152486,3.77356034101119e-11
sensitivity,Circulatory system disorders,I83 (varicose veins of lower extremities),2.08362692005717,IGFBP2;Insulin-like growth factor-binding protein 2,1.27239528593351,1.19857693514537,1.35075998560698,2.78732487882281e-15
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.455015915792762,IGFBP2;Insulin-like growth factor-binding protein 2,1.49847848687241,1.32527224612189,1.69432188909877,1.09240838392679e-10
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.535386298800265,IGFBP2;Insulin-like growth factor-binding protein 2,1.42566636435422,1.27200096279199,1.59789547485064,1.09695076345622e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.78580531320458,IGFBP2;Insulin-like growth factor-binding protein 2,1.30152535673092,1.2515462236381,1.35350035198011,9.88395215229072e-40
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243266042806976,C1QA;Complement C1q subcomponent subunit A,1.54356129637644,1.29562902748702,1.83893801784647,1.17932709773836e-06
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513685201160693,C1QA;Complement C1q subcomponent subunit A,1.35424981119401,1.2000613209421,1.52824903120722,8.78356047707113e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1200997232092,C1QA;Complement C1q subcomponent subunit A,1.21042084043857,1.14006774833665,1.28511539169984,4.08787189508481e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544482446829421,C1QA;Complement C1q subcomponent subunit A,2.06545122078882,1.83804643538031,2.32099073415157,3.6079927974509e-34
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0646678424456202,C1QA;Complement C1q subcomponent subunit A,2.37258606186422,1.69879901692876,3.31361424444976,3.99749515592877e-07
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01868571877208,C1QA;Complement C1q subcomponent subunit A,1.24722592089123,1.14387419102114,1.35991572320931,5.56553112374904e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33931205380848,C1QA;Complement C1q subcomponent subunit A,1.41916787845398,1.31636903533967,1.52999456320079,7.18647203425935e-20
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774692084412018,C1QA;Complement C1q subcomponent subunit A,1.34848599944819,1.22132970211192,1.48888092016709,3.28639570419794e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.42554874431481,C1QA;Complement C1q subcomponent subunit A,1.27675986681105,1.22448520407538,1.33126619421285,2.22396995100178e-30
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775011281809798,C1QA;Complement C1q subcomponent subunit A,1.27955940037919,1.15899712285739,1.41266291935413,1.04822382780023e-06
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07961683417085,C1QA;Complement C1q subcomponent subunit A,1.28590718331007,1.18194992897856,1.39900789665215,5.01744808109409e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.21371291884791,C1QA;Complement C1q subcomponent subunit A,1.89576630116591,1.57322164116743,2.2844396330382,1.79238290211301e-11
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.453198877793254,C1QA;Complement C1q subcomponent subunit A,1.41260324039718,1.24192485628753,1.60673804431741,1.45897293731416e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103882867167133,C1QA;Complement C1q subcomponent subunit A,1.89815454229651,1.45307665407302,2.4795599436145,2.58874087807576e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.532431775852295,RBKS;Ribokinase,0.732065288099757,0.64713828923907,0.828137656127156,7.14754740786587e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216117955968491,RBKS;Ribokinase,2.01848182280051,1.67245212806069,2.43610492678224,2.47859936516025e-13
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100957073052538,RBKS;Ribokinase,3.17277286088989,2.43915458355018,4.12703962868464,7.56537069992578e-18
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214013950538998,DPP6;Dipeptidyl aminopeptidase-like protein 6,1.94950925069788,1.62298278207481,2.34172929037359,9.48972938733665e-13
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101026108315835,DPP6;Dipeptidyl aminopeptidase-like protein 6,3.1032596013841,2.42224625556305,3.97573951511551,3.28769052543021e-19
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.402386244005146,CHAD;Chondroadherin,1.55197587253262,1.3282175582198,1.81342965541854,3.14541415641692e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.551996454329344,DPP4;Dipeptidyl peptidase 4,0.740192033592222,0.65628930606662,0.834821231321073,9.52802049843663e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33825100268053,DPP4;Dipeptidyl peptidase 4,0.775895698825604,0.718524369799578,0.837847901559686,9.55004230961421e-11
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08234252720944,DPP4;Dipeptidyl peptidase 4,0.764968639237303,0.701073891538782,0.834686651548483,1.73915044152696e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.225053249206285,DPP4;Dipeptidyl peptidase 4,2.4050836903723,2.00311542251067,2.88771555183012,5.19264228183153e-21
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104453327441094,DPP4;Dipeptidyl peptidase 4,3.77337312385755,2.90822624686988,4.8958861942654,1.61443843353924e-23
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.541022592152199,MMP10;Stromelysin-2,1.99094135482177,1.76542761761187,2.24526196304865,3.00612158052019e-29
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34237503222096,MMP10;Stromelysin-2,1.22865612022458,1.13878957686261,1.32561440009338,1.074579289376e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783011033337287,MMP10;Stromelysin-2,1.30860038553919,1.18375008752274,1.44661866308029,1.46224936237029e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223381963389079,MMP10;Stromelysin-2,1.6041079684176,1.32973003854527,1.93510133617489,7.91714619791213e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104738943124777,MMP10;Stromelysin-2,1.90608985219811,1.44773102703031,2.50956735527403,4.29754521696212e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33958341505511,NCAN;Neurocan core protein,0.794384164765943,0.73436036160334,0.859314083691979,9.33760390621061e-09
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246645619573796,OGN;Mimecan,1.65407840593499,1.38419716102935,1.97657924030552,3.07014880348592e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518625150361854,OGN;Mimecan,1.39760693498862,1.23565941300147,1.5807795612414,9.95596530302284e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14412635735439,OGN;Mimecan,1.2453511900443,1.17215831860403,1.32311443081493,1.24789308291581e-12
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.203071705999487,OGN;Mimecan,1.69449589959548,1.39974126321351,2.0513193610896,6.33633361906137e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,OGN;Mimecan,4.38640640871297,3.89618004257719,4.93831418777845,4.86191911562989e-132
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.065040009460365,OGN;Mimecan,3.67601865182592,2.68230385683656,5.03787559121251,5.67188583418515e-16
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.055206135767661,OGN;Mimecan,3.00167180294769,2.11675376735915,4.25653363728372,6.92367152170358e-10
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00874508952365,OGN;Mimecan,1.3025041211764,1.19358260148112,1.42136537812823,3.00125136329279e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,OGN;Mimecan,1.47118973288031,1.36286075004857,1.58812940357649,4.45530544165877e-23
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.746460238156361,OGN;Mimecan,1.29227931767164,1.16657135016676,1.43153338597177,9.07723500024963e-07
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60328187241126,OGN;Mimecan,1.25007307409297,1.16488205731988,1.34149434335662,5.71870042840613e-10
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72526363690323,OGN;Mimecan,1.24846522882309,1.16731440154248,1.33525760114042,9.70281816777862e-11
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.75081513684418,OGN;Mimecan,1.20767794755485,1.12994760810226,1.29075544259952,2.70999986507704e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781126716111724,OGN;Mimecan,1.4555997927002,1.31897939844216,1.60637138003167,8.29344405349051e-14
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37165770093495,OGN;Mimecan,1.21884109928115,1.12982070150619,1.31487555796812,3.14874792888687e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,OGN;Mimecan,1.37294772122759,1.31569514509031,1.43269164764961,3.5188732208387e-48
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23266631912419,OGN;Mimecan,1.28686896605515,1.23218127031086,1.34398385667561,5.07253738247065e-30
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.07307182560876,OGN;Mimecan,1.26665069250001,1.19103317919096,1.34706908660647,5.21513733706323e-14
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71750954292834,OGN;Mimecan,1.27289654708751,1.20602814723549,1.34347247475223,1.88402301901823e-18
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773495925333964,OGN;Mimecan,1.44568426089921,1.30834497863117,1.59744029009714,4.58273358951964e-13
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805528134254689,OGN;Mimecan,1.41058258059714,1.2789633814406,1.55574682243277,5.85074363773426e-12
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08191348640698,OGN;Mimecan,1.25801648516899,1.15716349067181,1.36765935817603,7.2987030309926e-08
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11685689727547,OGN;Mimecan,1.28544615828449,1.20858510288682,1.36719526155129,1.43526522608139e-15
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406616398878844,OGN;Mimecan,1.48861963277624,1.29897858070352,1.70594684470217,1.05152495738484e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703334913861229,OGN;Mimecan,1.44822654550149,1.30404571640361,1.6083486190035,4.46669594552674e-12
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0453362769060947,OGN;Mimecan,2.87525450601578,1.96450849273911,4.20822231358095,5.4948287544987e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.79237657500594,OGN;Mimecan,1.27317842167297,1.22207562244493,1.32641815583448,6.95560171969075e-31
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543199146683522,SCG3;Secretogranin-3,2.25170604790999,2.00097486152565,2.53385498422936,2.16825201025893e-41
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0571327252309935,SCG3;Secretogranin-3,2.36435604812464,1.65283159476893,3.38218336338439,2.466803039979e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.224621689785624,SCG3;Secretogranin-3,1.60230264661486,1.33211485844949,1.92729159581425,5.63101568645602e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33402460667211,BCAN;Brevican core protein,0.78078028745242,0.72269872859466,0.84352972151996,3.51101144838198e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80001592071484,BCAN;Brevican core protein,0.775487223751898,0.701950575859941,0.856727602888125,5.67207956829554e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.401366941125203,SYT1;Synaptotagmin-1,2.70133343709684,2.34420382502998,3.11287024637633,6.21296858401146e-43
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.240599709689606,PTGDS;Prostaglandin-H2 D-isomerase,1.5506333097173,1.29094231855346,1.86256475339587,2.72261599126502e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.551869782639013,PTGDS;Prostaglandin-H2 D-isomerase,4.17051403495373,3.72410830298076,4.67043004679123,6.09384374934972e-135
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0635563764920852,PTGDS;Prostaglandin-H2 D-isomerase,3.11560133687876,2.20323578558886,4.40577978709906,1.29107069539144e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0576208547755767,PTGDS;Prostaglandin-H2 D-isomerase,3.94486107861403,2.75972480823876,5.6389422898638,5.12406188147567e-14
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97670053454115,PTGDS;Prostaglandin-H2 D-isomerase,1.23342797177055,1.16854080355198,1.30191821879187,2.76479996719987e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00861400123341,PTGDS;Prostaglandin-H2 D-isomerase,1.27237370471839,1.1614203171654,1.39392674687319,2.28519784189717e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34337877700709,PTGDS;Prostaglandin-H2 D-isomerase,1.38349553092103,1.27872021359977,1.49685589053929,6.54329735413478e-16
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.785147786678328,PTGDS;Prostaglandin-H2 D-isomerase,1.4279226932294,1.28744298463818,1.58373088530404,1.56633290183831e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.41571457205852,PTGDS;Prostaglandin-H2 D-isomerase,1.24248634231931,1.18894289971089,1.29844108680528,4.44423942083337e-22
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06518488986345,PTGDS;Prostaglandin-H2 D-isomerase,1.20289844355678,1.12869228835837,1.28198330088341,1.29812462915034e-08
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773544384346166,PTGDS;Prostaglandin-H2 D-isomerase,1.36273987667449,1.22832286887986,1.51186631668944,5.17988551502456e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80377215844657,PTGDS;Prostaglandin-H2 D-isomerase,1.42717814911659,1.28819444347011,1.58115685069179,1.01504698382305e-11
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12697389622945,PTGDS;Prostaglandin-H2 D-isomerase,1.22867160172314,1.15340962477993,1.30884455309529,1.71056122370817e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702809246023055,PTGDS;Prostaglandin-H2 D-isomerase,1.42181754884746,1.27486130503229,1.58571378253527,2.57275502246187e-10
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0476729634705917,PTGDS;Prostaglandin-H2 D-isomerase,2.68793563769925,1.7764024028506,4.06720795964904,2.88288188379401e-06
sensitivity,Circulatory system disorders,I95 (hypotension),4.79974443956395,PTGDS;Prostaglandin-H2 D-isomerase,1.22123859685799,1.17108550426793,1.2735395537049,9.50143257691909e-21
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.395745167562621,PTPRZ1;Receptor-type tyrosine-protein phosphatase zeta,1.47340805711348,1.26230283086573,1.71981813688718,9.00171744953953e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100472678281917,PTPRZ1;Receptor-type tyrosine-protein phosphatase zeta,2.15923974658162,1.60257240694248,2.90927028508684,4.18702570955471e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35127102692635,SSC4D;Scavenger receptor cysteine-rich domain-containing group B protein,0.767719055912112,0.711120534721744,0.828822288251329,1.33267672529405e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223196650075057,SSC4D;Scavenger receptor cysteine-rich domain-containing group B protein,0.55650388866701,0.46527203154199,0.665624746613538,1.40411026706259e-10
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.526076379961632,SSC4D;Scavenger receptor cysteine-rich domain-containing group B protein,0.72838699449212,0.644555440168488,0.823121768403007,3.77154737559187e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104650014808964,SSC4D;Scavenger receptor cysteine-rich domain-containing group B protein,0.466700533328346,0.362434910094211,0.600961391253249,3.4771020244201e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.528503562945368,STC2;Stanniocalcin-2,1.97901320545968,1.75380104496571,2.23314570294394,1.67954555248993e-28
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0651285796048866,STC2;Stanniocalcin-2,2.24931846544464,1.59758962125575,3.16691689259559,3.42004945635834e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34487402947234,STC2;Stanniocalcin-2,1.29629307300976,1.20121833276256,1.39889284512379,2.43344660930226e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782191320836707,STC2;Stanniocalcin-2,1.30702145863997,1.18179057969493,1.44552268624982,1.88535863741954e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.806626994325932,STC2;Stanniocalcin-2,1.37683073123728,1.24712335739253,1.52002835264252,2.38104775141731e-10
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11569255404323,STC2;Stanniocalcin-2,1.23319918529683,1.15983765236601,1.31120094912805,2.10546372655706e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407162904692255,STC2;Stanniocalcin-2,1.46607838984327,1.27526206189048,1.68544639521317,7.54386280234378e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702302761731423,STC2;Stanniocalcin-2,1.34986397120232,1.21465966712102,1.50011792609276,2.52814371746415e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.398835583468952,LRTM2;Leucine-rich repeat and transmembrane domain-containing protein 2,1.43782882239658,1.23959101163537,1.66776921025501,1.60615964513619e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,RTBDN;Retbindin,2.96100388760481,2.64096717213946,3.31982317497274,3.17674254548517e-77
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0574564618707031,RTBDN;Retbindin,2.66198311912862,1.88003994682887,3.7691508302673,3.43420054581495e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,RTBDN;Retbindin,1.26437337826775,1.14618515510141,1.39474851210296,2.80131164454725e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.386586146948485,BGLAP;Osteocalcin,1.74304538604815,1.49867415581186,2.02726336878606,5.61419807231521e-13
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0479408273217057,BGLAP;Osteocalcin,2.86305203532038,1.89920755328115,4.31604589124058,5.08930083759889e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36612648130744,BGLAP;Osteocalcin,1.27684280334584,1.17742666383037,1.38465315466217,3.43735711886464e-09
sensitivity,Circulatory system disorders,I72 (other aneurysm),0.326774982290167,BGLAP;Osteocalcin,1.47261185970714,1.24905492208373,1.73618121269831,4.08098229054485e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.393580165445075,SLITRK1;SLIT and NTRK-like protein 1,2.14734664051533,1.85861574766054,2.48093109096731,3.29082001166896e-25
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245865884125788,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.64017773993928,1.34020962809294,2.00728525015921,1.57485003393468e-06
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1346665079554,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.22276620566821,1.13923937504164,1.31241706219079,2.53194752830471e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,3.91500390729706,3.47996994052452,4.40442183585099,3.62450270745065e-114
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0613946487631949,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,2.9883843659963,2.06050511847869,4.33410285606309,7.86960812262761e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0574564618707031,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,3.74241880343254,2.57463680413475,5.4398734912019,4.65628846244727e-12
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.32718281212522,1.21426432592471,1.45060196465808,4.39999690796248e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.37242538376608,1.22081319316985,1.5428662178157,1.15510051124045e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.247009583056972,SERPIND1;Heparin cofactor 2,0.583349576122792,0.482753032927429,0.70490852413515,2.39288202443494e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36687842579639,SERPIND1;Heparin cofactor 2,0.787603270964463,0.72592956831493,0.85451666319894,9.52658962458932e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107381936987365,SERPIND1;Heparin cofactor 2,0.447101234493068,0.33814361552978,0.591167494237728,1.61834937228665e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13450350455691,LY6D;Lymphocyte antigen 6D,1.20046517991643,1.13051907849371,1.27473890145394,2.44359941456234e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544764101238642,LY6D;Lymphocyte antigen 6D,4.0149521912371,3.58130064263511,4.50111361945271,1.42680379031398e-125
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0634291377601585,LY6D;Lymphocyte antigen 6D,2.94280826533739,2.10375869761876,4.11649895795581,2.92026729696918e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0555225064445766,LY6D;Lymphocyte antigen 6D,3.05775932975938,2.13521234745725,4.37890504420557,1.06054014283708e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34874375857884,LY6D;Lymphocyte antigen 6D,1.35569041191645,1.25682231226414,1.46233598419433,3.36823981977209e-15
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60830659465492,LY6D;Lymphocyte antigen 6D,1.21397279318849,1.13265665034077,1.3011268173444,4.22142348486402e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.779607220789525,LY6D;Lymphocyte antigen 6D,1.37374539186934,1.24413871684081,1.51685368852942,3.37757486306289e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.41044104410441,LY6D;Lymphocyte antigen 6D,1.23284950429744,1.18191498052627,1.28597904696129,2.38291713946998e-22
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23245216058717,LY6D;Lymphocyte antigen 6D,1.22250158251195,1.17097833690784,1.27629185966899,5.99542319382124e-20
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.777963007065174,LY6D;Lymphocyte antigen 6D,1.36749481571535,1.23831670111516,1.5101484695509,6.32702965844711e-10
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406955969349267,LY6D;Lymphocyte antigen 6D,1.45728113153639,1.27060900596544,1.67137828109313,7.26994480060992e-08
sensitivity,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0991807668656894,LY6D;Lymphocyte antigen 6D,1.989861153061,1.5107959546675,2.6208353260601,9.76523315750077e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.238254637104713,CST3;Cystatin-C,1.80869471370952,1.52039504990922,2.15166220621153,2.24353948439364e-11
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.509671960170809,CST3;Cystatin-C,1.40165111512603,1.24033018431222,1.58395391274256,6.22092280998653e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13570809362439,CST3;Cystatin-C,1.26058725525594,1.18660365487582,1.33918366219763,6.17198888988922e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.550436995679365,CST3;Cystatin-C,4.07180871071401,3.68247474552411,4.50230546639818,4.48485817890101e-165
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.060970812681929,CST3;Cystatin-C,2.94515648263216,2.14403389524813,4.04562013987487,2.58372837846557e-11
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0570596568550291,CST3;Cystatin-C,2.8543808388267,2.04413293891484,3.98579261551659,7.41202619249147e-10
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97005697660322,CST3;Cystatin-C,1.22697421781413,1.16436492472146,1.29295008739699,1.93897962251805e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00271856900831,CST3;Cystatin-C,1.33327902178835,1.22086520437273,1.45604358578983,1.5486061916046e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33625453971261,CST3;Cystatin-C,1.4974454076547,1.38816103312518,1.61533330456478,1.58225192135401e-25
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61169118810314,CST3;Cystatin-C,1.30004555941463,1.21267282566866,1.3937134738892,1.44422028558687e-13
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71365395245992,CST3;Cystatin-C,1.21345138147128,1.13398408191764,1.29848758785444,2.16273818232939e-08
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.678661616161616,CST3;Cystatin-C,1.32680634600018,1.19212312915022,1.47670575021997,2.2449342379129e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.785371230611762,CST3;Cystatin-C,1.51876618799889,1.3757909930756,1.67659967641751,1.18791868190347e-16
sensitivity,Circulatory system disorders,I50 (heart failure),4.4085829413049,CST3;Cystatin-C,1.31704163870372,1.26209384529644,1.37438169478748,9.18672217690276e-37
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21985673696426,CST3;Cystatin-C,1.24941734390612,1.19605913837015,1.30515594854333,1.52843518939948e-23
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06087883453748,CST3;Cystatin-C,1.24470561017452,1.17022904984477,1.32392206141648,3.56068736950685e-12
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771927060769564,CST3;Cystatin-C,1.42718462674283,1.29170395027589,1.57687522622812,2.75405938216059e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.801859841992237,CST3;Cystatin-C,1.5083734000189,1.36757788494372,1.66366416050827,2.01357889789681e-16
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13410985679524,CST3;Cystatin-C,1.28379630556324,1.20777755217458,1.36459975697544,1.04294885836639e-15
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405751428008666,CST3;Cystatin-C,1.56645694154664,1.36574197519091,1.79666979143455,1.40494610730236e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703836599503174,CST3;Cystatin-C,1.37998379996488,1.24255203497408,1.53261612758554,1.77268932056291e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.78854860712944,CST3;Cystatin-C,1.25361518430683,1.20365234592733,1.3056519481245,1.24983630357797e-27
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.21015121750651,IGSF9;Protein turtle homolog A,2.42618972452433,1.99962034641217,2.94375709366488,2.61454417737036e-19
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100472678281917,IGSF9;Protein turtle homolog A,3.38273051945553,2.62746003304073,4.35510554808065,3.27676092790955e-21
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534531980805442,C19orf12;Protein C19orf12,0.722280835696315,0.639634760017179,0.815605464593819,1.54189378980127e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214080866017691,C19orf12;Protein C19orf12,2.55040316522614,2.1172922257202,3.07211079612924,6.224660239537e-23
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100955034627576,C19orf12;Protein C19orf12,3.76829598849964,2.91207665083627,4.87626404094294,6.27103124969428e-24
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.397247641342129,RNASE4;Ribonuclease 4,3.01195070269059,2.64314164630077,3.43222129170977,1.75531698071703e-61
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36230098559514,RNASE4;Ribonuclease 4,1.41382034113157,1.30368629894686,1.53325839092742,5.80857919957667e-17
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.58285673604024,RNASE4;Ribonuclease 4,1.22032442350741,1.13116965071051,1.31650605872718,2.68678490115709e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.755822192829137,RNASE4;Ribonuclease 4,1.41194903502147,1.26753691014637,1.57281422066664,3.69168299953473e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.27669960709608,RNASE4;Ribonuclease 4,1.2535370260417,1.19683933227038,1.3129206513264,1.08160628339994e-21
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.678856115618421,RNASE4;Ribonuclease 4,1.35001763036909,1.20372081053667,1.51409495154845,2.92334178574851e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,MIA;Melanoma-derived growth regulatory protein,2.42221476769722,2.15187520837595,2.72651702013822,1.30990565174047e-48
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774843163090719,MIA;Melanoma-derived growth regulatory protein,1.30297622359238,1.17952977476297,1.43934224940462,1.87534064388971e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.535105256968128,SCARA5;Scavenger receptor class A member 5,3.15078138342312,2.79425968329776,3.55279195611821,2.73499543938754e-78
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.05473988778323,SCARA5;Scavenger receptor class A member 5,2.95201645390139,2.04841247651049,4.25422186402111,6.39931648347958e-09
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0469070653767223,SCARA5;Scavenger receptor class A member 5,3.27329768615582,2.20985658089012,4.84849461944599,3.30373669553675e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.393599925472203,BCHE;Cholinesterase,0.657985110476112,0.565896346677063,0.765059552249288,5.29016628352298e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,ERBB2;Receptor tyrosine-protein kinase erbB-2,0.725251057040771,0.642931700075039,0.818110377319029,1.73305923473322e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216284236811577,ERBB2;Receptor tyrosine-protein kinase erbB-2,2.83173361105342,2.35623164132912,3.4031947892213,1.28208503423334e-28
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.269855026788528,ERBB2;Receptor tyrosine-protein kinase erbB-2,1.54150316604646,1.29759411926191,1.83125984902189,8.46668343535538e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100241759537708,ERBB2;Receptor tyrosine-protein kinase erbB-2,4.48303830015978,3.50754755373885,5.72982464037487,4.34096649077732e-33
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.537402826492728,EPHA2;Ephrin type-A receptor 2,4.32137914537059,3.87696481284296,4.81673644707394,5.73567973572736e-154
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0593059162764064,EPHA2;Ephrin type-A receptor 2,3.14902366024096,2.24780128347768,4.41157769845886,2.58210187233364e-11
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0552373158756137,EPHA2;Ephrin type-A receptor 2,3.14461703217257,2.21236351872851,4.46970680691434,1.70275906575826e-10
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00778369520688,EPHA2;Ephrin type-A receptor 2,1.24334921643968,1.1381526411242,1.35826884563938,1.37199181291703e-06
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.98516804726393,EPHA2;Ephrin type-A receptor 2,1.2273043520067,1.15174636437162,1.30781916839512,2.65258158863045e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35049155429673,EPHA2;Ephrin type-A receptor 2,1.43934719982978,1.33296096441377,1.55422432986923,1.46053307593509e-20
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59552594785755,EPHA2;Ephrin type-A receptor 2,1.25111025991741,1.16565747404865,1.34282747489618,5.41393983372121e-10
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.67734253100106,EPHA2;Ephrin type-A receptor 2,1.20822695802086,1.12802407513322,1.29413229227038,6.75772088620445e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.765436646814432,EPHA2;Ephrin type-A receptor 2,1.36271417483323,1.23143173621001,1.50799258106397,2.12738251149109e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.37716691431401,EPHA2;Ephrin type-A receptor 2,1.32447152557316,1.26862489438344,1.38277660309248,1.98929004325285e-37
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20029957560123,EPHA2;Ephrin type-A receptor 2,1.2184466821326,1.16603145545888,1.27321806821728,1.2872492417874e-18
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71085573568643,EPHA2;Ephrin type-A receptor 2,1.22279853652538,1.15831984125408,1.29086648408764,3.40170658242986e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769892296981858,EPHA2;Ephrin type-A receptor 2,1.43375035207226,1.29582179367915,1.58636016317558,2.92169568010922e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.796902527963289,EPHA2;Ephrin type-A receptor 2,1.56159555304843,1.41381459489651,1.72482352361,1.53638560907532e-18
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14861978140489,EPHA2;Ephrin type-A receptor 2,1.33178584172683,1.25251950845305,1.41606858516289,5.61402483583129e-20
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407569737434973,EPHA2;Ephrin type-A receptor 2,1.44190421855165,1.25516273696984,1.65642885519075,2.32279411388851e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.694899967202361,EPHA2;Ephrin type-A receptor 2,1.52658516009784,1.37240923634719,1.6980811475983,6.81981498526012e-15
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0449952959463328,EPHA2;Ephrin type-A receptor 2,3.36543136371959,2.29382640374965,4.93765711537413,5.47569271144645e-10
sensitivity,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.65382920225827,EPHA2;Ephrin type-A receptor 2,1.20447506133701,1.12286287133654,1.29201900821243,2.0243946242208e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216897546602279,EPHA2;Ephrin type-A receptor 2,2.21327197110655,1.83844187920078,2.66452416772371,4.78575054811897e-17
sensitivity,Circulatory system disorders,I95 (hypotension),4.74252235584335,EPHA2;Ephrin type-A receptor 2,1.31174758023373,1.2587961330331,1.36692643796341,4.07092235462335e-38
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100229095074455,EPHA2;Ephrin type-A receptor 2,3.26859434958718,2.52639497566039,4.22883560372842,2.01529222260782e-19
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.390642847352309,AFM;Afamin,0.641533296667308,0.555814974722424,0.740471180968742,1.31153493941809e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.208916846503512,GPD1;Glycerol-3-phosphate dehydrogenase,2.05978439063832,1.69898506332432,2.49720367029936,1.91534663482031e-13
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103274963853762,GPD1;Glycerol-3-phosphate dehydrogenase,2.94536394038231,2.27321412631264,3.81625674453128,2.99834212090978e-16
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212577088394692,ADH1B;All-trans-retinol dehydrogenase,2.07446031107776,1.6952102846577,2.5385556123533,1.40207340108732e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107418910398617,ADH1B;All-trans-retinol dehydrogenase,2.9373636608876,2.22722877617359,3.8739196299027,2.33115056384413e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549773047425262,IGFBP1;Insulin-like growth factor-binding protein 1,2.03322110640723,1.81421547901993,2.278664312672,2.97047062206004e-34
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.056587574149235,IGFBP1;Insulin-like growth factor-binding protein 1,2.62151354003058,1.85683057993554,3.70110946837282,4.3254911307938e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34481746109425,IGFBP1;Insulin-like growth factor-binding protein 1,1.33355598249751,1.2377638782175,1.43676155828359,3.77637868460795e-14
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60622879444586,IGFBP1;Insulin-like growth factor-binding protein 1,1.20297401367813,1.12301139273292,1.28863027298694,1.3960733194591e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.41723588118344,IGFBP1;Insulin-like growth factor-binding protein 1,1.23711259685913,1.18707628692779,1.28925798127803,5.46265304879605e-24
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.453080753832633,IGFBP1;Insulin-like growth factor-binding protein 1,1.37582103877805,1.21013882056872,1.56418709867908,1.09717080931072e-06
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103396476716283,IGFBP1;Insulin-like growth factor-binding protein 1,1.90484091906841,1.46879015428901,2.47034534944427,1.18313315307465e-06
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.244669000636537,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.71052920635362,1.44595324052631,2.02351644837681,3.81740683406151e-10
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.506897785552419,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.49626710236405,1.32733573339043,1.68669853850636,4.31655975889037e-11
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11961389192954,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.31262297801971,1.23667692373708,1.39323298539341,3.69350570960511e-19
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.206685480345005,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.65816368679515,1.37926150955309,1.99346301855184,7.36360633652814e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534002829417976,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,3.10973623067363,2.83137755991254,3.41546092661091,2.66298248473708e-124
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0655646507192243,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.57165797702967,1.92775278555949,3.43063944731944,1.32995492768705e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0576403243758944,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.55907044684787,1.87854502243178,3.486124353545,2.5649036364937e-09
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97106476757948,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.27248407992554,1.20905800110364,1.339237432932,2.52949480845708e-20
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01689518616544,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.34199856125831,1.23170685090229,1.46216621032843,1.78239110706513e-11
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.67798428185399,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.2462833104662,1.2092107361501,1.28449247390224,2.53949030931226e-46
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.0010838367822,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.2878563036089,1.21082746732829,1.36978545952945,9.02882836087032e-16
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33402460667211,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.78030999684417,1.65693359951987,1.91287308422119,7.94899957977963e-56
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.732571565075447,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.29811499394411,1.17298516214967,1.43659322545421,4.53222055549455e-07
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61026091820833,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.37514998396069,1.28438270567947,1.47233178243915,6.03688955309833e-20
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71100386870338,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.29058671249657,1.20766612786403,1.37920077746871,5.11269438785141e-14
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.73292964704007,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.21344367832628,1.13565134820683,1.29656479763352,1.04693859170884e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.78342479917283,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.58000164791024,1.43595841047253,1.73849408812445,6.68135285823434e-21
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3726588762606,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.23517205246953,1.14643244909998,1.33078054481057,2.8170289380375e-08
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.33475479744136,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.20279205682473,1.16408284493265,1.24278846497764,1.89306017025292e-28
sensitivity,Circulatory system disorders,I50 (heart failure),4.40073780023256,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.47577111286685,1.41610661374339,1.53794944281427,2.83187775458049e-76
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20650482100624,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.32324510443768,1.26789733788818,1.38100897769431,8.82341620066192e-38
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06389088298636,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.2619374763441,1.18772523128298,1.34078670070982,5.33593433968257e-14
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.618708470934627,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.33584257170208,1.19680182204943,1.49103664741741,2.42204283299107e-07
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769827534761592,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.38064019755627,1.25143326750999,1.52318737610434,1.24368421697921e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80001592071484,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.66689905305892,1.51767851573895,1.83079118816929,1.2818849427143e-26
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07869283127015,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.28990811291939,1.18647867622097,1.40235385019714,2.37768546099572e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.10956861638895,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.37064586397545,1.29070519329039,1.45553771240644,8.40437868904631e-25
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40194205666985,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.70870721769967,1.4981265370605,1.94888768311101,1.42051056580128e-15
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70101368171589,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.60487356580349,1.45082946455671,1.77527354188507,4.0042458182412e-20
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0457020228112705,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.47675021149517,1.74149991990658,3.52241854278719,4.48615139544765e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216673955392994,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.25112893776561,1.90698410734363,2.65738003527712,9.1700209012242e-22
sensitivity,Circulatory system disorders,I95 (hypotension),4.79937685993329,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.34878149435982,1.29621717788878,1.40347740375618,2.97429170827912e-49
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0993601208219069,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.88383318741352,2.30550635465052,3.6072309391176,1.78313815805531e-20
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.506897785552419,GGT5;Glutathione hydrolase 5 proenzyme,1.38164661656481,1.22263059143701,1.56134435571528,2.19521249302772e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11961389192954,GGT5;Glutathione hydrolase 5 proenzyme,1.21549403515225,1.14481790904444,1.29053340083043,1.714976260029e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534002829417976,GGT5;Glutathione hydrolase 5 proenzyme,2.1310371119943,1.89431339734132,2.3973431107391,2.28978484842121e-36
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0655646507192243,GGT5;Glutathione hydrolase 5 proenzyme,2.6712883776437,1.91990811390419,3.71673078771645,5.51957678945993e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33402460667211,GGT5;Glutathione hydrolase 5 proenzyme,1.4514340673007,1.34589012218726,1.56525470912696,3.97236818473953e-22
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71100386870338,GGT5;Glutathione hydrolase 5 proenzyme,1.20074540084479,1.12339982204337,1.28341618839447,7.23725929408585e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.78342479917283,GGT5;Glutathione hydrolase 5 proenzyme,1.30619333776593,1.18430617678056,1.44062495752755,9.07037267703247e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.40073780023256,GGT5;Glutathione hydrolase 5 proenzyme,1.265681048775,1.21367064248379,1.31992029892869,3.60846189316133e-28
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80001592071484,GGT5;Glutathione hydrolase 5 proenzyme,1.3863038716636,1.25815291456524,1.52750782702244,4.10344037831264e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216673955392994,GGT5;Glutathione hydrolase 5 proenzyme,2.31422681362391,1.92586053986379,2.78091047302659,3.48220045364615e-19
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0993601208219069,GGT5;Glutathione hydrolase 5 proenzyme,3.41156331333786,2.61457707590375,4.45149020397103,1.56925281522129e-19
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,DPT;Dermatopontin,2.96318014235624,2.64204000355115,3.3233548864713,6.78473818086457e-77
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34461664744855,DPT;Dermatopontin,1.223588917979,1.13461632072085,1.3195384315024,1.61609897599778e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37606076234235,GHR;Growth hormone receptor,0.794030838823817,0.731459931216048,0.861954217991241,3.64531998573968e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37441301110983,LCAT;Phosphatidylcholine-sterol acyltransferase,0.734752786673928,0.678081888941163,0.796159971722745,5.22175604480701e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,"KRT18;Keratin, type I cytoskeletal 18",1.40937134429482,1.24749193217588,1.59225685945306,3.54157916089279e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214013950538998,"KRT18;Keratin, type I cytoskeletal 18",3.17397431770698,2.64905622047994,3.80290644327598,5.66415304153369e-36
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.27196569658951,"KRT18;Keratin, type I cytoskeletal 18",1.81121247439446,1.52446975891333,2.15188960503913,1.42900827328716e-11
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101026108315835,"KRT18;Keratin, type I cytoskeletal 18",5.11510421851767,4.04559754859816,6.46734897675708,2.37949584263711e-42
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,TAFA5;Chemokine-like protein TAFA-5,4.42698627944339,3.94297459912759,4.97041181110227,6.02341590695078e-140
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0613946487631949,TAFA5;Chemokine-like protein TAFA-5,2.70808946075217,1.91092881880525,3.83779262485675,2.13859696126616e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0574564618707031,TAFA5;Chemokine-like protein TAFA-5,4.1320637920781,2.91449369541716,5.85829065564644,1.63993383226052e-15
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,TAFA5;Chemokine-like protein TAFA-5,1.36784419148092,1.26759164769827,1.4760256077464,7.28725971405026e-16
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60490631409171,TAFA5;Chemokine-like protein TAFA-5,1.24885393311771,1.16470040320191,1.33908783922109,4.28120556362805e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,TAFA5;Chemokine-like protein TAFA-5,1.37629580208934,1.24579967418297,1.5204612540062,3.29881614773029e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.38493054861596,TAFA5;Chemokine-like protein TAFA-5,1.28344029729054,1.2299272639335599,1.33928163478634,1.58606539304617e-30
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,TAFA5;Chemokine-like protein TAFA-5,1.35809352162268,1.23038973218184,1.49905185749787,1.24006081215054e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702771380925911,TAFA5;Chemokine-like protein TAFA-5,1.35826453712915,1.22273829910648,1.50881227337921,1.13293205044068e-08
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0455562818151207,TAFA5;Chemokine-like protein TAFA-5,2.70361144246893,1.80421805260774,4.05134779650612,1.43816902282511e-06
sensitivity,Circulatory system disorders,I95 (hypotension),4.80361515338522,TAFA5;Chemokine-like protein TAFA-5,1.21105922498946,1.16307553092648,1.26102252814462,1.63436598242829e-20
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.237861214861411,AOC3;Membrane primary amine oxidase,1.60516223648353,1.3382862265515,1.92525765737877,3.38222803515744e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549526304386362,AOC3;Membrane primary amine oxidase,1.35565154606151,1.20179793630773,1.5292014229823,7.39355763333832e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33995428391266,AOC3;Membrane primary amine oxidase,1.51731321496781,1.4045586746553,1.63911941441746,3.57751525072597e-26
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61102446151112,AOC3;Membrane primary amine oxidase,1.23555551746722,1.15174840558106,1.32546086397535,3.58528026249254e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802501917743553,AOC3;Membrane primary amine oxidase,1.32890324026044,1.20288066591349,1.46812886100682,2.2232306729496e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220030647125849,AOC3;Membrane primary amine oxidase,2.14705399772723,1.78341450232539,2.58483984690362,7.00590032784944e-16
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102122979634321,AOC3;Membrane primary amine oxidase,3.48888699011556,2.71386855274434,4.48523286711459,1.85464099421645e-22
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248422712933753,SPON1;Spondin-1,1.92364982739198,1.61714685009903,2.28824528718502,1.49131874349532e-13
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.512295081967213,SPON1;Spondin-1,1.43162113052102,1.26705501113601,1.61756122926086,8.45895781522964e-09
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13248638838475,SPON1;Spondin-1,1.26009490062545,1.18664398565081,1.33809228191674,4.53360128348289e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543199146683522,SPON1;Spondin-1,2.5383574105959,2.26347062817244,2.84662776875948,3.99124303661413e-57
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0630181768053723,SPON1;Spondin-1,2.43255302355554,1.74339490375949,3.39413302152539,1.69116170606048e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34200332042058,SPON1;Spondin-1,1.75301531246384,1.62617145908193,1.88975317982004,1.38576890600253e-48
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60980535809753,SPON1;Spondin-1,1.34015776432906,1.2504686615123,1.43627976339636,1.18690030484538e-16
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.780464731271802,SPON1;Spondin-1,1.57518451409563,1.42833456167346,1.73713240582772,9.03522360119629e-20
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36263561893805,SPON1;Spondin-1,1.23523257204435,1.14565824941362,1.3318103438091,3.79188900945788e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.40968979153832,SPON1;Spondin-1,1.33905261762366,1.28384400451352,1.3966353439055,4.52127299814222e-42
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23328124373923,SPON1;Spondin-1,1.2536540123344,1.20085553597136,1.30877389957723,7.24740870957947e-25
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.808838035115407,SPON1;Spondin-1,1.44429864292418,1.31122941257572,1.5908723141399,9.02975844531337e-14
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13093145869947,SPON1;Spondin-1,1.25145680730007,1.17795810331093,1.32954146343207,3.76874308464572e-13
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700791598397062,SPON1;Spondin-1,1.48986573833778,1.34284827666681,1.65297893800964,5.42371554557164e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.224621689785624,SPON1;Spondin-1,2.76970271712211,2.32213230012354,3.30353836464249,9.48222814194813e-30
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.274378207658902,SPON1;Spondin-1,1.57647736498392,1.33787572478437,1.85763209262744,5.43766677590818e-08
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.451516226980559,SPON1;Spondin-1,1.39395584321975,1.22390596826085,1.58763250056508,5.61937642478063e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.81064280482252,SPON1;Spondin-1,1.21924590907466,1.17117111970127,1.2692940952766,4.5429753481801e-22
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104396470217459,SPON1;Spondin-1,3.9061950386979,3.03802914519093,5.02245335746745,2.28679016661627e-26
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,ITGAM;Integrin alpha-M,1.65769253332757,1.37902767950542,1.99266815009509,7.35028170408429e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102507490932029,ITGAM;Integrin alpha-M,2.26395485532004,1.73448241213183,2.95505538198426,1.83713227136669e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545847241311604,AMBP;Protein AMBP,3.74026505799474,3.3564122050736,4.16801687316877,5.30454141996206e-126
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0548310030157051,AMBP;Protein AMBP,3.06079442299163,2.17525730825892,4.30682957103369,1.36392514810775e-10
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61001436809888,AMBP;Protein AMBP,1.25752011582405,1.17394603383188,1.34704389821091,6.55430104940539e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.779704182583994,AMBP;Protein AMBP,1.32622991417394,1.20202665189405,1.463266877218,1.82650565664429e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.41705187467899,AMBP;Protein AMBP,1.21245461100232,1.16269532906244,1.26434341567896,2.05716600015462e-19
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805929760574151,AMBP;Protein AMBP,1.48337235309043,1.34689769535607,1.63367533072461,1.16944521144727e-15
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1381350380179,AMBP;Protein AMBP,1.22502443320365,1.15362897027388,1.30083839831939,3.48166043307838e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409723583611056,AMBP;Protein AMBP,1.56989671846983,1.37227367903194,1.79597972643544,5.02408426850744e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698518591190032,AMBP;Protein AMBP,1.33866595466066,1.20650066725805,1.48530919774805,3.80871031871699e-08
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.043069694596711,AMBP;Protein AMBP,2.98582978581028,2.03146542099127,4.38854603071788,2.59176709714613e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.8011648727888,AMBP;Protein AMBP,1.2142672077393,1.16663098771685,1.2638485239249,1.94721392312858e-21
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,IL12A_IL12B;Interleukin-12,2.11394726304169,1.88110839632818,2.3756063391372,2.99530763296189e-36
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0574564618707031,IL12A_IL12B;Interleukin-12,2.6808060548317,1.88461996779085,3.81335294459742,4.14210760361386e-08
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0116638895501,IL12A_IL12B;Interleukin-12,1.25000758190268,1.14559721984097,1.36393396191296,5.32259843954366e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,IL12A_IL12B;Interleukin-12,1.21527651279066,1.12640258958377,1.31116264841541,4.85586878704313e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,IL12A_IL12B;Interleukin-12,1.37323625953079,1.24370677571571,1.51625597070893,3.50696843377736e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.38493054861596,IL12A_IL12B;Interleukin-12,1.24759777480308,1.19591066551386,1.30151879448687,1.21704590331409e-24
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,IL12A_IL12B;Interleukin-12,1.32470462543615,1.20075494016416,1.46144919829523,2.02322698868761e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212074084546868,GFER;FAD-linked sulfhydryl oxidase ALR,1.67068344689373,1.38169924065191,2.02010907844735,1.17998080895863e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100959111559818,GFER;FAD-linked sulfhydryl oxidase ALR,2.34233904818769,1.78600981213679,3.07196084779661,7.64943155891905e-10
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1420141620771,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.21823095808543,1.14521738752921,1.2958995238796,3.85165357572586e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549526304386362,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.74705468242462,1.55024980826728,1.96884401927019,5.71066373601445e-20
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33995428391266,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.37243428931911,1.26962110895147,1.48357322134824,1.60444808604172e-15
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.75214095875578,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.20364341563036,1.12400608877045,1.28892315305438,1.11441825338183e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.41115272575946,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.30124988346872,1.24617927228692,1.35875415109417,7.76888221896173e-33
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7231527093596,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.2011674896469,1.13694691031267,1.26901557592329,6.23237388708775e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772618251877482,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.38659592083657,1.25178617896554,1.5359238502453,3.76783495813365e-10
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08575924468922,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.26581224806742,1.16074974933259,1.38038422862358,9.72327811985385e-08
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13460772600557,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.24896046735162,1.17345871652284,1.32932009200071,2.79508774083233e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407047626538718,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.4401631536091,1.25153617978804,1.65721929777897,3.53366031270608e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702686743430764,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.30558292377751,1.17235646860477,1.45394921809748,1.20040475210352e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220030647125849,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.98225877749525,1.6466125459336,2.38632328574241,4.86973042448922e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,OPTC;Opticin,2.06611623840744,1.8503670286674,2.30702138790555,4.72288217676679e-38
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243707473045953,NOTCH3;Neurogenic locus notch homolog protein 3,1.72765415062923,1.45440083137149,2.05224639576957,4.83747311749998e-10
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.50659548350642,NOTCH3;Neurogenic locus notch homolog protein 3,1.55224961968148,1.37621444654228,1.75080191016385,8.08397340940737e-13
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13608520931684,NOTCH3;Neurogenic locus notch homolog protein 3,1.29233951310515,1.217610752275,1.37165462280318,3.20820182183831e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,NOTCH3;Neurogenic locus notch homolog protein 3,1.88995363368863,1.68770056275111,2.11644459706187,2.9666768753609e-28
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34461664744855,NOTCH3;Neurogenic locus notch homolog protein 3,1.64113201220291,1.52431683848969,1.7668992518286,1.71881561698066e-39
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60560787922695,NOTCH3;Neurogenic locus notch homolog protein 3,1.26114563469883,1.17707825064569,1.35121714384531,4.33887515499877e-11
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72410422816036,NOTCH3;Neurogenic locus notch homolog protein 3,1.2517582228785,1.17119237683771,1.33786616061715,3.70287553689568e-11
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.670026566651039,NOTCH3;Neurogenic locus notch homolog protein 3,1.33388207667302,1.19976530982189,1.48299119828167,9.90029802387562e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783488276910483,NOTCH3;Neurogenic locus notch homolog protein 3,1.34608778157758,1.22070574683882,1.48434814893331,2.55776388539108e-09
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35328613175907,NOTCH3;Neurogenic locus notch homolog protein 3,1.22953641640845,1.14051906075844,1.32550156440982,7.08610695658701e-08
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.40475337394004,NOTCH3;Neurogenic locus notch homolog protein 3,1.20375067888241,1.16489714106124,1.24390012288106,1.60581097183971e-28
sensitivity,Circulatory system disorders,I50 (heart failure),4.41797849969538,NOTCH3;Neurogenic locus notch homolog protein 3,1.30135143139372,1.24798001555174,1.35700534214226,6.39983950940862e-35
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22007806153785,NOTCH3;Neurogenic locus notch homolog protein 3,1.24744272327342,1.19493877493895,1.30225362209651,6.94698694187344e-24
sensitivity,Circulatory system disorders,I83 (varicose veins of lower extremities),2.0823283486091,NOTCH3;Neurogenic locus notch homolog protein 3,1.26946041196535,1.1940064406218,1.34968261704519,2.32268711254689e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220169901020964,NOTCH3;Neurogenic locus notch homolog protein 3,2.90976640525833,2.45924160002809,3.44282584235451,1.50121191642549e-35
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.273277376537185,NOTCH3;Neurogenic locus notch homolog protein 3,1.70823676537464,1.45454646906063,2.00617368275772,6.66674579037981e-11
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.454306159455612,NOTCH3;Neurogenic locus notch homolog protein 3,1.37092341332192,1.20582252751261,1.558629866595,1.4455204930897e-06
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103231335579751,NOTCH3;Neurogenic locus notch homolog protein 3,4.38756335986258,3.48274296446148,5.52745707427918,4.00276337170361e-36
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,EGLN1;Egl nine homolog 1,1.45272248470843,1.29286907261588,1.63234055348499,3.41700081636694e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34334568365992,EGLN1;Egl nine homolog 1,1.27416732607403,1.18272015525929,1.37268513402371,1.81342009807311e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.799212598425196,FURIN;Furin,1.28546265843017,1.16596140856175,1.41721178255519,4.55243448319483e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.247602578210973,AGRN;Agrin,1.86858687693864,1.57262230224279,2.22025143080302,1.19500511061454e-12
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12937475422729,AGRN;Agrin,1.23523944706403,1.16363408467829,1.31125111551274,4.09370616517152e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.541402527857621,AGRN;Agrin,3.5556904871806,3.17898428171897,3.97703597131036,3.30888762521648e-109
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0628103715626042,AGRN;Agrin,3.10642023864976,2.25214239687299,4.28474092601395,4.9126438242397e-12
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0569442535393798,AGRN;Agrin,2.50859550872809,1.76935482212914,3.55669272646967,2.42357753659092e-07
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96323173681664,AGRN;Agrin,1.23575665100837,1.17398208898489,1.3007817707269,5.94678415338702e-16
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00658606114223,AGRN;Agrin,1.33282557394916,1.22245634022108,1.45315947255151,7.29692177475977e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34349821720544,AGRN;Agrin,1.48062982821107,1.37344686652186,1.59617728331935,1.35872597144066e-24
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60647325833826,AGRN;Agrin,1.22038290819578,1.13902198324416,1.3075554857813,1.5335860518941e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.777889091873416,AGRN;Agrin,1.42666582913232,1.2932563787903,1.57383750151512,1.30406787183458e-12
sensitivity,Circulatory system disorders,I50 (heart failure),4.40698779908097,AGRN;Agrin,1.25262151607411,1.2012629170256,1.30617589229915,5.3686717883373e-26
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.81009870620158,AGRN;Agrin,1.45442291104756,1.32065263182578,1.60174292104021,2.74455513605872e-14
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13189481856002,AGRN;Agrin,1.27584544714566,1.20120946010091,1.35511886899855,2.36044487429499e-15
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404953803813642,AGRN;Agrin,1.59201429959159,1.39021227203918,1.82310973732554,1.76909178086917e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700442695523856,AGRN;Agrin,1.44366739222945,1.30135333713607,1.60154469959194,4.07746416891397e-12
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223880597014925,AGRN;Agrin,2.04101658391845,1.70653984164279,2.44104977462467,5.59409692983295e-15
sensitivity,Circulatory system disorders,I95 (hypotension),4.80456186736646,AGRN;Agrin,1.21346356353105,1.16584631362827,1.26302566882498,2.72347715959563e-21
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104052143866813,AGRN;Agrin,2.57954780739782,1.99730125721382,3.33152891513879,3.86458335101619e-13
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1267673136832,VWC2;Brorin,1.2030881682786,1.13175164709181,1.27892117000343,3.05696183937221e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.533797157080309,VWC2;Brorin,4.06163203674458,3.62100719213599,4.555874630058,1.79728867249668e-126
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0657855391423957,VWC2;Brorin,2.66382727169082,1.91981477781449,3.69617726428891,4.54886889608691e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0578345930638374,VWC2;Brorin,3.87699676742922,2.76885693414148,5.42863148663085,3.02983790396287e-15
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97279036914194,VWC2;Brorin,1.27213663031948,1.20732315227348,1.34042953053054,1.85376947123544e-19
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01433648815941,VWC2;Brorin,1.35212277879938,1.23855686272692,1.47610179553884,1.58624658416549e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33453381352541,VWC2;Brorin,1.27622121324124,1.18125286079953,1.37882466927913,6.32894115873354e-10
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61170692592963,VWC2;Brorin,1.24923696372787,1.16402191608511,1.34069038561807,6.68669251673706e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.784071184885182,VWC2;Brorin,1.40698877732785,1.27365010091041,1.55428670567488,1.79769420645483e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.40537495976826,VWC2;Brorin,1.30838139537633,1.25351073455445,1.36565394182714,9.44121536737759e-35
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06082432973189,VWC2;Brorin,1.23666027729047,1.16225330916759,1.31583074822429,1.9583890283193e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.768432397908267,VWC2;Brorin,1.29476875339391,1.17018444030182,1.43261700209654,5.59707272111116e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.794728434504792,VWC2;Brorin,1.46592503628664,1.32741526972587,1.61888766915856,4.25241816885994e-14
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07634243265371,VWC2;Brorin,1.2704869613139,1.16722643273398,1.38288259552849,3.10924540895676e-08
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.10864686735539,VWC2;Brorin,1.2356227718027,1.16135304367518,1.31464212584818,2.2389210812421e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401301734981132,VWC2;Brorin,1.59993333654458,1.39351595574231,1.83692671105663,2.58741671107985e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703381024698265,VWC2;Brorin,1.54185415390477,1.38759467399005,1.71326272468124,8.2444780241563e-16
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.402386244005146,CELSR2;Cadherin EGF LAG seven-pass G-type receptor 2,3.26681419131798,2.80597618228033,3.80333768618223,1.44965367838479e-52
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,NPY;Pro-neuropeptide Y,1.54692955030395,1.37342172478362,1.74235705641004,6.59736846910521e-13
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245215996333218,PALM2;Paralemmin-2,1.70602591655471,1.42813660158257,2.03798741992264,3.89783989912303e-09
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519843359974351,PALM2;Paralemmin-2,1.40929971090909,1.24233944846266,1.59869806728441,9.67036424454513e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04062915577566,PALM2;Paralemmin-2,1.20231903775999,1.12675769423336,1.28294759020365,2.64136821787106e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.401366941125203,PALM2;Paralemmin-2,2.75947818463066,2.44280095281021,3.11720848262013,7.02087731955028e-60
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3650779059613,PALM2;Paralemmin-2,1.47815408554723,1.36794658947443,1.59724035823609,4.82340914178059e-23
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59508355199558,PALM2;Paralemmin-2,1.2615797670638,1.17218682851666,1.35778996141667,5.76169154789991e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.76285164482727,PALM2;Paralemmin-2,1.40753714056911,1.26918495690572,1.56097091389387,9.45022012185414e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.3056453848286,PALM2;Paralemmin-2,1.27982218208514,1.22385314840066,1.33835078162577,2.95822931908696e-27
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.03758154920518,PALM2;Paralemmin-2,1.21652861598495,1.14020456424374,1.2979617166257,3.04964282299215e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.770341839191141,PALM2;Paralemmin-2,1.39983424100789,1.26234661872543,1.55229623403804,1.80842439020921e-10
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.401127741994636,PALM2;Paralemmin-2,1.4449492824398,1.25354326590137,1.66558146465091,3.83864528505085e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.683690091082203,PALM2;Paralemmin-2,1.4836653761176,1.33050655249683,1.65445479705402,1.27693606172617e-12
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.210690239545641,PALM2;Paralemmin-2,2.6959951831568,2.27625466064261,3.19313570369703,1.55303794204279e-30
sensitivity,Circulatory system disorders,I95 (hypotension),4.52297144960544,PALM2;Paralemmin-2,1.22552931031398,1.17306124507256,1.2803441395302,8.26298757848692e-20
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105308944392298,PALM2;Paralemmin-2,3.76878933704078,3.0329249614509,4.68319303890638,5.04920565020378e-33
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544975327480628,IL1RN;Interleukin-1 receptor antagonist protein,1.47074707674455,1.31331979240376,1.6470451266051,2.4129121788537e-11
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96844881809881,IL1RN;Interleukin-1 receptor antagonist protein,1.22040637440441,1.16019667661805,1.28374072146841,1.19903394309146e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01122039063582,IL1RN;Interleukin-1 receptor antagonist protein,1.23523188043493,1.13397739236805,1.34552752877774,1.29026906078424e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3483502538071,IL1RN;Interleukin-1 receptor antagonist protein,1.23978656867516,1.15105089310678,1.33536296706972,1.40604469935274e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.777079131569581,IL1RN;Interleukin-1 receptor antagonist protein,1.30288028667203,1.18261853142265,1.43537158965077,8.58008619514549e-08
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.625173109642701,IL1RN;Interleukin-1 receptor antagonist protein,1.33004297119622,1.19432463704201,1.48118380075438,2.06115500102251e-07
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.779395473967399,IL1RN;Interleukin-1 receptor antagonist protein,1.28744053216254,1.16843504861869,1.41856676228126,3.2973995632021e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.81344258401615,IL1RN;Interleukin-1 receptor antagonist protein,1.2776836160699,1.16195651421953,1.40493676208697,4.22219468347104e-07
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405643389991491,IL1RN;Interleukin-1 receptor antagonist protein,1.3907158871232,1.21804728956288,1.58786173186343,1.08163242486136e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.225349885348303,IL1RN;Interleukin-1 receptor antagonist protein,1.90755187403756,1.61927038335587,2.24715661420488,1.1141175335078e-14
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104736873307906,IL1RN;Interleukin-1 receptor antagonist protein,2.19800463586724,1.74978263702309,2.76104258727431,1.3029665042204e-11
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243715481829438,COL18A1;Collagen alpha-1(XVIII) chain,1.69040525799814,1.4177116459802,2.01555086633441,4.95584835642192e-09
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.502828409805154,COL18A1;Collagen alpha-1(XVIII) chain,1.52745119269691,1.35099396971227,1.72695600304427,1.35036443569342e-11
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14159292035398,COL18A1;Collagen alpha-1(XVIII) chain,1.30226560718698,1.2266899070373,1.38249748525118,4.79469855092551e-18
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.55530394029498,COL18A1;Collagen alpha-1(XVIII) chain,4.24700125516537,3.79690568188916,4.75045238742982,3.01859651979611e-141
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0647846401507715,COL18A1;Collagen alpha-1(XVIII) chain,2.95978395214181,2.12994909178836,4.11292508216748,1.0193974568299e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0569543187085117,COL18A1;Collagen alpha-1(XVIII) chain,2.79070302964383,1.95806405856502,3.97740991444925,1.37245731735641e-08
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.98055981285795,COL18A1;Collagen alpha-1(XVIII) chain,1.21054240055555,1.14976691476055,1.27453041545207,3.58717304137021e-13
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01460959159997,COL18A1;Collagen alpha-1(XVIII) chain,1.28911615203804,1.18217179393289,1.4057351579306,9.0621058139876e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35151109184759,COL18A1;Collagen alpha-1(XVIII) chain,1.64826810416868,1.52863759583733,1.77726084365448,1.24133545582306e-38
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.6087008013896,COL18A1;Collagen alpha-1(XVIII) chain,1.3085749551509,1.22105947338363,1.40236282554124,2.63654003723846e-14
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781971432500933,COL18A1;Collagen alpha-1(XVIII) chain,1.46784297105525,1.3299619347125,1.62001853695313,2.42798338108675e-14
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35437056369496,COL18A1;Collagen alpha-1(XVIII) chain,1.22366431335372,1.13494173506236,1.31932266257981,1.47149228752869e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.42793462109955,COL18A1;Collagen alpha-1(XVIII) chain,1.39673797588563,1.33900045263409,1.4569651335392,2.83002981150768e-54
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22034473805101,COL18A1;Collagen alpha-1(XVIII) chain,1.23694657203126,1.18476706082969,1.29142417327876,4.04009096485828e-22
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.05886988730396,COL18A1;Collagen alpha-1(XVIII) chain,1.20007591429775,1.12912359722687,1.27548676124976,4.4750949833354e-09
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772481572481572,COL18A1;Collagen alpha-1(XVIII) chain,1.37891661482055,1.24866167866441,1.52275917737938,2.20323819687764e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.810210222021199,COL18A1;Collagen alpha-1(XVIII) chain,1.55164361050043,1.40803360479567,1.7099008758077,7.60342725492381e-19
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07372519714459,COL18A1;Collagen alpha-1(XVIII) chain,1.25544770224985,1.15408234804193,1.36571617767015,1.18184297655372e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1382495819065,COL18A1;Collagen alpha-1(XVIII) chain,1.31088287343766,1.23404544120795,1.39250456303302,1.58156795540857e-18
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.410915811411269,COL18A1;Collagen alpha-1(XVIII) chain,1.47561287466542,1.28799028490625,1.69056659929453,2.05234126560056e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.706484305815212,COL18A1;Collagen alpha-1(XVIII) chain,1.42231565744556,1.2818569489673,1.5781650448941,3.1236888665773e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.221951602765556,COL18A1;Collagen alpha-1(XVIII) chain,1.60034777200439,1.33075798635623,1.92455203546967,5.85436686039201e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.79930536369735,COL18A1;Collagen alpha-1(XVIII) chain,1.25690086386868,1.20734092150947,1.30849518429202,8.02051474150918e-29
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212577088394692,HEG1;Protein HEG homolog 1,2.85973282499633,2.32361599232771,3.51954533682177,3.4138832858635e-23
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.266803969294139,HEG1;Protein HEG homolog 1,1.63827055613416,1.36034504505799,1.97297768301257,1.94587777679917e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107418910398617,HEG1;Protein HEG homolog 1,4.28128498626572,3.22149086520251,5.68972624805877,1.22280324053398e-23
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245078504821869,LAYN;Layilin,1.68838998586903,1.41592511017597,2.01328497100285,5.44064693492204e-09
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12316341380753,LAYN;Layilin,1.27106440748778,1.19679725765559,1.34994019884961,5.79423768456685e-15
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534898109893619,LAYN;Layilin,5.19303289880169,4.60704321722297,5.85355713339547,3.70313141425253e-160
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0656742556917688,LAYN;Layilin,3.24532117263491,2.37412843754209,4.43620039548333,1.56668664449709e-13
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0577367205542725,LAYN;Layilin,4.12596192220494,2.97445079145889,5.72326220099792,2.08878386658112e-17
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97189575881451,LAYN;Layilin,1.20366968020593,1.1430565362863,1.26749697241936,2.03846661687871e-12
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01461119859668,LAYN;Layilin,1.29340318242127,1.18625493718909,1.41022957195147,5.50429098158918e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.332268051533,LAYN;Layilin,1.63972663966364,1.520199646425,1.7686515446478,1.51726993405059e-37
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61096657994796,LAYN;Layilin,1.34902351080262,1.25853577311629,1.44601724605096,2.88612514989311e-17
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.7098797491111,LAYN;Layilin,1.23051309003455,1.15077706591897,1.3157739318842,1.29040471720919e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.78274378585086,LAYN;Layilin,1.54340098055847,1.40001961094982,1.70146658529501,2.68719409024127e-18
sensitivity,Circulatory system disorders,I50 (heart failure),4.40195999678689,LAYN;Layilin,1.42756792738398,1.36843994829762,1.48925072658882,4.08064153490353e-61
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20336512178825,LAYN;Layilin,1.30386736007522,1.24872112816099,1.36144896913312,2.35502483313282e-33
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769123478191563,LAYN;Layilin,1.38565494813005,1.25465312797615,1.53033503242003,1.21822277417269e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.797368683344961,LAYN;Layilin,1.52640210167937,1.38498860348489,1.68225454718452,1.51702377564273e-17
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.10507195188406,LAYN;Layilin,1.32566778165454,1.24711292999475,1.40917075354536,1.48968220637785e-19
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402615004384915,LAYN;Layilin,1.57196004806648,1.37256329749898,1.80032381546251,6.32702003537183e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702188354046559,LAYN;Layilin,1.45699697531075,1.31307259449252,1.61669674241059,1.31595628340259e-12
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0457784323872457,LAYN;Layilin,2.97173588357161,2.04589434305813,4.31655436737096,1.07625874335152e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.217036358567958,LAYN;Layilin,1.67743788340037,1.39559721512395,2.01619623640249,3.55654018132627e-08
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.532328488545965,LAYN;Layilin,1.37836882311129,1.22172955723281,1.55509097842278,1.85041715657704e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.80144043212963,LAYN;Layilin,1.26081034728838,1.21086221056479,1.3128188475615,2.67665442814973e-29
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.535105256968128,RGMB;RGM domain family member B,4.40597181772874,3.87383216988816,5.01121029700683,6.6623211413368e-113
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0644896523421469,RGMB;RGM domain family member B,2.79653376727301,1.96293480820213,3.9841369559599,1.23574703079172e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.05473988778323,RGMB;RGM domain family member B,3.41221455369889,2.31325278585607,5.03326235319575,6.06680353035277e-10
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246645619573796,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.59310018283964,1.33967644140879,1.89446355412118,1.37836646823396e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,3.52370592789397,3.15985694201842,3.92945114102028,1.37883194470951e-113
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.065040009460365,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,2.74484621738303,1.99251492193235,3.78124182366237,6.48650012608232e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.055206135767661,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,2.89864175885521,2.04757745202402,4.10344626420544,1.96038223293489e-09
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97398522117623,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.21629131763185,1.15541754593023,1.28037225551702,7.75138025484491e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00874508952365,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.27363149769997,1.16799871196274,1.3888176205328,4.36577315814868e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.45204424696073,1.34719096168656,1.56505837338174,1.78673873661504e-22
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72526363690323,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.24604942443267,1.16604700357373,1.33154080699186,8.18002702281178e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781126716111724,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.51339823728954,1.37225574472148,1.669057851236,1.08292371861537e-16
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.3428551610241,1.28785796479858,1.40020097928353,2.01407393616694e-43
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.07307182560876,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.22020004332345,1.14843126437926,1.29645386006738,1.23667367878081e-10
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71750954292834,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.20528867518022,1.14313467644616,1.27082208286603,4.77385448675774e-12
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773495925333964,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.46670286753022,1.32918930253777,1.61844313485982,2.4335327500884e-14
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805528134254689,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.58638062776312,1.44074438972408,1.74673836253776,5.86911837634349e-21
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08191348640698,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.25647895819283,1.15542611610082,1.36636981835677,9.44360556618422e-08
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11685689727547,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.3526179371946,1.2733720184193,1.43679557706295,1.06621170136151e-22
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406616398878844,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.5682915558413,1.3698058905747,1.79553790872606,7.1403531538724e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703334913861229,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.49664393433164,1.34967977606648,1.65961075055877,2.06818487382018e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,2.3265183792642,1.94959009460578,2.77632092203906,7.75245195223804e-21
sensitivity,Circulatory system disorders,I95 (hypotension),4.79237657500594,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.31041334807595,1.25905290097419,1.36386893790321,4.38006561003711e-40
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102507490932029,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,2.99609837306568,2.32798037933144,3.855962679404,1.54129697465256e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",2.38859858528589,2.14311957618747,2.66219545797787,8.47696840302691e-56
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.39696634406735,1.29765861210586,1.50387393745259,6.36924014668013e-19
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.30002868338193,1.17907634144368,1.43338859258799,1.39298180600801e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.38493054861596,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.22396099380421,1.17420400633158,1.27582643754935,1.37423566054875e-21
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.39083381497623,1.26375335825886,1.53069322288209,1.49640540972914e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406608881924747,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.39764011845347,1.22198155705349,1.59854941298852,1.0321163217905e-06
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702771380925911,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.32724229479441,1.19797079588269,1.47046331608874,6.13739847171874e-08
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243707473045953,CCL15;C-C motif chemokine 15,1.55758629128909,1.31052747941716,1.85122028565984,4.93245956346455e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13608520931684,CCL15;C-C motif chemokine 15,1.22139879616714,1.15112874941398,1.29595844082427,3.70589716948173e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,CCL15;C-C motif chemokine 15,2.89990789457484,2.58276266007568,3.25599635112081,1.42967516561562e-72
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34461664744855,CCL15;C-C motif chemokine 15,1.3082264320963,1.21423905594307,1.40948883933416,1.62822289117557e-12
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60560787922695,CCL15;C-C motif chemokine 15,1.24224758075931,1.16032892869417,1.3299496493973,4.59636104377755e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783488276910483,CCL15;C-C motif chemokine 15,1.29638969066094,1.17518128068445,1.43009955797895,2.18270405511918e-07
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35328613175907,CCL15;C-C motif chemokine 15,1.2038503862379,1.11719286224123,1.29722969187052,1.13084257719582e-06
sensitivity,Circulatory system disorders,I50 (heart failure),4.41797849969538,CCL15;C-C motif chemokine 15,1.25666395372356,1.2055326066526,1.30996398096033,4.29782981436393e-27
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805696449473273,CCL15;C-C motif chemokine 15,1.3369531353593,1.21374280754287,1.4726708780797,3.93784216105021e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14282892917802,CCL15;C-C motif chemokine 15,1.26316899739484,1.19010469503028,1.34071894904918,1.5292687056494e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220169901020964,CCL15;C-C motif chemokine 15,1.71898219313491,1.43121905847568,2.06460343216922,6.81030238237737e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.78418322403836,CCL15;C-C motif chemokine 15,1.21012590840267,1.16297834951552,1.25918484621613,5.13273828352309e-21
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534183694195068,NEFL;Neurofilament light polypeptide,2.62111327222647,2.38169889867274,2.88459418177098,1.5330593712815e-86
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0567249447944733,NEFL;Neurofilament light polypeptide,2.68716158212415,2.01951387004312,3.57553244647426,1.17771713711713e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.32517631755452,NEFL;Neurofilament light polypeptide,1.21321691294217,1.12526445767271,1.30804387165407,4.81438012520935e-07
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60052128937669,NEFL;Neurofilament light polypeptide,1.23635476379788,1.15451224742383,1.32399903541651,1.26639760142165e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782310857096532,NEFL;Neurofilament light polypeptide,1.42153590014707,1.29345559370189,1.56229894960946,2.84975309221168e-13
sensitivity,Circulatory system disorders,I50 (heart failure),4.42192161510482,NEFL;Neurofilament light polypeptide,1.22627436086103,1.17664545370726,1.27799653104277,3.7689328811793e-22
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.05496158380421,NEFL;Neurofilament light polypeptide,1.2177701470295,1.14632515394949,1.29366796662092,1.69243552122049e-10
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.6987481710291,NEFL;Neurofilament light polypeptide,1.32586714390561,1.2586537627716,1.39666978742224,2.24021210230439e-26
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77043164446607,NEFL;Neurofilament light polypeptide,1.48867072497092,1.35370135089149,1.63709707900194,2.30065780767402e-16
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805371850529476,NEFL;Neurofilament light polypeptide,1.52339578682674,1.38915162446064,1.67061297158437,3.76858168823953e-19
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12145482923623,NEFL;Neurofilament light polypeptide,1.30226835112179,1.22728450147381,1.38183351643153,2.57696933521149e-18
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.692189022409873,NEFL;Neurofilament light polypeptide,1.37248253356522,1.23963834723585,1.51956278953608,1.08860837035251e-09
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0445569620253164,NEFL;Neurofilament light polypeptide,2.44035998732285,1.75112190545385,3.4008808005762,1.37505706994376e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.77402280130293,NEFL;Neurofilament light polypeptide,1.25016167487032,1.2014482341599,1.30085023131055,3.40836097047277e-28
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.541402527857621,IL10RB;Interleukin-10 receptor subunit beta,3.46933547301153,3.1122752060035,3.86735999473261,1.3200908694905e-111
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0569442535393798,IL10RB;Interleukin-10 receptor subunit beta,2.52740746082939,1.77694313092066,3.59481874343746,2.49200650659034e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34349821720544,IL10RB;Interleukin-10 receptor subunit beta,1.27377613921089,1.18115679926828,1.37365814075501,3.32945104104261e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.777889091873416,IL10RB;Interleukin-10 receptor subunit beta,1.38703464121827,1.25658796446712,1.5310230165664,8.45014941804094e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.40698779908097,IL10RB;Interleukin-10 receptor subunit beta,1.21344750533233,1.16350285777544,1.26553608214811,1.85177100973342e-19
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.81009870620158,IL10RB;Interleukin-10 receptor subunit beta,1.46186832787729,1.32684253330104,1.61063498826344,1.59925578349984e-14
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700442695523856,IL10RB;Interleukin-10 receptor subunit beta,1.39709052546567,1.2587888455884,1.55058725153667,3.23109901281093e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223880597014925,IL10RB;Interleukin-10 receptor subunit beta,2.24703788643099,1.87802401976739,2.68855946990585,9.11464244409538e-19
sensitivity,Circulatory system disorders,I95 (hypotension),4.80456186736646,IL10RB;Interleukin-10 receptor subunit beta,1.2263118690856,1.17811716350768,1.27647813548758,2.0005889220444e-23
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104052143866813,IL10RB;Interleukin-10 receptor subunit beta,2.64009030750486,2.03942508685792,3.41766749693154,1.69497274392936e-13
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212144714631141,LGALS3BP;Galectin-3-binding protein,2.552569227793,2.10683867458455,3.09260017925224,1.06438807086374e-21
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107176247919184,LGALS3BP;Galectin-3-binding protein,3.26143689786099,2.50781810758703,4.24152397917078,1.16384214226714e-18
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54409116989494,MEPE;Matrix extracellular phosphoglycoprotein,2.85087870353822,2.52387982868758,3.22024420097453,9.81882708427699e-64
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.063121350796907,MEPE;Matrix extracellular phosphoglycoprotein,2.57615780180893,1.80655954060298,3.67360658238028,1.72857369863058e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.247841381515829,IGFBP4;Insulin-like growth factor-binding protein 4,1.7786674179071,1.49625555456487,2.11438331765747,6.66781123135417e-11
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.515371247078564,IGFBP4;Insulin-like growth factor-binding protein 4,1.54396550646154,1.36741092924914,1.74331609770886,2.37490250466528e-12
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14799999999999,IGFBP4;Insulin-like growth factor-binding protein 4,1.28613171093036,1.21102461366684,1.3658969100984,2.47432363810885e-16
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.197719238681072,IGFBP4;Insulin-like growth factor-binding protein 4,1.76246941404545,1.45207441631803,2.13921435467628,9.82789118726497e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5326391670004,IGFBP4;Insulin-like growth factor-binding protein 4,4.79927069208729,4.31027227306985,5.34374575820556,5.58403819626963e-180
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0658840440824149,IGFBP4;Insulin-like growth factor-binding protein 4,3.29629753859463,2.43358156946213,4.46485032566486,1.31276615720589e-14
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0559228264994307,IGFBP4;Insulin-like growth factor-binding protein 4,3.19314452472012,2.28252984279355,4.46704869508789,1.21830385886173e-11
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97754537065518,IGFBP4;Insulin-like growth factor-binding protein 4,1.25738076031535,1.19357272034922,1.32459995897747,6.73471554058468e-18
sensitivity,Circulatory system disorders,I22 (subsequent myocardial infarction),0.101936799184505,IGFBP4;Insulin-like growth factor-binding protein 4,2.00439570916953,1.53542080145656,2.61661308426067,3.16849415026504e-07
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01183810590305,IGFBP4;Insulin-like growth factor-binding protein 4,1.33916152342652,1.22708463954934,1.4614750507224,5.79420697888555e-11
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.73432155074116,IGFBP4;Insulin-like growth factor-binding protein 4,1.20631619158564,1.16978154178264,1.24399189259227,6.19512215995272e-33
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.99846737113817,IGFBP4;Insulin-like growth factor-binding protein 4,1.22440933010233,1.15004779039458,1.30357905137773,2.40016131934073e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33648586370649,IGFBP4;Insulin-like growth factor-binding protein 4,1.71833807131736,1.59344841355566,1.85301620198043,6.54675168065259e-45
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60202360876897,IGFBP4;Insulin-like growth factor-binding protein 4,1.38976747487109,1.29613389536052,1.49016520679163,2.27430134161518e-20
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71563715075961,IGFBP4;Insulin-like growth factor-binding protein 4,1.26783924554407,1.18525324820799,1.35617966453333,5.00840908659033e-12
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.668842741854737,IGFBP4;Insulin-like growth factor-binding protein 4,1.36777414075902,1.22826942486446,1.52312356088773,1.15738806168439e-08
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.82999959915019,IGFBP4;Insulin-like growth factor-binding protein 4,1.21415698674138,1.15199581024183,1.27967235240505,4.58899352676078e-13
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.74957461715543,IGFBP4;Insulin-like growth factor-binding protein 4,1.2137168651764,1.13537185754208,1.29746797846716,1.27681471625866e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.779267488560752,IGFBP4;Insulin-like growth factor-binding protein 4,1.58857792043929,1.43917948114383,1.75348512285733,4.12233676655849e-20
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.38927310932941,IGFBP4;Insulin-like growth factor-binding protein 4,1.21538244022692,1.17587031565028,1.2562222690306,6.02173980210556e-31
sensitivity,Circulatory system disorders,I50 (heart failure),4.41176470588235,IGFBP4;Insulin-like growth factor-binding protein 4,1.4790649361103,1.41744228849831,1.54336659981311,1.20023278734123e-72
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2187150894725,IGFBP4;Insulin-like growth factor-binding protein 4,1.31986443974315,1.26365142517888,1.37857806716903,7.67831636219961e-36
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.08203915596256,IGFBP4;Insulin-like growth factor-binding protein 4,1.29656352257981,1.21962146874669,1.37835960678199,8.74097403680621e-17
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71678153550248,IGFBP4;Insulin-like growth factor-binding protein 4,1.26177431169344,1.1959311680045,1.33124251315061,1.84144539041666e-17
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.76955365887785,IGFBP4;Insulin-like growth factor-binding protein 4,1.53994326899118,1.39402794008464,1.70113180914239,1.88839211694366e-17
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805983880322393,IGFBP4;Insulin-like growth factor-binding protein 4,1.664004665265,1.50988351215633,1.83385771400952,9.74656489906509e-25
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08395664173433,IGFBP4;Insulin-like growth factor-binding protein 4,1.28101803700803,1.17698966227779,1.39424097231587,9.97867269680241e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.10990969100554,IGFBP4;Insulin-like growth factor-binding protein 4,1.38123421622719,1.29928428751698,1.46835298356658,4.20069417688335e-25
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405894467438466,IGFBP4;Insulin-like growth factor-binding protein 4,1.7750378089695,1.5500933241588,2.0326255033587,1.04336339084565e-16
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698447006083893,IGFBP4;Insulin-like growth factor-binding protein 4,1.58550939177707,1.42815469729634,1.76020149369833,5.48925177356204e-18
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0439279581486362,IGFBP4;Insulin-like growth factor-binding protein 4,3.16309322720449,2.17489947198442,4.60028561911325,1.68481850655041e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.221720632003675,IGFBP4;Insulin-like growth factor-binding protein 4,1.61994018942432,1.34704528557456,1.94812026396929,2.9730250937424e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.78455455877335,IGFBP4;Insulin-like growth factor-binding protein 4,1.33945290528657,1.28605504647007,1.39506787863018,5.00346074513214e-45
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,2.86644512413918,2.56388508824375,3.20470979271912,1.95457986065639e-76
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0613946487631949,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,2.65363964208177,1.90111222398388,3.70404401233684,9.71520724671125e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0574564618707031,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,2.86789787467483,2.04365381247955,4.02457508670966,1.09948271659113e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,1.27649406248559,1.1816398019461,1.37896259831242,5.77157950145353e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,1.35808090657143,1.22743074713422,1.50263772770896,3.0156824553111e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,1.34265575253557,1.21470492057265,1.4840842737074,8.09494605248269e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,VMO1;Vitelline membrane outer layer protein 1 homolog,2.07882095914414,1.8447938176235,2.34253635224342,3.17770677626296e-33
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,VMO1;Vitelline membrane outer layer protein 1 homolog,1.28182818351009,1.16176598395664,1.41429815877798,7.49101745256404e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,NOMO1;Nodal modulator 1,1.43228147936325,1.26977328279786,1.61558780919284,5.00570102122792e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,NOMO1;Nodal modulator 1,2.06506083471547,1.71957591676597,2.47995811612436,8.28671236810499e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102507490932029,NOMO1;Nodal modulator 1,2.90311582458782,2.23230441988709,3.7755072363287,1.86307425770632e-15
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.32101466893589,"NOS3;Nitric oxide synthase, endothelial",1.29889540192235,1.20271001482972,1.40277310767542,2.7000414063789e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781881364150638,"NOS3;Nitric oxide synthase, endothelial",1.31155401155378,1.18483158017244,1.45182990900062,1.68286806550297e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.694079080496984,"NOS3;Nitric oxide synthase, endothelial",1.33813564542192,1.20296970062013,1.48848886603352,8.26253419696087e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214080866017691,"NOS3;Nitric oxide synthase, endothelial",1.87366658905053,1.55444433073138,2.25844465286992,4.43303416090534e-11
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100955034627576,"NOS3;Nitric oxide synthase, endothelial",2.01354329079864,1.53574328924888,2.6399962886396,4.10335014913373e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,CLMP;CXADR-like membrane protein,4.04091426106188,3.68918715304696,4.42617503201671,1.82957514191754e-198
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645035183737294,CLMP;CXADR-like membrane protein,2.52132487989728,1.88833829609479,3.36649379146518,3.61311968258713e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547516621040281,CLMP;CXADR-like membrane protein,3.60988653752417,2.72728540524403,4.77811408690182,2.86653778205176e-19
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02392419436939,CLMP;CXADR-like membrane protein,1.25167948445895,1.14666583074135,1.36631047146709,5.13853267930655e-07
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00406736825478,CLMP;CXADR-like membrane protein,1.2160388498682,1.14044722402723,1.29664087318912,2.32267264994763e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,CLMP;CXADR-like membrane protein,1.33846638800719,1.23892176048751,1.4460092065217,1.43215936791786e-13
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60963817535032,CLMP;CXADR-like membrane protein,1.25851729848987,1.17170782701401,1.35175830875396,2.87349398585638e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778575480741016,CLMP;CXADR-like membrane protein,1.482002261213,1.34424140050071,1.63388116258163,2.72534048948365e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.41849455578349,CLMP;CXADR-like membrane protein,1.33221977313864,1.27631861745129,1.39056932937775,2.69173917817728e-39
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23386695833747,CLMP;CXADR-like membrane protein,1.20209596667426,1.15009065207393,1.25645288090006,3.42591973328147e-16
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06780193047163,CLMP;CXADR-like membrane protein,1.20768735850114,1.1343562438138,1.28575900546007,3.54059962949371e-09
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73026831947277,CLMP;CXADR-like membrane protein,1.20608940869641,1.14176342532376,1.27403946343542,2.07327525318153e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778925943322373,CLMP;CXADR-like membrane protein,1.3832472417324,1.25187814393456,1.5284018984042,1.8628764570101e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80476199800278,CLMP;CXADR-like membrane protein,1.50385808976786,1.36521814204469,1.6565771318956,1.35592031996916e-16
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13499851323223,CLMP;CXADR-like membrane protein,1.29779776070159,1.21969102716012,1.3809063034625,1.85827311740388e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409130060292851,CLMP;CXADR-like membrane protein,1.63237464212769,1.43100705569208,1.86207815095138,2.98455865974855e-13
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697505828875957,CLMP;CXADR-like membrane protein,1.48102480490438,1.33385877243753,1.64442781954623,1.91146860955396e-13
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0430073894514602,CLMP;CXADR-like membrane protein,2.73183732335053,1.94745260945254,3.83215238462154,5.89292002547949e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.80223213408523,CLMP;CXADR-like membrane protein,1.307215347584,1.25416260937963,1.36251228682732,8.30328557944037e-37
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220169901020964,SELE;E-selectin,3.14227308275592,2.58407740483447,3.8210465786124,1.78301194980522e-30
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.273277376537185,SELE;E-selectin,1.62516330787396,1.36948968482426,1.92856931054487,2.69153420854007e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103231335579751,SELE;E-selectin,5.51800962505603,4.17788374804669,7.28800322326985,2.39144283561813e-33
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543765281173594,SERPINB8;Serpin B8,2.06103178478537,1.83660329423676,2.31288489529845,9.65412455673244e-35
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34056127441387,SERPINB8;Serpin B8,1.25876733363502,1.16783342986048,1.35678184894563,1.79420947067489e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34056127441387,IL18R1;Interleukin-18 receptor 1,1.21208460479292,1.12437388031215,1.30663751168619,5.20175436648736e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804813252070636,IL18R1;Interleukin-18 receptor 1,1.26886697746711,1.15164938128331,1.39801525765804,1.47191731732185e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212666328481679,IL18R1;Interleukin-18 receptor 1,2.7150793445239,2.25677416386246,3.26645703637609,3.36920276682389e-26
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103374292958845,IL18R1;Interleukin-18 receptor 1,3.77608726757894,2.94686532100317,4.8386449664818,8.36750270889759e-26
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.539227305048589,SCGB1A1;Uteroglobin,2.99586828452066,2.65483128650937,3.38071455757084,7.77218557536921e-71
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34387351778656,SCGB1A1;Uteroglobin,1.23467403356632,1.14481021032296,1.3315918703528,4.56243819546806e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.552659428526633,FAS;Tumor necrosis factor receptor superfamily member 6,2.37011306533167,2.1359714341459,2.62992091216899,1.89003077187632e-59
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220892954883102,FAS;Tumor necrosis factor receptor superfamily member 6,2.0280618827879,1.70975672842229,2.40562586012607,4.76901460437315e-16
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103570242119867,FAS;Tumor necrosis factor receptor superfamily member 6,2.46443491939497,1.93920653098117,3.13191987284632,1.63589487817001e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549782503624939,"CA5A;Carbonic anhydrase 5A, mitochondrial",1.46702905045145,1.30076026460532,1.65455102944853,4.25567523455538e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.210928083567697,"CA5A;Carbonic anhydrase 5A, mitochondrial",2.47117304488511,2.05086831126416,2.9776149859191,1.88518518792426e-21
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0984054303731373,"CA5A;Carbonic anhydrase 5A, mitochondrial",3.63121713443255,2.78752712308577,4.730263525759,1.18975912418561e-21
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.237861214861411,IL18BP;Interleukin-18-binding protein,1.58964496612451,1.33306297820656,1.89561270520368,2.45886649646453e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549526304386362,IL18BP;Interleukin-18-binding protein,3.0144759096905,2.69829796681797,3.36770257467914,7.73764126015714e-85
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0628338045868677,IL18BP;Interleukin-18-binding protein,2.33865436032935,1.6725571781517,3.27002525745129,6.79024610933546e-07
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0569655064037086,IL18BP;Interleukin-18-binding protein,2.87502592935867,2.03302395077042,4.06575342673771,2.33032439772838e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33995428391266,IL18BP;Interleukin-18-binding protein,1.34142435427279,1.24436331571924,1.44605620842825,1.7880586658032e-14
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.784074831001415,IL18BP;Interleukin-18-binding protein,1.36618425806005,1.23862157658887,1.50688431579827,4.4070073557257e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.41115272575946,IL18BP;Interleukin-18-binding protein,1.25667249655119,1.20520272173972,1.31034035610921,9.37463954218033e-27
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772618251877482,IL18BP;Interleukin-18-binding protein,1.36509334290894,1.2368096586378,1.50668279620869,6.37073072808632e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802501917743553,IL18BP;Interleukin-18-binding protein,1.5002936035096,1.36208140899799,1.65253037143182,1.92508283657352e-16
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13460772600557,IL18BP;Interleukin-18-binding protein,1.25650532641915,1.18327328653005,1.33426965122279,9.15150773193326e-14
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407047626538718,IL18BP;Interleukin-18-binding protein,1.45124874840939,1.26702232891062,1.66226188892082,7.57852759121354e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702686743430764,IL18BP;Interleukin-18-binding protein,1.37893281537987,1.24340108990344,1.52923760866183,1.15058559575212e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220030647125849,IL18BP;Interleukin-18-binding protein,2.84203002364059,2.38321165679207,3.38918057582296,2.99319420775729e-31
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.273573579483949,IL18BP;Interleukin-18-binding protein,1.53420193167675,1.30000378356625,1.8105913205142,4.09667434348868e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.78653060418846,IL18BP;Interleukin-18-binding protein,1.25176441484828,1.20273423582118,1.30279333838919,3.2389188144565e-28
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102122979634321,IL18BP;Interleukin-18-binding protein,3.68085650872008,2.86513532805012,4.72881839302424,2.09036423610036e-24
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,SLITRK2;SLIT and NTRK-like protein 2,1.55761781158249,1.38556270337733,1.751038217935,1.16724079056604e-13
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,SLITRK2;SLIT and NTRK-like protein 2,1.20742813322801,1.11947475702813,1.30229171114204,1.03626293149348e-06
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103618839077987,SLITRK2;SLIT and NTRK-like protein 2,1.93409245497057,1.48726455727332,2.51516356392714,8.58986766712824e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.247602578210973,CSF1;Macrophage colony-stimulating factor 1,1.75651791561382,1.47915351840645,2.08589247125362,1.32421873909465e-10
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12937475422729,CSF1;Macrophage colony-stimulating factor 1,1.21188878594081,1.1417121358384,1.28637892458819,2.71060902036181e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.541402527857621,CSF1;Macrophage colony-stimulating factor 1,3.20756321663821,2.86998322631458,3.58485084316751,9.10759405064178e-94
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0628103715626042,CSF1;Macrophage colony-stimulating factor 1,2.61109425834533,1.87961993771752,3.62722968040179,1.04725813763727e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0569442535393798,CSF1;Macrophage colony-stimulating factor 1,2.39622622516331,1.69043290638139,3.39670394517565,9.15398909503849e-07
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96323173681664,CSF1;Macrophage colony-stimulating factor 1,1.22570132035642,1.16440914796193,1.29021979031429,7.51493782225669e-15
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00658606114223,CSF1;Macrophage colony-stimulating factor 1,1.2446028944932,1.14134777436432,1.3571992689464,7.34714555542959e-07
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.98671557450183,CSF1;Macrophage colony-stimulating factor 1,1.21036092250655,1.1376161121791,1.28775739640744,1.5703315835535e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34349821720544,CSF1;Macrophage colony-stimulating factor 1,1.50268833438333,1.39451109596388,1.61925727004056,1.21203212746986e-26
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60647325833826,CSF1;Macrophage colony-stimulating factor 1,1.21262050691993,1.13200396442355,1.29897821917218,3.96388822534422e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.777889091873416,CSF1;Macrophage colony-stimulating factor 1,1.47954460855023,1.34152857602624,1.63175968653182,4.48501389552175e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.40698779908097,CSF1;Macrophage colony-stimulating factor 1,1.35332368250419,1.29797531615526,1.41103221827959,9.00374650865317e-46
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.780190625921194,CSF1;Macrophage colony-stimulating factor 1,1.38909754324093,1.25931373380072,1.53225676243069,5.13010894582962e-11
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.81009870620158,CSF1;Macrophage colony-stimulating factor 1,1.52461732363413,1.38492008059146,1.67840586334237,7.87584830751668e-18
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08142118405788,CSF1;Macrophage colony-stimulating factor 1,1.23901912305329,1.13956731996132,1.34715023886772,5.15777709261593e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13189481856002,CSF1;Macrophage colony-stimulating factor 1,1.31710420908249,1.24026941486032,1.39869892524778,2.67364801314031e-19
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404953803813642,CSF1;Macrophage colony-stimulating factor 1,1.58555028871534,1.38479139594469,1.81541402221833,2.50563573903095e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700442695523856,CSF1;Macrophage colony-stimulating factor 1,1.47209912644692,1.32749929601273,1.63244970795449,2.29641510825424e-13
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0471133271824267,CSF1;Macrophage colony-stimulating factor 1,2.94320093018187,2.02324920629818,4.28144574996403,1.65001544707774e-08
sensitivity,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.67593264039964,CSF1;Macrophage colony-stimulating factor 1,1.24737953432347,1.16525319959271,1.33529408303095,2.00171258186629e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223880597014925,CSF1;Macrophage colony-stimulating factor 1,2.4773128903639,2.07925631298948,2.95157413659091,3.29181798543545e-24
sensitivity,Circulatory system disorders,I95 (hypotension),4.80456186736646,CSF1;Macrophage colony-stimulating factor 1,1.25721296831517,1.20801776447326,1.30841159309362,2.61697968086416e-29
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104052143866813,CSF1;Macrophage colony-stimulating factor 1,2.75157024002881,2.13450282956189,3.54702682093245,5.61881326105423e-15
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,CD83;CD83 antigen,2.99962460389806,2.66773468930801,3.37280457474747,2.68291970845818e-75
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0631736881588818,CD83;CD83 antigen,2.35818369122036,1.67585645930292,3.31832138168374,8.53540944054704e-07
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0572737686139748,CD83;CD83 antigen,3.41410175809266,2.41287530322562,4.83078872705488,4.09863132267256e-12
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96836982968369,CD83;CD83 antigen,1.21654846360204,1.15496847154417,1.28141174478448,1.40249228138922e-13
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01435520227785,CD83;CD83 antigen,1.24834446273226,1.14407146289806,1.36212111583204,6.21836777707223e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34334568365992,CD83;CD83 antigen,1.33959133268209,1.24097546876108,1.44604384516039,6.6929224237356e-14
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.788350588793171,CD83;CD83 antigen,1.39511752055778,1.26372999026566,1.54016515486677,4.16417310841694e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.392605283079,CD83;CD83 antigen,1.2822869390382,1.22899612656835,1.33788850793136,1.64544157886133e-30
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7062902426944,CD83;CD83 antigen,1.22061400495315,1.15667603894256,1.2880862911709,3.81151586643858e-13
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802926925739147,CD83;CD83 antigen,1.57734183022525,1.42967736259669,1.74025784730859,1.01292673088246e-19
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1320894476587,CD83;CD83 antigen,1.27127782306055,1.19582840197411,1.3514876388097,1.48355616658414e-14
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.391466814290515,CD83;CD83 antigen,1.54401240396798,1.34246244216097,1.77582197366316,1.15380242857155e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686707169856127,CD83;CD83 antigen,1.39438141887781,1.25332822149371,1.5513091526771,9.98030265942937e-10
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0454114673827199,CD83;CD83 antigen,2.64372269512131,1.7766597984859,3.93393810939823,1.63356851589776e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.219246266887888,CD83;CD83 antigen,2.19209003110122,1.82228894050063,2.6369356679151,8.37750832484013e-17
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.277035717819333,CD83;CD83 antigen,1.50536287679701,1.27536228191259,1.77684209653764,1.33020650181229e-06
sensitivity,Circulatory system disorders,I95 (hypotension),4.80462005596459,CD83;CD83 antigen,1.24950595489311,1.19981954858993,1.30124995308518,5.36088638574457e-27
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102677513624516,CD83;CD83 antigen,2.45179821753518,1.87688824851019,3.20280896013934,4.76171989828964e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54409116989494,CRHBP;Corticotropin-releasing factor-binding protein,1.99029899223649,1.76720384311462,2.2415580941223,7.66742356633305e-30
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.808188590511194,CRHBP;Corticotropin-releasing factor-binding protein,1.34482984044249,1.21942055901241,1.48313663106461,2.99638184730557e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701941709178629,CRHBP;Corticotropin-releasing factor-binding protein,1.30505596697815,1.17495880424669,1.44955812134812,6.72210365110478e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.204153467089053,KHK;Ketohexokinase,2.09652266542009,1.69883631861471,2.58730475588392,5.27036523154651e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100867933380248,KHK;Ketohexokinase,3.18979404733141,2.37516398816199,4.28382466015098,1.26247127124948e-14
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.240580574609802,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.93391623171592,1.62840437700006,2.29674646182442,5.5632713367889e-14
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.514644517744307,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.50700328982734,1.33504303629537,1.70111288835482,3.2572617821252e-11
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14662289863722,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.26446547423391,1.19070140336385,1.3427992366622,1.98742832728495e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.551836799744999,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,4.35114933816147,3.95204623180419,4.79055644911824,3.62291008294767e-197
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0635513276269537,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,3.16587235009859,2.34627247799441,4.27177483907845,4.73242947041762e-14
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0576162756044741,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,3.08285086599381,2.23739421113211,4.24778495209829,5.81724451956229e-12
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.99614813625968,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.21756363184016,1.14371746916324,1.29617780400294,6.98372132961598e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34529147982062,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.61411712566938,1.49723473662279,1.74012399769454,9.1172925165422e-36
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61544759280337,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.35621258613791,1.26539594111972,1.4535470827979,6.92418153423948e-18
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781110249836026,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.50864692693958,1.36691925957802,1.66506948688899,3.09364508240541e-16
sensitivity,Circulatory system disorders,I50 (heart failure),4.41353323178064,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.33721735198835,1.28153256149031,1.39532174225778,6.88534535017104e-41
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20438015193147,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.26295309211136,1.20921236677483,1.31908220317652,6.79798389862036e-26
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.07299328270445,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.23045935181101,1.15736902518872,1.30816548871461,3.18923292901698e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775486667594599,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.33426390023218,1.20783318546502,1.47392883130412,1.36606624738997e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.803708198221497,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.46188326165686,1.3257100118878,1.6120438493704,2.70587203720975e-14
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12680254571819,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.25851682627809,1.1840016466758,1.33772162097236,1.53844246404323e-13
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405727923627684,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.51637473923648,1.32245613629541,1.73872863279667,2.47101632153906e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.706734884832075,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.43448495003314,1.29260969007817,1.59193226514274,1.11852220822402e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222544558586842,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.66542116826939,1.38697185232098,1.99977213890704,4.64557941389972e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.79127987063544,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.23669923543967,1.187522578654,1.28791235335549,1.04819958564848e-24
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103289369140314,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.98923248253899,1.52963560387608,2.58692061008589,2.88497857071523e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.541402527857621,BTN2A1;Butyrophilin subfamily 2 member A1,4.11591971617552,3.65593719275765,4.6337762977881,4.31694076258187e-121
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0628103715626042,BTN2A1;Butyrophilin subfamily 2 member A1,2.72353626602583,1.94210888259983,3.81937895388654,6.35202256305059e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0569442535393798,BTN2A1;Butyrophilin subfamily 2 member A1,3.09772224440821,2.17226624482223,4.41745256888929,4.25786655984689e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34349821720544,BTN2A1;Butyrophilin subfamily 2 member A1,1.28363026323263,1.19030556569584,1.38427198878418,8.96253168689829e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.777889091873416,BTN2A1;Butyrophilin subfamily 2 member A1,1.34477138051921,1.21862352564111,1.48397764183335,3.76556774441288e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.40698779908097,BTN2A1;Butyrophilin subfamily 2 member A1,1.20069508573807,1.15135826562816,1.25214603651541,1.29999965893229e-17
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.780190625921194,BTN2A1;Butyrophilin subfamily 2 member A1,1.32509529698877,1.20069479816507,1.46238456998826,2.19055936101763e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.81009870620158,BTN2A1;Butyrophilin subfamily 2 member A1,1.42092931465443,1.28970359564889,1.56550708554741,1.19498447729749e-12
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13189481856002,BTN2A1;Butyrophilin subfamily 2 member A1,1.24104840108135,1.16839124483174,1.31822378902571,2.28289633267563e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404953803813642,BTN2A1;Butyrophilin subfamily 2 member A1,1.40547731301505,1.22619571389443,1.61097160511692,1.0145829170439e-06
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700442695523856,BTN2A1;Butyrophilin subfamily 2 member A1,1.43625160683095,1.29410646844532,1.59401002036771,9.84714255432925e-12
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0471133271824267,BTN2A1;Butyrophilin subfamily 2 member A1,2.63695356914353,1.78660364154612,3.89203512414272,1.05251415982688e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223880597014925,BTN2A1;Butyrophilin subfamily 2 member A1,1.65729585004507,1.37994885800357,1.99038501944941,6.4272224954326e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.80456186736646,BTN2A1;Butyrophilin subfamily 2 member A1,1.22482885902108,1.17665492130517,1.27497510674311,3.92083530563325e-23
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104052143866813,BTN2A1;Butyrophilin subfamily 2 member A1,1.93400325685394,1.48091444705194,2.52571551649564,1.27836553185546e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.542652924858768,CD28;T-cell-specific surface glycoprotein CD28,1.7154091875519,1.52396645311185,1.93090121815268,3.9573924630629e-19
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804820836366577,CD28;T-cell-specific surface glycoprotein CD28,1.34571571444432,1.21992847598294,1.48447291767925,3.02352238981578e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212074084546868,CD28;T-cell-specific surface glycoprotein CD28,2.20726986365789,1.83310264503412,2.6578109328524,6.57240300429159e-17
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100959111559818,CD28;T-cell-specific surface glycoprotein CD28,2.99459200591068,2.3070514970175,3.88703125762785,1.70008808117229e-16
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544707293571667,SCLY;Selenocysteine lyase,0.701270439762077,0.621361588853489,0.791455794027292,8.97743478241466e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.209886229894076,SCLY;Selenocysteine lyase,2.63982295761603,2.1921770458723,3.17887885044601,1.32726016324697e-24
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.267258828384459,SCLY;Selenocysteine lyase,1.62312469935171,1.36365717878878,1.93196195541288,5.03410104610666e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101964782932664,SCLY;Selenocysteine lyase,4.39666543640161,3.42029308541127,5.65175745964593,6.73853743569653e-31
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54409116989494,TREM2;Triggering receptor expressed on myeloid cells 2,1.87999212038416,1.6776568016684,2.10673027355276,1.68098204657412e-27
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.99055532309163,TREM2;Triggering receptor expressed on myeloid cells 2,1.20293003958521,1.13069299698044,1.27978211946201,4.9948237520937e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34420842159444,TREM2;Triggering receptor expressed on myeloid cells 2,1.3027072414583,1.20890113441173,1.403792343841,4.05072443013873e-12
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781743524952621,TREM2;Triggering receptor expressed on myeloid cells 2,1.31476668064692,1.19338814957358,1.44849052268283,3.07098212348244e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.41290630784848,TREM2;Triggering receptor expressed on myeloid cells 2,1.23136005859923,1.18147928942729,1.28334673953404,5.9480497546528e-23
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.808188590511194,TREM2;Triggering receptor expressed on myeloid cells 2,1.45126307540845,1.31980296659553,1.59581738134511,1.4984370055346e-14
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13234117458793,TREM2;Triggering receptor expressed on myeloid cells 2,1.20960744215295,1.13922326748171,1.28434013408639,4.92467926112354e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701941709178629,TREM2;Triggering receptor expressed on myeloid cells 2,1.3706174558405,1.23686197111178,1.51883739182802,1.77121697306301e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.224989638635062,TREM2;Triggering receptor expressed on myeloid cells 2,2.40007082516726,2.01980489654149,2.85192890446125,2.58178341611397e-23
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104567426260234,TREM2;Triggering receptor expressed on myeloid cells 2,2.98143428061242,2.33021622129817,3.81464616389066,3.6923192632498e-18
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246645619573796,RELT;Tumor necrosis factor receptor superfamily member 19L,1.8689402005214,1.55932647859074,2.24002960321802,1.31063305186648e-11
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518625150361854,RELT;Tumor necrosis factor receptor superfamily member 19L,1.43475806352223,1.26164019382329,1.63163056386454,3.74307071093282e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14412635735439,RELT;Tumor necrosis factor receptor superfamily member 19L,1.26749874147631,1.18878589850283,1.3514233821812,4.2737311011897e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,RELT;Tumor necrosis factor receptor superfamily member 19L,4.60101017017506,4.09074329135729,5.17492618781035,7.3424357640302e-143
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.065040009460365,RELT;Tumor necrosis factor receptor superfamily member 19L,3.62354075086191,2.59461368176022,5.0605019411789,4.19989069549968e-14
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.055206135767661,RELT;Tumor necrosis factor receptor superfamily member 19L,3.37248032077361,2.3185957099775,4.90539315028561,2.03092352530719e-10
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97398522117623,RELT;Tumor necrosis factor receptor superfamily member 19L,1.20351465454286,1.13843715933504,1.27231223245161,6.5181786941018e-11
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00473810993211,RELT;Tumor necrosis factor receptor superfamily member 19L,1.23282433883917,1.15347831488218,1.31762845545085,6.97874472896609e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,RELT;Tumor necrosis factor receptor superfamily member 19L,1.61175301039509,1.48776941735314,1.74606880355104,1.47339238415346e-31
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60328187241126,RELT;Tumor necrosis factor receptor superfamily member 19L,1.27843636450884,1.18700312889907,1.37691257782485,8.70403389023123e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781126716111724,RELT;Tumor necrosis factor receptor superfamily member 19L,1.51943705995716,1.36711486017868,1.68873080559559,8.37617272103559e-15
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37165770093495,RELT;Tumor necrosis factor receptor superfamily member 19L,1.25735317706708,1.16039338639286,1.36241470385754,2.22985968454865e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,RELT;Tumor necrosis factor receptor superfamily member 19L,1.34652271027792,1.2869197063889,1.40888619569112,5.81580672461209e-38
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23266631912419,RELT;Tumor necrosis factor receptor superfamily member 19L,1.22259838739056,1.16725202858753,1.28056904613717,1.84773262511014e-17
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.07307182560876,RELT;Tumor necrosis factor receptor superfamily member 19L,1.23303971055095,1.15503063266355,1.31631740734832,3.33772626145423e-10
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773495925333964,RELT;Tumor necrosis factor receptor superfamily member 19L,1.32229739820796,1.18878304533475,1.47080698716997,2.68595744345968e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805528134254689,RELT;Tumor necrosis factor receptor superfamily member 19L,1.42390517881238,1.28271743598145,1.58063335024162,3.28423651537366e-11
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11685689727547,RELT;Tumor necrosis factor receptor superfamily member 19L,1.27018000529349,1.19011891398298,1.35562692676477,6.03250087279046e-13
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406616398878844,RELT;Tumor necrosis factor receptor superfamily member 19L,1.4752166908493,1.27401412227244,1.70819478914299,2.02561594915881e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703334913861229,RELT;Tumor necrosis factor receptor superfamily member 19L,1.52594997629008,1.36569859638526,1.70500528909002,8.29313809999003e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,RELT;Tumor necrosis factor receptor superfamily member 19L,1.82580282134696,1.50285684849106,2.21814602354547,1.34623555636634e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.79237657500594,RELT;Tumor necrosis factor receptor superfamily member 19L,1.24619838785135,1.19352003912816,1.3012017988552,1.72218086712224e-23
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,ISM1;Isthmin-1,1.75313680423288,1.5573516768126,1.97353539352545,1.51668211005605e-20
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.219246266887888,ISM1;Isthmin-1,1.78962321265396,1.48804584120806,2.15232028112101,6.35681470787522e-10
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102677513624516,ISM1;Isthmin-1,2.3010189319556,1.76712340178734,2.99621866806972,6.13522268035279e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.386586146948485,COL15A1;Collagen alpha-1(XV) chain,4.12678323770598,3.5668029304243,4.77467923605893,6.39091899454416e-81
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0433829573477029,COL15A1;Collagen alpha-1(XV) chain,3.13189066476073,2.0518513435659,4.78043361512187,1.21597566516254e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36612648130744,COL15A1;Collagen alpha-1(XV) chain,1.32641942720965,1.22143192306608,1.44043107409761,1.88963298212777e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.397582331716958,PBXIP1;Pre-B-cell leukemia transcription factor-interacting protein 1,2.56106726366742,2.2121071627721,2.96507585139296,2.60586584890942e-36
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.40213245093984,HIP1R;Huntingtin-interacting protein 1-related protein,2.31672461070314,2.00911531192827,2.67143099750028,6.6596220646917e-31
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36308166977504,HIP1R;Huntingtin-interacting protein 1-related protein,1.30656836437195,1.20538968792429,1.41623983337479,7.9041602811376e-11
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.771810538889144,HIP1R;Huntingtin-interacting protein 1-related protein,1.34215087492847,1.20605795918918,1.49360066599313,6.86953373291158e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.680397204854726,HIP1R;Huntingtin-interacting protein 1-related protein,1.36945282605039,1.22233853389556,1.53427302729346,5.87928450804055e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.211091480623178,HIP1R;Huntingtin-interacting protein 1-related protein,2.20130884454963,1.80645363877261,2.6824716256681,5.15538276662987e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105509427037937,HIP1R;Huntingtin-interacting protein 1-related protein,2.96085075397306,2.25718106340527,3.88388744236456,4.50106255123429e-15
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.402386244005146,RIDA;2-iminobutanoate/2-iminopropanoate deaminase,1.71026133659988,1.47685347313144,1.98055791768319,7.59900460515793e-13
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212577088394692,RIDA;2-iminobutanoate/2-iminopropanoate deaminase,2.17123493963148,1.78535907996036,2.64051148925244,8.12377277706806e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107418910398617,RIDA;2-iminobutanoate/2-iminopropanoate deaminase,3.07230385516809,2.36428639470967,3.9923466969152,4.53419011203394e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,LPL;Lipoprotein lipase,1.86744362802088,1.64289262795867,2.12268631831946,1.23344208748091e-21
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60935487067684,LPL;Lipoprotein lipase,1.22004081612671,1.13046912351506,1.31670964031889,3.18592282521244e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.244565749055976,CD74;HLA class II histocompatibility antigen gamma chain,1.613417818598,1.36099146325045,1.91266229631779,3.5788409146882e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.516189582355701,CD74;HLA class II histocompatibility antigen gamma chain,1.42785939002955,1.26831382620416,1.6074747397474,3.82306357872048e-09
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11816295368231,CD74;HLA class II histocompatibility antigen gamma chain,1.24155345350873,1.17007048003651,1.31740352758182,8.59950167949847e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.535105256968128,CD74;HLA class II histocompatibility antigen gamma chain,2.92742563684196,2.63065914241744,3.25767056668707,2.35163273155641e-86
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0644896523421469,CD74;HLA class II histocompatibility antigen gamma chain,2.47491368295945,1.80632912814751,3.39096438331902,1.69911214980104e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.05473988778323,CD74;HLA class II histocompatibility antigen gamma chain,2.55312470753577,1.81619660413917,3.58906395781924,6.88428022344932e-08
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97075412995042,CD74;HLA class II histocompatibility antigen gamma chain,1.24054799295884,1.17900738209234,1.30530083713561,1.01226986362537e-16
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01587425864667,CD74;HLA class II histocompatibility antigen gamma chain,1.25583211117481,1.15275406308196,1.36812728921663,1.85670520606246e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33958341505511,CD74;HLA class II histocompatibility antigen gamma chain,1.41746554173271,1.31645895948622,1.52622195133507,2.25404032635606e-20
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70861368852619,CD74;HLA class II histocompatibility antigen gamma chain,1.21243605634059,1.13473034213541,1.29546301542301,1.19780071427702e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778423204052494,CD74;HLA class II histocompatibility antigen gamma chain,1.45767568156003,1.3230636315492,1.60598352334989,2.48198671427685e-14
sensitivity,Circulatory system disorders,I50 (heart failure),4.40956062159817,CD74;HLA class II histocompatibility antigen gamma chain,1.35420511482886,1.29947541853177,1.41123984869269,4.76940912117299e-47
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22465208747514,CD74;HLA class II histocompatibility antigen gamma chain,1.23681047283768,1.18540762089488,1.29044230757196,9.87742047401148e-23
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772827767016884,CD74;HLA class II histocompatibility antigen gamma chain,1.3725172235559,1.24501673706542,1.51307486307199,1.94713396949804e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.796758153557026,CD74;HLA class II histocompatibility antigen gamma chain,1.52650504157094,1.38765636702934,1.67924689231959,3.52246059719843e-18
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12466554355366,CD74;HLA class II histocompatibility antigen gamma chain,1.31885664269918,1.24271193952079,1.39966696116438,7.40685333100257e-20
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.403186346466247,CD74;HLA class II histocompatibility antigen gamma chain,1.43012231665365,1.24975432183068,1.63652151856122,1.97947719546898e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703259677166588,CD74;HLA class II histocompatibility antigen gamma chain,1.37517244972776,1.24148929816468,1.52325055824959,1.02417781118706e-09
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0469070653767223,CD74;HLA class II histocompatibility antigen gamma chain,2.51375302269206,1.73832120278984,3.6350901369391,9.68335167632077e-07
sensitivity,Circulatory system disorders,I81 (portal vein thrombosis),0.0762195121951219,CD74;HLA class II histocompatibility antigen gamma chain,2.12071069421467,1.5760667590956,2.85356811353426,6.90603651229627e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220940463388405,CD74;HLA class II histocompatibility antigen gamma chain,2.62417703921034,2.21554543774534,3.10817598944243,5.65091585393673e-29
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.270312622424194,CD74;HLA class II histocompatibility antigen gamma chain,1.56295760297072,1.3267261601277,1.84125145195664,9.22031956027403e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.78332613051506,CD74;HLA class II histocompatibility antigen gamma chain,1.26552412649475,1.21643687910752,1.31659220650671,1.88272375525848e-31
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101639921033599,CD74;HLA class II histocompatibility antigen gamma chain,3.1580357490721,2.48056807789614,4.02052654038667,1.01754834641165e-20
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.542652924858768,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.81324991183739,1.61334765496869,2.03792110934832,1.7618980264168e-23
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645994832041343,LTBP3;Latent-transforming growth factor beta-binding protein 3,2.30853359879337,1.65823190649295,3.21386131571249,7.19756926976766e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34327451020118,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.24596687008067,1.15430759555988,1.34490446680776,1.69271565272801e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804820836366577,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.30932351197246,1.1857981716638,1.44571656456387,9.78997978069005e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212074084546868,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.68839517251758,1.39794707944668,2.03918896537128,5.38249262852687e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100959111559818,LTBP3;Latent-transforming growth factor beta-binding protein 3,2.43867463606715,1.87632933856234,3.16955763488406,2.64157932878249e-11
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513952943015711,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.36326682684317,1.20798312263947,1.53851192648303,5.1043926190341e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11704396485941,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.23478415213592,1.16308229807865,1.31090629174284,4.86075895335876e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544649504329767,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,3.35547585718596,2.9960583695182,3.75801030537614,2.1892165966967e-97
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0644556427985468,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,2.71131944678531,1.94417934815634,3.7811599786241,4.15694485227549e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547110086365235,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,3.10610177622849,2.17101679908263,4.44393993098834,5.57764693575243e-10
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96914496649681,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.26694446665596,1.20361233506092,1.33360903243726,1.5211948666405e-19
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01925033257688,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.34925096887246,1.23809516994256,1.47038630082672,8.56517570762692e-12
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00647121493114,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.20261224036141,1.13065647321614,1.27914732275238,4.60279485054272e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34274233068705,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.55275748179994,1.44043200483485,1.67384214540701,1.55802927524376e-30
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.6161973213935,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.2022849649055,1.12261911667603,1.28760424204941,1.39005834755202e-07
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69401799894123,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.24557507694419,1.16503734849058,1.33168028845993,1.20344514493645e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776057549456564,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.47935070473675,1.34062861889776,1.63242711423275,6.44274988658283e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.41886591639237,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.3579837926188,1.30239607958099,1.41594405106674,1.07004915076415e-46
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23016551093802,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.22417193620209,1.17294838649923,1.27763245734749,1.78396405649287e-20
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06426064966379,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.22825038175471,1.15604039304295,1.30497083783519,2.92209183049556e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774420651217365,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.29843765708732,1.17645582966183,1.4330672744654,2.12060592907383e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804163650237727,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.65670194744595,1.50386560989096,1.82507088706564,1.57052024891956e-24
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13743784790317,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.41435929204994,1.33166812563931,1.50218524307446,1.67294917023224e-29
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406885758998435,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.64966338173798,1.44036926774988,1.88936915968672,4.77909854072523e-13
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700930004894762,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.67852145535357,1.51350211293202,1.86153309731707,1.03114846029229e-22
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213011275918,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,2.05962388018575,1.70978450693805,2.48104396233432,2.801724353273e-14
sensitivity,Circulatory system disorders,I95 (hypotension),4.78088431634336,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.25561969428085,1.20636469545768,1.30688573911541,7.26826273698522e-29
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10354191493934,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,2.33164557021302,1.78847319067257,3.03978337134007,3.94128924851236e-10
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.2426614481409,HSPB6;Heat shock protein beta-6,1.52199500932738,1.28226594628587,1.80654318640154,1.56185509891173e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,HSPB6;Heat shock protein beta-6,2.85220357498327,2.58456517770864,3.1475566193148,1.59837496574757e-96
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547516621040281,HSPB6;Heat shock protein beta-6,2.50769742168559,1.81664194473187,3.46163225888563,2.27701093609436e-08
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00406736825478,HSPB6;Heat shock protein beta-6,1.23083593390447,1.15625141899852,1.31023155630171,7.41197863021114e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,HSPB6;Heat shock protein beta-6,1.30212278882168,1.20754553911096,1.40410750754549,6.79901976367116e-12
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60963817535032,HSPB6;Heat shock protein beta-6,1.26858757467795,1.18372341667646,1.35953586112689,1.646259864572e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778575480741016,HSPB6;Heat shock protein beta-6,1.29747064365112,1.1753244460946,1.43231094761128,2.43960476467342e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.41849455578349,HSPB6;Heat shock protein beta-6,1.22957067898484,1.17874797026085,1.28258465147955,8.33464215570257e-22
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23386695833747,HSPB6;Heat shock protein beta-6,1.20379334812124,1.15273796912233,1.25710999706574,4.93256650157881e-17
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.457943559434811,HSPB6;Heat shock protein beta-6,1.41444383242752,1.24596027392915,1.60571038816767,8.40145560339427e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.80223213408523,HSPB6;Heat shock protein beta-6,1.21241886237869,1.16429964790768,1.26252679067046,1.14065165951455e-20
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,CNTN3;Contactin-3,0.719183660277236,0.63238237534308,0.817899355479599,5.08527088593074e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,CNTN3;Contactin-3,0.725879160773542,0.670044311485775,0.786366732786578,4.32715532550773e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,CNTN3;Contactin-3,0.790014931808385,0.755556299213453,0.826045118186336,3.82333639539132e-25
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.553361268721053,CSTB;Cystatin-B,2.53388447856936,2.27050608613577,2.82781472815255,6.53753640379981e-62
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3439242588358,CSTB;Cystatin-B,1.42801905247408,1.32527897110443,1.53872389035915,8.55400098726248e-21
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.780124819971195,CSTB;Cystatin-B,1.4013599931979,1.27087137375467,1.54524672684515,1.3178532856291e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.40562402920944,CSTB;Cystatin-B,1.24183303010254,1.19107766109258,1.29475123665659,2.62624153582352e-24
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772494396413704,CSTB;Cystatin-B,1.27719166662289,1.15707863350796,1.40977329115959,1.20222754856784e-06
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.810891981179297,CSTB;Cystatin-B,1.33364580106924,1.21125834270804,1.46839948175971,4.5591226931799e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14659261361332,CSTB;Cystatin-B,1.20760137371387,1.13734964205894,1.28219240932425,6.88789887832393e-10
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.412362879333813,CSTB;Cystatin-B,1.42421030649554,1.24526635635171,1.62886838368516,2.44462291186255e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.707287262818329,CSTB;Cystatin-B,1.37704896038347,1.24237493534372,1.52632171283185,1.10832864446781e-09
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248672758491385,CDH2;Cadherin-2,1.67809070897405,1.4095547169508,1.99778582106884,5.9496265539737e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,CDH2;Cadherin-2,1.48667236673642,1.3209096928952,1.67323681392125,4.89012686177744e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,CDH2;Cadherin-2,1.31670311558148,1.2205274858575,1.42045723236125,1.16391079910731e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80173775671406,CDH2;Cadherin-2,1.30874002703355,1.18626180317351,1.4438637860358,8.00227341662327e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222866497051456,CDH2;Cadherin-2,3.15073806628743,2.64904252567102,3.7474484709671,1.83363839748462e-38
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104495268138801,CDH2;Cadherin-2,4.18790164642012,3.28478243358317,5.33932476646761,6.84640065525716e-31
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14731238329824,REG1A;Lithostathine-1-alpha,1.2208350564408,1.15010022614617,1.29592030429302,5.66512715367348e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54896968732596,REG1A;Lithostathine-1-alpha,3.26534455741731,2.91701350934734,3.65527106559082,6.16876504590196e-94
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0575282682007538,REG1A;Lithostathine-1-alpha,2.77391889182179,1.95180421332001,3.94231448313008,1.2788721133582e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34524686075898,REG1A;Lithostathine-1-alpha,1.37494237494223,1.27536686882719,1.48229233534209,1.02966321969801e-16
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60897998245474,REG1A;Lithostathine-1-alpha,1.20371329739412,1.1234278493627,1.28973632187004,1.4047485464568e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.785870212343719,REG1A;Lithostathine-1-alpha,1.44743547807448,1.31206481453105,1.59677284230619,1.56721622881549e-13
sensitivity,Circulatory system disorders,I50 (heart failure),4.40682036503362,REG1A;Lithostathine-1-alpha,1.25465853916142,1.20303604324473,1.30849616578814,3.57434831994498e-26
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.770315074748357,REG1A;Lithostathine-1-alpha,1.39370893422871,1.26207720916904,1.53906954284345,5.44235319496594e-11
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.806451612903225,REG1A;Lithostathine-1-alpha,1.40286109122462,1.27294124218796,1.54604091378897,8.66949215342271e-12
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1275312192081,REG1A;Lithostathine-1-alpha,1.26148361388252,1.18757907645402,1.33998732349316,4.65525842653197e-14
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409079174692694,REG1A;Lithostathine-1-alpha,1.50342576459292,1.3122128444341,1.72250183286124,4.23154183832359e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703665421006599,REG1A;Lithostathine-1-alpha,1.36411936074971,1.22939571010784,1.51360673790621,4.84050144169422e-09
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.517379238982173,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.38900614396892,1.22194310649045,1.57890989992543,5.01654214507945e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.402741468239949,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,2.04603220585965,1.78520577104166,2.34496653289008,7.87212854632782e-25
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35237196129336,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.50103435566749,1.38736806441405,1.6240132627283,5.0362789730516e-24
sensitivity,Circulatory system disorders,I50 (heart failure),4.30729821398923,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.26396334020576,1.20789793842991,1.32263105561778,4.52985962943947e-24
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.746075454823601,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.35811909926806,1.21992759078443,1.51196472784966,2.26001515467277e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.758128693522944,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.42943438062135,1.28606253476281,1.58878949761117,3.46499562403217e-11
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06908059402636,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.30480233968926,1.22237182087383,1.39279155211669,1.34332220102794e-15
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.687900490011307,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.49492390102324,1.33882905424169,1.66921793545654,8.93851468188347e-13
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.206956562639636,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,2.36378086088056,1.96600281136118,2.84204067561671,5.66345263243987e-20
sensitivity,Circulatory system disorders,I95 (hypotension),4.52923803898405,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.23207504032898,1.17886793760756,1.28768359591013,1.93467260857007e-20
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101093217350417,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,3.16275211019908,2.46936888596488,4.05083297494458,7.57749592065446e-20
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11816295368231,CXCL13;C-X-C motif chemokine 13,1.21002205180555,1.13980761780388,1.28456183568659,4.09336110356362e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.535105256968128,CXCL13;C-X-C motif chemokine 13,1.57100651415753,1.39513177978908,1.76905257501805,8.85364714996412e-14
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97075412995042,CXCL13;C-X-C motif chemokine 13,1.20828878772299,1.14768124978375,1.27209693005981,5.75910299288371e-13
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33958341505511,CXCL13;C-X-C motif chemokine 13,1.48687233068068,1.3799220776711,1.60211171595643,2.11447169703514e-25
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778423204052494,CXCL13;C-X-C motif chemokine 13,1.42788552001454,1.29338559771902,1.5763721676373,1.70510210618748e-12
sensitivity,Circulatory system disorders,I50 (heart failure),4.40956062159817,CXCL13;C-X-C motif chemokine 13,1.22280971478016,1.17277931724284,1.27497439337183,3.81851522597767e-21
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22465208747514,CXCL13;C-X-C motif chemokine 13,1.20543183152604,1.15477027448012,1.25831598939485,1.47898232043472e-17
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772827767016884,CXCL13;C-X-C motif chemokine 13,1.33415613321183,1.20834322545611,1.47306870290505,1.16465614726023e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.796758153557026,CXCL13;C-X-C motif chemokine 13,1.35534890535328,1.22912640422944,1.49453355563861,1.08556756948855e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12466554355366,CXCL13;C-X-C motif chemokine 13,1.22540632181996,1.15386762745464,1.30138034712768,3.51456812312628e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703259677166588,CXCL13;C-X-C motif chemokine 13,1.34375682544473,1.21131475718425,1.49067977189239,2.39031428011823e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220940463388405,CXCL13;C-X-C motif chemokine 13,2.04090775107294,1.70052738307603,2.44941921538196,1.81131390081352e-14
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246645619573796,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.64265602345923,1.37972464351629,1.95569371329783,2.45028611857558e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518625150361854,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.38546691419382,1.22777143010057,1.56341687325996,1.23450631095365e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,4.84311179148346,4.31304620672063,5.43832147873982,9.23164588540151e-157
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.065040009460365,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,2.88643178489657,2.09987449758886,3.96761256847857,6.55957784410166e-11
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.055206135767661,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,3.55239281020228,2.53612804022221,4.97589020658087,1.67137227270477e-13
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00874508952365,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.27887556654592,1.17294919830179,1.39436790363646,2.45890213116924e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.40081170339495,1.29907157707138,1.51051986896058,1.9324335457439e-18
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60328187241126,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.2246545836641,1.14274081664263,1.31244008041633,9.60735825473013e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781126716111724,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.46293096664897,1.32653386512872,1.61335271525301,2.56421903247322e-14
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.2981389187151,1.24473259078077,1.35383669132161,4.30643968362175e-34
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773495925333964,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.33452710261607,1.20892221452873,1.4731821172722,1.0531746986795e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805528134254689,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.43926099923854,1.3063837764887,1.58565366564551,1.7366821365282e-13
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11685689727547,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.28736538931166,1.21168234085452,1.36777568651266,3.05102741380782e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406616398878844,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.57079593387103,1.37210482048878,1.79825901711125,5.96065677583009e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703334913861229,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.4680535964543,1.3235369748235,1.62834994643789,3.82928867638791e-13
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0453362769060947,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,2.77581104300333,1.89557987584726,4.06478621377815,1.5523431226757e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.56494054815408,1.30377607963542,1.87841988935832,1.52840496520836e-06
sensitivity,Circulatory system disorders,I95 (hypotension),4.79237657500594,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.24993116537271,1.20064803076323,1.30123723034537,1.61190056392876e-27
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543445923163886,CANT1;Soluble calcium-activated nucleotidase 1,2.43927534361226,2.16997561672811,2.74199588054644,1.82260039935545e-50
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783646330120911,CANT1;Soluble calcium-activated nucleotidase 1,1.28251364750755,1.16221971826442,1.41525843194212,7.36138326716163e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.794295335248093,CANT1;Soluble calcium-activated nucleotidase 1,1.28740973623176,1.16732960236026,1.41984219846146,4.25867724754613e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223549893170847,CANT1;Soluble calcium-activated nucleotidase 1,1.92731792674991,1.60540560631969,2.31377938145302,1.96750023387352e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104815583901908,CANT1;Soluble calcium-activated nucleotidase 1,2.17526986616189,1.66769902238265,2.83732191907844,9.8915135663326e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,ACY1;Aminoacylase-1,0.655472921549465,0.581337895330825,0.739062005651793,5.28817021781027e-12
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222866497051456,ACY1;Aminoacylase-1,2.97513155663909,2.48959068124353,3.55536668979196,3.83159854498791e-33
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104495268138801,ACY1;Aminoacylase-1,4.75245030115939,3.74410407663677,6.03236005268268,1.44016343718019e-37
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.244565749055976,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.5569127923515,1.30578558964892,1.85633649368077,8.10451735812803e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.535105256968128,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,3.65806561323642,3.25735690296338,4.10806811454065,2.09292171251702e-106
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0644896523421469,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,2.3502387827694,1.68888783447136,3.27056789876301,4.01260867449656e-07
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.05473988778323,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,3.09615207696289,2.17078326221348,4.41599023290189,4.42134808239964e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33958341505511,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.22773470932606,1.13869739096623,1.3237340565125,9.22602880570987e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778423204052494,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.35676798729239,1.23046094774701,1.4960404673647,9.375361458719e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.40956062159817,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.20836583776114,1.15889535003622,1.25994810301252,7.03746468338487e-19
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.796758153557026,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.36656371147037,1.24023857953681,1.5057557540301,2.78045810608017e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703259677166588,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.29224931108355,1.16526429890873,1.43307255148877,1.18519857755991e-06
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0469070653767223,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,2.56568815111306,1.7514314541266,3.75850032455003,1.31819925474632e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220940463388405,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,2.08494780897954,1.74024632805593,2.49792646942386,1.60419254098759e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101639921033599,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,3.03435309659647,2.33873398567385,3.93687301387197,6.54100245819727e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549526304386362,PRSS2;Trypsin-2,2.87219432767306,2.55139885129974,3.23332443757857,2.87033970801386e-68
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33995428391266,PRSS2;Trypsin-2,1.28688552508132,1.19369457451587,1.38735183188336,4.82316534466319e-11
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802501917743553,PRSS2;Trypsin-2,1.38107411533954,1.25417114422143,1.52081772958104,5.19649034740182e-11
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.244669000636537,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.71665506864661,1.44381809674555,2.04104979107311,9.41514000059563e-10
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.506897785552419,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.38594063925966,1.22654563158127,1.56604973031059,1.6430518291125e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534002829417976,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,2.31439947534978,2.06282602134455,2.59665375367331,2.43142144211767e-46
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33402460667211,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.47629856575484,1.36906138499651,1.59193552541501,4.32185532344228e-24
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.78342479917283,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.39317076643032,1.26221035637746,1.5377189504343,4.60114503783512e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.40073780023256,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.28084110685654,1.22813991353344,1.33580378174788,7.72273470888658e-31
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80001592071484,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.49238912768596,1.3538911619973,1.64505491353501,7.81138447667514e-16
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.10956861638895,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.25918551925071,1.18496276503061,1.33805737925422,1.04578536059428e-13
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40194205666985,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.4448721112434,1.25897966936912,1.65821217660734,1.62745848665381e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70101368171589,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.40945284628047,1.2698988666455,1.5643429394780899,1.10737790126175e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216673955392994,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,2.29320314594718,1.91283630125455,2.74920580769669,2.98751037735345e-19
sensitivity,Circulatory system disorders,I95 (hypotension),4.79937685993329,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.21696663424893,1.16906072036127,1.26683564256398,9.42532786453843e-22
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0993601208219069,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,2.33224223379728,1.78431412131761,3.04842839728864,5.72438940616038e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,CD99L2;CD99 antigen-like protein 2,3.08347468932953,2.75128429219199,3.45577379506674,1.62298448428821e-83
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,CD99L2;CD99 antigen-like protein 2,1.27198360265732,1.17993731371367,1.37121037416545,3.44618681606073e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,CD99L2;CD99 antigen-like protein 2,1.20058736951838,1.15146587503849,1.25180438525708,9.7426024207639e-18
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773495925333964,CD99L2;CD99 antigen-like protein 2,1.29954598584829,1.17770938291359,1.43398685094651,1.82247716033978e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805528134254689,CD99L2;CD99 antigen-like protein 2,1.42562014769176,1.29489740243633,1.56953964204482,4.95413883598355e-13
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11685689727547,CD99L2;CD99 antigen-like protein 2,1.23369566189905,1.16147829626718,1.31040329473226,8.86209232608657e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406616398878844,CD99L2;CD99 antigen-like protein 2,1.69021449877071,1.47918551219166,1.93135007631454,1.22443488919642e-14
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703334913861229,CD99L2;CD99 antigen-like protein 2,1.33509073144868,1.20409560500067,1.48033698802444,4.13709169595524e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,NPPC;C-type natriuretic peptide,3.6715503046909,3.2309144715829,4.17228055971148,1.87354778938462e-88
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0631736881588818,NPPC;C-type natriuretic peptide,2.78709007803307,1.89979984611878,4.08878394160303,1.58923463545699e-07
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0572737686139748,NPPC;C-type natriuretic peptide,2.81023375382105,1.87413688692451,4.21389376956074,5.76466013679993e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,SLC39A5;Zinc transporter ZIP5,2.14485451499875,1.91793379295682,2.39862340785925,8.50937347396359e-41
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,SFTPD;Pulmonary surfactant-associated protein D,1.47163090326012,1.36497903439451,1.58661595589333,7.82306031667834e-24
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783222853535353,SFTPD;Pulmonary surfactant-associated protein D,1.28428882044101,1.16443454697004,1.41647959398116,5.56977090450397e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.399768919699595,PALM;Paralemmin-1,4.01846045747305,3.50232688954937,4.61065598886808,1.62714766781173e-87
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36142625607779,PALM;Paralemmin-1,1.2791722051642,1.17859805061425,1.38832872633028,3.79084070702683e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534002829417976,ADAM22;Disintegrin and metalloproteinase domain-containing protein 22,3.15794401237334,2.79985765958996,3.56182763474668,3.00084443741554e-78
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0576403243758944,ADAM22;Disintegrin and metalloproteinase domain-containing protein 22,2.67076462392183,1.86582226871639,3.82297059906971,7.94954212272995e-08
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.244565749055976,THY1;Thy-1 membrane glycoprotein,1.62519129098387,1.35782406058944,1.94520542753031,1.18747421106892e-07
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.203307659225085,THY1;Thy-1 membrane glycoprotein,1.62095538882829,1.33609748614393,1.96654540542144,9.65807571713374e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.535105256968128,THY1;Thy-1 membrane glycoprotein,3.86207903141884,3.44242866383306,4.33288701132208,2.73462721623078e-117
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0644896523421469,THY1;Thy-1 membrane glycoprotein,3.26454038581118,2.36429681629281,4.50756599473946,6.61269610655339e-13
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.05473988778323,THY1;Thy-1 membrane glycoprotein,3.25334699067401,2.28872172555099,4.62453190510942,4.88661227345897e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33958341505511,THY1;Thy-1 membrane glycoprotein,1.51446640275338,1.4025779310191,1.63528060319775,3.00244387832907e-26
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778423204052494,THY1;Thy-1 membrane glycoprotein,1.48894479145285,1.34850582862325,1.64400964752074,3.40242496685428e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.40956062159817,THY1;Thy-1 membrane glycoprotein,1.27388045804562,1.22075247905667,1.32932060285022,8.27579096654974e-29
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22465208747514,THY1;Thy-1 membrane glycoprotein,1.20508460768967,1.15392042206169,1.25851738467016,3.52615822307284e-17
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772827767016884,THY1;Thy-1 membrane glycoprotein,1.28534330966222,1.16275588049737,1.4208549287119,9.17363372921275e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.796758153557026,THY1;Thy-1 membrane glycoprotein,1.28766993791978,1.16662735552515,1.42127120641359,5.1712130717176e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703259677166588,THY1;Thy-1 membrane glycoprotein,1.29929747099106,1.16954366497497,1.44344667811945,1.07423660253591e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220940463388405,THY1;Thy-1 membrane glycoprotein,2.13884205780126,1.78100701982414,2.56857232863194,3.99326712391453e-16
sensitivity,Circulatory system disorders,I95 (hypotension),4.78332613051506,THY1;Thy-1 membrane glycoprotein,1.2187536165603,1.17002355159462,1.26951322975884,2.05431029130547e-21
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101639921033599,THY1;Thy-1 membrane glycoprotein,2.42776223921005,1.86139230129059,3.16646280638831,5.982387756007e-11
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248011967561609,CHRDL1;Chordin-like protein 1,1.87314260933302,1.57880533833659,2.22235328808528,6.21164201768941e-13
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511448579746636,CHRDL1;Chordin-like protein 1,1.35317287251934,1.19779583713252,1.52870528195004,1.1726095901829e-06
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12895856310067,CHRDL1;Chordin-like protein 1,1.22342613329883,1.15225896666856,1.2989888097517,4.25603347465063e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54229934924078,CHRDL1;Chordin-like protein 1,3.62435767470808,3.26958029272147,4.01763143222322,1.50481402222597e-132
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0629141025893085,CHRDL1;Chordin-like protein 1,2.74556761621642,2.01745775114489,3.73645571062812,1.32777731077015e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0570383336939205,CHRDL1;Chordin-like protein 1,3.04570643512702,2.21764362317007,4.182965915738,5.99358578159971e-12
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96421936838704,CHRDL1;Chordin-like protein 1,1.21886304149946,1.15789569901253,1.28304053223471,4.04407998932231e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00825111754396,CHRDL1;Chordin-like protein 1,1.24742861849786,1.14439272640281,1.35974139152275,5.00064110382086e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34372533543804,CHRDL1;Chordin-like protein 1,1.47833281795031,1.37153966162379,1.59344128484152,1.64180865664111e-24
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60713226718326,CHRDL1;Chordin-like protein 1,1.37770788409025,1.28575039503542,1.47624221716234,9.78723233899877e-20
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71110540961929,CHRDL1;Chordin-like protein 1,1.235989521752,1.15644476056413,1.32100568049227,4.30584524969861e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.779174783070657,CHRDL1;Chordin-like protein 1,1.4963443698429,1.35851732271215,1.64815452532508,2.97011795291778e-16
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36042297867284,CHRDL1;Chordin-like protein 1,1.21208485017538,1.12448222704634,1.30651214282299,5.03024574280163e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.40630889792679,CHRDL1;Chordin-like protein 1,1.31900542333046,1.26477971390007,1.37555598627559,3.17418752591136e-38
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23025381522891,CHRDL1;Chordin-like protein 1,1.26478661356246,1.21185149859016,1.32003399732379,4.84212950529056e-27
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06203875448912,CHRDL1;Chordin-like protein 1,1.21102795928478,1.13952898249016,1.28701309111471,6.97176791996401e-10
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.70707549031214,CHRDL1;Chordin-like protein 1,1.22407284928721,1.16055151760865,1.2910709413827,1.03477989369572e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781480679514182,CHRDL1;Chordin-like protein 1,1.39029925785797,1.26086535639065,1.53302017269602,3.86683400175057e-11
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.809469413479339,CHRDL1;Chordin-like protein 1,1.5330004382935,1.39373370417027,1.68618319035855,1.4700644979712e-18
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12948377963431,CHRDL1;Chordin-like protein 1,1.29025250078006,1.21462850654065,1.37058492107231,1.34556148871827e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405623597054306,CHRDL1;Chordin-like protein 1,1.48759391652946,1.30126236479266,1.70060682639359,6.00246599740266e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70160225458702,CHRDL1;Chordin-like protein 1,1.49366171855363,1.34782149775066,1.65528249341316,1.94562919706859e-14
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0471911437953477,CHRDL1;Chordin-like protein 1,2.47715855032755,1.73059075456593,3.54579178657407,7.1505374523339e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.224250531119679,CHRDL1;Chordin-like protein 1,1.95389730426456,1.64096466454977,2.32650632770315,5.41055248650011e-14
sensitivity,Circulatory system disorders,I95 (hypotension),4.80858548925825,CHRDL1;Chordin-like protein 1,1.28460022444238,1.2339702385422,1.33730756633721,2.83862234678632e-34
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104224022653976,CHRDL1;Chordin-like protein 1,2.27065217874091,1.7718952893804,2.90980022788128,9.13565593144998e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54228865532133,EPHA1;Ephrin type-A receptor 1,2.96734665031432,2.63392047319323,3.34298101736409,1.54535215602075e-71
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,HAVCR2;Hepatitis A virus cellular receptor 2,3.30754099774709,2.97864981859791,3.67274708946059,5.47748090784307e-111
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.065040009460365,HAVCR2;Hepatitis A virus cellular receptor 2,2.62977482020739,1.926764303917,3.58928987366933,1.11214274303644e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.055206135767661,HAVCR2;Hepatitis A virus cellular receptor 2,2.94895830380878,2.12290784189413,4.09643551452689,1.12488995283932e-10
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97398522117623,HAVCR2;Hepatitis A virus cellular receptor 2,1.21587712699877,1.15500138294882,1.27996140072526,8.74357251395143e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00874508952365,HAVCR2;Hepatitis A virus cellular receptor 2,1.3086080365428,1.20020878523363,1.42679758253149,1.08379092104699e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,HAVCR2;Hepatitis A virus cellular receptor 2,1.40778600529067,1.30566131554304,1.51789856458142,5.52023629032016e-19
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781126716111724,HAVCR2;Hepatitis A virus cellular receptor 2,1.40515877929825,1.27411431886567,1.5496813479004,9.76679585484929e-12
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,HAVCR2;Hepatitis A virus cellular receptor 2,1.32081661443092,1.26667893910392,1.37726812620007,8.17745273291424e-39
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71750954292834,HAVCR2;Hepatitis A virus cellular receptor 2,1.21785230549125,1.15485738411419,1.28428346079113,3.51430372544633e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773495925333964,HAVCR2;Hepatitis A virus cellular receptor 2,1.42562203411429,1.29172246570739,1.57340159214399,1.83322312437903e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805528134254689,HAVCR2;Hepatitis A virus cellular receptor 2,1.57201832311568,1.42802006768816,1.73053703104617,2.74054481095016e-20
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08191348640698,HAVCR2;Hepatitis A virus cellular receptor 2,1.26705850471666,1.16582592684262,1.37708144707571,2.52722129982469e-08
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11685689727547,HAVCR2;Hepatitis A virus cellular receptor 2,1.35178333031418,1.27224792965828,1.43629093788827,1.98519090320912e-22
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406616398878844,HAVCR2;Hepatitis A virus cellular receptor 2,1.55091493014128,1.35544874568809,1.77456884901544,1.71551991429806e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703334913861229,HAVCR2;Hepatitis A virus cellular receptor 2,1.47265075827417,1.3280178779937,1.63303543708453,2.15952877301039e-13
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0453362769060947,HAVCR2;Hepatitis A virus cellular receptor 2,2.69973680257973,1.8685314481741,3.90069902774486,1.22646138169703e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,HAVCR2;Hepatitis A virus cellular receptor 2,2.23960489081426,1.88139306149942,2.66601922245937,1.21966255548116e-19
sensitivity,Circulatory system disorders,I95 (hypotension),4.79237657500594,HAVCR2;Hepatitis A virus cellular receptor 2,1.29946347873124,1.24833993203311,1.35268069956407,1.82624863464954e-37
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102507490932029,HAVCR2;Hepatitis A virus cellular receptor 2,2.96767695522561,2.33120081895013,3.77792699753061,1.02822734481891e-18
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.542652924858768,GCG;Pro-glucagon,1.38906998653611,1.23055649921293,1.56800230524121,1.06155418578468e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.210690239545641,VSNL1;Visinin-like protein 1,1.81473768076312,1.46335592625863,2.25049339732504,5.7181082347513e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105308944392298,VSNL1;Visinin-like protein 1,2.15587880072989,1.59749150041523,2.90944484038159,5.09347126206426e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248733088474592,NPC2;NPC intracellular cholesterol transporter 2,1.72491640063636,1.43170821430957,2.07817246520382,9.73863464495549e-09
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518002322880371,NPC2;NPC intracellular cholesterol transporter 2,1.54617586275856,1.35643300004846,1.7624606585742,6.85979683948308e-11
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.05595739237621,NPC2;NPC intracellular cholesterol transporter 2,1.28857073600519,1.20563367092513,1.37721314668895,8.06537932939403e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.381546192680827,NPC2;NPC intracellular cholesterol transporter 2,3.32928951494505,2.92179119319337,3.79362108426668,7.14055870371655e-73
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0487567040468064,NPC2;NPC intracellular cholesterol transporter 2,2.60727717855882,1.76419441161854,3.85325689791579,1.52092456915827e-06
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.94818628151961,NPC2;NPC intracellular cholesterol transporter 2,1.27689016517092,1.20682419461254,1.35102403580307,2.08738397496418e-17
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.52528461742123,NPC2;NPC intracellular cholesterol transporter 2,1.21401657765721,1.17404057090233,1.2553537648991,7.23732387963545e-30
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.95839294509463,NPC2;NPC intracellular cholesterol transporter 2,1.22117084554615,1.14024972564357,1.30783476678341,1.11753444350724e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36590368747377,NPC2;NPC intracellular cholesterol transporter 2,1.79683081450057,1.65870697611438,1.94645650041335,9.24497886582975e-47
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.756112881837005,NPC2;NPC intracellular cholesterol transporter 2,1.34923506966457,1.20942502038351,1.50520722039925,8.01691151289217e-08
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60620068170145,NPC2;NPC intracellular cholesterol transporter 2,1.2453291374255,1.15475626848812,1.34300605490664,1.23533203466602e-08
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.689317901306443,NPC2;NPC intracellular cholesterol transporter 2,1.37576465947965,1.22681751759474,1.54279538002031,4.85430507417449e-08
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.72478003817326,NPC2;NPC intracellular cholesterol transporter 2,1.23656917449816,1.14994573306885,1.3297178113252,1.00159874773243e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.757540549333085,NPC2;NPC intracellular cholesterol transporter 2,1.50161713646356,1.34679020049725,1.67424296946065,2.43634781232663e-13
sensitivity,Circulatory system disorders,I50 (heart failure),4.31095075207347,NPC2;NPC intracellular cholesterol transporter 2,1.4292214196494,1.36444783775535,1.49706995743058,1.83137149699931e-51
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.08196992232688,NPC2;NPC intracellular cholesterol transporter 2,1.33081248945192,1.26878076838541,1.39587699168469,8.45793100645232e-32
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.04338404902257,NPC2;NPC intracellular cholesterol transporter 2,1.29097545513747,1.20759804368311,1.38010957742554,6.50317320611221e-14
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.753208108610749,NPC2;NPC intracellular cholesterol transporter 2,1.56403055586625,1.40292069291872,1.74364209754016,7.38993856407765e-16
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.783739156724575,NPC2;NPC intracellular cholesterol transporter 2,1.45183294801879,1.30414629909153,1.61624421310803,9.65757316474704e-12
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.05326792066776,NPC2;NPC intracellular cholesterol transporter 2,1.27559751426409,1.16244300098647,1.39976671287615,2.80704026998047e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08171435299658,NPC2;NPC intracellular cholesterol transporter 2,1.339953228057,1.25336098402714,1.43252795983115,9.05510867522386e-18
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406891580831918,NPC2;NPC intracellular cholesterol transporter 2,1.48847243180295,1.28300234940548,1.7268481084731,1.53763054877959e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.695834303002094,NPC2;NPC intracellular cholesterol transporter 2,1.55671224830311,1.39006552471553,1.74333726067543,1.84299895408778e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.20906894629251,NPC2;NPC intracellular cholesterol transporter 2,1.83592523154339,1.49962473411948,2.24764327976808,3.975823431838e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.50875145857642,NPC2;NPC intracellular cholesterol transporter 2,1.27752827259864,1.22111495584234,1.33654778322082,2.17785894406027e-26
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106820240113322,NPC2;NPC intracellular cholesterol transporter 2,2.1017692554432,1.59236432745811,2.77413524465084,1.56218073487822e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.244891562016339,XG;Glycoprotein Xg,1.66616352538013,1.36233158052561,2.03775713122357,6.69228692263059e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14254910416748,XG;Glycoprotein Xg,1.29859830845779,1.20839000482037,1.39554081050191,1.1356372866211e-12
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.207497308407556,XG;Glycoprotein Xg,1.66219132559935,1.35051228537881,2.04580145831309,1.61760557067453e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.551564401523181,XG;Glycoprotein Xg,3.96246236717237,3.607651253839,4.35216901704379,5.53119434846819e-182
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645767288951508,XG;Glycoprotein Xg,2.62218402218902,1.95706213300241,3.5133524532892,1.05982198977979e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0567714654868642,XG;Glycoprotein Xg,3.24413194951204,2.45221720363445,4.29178626193737,1.69291581777476e-16
sensitivity,Circulatory system disorders,I20 (angina pectoris),4.01952339936836,XG;Glycoprotein Xg,1.22868774620607,1.16308682560294,1.29798871799133,1.88720154683907e-13
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97913400072367,XG;Glycoprotein Xg,1.25346571152461,1.17798769044719,1.33377988811704,1.00677050402093e-12
sensitivity,Circulatory system disorders,I22 (subsequent myocardial infarction),0.10382791991537,XG;Glycoprotein Xg,1.93935365871421,1.49074774756745,2.52295709968731,8.02962338641295e-07
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01136809094472,XG;Glycoprotein Xg,1.46077127866607,1.32253715259094,1.61345390138593,7.9311692416523e-14
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68690563277249,XG;Glycoprotein Xg,1.2345121038065,1.18947847404194,1.2812507058375,1.10160688765043e-28
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3451946113664,XG;Glycoprotein Xg,1.34649628623034,1.22982604695142,1.47423471256476,1.24585554096541e-10
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60941250541061,XG;Glycoprotein Xg,1.30671405303631,1.20133647662071,1.42133502947125,4.49169955780726e-10
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72654239751723,XG;Glycoprotein Xg,1.24376663510619,1.14764417528314,1.34793995902235,1.06269991806713e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.785335187324964,XG;Glycoprotein Xg,1.43335629496553,1.27994955027831,1.60514941223315,4.56037427996708e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.41565622654923,XG;Glycoprotein Xg,1.37763243637795,1.31032287900628,1.44839959689931,4.81196870118082e-36
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21893043443634,XG;Glycoprotein Xg,1.28434202852517,1.21957156999774,1.35255239365674,2.58393890367427e-21
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.05825166447355,XG;Glycoprotein Xg,1.28281589640667,1.19196454432771,1.3805919244031,3.02181103266172e-11
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72579093105005,XG;Glycoprotein Xg,1.26875903713975,1.18955447651464,1.35323730531477,4.5619530424115e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773933147850621,XG;Glycoprotein Xg,1.39187094765042,1.2388146180744,1.56383748354907,2.65118642280746e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.809613424292323,XG;Glycoprotein Xg,1.53310994308685,1.37279857233817,1.71214200316983,3.38352688490478e-14
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13530193883828,XG;Glycoprotein Xg,1.32902930618583,1.23571407541454,1.42939125793178,1.88681886654096e-14
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407627334548376,XG;Glycoprotein Xg,1.68118995101863,1.45059004250834,1.94844826489961,5.14154587151389e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.706173130112399,XG;Glycoprotein Xg,1.63396829477209,1.45480198101732,1.83519985754586,1.17001287001796e-16
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0469704086425551,XG;Glycoprotein Xg,2.93878742242717,2.1485808815537,4.01961666342802,1.51779090582646e-11
sensitivity,Circulatory system disorders,I95 (hypotension),4.79375258178098,XG;Glycoprotein Xg,1.24622060158882,1.18603048696421,1.30946531720249,2.90975323169523e-18
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,CNTN4;Contactin-4,1.94603471633849,1.61857024944189,2.33975085017191,1.41705187709232e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102507490932029,CNTN4;Contactin-4,2.63830691234116,2.02224226180705,3.44205216910422,8.67029849867265e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,DLL1;Delta-like protein 1,4.28209728238406,3.80503050200447,4.81897769969031,1.10526015280567e-128
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0648482942933501,DLL1;Delta-like protein 1,3.03326404823971,2.16728289252343,4.24526526651577,9.82630816753239e-11
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0570103011716599,DLL1;Delta-like protein 1,3.13762978251133,2.19022665189372,4.49484104468829,4.52534101008788e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34111707163142,DLL1;Delta-like protein 1,1.45798555274603,1.3508439117442,1.57362508986803,3.58446930433309e-22
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60828245707624,DLL1;Delta-like protein 1,1.24605381432388,1.16221512349106,1.33594037524415,6.01708566044606e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774843163090719,DLL1;Delta-like protein 1,1.39607639423431,1.26318657349481,1.5429464969264,6.23943513715734e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.41395173603537,DLL1;Delta-like protein 1,1.31911092360418,1.26428775889601,1.37631137889947,1.91954951665655e-37
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781111657648794,DLL1;Delta-like protein 1,1.42167231717947,1.28680294040256,1.57067730728229,4.56657540092481e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.799212598425196,DLL1;Delta-like protein 1,1.42219727237944,1.28839358541258,1.569896889013,2.82012334579874e-12
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13639443580852,DLL1;Delta-like protein 1,1.31233385243725,1.23482778677349,1.39470471809904,2.11169891349453e-18
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405400086590309,DLL1;Delta-like protein 1,1.42188585268512,1.23818520241265,1.63284084975868,6.13516306273925e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705196391285506,DLL1;Delta-like protein 1,1.39056785326265,1.2519321510519,1.54455571166759,7.59821599384515e-10
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0452026256829527,DLL1;Delta-like protein 1,2.93791094948759,1.96216204338048,4.39888274071838,1.66913166905549e-07
sensitivity,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.65769254038356,DLL1;Delta-like protein 1,1.20911745636873,1.12819843609783,1.29584032074372,7.74469674893307e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216284236811577,DLL1;Delta-like protein 1,1.93971105777592,1.60567715045668,2.34323505605597,6.38040318504793e-12
sensitivity,Circulatory system disorders,I95 (hypotension),4.82351314515969,DLL1;Delta-like protein 1,1.25780223473251,1.20803050800828,1.30962459243394,8.52655616962792e-29
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00752149711709,CCL22;C-C motif chemokine 22,1.25154511723595,1.14646493463591,1.36625651003847,5.30936541852216e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,CCL7;C-C motif chemokine 7,1.47543069271692,1.31465914424734,1.65586322396703,3.90773181025604e-11
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96836982968369,CCL7;C-C motif chemokine 7,1.23201204549536,1.17104987032331,1.29614777193615,7.73446704087255e-16
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34334568365992,CCL7;C-C motif chemokine 7,1.24226396113558,1.15323580429445,1.33816496451947,1.08008873758789e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802926925739147,CCL7;C-C motif chemokine 7,1.30004417991693,1.18120165173784,1.43084363897503,8.10890354214762e-08
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08173314612296,CCL7;C-C motif chemokine 7,1.25102436798332,1.15103678228421,1.35969761642388,1.36693236926153e-07
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.391466814290515,CCL7;C-C motif chemokine 7,1.4359288338467,1.25322983936563,1.64526214673922,1.87939456480687e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686707169856127,CCL7;C-C motif chemokine 7,1.33461068184083,1.20354167660177,1.47995346294353,4.43116364315724e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.397582331716958,ATRAID;All-trans retinoic acid-induced differentiation factor,4.04899999712209,3.5120608120935,4.66802878818097,1.03142039645109e-82
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0481651376146789,ATRAID;All-trans retinoic acid-induced differentiation factor,3.05445500691934,2.01773050597735,4.6238560410601,1.30442604535827e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36781265111566,ATRAID;All-trans retinoic acid-induced differentiation factor,1.32130560038666,1.21843372048469,1.43286291265696,1.61359997039623e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.75981911254964,ATRAID;All-trans retinoic acid-induced differentiation factor,1.35705487188748,1.21721717098708,1.51295756353827,3.74141454937794e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.31200092581877,ATRAID;All-trans retinoic acid-induced differentiation factor,1.21070276334874,1.15616927086279,1.2678084586061,4.25838085772618e-16
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.748668013962888,ATRAID;All-trans retinoic acid-induced differentiation factor,1.36702430552164,1.2255520125139,1.52482753306705,2.03489233241989e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.771916927035471,ATRAID;All-trans retinoic acid-induced differentiation factor,1.31354408052691,1.17922419483357,1.46316371309767,7.22186367602347e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06787467144286,ATRAID;All-trans retinoic acid-induced differentiation factor,1.25960652140648,1.17882800735676,1.34592033686687,8.786384064369e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.682758620689655,ATRAID;All-trans retinoic acid-induced differentiation factor,1.39709651412814,1.24605856437364,1.56644216058187,1.01309528874762e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.52051636698939,ATRAID;All-trans retinoic acid-induced differentiation factor,1.21322680147517,1.16022974359532,1.26864466278591,2.22393463675812e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543888205168922,PRSS8;Prostasin,2.17952241800493,1.93985670949537,2.44879838151642,2.94755555792727e-39
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34853329626025,PRSS8;Prostasin,1.41441025530522,1.3089044095407,1.52842052920776,1.85450946128315e-18
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778341123346272,PRSS8;Prostasin,1.31473414865525,1.18652064456748,1.4568021968723,1.72509487377558e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.814781039985726,PRSS8;Prostasin,1.47229483171009,1.33263194621972,1.62659470803565,2.80630157216592e-14
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12928214493568,PRSS8;Prostasin,1.21425555371804,1.14071128445725,1.29254139046816,1.13001696338769e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698274151953977,PRSS8;Prostasin,1.43992186600315,1.29297509486022,1.60356915491721,3.17033766116292e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223740223740223,PRSS8;Prostasin,1.91197581236107,1.58865346161189,2.30110064616901,7.01528960159927e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104908946951702,PRSS8;Prostasin,2.37163516958677,1.82672056633674,3.07909894992883,8.95739279522665e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549782503624939,ADH4;All-trans-retinol dehydrogenase [NAD(+)] ADH4,0.706968047146252,0.624618578476835,0.800174437501655,4.06530069634196e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.210928083567697,ADH4;All-trans-retinol dehydrogenase [NAD(+)] ADH4,1.90578678726352,1.57867487865617,2.30067845356476,1.91695325395668e-11
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0984054303731373,ADH4;All-trans-retinol dehydrogenase [NAD(+)] ADH4,2.56569371191607,1.96793806969548,3.34501594574278,3.34435750818513e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.541402527857621,SMOC2;SPARC-related modular calcium-binding protein 2,3.38547074035274,3.01188656767675,3.80539302402262,7.134416918286e-93
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0569442535393798,SMOC2;SPARC-related modular calcium-binding protein 2,2.60693871762867,1.78921269221846,3.79839105044845,6.05864242480423e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34349821720544,SMOC2;SPARC-related modular calcium-binding protein 2,1.26068431180318,1.16524492172918,1.36394066551104,8.04698356131786e-09
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60647325833826,SMOC2;SPARC-related modular calcium-binding protein 2,1.20754431950294,1.12374344192775,1.29759447678055,2.7593402217667e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.777889091873416,SMOC2;SPARC-related modular calcium-binding protein 2,1.35901397679566,1.22505813300392,1.5076174259561,6.8778649840673e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.81009870620158,SMOC2;SPARC-related modular calcium-binding protein 2,1.39195151928204,1.25752086853233,1.5407529851118,1.74918707156991e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700442695523856,SMOC2;SPARC-related modular calcium-binding protein 2,1.41257273172947,1.26704832900992,1.57481106027333,4.75992995016949e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.402386244005146,MXRA8;Matrix remodeling-associated protein 8,2.45621679468321,2.12524288110651,2.83873480820355,4.55670878680574e-34
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13018465623365,GPR37;Prosaposin receptor GPR37,1.21485816703508,1.1422044926593,1.29213321738532,6.17771306166206e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549782503624939,GPR37;Prosaposin receptor GPR37,3.69484120021715,3.25902724682973,4.18893444603821,1.3817167942473e-92
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0642531574403148,GPR37;Prosaposin receptor GPR37,2.76271285307495,1.93114435249714,3.9523623900388,2.66756176996922e-08
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96325318596114,GPR37;Prosaposin receptor GPR37,1.20151905505073,1.13912921159803,1.26732597579933,1.49841438191409e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33808919251153,GPR37;Prosaposin receptor GPR37,1.30509532084382,1.20714679831679,1.41099143771365,2.23934520045398e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.779680090024917,GPR37;Prosaposin receptor GPR37,1.41454972782461,1.27682509921348,1.56713001155856,3.22711628552049e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.38288991104536,GPR37;Prosaposin receptor GPR37,1.27110046618796,1.21684827644857,1.32777144563885,4.3320919998038e-27
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.768009007016626,GPR37;Prosaposin receptor GPR37,1.35597616182294,1.22343302601217,1.50287863114607,6.53261808373152e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.798551744946193,GPR37;Prosaposin receptor GPR37,1.56154013023237,1.41076231136799,1.72843260602962,7.81066354466476e-18
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14429714704624,GPR37;Prosaposin receptor GPR37,1.2297902229125,1.15587855284596,1.3084281118007,6.12680543924336e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.398174030204918,GPR37;Prosaposin receptor GPR37,1.5650761944226,1.35575989463249,1.80670891951139,9.65980775923538e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.688336520076481,GPR37;Prosaposin receptor GPR37,1.45858479420687,1.3081289583061,1.62634546722852,1.07916484024023e-11
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0461875213366267,GPR37;Prosaposin receptor GPR37,3.11806826181382,2.04187860580173,4.76147291896095,1.40198634099009e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.74306704880313,GPR37;Prosaposin receptor GPR37,1.21961011980323,1.16997128288368,1.27135500339825,7.64097322760683e-21
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.218091795033008,CPM;Carboxypeptidase M,2.00152238145205,1.67365972399131,2.39361190690533,2.90682958630324e-14
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100174814873013,CPM;Carboxypeptidase M,2.49875981226838,1.93938953046677,3.2194670030547,1.41302590901488e-12
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248818681945807,PROS1;Vitamin K-dependent protein S,0.575878681355363,0.478705968860238,0.692776520896934,4.83936422007736e-09
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513253341849537,PROS1;Vitamin K-dependent protein S,0.702215099825868,0.61705987416373,0.799121879528686,8.33267786626272e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04179513532031,PROS1;Vitamin K-dependent protein S,0.782545511595536,0.733006096187117,0.835432994218911,2.00174002504884e-13
sensitivity,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0342098661253905,PROS1;Vitamin K-dependent protein S,0.311424083314963,0.193793568463814,0.500454996713033,1.4345491264165e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36882825554512,PROS1;Vitamin K-dependent protein S,0.638140682770676,0.589252818265983,0.691084570805071,2.29048083741565e-28
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14160581068047,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.24560744961689,1.17302978842581,1.32267563351757,7.48644157547226e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,NBL1;Neuroblastoma suppressor of tumorigenicity 1,4.80246408469403,4.28461336513535,5.38290373466346,5.0999668369585e-160
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0648482942933501,NBL1;Neuroblastoma suppressor of tumorigenicity 1,3.04281741850647,2.17412179474859,4.25861047192944,8.69552363295488e-11
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0570103011716599,NBL1;Neuroblastoma suppressor of tumorigenicity 1,3.67844980500857,2.57829414844879,5.24804083200063,6.78327806122134e-13
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.9673590504451,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.20066315544441,1.14002486049957,1.26452682111686,4.63817054350468e-12
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01365980396016,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.25584003414012,1.15103630280571,1.37018631602211,2.99608660917644e-07
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00678854284523,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.2267761362727,1.15271811905654,1.30559211627554,1.24673174081143e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34111707163142,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.46829778208297,1.36051296019057,1.58462171251039,5.38522879246166e-23
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60828245707624,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.22738107772315,1.14506339516849,1.31561651198462,7.280849902934e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774843163090719,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.47798252459691,1.33752673791555,1.63318779437496,1.74419976711328e-14
sensitivity,Circulatory system disorders,I50 (heart failure),4.41395173603537,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.32263934485374,1.26778785592703,1.37986401145636,2.69247499638057e-38
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2462165890326,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.23402544357923,1.18196871079174,1.28837487955232,1.14956794506598e-21
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.05707749048379,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.27145457021567,1.19578369342918,1.35191400669327,1.70291163870325e-14
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7194383639985,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.22180844094894,1.15827896592628,1.28882239105523,1.93352653107089e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781111657648794,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.45144178374088,1.31400008487094,1.60325960085141,2.13505337865047e-13
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.799212598425196,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.42369100066471,1.28998975406808,1.57124973976087,2.20892197481353e-12
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13639443580852,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.32159911716014,1.24372047011039,1.40435432917128,2.2897454572263e-19
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405400086590309,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.5081026834329,1.31355992149403,1.73145790044406,5.52681416863624e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705196391285506,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.52996688316657,1.37762042334845,1.69916083117937,1.92279372692313e-15
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0452026256829527,NBL1;Neuroblastoma suppressor of tumorigenicity 1,3.3975276532177,2.27756690322787,5.06821298554147,2.05094434777576e-09
sensitivity,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.65769254038356,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.2007356017658,1.12065634479631,1.28653711911115,2.04931414465928e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.82351314515969,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.28044882112074,1.22987233546017,1.33310518192608,2.69537586413102e-33
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534002829417976,ASGR1;Asialoglycoprotein receptor 1,2.93003476864558,2.63816979827777,3.254189230381,1.10023459024226e-89
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0655646507192243,ASGR1;Asialoglycoprotein receptor 1,2.23475898393264,1.62846158477495,3.06678877964311,6.36733161929009e-07
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0576403243758944,ASGR1;Asialoglycoprotein receptor 1,2.64420198623581,1.90924598327909,3.66207613123015,4.85327968993881e-09
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97106476757948,ASGR1;Asialoglycoprotein receptor 1,1.21625990214157,1.15537914503059,1.28034866815798,7.8739716773422e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01689518616544,ASGR1;Asialoglycoprotein receptor 1,1.24369451235689,1.14075743228235,1.35592019503389,7.51393484323324e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33402460667211,ASGR1;Asialoglycoprotein receptor 1,1.23816048369718,1.14806718523118,1.3353237537928,2.98596160600832e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.78342479917283,ASGR1;Asialoglycoprotein receptor 1,1.3503602558207,1.22437141391169,1.48931345487266,1.84652315569404e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.40073780023256,ASGR1;Asialoglycoprotein receptor 1,1.30079727774615,1.24750925008175,1.35636153213367,6.86242926029327e-35
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769827534761592,ASGR1;Asialoglycoprotein receptor 1,1.30387306174543,1.18097051223083,1.43956597013924,1.49684750801138e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80001592071484,ASGR1;Asialoglycoprotein receptor 1,1.53912682374836,1.39821762768689,1.6942365284728,1.34086005586058e-18
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.10956861638895,ASGR1;Asialoglycoprotein receptor 1,1.22238911766846,1.15061644368897,1.29863879765497,7.80245851881848e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40194205666985,ASGR1;Asialoglycoprotein receptor 1,1.63348851340612,1.42806608260576,1.86846025959876,8.28577310218482e-13
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70101368171589,ASGR1;Asialoglycoprotein receptor 1,1.36166173213838,1.22778982179684,1.51013034955497,5.02108507879422e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216673955392994,ASGR1;Asialoglycoprotein receptor 1,1.68873671424389,1.40753896480343,2.02611207316277,1.71546613576839e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545847241311604,CD5;T-cell surface glycoprotein CD5,2.26542765561693,2.02070231425209,2.53979145103991,1.16994992333556e-44
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0548310030157051,CD5;T-cell surface glycoprotein CD5,2.66428040063984,1.88165693457781,3.7724145792954,3.34136974474553e-08
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02538966767963,CD5;T-cell surface glycoprotein CD5,1.24836240821137,1.14550667510628,1.36045361943499,4.27075145514129e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805929760574151,CD5;T-cell surface glycoprotein CD5,1.38290354054845,1.25519268987029,1.52360846099179,5.47375512202995e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409723583611056,CD5;T-cell surface glycoprotein CD5,1.42697074035196,1.24673002975404,1.63326898785163,2.45784887868962e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698518591190032,CD5;T-cell surface glycoprotein CD5,1.34371630602948,1.21044012549752,1.49166693424623,2.9643280417146e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544649504329767,BSG;Basigin,4.18765929762083,3.73932007208738,4.68975376669506,1.20784697053061e-135
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0644556427985468,BSG;Basigin,2.44874854791661,1.75302111083241,3.42059169388803,1.50727980932387e-07
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547110086365235,BSG;Basigin,3.0778733245534,2.15417075594944,4.39765704544722,6.61355994771701e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34274233068705,BSG;Basigin,1.32741688585222,1.23026027901586,1.43224618310456,2.80442184533687e-13
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776057549456564,BSG;Basigin,1.36594669419822,1.23648942047638,1.50895781273422,8.33529189353166e-10
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774420651217365,BSG;Basigin,1.29051212044218,1.16795498214688,1.42592955932845,5.45841244751299e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804163650237727,BSG;Basigin,1.46237646120649,1.32592647175351,1.61286840548754,2.85147893087801e-14
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406885758998435,BSG;Basigin,1.44185297717021,1.25682165041629,1.65412491667851,1.76983939560026e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700930004894762,BSG;Basigin,1.39627834436063,1.25718064423818,1.55076617180332,4.5278982909737e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213011275918,BSG;Basigin,1.98090029276015,1.64272915299128,2.3886871202791,8.24624371529693e-13
sensitivity,Circulatory system disorders,I95 (hypotension),4.78088431634336,BSG;Basigin,1.2416765538065,1.1923688509042,1.2930232646581,1.18382734229296e-25
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10354191493934,BSG;Basigin,2.91161133009221,2.24653930479761,3.77357321076788,6.60997908200541e-16
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.23902651021295,TFF3;Trefoil factor 3,1.58598751743187,1.33528379947085,1.8837616441138,1.49167210929657e-07
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.503425266025704,TFF3;Trefoil factor 3,1.37445803569309,1.21738014887361,1.55180359531018,2.79560191512827e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.128752989544,TFF3;Trefoil factor 3,1.26959156636558,1.19553759969667,1.34823258239269,7.007079248121e-15
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.20330418648718,TFF3;Trefoil factor 3,1.79684068698664,1.48181003049178,2.17884640269247,2.54533934106832e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.55023355237115,TFF3;Trefoil factor 3,3.3495067506612,3.00684902336983,3.73121343490382,8.01909736827888e-107
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0611681136543015,TFF3;Trefoil factor 3,2.61637727862553,1.86479851285268,3.67086847020061,2.59692711145391e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.057244374259771,TFF3;Trefoil factor 3,2.67815764281964,1.87887761591214,3.81745372825214,5.11422426995771e-08
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.994071146245059,TFF3;Trefoil factor 3,1.24705933117131,1.14063165300899,1.36341734104864,1.22851384986166e-06
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.66928875778433,TFF3;Trefoil factor 3,1.20881151023756,1.17210535078403,1.24666717569831,1.85862622388365e-33
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.98517101171968,TFF3;Trefoil factor 3,1.22561730025343,1.15153240086509,1.30446851999302,1.60393337008981e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33465346534653,TFF3;Trefoil factor 3,1.56805473259548,1.4556163169761,1.68917840212384,2.17068930490858e-32
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61098325529719,TFF3;Trefoil factor 3,1.27006728931535,1.18580662947551,1.36031531557746,8.74355537305637e-12
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70337505942006,TFF3;Trefoil factor 3,1.24262782925717,1.16109556626344,1.32988529705059,3.52593140715747e-10
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85420009111256,TFF3;Trefoil factor 3,1.22329411555889,1.16043840554658,1.28955443564121,6.95520213057428e-14
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.7508457475221,TFF3;Trefoil factor 3,1.24204121418229,1.16109959404777,1.32862536998179,2.89615909487985e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781990521327014,TFF3;Trefoil factor 3,1.59014325716104,1.43962740561682,1.75639583438699,6.13072034228694e-20
sensitivity,Circulatory system disorders,I50 (heart failure),4.39293466356014,TFF3;Trefoil factor 3,1.42011379727971,1.36161134989975,1.48112983735976,5.05064349186177e-60
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2017144119005,TFF3;Trefoil factor 3,1.27536968935396,1.22110675440287,1.33204393363479,5.64066258835326e-28
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.05362801013941,TFF3;Trefoil factor 3,1.22652028790135,1.15328536410541,1.30440571211144,8.02685585649235e-11
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.70462915297192,TFF3;Trefoil factor 3,1.23743466569777,1.17310540851232,1.30529152858686,5.22518122496317e-15
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.770476905448654,TFF3;Trefoil factor 3,1.4518888262045,1.3143813050755,1.60378206500465,2.06062069458168e-13
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802466695655611,TFF3;Trefoil factor 3,1.51133166848951,1.37015666528061,1.66705273204032,1.53043078919591e-16
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08315379597968,TFF3;Trefoil factor 3,1.26329848284168,1.15782367446049,1.3783817795,1.48554222437894e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12702097006563,TFF3;Trefoil factor 3,1.31487306232992,1.23784156066,1.39669827301568,6.274159953489e-19
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405090305497371,TFF3;Trefoil factor 3,1.52386357206051,1.32628800074169,1.75087174501648,2.75473090925614e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702163851418173,TFF3;Trefoil factor 3,1.38467971660225,1.24724553436005,1.53725779307236,1.04391462499082e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.78211714302715,TFF3;Trefoil factor 3,1.29710635933393,1.24629570291206,1.3499885328123,2.77305433538397e-37
sensitivity,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0987303279821495,TFF3;Trefoil factor 3,2.04014471864468,1.55433488763141,2.67779518180692,2.77148117828858e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248672758491385,NPDC1;Neural proliferation differentiation and control protein 1,1.53407308708876,1.2885108881175,1.82643410950784,1.52374284695852e-06
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.510807825812559,NPDC1;Neural proliferation differentiation and control protein 1,1.40688994724079,1.24569590626816,1.58894262531284,3.83064735407578e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.15043146857289,NPDC1;Neural proliferation differentiation and control protein 1,1.20451033613221,1.1349396855914,1.27834559692334,8.7872009903853e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,NPDC1;Neural proliferation differentiation and control protein 1,4.7630870937762,4.25875420463357,5.32714441190659,1.63427526725537e-164
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0650515484239784,NPDC1;Neural proliferation differentiation and control protein 1,3.10377220041412,2.25400930639101,4.27389622782345,3.94434534230964e-12
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0571890591413752,NPDC1;Neural proliferation differentiation and control protein 1,2.70518318022012,1.90911720230115,3.83319370320747,2.18882264453274e-08
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.99334886592189,NPDC1;Neural proliferation differentiation and control protein 1,1.20673839237933,1.13408394764192,1.28404740290182,3.00278712690465e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,NPDC1;Neural proliferation differentiation and control protein 1,1.48412904176774,1.37666584494952,1.59998086732455,7.38118833772746e-25
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60935487067684,NPDC1;Neural proliferation differentiation and control protein 1,1.24895713770799,1.16565160682469,1.33821625835611,2.75232061889266e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783222853535353,NPDC1;Neural proliferation differentiation and control protein 1,1.55895775865705,1.41388597539194,1.71891463355331,5.1179006014592e-19
sensitivity,Circulatory system disorders,I50 (heart failure),4.4281764109093,NPDC1;Neural proliferation differentiation and control protein 1,1.32719861523994,1.27262367737308,1.38411393376773,7.38895616701688e-40
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22600184524048,NPDC1;Neural proliferation differentiation and control protein 1,1.21619722525886,1.16513499576602,1.26949726521165,3.75679894958431e-19
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773694390715667,NPDC1;Neural proliferation differentiation and control protein 1,1.37721563425143,1.24775085452197,1.52011348768279,2.09247260372911e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80173775671406,NPDC1;Neural proliferation differentiation and control protein 1,1.48215086697051,1.34499013097427,1.63329911638098,1.98851554522621e-15
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13901605261579,NPDC1;Neural proliferation differentiation and control protein 1,1.31081675326625,1.23418459697902,1.39220710163561,1.29836878500401e-18
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.414593698175787,NPDC1;Neural proliferation differentiation and control protein 1,1.40610463882407,1.22916162809564,1.60851934369753,6.80356286809158e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.711378097458799,NPDC1;Neural proliferation differentiation and control protein 1,1.35275900172237,1.22004870465355,1.49990480688273,9.73687475700603e-09
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473158133391163,NPDC1;Neural proliferation differentiation and control protein 1,2.77837878197144,1.90391154505186,4.05448912591095,1.16389802385499e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222866497051456,NPDC1;Neural proliferation differentiation and control protein 1,1.59017488880116,1.32471793343065,1.90882610792871,6.44020277869189e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.77973961120028,NPDC1;Neural proliferation differentiation and control protein 1,1.28936347050804,1.23850068764819,1.34231508763827,3.4990616910319e-35
sensitivity,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0986348930797759,NPDC1;Neural proliferation differentiation and control protein 1,1.99381767420837,1.51954553477865,2.61611700801367,6.39375376715237e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212294838724404,APOF;Apolipoprotein F,0.476869927918695,0.379530736522305,0.599173943688792,2.05610093327226e-10
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107252065172744,APOF;Apolipoprotein F,0.314159631323127,0.226409800234465,0.43591873607448,4.26335446770774e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543765281173594,NFASC;Neurofascin,1.37011542294943,1.21670689984704,1.54286646392809,2.02031432151174e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34056127441387,NFASC;Neurofascin,1.3948929950631,1.29296123550903,1.50486063637483,8.23157586652835e-18
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774800444973555,NFASC;Neurofascin,1.33941903126266,1.21278799781175,1.47927201171648,8.05630140660006e-09
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3708853798413,NFASC;Neurofascin,1.22094981335352,1.13296572182652,1.31576659205957,1.68139556107527e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804813252070636,NFASC;Neurofascin,1.47868095518061,1.34115177580931,1.63031314326405,4.05609717148123e-15
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212666328481679,NFASC;Neurofascin,3.82524273886778,3.15657991681179,4.63554935939647,1.23090407205792e-42
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.271696637998436,NFASC;Neurofascin,1.5596211575598,1.31831998279006,1.84508934618458,2.18980947401652e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103374292958845,NFASC;Neurofascin,8.14438289653279,6.18141146387191,10.7307163020963,3.03167859912319e-50
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.402935674197726,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,2.05521335842611,1.78040870951339,2.37243388334557,7.82859906335613e-23
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37470258838232,GCHFR;GTP cyclohydrolase 1 feedback regulatory protein,1.30830649695487,1.20527629975454,1.42014398716951,1.35085415252776e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,LSP1;Lymphocyte-specific protein 1,1.43873471440029,1.27910638489173,1.61828414185869,1.34020773972719e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,REG1B;Lithostathine-1-beta,2.71094749373679,2.42327082771222,3.03277546601594,5.38748620579212e-68
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34461664744855,REG1B;Lithostathine-1-beta,1.3354540843386,1.23982973175429,1.43845365673978,2.32972269463567e-14
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783488276910483,REG1B;Lithostathine-1-beta,1.45807281326873,1.32318500502514,1.60671132208984,2.65474533140111e-14
sensitivity,Circulatory system disorders,I50 (heart failure),4.41797849969538,REG1B;Lithostathine-1-beta,1.23257104230533,1.18261534313192,1.28463695583914,3.93626165330454e-23
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772140545178021,REG1B;Lithostathine-1-beta,1.32835508174596,1.20429577143019,1.46519423638332,1.37852694200131e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805696449473273,REG1B;Lithostathine-1-beta,1.34608806701211,1.22278511332571,1.48182461857445,1.33390679583969e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14282892917802,REG1B;Lithostathine-1-beta,1.22940782176866,1.15850394071828,1.3046512308701,9.466123988478e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407613995397277,REG1B;Lithostathine-1-beta,1.41731181973201,1.23848940325152,1.62195396188152,4.01361641893879e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70473401659346,REG1B;Lithostathine-1-beta,1.29521976851519,1.16871188324299,1.4354215720794,8.09786249945781e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213177915550253,IDUA;Alpha-L-iduronidase,2.28478327697121,1.89011096588674,2.76186674589143,1.3438471650553e-17
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103618839077987,IDUA;Alpha-L-iduronidase,2.86918720751143,2.18618303648982,3.76557456276172,2.99229059303829e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543199146683522,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,4.02287602223064,3.57147984948793,4.5313237571699,2.72110780150137e-116
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0630181768053723,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,2.55196026652282,1.81421046772245,3.58971647324192,7.38844430268121e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0571327252309935,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,2.68928063663822,1.87658947307296,3.85392247285408,7.09788552137501e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34200332042058,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.3022840950224,1.2075527710625,1.40444699791968,7.16519583787277e-12
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.780464731271802,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.42836608245413,1.29435136361723,1.57625643457715,1.31473502806572e-12
sensitivity,Circulatory system disorders,I50 (heart failure),4.40968979153832,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.2662719585271,1.21422586401872,1.32054893613049,2.91127954609679e-28
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.782775006408107,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.30823761632753,1.1854302310156,1.44376751663237,9.18414963292806e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.808838035115407,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.4896603352668,1.35192555672648,1.64142759446048,8.18004876824166e-16
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13093145869947,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.28370173439494,1.20850606348436,1.36357623075335,5.09425948808263e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404323300855982,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.56239393229503,1.36282728564548,1.79118427212598,1.55647138584659e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700791598397062,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.37716868619965,1.24083577854574,1.52848074099836,1.77602543139412e-09
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0472692178913989,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,2.73567867200173,1.84707280349476,4.05178278965787,5.11772784091419e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.224621689785624,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.64850111904601,1.37260367312458,1.97985477724225,8.84061106374256e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.81064280482252,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.22670676432191,1.1785063560419,1.27687854878199,1.67173741293333e-23
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24882990698501,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.63031248951272,1.3786005319007,1.92798330767844,1.11435680554515e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13594151353487,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.27308228882881,1.2002562265623,1.35032710371487,9.47960821062992e-16
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54409116989494,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,3.12340560298787,2.84430340184644,3.42989519136493,1.07864803781473e-125
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.063121350796907,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.55724518905071,1.90887034903239,3.42584972323442,3.10855930126377e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0572263004183439,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.75912850031923,2.04567661120885,3.72140446811641,2.95714359373122e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34420842159444,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.52102292453023,1.41401690818154,1.63612664287144,1.89063844531678e-29
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60848869496231,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.29019524995509,1.20524579121738,1.38113220982528,2.26658987058537e-13
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71082333372935,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.24293872287826,1.16376934657748,1.32749386583658,9.38417159514757e-11
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.86925011385913,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.21167912483786,1.15161014594461,1.27488135350144,1.34849589441455e-13
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781743524952621,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.50631445223814,1.36981589796655,1.65641472871627,2.84329545899523e-17
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.41935483870967,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.20593101230593,1.16785333890978,1.24525020222043,2.67767806358849e-30
sensitivity,Circulatory system disorders,I50 (heart failure),4.41290630784848,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.39090132585518,1.33515477207046,1.44897545867708,2.6651663306717e-56
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23614873678084,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.29859507862228,1.24503188751677,1.35446264078058,5.21980986405063e-34
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06881533101045,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.2700240792581,1.1961999740739,1.3484042775909,5.14876645001899e-15
sensitivity,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.777477206692716,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.27334527707966,1.15412272390479,1.4048836931096,1.45172421979053e-06
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71206572305255,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.22595027701431,1.16317982570048,1.2921081061618,3.03636288384774e-14
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78405814274993,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.49255532007201,1.35683231315377,1.64185460640838,1.81989219186283e-16
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.808188590511194,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.5534228225798,1.4149027553485,1.70550411085843,2.39888039056456e-20
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13234117458793,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.35179772773406,1.27411167198989,1.43422051369566,1.82549373883166e-23
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404986269977676,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.56361459991214,1.37129106294039,1.78291150809075,2.46884077603503e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701941709178629,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.55133983664626,1.40328801898266,1.71501164138093,9.42531656154178e-18
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473466166896823,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.4055399463842,1.70670149705547,3.39052988682182,5.36810963592409e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.224989638635062,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.69192577876045,1.42198038048178,2.01311697413453,3.03495901576713e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.81657743406702,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.29540486538014,1.24530369419892,1.34752171142478,7.46804039350003e-38
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104567426260234,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.08421992902991,1.63589918232123,2.65540368227438,2.7999103564781e-09
sensitivity,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.098699145265402,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.87627799174809,1.45198441092481,2.42455709292084,1.50049885076644e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,LGALS1;Galectin-1,2.66134867174226,2.39889401964092,2.9525175745965,3.10741256168556e-76
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,LGALS1;Galectin-1,1.29488193142216,1.20262341862172,1.39421799905176,7.25969672486649e-12
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60935487067684,LGALS1;Galectin-1,1.22016620804864,1.1397404100632,1.30626725359439,1.06704411202411e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783222853535353,LGALS1;Galectin-1,1.44548107116297,1.31398718144414,1.59013387390436,3.69121937608255e-14
sensitivity,Circulatory system disorders,I50 (heart failure),4.4281764109093,LGALS1;Galectin-1,1.2150027590501,1.16597522102121,1.26609183272902,1.91372518253208e-20
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80173775671406,LGALS1;Galectin-1,1.30728429182959,1.18835682440398,1.43811369158547,3.66823371611973e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13608520931684,"FABP4;Fatty acid-binding protein, adipocyte",1.20337067650581,1.12756295693356,1.2842750608021,2.45617766401958e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,"FABP4;Fatty acid-binding protein, adipocyte",3.74141742924468,3.38092298709864,4.14034996753017,1.03609228010232e-143
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0642648490749756,"FABP4;Fatty acid-binding protein, adipocyte",2.6072038804892,1.92521806138611,3.53077514219033,5.87446252953627e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0564971751412429,"FABP4;Fatty acid-binding protein, adipocyte",2.81644449479758,2.06455774610723,3.84215922622276,6.36237224437414e-11
sensitivity,Circulatory system disorders,I22 (subsequent myocardial infarction),0.103325925059461,"FABP4;Fatty acid-binding protein, adipocyte",1.91288065103526,1.46904326313525,2.49081322308763,1.46926857127789e-06
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01037684325505,"FABP4;Fatty acid-binding protein, adipocyte",1.30504314108911,1.18941353007607,1.43191376004845,1.86092661687801e-08
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68940971871145,"FABP4;Fatty acid-binding protein, adipocyte",1.20898384678686,1.16979478655042,1.24948577186068,1.5033581337722e-29
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34461664744855,"FABP4;Fatty acid-binding protein, adipocyte",1.62544069406361,1.50103988084934,1.76015140145578,5.89371123084853e-33
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60560787922695,"FABP4;Fatty acid-binding protein, adipocyte",1.23517562054619,1.14524256445851,1.33217089631403,4.34961417911498e-08
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85820414068151,"FABP4;Fatty acid-binding protein, adipocyte",1.20419046788572,1.1386576523325,1.27349487352622,7.61133665089757e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783488276910483,"FABP4;Fatty acid-binding protein, adipocyte",1.59456989539593,1.4395492512367,1.76628423731847,3.82425280538961e-19
sensitivity,Circulatory system disorders,I50 (heart failure),4.41797849969538,"FABP4;Fatty acid-binding protein, adipocyte",1.41015775490003,1.34793762052482,1.47524993992708,2.16372458820772e-50
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22007806153785,"FABP4;Fatty acid-binding protein, adipocyte",1.29135956167275,1.23286307020643,1.35263157590114,3.05693448240888e-27
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620112712310602,"FABP4;Fatty acid-binding protein, adipocyte",1.36016921447466,1.20847797468044,1.53090112585116,3.42075474459473e-07
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772140545178021,"FABP4;Fatty acid-binding protein, adipocyte",1.49267844971791,1.34378605772771,1.658068218106,7.93220998316666e-14
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805696449473273,"FABP4;Fatty acid-binding protein, adipocyte",1.62703407675437,1.47040793028257,1.80034385859931,4.28429742889606e-21
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14282892917802,"FABP4;Fatty acid-binding protein, adipocyte",1.33151021395732,1.24763838063207,1.42102028712396,6.39999843217543e-18
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407613995397277,"FABP4;Fatty acid-binding protein, adipocyte",1.70464902480541,1.48228794982306,1.96036694362717,7.48622574907504e-14
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70473401659346,"FABP4;Fatty acid-binding protein, adipocyte",1.54392038871196,1.38340226030798,1.72306366345665,8.88212404473999e-15
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0467435338111561,"FABP4;Fatty acid-binding protein, adipocyte",2.60447672109692,1.83671297431332,3.69317312263871,7.79348298333622e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.78418322403836,"FABP4;Fatty acid-binding protein, adipocyte",1.29512873929948,1.23970431358883,1.35303106795172,4.69074221896797e-31
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534531980805442,CALB2;Calretinin,2.50453579592646,2.22419184476127,2.8202151571823,6.66790271601052e-52
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0565473786250908,CALB2;Calretinin,2.5819470070324,1.80404324112689,3.69528301492342,2.1530551209777e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804869663693906,CALB2;Calretinin,1.28761478682193,1.16275537356774,1.42588189823221,1.18864595523082e-06
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246192075836362,RNASE6;Ribonuclease K6,1.66321016988248,1.38028928651322,2.00412195923685,8.90325502599101e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.515013565089437,RNASE6;Ribonuclease K6,1.52373289968057,1.33809280922422,1.73512773819856,2.10137847313076e-10
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04189686924493,RNASE6;Ribonuclease K6,1.25229794325268,1.172271554554,1.33778742014391,2.43252399858933e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.396030485137344,RNASE6;Ribonuclease K6,3.52183830771813,3.09788630460475,4.00380899946985,1.76960290511285e-82
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0436721371764814,RNASE6;Ribonuclease K6,2.72375606656372,1.80956560639685,4.09979449427911,1.56611223758678e-06
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.9691995660582,RNASE6;Ribonuclease K6,1.24260758324974,1.1752429303879,1.31383356242791,2.20400936036353e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.975946599148348,RNASE6;Ribonuclease K6,1.29342782143636,1.17584510697177,1.42276862772688,1.2156617266056e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37273901808785,RNASE6;Ribonuclease K6,1.62628720790998,1.50176907047059,1.7611296800665,5.38081896377249e-33
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60600808781051,RNASE6;Ribonuclease K6,1.24739456051499,1.15774583986382,1.34398512698211,6.27661713275768e-09
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69491525423728,RNASE6;Ribonuclease K6,1.23497424792854,1.14850001129181,1.3279594062269,1.21087592957856e-08
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.682294908143742,RNASE6;Ribonuclease K6,1.38581820504446,1.23671472051564,1.55289822751677,1.93098898263159e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.756687136318682,RNASE6;Ribonuclease K6,1.48569939646536,1.33410429044004,1.65452034932702,5.61751082135901e-13
sensitivity,Circulatory system disorders,I50 (heart failure),4.31304347826086,RNASE6;Ribonuclease K6,1.40288664752779,1.3401169047824,1.46859646258348,1.30314684730399e-47
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.09589009088997,RNASE6;Ribonuclease K6,1.25668265752452,1.19873814346794,1.31742808913557,2.3969521869834e-21
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.04345218875409,RNASE6;Ribonuclease K6,1.27863700194373,1.19700279141388,1.36583857152791,2.83291064128213e-13
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.59213135925464,RNASE6;Ribonuclease K6,1.20653809386277,1.13777425532796,1.27945782313592,3.58604037605328e-10
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.747831289261142,RNASE6;Ribonuclease K6,1.44603701635928,1.29749527935601,1.61158432400548,2.57109898288943e-11
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.759633534367662,RNASE6;Ribonuclease K6,1.52900209872276,1.37335441126211,1.70228995423704,9.05684249003583e-15
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.04861677581746,RNASE6;Ribonuclease K6,1.30909497130898,1.22488691780126,1.39909212760857,2.02718630919649e-15
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402733988447287,RNASE6;Ribonuclease K6,1.46326591922503,1.2623115588827,1.69621131589783,4.40503226943485e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686414520661537,RNASE6;Ribonuclease K6,1.49234234189021,1.33278648050958,1.67099959218287,3.93957113028004e-12
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.209233882093258,RNASE6;Ribonuclease K6,1.8888928773887,1.54633659163499,2.30733484646916,4.68189680783225e-10
sensitivity,Circulatory system disorders,I95 (hypotension),4.52477191361589,RNASE6;Ribonuclease K6,1.26673430343302,1.21154446152478,1.32443822447462,2.4002825736392e-25
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10802859309996,RNASE6;Ribonuclease K6,2.17118677253239,1.65253741879293,2.85261437811369,2.59546077691484e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.803798341180874,F9;Coagulation factor IX,1.29952502914312,1.18018148872767,1.43093695122269,9.78420454333379e-08
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245083388128399,EFNA4;Ephrin-A4,1.57344682430062,1.31700344863483,1.87982416558436,5.92971660747908e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12320574162679,EFNA4;Ephrin-A4,1.24587411218625,1.17275065979296,1.32355696452127,1.05149593207597e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.532902221423866,EFNA4;Ephrin-A4,4.38154614884114,3.93384818847819,4.88019510022103,5.56552477430535e-159
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0656755627201624,EFNA4;Ephrin-A4,3.22810307453977,2.35179706563583,4.43093054758779,4.10138912128007e-13
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0577378700698827,EFNA4;Ephrin-A4,2.90851071580534,2.05861295150804,4.10928852738322,1.4072759651257e-09
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97195650396533,EFNA4;Ephrin-A4,1.26627981294792,1.20237213843021,1.33358426516175,4.0728069033534e-19
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01662480564525,EFNA4;Ephrin-A4,1.35256540477296,1.23977659029552,1.47561519430897,1.06077758728635e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33628954937679,EFNA4;Ephrin-A4,1.52137561758075,1.40942917856907,1.64221360318303,5.28561309312521e-27
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61099881926794,EFNA4;Ephrin-A4,1.23076600339332,1.14793443601911,1.3195744526681,5.18744237063828e-09
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71191146800902,EFNA4;Ephrin-A4,1.23377412758978,1.15358948684993,1.3195323078633,8.94363681468333e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.784751130320473,EFNA4;Ephrin-A4,1.53171266429979,1.38745194275429,1.69097293656091,2.95143112230054e-17
sensitivity,Circulatory system disorders,I50 (heart failure),4.4041450777202,EFNA4;Ephrin-A4,1.39675963096738,1.33860740351435,1.45743812680117,1.6107307918188e-53
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21163464069491,EFNA4;Ephrin-A4,1.27063934881321,1.2166610355273,1.32701246083115,2.94327911831096e-27
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.76913880365042,EFNA4;Ephrin-A4,1.41310125726102,1.27832888223982,1.56208248989406,1.36537328787235e-11
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.79738457858225,EFNA4;Ephrin-A4,1.5590030040391,1.41278695727913,1.72035164543407,9.80733558560655e-19
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11314509455668,EFNA4;Ephrin-A4,1.28614493401918,1.20980173106744,1.36730569053136,7.61989489234073e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.400629845926929,EFNA4;Ephrin-A4,1.62507087720721,1.41525216641519,1.86599633522289,5.82136806501352e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702202361953399,EFNA4;Ephrin-A4,1.5136562762666,1.36275213943832,1.68127075817736,1.02505906101273e-14
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0457793435640214,EFNA4;Ephrin-A4,2.79747608331463,1.9007061478191,4.11734998894852,1.82047535829828e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.217040680193544,EFNA4;Ephrin-A4,1.96727971614566,1.63354662315432,2.36919438153835,9.74362295918646e-13
sensitivity,Circulatory system disorders,I95 (hypotension),4.8035371318822,EFNA4;Ephrin-A4,1.25865231395343,1.20865902905701,1.31071345130007,9.54285250856075e-29
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0995282361605987,EFNA4;Ephrin-A4,2.28349921129044,1.74235264312784,2.99271715661609,2.18460347268e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.82205803763422,1.62280858514433,2.04577146245021,3.18181905120524e-24
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.20375571907779,1.11677900823859,1.29750632893603,1.25729517936185e-06
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.28666535521048,1.16588262533776,1.41996089513668,5.39913956093903e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.27465626211074,1.15648770182997,1.40489914762363,1.0139455447406e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214013950538998,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",1.71431096825634,1.42420314954612,2.06351326832875,1.21066165125153e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101026108315835,"DDAH1;N(G),N(G)-dimethylarginine dimethylaminohydrolase 1",2.47686123218276,1.90249390792869,3.22463138406005,1.60544614545123e-11
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250128570760671,INHBB;Inhibin beta B chain,1.62111493626065,1.33938534381382,1.9621042209438,7.04821855493972e-07
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511574668878039,INHBB;Inhibin beta B chain,1.40396428742377,1.22767335985871,1.60557016614598,7.18928689935955e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04391852388859,INHBB;Inhibin beta B chain,1.20954634947759,1.13062995859671,1.29397099414418,3.2671362539271e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.402386244005146,INHBB;Inhibin beta B chain,3.96279126743163,3.4029222710018,4.61477323859335,3.02116190329137e-70
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0466951507085989,INHBB;Inhibin beta B chain,3.46570518342872,2.24875359771473,5.34123099598412,1.78118682407677e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37606076234235,INHBB;Inhibin beta B chain,1.54393716143183,1.42180295243224,1.67656281369537,5.16446661637728e-25
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60347458621903,INHBB;Inhibin beta B chain,1.25012035313343,1.1583570997461,1.34915294917345,9.51105477681859e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.761753434900458,INHBB;Inhibin beta B chain,1.35944182652148,1.21687102862866,1.51871647546638,5.56253831639147e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.32815776453125,INHBB;Inhibin beta B chain,1.32946870677434,1.2683736516075,1.39350659015361,1.80752382545047e-32
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.743355384651347,INHBB;Inhibin beta B chain,1.34339653791345,1.20138934402977,1.50218933357971,2.23368029748617e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.76237693225135,INHBB;Inhibin beta B chain,1.4128003189795,1.26497294675592,1.57790310569679,8.88542735434253e-10
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08155726058539,INHBB;Inhibin beta B chain,1.23237072057924,1.15215152333459,1.31817522450989,1.17127742570073e-09
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.399822301199466,INHBB;Inhibin beta B chain,1.46680668474082,1.25920369506794,1.70863686219112,8.65272038520559e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.68094068094068,INHBB;Inhibin beta B chain,1.39490816074045,1.24122505775092,1.56761963896056,2.29176191564391e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212577088394692,INHBB;Inhibin beta B chain,1.70972863002761,1.38824806145739,2.10565537204303,4.49405916595738e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.54300129062536,INHBB;Inhibin beta B chain,1.23859440767364,1.18360975828607,1.29613337164599,2.56071007404336e-20
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513027671177539,SORCS2;VPS10 domain-containing receptor SorCS2,1.36549424638301,1.20705373345599,1.54473200755241,7.40350659191443e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12339986652915,SORCS2;VPS10 domain-containing receptor SorCS2,1.21912512287158,1.14716692615602,1.29559703241874,1.7356378126462e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.542652924858768,SORCS2;VPS10 domain-containing receptor SorCS2,3.67661532228197,3.27785315422403,4.12388828664248,1.84246593758015e-109
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645994832041343,SORCS2;VPS10 domain-containing receptor SorCS2,2.77324556680448,1.98594022750095,3.87266991589102,2.1380540639317e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0565473786250908,SORCS2;VPS10 domain-containing receptor SorCS2,3.21663405551583,2.26040967672594,4.57737141795057,8.53658271609908e-11
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97362309223623,SORCS2;VPS10 domain-containing receptor SorCS2,1.24853593096344,1.18489182598953,1.31559855230237,9.15378304411601e-17
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),0.998887877868769,SORCS2;VPS10 domain-containing receptor SorCS2,1.29649026676641,1.18658136084589,1.41657965250842,9.18708597555527e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34327451020118,SORCS2;VPS10 domain-containing receptor SorCS2,1.4203957753249,1.31570372065519,1.53341829690665,2.61993288513751e-19
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59735330532383,SORCS2;VPS10 domain-containing receptor SorCS2,1.22338138947663,1.14035070386215,1.31245766679397,1.8821000793989e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.791967189930702,SORCS2;VPS10 domain-containing receptor SorCS2,1.43999915017782,1.30382996193535,1.59038955465857,6.26437853569201e-13
sensitivity,Circulatory system disorders,I50 (heart failure),4.40247728476551,SORCS2;VPS10 domain-containing receptor SorCS2,1.28156633487809,1.22791648063204,1.33756024664435,5.89135480519938e-30
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21467742929324,SORCS2;VPS10 domain-containing receptor SorCS2,1.22720924825417,1.17469629403644,1.28206971167463,4.47985966667345e-20
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.776180947183312,SORCS2;VPS10 domain-containing receptor SorCS2,1.33615543970115,1.20852923766387,1.47725955103415,1.5340596238401e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804820836366577,SORCS2;VPS10 domain-containing receptor SorCS2,1.43700051923763,1.30180318386231,1.5862386249223,6.39613380957693e-13
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12308574236344,SORCS2;VPS10 domain-containing receptor SorCS2,1.23758874174278,1.16395793549502,1.31587735860669,9.67294718565907e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408419094603611,SORCS2;VPS10 domain-containing receptor SorCS2,1.51405886543913,1.31858914168365,1.73850532781407,4.07069765001269e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.675839740995548,SORCS2;VPS10 domain-containing receptor SorCS2,1.38535607389809,1.24384561489107,1.54296596660383,3.04463636186721e-09
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0464365031294165,SORCS2;VPS10 domain-containing receptor SorCS2,2.88041427030598,1.94360853708359,4.26875382068025,1.35747075029478e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.77959084266926,SORCS2;VPS10 domain-containing receptor SorCS2,1.22921073788986,1.18007468874923,1.28039271797722,3.57883943983722e-23
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,DLK1;Protein delta homolog 1,2.36454169604513,2.10505113329254,2.65601977258906,1.04629047579963e-47
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.505260655055578,IL6;Interleukin-6,1.35441641463183,1.20496431920931,1.52240509945379,3.66736641348537e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1346665079554,IL6;Interleukin-6,1.24551103591288,1.17553854744994,1.31964855082461,9.90540292989906e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,IL6;Interleukin-6,1.59618408303036,1.43168715827025,1.77958125293077,3.55457318127977e-17
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,IL6;Interleukin-6,1.47494723323884,1.37468505010089,1.58252200435237,2.77469083517506e-27
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.746090959599968,IL6;Interleukin-6,1.28267465345981,1.1636827840689,1.41383398392773,5.39495779020866e-07
sensitivity,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.184224079870052,IL6;Interleukin-6,1.6657862728577,1.38430251210646,2.00450687806578,6.54083992401807e-08
sensitivity,Circulatory system disorders,"I38 (endocarditis, valve unspecified)",0.245724590293878,IL6;Interleukin-6,1.5779436972321,1.341494082309,1.85606954549427,3.65188082218224e-08
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.665501211808176,IL6;Interleukin-6,1.31151683559794,1.18358026922038,1.45328243025701,2.23813354200828e-07
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.7394066955244,IL6;Interleukin-6,1.21117853797927,1.13569533137621,1.29167868382798,5.35808994474236e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,IL6;Interleukin-6,1.36541208557603,1.24273983223245,1.50019345568732,8.89853415365958e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.38493054861596,IL6;Interleukin-6,1.31050266209834,1.25895816255144,1.36415750614481,7.86880193296652e-40
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775347518293045,IL6;Interleukin-6,1.32038550716113,1.20087548177335,1.45178906054992,9.37956738806376e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,IL6;Interleukin-6,1.5285861693767,1.39582421360219,1.67397560125408,5.49651358701142e-20
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.09107500644726,IL6;Interleukin-6,1.3274659803126,1.2253699372204,1.43806851740182,3.99063283987039e-12
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13718991664155,IL6;Interleukin-6,1.27223214313461,1.20055184422563,1.34819219495588,4.03556304324007e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406608881924747,IL6;Interleukin-6,1.49588427814995,1.31645437111922,1.6997700966375,6.51930334438043e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702771380925911,IL6;Interleukin-6,1.41555748065154,1.28279888142887,1.56205544769151,4.62851963547349e-12
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214013950538998,IL6;Interleukin-6,1.85634292484752,1.56938782299915,2.19576640275314,5.18788285776881e-13
sensitivity,Circulatory system disorders,I95 (hypotension),4.80361515338522,IL6;Interleukin-6,1.22282467541148,1.1763027150965,1.27118654714022,2.84071943603273e-24
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101026108315835,IL6;Interleukin-6,2.00544172791293,1.57698780321103,2.550302872264,1.39041561358147e-08
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.241349937127327,SCARB2;Lysosome membrane protein 2,1.87524201734432,1.57276058859446,2.23589823468062,2.46119163859141e-12
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13676948051948,SCARB2;Lysosome membrane protein 2,1.30065587717293,1.22422225198663,1.38186159259826,1.78379531010122e-17
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.20667436629992,SCARB2;Lysosome membrane protein 2,1.61216809865515,1.33291435190349,1.94992722121244,8.60903124474894e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.53022915650902,SCARB2;Lysosome membrane protein 2,4.25464341766609,3.82089914028442,4.73762586942871,1.59401982552408e-153
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0648232553428542,SCARB2;Lysosome membrane protein 2,3.16714487362319,2.34016098600597,4.28637461717432,8.22261618860164e-14
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0567421878166416,SCARB2;Lysosome membrane protein 2,3.03097838099261,2.18322336955717,4.20792030451192,3.48502644283388e-11
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.98907956318252,SCARB2;Lysosome membrane protein 2,1.25045743159807,1.18711832943841,1.3171760130926,3.52915750445812e-17
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02868968875542,SCARB2;Lysosome membrane protein 2,1.30840739051471,1.19972075173088,1.42694030847065,1.23773803427003e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34997763591265,SCARB2;Lysosome membrane protein 2,1.57011076362015,1.4555073909863,1.69373774760794,1.88822469118217e-31
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60705556460811,SCARB2;Lysosome membrane protein 2,1.28727928820085,1.19998239024414,1.38092690301376,1.81275154307983e-12
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71179962592502,SCARB2;Lysosome membrane protein 2,1.24896668444513,1.16740213917638,1.33623001578051,1.10466709193058e-10
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.87730285900199,SCARB2;Lysosome membrane protein 2,1.2018435914994,1.14077560794068,1.26618066548218,4.84152099276146e-12
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.784591991890522,SCARB2;Lysosome membrane protein 2,1.58218589224974,1.43434344055824,1.74526694712657,4.88125615019711e-20
sensitivity,Circulatory system disorders,I50 (heart failure),4.42132373983075,SCARB2;Lysosome membrane protein 2,1.39697467976501,1.3387214242835,1.45776277312438,2.12031290901947e-53
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22686148836634,SCARB2;Lysosome membrane protein 2,1.2714703684402,1.21726654885745,1.32808783691531,3.25980636270753e-27
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.0717277274021,SCARB2;Lysosome membrane protein 2,1.20546295301728,1.13350850903808,1.28198502217713,2.66881992608348e-09
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7302297214881,SCARB2;Lysosome membrane protein 2,1.21978242239246,1.15597107124128,1.28711625662046,4.26284627478139e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.762569209240067,SCARB2;Lysosome membrane protein 2,1.48568312275825,1.34386424616018,1.6424682385557,1.04357329258159e-14
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.799431875824287,SCARB2;Lysosome membrane protein 2,1.4624703130351,1.32569782093124,1.61335364872711,3.25276517285044e-14
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11590213439059,SCARB2;Lysosome membrane protein 2,1.2553547544377,1.18041187764532,1.33505566093843,4.4467733476993e-13
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405761817812943,SCARB2;Lysosome membrane protein 2,1.45553139465361,1.26889825465546,1.669615064131,8.25412227865911e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698505523066926,SCARB2;Lysosome membrane protein 2,1.47746517440763,1.32995026223949,1.64134208892263,3.51385729027989e-13
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0465973783909722,SCARB2;Lysosome membrane protein 2,3.14960599808041,2.2097716894756,4.48915966766603,2.22305525135273e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214840187275785,SCARB2;Lysosome membrane protein 2,1.96340709805821,1.63556969172116,2.35695699927568,4.54613985177163e-13
sensitivity,Circulatory system disorders,I95 (hypotension),4.81601401022257,SCARB2;Lysosome membrane protein 2,1.30702203562178,1.25484263119559,1.36137118641981,5.76489122193808e-38
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101304805899991,SCARB2;Lysosome membrane protein 2,2.17203420931852,1.67264451899052,2.82052316130937,5.91842815037179e-09
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245215996333218,YAP1;Transcriptional coactivator YAP1,1.74057754104914,1.44954181605418,2.09004676019049,2.90714180568203e-09
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.519843359974351,YAP1;Transcriptional coactivator YAP1,1.40617987329374,1.23662704024536,1.59897994440108,1.99602620571965e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04062915577566,YAP1;Transcriptional coactivator YAP1,1.2707355907885,1.19030171900629,1.35660472963501,6.88931569168279e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.401366941125203,YAP1;Transcriptional coactivator YAP1,3.89048465070199,3.44489408357967,4.39371151917093,3.25567698998503e-106
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0434981684981685,YAP1;Transcriptional coactivator YAP1,2.8542373876603,1.94422515739894,4.19018910135739,8.6032853069473e-08
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.96296039397933,YAP1;Transcriptional coactivator YAP1,1.22731997537798,1.14755027401882,1.31263471070994,2.3167917411043e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3650779059613,YAP1;Transcriptional coactivator YAP1,1.72265091916182,1.59316175631237,1.86266471532551,2.2859280267174e-42
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59508355199558,YAP1;Transcriptional coactivator YAP1,1.29400898692626,1.20132382205994,1.39384504618805,1.06707400008499e-11
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.691096110575377,YAP1;Transcriptional coactivator YAP1,1.32273189913677,1.18272568815017,1.47931147054939,9.58346667754113e-07
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.70732267021593,YAP1;Transcriptional coactivator YAP1,1.20925188603368,1.1259254744697,1.29874503866673,1.82932433987078e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.76285164482727,YAP1;Transcriptional coactivator YAP1,1.50792750195418,1.3581898163607,1.67417346512183,1.38780597178299e-14
sensitivity,Circulatory system disorders,I50 (heart failure),4.3056453848286,YAP1;Transcriptional coactivator YAP1,1.35088910792908,1.29079151003246,1.41378477293792,2.24167938920379e-38
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.09179778419141,YAP1;Transcriptional coactivator YAP1,1.23529487250495,1.17883853511598,1.29445498817773,8.49419530944955e-19
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.744814942133608,YAP1;Transcriptional coactivator YAP1,1.34323352918175,1.2063287308258,1.49567548862319,7.44638183078272e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.770341839191141,YAP1;Transcriptional coactivator YAP1,1.41805482142627,1.27632681421864,1.57552082598948,7.96163646381152e-11
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06137703700264,YAP1;Transcriptional coactivator YAP1,1.258904136472,1.1786318341012,1.34464349169296,7.43435382149828e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.683690091082203,YAP1;Transcriptional coactivator YAP1,1.39800424367497,1.24971714921076,1.56388656950696,4.72792370243299e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.210690239545641,YAP1;Transcriptional coactivator YAP1,1.88503517198021,1.5554946775007,2.28439071569941,1.00451638409318e-10
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.419388105878308,YAP1;Transcriptional coactivator YAP1,1.47465545061028,1.27893449764569,1.70032843903868,8.97691119543749e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.52297144960544,YAP1;Transcriptional coactivator YAP1,1.2842504368343,1.22866166124071,1.34235423513063,1.55007188383801e-28
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105308944392298,YAP1;Transcriptional coactivator YAP1,2.25913341484316,1.7418645313592,2.93001188908672,8.09787146949327e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543765281173594,CCL20;C-C motif chemokine 20,1.35380381740434,1.20525616155233,1.52065995137332,3.25205207829936e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34056127441387,CCL20;C-C motif chemokine 20,1.34075924776654,1.24520266342306,1.44364882382262,7.65348731798703e-15
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774800444973555,CCL20;C-C motif chemokine 20,1.32915295760679,1.20584913367651,1.46506518550008,1.0146223746672e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804813252070636,CCL20;C-C motif chemokine 20,1.36594671084141,1.24171615819628,1.50260621523099,1.45564438485024e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212666328481679,CCL20;C-C motif chemokine 20,2.54796341901768,2.13467392585546,3.0412689760337,3.85391495544394e-25
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103374292958845,CCL20;C-C motif chemokine 20,3.01718343950862,2.34891105597266,3.87558136120034,5.38626378087508e-18
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.392451766032947,CCER2;Coiled-coil domain-containing glutamate-rich protein 2,2.37232451091099,2.03958420201529,2.75934848853417,3.9096083380839e-29
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.508256659568484,ACE2;Angiotensin-converting enzyme 2,1.39815030104711,1.22801207534082,1.59186078343373,4.13707111408134e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33808919251153,ACE2;Angiotensin-converting enzyme 2,1.30524458062598,1.20337941859321,1.41573255195368,1.31426136109313e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.210928083567697,ACE2;Angiotensin-converting enzyme 2,3.37569053222662,2.7921572094517,4.08117656512693,3.32437828723122e-36
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.269693676287082,ACE2;Angiotensin-converting enzyme 2,1.73250116627498,1.44037759214854,2.0838704430738,5.44339202126372e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0984054303731373,ACE2;Angiotensin-converting enzyme 2,6.19945142327318,4.74166950262881,8.10541475491201,1.36798576735553e-40
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.244565749055976,ROBO2;Roundabout homolog 2,1.69848969659676,1.41621599603072,2.03702490123743,1.11263256189242e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33958341505511,ROBO2;Roundabout homolog 2,1.64183755737397,1.51823354775611,1.77550454525772,2.14021843409164e-35
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220940463388405,ROBO2;Roundabout homolog 2,2.02738001704354,1.68273764467871,2.44260877297498,1.05048574800024e-13
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101639921033599,ROBO2;Roundabout homolog 2,2.62339982812942,2.01524766083195,3.41507735847627,7.62721456703595e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.548103561676598,S100A11;Protein S100-A11,1.41964823305339,1.26435955324075,1.59400947336998,3.05527763540651e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35601332083674,S100A11;Protein S100-A11,1.21587304748921,1.12865851064541,1.30982689065563,2.64787924329607e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243273589221108,WFDC2;WAP four-disulfide core domain protein 2,1.59221613299679,1.33213685878436,1.90307189344546,3.1928808900165e-07
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.52572520987449,WFDC2;WAP four-disulfide core domain protein 2,1.48325767953174,1.31227452696532,1.67651912666292,2.8116356913077e-10
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13443175435311,WFDC2;WAP four-disulfide core domain protein 2,1.33348239306759,1.25403737406915,1.41796036497013,4.19614712360511e-20
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.193214634450377,WFDC2;WAP four-disulfide core domain protein 2,1.80681335926751,1.48415110401475,2.19962408571244,3.7733435219719e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.524868782804298,WFDC2;WAP four-disulfide core domain protein 2,4.23738410572877,3.81844674028545,4.70228479817439,9.62228049906214e-163
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0643834762923425,WFDC2;WAP four-disulfide core domain protein 2,3.40848085021915,2.54732393128069,4.56076338138501,1.54589374281137e-16
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0560980677332225,WFDC2;WAP four-disulfide core domain protein 2,3.31507491228869,2.41479787134307,4.55099029384746,1.23296082647058e-13
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.94481669583031,WFDC2;WAP four-disulfide core domain protein 2,1.32428409577562,1.25553725657737,1.39679516249876,5.33774004302142e-25
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00474288567149,WFDC2;WAP four-disulfide core domain protein 2,1.30620914639212,1.19425491707099,1.42865841264693,5.12973364030994e-09
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.6471679392606,WFDC2;WAP four-disulfide core domain protein 2,1.24199758000841,1.20340139005734,1.28183164943265,2.87175068014975e-41
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00348249312941,WFDC2;WAP four-disulfide core domain protein 2,1.31354847906915,1.2323539849569,1.40009252854829,5.39928707919584e-17
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34661886100225,WFDC2;WAP four-disulfide core domain protein 2,1.97096126219536,1.82951864451567,2.12333900434401,2.49288979951773e-71
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.745026221593273,WFDC2;WAP four-disulfide core domain protein 2,1.29354363193162,1.16572824303318,1.43537324218644,1.24212485464631e-06
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60387603374822,WFDC2;WAP four-disulfide core domain protein 2,1.39728081148294,1.30173363265502,1.49984114811286,2.10835712110163e-20
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.7054457509799,WFDC2;WAP four-disulfide core domain protein 2,1.24447059099354,1.16154242627388,1.33331940083835,5.09987920704918e-10
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.670819357930043,WFDC2;WAP four-disulfide core domain protein 2,1.34840341542983,1.20855395051355,1.50443575147823,8.76544581631368e-08
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.84594374830598,WFDC2;WAP four-disulfide core domain protein 2,1.20415118786416,1.14138498276509,1.27036898603832,1.03388931894345e-11
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.72424564253139,WFDC2;WAP four-disulfide core domain protein 2,1.32305756753324,1.23549643611996,1.41682426256469,1.11777911000027e-15
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.760740786930223,WFDC2;WAP four-disulfide core domain protein 2,1.61604712904865,1.46065234951136,1.78797393108639,1.33813029311259e-20
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35335829481038,WFDC2;WAP four-disulfide core domain protein 2,1.25395415644778,1.16042664741538,1.35501975068814,1.05216600256384e-08
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.33851446044082,WFDC2;WAP four-disulfide core domain protein 2,1.20521731511616,1.16507010149401,1.24674796374325,3.48950381357772e-27
sensitivity,Circulatory system disorders,I50 (heart failure),4.42702328798708,WFDC2;WAP four-disulfide core domain protein 2,1.55740422568692,1.49188589615601,1.62579988753632,9.25516577702827e-91
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21588723822404,WFDC2;WAP four-disulfide core domain protein 2,1.40865880620952,1.34771935716046,1.47235373727394,4.42578184378197e-52
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.04919741505107,WFDC2;WAP four-disulfide core domain protein 2,1.29557188560474,1.21662240968251,1.37964457781723,6.89718369446221e-16
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.70749093334444,WFDC2;WAP four-disulfide core domain protein 2,1.27479163662935,1.20684340055221,1.3465655246377,3.71008003325206e-18
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.779836546259904,WFDC2;WAP four-disulfide core domain protein 2,1.57284058161158,1.42303106629957,1.7384212852058,7.44697894382344e-19
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805142928473349,WFDC2;WAP four-disulfide core domain protein 2,1.70861634670529,1.5492361292477,1.8843930664373,8.02266465176602e-27
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07761759137905,WFDC2;WAP four-disulfide core domain protein 2,1.32963750635029,1.21940422095732,1.44983580334456,1.10176859148936e-10
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12972130353268,WFDC2;WAP four-disulfide core domain protein 2,1.44271930899133,1.35597646165769,1.5350111623559,4.88805165909842e-31
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407636953537706,WFDC2;WAP four-disulfide core domain protein 2,1.72988158304977,1.50863135854064,1.98357953679918,4.18693741974687e-15
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.707817216612886,WFDC2;WAP four-disulfide core domain protein 2,1.63225206391703,1.46970089991932,1.81278163489431,5.46973135198753e-20
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0477743389485491,WFDC2;WAP four-disulfide core domain protein 2,3.34830674431802,2.38361442332084,4.70342767872088,3.17833493143529e-12
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214034868981568,WFDC2;WAP four-disulfide core domain protein 2,1.74194551800748,1.44303923061534,2.10276624732677,7.54268511600015e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.79113170915012,WFDC2;WAP four-disulfide core domain protein 2,1.37120597783917,1.31568533700282,1.42906953568782,1.15812964618231e-50
sensitivity,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0872963086132357,WFDC2;WAP four-disulfide core domain protein 2,2.23067904107456,1.68492485246042,2.95320528807158,2.09063861900445e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543915801048559,GFRA1;GDNF family receptor alpha-1,4.04502009144909,3.63061048115533,4.50673175355899,1.12311783933109e-141
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0646007478025957,GFRA1;GDNF family receptor alpha-1,2.31913703018182,1.67868857606929,3.2039275428646,3.36983850927861e-07
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0548342243894796,GFRA1;GDNF family receptor alpha-1,3.25667669541019,2.3242803439419,4.56310837290845,6.8450615563385e-12
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.98003257525487,GFRA1;GDNF family receptor alpha-1,1.24473854274001,1.18266590609983,1.31006908357748,4.94215188967214e-17
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02547008882178,GFRA1;GDNF family receptor alpha-1,1.23603231644552,1.13463006297962,1.34649692190037,1.22232121442642e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34779362646862,GFRA1;GDNF family receptor alpha-1,1.30434514655507,1.20996785354096,1.40608385285847,4.10244395013857e-12
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60814109125265,GFRA1;GDNF family receptor alpha-1,1.22165622894378,1.14022912625978,1.30889827960517,1.27979756912629e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.77779083891697,GFRA1;GDNF family receptor alpha-1,1.32241826202831,1.19903710676955,1.45849536254768,2.23981715050765e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.4192018964836,GFRA1;GDNF family receptor alpha-1,1.29463566106452,1.24152971795177,1.35001318990985,1.29024153363826e-33
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73243365352505,GFRA1;GDNF family receptor alpha-1,1.22902997105405,1.16578523964718,1.29570577699738,1.99741660818967e-14
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.776181422607264,GFRA1;GDNF family receptor alpha-1,1.33575203145549,1.21076293401717,1.4736439639902,7.6762852434151e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805977173785151,GFRA1;GDNF family receptor alpha-1,1.58152989914232,1.43695492142142,1.7406508614807,7.13617057473715e-21
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13623458873513,GFRA1;GDNF family receptor alpha-1,1.29021336343926,1.21479534504182,1.3703135511603,1.11825092631405e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409747681690748,GFRA1;GDNF family receptor alpha-1,1.606311031802,1.40568656241967,1.83556932240094,3.34145823872694e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.694635218398022,GFRA1;GDNF family receptor alpha-1,1.66072454266231,1.49829942925025,1.84075756338039,4.47509725731616e-22
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0430722242888188,GFRA1;GDNF family receptor alpha-1,3.83182043950169,2.64679902161203,5.54739810642682,1.10981886053307e-12
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.211540721588905,GFRA1;GDNF family receptor alpha-1,1.64418359061489,1.36621410086535,1.97870866501451,1.42265305576231e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.80744632701654,GFRA1;GDNF family receptor alpha-1,1.28600435217855,1.23553984866927,1.33853003252254,7.48633127744359e-35
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.541402527857621,CXCL10;C-X-C motif chemokine 10,1.33779290672648,1.19205463483641,1.50134885514982,7.60726623132048e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34349821720544,CXCL10;C-X-C motif chemokine 10,1.35107973955167,1.25589157241764,1.45348253202545,6.889106489526e-16
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60647325833826,CXCL10;C-X-C motif chemokine 10,1.20304045449293,1.12435482588667,1.28723273278541,8.50206083628369e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.777889091873416,CXCL10;C-X-C motif chemokine 10,1.28283205740876,1.16469315257675,1.41295420504084,4.35264911140345e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.81009870620158,CXCL10;C-X-C motif chemokine 10,1.28527512006659,1.16917378162922,1.41290555794047,2.04039901435233e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223880597014925,CXCL10;C-X-C motif chemokine 10,1.88818421758476,1.58936072992778,2.24319097131471,4.79452264907231e-13
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104052143866813,CXCL10;C-X-C motif chemokine 10,2.10580009805571,1.64035822725402,2.7033083257641,5.11374248547737e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,MFAP5;Microfibrillar-associated protein 5,3.53191509825674,3.14746321032157,3.96332647205731,3.65764103528053e-102
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783488276910483,MFAP5;Microfibrillar-associated protein 5,1.35790565136789,1.22881376870067,1.50055916118727,1.94026455465968e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.41797849969538,MFAP5;Microfibrillar-associated protein 5,1.20205870568903,1.15215577958305,1.25412306003073,1.78532602983121e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.401366941125203,CALCB;Calcitonin gene-related peptide 2,2.74580834689192,2.37814315685405,3.17031523360225,3.78912428363824e-43
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3650779059613,CALCB;Calcitonin gene-related peptide 2,1.2798552638767,1.18167766880981,1.3861897704496,1.3659280733626e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212577088394692,FUOM;Fucose mutarotase,3.15077840582304,2.59825859475595,3.82079158042129,1.89546684745965e-31
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.266803969294139,FUOM;Fucose mutarotase,1.72920324537858,1.43821678677771,2.07906338690925,5.69276712885218e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107418910398617,FUOM;Fucose mutarotase,4.38098304405178,3.36960224519855,5.69592819437899,2.70806851061594e-28
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.517028652004465,HAVCR1;Hepatitis A virus cellular receptor 1,1.38977265074533,1.23320136494105,1.56622273999189,6.77089481057312e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12953703159009,HAVCR1;Hepatitis A virus cellular receptor 1,1.26931207919926,1.19641605040089,1.34664956547624,2.72911740953096e-15
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545847241311604,HAVCR1;Hepatitis A virus cellular receptor 1,2.97584655213361,2.67745473533499,3.30749296523123,5.47995469162148e-91
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645969541557373,HAVCR1;Hepatitis A virus cellular receptor 1,2.19950102994208,1.60170686854473,3.02040584062164,1.11010397068644e-06
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97589125932479,HAVCR1;Hepatitis A virus cellular receptor 1,1.27169658731598,1.20891799979923,1.33773523966034,1.33876375164813e-20
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02538966767963,HAVCR1;Hepatitis A virus cellular receptor 1,1.32159929284923,1.21433060281955,1.43834363294815,1.07309155964815e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34574959234592,HAVCR1;Hepatitis A virus cellular receptor 1,1.41175517589782,1.31090269778471,1.520366599323,7.5991637663768e-20
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61001436809888,HAVCR1;Hepatitis A virus cellular receptor 1,1.31050286682218,1.2239920175112,1.40312823889265,8.45388343902445e-15
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70946888570137,HAVCR1;Hepatitis A virus cellular receptor 1,1.2565143010853,1.17622795713502,1.34228078771183,1.21877501778834e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.779704182583994,HAVCR1;Hepatitis A virus cellular receptor 1,1.47163559605669,1.3366011761415,1.62031230126034,3.59505900254493e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.41705187467899,HAVCR1;Hepatitis A virus cellular receptor 1,1.35262649319545,1.29791005847315,1.40964962722189,1.29076325405207e-46
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23413196311565,HAVCR1;Hepatitis A virus cellular receptor 1,1.24490435013545,1.19326386084088,1.29877966797223,3.89782316585285e-24
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06884356949192,HAVCR1;Hepatitis A virus cellular receptor 1,1.23850503381521,1.16626355904096,1.31522133817417,3.04097829922344e-12
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72632633419103,HAVCR1;Hepatitis A virus cellular receptor 1,1.2024650208727,1.140956951679,1.26728894047633,5.8881009858536e-12
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778095723413429,HAVCR1;Hepatitis A virus cellular receptor 1,1.33705673899085,1.21301696579731,1.47378047767518,4.9905011547337e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805929760574151,HAVCR1;Hepatitis A virus cellular receptor 1,1.65159371726591,1.50334833247734,1.81445759973486,1.36769005714471e-25
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409723583611056,HAVCR1;Hepatitis A virus cellular receptor 1,1.41472658869182,1.23833283877033,1.61624666494272,3.28852594215741e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698518591190032,HAVCR1;Hepatitis A virus cellular receptor 1,1.37969652064754,1.24509987220891,1.5288432129623999,7.9619932320291e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.211528291909042,HAVCR1;Hepatitis A virus cellular receptor 1,2.65362745665352,2.23736142870378,3.14734069711082,3.63783669732059e-29
sensitivity,Circulatory system disorders,I95 (hypotension),4.8011648727888,HAVCR1;Hepatitis A virus cellular receptor 1,1.28429796272504,1.23434811743127,1.33626910736673,4.17517666102238e-35
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101811062163485,HAVCR1;Hepatitis A virus cellular receptor 1,3.80391270639133,3.02313674116901,4.7863372108832,4.2679430601241e-30
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,IGSF8;Immunoglobulin superfamily member 8,2.75215379292328,2.45038541082834,3.09108537229721,1.91663941894793e-65
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783222853535353,IGSF8;Immunoglobulin superfamily member 8,1.35277007336793,1.22655160605388,1.49197706999658,1.48300769630223e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80173775671406,IGSF8;Immunoglobulin superfamily member 8,1.37732682525562,1.24992780185393,1.5177110075918,1.01388792208144e-10
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.414593698175787,IGSF8;Immunoglobulin superfamily member 8,1.4534241218253,1.27082138017792,1.66226482403679,4.79720558162533e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.711378097458799,IGSF8;Immunoglobulin superfamily member 8,1.29283444855234,1.16592643578071,1.43355606329009,1.10413702856354e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222866497051456,IGSF8;Immunoglobulin superfamily member 8,1.94745293848641,1.62396814584546,2.33537397720622,6.4016422177104e-13
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104495268138801,IGSF8;Immunoglobulin superfamily member 8,2.28683533578285,1.75902273562349,2.97302345619281,6.48418773496178e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.551296237748972,CTSZ;Cathepsin Z,2.66665864653696,2.3752469778337,2.99382270707523,5.7360675205585e-62
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0630355559933024,CTSZ;Cathepsin Z,2.34587441321047,1.66518518785179,3.30481366439189,1.08150579539961e-06
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.801120779810177,CTSZ;Cathepsin Z,1.36614936146156,1.23870731198677,1.5067030441827,4.25400532504829e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220737499753641,CTSZ;Cathepsin Z,2.07938374883647,1.72887703999749,2.50095100744207,7.68388198960523e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10245094176058,CTSZ;Cathepsin Z,2.97138998975726,2.2799544336991,3.87251531904732,7.731035820365e-16
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11961389192954,SNCG;Gamma-synuclein,1.20821725908993,1.13561020704964,1.28546655894841,2.20851854312596e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534002829417976,SNCG;Gamma-synuclein,3.4766667956059,3.06401482587849,3.94489344685303,3.02509487768744e-83
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0576403243758944,SNCG;Gamma-synuclein,2.99082664133122,2.06504508073137,4.33164587154122,6.74656789084913e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33402460667211,SNCG;Gamma-synuclein,1.34933758619574,1.24699184594481,1.46008326152369,9.71949424998942e-14
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61026091820833,SNCG;Gamma-synuclein,1.22754957800092,1.1430443591942,1.3183022638881,1.7624941450371e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.40073780023256,SNCG;Gamma-synuclein,1.2521259541523,1.19875755644911,1.30787030006794,4.62743477923098e-24
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769827534761592,SNCG;Gamma-synuclein,1.41399795612009,1.27484651667749,1.56833798716618,5.59828931783082e-11
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80001592071484,SNCG;Gamma-synuclein,1.41933937149413,1.28200436077499,1.57138642668542,1.53588179664111e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70101368171589,SNCG;Gamma-synuclein,1.31529565841016,1.18022670080568,1.46582234400528,7.1470410804443e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,RTN4R;Reticulon-4 receptor,2.01458051542814,1.80123965197848,2.25318971225445,1.41364911265113e-34
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243707473045953,COL6A3;Collagen alpha-3(VI) chain,1.88838454188656,1.59035785017586,2.2422602420215,4.04200499119077e-13
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.50659548350642,COL6A3;Collagen alpha-3(VI) chain,1.52486131140604,1.35065151297166,1.72154104644441,9.34862863586714e-12
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13608520931684,COL6A3;Collagen alpha-3(VI) chain,1.31454253338527,1.23838887512714,1.39537919532873,2.65690090077264e-19
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.206494847369138,COL6A3;Collagen alpha-3(VI) chain,1.64120650387049,1.35845242611248,1.982814220484,2.81557000236242e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,COL6A3;Collagen alpha-3(VI) chain,4.38935374204296,3.9616313164445,4.86325574841171,6.6066654142095e-176
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0642648490749756,COL6A3;Collagen alpha-3(VI) chain,3.00999317060651,2.21550126431426,4.08939459120646,1.82213276860498e-12
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0564971751412429,COL6A3;Collagen alpha-3(VI) chain,3.08790619428382,2.22782543225623,4.28003223530832,1.29705452583652e-11
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97277292095944,COL6A3;Collagen alpha-3(VI) chain,1.22523013708683,1.16370408078126,1.29000912999977,1.09688068883264e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01037684325505,COL6A3;Collagen alpha-3(VI) chain,1.33561811441263,1.22493354532518,1.45630410266345,5.50207929319485e-11
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68940971871145,COL6A3;Collagen alpha-3(VI) chain,1.20850020934693,1.17218936833652,1.24593584914028,4.65621280156277e-34
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.98886550075738,COL6A3;Collagen alpha-3(VI) chain,1.2529253324122,1.17758232109892,1.33308887240703,1.03361681098711e-12
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34461664744855,COL6A3;Collagen alpha-3(VI) chain,1.69248285196254,1.57086789634316,1.82351311071767,1.66573063743526e-43
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60560787922695,COL6A3;Collagen alpha-3(VI) chain,1.32823878272737,1.23972887927908,1.42306781218728,7.17574908497979e-16
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72410422816036,COL6A3;Collagen alpha-3(VI) chain,1.20993886040391,1.13216387159943,1.29305667018622,1.88933772583882e-08
sensitivity,Circulatory system disorders,I37 (pulmonary valve disorders),0.212310089598753,COL6A3;Collagen alpha-3(VI) chain,1.59006953037392,1.31899011298864,1.91686130663613,1.15502045784305e-06
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.670026566651039,COL6A3;Collagen alpha-3(VI) chain,1.32399766131035,1.19037732325023,1.47261693659364,2.33356177287382e-07
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.75140581068416,COL6A3;Collagen alpha-3(VI) chain,1.22749311717167,1.14922125747691,1.31109596424612,1.07936432854602e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783488276910483,COL6A3;Collagen alpha-3(VI) chain,1.62450190463807,1.47364776568999,1.79079865597129,1.71211276802555e-22
sensitivity,Circulatory system disorders,I50 (heart failure),4.41797849969538,COL6A3;Collagen alpha-3(VI) chain,1.41513344222447,1.35668755024593,1.47609717428235,1.44332269672546e-58
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22007806153785,COL6A3;Collagen alpha-3(VI) chain,1.3144502924214,1.25910681744494,1.37222636499802,1.26586745980071e-35
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06000195446105,COL6A3;Collagen alpha-3(VI) chain,1.24559173141372,1.17202181969977,1.32377975843799,1.54847934388581e-12
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72235142371357,COL6A3;Collagen alpha-3(VI) chain,1.24640119876619,1.18207069752968,1.31423268636333,3.74730480414677e-16
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772140545178021,COL6A3;Collagen alpha-3(VI) chain,1.4269427585631,1.29268703079505,1.57514200089356,1.76137600193572e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805696449473273,COL6A3;Collagen alpha-3(VI) chain,1.55352432188963,1.41022502025438,1.71138490952833,4.59120449134533e-19
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07487027427724,COL6A3;Collagen alpha-3(VI) chain,1.24123863941363,1.14102880822572,1.350249309103,4.86102020792749e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14282892917802,COL6A3;Collagen alpha-3(VI) chain,1.32783019040538,1.25014655990708,1.41034105207875,3.01308690228012e-20
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407613995397277,COL6A3;Collagen alpha-3(VI) chain,1.57663251215169,1.37692853322039,1.80530072433023,4.4352393948166e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70473401659346,COL6A3;Collagen alpha-3(VI) chain,1.57043164322396,1.41653136937119,1.74105254522806,9.73407645751628e-18
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0467435338111561,COL6A3;Collagen alpha-3(VI) chain,3.38968219224578,2.39522967429637,4.79701194742566,5.57947749750063e-12
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220169901020964,COL6A3;Collagen alpha-3(VI) chain,1.82886079202757,1.52514600143294,2.1930567915945,7.24958644710379e-11
sensitivity,Circulatory system disorders,I95 (hypotension),4.78418322403836,COL6A3;Collagen alpha-3(VI) chain,1.31213518340697,1.26035445416325,1.36604328555929,6.37561153662329e-40
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103231335579751,COL6A3;Collagen alpha-3(VI) chain,2.05440508160136,1.58166051821606,2.66844888059154,6.80941978840913e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543765281173594,IL16;Pro-interleukin-16,2.00352353613821,1.79053105553163,2.2418525204903,8.490354621789e-34
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.533669125142411,GFRA3;GDNF family receptor alpha-3,2.11165959977284,1.87477030930381,2.37848137618985,7.77247643542966e-35
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222866497051456,LEPR;Leptin receptor,1.70632517931547,1.4284431926985,2.03826489737104,3.82229243580092e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104495268138801,LEPR;Leptin receptor,2.03517793434942,1.57816571540739,2.62453377615896,4.34457184019807e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534531980805442,PLIN1;Perilipin-1,1.3550899887943,1.20356630524082,1.52568983506324,5.09851062561708e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.554229699611447,LGALS3;Galectin-3,2.27522435665097,2.0276191744004,2.55306614696453,1.9380853859828e-44
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34772485102016,LGALS3;Galectin-3,1.23141677953451,1.14008714534106,1.33006261066606,1.1935130772331e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.397582331716958,RBP7;Retinoid-binding protein 7,2.03307218506292,1.7691959127724,2.33630570805432,1.47390904967681e-23
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36781265111566,RBP7;Retinoid-binding protein 7,1.35174940131343,1.24927707536788,1.46262705045887,6.71543826883688e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.397582331716958,EFCAB14;EF-hand calcium-binding domain-containing protein 14,3.89301938334142,3.38694179788826,4.47471519248468,1.42962582495687e-81
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36781265111566,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.28747711826679,1.18785633886794,1.39545269560147,7.76847917789082e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.75981911254964,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.30315808451246,1.16997528463028,1.45150159626393,1.47991005115857e-06
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.771916927035471,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.30307341146029,1.17080023749238,1.45029037514678,1.25113926169295e-06
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406541412099774,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.51247712246505,1.30607741358553,1.75149422399101,3.25643928136083e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.682758620689655,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.32828927972353,1.18563817568538,1.4881035773064,9.70223799777268e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.553017552296225,PI3;Elafin,2.88234544047235,2.56235774459979,3.24229325734114,1.40900497815635e-69
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0579501628599404,PI3;Elafin,2.49917851710293,1.71907195834588,3.63329366756625,1.6036671425238e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34498586862835,PI3;Elafin,1.24080436404215,1.14624508423419,1.34316429444464,9.56465531268236e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.787653432489704,PI3;Elafin,1.40411517979409,1.26566498352145,1.55771034499412,1.47312865053417e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.42110356228453,PI3;Elafin,1.26925952401438,1.21440356536593,1.32659338727795,3.78845595345073e-26
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772,PI3;Elafin,1.40383985592631,1.26477080723621,1.55820037101721,1.85267776645304e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80840420210105,PI3;Elafin,1.31450977883923,1.18630574530931,1.45656881920726,1.76081713053363e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.79881134045458,PI3;Elafin,1.22637172413285,1.17580056581256,1.2791179469396,2.14820869689408e-21
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243251726302573,CKAP4;Cytoskeleton-associated protein 4,1.63170411008479,1.36943767856536,1.94419822423524,4.33415568146737e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513654988530985,CKAP4;Cytoskeleton-associated protein 4,1.34891954905748,1.19515787111264,1.5224632609711,1.25271448466381e-06
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11801193467336,CKAP4;Cytoskeleton-associated protein 4,1.24596850302309,1.17379849121058,1.32257582723976,5.06071283868875e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546415865715352,CKAP4;Cytoskeleton-associated protein 4,4.12727651732523,3.69661714489173,4.60810811149424,2.87416572862561e-140
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0646640409147022,CKAP4;Cytoskeleton-associated protein 4,2.93486043818392,2.12366661664485,4.05591241304405,6.90268252108043e-11
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0548879697332052,CKAP4;Cytoskeleton-associated protein 4,3.20085639572573,2.25590737795962,4.54162336900771,7.14810370943874e-11
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96864307853318,CKAP4;Cytoskeleton-associated protein 4,1.20124983804401,1.14148003435699,1.26414928861513,1.89967197575653e-12
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02255107848717,CKAP4;Cytoskeleton-associated protein 4,1.30718487273213,1.20024641193152,1.42365123904006,7.6738058622795e-10
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00898600637333,CKAP4;Cytoskeleton-associated protein 4,1.23997844384663,1.16596487730782,1.31869027200412,7.39085058395104e-12
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34507983953433,CKAP4;Cytoskeleton-associated protein 4,1.546371352886,1.43488829347679,1.66651604302406,3.38492434440599e-30
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61941724620264,CKAP4;Cytoskeleton-associated protein 4,1.26997528097481,1.18592555156556,1.35998184047719,7.86715640991469e-12
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.6994826806192,CKAP4;Cytoskeleton-associated protein 4,1.24220214981269,1.1623060252279,1.32759027958812,1.61335702470241e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.7746465062462,CKAP4;Cytoskeleton-associated protein 4,1.48435386259222,1.34610553244233,1.63680063434168,2.40353312969344e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.42330888023253,CKAP4;Cytoskeleton-associated protein 4,1.40258550360658,1.34545145975982,1.46214572116819,3.11771255220726e-57
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22787888452568,CKAP4;Cytoskeleton-associated protein 4,1.24208333301388,1.19025229305929,1.29617142109048,2.09584043895402e-23
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06112575227156,CKAP4;Cytoskeleton-associated protein 4,1.3073913647375,1.23075668556014,1.38879780272107,3.40904711838041e-18
sensitivity,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.770287215620708,CKAP4;Cytoskeleton-associated protein 4,1.29607593448015,1.17328022458036,1.43172346447703,3.28008648414309e-07
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.62003335622486,CKAP4;Cytoskeleton-associated protein 4,1.31031950403957,1.17414027591382,1.46229308191497,1.38405335514208e-06
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72757664549369,CKAP4;Cytoskeleton-associated protein 4,1.26624040825156,1.20131156186599,1.33467854833476,1.50488680085144e-18
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.77300372768295,CKAP4;Cytoskeleton-associated protein 4,1.4841575192421,1.3454096180362,1.63721405911907,3.1496142923739e-15
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80478947884974,CKAP4;Cytoskeleton-associated protein 4,1.49624209892479,1.35884334059405,1.6475338633342,2.4177585828073e-16
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13243769625183,CKAP4;Cytoskeleton-associated protein 4,1.30719367509104,1.23104194050212,1.3880561238239,2.18114296560746e-18
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408203316651947,CKAP4;Cytoskeleton-associated protein 4,1.61220996867137,1.40967354042774,1.84384604558491,3.10567845821606e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699259492054762,CKAP4;Cytoskeleton-associated protein 4,1.47103167443815,1.32640594540122,1.63142678506748,2.67981653551004e-13
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0431144296156936,CKAP4;Cytoskeleton-associated protein 4,3.17300022532142,2.14152172715761,4.70129735421956,8.60108502875558e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213700348978551,CKAP4;Cytoskeleton-associated protein 4,2.08250417825079,1.73419874498058,2.50076507377507,3.97916122516495e-15
sensitivity,Circulatory system disorders,I95 (hypotension),4.7826343884807,CKAP4;Cytoskeleton-associated protein 4,1.31140013111039,1.26001131796361,1.36488480647601,2.58124868921907e-40
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103876759045117,CKAP4;Cytoskeleton-associated protein 4,2.591605024624,2.00213870485943,3.3546210296793,4.74180793733498e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,HAO1;Hydroxyacid oxidase 1,0.71519560910237,0.631326547780837,0.810206320449044,1.38608010684678e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213177915550253,HAO1;Hydroxyacid oxidase 1,2.94822745759757,2.45325108455224,3.54307196538696,9.30123084834504e-31
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.266468121791606,HAO1;Hydroxyacid oxidase 1,1.59034319845683,1.33633800795139,1.89262856689614,1.73684034515292e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103618839077987,HAO1;Hydroxyacid oxidase 1,5.23985863869325,4.0504549604559,6.77852705968566,1.8932158994089e-36
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.401366941125203,ZHX2;Zinc fingers and homeoboxes protein 2,1.46797766603624,1.26589815852429,1.70231579331257,3.76969989721948e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.225363249975289,IL1R2;Interleukin-1 receptor type 2,2.56269755668035,2.12025768420253,3.09746254709863,2.20121459215317e-22
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104741013023458,IL1R2;Interleukin-1 receptor type 2,3.84606035127357,2.91401782237543,5.07621474105481,1.84258565281572e-21
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.386586146948485,CYTL1;Cytokine-like protein 1,3.61248929896675,3.06523553071099,4.25744736559356,5.25778461722837e-53
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0433829573477029,CYTL1;Cytokine-like protein 1,3.75253259778531,2.35456892937457,5.98050060109377,2.67958191785668e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36612648130744,CYTL1;Cytokine-like protein 1,1.24212193171532,1.1410753326402,1.35211659485999,5.48890576333572e-07
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51554537194327,EFNA1;Ephrin-A1,1.38521458344079,1.22629316504284,1.56473141731163,1.59705252047255e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14377533867299,EFNA1;Ephrin-A1,1.27079525746675,1.19718383436466,1.34893283725054,3.50791471968902e-15
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.530661544858721,EFNA1;Ephrin-A1,4.89273542771266,4.34796495949225,5.50576193428893,3.68129148885401e-153
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0651491520739146,EFNA1;Ephrin-A1,3.41362868150246,2.47658016764386,4.70522251910883,6.43244598409962e-14
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0552988110755618,EFNA1;Ephrin-A1,3.75814637444713,2.65628104793986,5.31708200934689,7.54789120199257e-14
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97296749204031,EFNA1;Ephrin-A1,1.21994732454713,1.15895884855941,1.28414522786518,3.01298793065975e-14
sensitivity,Circulatory system disorders,I22 (subsequent myocardial infarction),0.102774922918807,EFNA1;Ephrin-A1,1.91837922467636,1.4743361612164,2.49615993046901,1.2344882410489e-06
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0044885610899,EFNA1;Ephrin-A1,1.30081429834853,1.19300505890024,1.41836602130408,2.55433127951483e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33737517831669,EFNA1;Ephrin-A1,1.52264823116068,1.41151455240339,1.64253186898363,1.54386120958188e-27
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60198511166253,EFNA1;Ephrin-A1,1.23932226741101,1.15614698395724,1.3284813296348,1.41836958360737e-09
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72618811684965,EFNA1;Ephrin-A1,1.21020366997456,1.13254548375699,1.29318684664337,1.71712629234879e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776511035150461,EFNA1;Ephrin-A1,1.46225120495115,1.3255878899088,1.61300401328214,3.19848062828332e-14
sensitivity,Circulatory system disorders,I50 (heart failure),4.41867877918559,EFNA1;Ephrin-A1,1.3935424861473,1.33609470452568,1.4534603378935,7.55380686163089e-54
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22976501305483,EFNA1;Ephrin-A1,1.219728113661,1.168517722821,1.27318280433382,1.12241486663533e-19
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.07458191329159,EFNA1;Ephrin-A1,1.22483407814755,1.15271017110609,1.30147070494921,5.76978096039241e-11
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71812346461684,EFNA1;Ephrin-A1,1.21499123293196,1.15209480985663,1.28132136649868,6.94785099681195e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772818911333359,EFNA1;Ephrin-A1,1.47278949716841,1.33418176043024,1.62579714946041,1.62584287432644e-14
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804904578265598,EFNA1;Ephrin-A1,1.5383181994057,1.39637578300763,1.69468914558644,2.79300938404833e-18
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11236584975172,EFNA1;Ephrin-A1,1.32511167132091,1.24699414150002,1.4081228476011,1.08317471987803e-19
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405322577456155,EFNA1;Ephrin-A1,1.76359806603683,1.5411708767948,2.01812672777553,1.60522845473962e-16
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702539035443589,EFNA1;Ephrin-A1,1.50448544465619,1.35613066386633,1.66906959151646,1.24566402913431e-14
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0454123640097142,EFNA1;Ephrin-A1,2.9064783852084,1.97770519476072,4.27142358024989,5.58712378557087e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.79838069534846,EFNA1;Ephrin-A1,1.22792615468962,1.17942865554901,1.27841784602815,1.74146028769747e-23
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,"ST3GAL1;CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1",1.81694069244723,1.62524606337515,2.0312453321775,8.88440212746445e-26
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54409116989494,"FABP1;Fatty acid-binding protein, liver",2.47894249376761,2.21827205881301,2.77024446257284,1.00474341924288e-57
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34420842159444,"FABP1;Fatty acid-binding protein, liver",1.31545000520241,1.22052051750025,1.41776290637953,7.25680452377872e-13
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781743524952621,"FABP1;Fatty acid-binding protein, liver",1.33894001392833,1.21359868043635,1.47722668934825,5.87276082974513e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.41290630784848,"FABP1;Fatty acid-binding protein, liver",1.23632392457081,1.18574555786953,1.28905972813635,2.41878260148142e-23
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.808188590511194,"FABP1;Fatty acid-binding protein, liver",1.41997389571284,1.28966031975879,1.56345499168572,9.37189280646174e-13
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404986269977676,"FABP1;Fatty acid-binding protein, liver",1.46503661673881,1.27894837999191,1.67820087343874,3.59108728318406e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701941709178629,"FABP1;Fatty acid-binding protein, liver",1.37250514324524,1.23777467428785,1.52190088177273,1.89663448965588e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.224989638635062,"FABP1;Fatty acid-binding protein, liver",2.30251209525611,1.9350212883125,2.7397951541009,5.42160552006822e-21
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104567426260234,"FABP1;Fatty acid-binding protein, liver",3.37179233786034,2.64657242847969,4.29573868725918,7.82848837692161e-23
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.2426614481409,ADM;Pro-adrenomedullin,1.94521413813512,1.65481495670141,2.28657471814446,7.27447023758994e-16
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.51628043414491,ADM;Pro-adrenomedullin,1.57861224296014,1.40465847188065,1.77410855628641,1.79904244065693e-14
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13036752755967,ADM;Pro-adrenomedullin,1.41692801735245,1.33615196280259,1.50258732707858,2.68905679290518e-31
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,ADM;Pro-adrenomedullin,3.37512862945764,3.08929228207107,3.68741194593206,7.01364614141776e-160
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645035183737294,ADM;Pro-adrenomedullin,2.88492808816838,2.20374435629722,3.77666767477831,1.25984921455592e-14
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547516621040281,ADM;Pro-adrenomedullin,3.0157711266122,2.26232927694372,4.02013782025333,5.21952163661625e-14
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97749312345654,ADM;Pro-adrenomedullin,1.22310375821704,1.16182731639423,1.28761200761528,1.59415527508787e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02392419436939,ADM;Pro-adrenomedullin,1.3058716153229,1.19927412672225,1.42194402239528,8.12502993422323e-10
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.71585697471488,ADM;Pro-adrenomedullin,1.25304692720388,1.21561367167275,1.29163289157031,3.90073711951682e-48
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,ADM;Pro-adrenomedullin,1.79047863469407,1.66708177721918,1.92300928790877,1.55992613990128e-57
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.748124791915552,ADM;Pro-adrenomedullin,1.30836229961292,1.18440550132977,1.44529209390407,1.20646068579405e-07
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60963817535032,ADM;Pro-adrenomedullin,1.41962360389634,1.32663084749267,1.51913486750938,3.79621773463828e-24
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70898245889416,ADM;Pro-adrenomedullin,1.23667142141041,1.1572318261497,1.32156424492892,3.58942988259822e-10
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.676417535879538,ADM;Pro-adrenomedullin,1.37548742216513,1.23900273067806,1.5270068432368,2.23998750521189e-09
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.8490699317165,ADM;Pro-adrenomedullin,1.23065282427449,1.16876660104983,1.29581592469736,3.17103225318873e-15
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.74613439943559,ADM;Pro-adrenomedullin,1.21762905913173,1.14009379143903,1.30043732960835,4.47493530206635e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778575480741016,ADM;Pro-adrenomedullin,1.70754450361418,1.55478484787146,1.87531299640248,4.57898928073935e-29
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36819103490363,ADM;Pro-adrenomedullin,1.28314337945988,1.19137044702421,1.38198570928483,4.5567580991273e-11
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.38816854134617,ADM;Pro-adrenomedullin,1.27864863091164,1.23755720182292,1.32110444585828,3.1220156424251e-49
sensitivity,Circulatory system disorders,I49 (other cardiac arrhythmias),1.98162885536682,ADM;Pro-adrenomedullin,1.2060222222678,1.13347102681172,1.2832172734887,3.26348015780609e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.41849455578349,ADM;Pro-adrenomedullin,1.54522249693559,1.48269883463427,1.61038270838381,9.82613235827523e-95
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23386695833747,ADM;Pro-adrenomedullin,1.3837435920694,1.32619512871498,1.44378929399961,9.07026300699942e-51
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06780193047163,ADM;Pro-adrenomedullin,1.26948969932106,1.19529428854298,1.34829063614681,8.11287279190327e-15
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73026831947277,ADM;Pro-adrenomedullin,1.23827244289567,1.17484518239063,1.30512399915941,1.63412269647531e-15
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778925943322373,ADM;Pro-adrenomedullin,1.56006005693183,1.41807204156741,1.71626497800778,6.58749977840895e-20
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80476199800278,ADM;Pro-adrenomedullin,1.59717989736737,1.45427878643492,1.75412283280844,1.22710676350736e-22
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07882680032893,ADM;Pro-adrenomedullin,1.26177169231765,1.16071933120557,1.37162168384027,4.78043793998712e-08
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13499851323223,ADM;Pro-adrenomedullin,1.41975616529954,1.33798619561107,1.5065234421088,5.18573458107359e-31
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409130060292851,ADM;Pro-adrenomedullin,1.72717169311341,1.51818951953784,1.96492072900118,9.96699127062519e-17
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697505828875957,ADM;Pro-adrenomedullin,1.50477407070624,1.35931481871645,1.66579880737853,3.31830284456371e-15
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0430073894514602,ADM;Pro-adrenomedullin,2.42072917537401,1.69595473144609,3.45523947771315,1.11780608693363e-06
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.52870682227618,ADM;Pro-adrenomedullin,1.40237425971258,1.24715613577365,1.57691046685539,1.60091330439928e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.80223213408523,ADM;Pro-adrenomedullin,1.32242189859507,1.27084967518672,1.37608696923721,3.88560531664816e-43
sensitivity,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0938912035678657,ADM;Pro-adrenomedullin,2.0726609974004,1.60647464683501,2.67413097281581,2.06457568301874e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,INHBC;Inhibin beta C chain,1.35002275236897,1.19672100577468,1.5229626814598,1.06037039228394e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,NOTCH1;Neurogenic locus notch homolog protein 1,1.88167392653912,1.67645757702574,2.11201095353622,7.41018192468938e-27
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220169901020964,NOTCH1;Neurogenic locus notch homolog protein 1,1.9945865594276,1.66347814192984,2.39160073268762,9.00404810344899e-14
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103231335579751,NOTCH1;Neurogenic locus notch homolog protein 1,2.84810551148006,2.19394918639482,3.69730760166444,3.80267203538148e-15
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24847436738426,PLAUR;Urokinase plasminogen activator surface receptor,1.6866429224999,1.41078790762003,2.0164365831701,9.64612178344214e-09
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.510548690849855,PLAUR;Urokinase plasminogen activator surface receptor,1.46178911030936,1.29116017920696,1.65496693394888,2.03252176295319e-09
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13608066986216,PLAUR;Urokinase plasminogen activator surface receptor,1.32563297979868,1.24787078268377,1.40824099859966,6.27480065704339e-20
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545686290129849,PLAUR;Urokinase plasminogen activator surface receptor,3.56430218718082,3.17602084645708,4.00005248571142,1.89105932706754e-103
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0635361858433436,PLAUR;Urokinase plasminogen activator surface receptor,2.81610020365508,2.0140006161855,3.93764544722252,1.41888903957654e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0576025424570463,PLAUR;Urokinase plasminogen activator surface receptor,2.94430963787528,2.07441960967372,4.17898057040098,1.50476392808436e-09
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97740435598335,PLAUR;Urokinase plasminogen activator surface receptor,1.27899393565238,1.21473782007661,1.34664901380315,8.22683471764934e-21
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01425929240498,PLAUR;Urokinase plasminogen activator surface receptor,1.34397054065599,1.23210682203897,1.46599043349345,2.60263846061225e-11
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.73410154397971,PLAUR;Urokinase plasminogen activator surface receptor,1.24239852003985,1.2052641855705,1.28067696781895,1.19770158415905e-44
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.99562767002948,PLAUR;Urokinase plasminogen activator surface receptor,1.23643653680876,1.16098107514686,1.31679606350367,3.94722417966202e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34898178774957,PLAUR;Urokinase plasminogen activator surface receptor,1.79835407499614,1.66639106263457,1.94076735741858,1.80565504175891e-51
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.742067044663284,PLAUR;Urokinase plasminogen activator surface receptor,1.36546256215871,1.23235637774419,1.51294547772776,2.64132793228973e-09
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61303202108121,PLAUR;Urokinase plasminogen activator surface receptor,1.3536175542445,1.26189849888073,1.45200306108933,2.72080489795204e-17
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71808977118711,PLAUR;Urokinase plasminogen activator surface receptor,1.24643609058643,1.16554473085501,1.33294148803427,1.23836537684182e-10
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.67314586154704,PLAUR;Urokinase plasminogen activator surface receptor,1.3435824465296,1.2069350326472,1.49570088015677,6.77734607632151e-08
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.76566605621466,PLAUR;Urokinase plasminogen activator surface receptor,1.25816292482769,1.17799635870575,1.34378509212895,8.10504941470117e-12
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782895521201764,PLAUR;Urokinase plasminogen activator surface receptor,1.62341060801836,1.47118849192385,1.79138296465343,5.14788731124395e-22
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35986401359864,PLAUR;Urokinase plasminogen activator surface receptor,1.24784318580148,1.15669181736328,1.34617760148133,1.05766812957812e-08
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.42724948252769,PLAUR;Urokinase plasminogen activator surface receptor,1.23144404871039,1.19176254532804,1.27244680666384,1.27053879042199e-35
sensitivity,Circulatory system disorders,I50 (heart failure),4.41202989440782,PLAUR;Urokinase plasminogen activator surface receptor,1.50244577249457,1.44020681639152,1.56737440317263,2.46570129769648e-79
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23752777216723,PLAUR;Urokinase plasminogen activator surface receptor,1.34399459598878,1.28718063355514,1.40331623002908,4.88420716989523e-41
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.07046351281335,PLAUR;Urokinase plasminogen activator surface receptor,1.28797038337213,1.21133501433934,1.36945410543466,6.18933370621432e-16
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.620327660251312,PLAUR;Urokinase plasminogen activator surface receptor,1.4141597243188,1.26508242359178,1.58080429274129,1.08065083216759e-09
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71395835408986,PLAUR;Urokinase plasminogen activator surface receptor,1.32377689415693,1.25449957562976,1.39687991893029,1.49389541778934e-24
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78325348388764,PLAUR;Urokinase plasminogen activator surface receptor,1.4812115775126,1.34118117918168,1.63586230660948,8.94322643222677e-15
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.811504266364341,PLAUR;Urokinase plasminogen activator surface receptor,1.71587193324827,1.5570278384577,1.8909209062219,1.23739484541666e-27
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.0819626484218,PLAUR;Urokinase plasminogen activator surface receptor,1.28266497384996,1.18027094601809,1.3939421627653,4.50130981874939e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13224338581725,PLAUR;Urokinase plasminogen activator surface receptor,1.47061931239483,1.38332209880735,1.56342558530168,4.71609874979014e-35
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407651924912503,PLAUR;Urokinase plasminogen activator surface receptor,1.73826719158341,1.5173855718127,1.99130193766481,1.53838248322694e-15
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70257145131757,PLAUR;Urokinase plasminogen activator surface receptor,1.63338969386325,1.47056405324509,1.81424391962478,5.2977231687414e-20
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222495927529897,PLAUR;Urokinase plasminogen activator surface receptor,2.57548528057668,2.14910050293649,3.08646544049652,1.24822671305558e-24
sensitivity,Circulatory system disorders,I95 (hypotension),4.81437125748503,PLAUR;Urokinase plasminogen activator surface receptor,1.37791263040721,1.32307883353521,1.43501896403455,5.33362904931594e-54
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105254796044008,PLAUR;Urokinase plasminogen activator surface receptor,3.2685341248271,2.52559736991155,4.23001522429262,2.21836271717321e-19
sensitivity,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0993482753139405,PLAUR;Urokinase plasminogen activator surface receptor,2.13173299877032,1.62101370299842,2.80336037236492,6.06833848361277e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220670839351628,GGH;Gamma-glutamyl hydrolase,1.66153202471326,1.38233568001408,1.99711886849337,6.32183276028444e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.548569165263887,GSTA1;Glutathione S-transferase A1,0.714759865288605,0.634480729719375,0.805196503372676,3.30654652950086e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223209876543209,GSTA1;Glutathione S-transferase A1,2.03064534908133,1.69830583931935,2.42801999397133,7.96239552785025e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104656214209549,GSTA1;Glutathione S-transferase A1,2.85465175199221,2.22101021976221,3.66906759484639,2.58519646067523e-16
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543915801048559,FGF21;Fibroblast growth factor 21,1.56516236998675,1.39423624016027,1.75704315657506,3.1325888677194e-14
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34779362646862,FGF21;Fibroblast growth factor 21,1.24412364313722,1.15488973928435,1.34025230873744,8.80790241344615e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805977173785151,FGF21;Fibroblast growth factor 21,1.33537861856382,1.21339511208895,1.46962521700573,3.26907531800192e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103775062656641,FGF21;Fibroblast growth factor 21,2.16568561478964,1.67665028068886,2.79735985263415,3.26738158153946e-09
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245865884125788,CD302;CD302 antigen,1.73258224930589,1.45810403833089,2.05872912473797,4.22085112957478e-10
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.505260655055578,CD302;CD302 antigen,1.44336211331924,1.27775005109091,1.63043952797085,3.59921504188714e-09
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1346665079554,CD302;CD302 antigen,1.32646291073314,1.24958971603,1.40806524812053,1.77691623900638e-20
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,CD302;CD302 antigen,3.8997780130098,3.52477141869359,4.31468221459632,2.18956621714735e-153
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0613946487631949,CD302;CD302 antigen,3.1362370606397,2.29854757867268,4.27921657649994,5.62106305511566e-13
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0574564618707031,CD302;CD302 antigen,3.20929360132106,2.32971783465071,4.42094972459377,9.66755552091758e-13
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96145632055323,CD302;CD302 antigen,1.21424771730455,1.15311225883873,1.27862444239743,1.77130017166678e-13
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.0116638895501,CD302;CD302 antigen,1.25657556400434,1.15219057408305,1.37041751908918,2.44914252362755e-07
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.99843965672447,CD302;CD302 antigen,1.24374131236071,1.16892754466489,1.32334331510359,5.53009889003418e-12
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,CD302;CD302 antigen,1.59574129600912,1.48115423979778,1.71919319093771,9.98855131912301e-35
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60490631409171,CD302;CD302 antigen,1.34483933757416,1.25522860338627,1.44084737951939,3.73197825376433e-17
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.7394066955244,CD302;CD302 antigen,1.21360426919131,1.13577916964651,1.29676204808174,1.03343156294346e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,CD302;CD302 antigen,1.48592707995991,1.34698843052084,1.63919692027676,2.63428726424298e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.38493054861596,CD302;CD302 antigen,1.37989056392275,1.32306878036304,1.43915267041566,6.44910952308512e-51
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21317751360064,CD302;CD302 antigen,1.26096431874177,1.20781757508659,1.31644964101959,4.87149223034789e-26
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06933566572575,CD302;CD302 antigen,1.2309806413369,1.15839553852826,1.30811392909145,2.05893713417587e-11
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72069637107993,CD302;CD302 antigen,1.23982962038463,1.17574290644128,1.3074095358447,2.04169021749439e-15
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775347518293045,CD302;CD302 antigen,1.47733306264638,1.33891846840951,1.63005666848462,7.55831835060228e-15
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,CD302;CD302 antigen,1.56212653972731,1.41793638497294,1.7209794120397,1.76212062340869e-19
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13718991664155,CD302;CD302 antigen,1.33545217149836,1.25739121187075,1.41835928669032,4.81729271145005e-21
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406608881924747,CD302;CD302 antigen,1.62663288594065,1.42138019524862,1.86152484357697,1.55614896297222e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702771380925911,CD302;CD302 antigen,1.53410718471622,1.38362660656014,1.70095374217251,4.49713515782841e-16
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0455562818151207,CD302;CD302 antigen,2.68391784157295,1.84776049741126,3.89845707298413,2.17725223659151e-07
sensitivity,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.66832618723456,CD302;CD302 antigen,1.21787586760865,1.13717993669109,1.3042980983461,1.74946491602605e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.80361515338522,CD302;CD302 antigen,1.27333104420287,1.22324685727278,1.32546586037884,3.79797726914435e-32
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.211086637298091,FTCD;Formimidoyltransferase-cyclodeaminase,2.52285447081546,2.06481998770862,3.08249373737259,1.39200639033613e-19
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105507007041445,FTCD;Formimidoyltransferase-cyclodeaminase,3.98094829758738,3.03624937918054,5.21958092663031,1.59611172924327e-23
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534887434136995,DKK4;Dickkopf-related protein 4,2.17782924508669,1.93879411927363,2.44633515936793,2.49145738899614e-39
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249165638001188,CD80;T-lymphocyte activation antigen CD80,1.64314308963956,1.36474274508735,1.97833564072723,1.57973165060008e-07
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518513442518102,CD80;T-lymphocyte activation antigen CD80,1.39568022481714,1.22625415028026,1.58851514549445,4.44378679454852e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04221647952066,CD80;T-lymphocyte activation antigen CD80,1.20993518687043,1.1331399144532,1.29193503622508,1.22731222916121e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.395745167562621,CD80;T-lymphocyte activation antigen CD80,1.58724900351815,1.37004218608965,1.83889184198048,7.59411275796431e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36386558474304,CD80;T-lymphocyte activation antigen CD80,1.56151350877044,1.44197947010964,1.6909564169365,5.4531522687931e-28
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.760916756163882,CD80;T-lymphocyte activation antigen CD80,1.31138673620254,1.17839620382536,1.4593862117896,6.73703589009e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.31566820276497,CD80;T-lymphocyte activation antigen CD80,1.28423901696627,1.22732523913286,1.34379201218394,2.86556353157689e-27
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.07689450222882,CD80;T-lymphocyte activation antigen CD80,1.20372970919229,1.14868053738947,1.26141704819437,8.24844068672743e-15
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.768368817032175,CD80;T-lymphocyte activation antigen CD80,1.32824359369628,1.19409045069763,1.4774685143529,1.73885129566067e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.05584108904014,CD80;T-lymphocyte activation antigen CD80,1.28619330623006,1.20421358617008,1.37375399180836,6.88385229440838e-14
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.681922196796338,CD80;T-lymphocyte activation antigen CD80,1.38801818735852,1.23976180730782,1.55400374255898,1.2771450321499e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.21015121750651,CD80;T-lymphocyte activation antigen CD80,3.06303895633931,2.53877011793241,3.69557195501147,1.48319637883374e-31
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.265482674966814,CD80;T-lymphocyte activation antigen CD80,1.61684305323244,1.35155035828716,1.93420943789249,1.48487596438224e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100472678281917,CD80;T-lymphocyte activation antigen CD80,4.02525831512957,3.12276274394735,5.18858005941194,5.84787100229494e-27
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.225807107838151,LAMP2;Lysosome-associated membrane glycoprotein 2,1.83966619787987,1.5269636432966,2.21640622190269,1.42671917879976e-10
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103717562840641,LAMP2;Lysosome-associated membrane glycoprotein 2,2.18907063268918,1.66890523049343,2.87136150534168,1.51448894017139e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546339525181285,THOP1;Thimet oligopeptidase,0.698689644830873,0.619772479645866,0.787655528159021,4.53728475403477e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223922003804692,THOP1;Thimet oligopeptidase,1.71126264011342,1.42103444926979,2.06076624317781,1.46405046228443e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104989996236207,THOP1;Thimet oligopeptidase,2.29421726300646,1.75935431127314,2.99168440157346,8.7131127308025e-10
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24549108115064,CD4;T-cell surface glycoprotein CD4,1.63964349669605,1.37914010508042,1.94935292386474,2.12527670296877e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.514393115045998,CD4;T-cell surface glycoprotein CD4,1.37729033543579,1.22054206265088,1.55416902549423,2.07059658104276e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13141057385654,CD4;T-cell surface glycoprotein CD4,1.22755985100382,1.15629799593111,1.30321352549184,1.82565304561591e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.539500565285518,CD4;T-cell surface glycoprotein CD4,2.35391981194457,2.09920210414205,2.63954503005309,1.32925913795664e-48
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0632786236899347,CD4;T-cell surface glycoprotein CD4,2.54173802197922,1.82397825090701,3.54194583688829,3.58983365226798e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34553176288475,CD4;T-cell surface glycoprotein CD4,1.40951413135104,1.30770054797955,1.5192546103524,2.88568993096111e-19
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.62018169890463,CD4;T-cell surface glycoprotein CD4,1.25770409277532,1.17432442265729,1.3470039066414,5.69806727224197e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.789661177960734,CD4;T-cell surface glycoprotein CD4,1.41620727840491,1.28407958081958,1.56193049509198,3.31285729874743e-12
sensitivity,Circulatory system disorders,I50 (heart failure),4.39172336732047,CD4;T-cell surface glycoprotein CD4,1.25582982360863,1.20425992929303,1.30960808999993,1.78700448809348e-26
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21067455287987,CD4;T-cell surface glycoprotein CD4,1.20095208676276,1.15043569919293,1.25368668210805,6.73812725402631e-17
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.05616751017167,CD4;T-cell surface glycoprotein CD4,1.2111458640185,1.13954112234319,1.28724999490396,7.2248048131918e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.800301103385432,CD4;T-cell surface glycoprotein CD4,1.32442897542236,1.20139099071318,1.4600676420064,1.62076048829453e-08
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.39013763738984,CD4;T-cell surface glycoprotein CD4,1.41793222755668,1.23350296016425,1.62993674670723,9.02415967783155e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.683886058635796,CD4;T-cell surface glycoprotein CD4,1.30841132291786,1.177594909238,1.45375984263335,5.68594125919846e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.251434318498708,SHISA5;Protein shisa-5,1.84222324709533,1.53729006152648,2.20764225117578,3.64836935850706e-11
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518489755830154,SHISA5;Protein shisa-5,1.5415163851655,1.35510702998118,1.75356832571868,4.6712042456334e-11
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04674350530552,SHISA5;Protein shisa-5,1.2826414644642,1.20094463710763,1.36989589322378,1.23410577904601e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.386586146948485,SHISA5;Protein shisa-5,4.35519177663428,3.83365911533722,4.94767396907548,3.48709659215578e-113
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0479408273217057,SHISA5;Protein shisa-5,2.97134969283939,2.02469666202993,4.36061320330573,2.63256899401562e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0433829573477029,SHISA5;Protein shisa-5,3.02479949723391,2.02570890346328,4.51664697865723,6.26997204496113e-08
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.9663300452213,SHISA5;Protein shisa-5,1.24711174395229,1.17951053059428,1.31858738142856,8.08366077232846e-15
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36612648130744,SHISA5;Protein shisa-5,1.69997720768991,1.5700870406649,1.8406129289758,4.0512209124797e-39
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60235072656734,SHISA5;Protein shisa-5,1.27129665001329,1.18015864917939,1.36947280220234,2.54173114801949e-10
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.68598524762908,SHISA5;Protein shisa-5,1.26082739918072,1.17257954445468,1.35571675119415,3.84350075267194e-10
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.691534427881202,SHISA5;Protein shisa-5,1.36563017145,1.21973938793681,1.52897068309741,6.44704089512842e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.754009962071014,SHISA5;Protein shisa-5,1.4860823161885,1.33411780721695,1.65535654988004,6.12842466785606e-13
sensitivity,Circulatory system disorders,I50 (heart failure),4.31967930700824,SHISA5;Protein shisa-5,1.39107946647307,1.32862428890671,1.45647049974929,4.789547100484e-45
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.09537297146704,SHISA5;Protein shisa-5,1.28379953620584,1.2246302025158,1.34582770029393,3.15120705241308e-25
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.0482976675984,SHISA5;Protein shisa-5,1.26535981281859,1.18469428529342,1.35151783525294,2.50801501782721e-12
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.61855670103092,SHISA5;Protein shisa-5,1.22826178374035,1.15869914890633,1.302000619247,4.78740611711692e-12
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.752034378714455,SHISA5;Protein shisa-5,1.5812469891405,1.42053676790908,1.76013891167787,5.32527110824201e-17
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.772889417360285,SHISA5;Protein shisa-5,1.55630058843341,1.3994907506662,1.73068062107964,3.27357135319091e-16
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06756037137366,SHISA5;Protein shisa-5,1.32495956334225,1.24021416823483,1.41549571796191,7.20221775126386e-17
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402368487231659,SHISA5;Protein shisa-5,1.56934541683928,1.35469119140404,1.81801214400892,1.91101537512581e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.688755663356368,SHISA5;Protein shisa-5,1.62054650557011,1.44893172324909,1.81248773463704,2.83991014602694e-17
sensitivity,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.63976668462601,SHISA5;Protein shisa-5,1.21079490713408,1.12396154299631,1.30433671532357,4.71063517395546e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214705009022178,SHISA5;Protein shisa-5,1.76482118411524,1.44713981498374,2.15224111703188,2.02361990590007e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.51562571703914,SHISA5;Protein shisa-5,1.29614794423802,1.23971223217978,1.35515279251421,3.3062002072371e-30
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105032423052333,SHISA5;Protein shisa-5,2.01637499500399,1.52406174859058,2.66771876155101,9.08997813830263e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.387399090656026,SERPINF1;Pigment epithelium-derived factor,2.70078400738639,2.34586844185372,3.10939612998509,1.88252654277422e-43
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248672758491385,NRCAM;Neuronal cell adhesion molecule,1.55944056159699,1.30902660586215,1.85775816493224,6.5200266806646e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,NRCAM;Neuronal cell adhesion molecule,1.3220056915706,1.22611274356253,1.42539832305065,3.70829843423191e-13
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222866497051456,NRCAM;Neuronal cell adhesion molecule,2.49703687139547,2.07784437272832,3.00079891398284,1.67691423073378e-22
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104495268138801,NRCAM;Neuronal cell adhesion molecule,4.05544253913293,3.12210933167142,5.26778931838503,9.44975980230051e-26
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33402460667211,CDCP1;CUB domain-containing protein 1,1.34725890810057,1.25182249139539,1.44997120433031,1.84244842869125e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.40073780023256,CDCP1;CUB domain-containing protein 1,1.21551145038111,1.16689087171461,1.26615789172867,7.23108847971484e-21
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80001592071484,CDCP1;CUB domain-containing protein 1,1.31651832953235,1.1980984623657,1.44664279809885,1.07637330563027e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216673955392994,CDCP1;CUB domain-containing protein 1,2.43694393102774,2.06837815308271,2.87118470774887,1.80867550489791e-26
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0993601208219069,CDCP1;CUB domain-containing protein 1,3.29615031440618,2.62460706941871,4.13951750025812,1.05343620106224e-24
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212965129885326,GLA;Alpha-galactosidase A,1.6858328800931,1.37674749948251,2.06430917845956,4.32720662822422e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220030647125849,SSC5D;Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D,1.71122166702712,1.42503598711653,2.05488115400387,8.75370021046395e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102122979634321,SSC5D;Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D,2.05367045168874,1.57306594146546,2.6811096807616,1.22013015068757e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534531980805442,PXN;Paxillin,1.43424229938209,1.27220694382335,1.61691537947026,3.72390527248922e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549526304386362,CD163;Scavenger receptor cysteine-rich type 1 protein M130,1.33116174044185,1.18483706914495,1.49555717436741,1.47450307945202e-06
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802501917743553,CD163;Scavenger receptor cysteine-rich type 1 protein M130,1.29530589770233,1.17629906994841,1.42635271206669,1.42369092552763e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220030647125849,CD163;Scavenger receptor cysteine-rich type 1 protein M130,2.99013187421998,2.50926446898232,3.56315116869785,1.80017801210286e-34
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.273573579483949,CD163;Scavenger receptor cysteine-rich type 1 protein M130,1.64169488608146,1.39466550051703,1.93247922027675,2.55218815326219e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102122979634321,CD163;Scavenger receptor cysteine-rich type 1 protein M130,4.97405488613483,3.87467395783934,6.38536875089186,2.44701028820663e-36
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,IFNLR1;Interferon lambda receptor 1,1.37519741833197,1.22075803038073,1.54917509639244,1.58957957604047e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.219246266887888,IFNLR1;Interferon lambda receptor 1,1.63920435012662,1.36258410611993,1.97198168495114,1.59932852281845e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249759452985853,CD59;CD59 glycoprotein,1.66822777466328,1.3976121533445,1.99124192036989,1.45345015339904e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12412945514133,CD59;CD59 glycoprotein,1.23370589971792,1.15781713075206,1.31456877478585,8.93905597092018e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.553812073103193,CD59;CD59 glycoprotein,4.09835579981566,3.70998615249975,4.52738085034775,1.00513339905187e-169
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0674777630099171,CD59;CD59 glycoprotein,2.99871701922122,2.19707166364404,4.09285864915868,4.52947214667698e-12
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0593216871906067,CD59;CD59 glycoprotein,3.01362233778521,2.15586048588765,4.21266573335732,1.08219967514307e-10
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.97868473231989,CD59;CD59 glycoprotein,1.23634166771495,1.15760616909943,1.32043242350491,2.62913790916488e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34813477243813,CD59;CD59 glycoprotein,1.37796047049762,1.27312460067568,1.49142908498216,2.00565859788305e-15
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781729627962182,CD59;CD59 glycoprotein,1.49583328912669,1.34831265134158,1.65949435142748,2.93045022926601e-14
sensitivity,Circulatory system disorders,I50 (heart failure),4.41674234293734,CD59;CD59 glycoprotein,1.28247329120944,1.22649441063199,1.3410071243766,8.68355099760921e-28
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771845057734829,CD59;CD59 glycoprotein,1.3380769262281,1.2049608441261,1.48589879018232,5.11285840419598e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.807095888727287,CD59;CD59 glycoprotein,1.35395003145856,1.22147969371621,1.50078687113447,8.00868165489815e-09
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409584271963956,CD59;CD59 glycoprotein,1.51148213447223,1.30908162681302,1.74517630989182,1.78425377357941e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.711284206210925,CD59;CD59 glycoprotein,1.38216344011063,1.23943315416226,1.54133021919176,5.88911978039736e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220949263502454,CD59;CD59 glycoprotein,1.65219248786706,1.36282211561672,2.00300537075527,3.20424087408272e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.80585417994203,CD59;CD59 glycoprotein,1.22159689998219,1.17080250983141,1.27459496671302,2.52760361487814e-20
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.532599441661551,FOLR1;Folate receptor alpha,3.56611965628423,3.20395435129453,3.96922303146998,8.89960079549392e-120
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.057270375417185,FOLR1;Folate receptor alpha,2.66644238328395,1.92363832749671,3.69607679455281,3.93545932278813e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3452737106968,FOLR1;Folate receptor alpha,1.41829089846299,1.31523473898855,1.52942209708504,1.09332940486337e-19
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60371553897147,FOLR1;Folate receptor alpha,1.29674722345868,1.20952394194159,1.39026050104347,2.5861997264861e-13
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.770476905448654,FOLR1;Folate receptor alpha,1.38797576006902,1.25829348985827,1.53102334714945,5.72321278773209e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.39415971157102,FOLR1;Folate receptor alpha,1.25172848662555,1.1999352674602,1.30575727434553,2.14610024522963e-25
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71796192476079,FOLR1;Folate receptor alpha,1.21265007965071,1.14950698416467,1.27926166255134,1.58546675686464e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.798908422155866,FOLR1;Folate receptor alpha,1.37469880477634,1.24765401213603,1.51468018013912,1.25768154074078e-10
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13613613613613,FOLR1;Folate receptor alpha,1.27961334374378,1.20432078924233,1.35961308989548,1.60242237163627e-15
sensitivity,Circulatory system disorders,I95 (hypotension),4.82379553932851,FOLR1;Folate receptor alpha,1.2509030576245,1.20144964134994,1.30239204850582,1.47376745818293e-27
sensitivity,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0948241801659423,FOLR1;Folate receptor alpha,1.9563379536834,1.49497935940989,2.56007426787006,1.0072620090589e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,CALB1;Calbindin,2.97738833944005,2.66010593394708,3.33251439752999,2.6103846904609e-80
sensitivity,Circulatory system disorders,I50 (heart failure),4.3326119987108,SHBG;Sex hormone-binding globulin,1.20535487566386,1.14762359087702,1.2659903367587,8.7482883166706e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212294838724404,SHBG;Sex hormone-binding globulin,2.16615050241859,1.75064352636077,2.68027609760305,1.13104893452267e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107252065172744,SHBG;Sex hormone-binding globulin,2.39542660735426,1.77727147014645,3.22858309920877,9.68317342347632e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36736343688647,APCS;Serum amyloid P-component,0.740894286984169,0.679429017011272,0.807920078097979,1.14502502559537e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214063758775463,APCS;Serum amyloid P-component,0.550883704108631,0.444066109724604,0.68339566746188,5.91216321664625e-08
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.269827725375337,APCS;Serum amyloid P-component,0.56653495865445,0.467425480301965,0.686658885540968,6.97928625901474e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105844454670961,APCS;Serum amyloid P-component,0.344173862257068,0.260685530401119,0.454400546431091,5.29719150486e-14
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34991119005328,LDLR;Low-density lipoprotein receptor,0.77707605644668,0.720425048448086,0.838181846679971,6.55616511629282e-11
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.510807825812559,REN;Renin,1.4203142771644,1.24675176121536,1.61803873767984,1.31743123210588e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,REN;Renin,2.70555302655101,2.37637092037174,3.08033443631529,4.20803269360611e-51
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,REN;Renin,1.43338745534189,1.32200890424391,1.55414959047236,2.68562252952005e-18
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71560867500395,REN;Renin,1.20038975004432,1.11764180734063,1.2892641833434,5.38818659248249e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783222853535353,REN;Renin,1.47921211632721,1.32861915477431,1.64687410777312,8.88425904272283e-13
sensitivity,Circulatory system disorders,I50 (heart failure),4.4281764109093,REN;Renin,1.28186316552628,1.22513950619264,1.34121311640625,5.72546613980329e-27
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80173775671406,REN;Renin,1.61567911216526,1.45279600152204,1.79682418643242,8.85995089957539e-19
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13901605261579,REN;Renin,1.34317556479786,1.25937644743248,1.43255068930989,2.79683501714385e-19
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.711378097458799,REN;Renin,1.46592450574628,1.31104837365758,1.63909639012964,1.89587838254993e-11
sensitivity,Circulatory system disorders,I95 (hypotension),4.77973961120028,REN;Renin,1.24241334575101,1.19045688515327,1.29663740111132,2.3106111624837e-23
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,NECTIN4;Nectin-4,5.35993315644653,4.74088400140208,6.05981572910844,2.28854299126732e-158
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0648482942933501,NECTIN4;Nectin-4,2.71508310014936,1.91274033061222,3.85398693316471,2.28719357740016e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0570103011716599,NECTIN4;Nectin-4,3.32341734168367,2.27976067943912,4.84485188582213,4.23660703110587e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34111707163142,NECTIN4;Nectin-4,1.28925550395406,1.19406627806618,1.39203307639488,8.45643260060413e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774843163090719,NECTIN4;Nectin-4,1.35674293751435,1.22687663458213,1.50035573798505,2.79808239156667e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.41395173603537,NECTIN4;Nectin-4,1.22583296900703,1.17465070784809,1.27924536022918,8.17553817394631e-21
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.799212598425196,NECTIN4;Nectin-4,1.35383046212496,1.22579826835755,1.4952353641626,2.27869165937208e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13639443580852,NECTIN4;Nectin-4,1.23518198485153,1.16193491792696,1.31304646427509,1.27062403125996e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405400086590309,NECTIN4;Nectin-4,1.41375754810334,1.22989099393034,1.62511183079073,1.11095639825582e-06
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705196391285506,NECTIN4;Nectin-4,1.31538341401852,1.18352325038761,1.4619345461176,3.65055860552683e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.82351314515969,NECTIN4;Nectin-4,1.22498866694339,1.17627392549125,1.27572090277616,1.11053040700177e-22
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11816295368231,MSR1;Macrophage scavenger receptor types I and II,1.2011683759346,1.13213711053063,1.27440877427746,1.2815101052696e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.535105256968128,MSR1;Macrophage scavenger receptor types I and II,1.60968974415434,1.43427145274272,1.80656253562097,6.15441146655643e-16
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33958341505511,MSR1;Macrophage scavenger receptor types I and II,1.40127139028136,1.30125739930232,1.50897240643845,4.26237769204069e-19
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70861368852619,MSR1;Macrophage scavenger receptor types I and II,1.20018744667036,1.12369159168206,1.28189079442065,5.61693055423106e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778423204052494,MSR1;Macrophage scavenger receptor types I and II,1.40309870047184,1.27412388873795,1.54512915162103,5.81036609357339e-12
sensitivity,Circulatory system disorders,I50 (heart failure),4.40956062159817,MSR1;Macrophage scavenger receptor types I and II,1.27487479137874,1.2235533064569,1.32834893675328,4.96641074713803e-31
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.772827767016884,MSR1;Macrophage scavenger receptor types I and II,1.27862510939152,1.15976726420778,1.40966400830709,7.91376381664516e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.796758153557026,MSR1;Macrophage scavenger receptor types I and II,1.42323853211515,1.29380819812519,1.56561685281676,4.0128866510277e-13
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12466554355366,MSR1;Macrophage scavenger receptor types I and II,1.22857661366464,1.15739531467029,1.3041356540083,1.37902294541104e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703259677166588,MSR1;Macrophage scavenger receptor types I and II,1.37788924781176,1.24433954984718,1.52577226968993,7.15252291434988e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220940463388405,MSR1;Macrophage scavenger receptor types I and II,2.8159879243061,2.38089835062742,3.33058653585447,1.18872133073574e-33
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.270312622424194,MSR1;Macrophage scavenger receptor types I and II,1.55277212221246,1.32040988578597,1.82602484991619,1.0342911519404e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.78332613051506,MSR1;Macrophage scavenger receptor types I and II,1.20615473792808,1.15933978575314,1.25486011064588,1.69240274963368e-20
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101639921033599,MSR1;Macrophage scavenger receptor types I and II,4.09184512274767,3.23991369291217,5.1677909029436,2.74874138760025e-32
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248818681945807,B2M;Beta-2-microglobulin,1.64199349491739,1.37046656832059,1.96731733533272,7.56852794279995e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513253341849537,B2M;Beta-2-microglobulin,1.51470386012139,1.33353978166985,1.72047944531036,1.67267184682157e-10
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04179513532031,B2M;Beta-2-microglobulin,1.29196780261501,1.21069123248494,1.37870066141296,1.09909984242844e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.390642847352309,B2M;Beta-2-microglobulin,3.3512623587677,2.94401584210872,3.81484339746242,9.18526190018528e-75
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0433265683077554,B2M;Beta-2-microglobulin,2.69156034673849,1.79931017580451,4.02626361899825,1.44450321973295e-06
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96897665060128,B2M;Beta-2-microglobulin,1.2030084041259,1.13847361585732,1.27120137018522,5.030827324809e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36882825554512,B2M;Beta-2-microglobulin,1.56000422917376,1.44275020282127,1.68678762982057,6.81711222125613e-29
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59337888027878,B2M;Beta-2-microglobulin,1.25970574140246,1.17016811992547,1.3560945029193,8.38978732108675e-10
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.68840082361015,B2M;Beta-2-microglobulin,1.21681680466826,1.13238626313921,1.30754247408338,8.86638804414675e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.757575757575757,B2M;Beta-2-microglobulin,1.43207882408421,1.28793517068422,1.59235480563894,3.24706592632924e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.3090160351531,B2M;Beta-2-microglobulin,1.33703452135739,1.27810937046581,1.39867632036049,1.43551919898893e-36
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.09189966151991,B2M;Beta-2-microglobulin,1.23287433019545,1.17671625758242,1.29171251290238,1.35408528491379e-18
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.04333798595062,B2M;Beta-2-microglobulin,1.26805588090876,1.18806999912718,1.35342674950851,9.06926805770864e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.746473085878646,B2M;Beta-2-microglobulin,1.40180327062623,1.25981078103497,1.55979964540709,5.69717667862798e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.765049785329313,B2M;Beta-2-microglobulin,1.45301254477227,1.30771466967136,1.61445421102156,3.63291170515903e-12
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06473988439306,B2M;Beta-2-microglobulin,1.34904649082653,1.26415692045408,1.43963649208808,1.73463680211733e-19
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404128042376364,B2M;Beta-2-microglobulin,1.48433708385698,1.28427082175231,1.71557006606038,8.94236978712937e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.676416819012797,B2M;Beta-2-microglobulin,1.50400273014431,1.34539301841326,1.68131109744375,7.08494412261933e-13
sensitivity,Circulatory system disorders,I95 (hypotension),4.53732985013062,B2M;Beta-2-microglobulin,1.22036955691177,1.16790534059181,1.2751905515582,6.51034118208222e-19
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804820836366577,BAIAP2;Brain-specific angiogenesis inhibitor 1-associated protein 2,1.30218668751265,1.17921812155832,1.43797838426561,1.81576939409935e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212074084546868,BAIAP2;Brain-specific angiogenesis inhibitor 1-associated protein 2,2.25693431300136,1.86486775319343,2.73142826588123,6.21829819567688e-17
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100959111559818,BAIAP2;Brain-specific angiogenesis inhibitor 1-associated protein 2,3.22565464658507,2.46179997644686,4.22652043162875,2.00032695489224e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.554905963257298,RETN;Resistin,3.07664864336476,2.75512407568942,3.43569531341327,1.33519457299881e-88
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.06322736164075,RETN;Resistin,2.72031430508629,1.96093375217827,3.77376844589311,2.06935206461608e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0573213156230233,RETN;Resistin,2.52328821352972,1.78485730784913,3.56722264605602,1.6094404960164e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35231598984771,RETN;Resistin,1.32715274972499,1.23160504000721,1.43011303452629,1.13217561749015e-13
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781095511172632,RETN;Resistin,1.29170222906795,1.17138932992743,1.42437241483365,2.87984052416938e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.41874376869391,RETN;Resistin,1.23904308097086,1.18858880054588,1.29163908981531,5.24207761847031e-24
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771559142975844,RETN;Resistin,1.32523189907744,1.20101444914739,1.46229680049159,2.05195900845623e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.542652924858768,CFC1;Cryptic protein,1.97999933048091,1.76027532874602,2.22715008537765,5.12953694491591e-30
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220875684128225,PLTP;Phospholipid transfer protein,1.74453835481126,1.45668850424122,2.0892689566414,1.46155178391175e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103562147058248,PLTP;Phospholipid transfer protein,2.15688895214767,1.66681465254696,2.79105414917488,5.06613038641091e-09
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.242476387884002,VEGFD;Vascular endothelial growth factor D,1.59588706082147,1.34177607488112,1.89812261417989,1.2754498689563e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11908349149822,VEGFD;Vascular endothelial growth factor D,1.26192092368201,1.18949139885425,1.33876076713152,1.22138161792599e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544670846394984,VEGFD;Vascular endothelial growth factor D,1.77478241167375,1.58572414411347,1.98638118772386,1.81949067568931e-23
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0625048831939995,VEGFD;Vascular endothelial growth factor D,2.19986499529581,1.59528819008496,3.03356222882217,1.51932842453143e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34083468919687,VEGFD;Vascular endothelial growth factor D,1.49071639480134,1.38466440706476,1.60489094569872,2.86980811951127e-26
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61822466614296,VEGFD;Vascular endothelial growth factor D,1.36078681061121,1.27146613321586,1.45638227834657,5.92807039401845e-19
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37118350645262,VEGFD;Vascular endothelial growth factor D,1.22317536030983,1.13628346872907,1.31671189737762,8.40342280803361e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.41904011037745,VEGFD;Vascular endothelial growth factor D,1.22975458516283,1.18005605765871,1.28154618580533,8.69984332501408e-23
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23206834889727,VEGFD;Vascular endothelial growth factor D,1.2114003911427,1.16137634861637,1.26357912265822,4.96283196782874e-19
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804195120042264,VEGFD;Vascular endothelial growth factor D,1.29465984499391,1.17746303272196,1.423521645826,9.58736113345106e-08
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13351822503962,VEGFD;Vascular endothelial growth factor D,1.21551706474002,1.14520041947431,1.29015123427252,1.36903987108858e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220892954883102,PLAT;Tissue-type plasminogen activator,2.03513568414283,1.70072020108873,2.43530784794591,8.61541525486088e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103570242119867,PLAT;Tissue-type plasminogen activator,2.6158996563833,2.02628380992274,3.37708418670491,1.59076831488624e-13
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00992098853442,CA6;Carbonic anhydrase 6,0.7981535488056,0.728832226930214,0.87406822027365,1.15346280236251e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34523809523809,CA6;Carbonic anhydrase 6,0.767828794547001,0.709571799663264,0.830868783138343,5.29794588461611e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773935591140317,CA6;Carbonic anhydrase 6,0.758516287681325,0.683782353563989,0.841418260765363,1.76388584315216e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80804879980987,CA6;Carbonic anhydrase 6,0.758997728657186,0.68578475821635,0.840026765256611,9.91532451901909e-08
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07539658962628,CA6;Carbonic anhydrase 6,0.769418546516621,0.704773879518927,0.839992679819302,4.79549653491723e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,CD300LG;CMRF35-like molecule 9,3.6411326553411,3.23517524192485,4.09803056167777,7.5821078939296e-102
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.065040009460365,CD300LG;CMRF35-like molecule 9,2.63875207466183,1.90700487825531,3.65128196101023,4.75037353823614e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,CD300LG;CMRF35-like molecule 9,1.30747678593878,1.21022292007393,1.41254600075197,1.05928307357101e-11
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60328187241126,CD300LG;CMRF35-like molecule 9,1.21709021206608,1.13368423973563,1.30663242231584,5.82370141058745e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,CD300LG;CMRF35-like molecule 9,1.20258886449752,1.15185459863429,1.25555775766157,4.92807000985226e-17
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.515071700321919,PGF;Placenta growth factor,1.39934802830868,1.23705041450838,1.58293864289241,9.18567857563225e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1175183622441,PGF;Placenta growth factor,1.25352055942515,1.17800009580285,1.33388256800661,1.02471338424403e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543765281173594,PGF;Placenta growth factor,3.42245960899052,3.12346265554255,3.75007837996287,2.41148033196163e-153
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0643513192020436,PGF;Placenta growth factor,2.63748733179522,1.9430669348672,3.58008224037619,4.94590319461836e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.054622422504438,PGF;Placenta growth factor,2.99378724054931,2.17719598314824,4.1166537652323,1.50124738795577e-11
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97233961583912,PGF;Placenta growth factor,1.2777826258944,1.2112430431664,1.34797755764141,2.61885200810166e-19
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01759799996093,PGF;Placenta growth factor,1.37957318036735,1.26179989721543,1.5083391306252,1.57780109814505e-12
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.70014172909495,PGF;Placenta growth factor,1.20430198716212,1.16677708837732,1.24303373003294,1.17019923379267e-30
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00716987078474,PGF;Placenta growth factor,1.20192489082104,1.12727742170716,1.28151545959948,1.88619992481497e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34056127441387,PGF;Placenta growth factor,1.60459353125972,1.48770462280066,1.73066639781862,1.60830615656839e-34
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61555956395576,PGF;Placenta growth factor,1.2757711045178,1.18853214689554,1.36941345286608,1.59236556371505e-11
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69518067572329,PGF;Placenta growth factor,1.22221568020573,1.13981334886385,1.31057525377271,1.75507017370543e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774800444973555,PGF;Placenta growth factor,1.50785385611316,1.36226534172792,1.66900175887278,2.23828861318532e-15
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3708853798413,PGF;Placenta growth factor,1.21022408161862,1.119867213919,1.30787142397365,1.43910330684463e-06
sensitivity,Circulatory system disorders,I50 (heart failure),4.41755214482487,PGF;Placenta growth factor,1.34534684691642,1.28820126367733,1.40502745148782,6.43313902111472e-41
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22940347953738,PGF;Placenta growth factor,1.22833424386987,1.17463264139147,1.28449096466112,1.93606435996748e-19
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06290489890983,PGF;Placenta growth factor,1.2443183488983,1.16822584182359,1.3253671490335,1.12575643695988e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.7731807798192,PGF;Placenta growth factor,1.38674810543164,1.25241632845162,1.5354880515617,3.18168533076549e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804813252070636,PGF;Placenta growth factor,1.64809541897485,1.4942058469482,1.81783421313306,1.69217804295794e-23
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07432366442035,PGF;Placenta growth factor,1.30456262612012,1.19421012358327,1.425112391748,3.72774070001141e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13590696938533,PGF;Placenta growth factor,1.28235014815441,1.20486313055739,1.36482050181991,5.26652805010256e-15
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406226197683729,PGF;Placenta growth factor,1.5743423229757,1.36931331592218,1.81007058143103,1.82852394378127e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699792798780249,PGF;Placenta growth factor,1.53350371477378,1.37973945010899,1.7044041489422,2.17394481298524e-15
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0429058995611896,PGF;Placenta growth factor,2.70834107403935,1.84928064458338,3.96646739088168,3.08519378043764e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212666328481679,PGF;Placenta growth factor,2.14931621444158,1.79687684490929,2.57088303115992,5.59985754065591e-17
sensitivity,Circulatory system disorders,I95 (hypotension),4.78309450532217,PGF;Placenta growth factor,1.29822121398841,1.24558654063246,1.35308006747872,4.32871677491655e-35
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103374292958845,PGF;Placenta growth factor,2.67957207373755,2.10796713074554,3.40617573852526,8.16982153931238e-16
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,FGFR2;Fibroblast growth factor receptor 2,2.41909225133747,2.14656793467637,2.72621575396975,1.48184681976856e-47
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34111707163142,FGFR2;Fibroblast growth factor receptor 2,1.2166206041606,1.12642724473829,1.31403577228994,6.06088654882531e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.799212598425196,FGFR2;Fibroblast growth factor receptor 2,1.29176484325626,1.16906081880138,1.42734781923811,4.97407123519211e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216284236811577,FGFR2;Fibroblast growth factor receptor 2,3.61004684799226,3.02002843235099,4.31533627468319,3.84688290477438e-45
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.269855026788528,FGFR2;Fibroblast growth factor receptor 2,1.6328047840561,1.37489116494214,1.93910000356188,2.27755971925033e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100241759537708,FGFR2;Fibroblast growth factor receptor 2,4.87685049793905,3.80829920188614,6.24522116525639,3.63805659973255e-36
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543765281173594,CLEC7A;C-type lectin domain family 7 member A,3.34471000303326,2.96389531697064,3.77445348367596,2.41356037742734e-85
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0643513192020436,CLEC7A;C-type lectin domain family 7 member A,3.0851434069268,2.20365555858966,4.31923664485727,5.29782522069593e-11
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.054622422504438,CLEC7A;C-type lectin domain family 7 member A,3.68147833929772,2.5638201595835,5.28636250559792,1.66408821543602e-12
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34056127441387,CLEC7A;C-type lectin domain family 7 member A,1.34128616188706,1.2428828264384,1.44748043001373,4.25426462302515e-14
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774800444973555,CLEC7A;C-type lectin domain family 7 member A,1.30082688020797,1.17744552935944,1.43713703103715,2.30778240086524e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.41755214482487,CLEC7A;C-type lectin domain family 7 member A,1.24044411434641,1.18909708853643,1.29400838304173,1.69261554424571e-23
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.7731807798192,CLEC7A;C-type lectin domain family 7 member A,1.28126263371092,1.15961492814966,1.41567161364792,1.11894941975701e-06
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13590696938533,CLEC7A;C-type lectin domain family 7 member A,1.23631181384157,1.16351669726025,1.31366133777309,7.32041239261156e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406226197683729,CLEC7A;C-type lectin domain family 7 member A,1.49349440495881,1.30104048859397,1.71441669740331,1.20632571159033e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699792798780249,CLEC7A;C-type lectin domain family 7 member A,1.42761213428176,1.28476893501446,1.58633692830189,3.62802218151915e-11
sensitivity,Circulatory system disorders,I95 (hypotension),4.78309450532217,CLEC7A;C-type lectin domain family 7 member A,1.20346259630446,1.15584858056892,1.25303802336375,2.42725077157737e-19
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.532745844181854,PIGR;Polymeric immunoglobulin receptor,1.92553130175603,1.70176438452987,2.17872158316825,2.61023381984199e-25
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34661242811053,PIGR;Polymeric immunoglobulin receptor,1.50873870613856,1.39563424960258,1.63100933073895,4.44014170664854e-25
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783373301358912,PIGR;Polymeric immunoglobulin receptor,1.47703107986277,1.33487229921321,1.63432922547457,4.22094709148317e-14
sensitivity,Circulatory system disorders,I50 (heart failure),4.40275650842266,PIGR;Polymeric immunoglobulin receptor,1.26940139411,1.21625867029403,1.32486611501719,8.05637580266522e-28
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775643204126102,PIGR;Polymeric immunoglobulin receptor,1.32539391102132,1.19746588376821,1.46698878288246,5.33713860169208e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.806112855799811,PIGR;Polymeric immunoglobulin receptor,1.63622050168441,1.4800733862683,1.80884107164607,6.45400100664136e-22
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11624139327663,PIGR;Polymeric immunoglobulin receptor,1.29456542760475,1.21693197282356,1.3771514626746,2.78371092476521e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405943167956486,PIGR;Polymeric immunoglobulin receptor,1.42369732553838,1.23738118402147,1.63806763907439,7.96016528889297e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.696571188374467,PIGR;Polymeric immunoglobulin receptor,1.63352889223343,1.4663629395203,1.81975182940337,5.13035131305311e-19
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.217756113153268,PIGR;Polymeric immunoglobulin receptor,3.43387302836579,2.86888908379337,4.11012194286256,3.04165996926371e-41
sensitivity,Circulatory system disorders,I95 (hypotension),4.80300262930774,PIGR;Polymeric immunoglobulin receptor,1.21700416172401,1.16835556945391,1.26767840918996,3.89063931997392e-21
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101855365381158,PIGR;Polymeric immunoglobulin receptor,4.80750907884598,3.78615264721991,6.1043876717853,5.41250084483182e-38
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13350705400948,LCN2;Neutrophil gelatinase-associated lipocalin,1.21761391013851,1.14528615952304,1.2945093432197,2.94518734916466e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.558545335942596,LCN2;Neutrophil gelatinase-associated lipocalin,3.60235213893666,3.23236606036114,4.01468790680585,7.58421005257722e-119
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0609644577211485,LCN2;Neutrophil gelatinase-associated lipocalin,2.74651286518995,1.94239786941699,3.8835158529689,1.08798920746521e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0589562707109313,LCN2;Neutrophil gelatinase-associated lipocalin,2.87870765124353,2.02470958242016,4.09291179993455,3.89056488383954e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34391059629659,LCN2;Neutrophil gelatinase-associated lipocalin,1.3481336010667,1.24807991855846,1.45620819572536,3.14155600012977e-14
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60993748212315,LCN2;Neutrophil gelatinase-associated lipocalin,1.22368402600931,1.14025699345597,1.31321500688361,2.10514925237077e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783013687486017,LCN2;Neutrophil gelatinase-associated lipocalin,1.31788725570959,1.19111454329035,1.45815264245195,8.84005823293119e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.41372520868798,LCN2;Neutrophil gelatinase-associated lipocalin,1.2699698759411,1.21648809291448,1.32580293649552,1.32814780786487e-27
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.779278912671929,LCN2;Neutrophil gelatinase-associated lipocalin,1.29849053793478,1.17354700900041,1.43673637628059,4.18848735272296e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.793860809738026,LCN2;Neutrophil gelatinase-associated lipocalin,1.28463054868589,1.1617707645877,1.42048302205527,1.04236501189343e-06
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13296513065699,LCN2;Neutrophil gelatinase-associated lipocalin,1.21589025638341,1.14319605682878,1.29320697594879,5.14270031548681e-10
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405006614429632,LCN2;Neutrophil gelatinase-associated lipocalin,1.44138780563311,1.25267837665176,1.65852532058625,3.27947772181443e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13036752755967,XCL1;Lymphotactin,1.21216457666348,1.14236382494311,1.28623029619388,2.03687678111348e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,XCL1;Lymphotactin,1.76886051775912,1.57459702777628,1.98709096746218,7.34847227248351e-22
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02392419436939,XCL1;Lymphotactin,1.29403851828103,1.18818543152737,1.40932184687908,3.21960502935521e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,XCL1;Lymphotactin,1.362495049495,1.2646306277101,1.46793278544882,4.17051832569379e-16
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778575480741016,XCL1;Lymphotactin,1.32457921710717,1.20112777684509,1.46071894782142,1.78817361747553e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.41849455578349,XCL1;Lymphotactin,1.21003425732292,1.16099381537188,1.26114617021112,1.68936812952421e-19
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80476199800278,XCL1;Lymphotactin,1.31914434702191,1.19797639059012,1.4525676982855,1.75609532865149e-08
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07882680032893,XCL1;Lymphotactin,1.22849488532858,1.13043412004625,1.33506204078194,1.24372806551631e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213177915550253,XCL1;Lymphotactin,1.77808895680972,1.4766290607182,2.14109313058688,1.26343727584137e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103618839077987,XCL1;Lymphotactin,2.1390680043174,1.64103900188713,2.78824081684388,1.87773116274197e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,SPINK5;Serine protease inhibitor Kazal-type 5,2.86865257702758,2.5347007431901,3.24660322517205,1.58697020690833e-62
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,ADGRG1;Adhesion G-protein coupled receptor G1,1.33477356943636,1.23572830974874,1.44175743778836,2.12766321959387e-13
sensitivity,Circulatory system disorders,I50 (heart failure),4.38493054861596,ADGRG1;Adhesion G-protein coupled receptor G1,1.22791954111165,1.17726696161798,1.28075147659933,1.26119392870355e-21
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,ADGRG1;Adhesion G-protein coupled receptor G1,1.27646687742546,1.15677243306927,1.40854643712513,1.18033221597996e-06
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.09107500644726,ADGRG1;Adhesion G-protein coupled receptor G1,1.2816547681684,1.1798678904025,1.39222277182951,4.16249542210802e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214013950538998,ADGRG1;Adhesion G-protein coupled receptor G1,3.1984204781418,2.60806416161117,3.92240869897814,5.8649080381654e-29
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.27196569658951,ADGRG1;Adhesion G-protein coupled receptor G1,1.63466879892059,1.37784478312503,1.93936364595722,1.74626885558646e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101026108315835,ADGRG1;Adhesion G-protein coupled receptor G1,6.65321819445295,5.00484183803736,8.84449774348082,6.63583198566055e-39
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544986127625842,AGER;Advanced glycosylation end product-specific receptor,2.51326346105894,2.24477904880545,2.8138596660795,1.54409392365222e-57
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12719774256566,MMP12;Macrophage metalloelastase,1.23446799874837,1.16271089690106,1.31065361475103,5.42833573503072e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545325219315577,MMP12;Macrophage metalloelastase,1.91031025581542,1.70185869438206,2.14429393316855,4.79811238356943e-28
sensitivity,Circulatory system disorders,I20 (angina pectoris),4.01511085421741,MMP12;Macrophage metalloelastase,1.23238944519035,1.17862531215601,1.28860608112881,4.25772109068796e-20
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97855119384864,MMP12;Macrophage metalloelastase,1.37671664613653,1.30814917897624,1.44887812048526,1.39362004817753e-34
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02984986288397,MMP12;Macrophage metalloelastase,1.37380268968648,1.26104585623165,1.49664171279995,3.64518702351714e-13
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.73415132924335,MMP12;Macrophage metalloelastase,1.25336041409067,1.21625006630902,1.29160307664099,4.36215319429324e-49
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35420991242116,MMP12;Macrophage metalloelastase,1.33896109063638,1.2419854691503,1.44350867765361,2.75192146149503e-14
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71435350878927,MMP12;Macrophage metalloelastase,1.29090696133045,1.20755226169769,1.38001545412915,6.49607423535405e-14
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.780680137999014,MMP12;Macrophage metalloelastase,1.49965459161876,1.35964498785636,1.65408170092179,5.33464073082206e-16
sensitivity,Circulatory system disorders,I50 (heart failure),4.41696815489206,MMP12;Macrophage metalloelastase,1.30395212210872,1.25061644332104,1.35956243485546,1.30810180840865e-35
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23647294589178,MMP12;Macrophage metalloelastase,1.21728127852424,1.16626962447906,1.27052413948231,2.21839785747456e-19
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.621314029862521,MMP12;Macrophage metalloelastase,1.32650070889484,1.18776730524871,1.48143842899435,5.3599713031513e-07
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.771157525195747,MMP12;Macrophage metalloelastase,1.2853415757248,1.16392578902891,1.41942294075733,7.1086298442489e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805098960080509,MMP12;Macrophage metalloelastase,1.61364273409723,1.4653645506159,1.77692497898244,2.256186157294e-22
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07340173638516,MMP12;Macrophage metalloelastase,1.755165985451,1.61534566444976,1.90708880723281,2.94141718340066e-40
sensitivity,Circulatory system disorders,I72 (other aneurysm),0.329310616816532,MMP12;Macrophage metalloelastase,1.56763018917518,1.34821578650445,1.82275303005088,5.10521565728674e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13174035522346,MMP12;Macrophage metalloelastase,1.345938787237,1.26715168116716,1.42962460288921,4.75933466215578e-22
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406391793253107,MMP12;Macrophage metalloelastase,1.6754395945146,1.46398385078839,1.91743770490062,6.51554183185818e-14
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.693045847648382,MMP12;Macrophage metalloelastase,1.54927338053091,1.39579817938714,1.71962397076315,1.94940312611011e-16
sensitivity,Circulatory system disorders,I95 (hypotension),4.8134801203865,MMP12;Macrophage metalloelastase,1.24999117431241,1.20095159082265,1.30103323714206,8.52495148184861e-28
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543765281173594,KYNU;Kynureninase,0.687931413614399,0.610667156337227,0.774971479841898,7.56065852836579e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212666328481679,KYNU;Kynureninase,2.08331411386013,1.72838127334554,2.51113441457725,1.33971745170576e-14
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103374292958845,KYNU;Kynureninase,3.5634821450337,2.74838957945816,4.62030750403205,8.8556606904728e-22
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.392451766032947,AHNAK;Neuroblast differentiation-associated protein AHNAK,2.17406871184625,1.88817280565934,2.50325327727528,3.6030249434627e-27
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534898109893619,EPHB6;Ephrin type-B receptor 6,3.96197043482273,3.5180936140101,4.46185106158017,3.6298429499585e-114
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0656742556917688,EPHB6;Ephrin type-B receptor 6,2.89420803372501,2.09074517535696,4.0064376286547,1.50284063730682e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0577367205542725,EPHB6;Ephrin type-B receptor 6,3.1869482108798,2.25512483884418,4.50380339211534,5.0871988738678e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.78274378585086,EPHB6;Ephrin type-B receptor 6,1.3064445004751,1.18403189466346,1.44151288534905,1.00825300616966e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.40195999678689,EPHB6;Ephrin type-B receptor 6,1.20781569252959,1.15773296217705,1.26006496729392,2.36509226440275e-18
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.797368683344961,EPHB6;Ephrin type-B receptor 6,1.31144074561256,1.18909380446335,1.44637607461846,5.7619529954381e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702188354046559,EPHB6;Ephrin type-B receptor 6,1.29960235142773,1.17065949813301,1.44274767729651,8.85603057429067e-07
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0457784323872457,EPHB6;Ephrin type-B receptor 6,2.6453849382082,1.79557152715871,3.89740055767785,8.62948361066418e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.80144043212963,EPHB6;Ephrin type-B receptor 6,1.23021808306613,1.181474069372,1.2809731259759,9.70695289295033e-24
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.551751125024457,CXCL16;C-X-C motif chemokine 16,2.57857045759345,2.29743232540946,2.89411162680872,3.41574166447902e-58
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97565374211,CXCL16;C-X-C motif chemokine 16,1.21192307837136,1.15100617393276,1.27606400482689,2.77720342822874e-13
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34677498287168,CXCL16;C-X-C motif chemokine 16,1.26083982805653,1.16901498500568,1.35987741167056,1.88247680168249e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782820888238165,CXCL16;C-X-C motif chemokine 16,1.32058694724258,1.19637099752066,1.45769990148676,3.44220141274234e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.42125984251968,CXCL16;C-X-C motif chemokine 16,1.2152941369619,1.16530552803341,1.26742712859732,9.15261361285473e-20
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80701891511646,CXCL16;C-X-C motif chemokine 16,1.50110473292243,1.36195696132062,1.65446888792814,2.74317808635832e-16
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14243323442136,CXCL16;C-X-C motif chemokine 16,1.26008675918106,1.1861909882595,1.33858599195163,6.49866164452374e-14
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.408282867747606,CXCL16;C-X-C motif chemokine 16,1.45485927307521,1.26929559377153,1.66755128973837,7.23238528527497e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703936176453335,CXCL16;C-X-C motif chemokine 16,1.54709047196269,1.3943393648844,1.71657559753121,1.91331098669699e-16
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97233961583912,CXCL17;C-X-C motif chemokine 17,1.21150517957652,1.15081242289924,1.27539881472868,2.54107071632014e-13
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34056127441387,CXCL17;C-X-C motif chemokine 17,1.37194292320841,1.27168611536874,1.48010374713879,3.14478918926858e-16
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804813252070636,CXCL17;C-X-C motif chemokine 17,1.42518018301635,1.29280080156298,1.57111486286742,1.0552160316494e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699792798780249,CXCL17;C-X-C motif chemokine 17,1.41451966305607,1.27394605875715,1.57060486463947,8.37790481408302e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54854743846169,NECTIN2;Nectin-2,4.43702130170822,3.95348173614435,4.97970127238086,2.54649500178062e-141
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0651478659138468,NECTIN2;Nectin-2,2.8272045594738,2.02884428240126,3.9397235610656,8.31814760929582e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0572737686139748,NECTIN2;Nectin-2,3.11191108120147,2.18646690942302,4.42905883257111,2.89920340332177e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35127102692635,NECTIN2;Nectin-2,1.38988578120334,1.28895159070002,1.49872384558841,1.14128252910726e-17
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60778086542278,NECTIN2;Nectin-2,1.23930401522478,1.1564674047878,1.32807412971062,1.21312173677563e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.784383458795171,NECTIN2;Nectin-2,1.48620225748892,1.34730283997436,1.63942143119597,2.47856990677342e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.42483165318563,NECTIN2;Nectin-2,1.31246514425808,1.25847122011911,1.36877564409407,7.07952844862724e-37
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.0785448204803,NECTIN2;Nectin-2,1.22525820107117,1.15320557516699,1.3018126963831,5.03828218738476e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774841374948113,NECTIN2;Nectin-2,1.42936708066313,1.29461144817046,1.57814937769222,1.54012620190777e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802926925739147,NECTIN2;Nectin-2,1.55710890946123,1.41262091378838,1.7163756619044,4.9907967140372e-19
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13818094456345,NECTIN2;Nectin-2,1.33661465487719,1.25834889118506,1.41974832905839,4.32594253743925e-21
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.415200284708766,NECTIN2;Nectin-2,1.60790041628291,1.40539808025891,1.83958110160964,4.67240435676433e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.712433951435752,NECTIN2;Nectin-2,1.45193059219597,1.30929891249304,1.61010020281808,1.57055904243274e-12
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473858790080556,NECTIN2;Nectin-2,3.2734543600036,2.23266331366349,4.79942648828853,1.24772499040944e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223196650075057,NECTIN2;Nectin-2,2.04697697093379,1.70509937100611,2.45740206745888,1.55065811795376e-14
sensitivity,Circulatory system disorders,I95 (hypotension),4.77097721679765,NECTIN2;Nectin-2,1.28529601194603,1.23447667710334,1.33820741125762,3.34565887236669e-34
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104650014808964,NECTIN2;Nectin-2,2.38425602786459,1.83016682536748,3.10609761231312,1.20261136575939e-10
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243950422978556,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.55717176021288,1.30927764961018,1.85200128599646,5.55842632837013e-07
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.517095613534928,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.41278663514485,1.25341058274212,1.59242797525873,1.52742220697131e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14160581068047,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.26879089839369,1.19584878877019,1.34618219206645,3.25740084656693e-15
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,3.61795818719551,3.23643451602101,4.04445737415627,2.97657976728834e-113
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0648482942933501,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,2.71205826374222,1.96972706884286,3.73415187427637,9.69063231586871e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0570103011716599,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,2.69469109134608,1.9133096672282,3.79518287193908,1.39919655168478e-08
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00678854284523,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.23449106857383,1.16079335046148,1.31286778803711,1.97924993424733e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34111707163142,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.50466756199103,1.39689122617461,1.62075931875387,4.54529626609365e-27
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60828245707624,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.35636775210273,1.26670600056176,1.45237606684449,2.42835550879942e-18
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.674104151062404,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.30615200274958,1.17568906903152,1.45109204399774,6.5396354637986e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774843163090719,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.51505175355541,1.37505942330637,1.66929645151772,4.51844652654918e-17
sensitivity,Circulatory system disorders,I50 (heart failure),4.41395173603537,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.35747110215005,1.30240344260312,1.41486710868131,2.02695523554774e-47
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2462165890326,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.28890625400711,1.23543626872681,1.34469043338892,7.93698461663275e-32
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781111657648794,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.29161846404427,1.17142250279487,1.42414735305133,2.82536354845735e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.799212598425196,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.39636124354424,1.26829270487861,1.53736177380208,1.02928298961173e-11
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13639443580852,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.27902683885302,1.2048351845303,1.35778708615993,6.92518645194908e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405400086590309,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.43685046234992,1.25609878311648,1.6436121735847,1.26393282092184e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705196391285506,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.40823644778102,1.27113143607904,1.56012968963784,5.73534174542025e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216284236811577,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.91806787412174,1.60165645774562,2.29698719219487,1.4312954079588e-12
sensitivity,Circulatory system disorders,I95 (hypotension),4.82351314515969,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.23151842919606,1.18346679531642,1.28152107642701,1.12045123809355e-24
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100241759537708,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,2.24947046629799,1.73244975948392,2.92078737120449,1.17094454431794e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220169901020964,ADAMTS13;A disintegrin and metalloproteinase with thrombospondin motifs 13,1.59739599354737,1.32991878461643,1.91866901176009,5.4614684748072e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103231335579751,ADAMTS13;A disintegrin and metalloproteinase with thrombospondin motifs 13,1.9497077245753,1.49483734073188,2.54299254352815,8.39682518861778e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.21015121750651,TCTN3;Tectonic-3,2.32750806559675,1.88949351680895,2.86706133004724,1.99321587554289e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100472678281917,TCTN3;Tectonic-3,3.03124983886051,2.25095452439705,4.08203519262707,2.81228608342445e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545965160352717,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,2.25332771524919,2.0107587738128,2.52515908841826,2.058485731788e-44
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34797901397103,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,1.20321505175026,1.11649500999832,1.29667078472706,1.2518758602599e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213532891901422,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,2.19368867949069,1.82825531697028,2.63216520026335,2.92144492873633e-17
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103791320695597,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,3.42042936584192,2.66127701795742,4.39613650430621,7.66708633233304e-22
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,TGFBR2;TGF-beta receptor type-2,4.48433486991114,4.02998455960261,4.98990974483631,7.41358610505818e-167
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0648482942933501,TGFBR2;TGF-beta receptor type-2,2.55638757824085,1.86087922644459,3.51184394844912,6.90516327177035e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0570103011716599,TGFBR2;TGF-beta receptor type-2,2.79604397061185,1.99768747000066,3.91345593492275,2.0484886979431e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34111707163142,TGFBR2;TGF-beta receptor type-2,1.31382304357755,1.21843139602366,1.41668295438594,1.27435536108338e-12
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60828245707624,TGFBR2;TGF-beta receptor type-2,1.21274063115249,1.13190670884018,1.29934722266569,4.2403178770594e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774843163090719,TGFBR2;TGF-beta receptor type-2,1.37678671354695,1.24826581003431,1.51854007324554,1.60421970488683e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.41395173603537,TGFBR2;TGF-beta receptor type-2,1.26924567186581,1.21720684397766,1.32350929796419,6.23324857454627e-29
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.05707749048379,TGFBR2;TGF-beta receptor type-2,1.22247511335308,1.15046826315648,1.29898881231838,8.85579487592584e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781111657648794,TGFBR2;TGF-beta receptor type-2,1.38728627488366,1.2578173662776,1.53008160014214,5.80123905574581e-11
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.799212598425196,TGFBR2;TGF-beta receptor type-2,1.3985554244824,1.26938948995102,1.54086455798892,1.16437214981759e-11
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13639443580852,TGFBR2;TGF-beta receptor type-2,1.28437320928756,1.20938983643824,1.36400562584013,3.51158245907016e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.405400086590309,TGFBR2;TGF-beta receptor type-2,1.5403620709995,1.34615717681108,1.76258415484187,3.31789499199524e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.705196391285506,TGFBR2;TGF-beta receptor type-2,1.4294470403692,1.28928964294067,1.5848408093621,1.15432105485632e-11
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0452026256829527,TGFBR2;TGF-beta receptor type-2,2.91199034236912,2.01346822006634,4.21148328518026,1.36659084279225e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.82351314515969,TGFBR2;TGF-beta receptor type-2,1.28492042932406,1.2345193134372,1.33737924690501,1.17041213256122e-34
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.533775814158053,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,2.03194232395052,1.81380365579911,2.27631562802336,1.99522056212458e-34
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33445371426284,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.42070873765356,1.31872142912094,1.53058354302367,2.48496221473907e-20
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782029286198779,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.31864718131347,1.19504101561399,1.45503825062656,3.62746052329667e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.39706326058533,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.21774030206002,1.1678279980114,1.26978582957964,2.81766209173669e-20
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.798674200826627,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.36967635483658,1.24320821283388,1.50900975205278,1.96359832876676e-10
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.403274106608105,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.42086704706953,1.23978124259711,1.62840273435574,4.41930028767086e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703338861470218,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.31752932304058,1.18803954598762,1.46113277368113,1.74789319749261e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.217391304347826,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.58561898002367,1.32008222698992,1.90456889609386,8.24143777638916e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0996889704123135,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.9962813966805,1.53244121053475,2.60051699689154,2.99200513195875e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34578248491967,OSM;Oncostatin-M,1.20982415798465,1.12140593278924,1.30521379497495,8.69156100337154e-07
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.393348828893259,OSM;Oncostatin-M,1.41793860491021,1.23139113471721,1.63274676145564,1.22194841017069e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,CCL27;C-C motif chemokine 27,1.83559960256451,1.63615137330723,2.05936073880757,4.21428318730293e-25
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37983460413259,"GSR;Glutathione reductase, mitochondrial",1.29568238445933,1.19656728093218,1.40300747659618,1.77383167430005e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.211202938475665,"GSR;Glutathione reductase, mitochondrial",2.17181519952234,1.7862954995701,2.6405380643972,7.33704646289049e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107860011474469,"GSR;Glutathione reductase, mitochondrial",2.65817451199006,2.03448047439911,3.47306932905342,7.73129141046542e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534531980805442,MUC13;Mucin-13,1.95824985973355,1.727787814345,2.2194522274717,6.99063820887415e-26
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214080866017691,MUC13;Mucin-13,2.33437220081371,1.91347815946259,2.84784728008724,6.43228074104594e-17
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100955034627576,MUC13;Mucin-13,3.35839270867963,2.52168906163742,4.4727170202296,1.16416005131271e-16
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.221890586340965,ACP5;Tartrate-resistant acid phosphatase type 5,2.11967632273859,1.76174048982343,2.55033459191763,1.70853037095203e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104037846220285,ACP5;Tartrate-resistant acid phosphatase type 5,3.19928269626156,2.44849878618812,4.18027969968216,1.56455384176546e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.393580165445075,HS6ST2;Heparan-sulfate 6-O-sulfotransferase 2,3.19896702162903,2.72438719223425,3.75621719065482,1.01900648816298e-45
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0423439742172245,HS6ST2;Heparan-sulfate 6-O-sulfotransferase 2,3.21517709036119,1.99674248045692,5.17711413642983,1.54634591840494e-06
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245006026357906,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.67792162312055,1.41113586706943,1.99514521530972,4.68244398381085e-09
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1411201834681,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.29573959926908,1.22059078572019,1.3755151429587,1.91124802144539e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.528503562945368,VSIG4;V-set and immunoglobulin domain-containing protein 4,3.96160110238293,3.56849958147318,4.39800620291024,5.40335780230606e-147
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0651285796048866,VSIG4;V-set and immunoglobulin domain-containing protein 4,2.52855936258812,1.83931645570961,3.47608070937711,1.11073091702435e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0552813425468904,VSIG4;V-set and immunoglobulin domain-containing protein 4,2.81303969803626,1.99844133830823,3.95968207374393,3.0473299274201e-09
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97784354665423,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.24027932710951,1.17808243927718,1.30575990097862,2.33721459724167e-16
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01012097730687,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.28207313032619,1.17549349840783,1.39831612316933,2.0078465351538e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34487402947234,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.59699330429583,1.481803082053,1.72113801412278,1.5646930385935e-34
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59555467354633,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.29019941316701,1.20367266208138,1.38294619307718,6.29887285293675e-13
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72564092404009,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.2285380747903,1.14939496886346,1.31313068361685,1.37670960738817e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782191320836707,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.48099761505939,1.34251809882355,1.63376116696948,4.48179674841595e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.42306926355199,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.42998206979929,1.3712510141318,1.4912285926309,1.01775795132402e-62
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22447545427165,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.26275519800988,1.20958683148293,1.3182606230477,2.17227459740528e-26
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.0759052373029,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.27959522896785,1.2042003232957,1.35971060489014,1.76176570200123e-15
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71924265230135,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.22623097800906,1.16271085852121,1.29322126856324,5.69521105991281e-14
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.774550484094052,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.57496164501678,1.42758940133344,1.73754735147027,1.28170394095504e-19
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.806626994325932,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.54430518530371,1.40195312133972,1.70111144877435,1.28013275375309e-18
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.0833893479894,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.24787006200215,1.1474864629751,1.35703534802835,2.27719850676217e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11569255404323,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.35366947157104,1.27378702991957,1.43856154539359,1.70832298470905e-22
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.407162904692255,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.61040737496252,1.4065844166773,1.84376556613642,5.15437925369575e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702302761731423,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.50333722803422,1.35510700169028,1.66778181971948,1.38774295548787e-14
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0453980222252926,VSIG4;V-set and immunoglobulin domain-containing protein 4,2.83877971973509,1.95101823956656,4.13049459700058,4.95446873622816e-08
sensitivity,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.66494500820319,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.20664801028291,1.12638937157537,1.29262531897237,8.84018956204904e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.223126135376352,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.73505278293624,1.44741692813496,2.07984866078207,2.54626288735793e-09
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.537772593368789,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.34886416262851,1.1976616809721,1.51915566652073,8.07980541231115e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.79298510127561,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.3088543759789,1.25720339476412,1.36262738762373,3.19716815359207e-39
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102647111076018,VSIG4;V-set and immunoglobulin domain-containing protein 4,2.24373925218989,1.73217217515626,2.90638881285776,9.29528856453157e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.401366941125203,KIAA0319;Dyslexia-associated protein KIAA0319,2.48489958655029,2.15957958251604,2.85922593695013,4.93913557516808e-37
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245865884125788,RBP5;Retinol-binding protein 5,1.5511564651169,1.30818852006353,1.83925049209048,4.4017206922561e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,RBP5;Retinol-binding protein 5,2.12201903944285,1.9010255544031,2.36870293159833,5.37794677406943e-41
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,RBP5;Retinol-binding protein 5,1.29965334794897,1.20594014246963,1.40064897530973,6.68770829919279e-12
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,RBP5;Retinol-binding protein 5,1.32071429096819,1.1962754513924,1.45809749446699,3.60069225473455e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,RBP5;Retinol-binding protein 5,1.46087395731264,1.32636735387999,1.60902084397005,1.45829339804768e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214013950538998,RBP5;Retinol-binding protein 5,2.51199082951223,2.12151151108663,2.97434065032318,1.19050743568829e-26
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101026108315835,RBP5;Retinol-binding protein 5,3.20061268277435,2.5372897558084,4.03734793067504,9.45162059093016e-23
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34014921248963,PROC;Vitamin K-dependent protein C,0.739718848440357,0.68558831499566,0.798123250892034,7.50134860668644e-15
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220385674931129,PROC;Vitamin K-dependent protein C,0.452949825200143,0.376123101670599,0.545469138262393,6.7432477866845e-17
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102287703837755,PROC;Vitamin K-dependent protein C,0.286112746016332,0.21823475089325,0.37510297098856,1.34675451959727e-19
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54854743846169,FAM3C;Protein FAM3C,4.81260388135071,4.26437818945821,5.43130911232209,5.03953595488022e-143
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0651478659138468,FAM3C;Protein FAM3C,2.92655283211565,2.07972250029318,4.11819917222454,7.2129256960451e-10
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0572737686139748,FAM3C;Protein FAM3C,3.11853514462839,2.16302302112956,4.49614329264223,1.10762906213474e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35127102692635,FAM3C;Protein FAM3C,1.28597369713613,1.19187837620918,1.38749756916114,8.72282665716977e-11
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60778086542278,FAM3C;Protein FAM3C,1.24153111990149,1.15798541523245,1.33110443482954,1.15182188902118e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.784383458795171,FAM3C;Protein FAM3C,1.4615378924779,1.32297756366299,1.61461015652785,8.17946361785037e-14
sensitivity,Circulatory system disorders,I50 (heart failure),4.42483165318563,FAM3C;Protein FAM3C,1.2648959566494,1.21239446192814,1.31967097457991,1.70259227559611e-27
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802926925739147,FAM3C;Protein FAM3C,1.42471099290807,1.29077993025295,1.57253871534502,2.10340808869569e-12
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13818094456345,FAM3C;Protein FAM3C,1.23767810805207,1.16467269791763,1.31525973081556,6.22944248600884e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.415200284708766,FAM3C;Protein FAM3C,1.47139309926515,1.28306585284808,1.68736284872625,3.25829019336234e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.712433951435752,FAM3C;Protein FAM3C,1.35281175414289,1.21852894857575,1.50189262576504,1.46629932383813e-08
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473858790080556,FAM3C;Protein FAM3C,2.97256987513585,1.98900894148039,4.44249971847213,1.07063879749616e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.77097721679765,FAM3C;Protein FAM3C,1.20059274650957,1.15278358680324,1.2503846857922,1.16918566292633e-18
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54409116989494,PRELP;Prolargin,3.07303848717548,2.72457346097725,3.46607117734846,1.14115402049123e-74
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.063121350796907,PRELP;Prolargin,3.25270978147094,2.30789611184449,4.58431420208989,1.61887411009183e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34420842159444,PRELP;Prolargin,1.21208863863369,1.12290752950356,1.30835249502192,8.10236453059692e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781743524952621,PRELP;Prolargin,1.41601762896187,1.2807792902576,1.56553587396585,1.10656134261863e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.533786485405837,SFRP1;Secreted frizzled-related protein 1,1.99817881573421,1.77893700830155,2.24444067497424,1.73025118997198e-31
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33650787299173,SFRP1;Secreted frizzled-related protein 1,1.37256956940606,1.2727998082074,1.4801598890189,1.95485472692788e-16
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.6136468418626,SFRP1;Secreted frizzled-related protein 1,1.21236245323529,1.13145152758207,1.29905937831533,4.64157977232664e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.784055542255207,SFRP1;Secreted frizzled-related protein 1,1.38238163909444,1.25279527121565,1.52537213382927,1.13553095650389e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.40537495976826,SFRP1;Secreted frizzled-related protein 1,1.2071923662158,1.15733396441846,1.25919868754736,2.13521554522018e-18
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.798706096124278,SFRP1;Secreted frizzled-related protein 1,1.3122449752804,1.19003421186235,1.44700619358985,5.08882567645022e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.215405480872791,SFRP1;Secreted frizzled-related protein 1,1.65159160303793,1.37243935172768,1.9875230331975,1.08828311988864e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0996929457271603,SFRP1;Secreted frizzled-related protein 1,2.19735669974696,1.6864428189006,2.86305376726056,5.5205105326664e-09
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13036752755967,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.21687068505087,1.14474887062239,1.29353633983591,3.04190741967813e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,5.3572910396349,4.73682605042317,6.05902918490924,2.35591161242466e-157
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645035183737294,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,3.33747920177159,2.37057529076627,4.69876129462963,5.01047428991886e-12
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547516621040281,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,3.49903308628152,2.40613396689782,5.08834200727307,5.54349006141545e-11
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00406736825478,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.22624686863047,1.15115550810032,1.30623653558975,2.5163898730824e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.41458458564063,1.30945383639153,1.52815585728961,1.3370917741048e-18
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60963817535032,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.29217744555823,1.20423265504116,1.38654482073675,1.02156828769284e-12
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778575480741016,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.37770198838044,1.24499056244475,1.5245599653866,5.64130527194277e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.41849455578349,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.28598310599671,1.23175606432581,1.34259744831386,2.56126269239091e-30
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23386695833747,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.23096404240217,1.17803975527469,1.28626599136611,1.90229093792497e-20
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778925943322373,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.36148946470703,1.23058132504322,1.50632349507101,2.19501910740447e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80476199800278,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.35625567367394,1.22744588575995,1.4985829303863,2.16404759229656e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13499851323223,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.21227867267625,1.13992006297101,1.28923038374759,8.75744127010314e-10
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409130060292851,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.47050897546019,1.27857101644842,1.69126049244853,6.53123446374256e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.697505828875957,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.37886348469173,1.23896088161751,1.53456379263085,3.97126270702895e-09
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0430073894514602,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,3.93481031815659,2.59639944525239,5.96315496376426,1.06008392833769e-10
sensitivity,Circulatory system disorders,I95 (hypotension),4.80223213408523,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.20117746422202,1.15299014274323,1.25137869533042,1.71432332826166e-18
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249256251507598,NPPB;Natriuretic peptides B,2.42590462106575,2.02083837644645,2.91216422802533,1.95459794358177e-21
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.508256659568484,NPPB;Natriuretic peptides B,1.99349964988959,1.75601279522895,2.26310472503804,1.56792819671413e-26
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13018465623365,NPPB;Natriuretic peptides B,1.78227995312278,1.6755273229093,1.89583409823947,4.12293937850035e-75
sensitivity,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0341434022896163,NPPB;Natriuretic peptides B,4.52083794760629,2.72036040970739,7.51296617741743,5.82801761821939e-09
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.20487687301651,NPPB;Natriuretic peptides B,1.8006931497803,1.48240359591923,2.18732322870213,3.08971320199052e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549782503624939,NPPB;Natriuretic peptides B,1.73415810453915,1.53722395635664,1.9563215360411,3.51878272761535e-19
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0642531574403148,NPPB;Natriuretic peptides B,2.7705735977114,1.9661885342897,3.90403968208904,5.75302155168185e-09
sensitivity,Circulatory system disorders,I22 (subsequent myocardial infarction),0.0984984019136832,NPPB;Natriuretic peptides B,2.81384673950257,2.13656849586506,3.70581775811661,1.78491891507271e-13
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00355972085352,NPPB;Natriuretic peptides B,1.31263840377021,1.20179552005658,1.43370444497187,1.50652238113769e-09
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.68794695911431,NPPB;Natriuretic peptides B,1.27650410247593,1.23661422797083,1.31768071786758,2.50966892469829e-51
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33808919251153,NPPB;Natriuretic peptides B,2.2285205470985,2.05934931494233,2.41158884158478,4.58129867522164e-88
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.746403782315662,NPPB;Natriuretic peptides B,1.4326343363879,1.29216791652504,1.58837030044603,8.5928955144781e-12
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61303347195865,NPPB;Natriuretic peptides B,1.84895541396137,1.72071338583029,1.98675511620287,4.9058670617251e-63
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69307050429314,NPPB;Natriuretic peptides B,1.36559514938362,1.27518363844438,1.46241690670925,4.8607907177909e-19
sensitivity,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.186776992287917,NPPB;Natriuretic peptides B,2.05256247245266,1.66861079985542,2.52486242069513,1.00746207157889e-11
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.676696272128572,NPPB;Natriuretic peptides B,2.19300225783391,1.96538947119691,2.44697500080522,8.22674721249164e-45
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.83209030437411,NPPB;Natriuretic peptides B,1.54910171585958,1.46872960419442,1.63387196610318,2.50401722296888e-58
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.7394805717737,NPPB;Natriuretic peptides B,1.43694156775402,1.34346484462123,1.53692229268681,4.4227076954606e-26
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.779680090024917,NPPB;Natriuretic peptides B,1.7040251431557,1.54151027857665,1.88367325788313,1.95850907100754e-25
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.3509414120169,NPPB;Natriuretic peptides B,1.591020815256,1.4722445472061,1.71937959585697,8.86955099373735e-32
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.36932832604814,NPPB;Natriuretic peptides B,1.70678183776244,1.64816262913715,1.76748592051308,1.70065743492493e-197
sensitivity,Circulatory system disorders,I49 (other cardiac arrhythmias),1.98877501220107,NPPB;Natriuretic peptides B,1.41668585679997,1.3290194509556,1.51013502128503,1.16661120072119e-26
sensitivity,Circulatory system disorders,I50 (heart failure),4.38288991104536,NPPB;Natriuretic peptides B,1.80777803317092,1.72903164900465,1.89011081381688,1.126173870597e-149
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.19458973520758,NPPB;Natriuretic peptides B,1.68703955432924,1.6125052028682,1.7650190850913,6.42068761773799e-114
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.04768526916177,NPPB;Natriuretic peptides B,1.33781783998691,1.25698235714092,1.42385178504664,5.57169178630383e-20
sensitivity,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.762985025908849,NPPB;Natriuretic peptides B,1.43940004165902,1.29867769127738,1.59537080974271,3.95220689330075e-12
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72639342280256,NPPB;Natriuretic peptides B,1.22919893553457,1.16463065291625,1.2973469480096,6.58959258386055e-14
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.768009007016626,NPPB;Natriuretic peptides B,1.45898711351782,1.31826718218369,1.61472835414517,2.8852457069757e-13
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.798551744946193,NPPB;Natriuretic peptides B,1.47016547460507,1.33110006706862,1.62375960770597,2.9349880265882e-14
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08009171728549,NPPB;Natriuretic peptides B,1.30941848219341,1.20329843291523,1.42489736096123,4.05994044049377e-10
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.14429714704624,NPPB;Natriuretic peptides B,1.33360099969777,1.25417180348077,1.41806060498166,3.98456697391667e-20
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.398174030204918,NPPB;Natriuretic peptides B,1.40815759417087,1.22443740510538,1.61944400077393,1.59703828918563e-06
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.688336520076481,NPPB;Natriuretic peptides B,1.34784973768341,1.21093674767658,1.50024261701441,4.70784066872821e-08
sensitivity,Circulatory system disorders,I83 (varicose veins of lower extremities),2.10349615567944,NPPB;Natriuretic peptides B,1.21382676210279,1.14035277756106,1.29203474344854,1.18267844276511e-09
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.452334043665313,NPPB;Natriuretic peptides B,1.47600657285529,1.29214680985196,1.68602776905947,9.69253065413552e-09
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.521000965561635,NPPB;Natriuretic peptides B,1.4159389197734,1.24981130448709,1.60414857613394,4.70749612480015e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.74306704880313,NPPB;Natriuretic peptides B,1.28866639143786,1.23657697461175,1.34295001647018,2.0154023114504e-33
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.386586146948485,PRAP1;Proline-rich acidic protein 1,2.67939338147685,2.30692818965325,3.11199495714733,4.15124699914858e-38
sensitivity,Circulatory system disorders,I50 (heart failure),4.31967930700824,PRAP1;Proline-rich acidic protein 1,1.20221111590674,1.14693736111437,1.26014864997114,1.73538331983587e-14
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.772889417360285,PRAP1;Proline-rich acidic protein 1,1.53587872621373,1.37557571907902,1.71486267816306,2.35276591592317e-14
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06756037137366,PRAP1;Proline-rich acidic protein 1,1.21291790970563,1.13326921350611,1.29816449450097,2.54694186717412e-08
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402368487231659,PRAP1;Proline-rich acidic protein 1,1.63064025103728,1.40005056521793,1.89920828173018,3.26054428829195e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549167327517842,ANG;Angiogenin,2.18376534153624,1.94341523908549,2.45384052310866,2.26123109575636e-39
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805765080873473,ANG;Angiogenin,1.31458718752515,1.1889767098035,1.45346789332056,9.39718263839946e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10279117577291,ANG;Angiogenin,0.39374843383512,0.296796669663342,0.522370514883036,1.02869716760289e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534531980805442,GPKOW;G-patch domain and KOW motifs-containing protein,1.40421233276119,1.24428966776434,1.58468910139024,3.73651780732957e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.32101466893589,GPKOW;G-patch domain and KOW motifs-containing protein,1.24737850932734,1.15498290328478,1.34716552176362,1.80731923870987e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.5508458022424501,CCL16;C-C motif chemokine 16,2.46163387496445,2.19551326580394,2.76001125966944,9.9481813671798e-54
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34461664744855,CCL16;C-C motif chemokine 16,1.21380301591914,1.12373837812765,1.31108609453137,8.40555805626656e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783488276910483,CCL16;C-C motif chemokine 16,1.30984765438543,1.18422635890276,1.44879470449272,1.54537546264642e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805696449473273,CCL16;C-C motif chemokine 16,1.41239816202853,1.27843059827913,1.56040427285363,1.11426578101328e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546263557268284,AREG;Amphiregulin,2.48528514476826,2.20062673123304,2.80676507430451,1.02913106216898e-48
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.99843965672447,AREG;Amphiregulin,1.21126129204261,1.13775445912125,1.28951717643357,1.9698657607561e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,AREG;Amphiregulin,1.64607159751331,1.52552813757009,1.77614010348959,9.24499054911072e-38
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60490631409171,AREG;Amphiregulin,1.2072337768531,1.12622493531022,1.29406954710477,1.07151750956609e-07
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69585876458776,AREG;Amphiregulin,1.22214384345248,1.14070408276933,1.30939793821254,1.18745587600911e-08
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.83107020020278,AREG;Amphiregulin,1.21108620764674,1.14760721680987,1.27807648894835,3.1224849988429e-12
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.7394066955244,AREG;Amphiregulin,1.27763093449419,1.19260554994198,1.36871810202115,3.1038745244856e-12
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.776976135732973,AREG;Amphiregulin,1.51162143793772,1.36344733620159,1.675898519116,4.17134171266725e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.38493054861596,AREG;Amphiregulin,1.4303438097999,1.36996863983109,1.49337974224368,1.72261234956359e-59
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21317751360064,AREG;Amphiregulin,1.32967854423054,1.27225768467154,1.38969098185757,1.10506604037111e-36
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06933566572575,AREG;Amphiregulin,1.23370297383882,1.15947859774884,1.31267884600354,3.26930877990571e-11
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.72069637107993,AREG;Amphiregulin,1.25814096673545,1.19224600302498,1.32767791895448,5.9447273124726e-17
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.775347518293045,AREG;Amphiregulin,1.45562500098836,1.31513609169835,1.6111215842051,4.16786359969731e-13
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,AREG;Amphiregulin,1.442851310079,1.30416602744511,1.59628441409029,1.15661644188439e-12
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13718991664155,AREG;Amphiregulin,1.30385298958806,1.22671042084107,1.38584672435743,1.50537455918026e-17
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406608881924747,AREG;Amphiregulin,1.44921069940653,1.25601714930322,1.67212020348563,3.72310899826846e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702771380925911,AREG;Amphiregulin,1.32762337483052,1.19338354591096,1.47696340496375,1.88265195679005e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214013950538998,AREG;Amphiregulin,2.33684925534552,1.92165580294963,2.84174951301205,1.82337796068306e-17
sensitivity,Circulatory system disorders,I95 (hypotension),4.80361515338522,AREG;Amphiregulin,1.28655067557518,1.23564231736914,1.33955645380222,2.10393097637741e-34
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101026108315835,AREG;Amphiregulin,3.40962792042236,2.56489794061522,4.53256340988568,3.04616620195653e-17
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248672758491385,SEMA3F;Semaphorin-3F,1.57193105631081,1.32262123888741,1.86823496640126,2.84396349451891e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,SEMA3F;Semaphorin-3F,2.76701682030401,2.46930412127138,3.10062337720606,9.43343051141012e-69
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0650515484239784,SEMA3F;Semaphorin-3F,2.4402008648612,1.76145671831554,3.38048627533898,8.12503931682186e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,SEMA3F;Semaphorin-3F,1.2373790723931,1.14799759590198,1.33371966479897,2.57768135362949e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783222853535353,SEMA3F;Semaphorin-3F,1.40292700829326,1.27248515533189,1.54674039406404,1.04902866916887e-11
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80173775671406,SEMA3F;Semaphorin-3F,1.32885330276211,1.20617870858189,1.46400453572745,8.75698385832298e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222866497051456,SEMA3F;Semaphorin-3F,1.67674805127207,1.3988040077274,2.00991991151958,2.27824154953274e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104495268138801,SEMA3F;Semaphorin-3F,1.92047677356666,1.47741849984884,2.49640236546811,1.07930660013541e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545308740978348,CCL18;C-C motif chemokine 18,1.47202835010293,1.31063625877233,1.65329430572634,6.7751614749388e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34983352721729,CCL18;C-C motif chemokine 18,1.3018816764132,1.20840989219904,1.4025836020724,3.92376424947314e-12
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248672758491385,COL4A1;Collagen alpha-1(IV) chain,1.69049930857903,1.42701441184262,2.00263423311617,1.25441220757292e-09
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.510807825812559,COL4A1;Collagen alpha-1(IV) chain,1.53314038835546,1.36078768426096,1.72732269522508,2.17100161319308e-12
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.15043146857289,COL4A1;Collagen alpha-1(IV) chain,1.32011484137796,1.24459305537991,1.40021928203223,2.46919835314495e-20
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,COL4A1;Collagen alpha-1(IV) chain,1.34659235691473,1.19874018427679,1.51268056204786,5.31147913379096e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,COL4A1;Collagen alpha-1(IV) chain,1.75938436874686,1.635319066054,1.89286202383735,8.49551733898043e-52
sensitivity,Circulatory system disorders,I33 (acute and subacute endocarditis),0.128192485948131,COL4A1;Collagen alpha-1(IV) chain,1.79499717510672,1.42062090338453,2.26803283758873,9.49448956873977e-07
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60935487067684,COL4A1;Collagen alpha-1(IV) chain,1.32018286739567,1.23316621349272,1.41333973011525,1.41183072805267e-15
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71560867500395,COL4A1;Collagen alpha-1(IV) chain,1.24200704853467,1.16245403110299,1.32700430927674,1.38919180319517e-10
sensitivity,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.187310225166607,COL4A1;Collagen alpha-1(IV) chain,2.09337980037076,1.72952108156689,2.53378755269648,3.36033141350613e-14
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783222853535353,COL4A1;Collagen alpha-1(IV) chain,1.40673718487437,1.27653822068894,1.55021563415489,5.69403549000928e-12
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36396124523507,COL4A1;Collagen alpha-1(IV) chain,1.26786237707559,1.17714752631998,1.3655680118779,3.70872280681637e-10
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.40695964053275,COL4A1;Collagen alpha-1(IV) chain,1.24345991926413,1.20358429932322,1.28465664738713,3.16996077731257e-39
sensitivity,Circulatory system disorders,I50 (heart failure),4.4281764109093,COL4A1;Collagen alpha-1(IV) chain,1.39149984462015,1.33492843168741,1.45046863308646,7.09804425549504e-55
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22600184524048,COL4A1;Collagen alpha-1(IV) chain,1.29690267030936,1.2427395194709,1.35342645011534,6.95751230187982e-33
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773694390715667,COL4A1;Collagen alpha-1(IV) chain,1.27952204571859,1.15991414409289,1.41146366204563,8.54113907957374e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80173775671406,COL4A1;Collagen alpha-1(IV) chain,1.40743921341784,1.27878240833142,1.54904002945342,2.79529915550078e-12
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13901605261579,COL4A1;Collagen alpha-1(IV) chain,1.26859099207421,1.1952465178015,1.34643613782032,4.89301185019031e-15
sensitivity,Circulatory system disorders,I81 (portal vein thrombosis),0.074913750616067,COL4A1;Collagen alpha-1(IV) chain,2.65650123628133,1.9827241888947,3.55924382114805,5.91670943661814e-11
sensitivity,Circulatory system disorders,I83 (varicose veins of lower extremities),2.08774214553149,COL4A1;Collagen alpha-1(IV) chain,1.21294295813223,1.14132106334138,1.28905937771386,5.07606952992261e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222866497051456,COL4A1;Collagen alpha-1(IV) chain,3.56207472797039,3.01717151051432,4.2053878354043,7.69910407985379e-51
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.270697490614503,COL4A1;Collagen alpha-1(IV) chain,1.7222644972058,1.46503595301948,2.02465679577498,4.48796557884671e-11
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104495268138801,COL4A1;Collagen alpha-1(IV) chain,5.37793811965055,4.2452298551658,6.81287454520197,3.55129441632257e-44
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.251434318498708,ADAMTSL2;ADAMTS-like protein 2,1.64754843396313,1.35856100630884,1.99800806121273,3.89498765632502e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.386586146948485,ADAMTSL2;ADAMTS-like protein 2,1.54528430276177,1.32664574266614,1.79995570751465,2.25241293087868e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36612648130744,ADAMTSL2;ADAMTS-like protein 2,1.53333469038847,1.41251401826463,1.66448986866497,1.83339619272196e-24
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.754009962071014,ADAMTSL2;ADAMTS-like protein 2,1.30788461561236,1.17387325205861,1.45719494396494,1.13612079997819e-06
sensitivity,Circulatory system disorders,I50 (heart failure),4.31967930700824,ADAMTSL2;ADAMTS-like protein 2,1.27353388821444,1.21652189538644,1.33321773375513,4.29764642286653e-25
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.772889417360285,ADAMTSL2;ADAMTS-like protein 2,1.5087890290059,1.35466117149421,1.68045292944922,7.36290293300991e-14
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06756037137366,ADAMTSL2;ADAMTS-like protein 2,1.20264530900302,1.12548252112828,1.28509835747341,4.92680467712443e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214705009022178,ADAMTSL2;ADAMTS-like protein 2,3.8098935552045,3.11628825258504,4.65787748933302,6.72172195546818e-39
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.105032423052333,ADAMTSL2;ADAMTS-like protein 2,5.88487040783139,4.47242507447026,7.74338287177939,1.02114047502419e-36
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511639805576873,F7;Coagulation factor VII,0.68047760538981,0.602565437770359,0.768463875310287,5.47287281805686e-10
sensitivity,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0334448160535117,F7;Coagulation factor VII,0.300301218059619,0.190432108064896,0.473558910230406,2.2627081253585e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.550436995679365,F7;Coagulation factor VII,1.45714741932415,1.29271020162723,1.64250162098999,7.16341612858815e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34020211590083,F7;Coagulation factor VII,0.695971949213987,0.645138053212857,0.750811321205542,7.51790737858558e-21
sensitivity,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.186882794979737,F7;Coagulation factor VII,0.571133844642597,0.468298292991899,0.696551478785502,3.19929598927542e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513253341849537,ADIPOQ;Adiponectin,1.45822137357571,1.26483643481407,1.68117356191246,2.03056815752962e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.390642847352309,ADIPOQ;Adiponectin,1.90487950089508,1.62722519789544,2.22991010563458,1.08251947089774e-15
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36882825554512,ADIPOQ;Adiponectin,1.31986494144867,1.20821835225435,1.44182834205003,7.53303545180889e-10
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59337888027878,ADIPOQ;Adiponectin,1.39390358455186,1.28488059951705,1.51217724336162,1.32334659028062e-15
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.688377624296757,ADIPOQ;Adiponectin,1.36720077268382,1.20811595230102,1.54723389693433,7.21533033408182e-07
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.72575373151386,ADIPOQ;Adiponectin,1.21952094571509,1.12711723333528,1.31950013099963,7.95374528724366e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.757575757575757,ADIPOQ;Adiponectin,1.34042427888497,1.19135893857649,1.50814098861855,1.11070377064734e-06
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.2059268923421,ADIPOQ;Adiponectin,1.26129796401712,1.21275725567596,1.31178151817942,4.44098269415514e-31
sensitivity,Circulatory system disorders,I50 (heart failure),4.3090160351531,ADIPOQ;Adiponectin,1.27174643615471,1.20939925516401,1.33730775090717,7.04725579050285e-21
sensitivity,Circulatory system disorders,I83 (varicose veins of lower extremities),2.04278553105363,ADIPOQ;Adiponectin,1.21552604864367,1.12925761458304,1.30838486794426,2.03200119074457e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11961389192954,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.23448887635381,1.16243570299048,1.3110082406457,6.631567696513e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534002829417976,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,3.19505163754217,2.85556872004858,3.57489381883523,2.48665874923036e-91
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0655646507192243,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,2.48262483156196,1.79423738648278,3.43512296685007,4.05982888439081e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0576403243758944,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,2.49895967391621,1.76668830450109,3.53474884955609,2.25954769577541e-07
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97106476757948,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.21759543940977,1.15639669168855,1.28203294313018,7.28360193167595e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01689518616544,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.30449420638006,1.19632625417881,1.42244235511428,1.75697472654992e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33402460667211,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.48621421954757,1.3783920072292,1.60247062867515,6.25584046355016e-25
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61026091820833,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.22959469028781,1.14752752403405,1.31753101404398,4.50317553576327e-09
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71100386870338,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.25365226366906,1.17253883729004,1.34037692246931,3.49823948001036e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.78342479917283,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.47288766350854,1.33541028703323,1.62451801545968,9.5252713782165e-15
sensitivity,Circulatory system disorders,I50 (heart failure),4.40073780023256,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.3529378558964,1.29730413454252,1.41095737936812,3.32347326587926e-45
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20650482100624,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.24068269348677,1.18834582592031,1.29532456995461,1.04745010272812e-22
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769827534761592,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.30383308478286,1.18044099043577,1.44012341722124,1.69265703554585e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80001592071484,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.47044295833189,1.33425642892193,1.62052994225022,7.51883048159612e-15
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.10956861638895,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.25716380409063,1.1830694931021,1.3358985583945,1.53487367877432e-13
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70101368171589,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.48537503204025,1.33893303512326,1.64783370634025,7.93146767938152e-14
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216673955392994,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.89423447299717,1.57684422580529,2.27550964132707,8.65260783610187e-12
sensitivity,Circulatory system disorders,I95 (hypotension),4.79937685993329,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.2360443015324,1.18741773257264,1.28666220272844,4.24126488706795e-25
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.53255385601025,HNMT;Histamine N-methyltransferase,2.28195328528751,2.03057516925058,2.56445113438294,1.18965681666071e-43
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0579166000958619,HNMT;Histamine N-methyltransferase,2.38747391578046,1.68241492789139,3.38800589797195,1.09831291119378e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33643230679837,HNMT;Histamine N-methyltransferase,1.20974286646012,1.12060899242303,1.30596649932885,1.08221696896604e-06
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783185487093422,HNMT;Histamine N-methyltransferase,1.34073747037769,1.21381607962865,1.48093026171207,7.52579469505354e-09
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.611681925398792,HNMT;Histamine N-methyltransferase,1.37409894083842,1.22768974128325,1.53796829583318,3.2282049151789e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.217712619342467,HNMT;Histamine N-methyltransferase,2.46322801203142,2.05746877028954,2.94900818271104,9.60215223186254e-23
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0998362685196278,HNMT;Histamine N-methyltransferase,3.65124527961747,2.85896696094654,4.6630801523901,3.15659902325702e-25
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.21015121750651,UPB1;Beta-ureidopropionase,2.16660200870217,1.77552385655529,2.64381931382182,2.68979435440553e-14
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100472678281917,UPB1;Beta-ureidopropionase,3.22209679537137,2.45410306676337,4.23042858278759,3.68316335400005e-17
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.244669000636537,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.59283253961244,1.33382117761781,1.90214066309809,2.72971153056963e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.11961389192954,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.26915571875762,1.1948675064032,1.34806263441198,9.54675427612019e-15
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.206685480345005,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.61338018974611,1.33448889761472,1.95055623266543,7.81565097593645e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534002829417976,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,3.27453581154576,2.93275161085038,3.65615169775203,9.81517244312339e-99
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0655646507192243,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.50055595010363,1.8128839905672,3.4490789769964,2.32743139291007e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0576403243758944,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.53469668189546,1.80013730642168,3.56899845711375,9.99231484245244e-08
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01689518616544,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.30104162483848,1.19330207141869,1.41850864932292,2.41628439521297e-09
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.0010838367822,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.22707963678647,1.15273270132346,1.30622167071973,1.38869307100751e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33402460667211,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.52719281825604,1.41556499694785,1.647623322957,7.93717333196341e-28
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61026091820833,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.21354272976133,1.13193853502665,1.30102996884183,5.05643462966852e-08
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71100386870338,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.34882618531026,1.26161280915081,1.44206848962102,1.72390957794158e-18
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.85805460818923,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.21170979843288,1.150634429326,1.27602703186823,3.40454956947538e-13
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.78342479917283,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.51527031275836,1.37402664374666,1.67103318642063,8.46042776338935e-17
sensitivity,Circulatory system disorders,I50 (heart failure),4.40073780023256,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.37697268233024,1.32018269709607,1.43620558885855,4.04866382489353e-50
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.20650482100624,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.2568712294128,1.20384739106484,1.31223051945839,2.58559088154715e-25
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.769827534761592,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.37313637851867,1.24291495222941,1.51700123216746,4.44414636665267e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80001592071484,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.61671900324365,1.46732314759653,1.78132563350514,2.70801986511992e-22
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.10956861638895,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.32856301669659,1.24997454860419,1.41209250324734,6.72406305929937e-20
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40194205666985,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.53706718286776,1.34101613572172,1.76178008728994,6.62491469331343e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70101368171589,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.59397578988273,1.43660094578597,1.76859052347499,1.4875722900229e-18
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216673955392994,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.45658611143669,2.05519071072014,2.93637728675265,5.39652875543932e-23
sensitivity,Circulatory system disorders,I95 (hypotension),4.79937685993329,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.26628511767557,1.21610050713798,1.31854068790771,2.5563501887613e-30
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.0993601208219069,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.86050014725869,2.2135363712128,3.69655597209987,9.44748039217034e-16
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54361741939296,SORD;Sorbitol dehydrogenase,0.717413300630578,0.639000151742313,0.805448703757451,1.87082926167986e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.210220240083302,SORD;Sorbitol dehydrogenase,1.75991581756827,1.45306496525895,2.13156586868434,7.35376499300495e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102128996779008,SORD;Sorbitol dehydrogenase,2.59136775399941,1.98126464054927,3.38934370453727,3.60312758542257e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.534002829417976,CRIP2;Cysteine-rich protein 2,2.03902473067599,1.8222115904202,2.28163506047591,2.00113190896584e-35
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33402460667211,CRIP2;Cysteine-rich protein 2,1.23787080987933,1.14746350058791,1.33540120549909,3.49031970765859e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80001592071484,CRIP2;Cysteine-rich protein 2,1.32462817117981,1.20124514651365,1.46068418838206,1.74472577887505e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36386558474304,HEPH;Hephaestin,1.38168947372964,1.27387820305119,1.498625062618,6.19684877617507e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100472678281917,HEPH;Hephaestin,2.3158846275419,1.71654844978232,3.12448017926031,3.88205100585887e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36882825554512,CFP;Properdin,0.692035247354943,0.639151417079075,0.749294722321436,1.1266972616463e-19
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246645619573796,THBS2;Thrombospondin-2,1.78898190552883,1.49628942666761,2.13892860650449,1.76015366085019e-10
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518625150361854,THBS2;Thrombospondin-2,1.42654204786396,1.2622739582066,1.61218743450526,1.25964456617731e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14412635735439,THBS2;Thrombospondin-2,1.27916123338751,1.20482119259556,1.3580882134688,7.65823836152692e-16
sensitivity,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0335147070420313,THBS2;Thrombospondin-2,3.69366196968958,2.25389128399587,6.05314854501034,2.16622547339454e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,THBS2;Thrombospondin-2,1.72696764263131,1.53295688544176,1.9455323675565,2.56180022375947e-19
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,THBS2;Thrombospondin-2,1.74664883997951,1.61872249505802,1.88468510168719,7.8887668207759e-47
sensitivity,Circulatory system disorders,I33 (acute and subacute endocarditis),0.122251799270432,THBS2;Thrombospondin-2,1.91469107128344,1.49797173255493,2.44733716850568,2.13767244046379e-07
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60328187241126,THBS2;Thrombospondin-2,1.22698929480126,1.14440239985413,1.31553615209894,8.72057818247053e-09
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72526363690323,THBS2;Thrombospondin-2,1.20534591135827,1.12785550271578,1.28816037385086,3.61163193649534e-08
sensitivity,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.185305655765174,THBS2;Thrombospondin-2,1.74451227545181,1.42358139401227,2.13779351992277,8.10138486112198e-08
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.83922282458153,THBS2;Thrombospondin-2,1.20246372462177,1.14189996943793,1.26623964246447,2.70109675652602e-12
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781126716111724,THBS2;Thrombospondin-2,1.49818074075102,1.35850852502537,1.6522130635252,5.67451528607037e-16
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.37165770093495,THBS2;Thrombospondin-2,1.21628808043603,1.12851904952759,1.31088322809441,2.99258508929274e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,THBS2;Thrombospondin-2,1.37423602604443,1.31773499710913,1.43315967127038,7.98489476035768e-50
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23266631912419,THBS2;Thrombospondin-2,1.27296532284681,1.21946816213943,1.32880936418019,3.14073390844155e-28
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805528134254689,THBS2;Thrombospondin-2,1.60625159058525,1.45834748705384,1.76915597630978,6.88953799675354e-22
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11685689727547,THBS2;Thrombospondin-2,1.22910283611078,1.15679818205856,1.30592682904052,2.58168787377745e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703334913861229,THBS2;Thrombospondin-2,1.3514367761217,1.21799526283179,1.49949791726443,1.36411683006471e-08
sensitivity,Circulatory system disorders,I81 (portal vein thrombosis),0.0788410367596333,THBS2;Thrombospondin-2,2.58239807327287,1.9014272118943,3.50724958974349,1.2445967563574e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,THBS2;Thrombospondin-2,4.52262178799779,3.74920008778493,5.45559248862517,4.95775156350493e-56
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.270633321480779,THBS2;Thrombospondin-2,1.74420878357415,1.47966443125885,2.05605015328304,3.38606088445486e-11
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102507490932029,THBS2;Thrombospondin-2,8.5921602090816,6.46453590155214,11.4200335774761,1.1451992200367e-49
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538058260081201,DCXR;L-xylulose reductase,0.706714869582223,0.624586865415423,0.799642026664183,3.64316344209694e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.216284236811577,DCXR;L-xylulose reductase,2.14975075111537,1.78381531316798,2.59075491605329,9.05521466537289e-16
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100241759537708,DCXR;L-xylulose reductase,3.29921656829012,2.53769971730891,4.28925057217675,4.87094233204867e-19
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.402386244005146,PENK;Proenkephalin-A,4.44769469402785,3.79555663287756,5.21188062903069,5.40922648351277e-76
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0420344682639764,PENK;Proenkephalin-A,3.22744277937642,2.03245419783773,5.12502909302,6.83760233040138e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37606076234235,PENK;Proenkephalin-A,1.26443824221598,1.16532931956224,1.37197618007143,1.76183922332908e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,ITGA5;Integrin alpha-5,1.25589832884644,1.16460257149473,1.35435096143992,3.27425370887207e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805528134254689,ITGA5;Integrin alpha-5,1.29100708598308,1.17146832697424,1.4227437974046,2.5734446545212e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,ITGA5;Integrin alpha-5,3.39989321260679,2.85317495084459,4.05137226292694,1.3129075913506e-42
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.270633321480779,ITGA5;Integrin alpha-5,1.81457190149266,1.53659854877898,2.14283111766774,2.16491628726496e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102507490932029,ITGA5;Integrin alpha-5,5.57745285947567,4.3919272769343,7.08299077788639,3.96801013704795e-45
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.221520848444453,PRCP;Lysosomal Pro-X carboxypeptidase,2.44025376117555,2.03336606069394,2.92856192204723,9.20010581023818e-22
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.10386454495571,PRCP;Lysosomal Pro-X carboxypeptidase,4.34023223664581,3.39398870342053,5.55028832271438,1.28692463541565e-31
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248672758491385,CCDC80;Coiled-coil domain-containing protein 80,1.58599541393777,1.33323022579776,1.88668198812139,1.92006557658586e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,CCDC80;Coiled-coil domain-containing protein 80,2.66342928226106,2.37659970031883,2.98487605660053,1.04025999716828e-63
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0650515484239784,CCDC80;Coiled-coil domain-containing protein 80,2.37901040745544,1.70660255237926,3.31634949853489,3.15900736193646e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,CCDC80;Coiled-coil domain-containing protein 80,1.25289740009131,1.16201550189311,1.35088722361982,4.40577263667254e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783222853535353,CCDC80;Coiled-coil domain-containing protein 80,1.34913197337934,1.22236620382251,1.48904401635331,2.70983839661554e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80173775671406,CCDC80;Coiled-coil domain-containing protein 80,1.35061091373344,1.2249911618045,1.48911265417521,1.59733122370903e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.711378097458799,CCDC80;Coiled-coil domain-containing protein 80,1.31312905416303,1.18395539081178,1.45639601480662,2.52213105784017e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222866497051456,CCDC80;Coiled-coil domain-containing protein 80,1.67697936067723,1.3958414302054,2.01474158545615,3.34946061061598e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.77973961120028,CCDC80;Coiled-coil domain-containing protein 80,1.21638608797072,1.16849774341941,1.26623703241304,1.19301291844313e-21
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.550574170206072,RARRES2;Retinoic acid receptor responder protein 2,2.38481649516369,2.14808310994762,2.64763951137044,1.09372420168474e-59
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97031696806154,RARRES2;Retinoic acid receptor responder protein 2,1.24490131113528,1.18358380127455,1.30939547567097,1.89161089216474e-17
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33774000629524,RARRES2;Retinoic acid receptor responder protein 2,1.21949025527593,1.1315540851775,1.31426018622845,2.02924436873395e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.782767347419221,RARRES2;Retinoic acid receptor responder protein 2,1.28402738278875,1.16587750074968,1.41415055929219,3.85035739420018e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.803126104543847,RARRES2;Retinoic acid receptor responder protein 2,1.40876178710454,1.28138104666543,1.54880531280727,1.36557297916086e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406368401421307,RARRES2;Retinoic acid receptor responder protein 2,1.41332762384386,1.23779123488945,1.61375756752595,3.17518095599428e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.243442751688393,CD300E;CMRF35-like molecule 2,1.6184224363886,1.35852076699711,1.92804647984565,7.02797628871011e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.515979674716995,CD300E;CMRF35-like molecule 2,1.37626266672576,1.219324773809,1.55339985581216,2.34069591434283e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12937317068379,CD300E;CMRF35-like molecule 2,1.31028874255802,1.23448271882613,1.39074979559603,6.23065531120473e-19
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.546792022343731,CD300E;CMRF35-like molecule 2,3.52014203586224,3.15607978790106,3.92619983821297,4.9483684000732e-113
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0647109577221742,CD300E;CMRF35-like molecule 2,3.04876393619637,2.23554077398455,4.15781346814111,1.8932164626635e-12
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0549278091650973,CD300E;CMRF35-like molecule 2,2.9555478719029,2.10451729009021,4.15072057817845,3.99043327614225e-10
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97885196374622,CD300E;CMRF35-like molecule 2,1.28230906697406,1.21876211017061,1.34916939862341,8.90813025879475e-22
sensitivity,Circulatory system disorders,I22 (subsequent myocardial infarction),0.10208288344883,CD300E;CMRF35-like molecule 2,2.09925298959523,1.62617572289239,2.70995505115909,1.25507479309926e-08
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.02525827866598,CD300E;CMRF35-like molecule 2,1.28196714921235,1.17727582524768,1.39596833334608,1.09923397723507e-08
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.71503603273482,CD300E;CMRF35-like molecule 2,1.22019263707826,1.18399658462586,1.25749524188913,2.26430719683569e-38
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34409131162058,CD300E;CMRF35-like molecule 2,1.56445924345094,1.45210921057019,1.68550182493369,5.54964136822026e-32
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.748570642670491,CD300E;CMRF35-like molecule 2,1.30317768542535,1.17869925641706,1.4408018589516,2.34446207698029e-07
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60692456327142,CD300E;CMRF35-like molecule 2,1.3001672637258,1.21335034429819,1.39319605553992,9.72501163527582e-14
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70455663812616,CD300E;CMRF35-like molecule 2,1.26516359651261,1.18388564532151,1.35202156751046,3.84897124056047e-12
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.775193798449612,CD300E;CMRF35-like molecule 2,1.50504539143464,1.36610312779014,1.65811905719215,1.31207596058832e-16
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36867260482294,CD300E;CMRF35-like molecule 2,1.21260122931221,1.12538054347384,1.30658180457841,4.16137686568939e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.42078600546167,CD300E;CMRF35-like molecule 2,1.41393809130992,1.35638453257386,1.47393373932349,5.40790295703916e-60
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.2293420580138,CD300E;CMRF35-like molecule 2,1.26520248423031,1.21231531383659,1.32039685371682,3.54462305782789e-27
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.07443563148261,CD300E;CMRF35-like molecule 2,1.25348875926663,1.18001358662784,1.33153896481645,2.28752712050845e-13
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.73317591499409,CD300E;CMRF35-like molecule 2,1.214710100453,1.1521004238947,1.28072223353109,5.8493719906627e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.779470666771381,CD300E;CMRF35-like molecule 2,1.48742738734585,1.3494915707591,1.63946206153921,1.28225862707721e-15
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.807354587777712,CD300E;CMRF35-like molecule 2,1.63408543873479,1.48601979981382,1.79690420102047,3.92123977881015e-24
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13392200147167,CD300E;CMRF35-like molecule 2,1.3773221071001,1.2969514216626,1.46267327751939,1.69694883045097e-25
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.410447761194029,CD300E;CMRF35-like molecule 2,1.57168672645246,1.37641071502687,1.79466720153992,2.3944033571645e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699754299754299,CD300E;CMRF35-like molecule 2,1.55481891559518,1.40317821248222,1.72284734667886,3.46603034281361e-17
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0431457148460482,CD300E;CMRF35-like molecule 2,2.85462752302209,1.95139331288374,4.17593841353947,6.49629721766485e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213863872701944,CD300E;CMRF35-like molecule 2,1.82181636422572,1.51930125936754,2.18456665160816,9.51581837696125e-11
sensitivity,Circulatory system disorders,I95 (hypotension),4.79794993100729,CD300E;CMRF35-like molecule 2,1.28313856911292,1.23266085023393,1.33568336110674,4.21635579821422e-34
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103952142787094,CD300E;CMRF35-like molecule 2,2.18414412676652,1.69325258877252,2.81735022767448,1.80254145173242e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543765281173594,CTSO;Cathepsin O,1.55538484412982,1.38232963559209,1.75010500466664,2.13759915028068e-13
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804813252070636,CTSO;Cathepsin O,1.26971773726303,1.15247367717114,1.39888933192609,1.35972886215751e-06
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103374292958845,CTSO;Cathepsin O,1.95660356864376,1.49504145285247,2.56066312912279,1.01097179262691e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34952498310609,IGSF3;Immunoglobulin superfamily member 3,1.26148294803802,1.16977919559407,1.36037573089383,1.61635615019615e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.7975241042733,IGSF3;Immunoglobulin superfamily member 3,1.39286843846992,1.26337774370256,1.53563136326896,2.81465005892036e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.214013950538998,IGSF3;Immunoglobulin superfamily member 3,3.12507338733795,2.6564851377393,3.67631782971649,5.28939751252213e-43
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.27196569658951,IGSF3;Immunoglobulin superfamily member 3,1.76998876694513,1.50184764672,2.08600402441222,9.61232661350511e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101026108315835,IGSF3;Immunoglobulin superfamily member 3,4.50266850880229,3.66789919826887,5.52742117605864,6.68722783092113e-47
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212975098296199,PCBD1;Pterin-4-alpha-carbinolamine dehydratase,2.18730837569807,1.7947608011803,2.66571340718641,8.80989959346367e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.107619961163231,PCBD1;Pterin-4-alpha-carbinolamine dehydratase,3.14502968401123,2.41027516810935,4.10376866682428,3.16961210368455e-17
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245083388128399,ACVRL1;Serine/threonine-protein kinase receptor R3,1.99797816913648,1.67746889629623,2.37972624896945,8.59796348745419e-15
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.507755719718842,ACVRL1;Serine/threonine-protein kinase receptor R3,1.3606772739902,1.20223569125106,1.53999973335242,1.08313793559475e-06
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12320574162679,ACVRL1;Serine/threonine-protein kinase receptor R3,1.3147674054316,1.23714661453985,1.39725826354727,1.20539573474879e-18
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.207035215893934,ACVRL1;Serine/threonine-protein kinase receptor R3,1.64407035238427,1.35541452822935,1.99419975756048,4.48408671137466e-07
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.532902221423866,ACVRL1;Serine/threonine-protein kinase receptor R3,4.3638676747708,3.8881568479747,4.89778108947147,3.84048924134641e-138
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0656755627201624,ACVRL1;Serine/threonine-protein kinase receptor R3,3.27092046958988,2.37540280319083,4.50404483147465,3.85382614044377e-13
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0577378700698827,ACVRL1;Serine/threonine-protein kinase receptor R3,3.03402641405556,2.14277901842736,4.29597088734929,3.97970735944931e-10
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01662480564525,ACVRL1;Serine/threonine-protein kinase receptor R3,1.24854213465648,1.14349069233058,1.36324455674878,7.41886241119691e-07
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00249306365354,ACVRL1;Serine/threonine-protein kinase receptor R3,1.21103584370943,1.13722067798352,1.28964223315877,2.4097732754873e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33628954937679,ACVRL1;Serine/threonine-protein kinase receptor R3,1.71201555559483,1.5859382897298,1.84811558027143,3.54186755929185e-43
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61099881926794,ACVRL1;Serine/threonine-protein kinase receptor R3,1.31331601120215,1.22448386993722,1.40859262226815,2.39343372079284e-14
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71191146800902,ACVRL1;Serine/threonine-protein kinase receptor R3,1.22845439303684,1.1478984569571,1.31466349364376,2.74905042014219e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.784751130320473,ACVRL1;Serine/threonine-protein kinase receptor R3,1.57880157168536,1.42906469127044,1.74422782816096,2.65171088059623e-19
sensitivity,Circulatory system disorders,I50 (heart failure),4.4041450777202,ACVRL1;Serine/threonine-protein kinase receptor R3,1.40938904228127,1.35015513793267,1.47122165201253,2.65430198911838e-55
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.21163464069491,ACVRL1;Serine/threonine-protein kinase receptor R3,1.27232670808991,1.21782036465425,1.32927260793386,4.22190366318454e-27
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.76913880365042,ACVRL1;Serine/threonine-protein kinase receptor R3,1.33885177427888,1.2103242897515,1.48102792670362,1.45275321839904e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.79738457858225,ACVRL1;Serine/threonine-protein kinase receptor R3,1.57852974048953,1.42963064036101,1.74293700153258,1.7104843465185e-19
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11314509455668,ACVRL1;Serine/threonine-protein kinase receptor R3,1.29342663268122,1.21620362099215,1.37555292983285,2.57510053276996e-16
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.400629845926929,ACVRL1;Serine/threonine-protein kinase receptor R3,1.68899789584273,1.46986969180354,1.94079373706991,1.43995502654791e-13
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.702202361953399,ACVRL1;Serine/threonine-protein kinase receptor R3,1.50320034998841,1.35260723110936,1.6705598197579,3.796195213991e-14
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0457793435640214,ACVRL1;Serine/threonine-protein kinase receptor R3,2.79853512785214,1.89208898200976,4.13923390299725,2.56240805307218e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.217040680193544,ACVRL1;Serine/threonine-protein kinase receptor R3,1.61570527186639,1.33763028398237,1.95158823540156,6.40159908967942e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.8035371318822,ACVRL1;Serine/threonine-protein kinase receptor R3,1.26848209510133,1.21786177244966,1.32120644722771,2.46938322743891e-30
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.250632436990536,GM2A;Ganglioside GM2 activator,1.69169686428136,1.40584615194142,2.03566960486201,2.59124065454216e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.521967090326053,GM2A;Ganglioside GM2 activator,1.39493886278102,1.22444903077785,1.58916735771409,5.60284795527038e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.06224221972253,GM2A;Ganglioside GM2 activator,1.20777173822817,1.1305580954217,1.29025883549892,2.13822469107431e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.382108865863378,GM2A;Ganglioside GM2 activator,3.84728836872235,3.38144628081232,4.37730679801025,4.79942463116023e-93
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36683889149835,GM2A;Ganglioside GM2 activator,1.43052564552928,1.31940904853293,1.55100014267173,4.00018225621093e-18
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.69252799361487,GM2A;Ganglioside GM2 activator,1.21494687510084,1.12951296427613,1.3068428216433,1.66191571688587e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.758657831268878,GM2A;Ganglioside GM2 activator,1.36877505473809,1.22810569932688,1.52555692193281,1.39823874926794e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.32011331444759,GM2A;Ganglioside GM2 activator,1.31073954843697,1.25180331669213,1.37245056066526,9.56125672178516e-31
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.04484094377274,GM2A;Ganglioside GM2 activator,1.20602338080869,1.12856267619583,1.28880072479451,3.18705091923601e-08
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.751950151092787,GM2A;Ganglioside GM2 activator,1.41016963282491,1.26490526681189,1.572116462408,5.76633226652918e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.787383122817706,GM2A;Ganglioside GM2 activator,1.434010192983,1.28929709558095,1.59496615685195,3.10299930660625e-11
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.08570615034168,GM2A;Ganglioside GM2 activator,1.2612950771922,1.18042860057496,1.34770139504787,6.57963640056988e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.410008903050466,GM2A;Ganglioside GM2 activator,1.50460674317421,1.29906521746984,1.74266959130393,5.00333627223157e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.698808742144264,GM2A;Ganglioside GM2 activator,1.529297821404,1.36671393589509,1.71122263783702,1.28607206861153e-13
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.428681861837944,GM2A;Ganglioside GM2 activator,1.42425772114516,1.23380545776398,1.64410851279411,1.37451844444128e-06
sensitivity,Circulatory system disorders,I95 (hypotension),4.49617871840094,GM2A;Ganglioside GM2 activator,1.24346126460181,1.1888127487761,1.30062191725059,2.05076356479167e-21
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54361741939296,SCG2;Secretogranin-2,3.89414788568375,3.45722907028681,4.38628376867062,4.97748564706268e-111
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0647999057455916,SCG2;Secretogranin-2,2.46075782437466,1.7569672377429,3.44646669564545,1.61521354716891e-07
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0550033394884689,SCG2;Secretogranin-2,3.00429549321217,2.08767245988463,4.32337523436686,3.1552702749634e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.780190625921194,SCG2;Secretogranin-2,1.35624955620223,1.2296914270742,1.49583287172722,1.08182907913456e-09
sensitivity,Circulatory system disorders,I50 (heart failure),4.41890419102348,SCG2;Secretogranin-2,1.20121511217255,1.15198431387923,1.25254982062453,8.96193334947837e-18
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802565060880854,SCG2;Secretogranin-2,1.29674857604661,1.17697680311322,1.42870859054404,1.47614659491694e-07
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409046214355948,SCG2;Secretogranin-2,1.41675244615492,1.23759175076277,1.62184944465642,4.41334488474651e-07
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0432050274941084,SCG2;Secretogranin-2,3.04258648631988,2.02013441951949,4.58253294300004,1.00890425188889e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248818681945807,CFD;Complement factor D,1.58890743467803,1.31637498427557,1.91786296923934,1.41281511338839e-06
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513253341849537,CFD;Complement factor D,1.58614858450039,1.39085586720806,1.80886272361408,5.92518560155825e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.390642847352309,CFD;Complement factor D,3.47008500861356,3.03939674643435,3.9618026113672,1.28156160882543e-75
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36882825554512,CFD;Complement factor D,1.44673547215553,1.33382640436073,1.56920234863414,5.20250898520133e-19
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59337888027878,CFD;Complement factor D,1.21985678571759,1.13129496699316,1.31535154055913,2.36684590243098e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.757575757575757,CFD;Complement factor D,1.3745288077675,1.23247396262033,1.53295688240416,1.09402260730978e-08
sensitivity,Circulatory system disorders,I50 (heart failure),4.3090160351531,CFD;Complement factor D,1.25228561712325,1.19558271398788,1.31167776892904,1.80199026034872e-21
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.746473085878646,CFD;Complement factor D,1.3452773741635,1.2053728097259,1.50142030650898,1.19760973013372e-07
sensitivity,Circulatory system disorders,I09 (other rheumatic heart diseases),0.0331590855894515,HGF;Hepatocyte growth factor,2.8615796520444,1.87392075179329,4.36978890230988,1.12960870699187e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543765281173594,HGF;Hepatocyte growth factor,1.45272373324586,1.29235106653098,1.63299764266121,3.92379391932246e-10
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97233961583912,HGF;Hepatocyte growth factor,1.22890636064322,1.16777801114078,1.29323452644399,2.41132384917306e-15
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34056127441387,HGF;Hepatocyte growth factor,1.44068154610373,1.33718865639186,1.55218435885057,8.0314583611134e-22
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774800444973555,HGF;Hepatocyte growth factor,1.39079862790813,1.26060439711896,1.53443921646785,4.76219252076319e-11
sensitivity,Circulatory system disorders,I50 (heart failure),4.41755214482487,HGF;Hepatocyte growth factor,1.23395223502366,1.18359158389731,1.28645568204039,4.68410522848848e-23
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.7731807798192,HGF;Hepatocyte growth factor,1.30414611903225,1.1818892873905,1.43904942529945,1.24038225267601e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804813252070636,HGF;Hepatocyte growth factor,1.39919579417223,1.27083848781577,1.54051745300389,7.80665159307818e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406226197683729,HGF;Hepatocyte growth factor,1.40313214008105,1.22517017154478,1.6069439562392,9.84599489897187e-07
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699792798780249,HGF;Hepatocyte growth factor,1.3135063895785,1.18438648703026,1.4567027354302,2.40032971612116e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212666328481679,HGF;Hepatocyte growth factor,2.92164173186637,2.47217350796151,3.45282820234639,2.74026326975703e-36
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103374292958845,HGF;Hepatocyte growth factor,4.0362154731918,3.25723793217898,5.00148766692482,2.9723676718915e-37
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,TGFA;Protransforming growth factor alpha,2.30594397243455,2.05115967601887,2.59237623778164,1.9018728893794e-44
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96836982968369,TGFA;Protransforming growth factor alpha,1.22620285469101,1.16459398968213,1.29107092615408,8.95410351828064e-15
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01435520227785,TGFA;Protransforming growth factor alpha,1.25155539721859,1.14720536170393,1.36539713341336,4.37933013432905e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34334568365992,TGFA;Protransforming growth factor alpha,1.40805211023113,1.30535605409,1.51882755583377,8.25800498120046e-19
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.70821608338948,TGFA;Protransforming growth factor alpha,1.21418902220865,1.13530104819951,1.29855863692723,1.49386545209931e-08
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.72997367431365,TGFA;Protransforming growth factor alpha,1.21664400417133,1.13811735234806,1.30058875724211,8.38917765398166e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.788350588793171,TGFA;Protransforming growth factor alpha,1.41119589070681,1.27875842847383,1.55734953342561,7.36814513536415e-12
sensitivity,Circulatory system disorders,I50 (heart failure),4.392605283079,TGFA;Protransforming growth factor alpha,1.27955516611301,1.22681854992867,1.33455874401449,1.6706512304674e-30
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.614782453990155,TGFA;Protransforming growth factor alpha,1.35369825257922,1.21073579410125,1.51354157361501,1.04896907661369e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802926925739147,TGFA;Protransforming growth factor alpha,1.46530027015265,1.32916800419106,1.61537508797932,1.59465334440992e-14
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1320894476587,TGFA;Protransforming growth factor alpha,1.25500029137461,1.181326600929,1.33326865755138,1.8586781777598e-13
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.391466814290515,TGFA;Protransforming growth factor alpha,1.48409772773486,1.29067177857702,1.70651137030059,3.00267060727706e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686707169856127,TGFA;Protransforming growth factor alpha,1.37709099842408,1.23886622009091,1.53073801447381,3.05027026853583e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.219246266887888,TGFA;Protransforming growth factor alpha,1.5776287241207,1.3097549345177,1.90028861550899,1.56993553704367e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.550094330255188,IGFBP6;Insulin-like growth factor-binding protein 6,4.78913934035763,4.29233376132281,5.34344645517331,6.75390835324432e-173
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0633512828634779,IGFBP6;Insulin-like growth factor-binding protein 6,2.75636345766266,1.93044144843061,3.93564876930851,2.41144379685119e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0574348411629565,IGFBP6;Insulin-like growth factor-binding protein 6,3.62487015277854,2.53717767921128,5.17885827711892,1.4957788352318e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.535105256968128,STC1;Stanniocalcin-1,1.96548615339134,1.7496423872379,2.20795737880567,4.95277918242179e-30
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.33958341505511,STC1;Stanniocalcin-1,1.23662466652901,1.146656999133,1.33365127237199,3.56921818786752e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778423204052494,STC1;Stanniocalcin-1,1.31359786552633,1.19046709994248,1.44946412412296,5.57912433233157e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.796758153557026,STC1;Stanniocalcin-1,1.27033522974895,1.15232560319578,1.40043021821771,1.50827815589115e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.220940463388405,STC1;Stanniocalcin-1,2.00083248082676,1.67022225853784,2.39688496298451,5.20668754607852e-14
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101639921033599,STC1;Stanniocalcin-1,2.49304060660939,1.92080134701651,3.23575963535072,6.59371795556991e-12
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34240164974619,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.730744492020808,0.677505606385707,0.788166928193281,4.3772412929903e-16
sensitivity,Circulatory system disorders,I50 (heart failure),4.40208939750388,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.797479675164221,0.7647542203313,0.831605521607347,3.49183866235133e-26
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78335179617028,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.776533150942195,0.70359054556232,0.85703785861745,5.02734164518056e-07
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.0885484700946,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.796458904623188,0.732919596812344,0.865506652452064,8.09247375493591e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37002152229756,TTR;Transthyretin,0.732691233362847,0.674021549878884,0.796467773980276,2.79316933880026e-13
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212182015267879,TTR;Transthyretin,0.401652726841245,0.327256719487771,0.492961346161255,2.59816446669456e-18
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.270370199195821,TTR;Transthyretin,0.589071156569132,0.489702077065693,0.708603952797089,1.97430748735622e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.106054318255175,TTR;Transthyretin,0.294514377032225,0.22265115393204,0.389572282680172,1.0774692656197e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544649504329767,LAMP3;Lysosome-associated membrane glycoprotein 3,2.01757910439149,1.78805477981534,2.27656640525161,4.63452989719521e-30
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96914496649681,LAMP3;Lysosome-associated membrane glycoprotein 3,1.20767823987105,1.14634438422568,1.27229369387385,1.28605114952238e-12
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00647121493114,LAMP3;Lysosome-associated membrane glycoprotein 3,1.20441256533555,1.13115235245269,1.28241754914161,6.28865659222018e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34274233068705,LAMP3;Lysosome-associated membrane glycoprotein 3,1.48956346023073,1.37853140010632,1.60953845656575,6.62153488185524e-24
sensitivity,Circulatory system disorders,I50 (heart failure),4.41886591639237,LAMP3;Lysosome-associated membrane glycoprotein 3,1.22637525163787,1.17538599111513,1.27957647036696,4.58883805908118e-21
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804163650237727,LAMP3;Lysosome-associated membrane glycoprotein 3,1.48686271481635,1.34553019409253,1.64304059650037,7.03328786257057e-15
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13743784790317,LAMP3;Lysosome-associated membrane glycoprotein 3,1.23937894103823,1.16570198540914,1.31771257037871,6.73026692155936e-12
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406885758998435,LAMP3;Lysosome-associated membrane glycoprotein 3,1.47145625292343,1.27872352702077,1.69323818520177,6.95204032845659e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.700930004894762,LAMP3;Lysosome-associated membrane glycoprotein 3,1.41217809771064,1.26916727671503,1.57130349658505,2.3667227720329e-10
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,CBLN4;Cerebellin-4,0.748220642263317,0.665092740257519,0.841738445817596,1.3849087974032e-06
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.542652924858768,GSTA3;Glutathione S-transferase A3,0.736134078189622,0.65317116106792,0.829634578762023,5.13027417202563e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212074084546868,GSTA3;Glutathione S-transferase A3,1.75080034452147,1.44669699492832,2.11882782443215,8.73800434391096e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100959111559818,GSTA3;Glutathione S-transferase A3,2.12218774684503,1.61511321060306,2.78846139285653,6.61788723234752e-08
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.552322714271624,CES1;Liver carboxylesterase 1,0.718483312637126,0.641728645814816,0.804418306560968,9.71745080295987e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222335904297182,CES1;Liver carboxylesterase 1,1.94994644576059,1.61783077835957,2.35024032933145,2.38402460956186e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104246572648059,CES1;Liver carboxylesterase 1,3.30790602546044,2.55442059468324,4.28364940998857,1.18043784882698e-19
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.215093037884783,PTS;6-pyruvoyl tetrahydrobiopterin synthase,2.89490044763706,2.41098089563632,3.47594981648223,4.71350663742746e-30
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101432222988599,PTS;6-pyruvoyl tetrahydrobiopterin synthase,4.4298299621909,3.45634331166979,5.67750125621751,6.61463375499984e-32
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13036752755967,RSPO3;R-spondin-3,1.22851076936148,1.15736262222818,1.30403270457406,1.36848276161387e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,RSPO3;R-spondin-3,3.66449269605598,3.2968039349134,4.07318936295808,4.80315311499251e-128
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0645035183737294,RSPO3;R-spondin-3,2.62410005865939,1.91167050442715,3.60203345812443,2.3821330435955e-09
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547516621040281,RSPO3;R-spondin-3,3.46302646661802,2.50160561393277,4.79394203534883,7.09507457014986e-14
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97749312345654,RSPO3;R-spondin-3,1.21312695731207,1.15235778958879,1.27710076493031,1.7277117850639e-13
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),2.00406736825478,RSPO3;R-spondin-3,1.23317106112087,1.15940384464993,1.31163172608345,2.74493320160981e-11
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,RSPO3;R-spondin-3,1.36941870957205,1.27060485905076,1.47591722852924,1.91132810749506e-16
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60963817535032,RSPO3;R-spondin-3,1.29460117669372,1.20870915453619,1.38659676764,1.68411482872716e-13
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.778575480741016,RSPO3;R-spondin-3,1.51462683021909,1.37352382160747,1.67022544402229,8.71500959737134e-17
sensitivity,Circulatory system disorders,I50 (heart failure),4.41849455578349,RSPO3;R-spondin-3,1.28963449630868,1.23670988789723,1.34482399659405,1.22725637752709e-32
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23386695833747,RSPO3;R-spondin-3,1.23234006570086,1.18066401328885,1.28627790839599,1.19475960112385e-21
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06780193047163,RSPO3;R-spondin-3,1.2181156441692,1.14640616928463,1.29431065736122,1.8454972504832e-10
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.778925943322373,RSPO3;R-spondin-3,1.32115563761886,1.19744018655358,1.45765294869198,2.82639229261401e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80476199800278,RSPO3;R-spondin-3,1.31022202620268,1.18907315719902,1.44371416304651,4.80773411338397e-08
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13499851323223,RSPO3;R-spondin-3,1.20588004478037,1.13551106237688,1.28060987742,1.04418719336731e-09
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409130060292851,RSPO3;R-spondin-3,1.49139750698839,1.30310964561393,1.70689130522342,6.44214403448293e-09
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0430073894514602,RSPO3;R-spondin-3,2.99480668024269,2.05465851896071,4.3651375492619,1.1567110918302e-08
sensitivity,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.66686725237694,RSPO3;R-spondin-3,1.21427426050777,1.13421479318918,1.29998478999362,2.41922943677011e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.80223213408523,RSPO3;R-spondin-3,1.22372920553742,1.1757878469334,1.27362531632807,4.08638932795473e-23
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544825144565516,DPY30;Protein dpy-30 homolog,2.00307410608482,1.79083981488831,2.24046050412262,5.27173579943954e-34
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35002164757743,DPY30;Protein dpy-30 homolog,1.31631406104839,1.22270998752874,1.41708395693706,2.82664249253954e-13
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.779088250878191,DPY30;Protein dpy-30 homolog,1.2714590065079,1.15358442894237,1.40137814335115,1.31012161186184e-06
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805358580997466,DPY30;Protein dpy-30 homolog,1.33932107155211,1.2176348290735,1.47316821913544,1.83598598923172e-09
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.40650406504065,DPY30;Protein dpy-30 homolog,1.42208266024541,1.24418580591551,1.62541565974753,2.41489738296145e-07
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248672758491385,NTproBNP;N-terminal prohormone of brain natriuretic peptide,3.09691103564394,2.60439344987606,3.68256876208534,1.82950213685396e-37
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.510807825812559,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.22671634696616,1.97278735994385,2.51333001747711,2.10692110526794e-38
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.15043146857289,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.99169096867706,1.87793990704206,2.11233218903043,1.1093376019219e-116
sensitivity,Circulatory system disorders,I09 (other rheumatic heart diseases),0.033520654638667,NTproBNP;N-terminal prohormone of brain natriuretic peptide,4.90700066857373,3.05063323892556,7.89300242787086,5.41244368363589e-11
sensitivity,Circulatory system disorders,I11 (hypertensive heart disease),0.209015262057814,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.04613475528695,1.70615978271428,2.45385425164151,1.14042400495534e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.67823580765321,2.38682216206567,3.00522894223003,4.64920244479651e-63
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0650515484239784,NTproBNP;N-terminal prohormone of brain natriuretic peptide,3.55081719917885,2.58271720830084,4.8817976437611,6.0983286418202e-15
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0571890591413752,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.87158838526171,2.0463797772944,4.02956476889757,1.04396183555886e-09
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97292371250936,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.2079508375577,1.14666746143236,1.27250948948499,1.14421589047223e-12
sensitivity,Circulatory system disorders,I22 (subsequent myocardial infarction),0.104594253236501,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.80197555515896,2.19064397875032,3.58390824244619,2.31297521054881e-16
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01881651430489,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.43151247770343,1.31513934267046,1.55818315773258,1.11017320463911e-16
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69191402251791,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.37534164563772,1.33320801552207,1.41880683299429,1.19781833707605e-89
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.61194767173998,2.42273461711493,2.81593806920218,3.38748793603462e-138
sensitivity,Circulatory system disorders,I31 (other diseases of pericardium),0.74662242237497,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.4334721057996,1.29647428905486,1.58494641617886,2.12340792298847e-12
sensitivity,Circulatory system disorders,I33 (acute and subacute endocarditis),0.128192485948131,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.97226371025041,1.56414518342344,2.48686898377111,9.37258061945519e-09
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60935487067684,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.17824536282506,2.03264189877641,2.33427878443569,8.46381150457867e-108
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71560867500395,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.52100503378511,1.42399968100997,1.62461856112132,1.05598916421107e-35
sensitivity,Circulatory system disorders,I36 (nonrheumatic tricuspid valve disorders),0.187310225166607,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.06303454611565,1.69345819734625,2.51326637122556,6.47459961380608e-13
sensitivity,Circulatory system disorders,I37 (pulmonary valve disorders),0.210966304540704,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.86267693763002,1.54937867427545,2.23932691961263,3.59427218621096e-11
sensitivity,Circulatory system disorders,"I38 (endocarditis, valve unspecified)",0.250498037436635,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.78661481490981,1.50544481372733,2.12029857737006,3.08553401584314e-11
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.682195681404729,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.64849784618298,2.38819143048537,2.9371769581345,5.01129221174131e-76
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.86963921708325,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.64005119280249,1.55868503280515,1.72566481258381,5.89174123875354e-81
sensitivity,Circulatory system disorders,I45 (other conduction disorders),1.75906710149224,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.52524527651773,1.43012961049493,1.62668693555302,8.60874053123151e-38
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783222853535353,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.90574399796567,1.73273969589929,2.09602180545488,2.98738522793412e-40
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36396124523507,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.80791175697386,1.67850846422058,1.94729129502607,4.69900604368293e-55
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.40695964053275,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.91040426728856,1.84721697089228,1.97575299598477,2.302559425514e-311
sensitivity,Circulatory system disorders,I49 (other cardiac arrhythmias),1.99620720630801,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.55035802528834,1.45726307157225,1.6494002033433,8.59193379890751e-44
sensitivity,Circulatory system disorders,I50 (heart failure),4.4281764109093,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.14960962177519,2.05912378201698,2.2440717582807,1.62856105885978e-266
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22600184524048,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.88418545161786,1.80437859713408,1.96752212741116,5.27663507197135e-181
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.07546049898106,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.43898043878441,1.35476896243553,1.52842644068376,2.78370592520522e-32
sensitivity,Circulatory system disorders,"I64 (stroke, not specified as haemorrhage or infarction)",0.769030500871167,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.48785921546093,1.34700669833085,1.64344026482953,4.85989274449222e-15
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.609936637650263,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.32223636863724,1.18390567010096,1.4767299952182,7.26323038131975e-07
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71623011790773,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.27422536048765,1.20825291309039,1.34380000388909,4.09729776525229e-19
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773694390715667,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.52605933039731,1.38390034214229,1.68282137735986,2.40420510555947e-17
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80173775671406,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.5816122257568,1.43743069712421,1.74025588688761,5.4491505250151e-21
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08212713019095,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.38098339775966,1.27372116046436,1.49727837150208,5.08054127471781e-15
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13901605261579,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.47625388740449,1.39019886351606,1.56763582338499,5.15180375284658e-37
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.414593698175787,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.53899078943216,1.34916670429134,1.75552260697175,1.3718782301592e-10
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.711378097458799,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.45815901422674,1.31617308079111,1.6154620861055,5.35545182303772e-13
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473158133391163,NTproBNP;N-terminal prohormone of brain natriuretic peptide,2.63121796569193,1.82285569617145,3.79805598299474,2.39089306262649e-07
sensitivity,Circulatory system disorders,I83 (varicose veins of lower extremities),2.08774214553149,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.29397196554382,1.2159918640692,1.37695283750521,4.41815170057432e-16
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.453944381944855,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.51708824048291,1.3327040990895,1.72698255447999,2.89932777094989e-10
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.527272009163079,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.44899000392156,1.28218981547874,1.63748924388442,2.7884424684991e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.77973961120028,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.39037492345991,1.33530180701225,1.44771947258244,1.69103983487238e-57
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1175183622441,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.22931120425035,1.15774952980006,1.305296178489,1.51199418652737e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543765281173594,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,4.10719131164611,3.66149459115638,4.6071406226313,2.20365492523106e-128
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0643513192020436,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,2.49779265902306,1.78600904800338,3.49324555463152,8.84658210835387e-08
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.054622422504438,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,2.58782457088428,1.79640024043859,3.72791979143656,3.30431353180029e-07
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01759799996093,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.27225067481994,1.16713014693344,1.38683914885809,4.44068024783162e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34056127441387,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.37944029746802,1.27875872931485,1.48804891075754,8.87397174751662e-17
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.774800444973555,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.42720732187877,1.29281045334853,1.57557570357551,1.79637582853992e-12
sensitivity,Circulatory system disorders,I50 (heart failure),4.41755214482487,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.29131721656971,1.23821443268065,1.34669739731535,7.97818007750968e-33
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06290489890983,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.20737212245057,1.13617993568381,1.2830251585049,1.22186437499531e-09
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.7731807798192,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.41192608786193,1.27845953921321,1.55932606112192,9.8468160542717e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804813252070636,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.58559273918642,1.438232052271,1.74805194376725,2.0040627966798e-20
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13590696938533,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.26559278367491,1.19143623555584,1.3443649322473,2.07939433729317e-14
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406226197683729,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.6494153781738,1.4387533273639,1.89092253551267,7.08259238040131e-13
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699792798780249,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.43892120442453,1.29601162876404,1.59758923962517,9.20628563970501e-12
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.212666328481679,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.92341140755875,1.59435045725477,2.32038785819846,8.34346589992431e-12
sensitivity,Circulatory system disorders,I95 (hypotension),4.78309450532217,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.23916454734526,1.1903005488692,1.29003450166949,1.51612730340289e-25
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103374292958845,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,2.34876626800918,1.8004399736668,3.06408603587177,3.07319427915018e-10
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.209057832633123,MVK;Mevalonate kinase,2.08940321989038,1.72440253041899,2.53166284453755,5.384270659389e-14
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.098470689897711,MVK;Mevalonate kinase,3.21736815371904,2.43789206029977,4.24606897291942,1.51176436825249e-16
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,SMOC1;SPARC-related modular calcium-binding protein 1,2.11578707246034,1.88620682991392,2.37331074460938,1.90643079004997e-37
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0547516621040281,SMOC1;SPARC-related modular calcium-binding protein 1,2.60340024092788,1.82513582977596,3.7135278941378,1.29057242961963e-07
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34575772437469,SMOC1;SPARC-related modular calcium-binding protein 1,1.22206362586302,1.13347168358853,1.31757989836084,1.76143685459913e-07
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60963817535032,SMOC1;SPARC-related modular calcium-binding protein 1,1.2126227874124,1.13191502523829,1.29908517138223,4.10925360233838e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80476199800278,SMOC1;SPARC-related modular calcium-binding protein 1,1.29663847359672,1.17656603034625,1.42896470563277,1.6100245331288e-07
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.409130060292851,SMOC1;SPARC-related modular calcium-binding protein 1,1.39864378742152,1.22077990452531,1.6024218918098,1.33389781048014e-06
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.213177915550253,SMOC1;SPARC-related modular calcium-binding protein 1,1.90772874215594,1.58578128794011,2.29503840241134,7.43005979466523e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103618839077987,SMOC1;SPARC-related modular calcium-binding protein 1,1.94226772004509,1.49001953515427,2.53178150173619,9.16821760842794e-07
sensitivity,Circulatory system disorders,I81 (portal vein thrombosis),0.0789733464955577,GGT1;Glutathione hydrolase 1 proenzyme,2.29514701957723,1.69344397346623,3.11064311781867,8.51876049799179e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.221221458481472,GGT1;Glutathione hydrolase 1 proenzyme,3.38182063928083,2.85679391419383,4.00333772045757,1.75438844598371e-45
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100704934541792,GGT1;Glutathione hydrolase 1 proenzyme,4.77944426555395,3.77281872049329,6.05464751419328,1.95671598536315e-38
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518489755830154,CKB;Creatine kinase B-type,1.3711035275754,1.20745932263742,1.5569260579507,1.13249463589508e-06
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04674350530552,CKB;Creatine kinase B-type,1.26252263830156,1.18333289090258,1.34701183790146,1.74722718432102e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.386586146948485,CKB;Creatine kinase B-type,2.97094051891803,2.60092894711701,3.39359042342646,6.1817813773247e-58
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0433829573477029,CKB;Creatine kinase B-type,2.82543620445261,1.929709682845,4.13693822257346,9.34373335709258e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.36612648130744,CKB;Creatine kinase B-type,1.51486740009031,1.40106753723713,1.63791050671383,1.93149582894967e-25
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60235072656734,CKB;Creatine kinase B-type,1.34193658306267,1.24774714559911,1.44323615510838,2.35387848809758e-15
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.68598524762908,CKB;Creatine kinase B-type,1.22975727511458,1.14472884222409,1.32110146954889,1.53604325841731e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.754009962071014,CKB;Creatine kinase B-type,1.40017138332784,1.25991968631711,1.55603561400084,4.09291288246691e-10
sensitivity,Circulatory system disorders,I48 (atrial fibrillation and flutter),7.1925158641284,CKB;Creatine kinase B-type,1.22792818462897,1.18520220864058,1.27219441173303,6.35790613861905e-30
sensitivity,Circulatory system disorders,I50 (heart failure),4.31967930700824,CKB;Creatine kinase B-type,1.33875684561268,1.27967907798006,1.40056200223565,8.72386673596754e-37
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.09537297146704,CKB;Creatine kinase B-type,1.27765502617693,1.21982755192339,1.33822388528709,3.44410961156382e-25
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.0482976675984,CKB;Creatine kinase B-type,1.23062578205133,1.15313747879102,1.31332112892318,4.00071790083219e-10
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.61855670103092,CKB;Creatine kinase B-type,1.21843429619075,1.15029733306542,1.29060729905163,1.70932972217455e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.752034378714455,CKB;Creatine kinase B-type,1.38327308622174,1.24449687291415,1.53752449902493,1.7986140736161e-09
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.06756037137366,CKB;Creatine kinase B-type,1.26495771499032,1.18528013712088,1.34999142447484,1.43424072421269e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.688755663356368,CKB;Creatine kinase B-type,1.43818379845969,1.2882086418085,1.60561928481412,9.98894194427622e-11
sensitivity,Circulatory system disorders,I83 (varicose veins of lower extremities),2.03384238310708,CKB;Creatine kinase B-type,1.28287228469891,1.2011735840688,1.37012778225926,1.17447251586198e-13
sensitivity,Circulatory system disorders,I87 (other disorders of veins),0.427438341447804,CKB;Creatine kinase B-type,1.53899019630843,1.34097303773319,1.7662479093071,8.51095046879247e-10
sensitivity,Circulatory system disorders,I95 (hypotension),4.51562571703914,CKB;Creatine kinase B-type,1.26856039567044,1.21420879503273,1.3253449357696,1.79680155693358e-26
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248824993088194,LGALS9;Galectin-9,1.59310888257527,1.346713038038,1.88458553534001,5.56462139259405e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511150582198539,LGALS9;Galectin-9,1.35252861673535,1.19993501394943,1.52452727674561,7.64599536503575e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13001383125864,LGALS9;Galectin-9,1.29413364180272,1.21984751330673,1.37294363809918,1.24511737140125e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544080405191516,LGALS9;Galectin-9,2.69304339200809,2.4316843204788,2.9824935128958,1.17097774320748e-80
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.063120105726177,LGALS9;Galectin-9,2.32546563231497,1.70782270067762,3.16648233152795,8.40978987864948e-08
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.96375828049348,LGALS9;Galectin-9,1.26061899056562,1.19779387001253,1.3267393323344,6.71562860283042e-19
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01155783858539,LGALS9;Galectin-9,1.25681276204026,1.15327699454281,1.3696434822698,1.87719647895273e-07
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.71800122875281,LGALS9;Galectin-9,1.20192546447828,1.16623584953626,1.23870726726139,5.82570055759521e-33
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34610816375009,LGALS9;Galectin-9,1.58864453967669,1.47724872045608,1.7084404531861,9.70337717427527e-36
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.61037621720246,LGALS9;Galectin-9,1.33202666191461,1.24462380414705,1.42556732575697,1.23548987038639e-16
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71669570727071,LGALS9;Galectin-9,1.20703716356355,1.12955605158435,1.28983303854642,2.71386592849437e-08
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.777779971178711,LGALS9;Galectin-9,1.44719563658625,1.31406234277022,1.59381723559559,6.05012612851694e-14
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.35894939701587,LGALS9;Galectin-9,1.21656382294847,1.12913566944392,1.31076147477998,2.5796137241368e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.4108280254777,LGALS9;Galectin-9,1.35605307203634,1.30116751218727,1.41325380241628,2.55949299970841e-47
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22803708311594,LGALS9;Galectin-9,1.26522257020121,1.21255803730774,1.32017446002074,2.10994241879338e-27
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.05891669306303,LGALS9;Galectin-9,1.25521780323863,1.18165329414576,1.33336211338217,1.62156731512206e-13
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.7060733233035,LGALS9;Galectin-9,1.20997140094712,1.14765860349253,1.27566750831182,1.60266304280672e-12
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.780092821171126,LGALS9;Galectin-9,1.41058203592049,1.28066898857514,1.55367366416466,2.98988169126574e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.810132585113319,LGALS9;Galectin-9,1.49587234263369,1.36133435904986,1.64370644917694,5.52178630566552e-17
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12446738282422,LGALS9;Galectin-9,1.35975649399743,1.2810201171509,1.44333230853579,5.66381208658366e-24
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406953773212169,LGALS9;Galectin-9,1.44808638546145,1.26720754106817,1.65478353923875,5.36887491526996e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699936728883264,LGALS9;Galectin-9,1.51662261898367,1.37064539748018,1.67814678591671,7.27302041022889e-16
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.224985198342214,LGALS9;Galectin-9,2.08994611498186,1.76689272618009,2.47206562051497,7.69173409289017e-18
sensitivity,Circulatory system disorders,I95 (hypotension),4.81053320378338,LGALS9;Galectin-9,1.24089630503083,1.19258898089049,1.29116037839742,1.67743223432686e-26
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104565363216667,LGALS9;Galectin-9,2.36661756253052,1.86207924381287,3.00786269214264,1.89569810457647e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,DSG2;Desmoglein-2,2.3321026754978,2.07881070797255,2.61625691468962,3.1224904276896e-47
sensitivity,Circulatory system disorders,I10 (essential (primary) hypertension),19.4968208726156,LEP;Leptin,1.27545266466684,1.23331332327012,1.31903180571532,1.00312434823408e-45
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.549711302697144,LEP;Leptin,2.49633262888351,2.13927726293791,2.91298220291014,3.40839798735278e-31
sensitivity,Circulatory system disorders,I20 (angina pectoris),4.02247794558188,LEP;Leptin,1.33783148552806,1.25654903901699,1.42437185346175,8.96534491010084e-20
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97292371250936,LEP;Leptin,1.23979562177973,1.15374021626048,1.33226974506118,4.73300870043292e-09
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.01881651430489,LEP;Leptin,1.35018947546662,1.19653269152092,1.52357861392287,1.11175746841043e-06
sensitivity,Circulatory system disorders,I25 (chronic ischaemic heart disease),8.69191402251791,LEP;Leptin,1.31171341212556,1.25717921141851,1.36861320957469,5.53558059254078e-36
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.35124441103153,LEP;Leptin,1.35643226728446,1.22028445315478,1.50777016864697,1.61440547479149e-08
sensitivity,Circulatory system disorders,I44 (atrioventricular and left bundle-branch block),2.86963921708325,LEP;Leptin,1.26577278389459,1.17743400933542,1.36073930916313,1.71321124145089e-10
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.783222853535353,LEP;Leptin,1.56760133022019,1.36701643429814,1.79761842568469,1.23233722468341e-10
sensitivity,Circulatory system disorders,I50 (heart failure),4.4281764109093,LEP;Leptin,1.35977562481596,1.28239618666317,1.44182411728371,8.61615436858805e-25
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.22600184524048,LEP;Leptin,1.23097582943814,1.15906766351742,1.30734515365776,1.31777145618213e-11
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.07546049898106,LEP;Leptin,1.26717545931923,1.16362956248913,1.3799354162729,5.2029880225377e-08
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71623011790773,LEP;Leptin,1.21588267990933,1.12835194417315,1.31020352199317,2.93031101697489e-07
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773694390715667,LEP;Leptin,1.53941873365999,1.3404024987838,1.76798390012966,1.00990848624647e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.80173775671406,LEP;Leptin,1.71484538168809,1.498107001806,1.9629403504235,5.15639854085187e-15
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13901605261579,LEP;Leptin,1.33778955007259,1.22913500017437,1.45604907518664,1.65564722049729e-11
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.711378097458799,LEP;Leptin,1.54394914820476,1.33620022157971,1.78399833628526,3.84378468320455e-09
sensitivity,Circulatory system disorders,I95 (hypotension),4.77973961120028,LEP;Leptin,1.33410706545406,1.2606082360116,1.41189118970507,2.06051016157752e-23
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.221890586340965,GUSB;Beta-glucuronidase,1.9623123083892,1.62141929548911,2.37487589198462,4.38924407763251e-12
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104037846220285,GUSB;Beta-glucuronidase,2.99815340949999,2.29866687034811,3.91049437517456,5.47400512294259e-16
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.245083506275323,CCL3;C-C motif chemokine 3,1.60649613602303,1.36048454252751,1.89699313324225,2.271308969898e-08
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.515514823520116,CCL3;C-C motif chemokine 3,1.34966912444711,1.19968755611885,1.51840096714762,6.06447710703908e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1318672625875,CCL3;C-C motif chemokine 3,1.20140487577604,1.13254542072968,1.27445102785236,1.10764786975336e-09
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.538603195976317,CCL3;C-C motif chemokine 3,2.09461928257594,1.88124435581859,2.33219566898307,1.83711591090132e-41
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34334568365992,CCL3;C-C motif chemokine 3,1.44196237680446,1.34088321713508,1.55066113853084,5.58563735885584e-23
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.788350588793171,CCL3;C-C motif chemokine 3,1.39450617812906,1.26733290641903,1.53444092786552,9.37323960269227e-12
sensitivity,Circulatory system disorders,I50 (heart failure),4.392605283079,CCL3;C-C motif chemokine 3,1.24188618766568,1.19177559554684,1.29410378000493,6.42900372581401e-25
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.782763391974698,CCL3;C-C motif chemokine 3,1.29182312871232,1.17273601838174,1.42300310531851,2.11385940237235e-07
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.802926925739147,CCL3;C-C motif chemokine 3,1.41615163947732,1.28843117340331,1.55653286523403,5.38905186042907e-13
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.1320894476587,CCL3;C-C motif chemokine 3,1.21943117458217,1.14914896253418,1.29401186271238,5.75389246849093e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.391466814290515,CCL3;C-C motif chemokine 3,1.48481375182124,1.29771046879521,1.69889349790349,8.80830976455527e-09
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.686707169856127,CCL3;C-C motif chemokine 3,1.40470943426088,1.26839197681788,1.55567729122022,6.80904873128327e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.219246266887888,CCL3;C-C motif chemokine 3,1.81015921584071,1.52129364375173,2.15387502613389,2.23257902447663e-11
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102677513624516,CCL3;C-C motif chemokine 3,1.98103833150984,1.54290311270213,2.54358996271527,8.30154877424898e-08
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.766415008007321,C1RL;Complement C1r subcomponent-like protein,1.34892461026471,1.2083219589534,1.50588805466538,9.8547442859263e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.677624650885948,C1RL;Complement C1r subcomponent-like protein,1.34467486870622,1.19612377000445,1.51167508570068,7.1116341505518e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,ALDH1A1;Retinal dehydrogenase 1,2.28763301784564,1.90711738946226,2.74407063416959,4.86719626218511e-19
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.270633321480779,ALDH1A1;Retinal dehydrogenase 1,1.55397086443078,1.30645999475462,1.84837305175448,6.36091848078544e-07
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102507490932029,ALDH1A1;Retinal dehydrogenase 1,3.6547241698395,2.83410690057141,4.712951637398,1.70200781965917e-23
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.248011967561609,ANGPTL4;Angiopoietin-related protein 4,1.84875134392789,1.55724387000675,2.19482741111087,2.2339250743528e-12
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.12895856310067,ANGPTL4;Angiopoietin-related protein 4,1.30043021704502,1.22531333358317,1.38015208278069,4.9926690409136e-18
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54229934924078,ANGPTL4;Angiopoietin-related protein 4,2.85481935782796,2.54090044775237,3.20752179529054,1.02225251446651e-69
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0629141025893085,ANGPTL4;Angiopoietin-related protein 4,2.79530476124367,1.99399222050749,3.91863550312292,2.45805521202484e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34372533543804,ANGPTL4;Angiopoietin-related protein 4,1.4691015907612,1.36332341568689,1.58308693237669,6.18364326138536e-24
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60713226718326,ANGPTL4;Angiopoietin-related protein 4,1.25464294871955,1.17138367395133,1.34382010247915,9.47050582023774e-11
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.779174783070657,ANGPTL4;Angiopoietin-related protein 4,1.49857788434212,1.35840335443611,1.65321711559784,6.84986895639618e-16
sensitivity,Circulatory system disorders,I50 (heart failure),4.40630889792679,ANGPTL4;Angiopoietin-related protein 4,1.37041622193541,1.31434779596124,1.42887645653198,1.84006922749705e-49
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23025381522891,ANGPTL4;Angiopoietin-related protein 4,1.23284252157008,1.18118251977345,1.28676191659422,9.31933068877878e-22
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.781480679514182,ANGPTL4;Angiopoietin-related protein 4,1.35841680245327,1.23144214664318,1.49848388267165,9.48025126725019e-10
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.809469413479339,ANGPTL4;Angiopoietin-related protein 4,1.28894629705541,1.17001006189574,1.41997287955024,2.76698954230557e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.12948377963431,ANGPTL4;Angiopoietin-related protein 4,1.25990065474207,1.18646377288675,1.33788295613726,4.70162368349099e-14
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.70160225458702,ANGPTL4;Angiopoietin-related protein 4,1.32169001916562,1.19147458169332,1.46613661223003,1.36037741538324e-07
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.533769277737291,ANGPTL4;Angiopoietin-related protein 4,1.37660430000208,1.2234986857143,1.54886917404236,1.07772060652527e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.80858548925825,ANGPTL4;Angiopoietin-related protein 4,1.22663218820655,1.1787930514568,1.27641278788073,7.95370027069947e-24
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.518170197224251,RNASE1;Ribonuclease pancreatic,1.43592513724283,1.2590430920539,1.63765721187689,6.87537361764111e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.04090961033024,RNASE1;Ribonuclease pancreatic,1.30051393076787,1.21693091818883,1.38983771292337,8.98848595871087e-15
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.400045719510801,RNASE1;Ribonuclease pancreatic,4.16104747972447,3.64693240647872,4.74763834332734,1.19924607755894e-99
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0433582072522306,RNASE1;Ribonuclease pancreatic,3.17860303999416,2.09596988851733,4.82044963585199,5.24042068466041e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.37441301110983,RNASE1;Ribonuclease pancreatic,1.60882910947039,1.48324727183596,1.74504356261209,1.92695539751926e-30
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.59910064927616,RNASE1;Ribonuclease pancreatic,1.21988689692234,1.13163465246076,1.31502162650009,2.13079842984181e-07
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.68730969115593,RNASE1;Ribonuclease pancreatic,1.2733553655239,1.18366103767484,1.36984646389443,8.91304722182956e-11
sensitivity,Circulatory system disorders,I42 (cardiomyopathy),0.684273160014646,RNASE1;Ribonuclease pancreatic,1.33259249326825,1.18804592567173,1.49472567915323,9.51728259581292e-07
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.760395496997237,RNASE1;Ribonuclease pancreatic,1.41752527347198,1.27126082733912,1.58061812156804,3.3971980580065e-10
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.33268996576365,RNASE1;Ribonuclease pancreatic,1.22912115562129,1.13205380741244,1.33451149168337,8.8768500577185e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.3326119987108,RNASE1;Ribonuclease pancreatic,1.39515906436992,1.33199672111105,1.46131652131243,4.50537940573907e-45
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.09010764662212,RNASE1;Ribonuclease pancreatic,1.28126800590198,1.22180241367301,1.34362781131924,1.58156560520154e-24
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.04478842278805,RNASE1;Ribonuclease pancreatic,1.251739462107,1.1714188104315,1.33756745840436,3.22658861949973e-11
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.749303239365833,RNASE1;Ribonuclease pancreatic,1.39568948469463,1.25090255551321,1.55723491738169,2.42949146286158e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.761021093767854,RNASE1;Ribonuclease pancreatic,1.41869973916337,1.2722408745277,1.5820187750605,3.15317058118772e-10
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.07381936987365,RNASE1;Ribonuclease pancreatic,1.27794832711887,1.16588714037673,1.40078046169906,1.62493880886928e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.05007172937202,RNASE1;Ribonuclease pancreatic,1.25584415801959,1.17467479775991,1.34262227489645,2.35062292353784e-11
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.402129458267644,RNASE1;Ribonuclease pancreatic,1.50846338149266,1.29880177706008,1.75197001843878,7.28152060796183e-08
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.683756774680418,RNASE1;Ribonuclease pancreatic,1.48339719269809,1.32241496369901,1.66397635515973,1.71997854554648e-11
sensitivity,Circulatory system disorders,I95 (hypotension),4.53576096677291,RNASE1;Ribonuclease pancreatic,1.23650572274025,1.18238105952115,1.29310799598616,1.45881620639649e-20
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.804544302728271,CTSD;Cathepsin D,1.31333241483675,1.18710537336664,1.45298140380687,1.24524465302879e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.22566698302225,CTSD;Cathepsin D,2.70586291130963,2.27699243112685,3.21551094975649,1.22836871991881e-29
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.109635251950242,CTSD;Cathepsin D,4.15432426665115,3.31524191646841,5.20577699828049,3.72084228344137e-35
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.249223648555096,FSTL3;Follistatin-related protein 3,1.88094221281032,1.59288968353667,2.22108514136178,9.3808456530311e-14
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.513945719425171,FSTL3;Follistatin-related protein 3,1.39271099542393,1.23486468602663,1.57073397492305,6.76611751718015e-08
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.1314492667577,FSTL3;Follistatin-related protein 3,1.2606219140886,1.18776518507128,1.33794762656311,2.43745699644847e-14
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.544953728474327,FSTL3;Follistatin-related protein 3,3.90643873332299,3.56086378929311,4.28555105732802,8.02577802749576e-183
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.0632211158526948,FSTL3;Follistatin-related protein 3,2.82480067611248,2.10918805834342,3.7832088173459,3.23786592977846e-12
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0573167839354889,FSTL3;Follistatin-related protein 3,2.60720830781102,1.90100339363647,3.5757617177714,2.75498742596854e-09
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00526378279969,FSTL3;Follistatin-related protein 3,1.23760677100325,1.13543911349846,1.34896755046054,1.23837866532799e-06
sensitivity,Circulatory system disorders,I26 (pulmonary embolism),1.98363600079824,FSTL3;Follistatin-related protein 3,1.22648581109229,1.15270615507087,1.30498777870951,1.12203962080492e-10
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34435786092439,FSTL3;Follistatin-related protein 3,1.59510938611822,1.48171048600465,1.71718697931551,2.30157992869564e-35
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60902643968137,FSTL3;Follistatin-related protein 3,1.27289203180125,1.18824035761111,1.36357439321498,6.32725314168555e-12
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.777048402404302,FSTL3;Follistatin-related protein 3,1.59752974584423,1.45193159443611,1.75772832455533,7.40801927236969e-22
sensitivity,Circulatory system disorders,I47 (paroxysmal tachycardia),1.36108568472161,FSTL3;Follistatin-related protein 3,1.20666029539898,1.11981128204862,1.30024504292244,8.25728647282529e-07
sensitivity,Circulatory system disorders,I50 (heart failure),4.40200163480133,FSTL3;Follistatin-related protein 3,1.42906049708468,1.37085772658743,1.48973439381761,1.50778296455512e-63
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23090064920708,FSTL3;Follistatin-related protein 3,1.29607456935491,1.24203307576168,1.35246743594036,7.82107474806626e-33
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06618944696714,FSTL3;Follistatin-related protein 3,1.22370532633475,1.15186487614867,1.30002638044392,6.14732943085528e-11
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71427721712235,FSTL3;Follistatin-related protein 3,1.24264859128766,1.17864498713445,1.31012776390238,8.13769007362124e-16
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.785298888317442,FSTL3;Follistatin-related protein 3,1.40341927975528,1.27385475161935,1.54616189348514,7.00292787431773e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.81144734498387,FSTL3;Follistatin-related protein 3,1.63386612909086,1.48767050290714,1.794428620164,1.01028730815367e-24
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13384091364456,FSTL3;Follistatin-related protein 3,1.3216112445043,1.24479782194062,1.40316463510291,7.0120066098531e-20
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.403648667365796,FSTL3;Follistatin-related protein 3,1.61399421562889,1.41405914553482,1.84219828166966,1.29623388275727e-12
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.699092961539985,FSTL3;Follistatin-related protein 3,1.52730587397135,1.37931069586255,1.69118041327784,3.82212948777974e-16
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0474214582098399,FSTL3;Follistatin-related protein 3,2.50995492129204,1.7729546087396,3.5533192309964,2.11755417996348e-07
sensitivity,Circulatory system disorders,I80 (phlebitis and thrombophlebitis),1.66670046026886,FSTL3;Follistatin-related protein 3,1.2054281339447,1.12576494079592,1.29072858236114,8.51617490354169e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.225345430824882,FSTL3;Follistatin-related protein 3,2.64109155361329,2.25385139691907,3.0948644636033,3.32242765243754e-33
sensitivity,Circulatory system disorders,I89 (other non-infective disorders of lymphatic vessels and lymph nodes),0.528461721162219,FSTL3;Follistatin-related protein 3,1.35414514521466,1.20182750162326,1.52576727677783,6.37102466340695e-07
sensitivity,Circulatory system disorders,I95 (hypotension),4.81032770605759,FSTL3;Follistatin-related protein 3,1.32785743962666,1.2759164348913,1.38191289943067,4.24377055283073e-44
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.104732733919573,FSTL3;Follistatin-related protein 3,3.52736574510867,2.85696302544854,4.35508229855815,9.98238237620188e-32
sensitivity,Circulatory system disorders,I99 (other and unspecified disorders of circulatory system),0.0968781510112892,FSTL3;Follistatin-related protein 3,2.13723801149885,1.6543745423368,2.76103518332889,6.1417688061027e-09
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.246645619573796,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.68656564189608,1.41945468611604,2.00394115588681,2.822307270925e-09
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.14412635735439,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.23308733315584,1.16174440266895,1.30881144569858,5.5655194827018e-12
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.529780378358076,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,4.32625047501759,3.88962023120977,4.81189475065247,2.3113135464776e-160
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.065040009460365,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,3.02583214615796,2.22591914198927,4.11320429570527,1.56982194865823e-12
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.055206135767661,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,3.28674706907136,2.36019043568581,4.57704858587404,1.8885551893248e-12
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97398522117623,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.23094712127531,1.16929164956516,1.29585361867543,2.27544993360614e-15
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00874508952365,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.2747598379691,1.16908144091678,1.38999096865714,3.84056526682063e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3430385505469,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.50372755209233,1.39518673731454,1.62071247557438,1.37075111370742e-26
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60328187241126,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.23588484931066,1.1532925465523,1.32439194662424,1.95607689072235e-09
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.72526363690323,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.22936029810995,1.15037806790883,1.31376526094267,1.09514293380498e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781126716111724,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.51104590016765,1.37060629812125,1.66587568986311,1.09437459122251e-16
sensitivity,Circulatory system disorders,I50 (heart failure),4.42124105011933,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.36189564074138,1.30593033185496,1.42025932856299,3.49415828791236e-47
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23266631912419,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.21317851723719,1.16218646310277,1.26640789702236,1.1412449195781e-18
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.07307182560876,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.22037255283705,1.14851946299043,1.29672087910489,1.25538303054146e-10
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71750954292834,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.21616629133785,1.15333382258569,1.28242180990628,4.80087310453607e-13
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.773495925333964,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.42272300149131,1.28928478916326,1.56997178279446,2.27335547590014e-12
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805528134254689,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.61020010399572,1.46275801684118,1.77250395831489,2.4307217410417e-22
sensitivity,Circulatory system disorders,I71 (aortic aneurysm and dissection),1.08191348640698,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.24120434573589,1.14156905950399,1.3495357245781,4.1663203236164e-07
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.11685689727547,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.35569984863337,1.27614036712519,1.4402193731438,6.06098296275545e-23
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.406616398878844,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.63085818977476,1.42573695840005,1.86549027819275,9.91079242647216e-13
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.703334913861229,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.50023791515718,1.35312192741428,1.66334885014843,1.33039014540026e-14
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0453362769060947,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,2.76529796478765,1.90479060548316,4.0145477471625,8.89755949072651e-08
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.222822550430856,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,2.02054903003115,1.69207981543085,2.41278120897641,7.81507759887962e-15
sensitivity,Circulatory system disorders,I95 (hypotension),4.79237657500594,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.31066236733141,1.2590830689192,1.36435465105044,8.0273924964923e-40
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102507490932029,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,2.41068320668384,1.86863755749198,3.10996292442465,1.27845060852851e-11
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.545055289781193,ANGPTL7;Angiopoietin-related protein 7,1.61605481569767,1.43557057294333,1.81923007935794,1.95939665839425e-15
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103618839077987,ANGPTL7;Angiopoietin-related protein 7,2.72745334486094,2.08925938519775,3.56059271581974,1.61157431982028e-13
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.543915801048559,VWA1;von Willebrand factor A domain-containing protein 1,1.43357442826882,1.27528347017445,1.61151280436901,1.60549537295109e-09
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34779362646862,VWA1;von Willebrand factor A domain-containing protein 1,1.24343440279529,1.15419276129003,1.33957616605288,9.81988082508437e-09
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.805977173785151,VWA1;von Willebrand factor A domain-containing protein 1,1.38919906612206,1.26213396126948,1.52905642707951,1.8582373596567e-11
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.211540721588905,VWA1;von Willebrand factor A domain-containing protein 1,1.97184966122641,1.64048843916635,2.37014232691245,4.71534255600535e-13
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.103775062656641,VWA1;von Willebrand factor A domain-containing protein 1,2.31493979116046,1.78443672466239,3.00315845478462,2.60352218076487e-10
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.101026108315835,CES2;Cocaine esterase,1.94418465947283,1.48551609032591,2.54447192779999,1.28106098094886e-06
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.3449885765372,ICAM1;Intercellular adhesion molecule 1,1.4006674227123,1.29832498582851,1.51107715746191,3.20340179110743e-18
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.807107303627025,ICAM1;Intercellular adhesion molecule 1,1.3462796742792,1.22135135233419,1.48398653500764,2.17432515556125e-09
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.221839285360587,ICAM1;Intercellular adhesion molecule 1,3.67822672915539,3.077582310659,4.39609748997294,1.68749972473945e-46
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.273831256448924,ICAM1;Intercellular adhesion molecule 1,1.66850323030756,1.41350271764509,1.9695066693503,1.45232409348532e-09
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.102962141612545,ICAM1;Intercellular adhesion molecule 1,5.41262955849316,4.22033482974175,6.94176171307872,2.24768883411251e-40
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.401366941125203,PRND;Prion-like protein doppel,2.07472428351763,1.78242533515354,2.41495717532928,4.51677403677917e-21
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.395745167562621,FCAMR;High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor,1.48547977330991,1.27834829599192,1.726172877792,2.40360063110102e-07
sensitivity,Circulatory system disorders,I85 (oesophageal varices),0.21015121750651,FCAMR;High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor,3.00070689234492,2.48476686951632,3.62377733067531,3.50938486869007e-30
sensitivity,Circulatory system disorders,I86 (varicose veins of other sites),0.265482674966814,FCAMR;High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor,1.67496499862698,1.39660499206006,2.00880546938847,2.66263366717126e-08
sensitivity,Circulatory system disorders,I98 (other disorders of circulatory system in diseases classified elsewhere),0.100472678281917,FCAMR;High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor,3.58555350114828,2.76212687349869,4.65445451943059,8.62764643108606e-22
sensitivity,Circulatory system disorders,I05 (rheumatic mitral valve diseases),0.24882990698501,COLEC12;Collectin-12,1.86152552148507,1.56728668005919,2.21100409467489,1.45384668761054e-12
sensitivity,Circulatory system disorders,I07 (rheumatic tricuspid valve diseases),0.511160670232292,COLEC12;Collectin-12,1.37000154187768,1.21213663775376,1.54842627991623,4.65798260616133e-07
sensitivity,Circulatory system disorders,I08 (multiple valve diseases),2.13594151353487,COLEC12;Collectin-12,1.29405580962359,1.21874286333281,1.37402276460616,3.57323490259107e-17
sensitivity,Circulatory system disorders,I12 (hypertensive renal disease),0.54409116989494,COLEC12;Collectin-12,4.35273290254291,3.92939930116158,4.82167432443908,1.20663884275183e-174
sensitivity,Circulatory system disorders,I13 (hypertensive heart and renal disease),0.063121350796907,COLEC12;Collectin-12,3.03984728834891,2.24605475801518,4.11417909715082,5.99918736957028e-13
sensitivity,Circulatory system disorders,I15 (secondary hypertension),0.0572263004183439,COLEC12;Collectin-12,3.13994993198127,2.28565873097704,4.3135422807125,1.639450331553e-12
sensitivity,Circulatory system disorders,I21 (acute myocardial infarction),2.97204213938411,COLEC12;Collectin-12,1.21862060269074,1.15746586536625,1.28300645205847,5.20432384212722e-14
sensitivity,Circulatory system disorders,I24 (other acute ischaemic heart diseases),1.00762634844114,COLEC12;Collectin-12,1.28581273356741,1.17920219710237,1.40206182609459,1.25065799504655e-08
sensitivity,Circulatory system disorders,I27 (other pulmonary heart diseases),1.34420842159444,COLEC12;Collectin-12,1.53683107211547,1.42537589627855,1.65700132181695,4.717697592848e-29
sensitivity,Circulatory system disorders,I34 (nonrheumatic mitral valve disorders),1.60848869496231,COLEC12;Collectin-12,1.33452254187714,1.24491420078203,1.43058084939465,4.04441554519413e-16
sensitivity,Circulatory system disorders,I35 (nonrheumatic aortic valve disorders),1.71082333372935,COLEC12;Collectin-12,1.22100962132248,1.14210991914479,1.30535990483159,4.6665277959085e-09
sensitivity,Circulatory system disorders,I46 (cardiac arrest),0.781743524952621,COLEC12;Collectin-12,1.54724285191489,1.4041967782654,1.70486108489651,1.16006224190318e-18
sensitivity,Circulatory system disorders,I50 (heart failure),4.41290630784848,COLEC12;Collectin-12,1.37029603144805,1.31382395348767,1.4291954480033,9.83888057989018e-49
sensitivity,Circulatory system disorders,I51 (complications and ill-defined descriptions of heart disease),4.23614873678084,COLEC12;Collectin-12,1.29394870064914,1.23955435562299,1.3507299880126,6.22594966961035e-32
sensitivity,Circulatory system disorders,I63 (cerebral infarction),2.06881533101045,COLEC12;Collectin-12,1.26604762228425,1.1912487818157,1.3455431026326,3.14231543991133e-14
sensitivity,Circulatory system disorders,"I65 (occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction)",0.62022241096648,COLEC12;Collectin-12,1.3149376841701,1.17756966078979,1.4683302150388,1.15353348475584e-06
sensitivity,Circulatory system disorders,I67 (other cerebrovascular diseases),2.71206572305255,COLEC12;Collectin-12,1.22965279704352,1.16568801507661,1.29712751758674,3.32799365156193e-14
sensitivity,Circulatory system disorders,I69 (sequelae of cerebrovascular disease),0.78405814274993,COLEC12;Collectin-12,1.44959019397624,1.31436584492669,1.59872667003855,1.07740698478473e-13
sensitivity,Circulatory system disorders,I70 (atherosclerosis),0.808188590511194,COLEC12;Collectin-12,1.57399141240248,1.42997935533505,1.73250680653097,1.94159509829274e-20
sensitivity,Circulatory system disorders,I73 (other peripheral vascular diseases),2.13234117458793,COLEC12;Collectin-12,1.35962045138572,1.2796707982783,1.44456509776842,2.92022844152008e-23
sensitivity,Circulatory system disorders,I74 (arterial embolism and thrombosis),0.404986269977676,COLEC12;Collectin-12,1.6480067193648,1.44166061005982,1.8838873227998,2.48944157314882e-13
sensitivity,Circulatory system disorders,I77 (other disorders of arteries and arterioles),0.701941709178629,COLEC12;Collectin-12,1.57884241783445,1.4241106422545,1.75038603489902,4.0236251961516e-18
sensitivity,Circulatory system disorders,"I79 (disorders of arteries, arterioles and capillaries in diseases classified elsewhere)",0.0473466166896823,COLEC12;Collectin-12,2.64482491103294,1.85403310763214,3.77290933005728,8.04462150814921e-08
sensitivity,Circulatory system disorders,I95 (hypotension),4.81657743406702,COLEC12;Collectin-12,1.25977028884205,1.20990675261122,1.31168883653561,3.76088191884487e-29
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0641050545864252,CDH3;Cadherin-3,3.30495803915639,2.35918301614623,4.62988567051783,3.64640140858256e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376940563856451,CDH3;Cadherin-3,1.48176207653495,1.2868817622917,1.70615429932519,4.61035794761427e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.3380984796914,CSF1R;Macrophage colony-stimulating factor 1 receptor,1.62345327425431,1.38540655659363,1.90240223791588,2.1044683816925e-09
primary,Nervous system disorders,G20 (parkinson's disease),1.52192485744372,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,0.79902109767283,0.744158944301892,0.85792789217258,6.32343119609838e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0614311475734696,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,2.53760842493201,1.81801508315917,3.54202590393038,4.42155851501041e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370634637491576,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.49606601838139,1.3006122040676,1.72089230314434,1.70560269173966e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,KLK4;Kallikrein-4,3.90481975151384,2.88120834737521,5.29209118309797,1.59929918124163e-18
primary,Nervous system disorders,G62 (other polyneuropathies),0.982264665757162,KLK4;Kallikrein-4,1.30672264034009,1.19882443355705,1.42433204644566,1.17134771474217e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,KLK4;Kallikrein-4,2.20683598785861,1.93441044360115,2.51762757661788,5.25758941877754e-32
primary,Nervous system disorders,G30 (alzheimer's disease),1.36943361479536,NPTXR;Neuronal pentraxin receptor,0.779053846852315,0.722631266204087,0.839881866008246,7.56488356613378e-11
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607307277892056,CCN5;CCN family member 5,2.92245145918866,2.11010066334668,4.04754269768726,1.0910110936749e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,CCN5;CCN family member 5,1.71064929534776,1.48007191013913,1.97714786128109,3.65338019682124e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0612953756044405,SRPX;Sushi repeat-containing protein SRPX,2.56354168121489,1.81578722693823,3.61922688618496,8.79091542735789e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.949496789471287,SRPX;Sushi repeat-containing protein SRPX,1.27693612288057,1.15892513354063,1.4069639312556,7.76896670365807e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.342885689631681,SRPX;Sushi repeat-containing protein SRPX,1.6821398890571,1.43851389494339,1.96702625974174,7.26891917184603e-11
primary,Nervous system disorders,G25 (other extrapyramidal and movement disorders),0.940267644649057,ANGPT2;Angiopoietin-2,1.22720797535601,1.12207174006401,1.34219529910938,7.45046193852277e-06
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.01288955421194,ANGPT2;Angiopoietin-2,1.22603777355412,1.12516735080286,1.3359511552739,3.28453385808026e-06
primary,Nervous system disorders,G40 (epilepsy),0.82579630357845,ANGPT2;Angiopoietin-2,1.33666935916819,1.21478086925036,1.47078787702811,2.71217165148007e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,ANGPT2;Angiopoietin-2,2.48980896025342,1.79388648698339,3.45570843168721,4.92894264129166e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.982264665757162,ANGPT2;Angiopoietin-2,1.34429609801228,1.2320962681199,1.46671331282305,2.85766878037841e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,ANGPT2;Angiopoietin-2,2.19919880373557,1.9151504483748,2.52537620867134,5.7848509449972e-29
primary,Nervous system disorders,G81 (hemiplegia),0.96374751762003,ANGPT2;Angiopoietin-2,1.42359955577705,1.30405341197419,1.5541048216273,2.96823898134076e-15
primary,Nervous system disorders,G25 (other extrapyramidal and movement disorders),0.946421283790349,GDF15;Growth/differentiation factor 15,1.25785802309064,1.15476604026244,1.37015356452109,1.45528533513428e-07
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00718588390245,GDF15;Growth/differentiation factor 15,1.4060566251764,1.29757921497664,1.5236027291313,8.85896502406608e-17
primary,Nervous system disorders,G40 (epilepsy),0.816814228629632,GDF15;Growth/differentiation factor 15,1.43866928490262,1.31594266026823,1.57284156355289,1.29590404346854e-15
primary,Nervous system disorders,G47 (sleep disorders),2.63137099960489,GDF15;Growth/differentiation factor 15,1.22208517642816,1.15996804315668,1.28752872741315,4.87191607755249e-14
primary,Nervous system disorders,G51 (facial nerve disorders),0.408218805279629,GDF15;Growth/differentiation factor 15,1.41318384177061,1.24593136761468,1.6028881064813,7.39317257576218e-08
primary,Nervous system disorders,G55 (nerve root and plexus compressions in diseases classified elsewhere),1.57656344161272,GDF15;Growth/differentiation factor 15,1.22252294445386,1.14354449452372,1.306956009909,3.71384677055054e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0658174919663943,GDF15;Growth/differentiation factor 15,2.89788238229875,2.35237402239342,3.56989246679964,1.53799383112771e-23
primary,Nervous system disorders,G62 (other polyneuropathies),0.990214352283317,GDF15;Growth/differentiation factor 15,1.42349645738492,1.31283207052408,1.54348923193087,1.21151854224238e-17
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373697866243271,GDF15;Growth/differentiation factor 15,2.56665211868501,2.32582586063275,2.83241458866488,1.90587247316563e-78
primary,Nervous system disorders,G72 (other myopathies),0.0948546207750977,GDF15;Growth/differentiation factor 15,1.8109521702692,1.4285487887013,2.29571981646086,9.24389307098594e-07
primary,Nervous system disorders,G81 (hemiplegia),0.958181394987974,GDF15;Growth/differentiation factor 15,1.47989739388633,1.36465914144905,1.60486690772176,2.62616791969144e-21
primary,Nervous system disorders,G93 (other disorders of brain),0.875397243181064,GDF15;Growth/differentiation factor 15,1.35684779965372,1.24340601397824,1.48063941361745,7.36219011002287e-12
primary,Nervous system disorders,G99 (other disorders of nervous system in diseases classified elsewhere),0.503739295539969,GDF15;Growth/differentiation factor 15,1.50516333428111,1.34729754086169,1.68152660726692,4.72096684382267e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.968455360260738,COL5A1;Collagen alpha-1(V) chain,1.27088553013227,1.15411073017359,1.3994757941958,1.09039761110588e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.343634632798532,COL5A1;Collagen alpha-1(V) chain,1.71832960758804,1.46609691099552,2.01395734358975,2.32970125029509e-11
primary,Nervous system disorders,G30 (alzheimer's disease),1.38500375247322,VGF;Neurosecretory protein VGF,0.754309296041447,0.696247298726245,0.817213244683998,5.22590345607604e-12
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0629590766002098,PRRT3;Proline-rich transmembrane protein 3,2.93463694805282,2.07428643018691,4.1518345256208,1.19088321460175e-09
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",0.957738621042354,C7;Complement component C7,1.30291749029555,1.18376272742599,1.43406609043127,6.39237619283572e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0627206838877532,C7;Complement component C7,2.72712993195288,1.92466628137824,3.86416997986144,1.67771388833928e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.943528096169974,C7;Complement component C7,1.29539660755164,1.17554777147233,1.42746420994409,1.7401159133267e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336927223719676,C7;Complement component C7,2.23890935147588,1.9194514869138,2.61153517986843,1.05362998150966e-24
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0665270902224744,KLK6;Kallikrein-6,2.43101876118726,1.73395301797254,3.40831161858967,2.57067017364582e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.9952588064731,PLA2G15;Phospholipase A2 group XV,1.25667094129205,1.15237041954872,1.3704116557472,2.36558401574366e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373207237484856,PLA2G15;Phospholipase A2 group XV,1.64384711030143,1.42976569404627,1.88998332614835,2.91161023264717e-12
primary,Nervous system disorders,G81 (hemiplegia),0.96496378939127,PLA2G15;Phospholipase A2 group XV,1.34874029900205,1.23533629051621,1.47255480804503,2.45056705894791e-11
primary,Nervous system disorders,G93 (other disorders of brain),0.883440894065795,PLA2G15;Phospholipase A2 group XV,1.26044567186779,1.14942880883867,1.38218502921936,8.63591719283608e-07
primary,Nervous system disorders,G30 (alzheimer's disease),1.38258108596921,GFAP;Glial fibrillary acidic protein,2.07231053697387,1.92343997346334,2.23270339646749,8.41481575354354e-82
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00957284208832,GFAP;Glial fibrillary acidic protein,1.43032391886412,1.3091446871867,1.56271994447858,2.30290542122628e-15
primary,Nervous system disorders,G40 (epilepsy),0.815471590678,GFAP;Glial fibrillary acidic protein,1.26896614417099,1.1488450577543,1.40164686628837,2.66969842451628e-06
primary,Nervous system disorders,G41 (status epilepticus),0.0683320939767268,GFAP;Glial fibrillary acidic protein,2.58373952392302,1.86587010938761,3.57779991967018,1.0934672225167e-08
primary,Nervous system disorders,G91 (hydrocephalus),0.243230747582768,GFAP;Glial fibrillary acidic protein,1.56783099143167,1.30920246532707,1.87755070953026,1.01298264833629e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.065920856195591,SPP1;Osteopontin,2.12295961167841,1.52548871613328,2.95443516897439,8.0276487219524e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0664166275980621,PODXL2;Podocalyxin-like protein 2,2.55077501744727,1.83965945851002,3.53677043842824,1.95768178688161e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0664166275980621,SEZ6L;Seizure 6-like protein,2.50767844840731,1.81065626827157,3.47302318546047,3.14876082517374e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373207237484856,SEZ6L;Seizure 6-like protein,1.42321073382142,1.23239241256892,1.64357454022482,1.54843114997651e-06
primary,Nervous system disorders,G25 (other extrapyramidal and movement disorders),0.940267644649057,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.24967625418776,1.14413332173594,1.36495521161054,7.39028980381108e-07
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.01288955421194,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.21170913534627,1.11406146067874,1.317915645145,7.47766714935415e-06
primary,Nervous system disorders,G40 (epilepsy),0.82579630357845,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.3173717046751,1.19974536483748,1.44653045483001,7.64165654282437e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,EDA2R;Tumor necrosis factor receptor superfamily member 27,3.48068825669284,2.74198198197146,4.41840640089426,1.214719038911e-24
primary,Nervous system disorders,G62 (other polyneuropathies),0.982264665757162,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.40036720349919,1.28729541410137,1.52337084646967,4.53555175272246e-15
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,EDA2R;Tumor necrosis factor receptor superfamily member 27,2.3001925097465,2.0450660926772,2.58714649900025,7.55676060457044e-44
primary,Nervous system disorders,G72 (other myopathies),0.0952084871565693,EDA2R;Tumor necrosis factor receptor superfamily member 27,2.24395277908599,1.7742287288945,2.83803547578964,1.53476724998433e-11
primary,Nervous system disorders,G81 (hemiplegia),0.96374751762003,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.35081131982044,1.24048686967651,1.47094763061126,4.60037518669014e-12
primary,Nervous system disorders,G93 (other disorders of brain),0.880677926297042,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.2384887932095,1.13110298952339,1.35606969932228,3.7983137849479e-06
primary,Nervous system disorders,G99 (other disorders of nervous system in diseases classified elsewhere),0.505639828860365,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.44240347410964,1.28414609080724,1.62016440108905,6.50304629984069e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.366908019282187,CRLF1;Cytokine receptor-like factor 1,1.40488939698522,1.21456959441725,1.62503180289845,4.7110132559412e-06
primary,Nervous system disorders,G20 (parkinson's disease),1.51705954114359,ITGA11;Integrin alpha-11,0.737563254445606,0.686986787874565,0.791863197240587,4.51284124032073e-17
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.0014530887955,ITGA11;Integrin alpha-11,0.763289756646409,0.699536273721409,0.832853526668382,1.27957126260143e-09
primary,Nervous system disorders,G81 (hemiplegia),0.967494543094802,ITGA11;Integrin alpha-11,0.78733649235594,0.720378782152363,0.860517782524367,1.34459754886503e-07
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00829892154111,CHI3L1;Chitinase-3-like protein 1,1.27366880859423,1.16771828875349,1.38923253117628,4.78676028638019e-08
primary,Nervous system disorders,G40 (epilepsy),0.833215074908265,CHI3L1;Chitinase-3-like protein 1,1.26862286310884,1.1516619956269,1.39746208081338,1.4267176492415e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0661137155908162,CHI3L1;Chitinase-3-like protein 1,2.84917419940555,2.0574236852029,3.94561104596096,2.9169250413424e-10
primary,Nervous system disorders,G62 (other polyneuropathies),1.00472219431327,CHI3L1;Chitinase-3-like protein 1,1.30538755370903,1.19627182845443,1.42445606830017,2.17928424976703e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.364722149856716,CHI3L1;Chitinase-3-like protein 1,1.84417887839862,1.60109776893296,2.12416493328709,2.12388468748808e-17
primary,Nervous system disorders,G81 (hemiplegia),0.963545848723301,CHI3L1;Chitinase-3-like protein 1,1.32875850209569,1.2157141910004,1.45231434325751,3.70999333261295e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37420505661548,FLT3LG;Fms-related tyrosine kinase 3 ligand,1.42627989704418,1.24078246122063,1.63950926797523,5.88723152330768e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.339392282811717,GSN;Gelsolin,0.689770988365695,0.587876106460386,0.809327018333325,5.26429642431937e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37492148241206,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.50900274630531,1.3120847119862,1.73547429335562,8.06418373417865e-09
primary,Nervous system disorders,G81 (hemiplegia),0.961557368990266,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.28276152620651,1.17453655631064,1.40095863706813,3.07276982537136e-08
primary,Nervous system disorders,G40 (epilepsy),0.803203608662631,OCLN;Occludin,1.33768306022137,1.20555548352555,1.48429167637333,4.18044130782465e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591366055588409,OCLN;Occludin,3.00119707605713,2.09911169352476,4.29095027059247,1.68808287056599e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.953532404133494,OCLN;Occludin,1.2752346490581,1.1591153481825,1.4029866938681,6.00020222567195e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336715657278063,OCLN;Occludin,1.60106976418179,1.3659303188981,1.87668752520631,6.32729989563212e-09
primary,Nervous system disorders,G81 (hemiplegia),0.923203173083498,OCLN;Occludin,1.38645973421532,1.25903875090936,1.52677635474844,3.07217035929166e-11
primary,Nervous system disorders,G93 (other disorders of brain),0.859008131943649,OCLN;Occludin,1.28928456618444,1.16581443689652,1.4258312815429,7.53660271513769e-07
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00659903476804,OMG;Oligodendrocyte-myelin glycoprotein,0.782234066305939,0.717378741037566,0.852952700556095,2.67087726888237e-08
primary,Nervous system disorders,G81 (hemiplegia),0.968594650043399,OMG;Oligodendrocyte-myelin glycoprotein,0.782589901405864,0.716244570768364,0.855080762602398,5.83471951109186e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.988348102882518,SUSD2;Sushi domain-containing protein 2,1.21625747751217,1.11512158064146,1.32656588957174,9.87206995622756e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,SUSD2;Sushi domain-containing protein 2,1.50942139861635,1.31455114837243,1.73317939086798,5.2887100995327e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,MOG;Myelin-oligodendrocyte glycoprotein,2.62012196217488,1.90698413227175,3.59994557924977,2.80930598969317e-09
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00682858694808,IGFBP2;Insulin-like growth factor-binding protein 2,1.21985978595282,1.12028670546713,1.32828309942711,4.77607494292513e-06
primary,Nervous system disorders,G40 (epilepsy),0.81808016008475,IGFBP2;Insulin-like growth factor-binding protein 2,1.25304199284163,1.13997507892186,1.37732329842638,2.93758603576654e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.065920856195591,IGFBP2;Insulin-like growth factor-binding protein 2,2.52526320168959,1.89435630800828,3.36629081385025,2.68619785748045e-10
primary,Nervous system disorders,G62 (other polyneuropathies),0.991774108861793,IGFBP2;Insulin-like growth factor-binding protein 2,1.34219998645247,1.23288452001046,1.46120806482162,1.12106816934244e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37428488315718,IGFBP2;Insulin-like growth factor-binding protein 2,1.78837760513658,1.5673007805763,2.04063859227966,5.90313873843265e-18
primary,Nervous system disorders,G81 (hemiplegia),0.959670526070401,IGFBP2;Insulin-like growth factor-binding protein 2,1.26904191543817,1.16345341765027,1.38421303226002,7.62822253645343e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376042397318993,C1QA;Complement C1q subcomponent subunit A,1.62883717973726,1.41441776814631,1.87576161572935,1.24894158353686e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,DPP6;Dipeptidyl aminopeptidase-like protein 6,1.91392374463343,1.66363489455026,2.20186779699756,1.10337401723591e-19
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.343634632798532,CHAD;Chondroadherin,0.551645573473633,0.46772944820001,0.650617231615752,1.60283738259797e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369329901970414,MMP10;Stromelysin-2,1.53188633125372,1.32399482852383,1.77242061775903,9.95213908710012e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376940563856451,NCAN;Neurocan core protein,0.678102505050369,0.584998534404654,0.786024204015385,2.53411588499891e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607307277892056,OGN;Mimecan,4.12467314695141,2.96851869153131,5.73111721267484,3.08168967213606e-17
primary,Nervous system disorders,G62 (other polyneuropathies),0.988348102882518,OGN;Mimecan,1.2450533036318,1.13883643771906,1.36117679198009,1.45375749372329e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,OGN;Mimecan,2.01194521932747,1.75369920124694,2.30821999730425,1.97504535633685e-23
primary,Nervous system disorders,G81 (hemiplegia),0.967729271356784,OGN;Mimecan,1.34051474837078,1.22568791114083,1.46609897533134,1.41835831339859e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,BCAN;Brevican core protein,0.664387161220826,0.57496071402603,0.767722540387488,2.96212377000148e-08
primary,Nervous system disorders,G81 (hemiplegia),0.969759341355288,BCAN;Brevican core protein,0.769093692020274,0.702907959892708,0.841511465022623,1.0758056246588e-08
primary,Nervous system disorders,G30 (alzheimer's disease),1.38572858833166,SYT1;Synaptotagmin-1,1.51341071390012,1.39880444862799,1.6374068521116,6.14310683854066e-25
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0651517245464057,PTGDS;Prostaglandin-H2 D-isomerase,3.75993300402194,2.70941782407448,5.21776156823009,2.33733119551612e-15
primary,Nervous system disorders,G62 (other polyneuropathies),1.0,PTGDS;Prostaglandin-H2 D-isomerase,1.23726715155801,1.1295340795036,1.3552756239079,4.63779638460806e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371255356543375,PTGDS;Prostaglandin-H2 D-isomerase,1.85656410805373,1.59966608515123,2.15471861240808,3.87201750427427e-16
primary,Nervous system disorders,G81 (hemiplegia),0.963383513679254,PTGDS;Prostaglandin-H2 D-isomerase,1.30107607082862,1.18596438396603,1.42736069056467,2.56846599208508e-08
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.01323488984016,SSC4D;Scavenger receptor cysteine-rich domain-containing group B protein,0.791049676525546,0.724134273764516,0.864148561119845,2.01626579827797e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0588523786169691,STC2;Stanniocalcin-2,2.32890229280165,1.63257810377039,3.32222138523768,3.09594706075187e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378691258706955,STC2;Stanniocalcin-2,1.41313438605228,1.22293949008366,1.63290891269424,2.74846617351048e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.352194803377338,DMP1;Dentin matrix acidic phosphoprotein 1,0.545311257847544,0.462388991923059,0.643104340997703,5.79075737776425e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0669357220198838,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,2.70068194655917,1.88606798593974,3.86713683220519,5.83144345820177e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,CD38;ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,1.52780082221808,1.28900303590951,1.81083774618364,1.02095527111229e-06
primary,Nervous system disorders,G81 (hemiplegia),0.973346495557749,LY6D;Lymphocyte antigen 6D,1.2640399349776,1.15700373516133,1.38097821870505,2.09813273048296e-07
primary,Nervous system disorders,G40 (epilepsy),0.826920413855862,CST3;Cystatin-C,1.27229168530644,1.15484862116234,1.40167819646412,1.09654167850618e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0664724628047469,CST3;Cystatin-C,3.08030319851408,2.28605375080606,4.15050074453871,1.42057942988305e-13
primary,Nervous system disorders,G62 (other polyneuropathies),1.00001960822761,CST3;Cystatin-C,1.31734990314875,1.20671247134402,1.43813112778486,7.35901161695058e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367639869370514,CST3;Cystatin-C,1.79555954886411,1.55952260565756,2.0673211672733,3.95906157118388e-16
primary,Nervous system disorders,G72 (other myopathies),0.0918884044653854,CST3;Cystatin-C,2.07392612849703,1.5776595996752,2.72629760396234,1.71965384138212e-07
primary,Nervous system disorders,G81 (hemiplegia),0.95988089641122,CST3;Cystatin-C,1.38424954986622,1.26630933367116,1.51317436060408,8.27555906621947e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.335672871528837,RNASE4;Ribonuclease 4,1.811925957156,1.5490575439906,2.11940201121129,1.06632996005108e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0641050545864252,SCARA5;Scavenger receptor class A member 5,5.13071368952239,3.68519579773065,7.14323591166118,3.48693769818061e-22
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376940563856451,SCARA5;Scavenger receptor class A member 5,2.21488545604288,1.92748587515424,2.54513801975213,3.48211982295107e-29
primary,Nervous system disorders,G40 (epilepsy),0.8270413726418,EPHA2;Ephrin type-A receptor 2,1.28155938296146,1.16199845444904,1.41342223457199,6.88111829465736e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0691253608750457,EPHA2;Ephrin type-A receptor 2,4.15643462690758,3.0760745346775,5.61623218585879,1.7502812714144e-20
primary,Nervous system disorders,G62 (other polyneuropathies),0.980891979525664,EPHA2;Ephrin type-A receptor 2,1.3291806684523,1.21549180371007,1.45350321902189,4.44199631143977e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372140315200813,EPHA2;Ephrin type-A receptor 2,2.28206948843226,1.98268124217087,2.6266658700676,1.33474636940013e-30
primary,Nervous system disorders,G81 (hemiplegia),0.969766115231032,EPHA2;Ephrin type-A receptor 2,1.36750921080186,1.25016706219726,1.49586523127646,8.0380678821723e-12
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00590897413094,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.24899443452654,1.1466759281439,1.36044287596006,3.42366761617459e-07
primary,Nervous system disorders,G40 (epilepsy),0.819459156956408,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.3369940477268,1.21589996735948,1.47014814675819,2.02708766008938e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0632023858900673,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,3.00165876922811,2.24475290907062,4.01378491613775,1.22415961811021e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.990491283676703,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.3914098378897,1.27737135509206,1.51562920935918,3.70688222217878e-14
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.27587039721224,2.0041336248153,2.58445145611703,8.00172206557984e-37
primary,Nervous system disorders,G72 (other myopathies),0.0948054513134505,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.03830097874955,1.57414686336946,2.63931592194536,6.61454896008478e-08
primary,Nervous system disorders,G81 (hemiplegia),0.969759341355288,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.47717434462097,1.35603105697751,1.60914016915659,4.03567438848842e-19
primary,Nervous system disorders,G93 (other disorders of brain),0.871277675001491,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.31927004066241,1.20356216402881,1.44610182357623,3.29495789014884e-09
primary,Nervous system disorders,G99 (other disorders of nervous system in diseases classified elsewhere),0.504102006523673,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.35773078631236,1.204480423042,1.53047974282941,5.59717949084939e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0632023858900673,GGT5;Glutathione hydrolase 5 proenzyme,3.65268438717677,2.62078602233984,5.09087850690422,2.0405836369558e-14
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,GGT5;Glutathione hydrolase 5 proenzyme,2.2459850290324,1.95534110469483,2.57983056691531,2.52218260928296e-30
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0658174919663943,DPT;Dermatopontin,2.46058111661555,1.76916520164759,3.42221259258695,8.81952768573155e-08
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",0.966363129529827,GHR;Growth hormone receptor,0.781593577326592,0.70897337264537,0.861652275936387,7.31788780343971e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.985309217281415,"KRT18;Keratin, type I cytoskeletal 18",1.27192888344307,1.16106145404875,1.39338282129276,2.3498192256596e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,"KRT18;Keratin, type I cytoskeletal 18",1.55000606849003,1.33678583753954,1.7972353872165,6.46644238746458e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0669357220198838,TAFA5;Chemokine-like protein TAFA-5,3.53126505723761,2.55178191790238,4.88671575614808,2.70312366463506e-14
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,TAFA5;Chemokine-like protein TAFA-5,1.72987626279136,1.49944799705615,1.99571568366765,5.73158101318014e-14
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0663634766654305,AOC3;Membrane primary amine oxidase,4.14393582618606,3.03885639926641,5.65087713117796,2.62211463951756e-19
primary,Nervous system disorders,G62 (other polyneuropathies),0.99839473787244,AOC3;Membrane primary amine oxidase,1.28212023036635,1.17395677210156,1.40024941648572,3.26654233811132e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368989281739911,AOC3;Membrane primary amine oxidase,2.90478077838883,2.53785858759256,3.32475237657011,4.93156226208726e-54
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0626431493843353,SPON1;Spondin-1,2.66424160970469,1.91159591104261,3.71322375920465,7.23867045361118e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.993481504751433,SPON1;Spondin-1,1.38085314212897,1.26572166234982,1.50645711205381,3.73065875034952e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.36812218523595,SPON1;Spondin-1,2.0060267736245,1.74560480044255,2.30530038384295,9.97282017575837e-23
primary,Nervous system disorders,G20 (parkinson's disease),1.51833591954587,ITGAM;Integrin alpha-M,0.742318639972645,0.691041238410281,0.79740098364966,3.37425222315523e-16
primary,Nervous system disorders,G40 (epilepsy),0.82699956680975,AMBP;Protein AMBP,1.27038005473841,1.15444738941675,1.39795498545197,9.50814025560379e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0661581569115815,AMBP;Protein AMBP,3.84242526022852,2.85864523081678,5.16476536552377,4.63846278046183e-19
primary,Nervous system disorders,G62 (other polyneuropathies),0.983683347646186,AMBP;Protein AMBP,1.26786657303846,1.16176908713003,1.38365331358519,1.0217754057597e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373700805792362,AMBP;Protein AMBP,1.97717783568523,1.72365802842846,2.26798595165027,2.10828992926039e-22
primary,Nervous system disorders,G81 (hemiplegia),0.963188270160661,AMBP;Protein AMBP,1.36068207515398,1.2462850008291,1.48557970962792,6.25557578895483e-12
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0669357220198838,IL12A_IL12B;Interleukin-12,2.42355005323786,1.73349209512742,3.3883020736345,2.246321377851e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,IL12A_IL12B;Interleukin-12,1.48117853781924,1.28259413787312,1.71050981453445,8.86391540647236e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368989281739911,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.89411455340041,1.63967564313108,2.18803636952996,4.0029120872752e-18
primary,Nervous system disorders,G81 (hemiplegia),0.964171164828287,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.26183201173963,1.15071826548426,1.38367493904412,7.61585009221702e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0624365878404745,AGRN;Agrin,3.47420361325829,2.52612271933656,4.77810941407746,1.86913237123412e-14
primary,Nervous system disorders,G62 (other polyneuropathies),0.992152795444316,AGRN;Agrin,1.35848412547815,1.24552241182805,1.48169081635997,4.62140818015227e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.366908019282187,AGRN;Agrin,1.88072693978425,1.63554029037741,2.16266994022752,7.78995790803382e-19
primary,Nervous system disorders,G81 (hemiplegia),0.971652003910068,AGRN;Agrin,1.31120149473241,1.20118525840945,1.43129408869458,1.36396706274902e-09
primary,Nervous system disorders,G93 (other disorders of brain),0.87260720883613,AGRN;Agrin,1.27123646641255,1.15858984502841,1.39483542037901,3.99063029523513e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0614335823705435,VWC2;Brorin,3.49336290944932,2.50031295559942,4.88082277451964,2.29438730296715e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.987875173921685,VWC2;Brorin,1.2927809604867,1.18245800665285,1.41339701062853,1.67628063134453e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372631412035201,VWC2;Brorin,1.88362024714577,1.63574147478875,2.16906234276152,1.42404274604627e-18
primary,Nervous system disorders,G81 (hemiplegia),0.97104730132253,VWC2;Brorin,1.2965785810137,1.18525220629707,1.41836143211712,1.42385298393993e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,NPY;Pro-neuropeptide Y,1.89501182716561,1.64415697723205,2.18414048951893,1.11321706922608e-18
primary,Nervous system disorders,G40 (epilepsy),0.801252532694787,PALM2;Paralemmin-2,1.29766341069575,1.17062696515163,1.43848585210099,7.15911700444545e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591675579728284,PALM2;Paralemmin-2,3.06243795287104,2.25458228035328,4.15976223041875,7.89878012471485e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.963096515051235,PALM2;Paralemmin-2,1.36245763832818,1.24180904813555,1.49482790371502,6.2400308941995e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336891944185199,PALM2;Paralemmin-2,1.7005244871726,1.46480900718019,1.97417104707762,3.07858345737949e-12
primary,Nervous system disorders,G81 (hemiplegia),0.921364714468162,PALM2;Paralemmin-2,1.29444205634671,1.17672844960376,1.42393110135418,1.12417567040835e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.994740677999487,IL1RN;Interleukin-1 receptor antagonist protein,1.31467670909531,1.20690672615941,1.43206994540305,3.62291723449751e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367350947844023,IL1RN;Interleukin-1 receptor antagonist protein,1.481411906378,1.29133920384829,1.69946148139735,2.03046252483977e-08
primary,Nervous system disorders,G81 (hemiplegia),0.974102644836272,IL1RN;Interleukin-1 receptor antagonist protein,1.24696034005471,1.14306179059884,1.36030274343677,6.61664163610978e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.066349231129498,COL18A1;Collagen alpha-1(XVIII) chain,3.4402604298728,2.51587648550119,4.70428174576736,1.00468554652923e-14
primary,Nervous system disorders,G62 (other polyneuropathies),0.994245899714252,COL18A1;Collagen alpha-1(XVIII) chain,1.28318789880188,1.17600692583805,1.40013731845856,2.10632969584541e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374758456463607,COL18A1;Collagen alpha-1(XVIII) chain,2.02858910922335,1.76480310352975,2.33180334159029,2.46552433174419e-23
primary,Nervous system disorders,G81 (hemiplegia),0.960034412638823,COL18A1;Collagen alpha-1(XVIII) chain,1.36401470125188,1.24852563642275,1.49018654559792,6.09563029572532e-12
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0613302734143156,LAYN;Layilin,4.36420877233375,3.16360935108527,6.02043934469376,2.80039902412944e-19
primary,Nervous system disorders,G62 (other polyneuropathies),0.986208949300526,LAYN;Layilin,1.31170136754954,1.20131101719632,1.43223566004319,1.45642600937997e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372004669845855,LAYN;Layilin,2.31492756025884,2.02066730936359,2.65203954377514,1.04207543638388e-33
primary,Nervous system disorders,G81 (hemiplegia),0.969411018377178,LAYN;Layilin,1.32305915957167,1.21120605873993,1.44524173000554,5.23924148738849e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0641050545864252,RGMB;RGM domain family member B,2.83549246897268,1.99193129117616,4.03629260568191,7.25634548897126e-09
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00946743242448,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.27113207640846,1.16641052284162,1.38525564030245,4.52470759591295e-08
primary,Nervous system disorders,G40 (epilepsy),0.804884818207049,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.28772896231231,1.16858200601123,1.41902397251357,3.30865224348415e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607307277892056,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,3.65507304598187,2.65645634050568,5.02909035912107,1.71511213923476e-15
primary,Nervous system disorders,G62 (other polyneuropathies),0.988348102882518,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.40840471431464,1.29111090394435,1.53635433892145,1.17226972059902e-14
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.99073684128294,1.73665288696722,2.28199498067917,4.94475694116444e-23
primary,Nervous system disorders,G81 (hemiplegia),0.967729271356784,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.48274374165897,1.35859756836693,1.6182341663334,1.05621574764638e-18
primary,Nervous system disorders,G93 (other disorders of brain),0.872190540087219,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.32493849740808,1.20754397365032,1.45374583470227,2.78190986696235e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.985309217281415,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.3276062479634,1.21775101416002,1.44737169514675,1.2722389975179e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0658174919663943,CCL15;C-C motif chemokine 15,2.72332967606374,1.95981187496828,3.78430430964171,2.39787250451711e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.990214352283317,CCL15;C-C motif chemokine 15,1.26275222952755,1.15765492854193,1.37739075251478,1.42554385422395e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373697866243271,CCL15;C-C motif chemokine 15,2.04143540354069,1.77468966473258,2.34827451224116,1.70307322852242e-23
primary,Nervous system disorders,G12 (spinal muscular atrophy and related syndromes),0.570254095552824,NEFL;Neurofilament light polypeptide,2.01770270023901,1.82191209178472,2.2345338202151,2.08651219330479e-41
primary,Nervous system disorders,G20 (parkinson's disease),1.52194097937103,NEFL;Neurofilament light polypeptide,1.21571844692114,1.13427609197147,1.30300845856277,3.36503960966844e-08
primary,Nervous system disorders,G23 (other degenerative diseases of basal ganglia),0.118738553804665,NEFL;Neurofilament light polypeptide,1.79999373842434,1.43113104581075,2.26392786869587,5.06756392320214e-07
primary,Nervous system disorders,G30 (alzheimer's disease),1.36666465390576,NEFL;Neurofilament light polypeptide,1.45246976023268,1.35183700793402,1.56059376389948,2.21827333470204e-24
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00912441839386,NEFL;Neurofilament light polypeptide,1.5424323990219,1.42131524358241,1.67387053385566,2.86219338117256e-25
primary,Nervous system disorders,G35 (multiple sclerosis),0.231017083105355,NEFL;Neurofilament light polypeptide,1.56571295694596,1.31412020177197,1.86547399563822,5.26635678633255e-07
primary,Nervous system disorders,G40 (epilepsy),0.816900260756192,NEFL;Neurofilament light polypeptide,1.51223932045557,1.37799249678404,1.65956474194816,2.78729878332265e-18
primary,Nervous system disorders,G45 (transient cerebral ischaemic attacks and related syndromes),1.33289986996098,NEFL;Neurofilament light polypeptide,1.23664605741958,1.14775157317333,1.33242550659561,2.39686365901545e-08
primary,Nervous system disorders,G55 (nerve root and plexus compressions in diseases classified elsewhere),1.57491458261731,NEFL;Neurofilament light polypeptide,1.24452233136922,1.16176518319855,1.33317459988984,4.64204759876863e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0664331440995289,NEFL;Neurofilament light polypeptide,3.33559171261998,2.60212493549815,4.27580241114329,1.94151884833807e-21
primary,Nervous system disorders,G62 (other polyneuropathies),0.985341032992771,NEFL;Neurofilament light polypeptide,1.63684184526831,1.50768961862162,1.77705755437305,6.98768315930645e-32
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.364456436381209,NEFL;Neurofilament light polypeptide,2.34536315549032,2.08192105975649,2.64214068317023,1.13777970571016e-44
primary,Nervous system disorders,G81 (hemiplegia),0.954071444419791,NEFL;Neurofilament light polypeptide,1.3599628882839,1.2472354182432,1.48287887792234,3.30076446885254e-12
primary,Nervous system disorders,G83 (other paralytic syndromes),0.263953254080193,NEFL;Neurofilament light polypeptide,1.65706116020932,1.41611940815865,1.93899728571945,2.97869239381231e-10
primary,Nervous system disorders,G99 (other disorders of nervous system in diseases classified elsewhere),0.515817046141446,NEFL;Neurofilament light polypeptide,1.47262826369296,1.31151855192611,1.65352903307579,5.85483991857691e-11
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0624365878404745,IL10RB;Interleukin-10 receptor subunit beta,3.36839830385476,2.44753814479181,4.63572228998977,9.1018167065784e-14
primary,Nervous system disorders,G62 (other polyneuropathies),0.992152795444316,IL10RB;Interleukin-10 receptor subunit beta,1.29657826094711,1.18809667526075,1.41496497866361,5.67492324078505e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.366908019282187,IL10RB;Interleukin-10 receptor subunit beta,1.74904153042868,1.51755767446566,2.01583526388308,1.17766255049103e-14
primary,Nervous system disorders,G81 (hemiplegia),0.971652003910068,IL10RB;Interleukin-10 receptor subunit beta,1.29519383386123,1.18587834606267,1.41458613595724,8.95474440169407e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.959396171509116,LGALS3BP;Galectin-3-binding protein,1.27365771407813,1.15809766312475,1.40074885243592,6.21058403862704e-07
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.02057024859026,IGFBP4;Insulin-like growth factor-binding protein 4,1.2754673272269,1.17002334066522,1.39041405951646,3.2650622655391e-08
primary,Nervous system disorders,G40 (epilepsy),0.80528556510563,IGFBP4;Insulin-like growth factor-binding protein 4,1.29583104263122,1.1749039170166,1.42920460705468,2.16297932451129e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0555643752976663,IGFBP4;Insulin-like growth factor-binding protein 4,3.41953159486595,2.47742310868087,4.71990282455734,7.59298141723355e-14
primary,Nervous system disorders,G62 (other polyneuropathies),0.985251089747417,IGFBP4;Insulin-like growth factor-binding protein 4,1.40084305324657,1.28307306775542,1.52942284359695,5.34771111457364e-14
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.377118812274224,IGFBP4;Insulin-like growth factor-binding protein 4,2.02053870318656,1.76226283171397,2.31666728572159,6.78653159488209e-24
primary,Nervous system disorders,G81 (hemiplegia),0.964387266111232,IGFBP4;Insulin-like growth factor-binding protein 4,1.51357115148232,1.3858953521441,1.65300910134036,3.02392924200494e-20
primary,Nervous system disorders,G93 (other disorders of brain),0.867462173452459,IGFBP4;Insulin-like growth factor-binding protein 4,1.26682368005617,1.15313838763685,1.39171694703521,8.21810098753555e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0669357220198838,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,2.34646050568496,1.69265107144708,3.25281270169419,3.08449142848162e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,VMO1;Vitelline membrane outer layer protein 1 homolog,1.63783193747008,1.41862421231495,1.89091193574064,1.69757694970308e-11
primary,Nervous system disorders,G09 (sequelae of inflammatory diseases of central nervous system),0.026078757848703,"NOS3;Nitric oxide synthase, endothelial",3.75554720360122,2.29957109404852,6.1333762782893,1.24120880896336e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367314987655807,"NOS3;Nitric oxide synthase, endothelial",1.45442029579703,1.25482537590616,1.68576316469433,6.55853051275812e-07
primary,Nervous system disorders,G93 (other disorders of brain),0.875224870131182,"NOS3;Nitric oxide synthase, endothelial",1.27469918933597,1.15909152689373,1.40183754741808,5.62922480741117e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,CLMP;CXADR-like membrane protein,3.21003527849916,2.43744592785793,4.22750977629472,1.02151003969462e-16
primary,Nervous system disorders,G62 (other polyneuropathies),0.982264665757162,CLMP;CXADR-like membrane protein,1.27747636541809,1.1662192524309,1.39934738755181,1.38317429055217e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,CLMP;CXADR-like membrane protein,1.69932342946174,1.48100949267171,1.94981877712901,4.10232962731937e-14
primary,Nervous system disorders,G81 (hemiplegia),0.96374751762003,CLMP;CXADR-like membrane protein,1.27989068938109,1.16779357932709,1.40274805904338,1.31414559941736e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373697866243271,SELE;E-selectin,1.50622106764575,1.3036649740326,1.74024918196749,2.71823816246956e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37420505661548,IL18R1;Interleukin-18 receptor 1,2.01551340127366,1.75131042173849,2.31957408594712,1.42084629051241e-22
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0626406968777527,SCGB1A1;Uteroglobin,2.43686060515304,1.71645112363718,3.4596322185764,6.310684459022e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660335217230864,FAS;Tumor necrosis factor receptor superfamily member 6,2.55686852638052,1.90128190651496,3.43850990155301,5.27140770062272e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374924723662995,FAS;Tumor necrosis factor receptor superfamily member 6,1.50622109702348,1.31150362563424,1.72984805285724,6.65524138985149e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0663634766654305,IL18BP;Interleukin-18-binding protein,3.25221914152586,2.36872186140444,4.46524748930887,3.05462320549279e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.99839473787244,IL18BP;Interleukin-18-binding protein,1.33036960865308,1.21986884706271,1.45087998590127,1.10300854301738e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368989281739911,IL18BP;Interleukin-18-binding protein,1.92552831396998,1.67374755816349,2.21518428499951,5.010784374276e-20
primary,Nervous system disorders,G81 (hemiplegia),0.964171164828287,IL18BP;Interleukin-18-binding protein,1.35010492562976,1.23630159423284,1.47438401658038,2.36744201441098e-11
primary,Nervous system disorders,G93 (other disorders of brain),0.878744987025241,IL18BP;Interleukin-18-binding protein,1.27220975685707,1.15965982537942,1.39568313915918,3.50157581065993e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,SLITRK2;SLIT and NTRK-like protein 2,3.21284348407767,2.3290729011875,4.4319622833263,1.15011255174131e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,SLITRK2;SLIT and NTRK-like protein 2,1.7330350228392,1.50589347778469,1.9944374782774,1.70172842912684e-14
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00150323097046,CSF1;Macrophage colony-stimulating factor 1,1.24522408133967,1.14209401270282,1.35766670300521,6.62230214749991e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0624365878404745,CSF1;Macrophage colony-stimulating factor 1,2.76715587880686,1.99356303294556,3.84093782392305,1.17291711561356e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.992152795444316,CSF1;Macrophage colony-stimulating factor 1,1.38793410677255,1.27243811787389,1.51391337439754,1.411726281161e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.366908019282187,CSF1;Macrophage colony-stimulating factor 1,1.88768542443445,1.64086340024495,2.17163492164572,6.30205826466224e-19
primary,Nervous system disorders,G81 (hemiplegia),0.971652003910068,CSF1;Macrophage colony-stimulating factor 1,1.30956132161481,1.19942841975249,1.42980675363972,1.77540397565589e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0627992778083052,CD83;CD83 antigen,2.5526506059257,1.83638919097146,3.54828113123767,2.44418628974999e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.99994094836919,CD83;CD83 antigen,1.31583388529963,1.20634971135448,1.43525446842334,5.92159748164903e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376877024241829,CD83;CD83 antigen,1.65217052577481,1.43940428151212,1.89638691596181,9.45516704653992e-13
primary,Nervous system disorders,G81 (hemiplegia),0.967494543094802,CD83;CD83 antigen,1.37218166744819,1.25678095282756,1.49817875919005,1.67493790420701e-12
primary,Nervous system disorders,G93 (other disorders of brain),0.879568319728025,CD83;CD83 antigen,1.31274642394184,1.19661400814878,1.44014959029112,8.50599047863291e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368721438798125,CRHBP;Corticotropin-releasing factor-binding protein,1.53492414499696,1.32936214744458,1.77227261617427,5.19356448501573e-09
primary,Nervous system disorders,G81 (hemiplegia),0.976462729380329,CRHBP;Corticotropin-releasing factor-binding protein,1.24467225620775,1.13912843925418,1.35999503830103,1.28993060843735e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0631761825791676,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,3.20273381740767,2.37981634111913,4.31020819881548,1.56640532826546e-14
primary,Nervous system disorders,G62 (other polyneuropathies),1.00590075640568,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.27387444665877,1.16732402877768,1.39015052020251,5.58876118242018e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369273301737756,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.72768606053224,1.50054084059489,1.98921551683595,2.89723971491045e-14
primary,Nervous system disorders,G72 (other myopathies),0.0927900181631525,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.99954222939613,1.51883757929847,2.63238754533921,7.85193556237201e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0624365878404745,BTN2A1;Butyrophilin subfamily 2 member A1,3.39195289063525,2.41912187059396,4.75600032893919,1.4152293390329e-12
primary,Nervous system disorders,G62 (other polyneuropathies),0.992152795444316,BTN2A1;Butyrophilin subfamily 2 member A1,1.30140740137054,1.19260838302681,1.42013191291139,3.33142763247669e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.366908019282187,BTN2A1;Butyrophilin subfamily 2 member A1,1.96304702880342,1.70324087186915,2.26248307032757,1.25338774408903e-20
primary,Nervous system disorders,G81 (hemiplegia),0.971652003910068,BTN2A1;Butyrophilin subfamily 2 member A1,1.3279202807168,1.2159951695224,1.45014743161486,2.73557284937969e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.066222507625622,CD28;T-cell-specific surface glycoprotein CD28,3.10990235641294,2.24123372194945,4.31525394772769,1.13103756659957e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369314760547549,CD28;T-cell-specific surface glycoprotein CD28,1.65884252606991,1.43788171842859,1.91375861521163,3.93841541932461e-12
primary,Nervous system disorders,G62 (other polyneuropathies),0.993136541524907,TREM2;Triggering receptor expressed on myeloid cells 2,1.25276573883992,1.14946029141249,1.36535555698282,2.8634037683701e-07
primary,Nervous system disorders,G81 (hemiplegia),0.976462729380329,TREM2;Triggering receptor expressed on myeloid cells 2,1.23589894226537,1.13330617627484,1.34777893870954,1.66598921038002e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607307277892056,RELT;Tumor necrosis factor receptor superfamily member 19L,2.69061549319206,1.89285330744731,3.82460262700873,3.46683045314887e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,RELT;Tumor necrosis factor receptor superfamily member 19L,1.62212352453158,1.3949956909188,1.88623143853993,3.27212222960476e-10
primary,Nervous system disorders,G81 (hemiplegia),0.967729271356784,RELT;Tumor necrosis factor receptor superfamily member 19L,1.30278439164168,1.18440959637777,1.43299005369071,5.26349998853007e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0592808773569848,HIP1R;Huntingtin-interacting protein 1-related protein,2.76917524929086,1.91824150138738,3.99758401418118,5.40390373156818e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.33753734577052,HIP1R;Huntingtin-interacting protein 1-related protein,1.49216259331129,1.26947953040135,1.75390713403119,1.21265938564028e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0641050545864252,CD74;HLA class II histocompatibility antigen gamma chain,3.59961012710186,2.6703155764533,4.85230778766004,4.23051890517294e-17
primary,Nervous system disorders,G62 (other polyneuropathies),0.989790351492479,CD74;HLA class II histocompatibility antigen gamma chain,1.34104524987343,1.23030075255676,1.46175832085832,2.50633231656585e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376940563856451,CD74;HLA class II histocompatibility antigen gamma chain,2.04781797230923,1.79103335466439,2.34141839781565,1.00840621305582e-25
primary,Nervous system disorders,G81 (hemiplegia),0.965431329803799,CD74;HLA class II histocompatibility antigen gamma chain,1.39236512807274,1.27651698478827,1.5187268739668,8.12725952096721e-14
primary,Nervous system disorders,G62 (other polyneuropathies),0.976169390548265,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.32627172139368,1.21289782917529,1.45024307625695,5.88797323369109e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369314760547549,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.5291032091305,1.32221941092215,1.76835750924463,1.02937833926169e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0601883312299776,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,3.48924445225196,2.49946378451201,4.87097549602947,2.10516176825212e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.991217308328951,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.27429746937705,1.16815345895067,1.39008623226559,4.69240316500202e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374815505321214,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,2.01228460985816,1.75056560571738,2.31313201735883,7.83429087662766e-23
primary,Nervous system disorders,G81 (hemiplegia),0.961052099140111,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.33277660184212,1.22043012783368,1.45546511013361,1.62017088180007e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,HSPB6;Heat shock protein beta-6,2.83729360072317,2.14769012918467,3.74832238008225,2.13193460824418e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.982264665757162,HSPB6;Heat shock protein beta-6,1.30837507398985,1.19780878938347,1.42914741435406,2.42126533490427e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,HSPB6;Heat shock protein beta-6,1.94146475150711,1.70202081581718,2.21459417318281,5.13968924034365e-23
primary,Nervous system disorders,G71 (primary disorders of muscles),0.0466318223327569,HSPB6;Heat shock protein beta-6,2.39530232124289,1.69142239882338,3.39209958088696,8.63105238211993e-07
primary,Nervous system disorders,G72 (other myopathies),0.0952084871565693,HSPB6;Heat shock protein beta-6,2.23459556540208,1.74157384532852,2.86718668537003,2.57947340604949e-10
primary,Nervous system disorders,G62 (other polyneuropathies),0.982482711891428,CSTB;Cystatin-B,1.27531986722308,1.16859968625148,1.3917860691466,4.91612477153165e-08
primary,Nervous system disorders,G81 (hemiplegia),0.959566801377635,CSTB;Cystatin-B,1.28528198041548,1.17663502765863,1.40396106723757,2.55256049837001e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374362994903959,CDH2;Cadherin-2,1.7622494014586,1.53077297621833,2.02872862350444,3.11930311337943e-15
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0650489838560249,REG1A;Lithostathine-1-alpha,3.03156422009442,2.17719383155731,4.22120506100413,5.15454732807673e-11
primary,Nervous system disorders,G62 (other polyneuropathies),1.00434954527481,REG1A;Lithostathine-1-alpha,1.29451203840977,1.18679305628171,1.41200810766291,5.76565018504239e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370669768725724,REG1A;Lithostathine-1-alpha,2.39384659716695,2.08034077939733,2.75459750994637,3.59262023699936e-34
primary,Nervous system disorders,G81 (hemiplegia),0.959886235705397,REG1A;Lithostathine-1-alpha,1.2831921768557,1.17423517006591,1.40225927882167,3.63568317915458e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.953809378734972,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.37056328135281,1.2477165060276,1.5055052162234,4.7324793592977e-11
primary,Nervous system disorders,G81 (hemiplegia),0.908622546953304,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.30582818749925,1.1854171382407,1.43847022306281,6.44456329150038e-08
primary,Nervous system disorders,G41 (status epilepticus),0.0718697797288372,CXCL13;C-X-C motif chemokine 13,2.18627046913144,1.59578136899724,2.99525903551547,1.11888331191288e-06
primary,Nervous system disorders,G81 (hemiplegia),0.965431329803799,CXCL13;C-X-C motif chemokine 13,1.29165982786303,1.18258311179545,1.41079734208459,1.30469756359126e-08
primary,Nervous system disorders,G93 (other disorders of brain),0.870637032399436,CXCL13;C-X-C motif chemokine 13,1.28499832043024,1.17089596015672,1.41021981431001,1.25461470877634e-07
primary,Nervous system disorders,G40 (epilepsy),0.804884818207049,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.29265425229117,1.17292047427586,1.4246106642465,2.26614131874891e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607307277892056,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,3.94317880859104,2.87745883935723,5.40360783057967,1.40769508177593e-17
primary,Nervous system disorders,G62 (other polyneuropathies),0.988348102882518,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.30400680109703,1.19506678752584,1.42287757894077,2.46843978655495e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,2.0654053992453,1.80266159470171,2.36644496990992,1.4924166723871e-25
primary,Nervous system disorders,G81 (hemiplegia),0.967729271356784,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.30852336656862,1.19837742119418,1.42879310855993,2.0509001517797e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0641050545864252,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,3.47392351678876,2.49846671984109,4.83022027256202,1.3124008313517e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.989790351492479,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.28901301216334,1.18130508864435,1.40654142735743,1.18011552180327e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376940563856451,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.6485892586596,1.43430929893674,1.89488177046788,1.96244113929072e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.469626374738,1.27500301166672,1.69395810171633,1.08507014311309e-07
primary,Nervous system disorders,G81 (hemiplegia),0.969759341355288,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.32257720790554,1.21061688411756,1.44489185126988,5.8244407768529e-10
primary,Nervous system disorders,G93 (other disorders of brain),0.871277675001491,TNFRSF6B;Tumor necrosis factor receptor superfamily member 6B,1.29457197210491,1.17888608364613,1.42161029314742,6.45730959067283e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0573210437015637,PALM;Paralemmin-1,3.05897613052207,2.14864567108451,4.3549921203996,5.51644659184136e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0632023858900673,ADAM22;Disintegrin and metalloproteinase domain-containing protein 22,2.92487116077009,2.07119899435622,4.13039564542838,1.09419768836358e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,ADAM22;Disintegrin and metalloproteinase domain-containing protein 22,1.44718174596862,1.25568303735878,1.66788508210642,3.32738612358687e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0641050545864252,THY1;Thy-1 membrane glycoprotein,2.78450631054851,1.99926779628313,3.87815749740935,1.37336022060529e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.989790351492479,THY1;Thy-1 membrane glycoprotein,1.24142649663175,1.13578070280746,1.35689904110004,1.88214378500416e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376940563856451,THY1;Thy-1 membrane glycoprotein,1.75399925522382,1.52291625257872,2.02014613877575,6.40832028615111e-15
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0625390869293308,CHRDL1;Chordin-like protein 1,3.06171318976315,2.25497886546167,4.15706231217845,7.44266999152773e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.991826253993766,CHRDL1;Chordin-like protein 1,1.38414560752631,1.26847431433061,1.51036488574496,2.85493266898335e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.36751050728179,CHRDL1;Chordin-like protein 1,2.03060301617915,1.77285501184537,2.32582392906675,1.4921036139531e-24
primary,Nervous system disorders,G81 (hemiplegia),0.973250303528766,CHRDL1;Chordin-like protein 1,1.36674259400301,1.25173289710447,1.49231942580014,3.25254098495138e-12
primary,Nervous system disorders,G81 (hemiplegia),0.973231245226858,EPHA1;Ephrin type-A receptor 1,1.2987186254167,1.18373778255039,1.42486798416644,3.27098934672319e-08
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00946743242448,HAVCR2;Hepatitis A virus cellular receptor 2,1.27572404219709,1.17065186761642,1.39022699818811,2.81170470819332e-08
primary,Nervous system disorders,G40 (epilepsy),0.804884818207049,HAVCR2;Hepatitis A virus cellular receptor 2,1.29771200726347,1.17721017454031,1.43054867364987,1.59633126993531e-07
primary,Nervous system disorders,G51 (facial nerve disorders),0.405256531318854,HAVCR2;Hepatitis A virus cellular receptor 2,1.4314206874594,1.24922229925845,1.64019261079716,2.42525504088246e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607307277892056,HAVCR2;Hepatitis A virus cellular receptor 2,3.30086585782839,2.40643334957618,4.52774452003673,1.30247679005022e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.988348102882518,HAVCR2;Hepatitis A virus cellular receptor 2,1.3788212354454,1.2636157794551,1.50453011922264,5.35883813833646e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,HAVCR2;Hepatitis A virus cellular receptor 2,1.93462643484463,1.68957612032489,2.21521800490406,1.29798719091993e-21
primary,Nervous system disorders,G81 (hemiplegia),0.967729271356784,HAVCR2;Hepatitis A virus cellular receptor 2,1.37097105186691,1.25556073867633,1.49698980476132,2.03040382764233e-12
primary,Nervous system disorders,G93 (other disorders of brain),0.872190540087219,HAVCR2;Hepatitis A virus cellular receptor 2,1.30565846590828,1.18965445069056,1.43297411160729,1.9303020670591e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369314760547549,GCG;Pro-glucagon,1.62940930858593,1.40862529041266,1.88479840094928,4.96807029871155e-11
primary,Nervous system disorders,G40 (epilepsy),0.803588114371145,NPC2;NPC intracellular cholesterol transporter 2,1.30682445301134,1.1761177004606,1.45205717958293,6.4563283781526e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0623268698060941,NPC2;NPC intracellular cholesterol transporter 2,3.03531327638527,2.18356786094762,4.21929945506819,3.91128245918484e-11
primary,Nervous system disorders,G62 (other polyneuropathies),0.965501273442926,NPC2;NPC intracellular cholesterol transporter 2,1.32541704604911,1.20461775900107,1.45833010748098,7.55874926382384e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.339429204765863,NPC2;NPC intracellular cholesterol transporter 2,1.84809757291,1.58182468929252,2.15919290052517,1.01685667461298e-14
primary,Nervous system disorders,G81 (hemiplegia),0.923034214726906,NPC2;NPC intracellular cholesterol transporter 2,1.52395354042058,1.38363423221667,1.67850313275332,1.24576117676116e-17
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.066134993191986,XG;Glycoprotein Xg,3.64805141871932,2.76238090191425,4.8176843187693,7.43850434949783e-20
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37355539126036,XG;Glycoprotein Xg,2.0259246656981,1.74815599401237,2.3478286635414,6.36096990436754e-21
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,MFGE8;Lactadherin,1.64393250062287,1.42639687128962,1.89464385473643,6.69348148617151e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,CNTN4;Contactin-4,1.54957699218414,1.34472351645164,1.78563758670818,1.41226273702831e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0664166275980621,DLL1;Delta-like protein 1,4.45222367826393,3.2026374496788,6.18936610613918,6.3849700027341e-19
primary,Nervous system disorders,G62 (other polyneuropathies),0.9952588064731,DLL1;Delta-like protein 1,1.35978361567453,1.24537266818457,1.48470536466187,7.2135108084352e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373207237484856,DLL1;Delta-like protein 1,2.24039650238016,1.94288339595659,2.58346769462504,1.30611620289326e-28
primary,Nervous system disorders,G81 (hemiplegia),0.96496378939127,DLL1;Delta-like protein 1,1.39803145517994,1.27880331366197,1.52837573127307,1.74243785410738e-13
primary,Nervous system disorders,G81 (hemiplegia),0.972145067851757,CCL22;C-C motif chemokine 22,1.2411561877186,1.13565313885493,1.35646055085571,1.87420427992361e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0570047427946005,ATRAID;All-trans retinoic acid-induced differentiation factor,3.25900392182434,2.23201282215932,4.75853295152275,9.51161155855861e-10
primary,Nervous system disorders,G62 (other polyneuropathies),0.951357284972671,ATRAID;All-trans retinoic acid-induced differentiation factor,1.33734411495648,1.21429792162639,1.4728587193934,3.57436438256253e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.330718000182465,ATRAID;All-trans retinoic acid-induced differentiation factor,1.57347005954431,1.33552569046575,1.85380786454131,6.00796979086185e-08
primary,Nervous system disorders,G81 (hemiplegia),0.920932358318098,ATRAID;All-trans retinoic acid-induced differentiation factor,1.2696639149661,1.15103962254965,1.4005134361893,1.83552783221845e-06
primary,Nervous system disorders,G40 (epilepsy),0.822103230686545,PRSS8;Prostasin,1.30367977124347,1.18005847577635,1.44025146281949,1.81734242564967e-07
primary,Nervous system disorders,G41 (status epilepticus),0.0688434303697875,PRSS8;Prostasin,2.20268054262257,1.60262404183378,3.02741094991716,1.1354073037431e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.062949994098438,PRSS8;Prostasin,2.29558420395478,1.64729056480769,3.19901476401758,9.2068573576456e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.996389321863346,PRSS8;Prostasin,1.26709201242834,1.15760973874287,1.38692869818395,2.83210061372569e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367958127545699,PRSS8;Prostasin,1.9326770297052,1.67555447189424,2.22925638277064,1.48230215274606e-19
primary,Nervous system disorders,G81 (hemiplegia),0.975715524718126,PRSS8;Prostasin,1.47057519131335,1.34382633943202,1.60927891487849,5.02238084140616e-17
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0624365878404745,SMOC2;SPARC-related modular calcium-binding protein 2,3.01623248693817,2.13707609230523,4.25705872056606,3.39093679843325e-10
primary,Nervous system disorders,G62 (other polyneuropathies),0.992152795444316,SMOC2;SPARC-related modular calcium-binding protein 2,1.26413417198589,1.15316138442863,1.3857862623229,5.73635024465186e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.366908019282187,SMOC2;SPARC-related modular calcium-binding protein 2,1.83362077631835,1.5778497017855,2.13085260753395,2.57451791990291e-15
primary,Nervous system disorders,G81 (hemiplegia),0.971652003910068,SMOC2;SPARC-related modular calcium-binding protein 2,1.27635220512905,1.16334936581932,1.40033166252725,2.48432070281127e-07
primary,Nervous system disorders,G40 (epilepsy),0.819953549429465,GPR37;Prosaposin receptor GPR37,1.29044635657851,1.1683950583719,1.42524721178399,4.9044449118287e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0658682634730539,GPR37;Prosaposin receptor GPR37,4.11484916297811,2.92899945702203,5.78080804810963,3.46234047015309e-16
primary,Nervous system disorders,G62 (other polyneuropathies),0.970951532501851,GPR37;Prosaposin receptor GPR37,1.30152035735416,1.18814644065902,1.42571250701027,1.4501386392904e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367331456748717,GPR37;Prosaposin receptor GPR37,2.10158548715929,1.81219557933734,2.43718813255994,8.75961800928926e-23
primary,Nervous system disorders,G81 (hemiplegia),0.951961921523139,GPR37;Prosaposin receptor GPR37,1.33713105606803,1.21974131188479,1.46581856634734,5.75727331660004e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376850080056234,CPM;Carboxypeptidase M,1.68968964290221,1.47098748078579,1.940907809634,1.19726488337207e-13
primary,Nervous system disorders,G81 (hemiplegia),0.966278069008684,CPM;Carboxypeptidase M,1.243922338517,1.13825788941766,1.35939561556936,1.44159188107447e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0664166275980621,NBL1;Neuroblastoma suppressor of tumorigenicity 1,4.16467519415965,3.01146732742884,5.75949116727005,6.43676580615118e-18
primary,Nervous system disorders,G62 (other polyneuropathies),0.9952588064731,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.32489713199252,1.21362606899423,1.44637006010981,3.26122504038258e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373207237484856,NBL1;Neuroblastoma suppressor of tumorigenicity 1,2.0332810732707,1.76263910569599,2.34547838497458,2.0863682311048e-22
primary,Nervous system disorders,G81 (hemiplegia),0.96496378939127,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.36555644404346,1.2492741920444,1.49266223039237,6.82384812848736e-12
primary,Nervous system disorders,G40 (epilepsy),0.819459156956408,ASGR1;Asialoglycoprotein receptor 1,1.27570418624833,1.15867106480809,1.40455839473394,7.05917983378391e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0632023858900673,ASGR1;Asialoglycoprotein receptor 1,3.06817771474567,2.27582273041823,4.13640059194417,1.90759016916366e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.990491283676703,ASGR1;Asialoglycoprotein receptor 1,1.34773962937087,1.23576319786889,1.46986260127278,1.54886236360209e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,ASGR1;Asialoglycoprotein receptor 1,1.9759298599119,1.72671431815144,2.26111451688852,4.12996564022004e-23
primary,Nervous system disorders,G81 (hemiplegia),0.969759341355288,ASGR1;Asialoglycoprotein receptor 1,1.37794783514158,1.26266721371433,1.50375349557539,6.38626788557652e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0661581569115815,CD5;T-cell surface glycoprotein CD5,3.3667463679991,2.44832290178078,4.62969206316319,8.06327401113951e-14
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373700805792362,CD5;T-cell surface glycoprotein CD5,1.72836876360756,1.50451984886639,1.98552287978463,1.05941497601124e-14
primary,Nervous system disorders,G81 (hemiplegia),0.963188270160661,CD5;T-cell surface glycoprotein CD5,1.26022850459957,1.15322844278134,1.37715635938958,3.2355539940617e-07
primary,Nervous system disorders,G40 (epilepsy),0.821218074656188,BSG;Basigin,1.28635950586898,1.16735812756007,1.41749197549005,3.68933496000765e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0601883312299776,BSG;Basigin,2.78409183864873,1.98261881015167,3.90956008605484,3.39753001955921e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.991217308328951,BSG;Basigin,1.27718196174679,1.16958750251756,1.39467441290215,5.07244697565748e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374815505321214,BSG;Basigin,1.56108836522402,1.35438283148002,1.79934124044878,7.95549808127979e-10
primary,Nervous system disorders,G81 (hemiplegia),0.961052099140111,BSG;Basigin,1.25159442383625,1.14474394937509,1.36841832851192,8.26461886122915e-07
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00088313217544,TFF3;Trefoil factor 3,1.30183994608638,1.19239445553955,1.42133103466949,3.92493699858697e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0666875882629844,TFF3;Trefoil factor 3,3.44247917465318,2.50393104292412,4.73282317474746,2.71441171137078e-14
primary,Nervous system disorders,G62 (other polyneuropathies),1.00129834362828,TFF3;Trefoil factor 3,1.31285769816154,1.20297138627679,1.4327816565584,1.03786034206687e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.364899064210464,TFF3;Trefoil factor 3,2.25391438579749,1.95277838157539,2.60148827252302,1.17013835176343e-28
primary,Nervous system disorders,G81 (hemiplegia),0.959025253021519,TFF3;Trefoil factor 3,1.44787889820821,1.32473356746461,1.58247164211957,3.33359827623521e-16
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0666248628311647,NPDC1;Neural proliferation differentiation and control protein 1,3.11462234347177,2.2720407141564,4.2696736383333,1.67270128234115e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374362994903959,NPDC1;Neural proliferation differentiation and control protein 1,1.73078095729779,1.50495061198144,1.99049902255638,1.46941485709907e-14
primary,Nervous system disorders,G72 (other myopathies),0.0940586298792914,NPDC1;Neural proliferation differentiation and control protein 1,1.98648755139924,1.50587939009226,2.62048396294365,1.19370230184965e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0600903293337727,NFASC;Neurofascin,2.55994150791377,1.80416040091527,3.63232699299644,1.39819960026026e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.989598522406921,NFASC;Neurofascin,1.33563509477814,1.22391505814972,1.45755303403154,8.38257736371935e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37420505661548,NFASC;Neurofascin,2.75757206512569,2.39553237929517,3.17432724353279,2.64633812106721e-45
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373697866243271,REG1B;Lithostathine-1-beta,1.93403330760445,1.68223318382745,2.22352339193131,1.88954026772033e-20
primary,Nervous system disorders,G93 (other disorders of brain),0.875397243181064,REG1B;Lithostathine-1-beta,1.27322127185707,1.16103562731403,1.39624691006219,2.8559979171226e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,IDUA;Alpha-L-iduronidase,1.4460946377837,1.25534664511403,1.66582649467057,3.20582897239149e-07
primary,Nervous system disorders,G40 (epilepsy),0.826020640611691,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.2646299200172,1.14874050457504,1.39221071097719,1.68727162053133e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0626431493843353,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,3.45527854101145,2.46518540310676,4.84302307685585,6.1286792302617e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.993481504751433,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.38710871177794,1.27132546514236,1.51343666987336,1.8655516729171e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.36812218523595,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,2.06056475179837,1.78859844153256,2.37388504751001,1.36560486809209e-23
primary,Nervous system disorders,G81 (hemiplegia),0.974872991898942,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.36184340441886,1.24725814882531,1.48695557523987,5.69604935538387e-12
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0627450980392156,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.86775596445927,2.15858004395352,3.80992323853281,3.63020605141514e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.993136541524907,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.32608277842746,1.21704263419183,1.44489230355484,1.14336656968872e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368721438798125,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.01322343645402,1.76746192880539,2.29315751532321,6.01649666339072e-26
primary,Nervous system disorders,G81 (hemiplegia),0.976462729380329,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.42146001941984,1.30456523476801,1.54882909107138,9.5665407618935e-16
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0658174919663943,"FABP4;Fatty acid-binding protein, adipocyte",3.18128833651076,2.40696742001228,4.20470813018639,4.21352806906432e-16
primary,Nervous system disorders,G62 (other polyneuropathies),0.990214352283317,"FABP4;Fatty acid-binding protein, adipocyte",1.33501126443231,1.21451677559841,1.46746023765955,2.14017839025818e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373697866243271,"FABP4;Fatty acid-binding protein, adipocyte",2.22039721851025,1.93999268595705,2.54133113163562,5.15359216961792e-31
primary,Nervous system disorders,G81 (hemiplegia),0.958181394987974,"FABP4;Fatty acid-binding protein, adipocyte",1.33432929484562,1.21216164862959,1.46880960067997,3.92784172002931e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367314987655807,CALB2;Calretinin,1.6149018111308,1.39060628268223,1.87537471394374,3.34454534383284e-10
primary,Nervous system disorders,G40 (epilepsy),0.799981503317842,RNASE6;Ribonuclease K6,1.36966972863472,1.23320768345931,1.52123214175562,4.23863671826267e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0594095603692532,RNASE6;Ribonuclease K6,2.66217583648609,1.86679684028462,3.79643892223959,6.40533249977042e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.964821817348458,RNASE6;Ribonuclease K6,1.32115580590648,1.20121703380818,1.45307018994466,9.71878313297084e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.335984640702139,RNASE6;Ribonuclease K6,1.85234838909159,1.58309828865217,2.16739199275584,1.44543985886101e-14
primary,Nervous system disorders,G81 (hemiplegia),0.925141404657766,RNASE6;Ribonuclease K6,1.429265400886,1.29744529150853,1.57447839962075,4.67715488440167e-13
primary,Nervous system disorders,G40 (epilepsy),0.820837253999079,EFNA4;Ephrin-A4,1.30153857601245,1.1809764222745,1.43440853932204,1.07288823531521e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0633086693309065,EFNA4;Ephrin-A4,3.94867472101747,2.89909336751189,5.37824418734885,2.99203399568275e-18
primary,Nervous system disorders,G62 (other polyneuropathies),0.992161920825478,EFNA4;Ephrin-A4,1.34011873055427,1.22734718969981,1.46325198530143,6.68365595888462e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373983418089716,EFNA4;Ephrin-A4,2.51325436064527,2.19310408958594,2.88014030492051,4.16897834574835e-40
primary,Nervous system disorders,G81 (hemiplegia),0.971393453997581,EFNA4;Ephrin-A4,1.38436842234469,1.26699298620611,1.51261763060255,6.24275675124883e-13
primary,Nervous system disorders,G93 (other disorders of brain),0.872753357510062,EFNA4;Ephrin-A4,1.26897746898721,1.15542267542237,1.39369241321884,6.3462717817362e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0626784595027508,INHBB;Inhibin beta B chain,3.00311405415569,2.07449868945501,4.34740887912381,5.6716160151022e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.343634632798532,INHBB;Inhibin beta B chain,1.95701974588658,1.66424382314671,2.30130118707512,4.63751157776336e-16
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.066222507625622,SORCS2;VPS10 domain-containing receptor SorCS2,3.32225974629949,2.41029245620081,4.57928239931493,2.24623534955916e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369314760547549,SORCS2;VPS10 domain-containing receptor SorCS2,1.66828287145101,1.444579962971,1.92662767760727,3.23502677879544e-12
primary,Nervous system disorders,G81 (hemiplegia),0.968594650043399,IL6;Interleukin-6,1.29337851720119,1.1880706902519,1.40802058537684,2.90202074458631e-09
primary,Nervous system disorders,G93 (other disorders of brain),0.880341033012788,IL6;Interleukin-6,1.25249906367393,1.14499919015729,1.37009171533874,8.77224223401839e-07
primary,Nervous system disorders,G40 (epilepsy),0.827237718779926,SCARB2;Lysosome membrane protein 2,1.28552306381154,1.16615300681076,1.41711210959437,4.38829438422691e-07
primary,Nervous system disorders,G47 (sleep disorders),2.63336277550685,SCARB2;Lysosome membrane protein 2,1.20312072646977,1.13903809461698,1.27080866680574,3.55192839838752e-11
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0644381796214256,SCARB2;Lysosome membrane protein 2,3.64422078541655,2.72086546729713,4.88092678321743,4.16765502005634e-18
primary,Nervous system disorders,G62 (other polyneuropathies),0.983639668753787,SCARB2;Lysosome membrane protein 2,1.43429535354792,1.31299049918416,1.566807347416,1.24684518379312e-15
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376628869509174,SCARB2;Lysosome membrane protein 2,1.9341381996671,1.68715922655941,2.21727180014905,2.96740892163984e-21
primary,Nervous system disorders,G81 (hemiplegia),0.964468029297229,SCARB2;Lysosome membrane protein 2,1.3980814269334,1.27897697660387,1.52827745306749,1.62787242175693e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591675579728284,YAP1;Transcriptional coactivator YAP1,3.55108214779122,2.63645539316306,4.78300693160318,7.4343211870348e-17
primary,Nervous system disorders,G62 (other polyneuropathies),0.963096515051235,YAP1;Transcriptional coactivator YAP1,1.28388445129012,1.1679262273975,1.41135565380494,2.29103181249403e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336891944185199,YAP1;Transcriptional coactivator YAP1,1.81201135319867,1.55737734038149,2.10827848780474,1.43041276596004e-14
primary,Nervous system disorders,G81 (hemiplegia),0.921364714468162,YAP1;Transcriptional coactivator YAP1,1.27446339455451,1.15695131956782,1.40391122477492,8.93506527759856e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37420505661548,CCL20;C-C motif chemokine 20,1.49349893723198,1.29922495952066,1.71682283284952,1.68435767969138e-08
primary,Nervous system disorders,G40 (epilepsy),0.819953549429465,ACE2;Angiotensin-converting enzyme 2,1.34860103876538,1.21295486165724,1.49941668832932,3.2133811889272e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.970951532501851,ACE2;Angiotensin-converting enzyme 2,1.31765442138604,1.19626142649909,1.45136601058791,2.22014367444514e-08
primary,Nervous system disorders,G81 (hemiplegia),0.951961921523139,ACE2;Angiotensin-converting enzyme 2,1.27912421093025,1.15952826783029,1.41105550626162,8.8656542322679e-07
primary,Nervous system disorders,G40 (epilepsy),0.806367377634794,WFDC2;WAP four-disulfide core domain protein 2,1.36406266957583,1.23687528046057,1.50432868691294,5.07083223998228e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660638341797762,WFDC2;WAP four-disulfide core domain protein 2,3.1346041337832,2.29558564992369,4.28027726861655,6.5599926069757e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.985548055820116,WFDC2;WAP four-disulfide core domain protein 2,1.33612900908209,1.22322615744141,1.45945270876551,1.24968237254689e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.363441126667492,WFDC2;WAP four-disulfide core domain protein 2,2.05906374101036,1.79224590234048,2.36560367302664,1.98099640435959e-24
primary,Nervous system disorders,G81 (hemiplegia),0.972239460510529,WFDC2;WAP four-disulfide core domain protein 2,1.55235698138035,1.42250752860881,1.6940593629034,5.7686978471202e-23
primary,Nervous system disorders,G93 (other disorders of brain),0.881808539400619,WFDC2;WAP four-disulfide core domain protein 2,1.26465505675736,1.15126648813368,1.38921129822398,9.63145518640085e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0661620191091478,GFRA1;GDNF family receptor alpha-1,5.26377613093698,3.93161741298801,7.04731316559218,6.71745439625404e-29
primary,Nervous system disorders,G62 (other polyneuropathies),0.979837214295473,GFRA1;GDNF family receptor alpha-1,1.37535926136786,1.26064212221403,1.50051554243496,7.37032044064817e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373722627737226,GFRA1;GDNF family receptor alpha-1,2.38139548718573,2.08532286462336,2.7195042852095,1.44961423772655e-37
primary,Nervous system disorders,G81 (hemiplegia),0.963244613434727,GFRA1;GDNF family receptor alpha-1,1.42803000364589,1.30862295012065,1.55833251367392,1.2718822852304e-15
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0658174919663943,MFAP5;Microfibrillar-associated protein 5,2.32923069764703,1.66598274131897,3.25652571800716,7.60953782805075e-07
primary,Nervous system disorders,G47 (sleep disorders),2.64276070208879,HAVCR1;Hepatitis A virus cellular receptor 1,1.20486456875682,1.14242505375295,1.27071673041187,6.68481187814469e-12
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0661581569115815,HAVCR1;Hepatitis A virus cellular receptor 1,3.44727567844576,2.57723077922808,4.6110382116277,7.47781791604396e-17
primary,Nervous system disorders,G62 (other polyneuropathies),0.983683347646186,HAVCR1;Hepatitis A virus cellular receptor 1,1.36657548222321,1.25428809350049,1.48891515297867,9.38857917242217e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373700805792362,HAVCR1;Hepatitis A virus cellular receptor 1,2.66333594854984,2.34591180706329,3.02371059026198,1.04389964110581e-51
primary,Nervous system disorders,G81 (hemiplegia),0.963188270160661,HAVCR1;Hepatitis A virus cellular receptor 1,1.36000102699158,1.24742461809614,1.48273712622498,3.06118066011126e-12
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0666248628311647,IGSF8;Immunoglobulin superfamily member 8,2.56192966365397,1.84406085755876,3.55925541969323,2.04680257375421e-08
primary,Nervous system disorders,G62 (other polyneuropathies),1.00041274396116,IGSF8;Immunoglobulin superfamily member 8,1.24927386863742,1.14535278141504,1.36262400911284,5.09683078102959e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374362994903959,IGSF8;Immunoglobulin superfamily member 8,1.68783622160884,1.46772534606104,1.94095654109956,2.10264751631158e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0665765924533474,CTSZ;Cathepsin Z,2.5822374381503,1.85548821850577,3.59363649980744,1.84786354061799e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.99768254841117,CTSZ;Cathepsin Z,1.25264102287065,1.14759032701098,1.36730808481571,4.64489045546836e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370174510840825,CTSZ;Cathepsin Z,1.85537397969149,1.60880116802229,2.13973775811463,1.9715325745488e-17
primary,Nervous system disorders,G81 (hemiplegia),0.965311568042693,CTSZ;Cathepsin Z,1.28764556002292,1.17814810588332,1.40731974186186,2.46732458291477e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0632023858900673,SNCG;Gamma-synuclein,2.44713825343191,1.71098243721654,3.50002752871733,9.51074052142518e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,SNCG;Gamma-synuclein,1.94137412027027,1.67340772651332,2.25225055145887,2.0633558416063e-18
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,RTN4R;Reticulon-4 receptor,2.77551676460846,2.05601124246921,3.74681477975331,2.59650527327153e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,RTN4R;Reticulon-4 receptor,1.87741436292131,1.63393421487721,2.15717662192911,6.22710700389323e-19
primary,Nervous system disorders,G40 (epilepsy),0.816814228629632,COL6A3;Collagen alpha-3(VI) chain,1.26866456078834,1.15237008492924,1.39669520135027,1.22791173202394e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0658174919663943,COL6A3;Collagen alpha-3(VI) chain,4.05698316382932,3.10987203872369,5.29253685896011,5.46887081398556e-25
primary,Nervous system disorders,G62 (other polyneuropathies),0.990214352283317,COL6A3;Collagen alpha-3(VI) chain,1.43777865864981,1.318675432419,1.56763932992724,1.87200311711026e-16
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373697866243271,COL6A3;Collagen alpha-3(VI) chain,2.16515636492456,1.89422562183022,2.47483828248707,9.78094747757257e-30
primary,Nervous system disorders,G72 (other myopathies),0.0948546207750977,COL6A3;Collagen alpha-3(VI) chain,2.04411984486638,1.5639161589606,2.67177106409181,1.6662098720082e-07
primary,Nervous system disorders,G81 (hemiplegia),0.958181394987974,COL6A3;Collagen alpha-3(VI) chain,1.38454821862579,1.26794078841744,1.51187956662589,4.21411845453373e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372535420588526,GFRA3;GDNF family receptor alpha-3,1.56671534220866,1.3572362038939,1.80852600046313,8.73304966536266e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0666248628311647,LEPR;Leptin receptor,2.17205605525353,1.57990584145616,2.98614473304004,1.78677040066304e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371456500488758,LGALS3;Galectin-3,1.42879316221661,1.23602333853858,1.65162730892336,1.39603372104603e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.330718000182465,RBP7;Retinoid-binding protein 7,1.50047577898062,1.28392147783289,1.75355549554918,3.34893141477856e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0570047427946005,EFCAB14;EF-hand calcium-binding domain-containing protein 14,2.71915703513164,1.87054276532188,3.95276446963968,1.59773407725852e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.330718000182465,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.59753666817911,1.35909891140264,1.87780549654251,1.34452507409975e-08
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00733146569708,PI3;Elafin,1.3791226457199,1.25872401679954,1.51103756387637,5.31471154369976e-12
primary,Nervous system disorders,G62 (other polyneuropathies),0.99589690475242,PI3;Elafin,1.27902346838047,1.1665482472185,1.40234322632486,1.60472064864208e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.377380976026376,PI3;Elafin,1.56095007997079,1.34427028936203,1.81255598032831,5.21747393055745e-09
primary,Nervous system disorders,G81 (hemiplegia),0.959051295316168,PI3;Elafin,1.34449312221438,1.22438378848234,1.47638491515999,5.64992943563536e-10
primary,Nervous system disorders,G40 (epilepsy),0.819930621255124,CKAP4;Cytoskeleton-associated protein 4,1.3716846963141,1.24619309543298,1.50981329699037,1.07528529151641e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0603829447398663,CKAP4;Cytoskeleton-associated protein 4,3.56584670730874,2.55697258001641,4.97278024778152,6.74751175318978e-14
primary,Nervous system disorders,G62 (other polyneuropathies),0.992478265116733,CKAP4;Cytoskeleton-associated protein 4,1.41317351882455,1.29582046279083,1.5411543895563,5.33878385165895e-15
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.3760277442232,CKAP4;Cytoskeleton-associated protein 4,1.9742045319397,1.7194759580407,2.26666939756012,4.91860156379244e-22
primary,Nervous system disorders,G81 (hemiplegia),0.960262315559372,CKAP4;Cytoskeleton-associated protein 4,1.4212525221465,1.30158357891517,1.55192395204567,4.74788013353418e-15
primary,Nervous system disorders,G93 (other disorders of brain),0.873028329278819,CKAP4;Cytoskeleton-associated protein 4,1.25620239305472,1.14510600835021,1.3780771743482,1.37903169357033e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0608320251177394,EFNA1;Ephrin-A1,3.87914169639719,2.78113775693401,5.41064183649653,1.40812569489378e-15
primary,Nervous system disorders,G62 (other polyneuropathies),0.990001574555188,EFNA1;Ephrin-A1,1.34336504622597,1.23098642437253,1.46600288329058,3.53622206412014e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.380772929792537,EFNA1;Ephrin-A1,2.1293308255929,1.857293499969,2.44121339190377,2.2852710473675e-27
primary,Nervous system disorders,G81 (hemiplegia),0.967380404648144,EFNA1;Ephrin-A1,1.33986436936486,1.22678303756147,1.46336921307777,7.85317484132048e-11
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0669357220198838,"ST3GAL1;CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1",2.39827027103717,1.76053803334492,3.26701280176994,2.92016379044743e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,"ST3GAL1;CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1",1.486655846946,1.2956567755077,1.70581102112686,1.58805693327138e-08
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00056895097212,"FABP1;Fatty acid-binding protein, liver",1.261224474523,1.15617122775153,1.37582317995347,1.69239845747569e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0627450980392156,"FABP1;Fatty acid-binding protein, liver",2.98257853275504,2.16549248368853,4.10796840490475,2.22759949215125e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368721438798125,"FABP1;Fatty acid-binding protein, liver",1.94876349289043,1.69616593397156,2.23897855461009,4.526479392456e-21
primary,Nervous system disorders,G81 (hemiplegia),0.976462729380329,"FABP1;Fatty acid-binding protein, liver",1.33427405334308,1.22224577415241,1.45657059085285,1.15434423413666e-10
primary,Nervous system disorders,G93 (other disorders of brain),0.872982955106555,"FABP1;Fatty acid-binding protein, liver",1.27260048143135,1.15926357060609,1.39701792275986,4.07866381641682e-07
primary,Nervous system disorders,G40 (epilepsy),0.82579630357845,ADM;Pro-adrenomedullin,1.27187253950216,1.15675221905673,1.39844966803591,6.75798469633904e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,ADM;Pro-adrenomedullin,2.92947960153648,2.26504991308004,3.78881307924408,2.61897334205329e-16
primary,Nervous system disorders,G62 (other polyneuropathies),0.982264665757162,ADM;Pro-adrenomedullin,1.26735950255872,1.16227462975989,1.38194542632123,8.09029970255128e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,ADM;Pro-adrenomedullin,1.88162785076275,1.65289369717858,2.14201516698235,1.18665446790699e-21
primary,Nervous system disorders,G81 (hemiplegia),0.96374751762003,ADM;Pro-adrenomedullin,1.44341532265487,1.32459509081747,1.57289409278202,5.59155612966354e-17
primary,Nervous system disorders,G93 (other disorders of brain),0.880677926297042,ADM;Pro-adrenomedullin,1.25271352770784,1.1430498675424,1.37289826722631,1.43294795286415e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0658174919663943,NOTCH1;Neurogenic locus notch homolog protein 1,2.71717550249495,1.94917426230446,3.78777970453495,3.68426601660432e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373697866243271,NOTCH1;Neurogenic locus notch homolog protein 1,1.64886751716428,1.43329905796081,1.89685751487727,2.64083429104396e-12
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00124414953492,PLAUR;Urokinase plasminogen activator surface receptor,1.32608834360778,1.21879656473965,1.44282511612434,5.50919940301145e-11
primary,Nervous system disorders,G40 (epilepsy),0.822815146189487,PLAUR;Urokinase plasminogen activator surface receptor,1.36913934626881,1.24535384123244,1.50522886543335,8.12893525715178e-11
primary,Nervous system disorders,G47 (sleep disorders),2.64657898447098,PLAUR;Urokinase plasminogen activator surface receptor,1.22589467778319,1.16243422276126,1.29281961214746,5.91593043524144e-14
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0631587257727075,PLAUR;Urokinase plasminogen activator surface receptor,2.58590306330193,1.89046047964156,3.53717770078015,2.77454037731201e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.991784618430169,PLAUR;Urokinase plasminogen activator surface receptor,1.43020281639513,1.31366619473626,1.55707751651112,1.56795107746489e-16
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371152745148362,PLAUR;Urokinase plasminogen activator surface receptor,2.05493889453834,1.80232773670326,2.3429555980815,5.18731402823972e-27
primary,Nervous system disorders,G81 (hemiplegia),0.978957360968277,PLAUR;Urokinase plasminogen activator surface receptor,1.49299544008225,1.37133654603795,1.62544737143226,2.42841655891152e-20
primary,Nervous system disorders,G93 (other disorders of brain),0.872780770989482,PLAUR;Urokinase plasminogen activator surface receptor,1.31869399743839,1.20361963843825,1.44477026075812,2.88166169866457e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373722627737226,FGF21;Fibroblast growth factor 21,1.47528582528578,1.28514300758775,1.69356114723328,3.32405041914321e-08
primary,Nervous system disorders,G40 (epilepsy),0.826693227091633,CD302;CD302 antigen,1.34410078071311,1.22124942001916,1.47931035143112,1.47556764706099e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0669357220198838,CD302;CD302 antigen,3.74333139736827,2.80103654727251,5.00262303402205,4.60136391624107e-19
primary,Nervous system disorders,G62 (other polyneuropathies),0.985309217281415,CD302;CD302 antigen,1.2961647721585,1.18758498729453,1.41467190521838,6.19250111180517e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,CD302;CD302 antigen,1.77681089843707,1.54587310323577,2.04224846282435,5.88059362813452e-16
primary,Nervous system disorders,G81 (hemiplegia),0.968594650043399,CD302;CD302 antigen,1.3809454822735,1.26482774742351,1.50772342628964,5.911252317477e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0633061644377621,DKK4;Dickkopf-related protein 4,3.03905162174724,2.17630443601021,4.24381562010528,6.83025505685367e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371989948356714,DKK4;Dickkopf-related protein 4,2.11074829881924,1.83458646003783,2.42848101085213,1.59855814505021e-25
primary,Nervous system disorders,G51 (facial nerve disorders),0.398978614746249,CD80;T-lymphocyte activation antigen CD80,1.43252762542676,1.23650173866143,1.65963001381006,1.68932225308818e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0612953756044405,CD80;T-lymphocyte activation antigen CD80,2.62412081658667,1.83930315850618,3.74381462250959,1.03196317365924e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.949496789471287,CD80;T-lymphocyte activation antigen CD80,1.34853753627511,1.22555707793801,1.48385866270925,8.85322981738748e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.342885689631681,CD80;T-lymphocyte activation antigen CD80,1.98233671127671,1.698927450583,2.31302333453195,3.52828636616921e-18
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375533316293427,CD4;T-cell surface glycoprotein CD4,1.69065473572266,1.46901134791434,1.94573952031046,2.40764018620508e-13
primary,Nervous system disorders,G40 (epilepsy),0.803913912304476,SHISA5;Protein shisa-5,1.35509903852435,1.22111531123292,1.50378378464158,1.06076560997599e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0612828544191747,SHISA5;Protein shisa-5,3.27662209823529,2.36511114637946,4.53942825946213,9.63859452382977e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.960684772463405,SHISA5;Protein shisa-5,1.34726894778815,1.22508282179124,1.48164155548293,7.98929863107188e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336012350724242,SHISA5;Protein shisa-5,1.87571125661391,1.60456017575328,2.19268355986488,2.89091143916117e-15
primary,Nervous system disorders,G81 (hemiplegia),0.921292083712465,SHISA5;Protein shisa-5,1.50957574461504,1.37115896623062,1.66196552322057,4.74094375528182e-17
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374362994903959,NRCAM;Neuronal cell adhesion molecule,2.04740507113817,1.77505475227778,2.36154266224365,7.63605684475839e-23
primary,Nervous system disorders,G62 (other polyneuropathies),0.990491283676703,CDCP1;CUB domain-containing protein 1,1.27227243611898,1.16835145564604,1.38543684255785,3.04502800367167e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,CDCP1;CUB domain-containing protein 1,1.63543967250519,1.43310309399825,1.86634369404771,2.87425310396662e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.99839473787244,CD163;Scavenger receptor cysteine-rich type 1 protein M130,1.25147944704384,1.14778319337171,1.36454411897451,3.71005221610241e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368989281739911,CD163;Scavenger receptor cysteine-rich type 1 protein M130,1.52887447940641,1.32833087202414,1.75969498489359,3.26654986730641e-09
primary,Nervous system disorders,G20 (parkinson's disease),1.51705954114359,IFNLR1;Interferon lambda receptor 1,0.799286562160656,0.743700376664962,0.859027410091532,1.11675785596231e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0670840787119856,CD59;CD59 glycoprotein,2.96742967081651,2.19483920111672,4.01197447483256,1.56336917653267e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.382253670041885,CD59;CD59 glycoprotein,1.59113731009545,1.37381465099286,1.84283806971202,5.69900757356967e-10
primary,Nervous system disorders,G81 (hemiplegia),0.967492260061919,CD59;CD59 glycoprotein,1.30546346386895,1.18926537087468,1.43301478142199,2.09119612919399e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0667176860736641,FOLR1;Folate receptor alpha,2.33225385122282,1.69997605892271,3.19969684160768,1.53130463517601e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.993840159014425,FOLR1;Folate receptor alpha,1.26706999758347,1.16062356953957,1.38327914485923,1.24302397248036e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374899405264294,FOLR1;Folate receptor alpha,1.66081557807468,1.44701562769779,1.90620497220476,5.38191970312248e-13
primary,Nervous system disorders,G81 (hemiplegia),0.965414184313494,FOLR1;Folate receptor alpha,1.30859655036363,1.19755747904008,1.42993130734419,2.76601546607335e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,CALB1;Calbindin,1.46112752970487,1.2688688429833,1.68251720409654,1.37855506580566e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336353651839648,APCS;Serum amyloid P-component,0.656947287041853,0.552861987974592,0.780628343671702,1.80660394782178e-06
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.01172503039096,REN;Renin,1.25401117182008,1.14418122081177,1.37438369940549,1.29784671972439e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0666248628311647,REN;Renin,5.56835526235864,3.95740435503649,7.83508015509605,6.54853498174116e-23
primary,Nervous system disorders,G62 (other polyneuropathies),1.00041274396116,REN;Renin,1.29787625270618,1.18337145576059,1.42346070554488,3.1514082244923e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374362994903959,REN;Renin,3.31993488535221,2.85138037046789,3.86548485678534,6.63708073207737e-54
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0664166275980621,NECTIN4;Nectin-4,3.88547440395847,2.76207751493657,5.46578119628302,6.43868919735079e-15
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373207237484856,NECTIN4;Nectin-4,1.69414026808144,1.46542106551986,1.95855738358511,1.04675026260193e-12
primary,Nervous system disorders,G81 (hemiplegia),0.96496378939127,NECTIN4;Nectin-4,1.30450580839144,1.1926531803794,1.42684850224913,6.17484300163954e-09
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00878556989581,MSR1;Macrophage scavenger receptor types I and II,1.23341622974352,1.13281213364677,1.34295489129101,1.34788092786043e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376940563856451,MSR1;Macrophage scavenger receptor types I and II,1.78713277717902,1.5621581706039,2.04450715898564,2.71922685418658e-17
primary,Nervous system disorders,G81 (hemiplegia),0.965431329803799,MSR1;Macrophage scavenger receptor types I and II,1.24051221896159,1.13703189894121,1.353410196166,1.23676356156717e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0612036722203332,B2M;Beta-2-microglobulin,3.06319389288389,2.19553382631679,4.27374732874977,4.4509891044466e-11
primary,Nervous system disorders,G62 (other polyneuropathies),0.959396171509116,B2M;Beta-2-microglobulin,1.3273315191809,1.20795206557704,1.45850900215106,3.88529849387825e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.337845498038682,B2M;Beta-2-microglobulin,1.67204613065438,1.43101916926951,1.95366933097299,9.64002570414003e-11
primary,Nervous system disorders,G81 (hemiplegia),0.922328994297916,B2M;Beta-2-microglobulin,1.34221556156527,1.21938835639767,1.47741497141247,1.84731865935646e-09
primary,Nervous system disorders,G93 (other disorders of brain),0.858388694838253,B2M;Beta-2-microglobulin,1.2846322430791,1.16229991303935,1.41984007866185,9.31183320043973e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369314760547549,BAIAP2;Brain-specific angiogenesis inhibitor 1-associated protein 2,1.51974370081405,1.31230620491492,1.75997103992488,2.27403363475477e-08
primary,Nervous system disorders,G81 (hemiplegia),0.962333215255638,RETN;Resistin,1.2907600344672,1.18201613574802,1.40950822597986,1.31605179737993e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372880697597638,VEGFD;Vascular endothelial growth factor D,1.8378982871516,1.60690221873165,2.10210059737236,6.61203993633383e-19
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373471714431733,CA6;Carbonic anhydrase 6,0.663327191721167,0.572420453438633,0.768670931713767,4.80427359920071e-08
primary,Nervous system disorders,G81 (hemiplegia),0.966839949590422,CA6;Carbonic anhydrase 6,0.759569767410276,0.692328228133944,0.833342059616382,6.06647851069184e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607307277892056,CD300LG;CMRF35-like molecule 9,3.46669424143679,2.44522663642437,4.91486915142752,2.94183929929438e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,CD300LG;CMRF35-like molecule 9,1.48331675155173,1.28283397121475,1.71513121323917,1.02734610374636e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0600903293337727,PGF;Placenta growth factor,2.85046072692821,2.12440358011008,3.82466233432873,2.88275948786485e-12
primary,Nervous system disorders,G62 (other polyneuropathies),0.989598522406921,PGF;Placenta growth factor,1.33439291418624,1.21925275354655,1.46040633843231,3.71219790948688e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37420505661548,PGF;Placenta growth factor,1.84266559159997,1.60068020171748,2.12123350986866,1.75223365780574e-17
primary,Nervous system disorders,G81 (hemiplegia),0.96142640717865,PGF;Placenta growth factor,1.39077485378714,1.26998307745678,1.5230554865346,1.11334742382219e-12
primary,Nervous system disorders,G93 (other disorders of brain),0.8746754134208,PGF;Placenta growth factor,1.30168999233813,1.18228197639687,1.43315796906344,7.83487189659998e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0664166275980621,FGFR2;Fibroblast growth factor receptor 2,2.99118662936612,2.15074295161334,4.16004964469932,7.49900598000421e-11
primary,Nervous system disorders,G62 (other polyneuropathies),0.9952588064731,FGFR2;Fibroblast growth factor receptor 2,1.26000143046181,1.15234801886653,1.37771192276393,3.93974699236598e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373207237484856,FGFR2;Fibroblast growth factor receptor 2,1.96404320059686,1.69986422414702,2.2692787100372,5.26978081598771e-20
primary,Nervous system disorders,G81 (hemiplegia),0.96496378939127,FGFR2;Fibroblast growth factor receptor 2,1.25164852715301,1.14327982291158,1.37028923639585,1.18614721164307e-06
primary,Nervous system disorders,G40 (epilepsy),0.819897218626181,CLEC7A;C-type lectin domain family 7 member A,1.28507984522864,1.16675319767166,1.41540662747565,3.5950965113174e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0600903293337727,CLEC7A;C-type lectin domain family 7 member A,3.12318217017205,2.21006811100914,4.41355939189888,1.08668137961609e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37420505661548,CLEC7A;C-type lectin domain family 7 member A,1.69608654457625,1.47207929615501,1.95418111932313,2.6643246832496e-13
primary,Nervous system disorders,G81 (hemiplegia),0.96142640717865,CLEC7A;C-type lectin domain family 7 member A,1.30640817309669,1.19558617957466,1.42750254552207,3.4279643818328e-09
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.01477480339979,PIGR;Polymeric immunoglobulin receptor,1.24865826559807,1.14593443722274,1.36059046102594,3.97985030885813e-07
primary,Nervous system disorders,G40 (epilepsy),0.799341246409993,PIGR;Polymeric immunoglobulin receptor,1.35245874388758,1.22652909721235,1.49131778290075,1.40689063752232e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0615274690377897,PIGR;Polymeric immunoglobulin receptor,2.55303567539363,1.81347745271308,3.59419476105494,7.83505642853987e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.99731263063601,PIGR;Polymeric immunoglobulin receptor,1.42553479150292,1.30721508257705,1.55456394962878,1.05923754498586e-15
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38115657197308,PIGR;Polymeric immunoglobulin receptor,2.08113028105587,1.81308628106952,2.38880151041286,2.04613041763247e-25
primary,Nervous system disorders,G81 (hemiplegia),0.968498926099753,PIGR;Polymeric immunoglobulin receptor,1.46647816982297,1.34321002283877,1.60105879646602,1.268255458153e-17
primary,Nervous system disorders,G93 (other disorders of brain),0.871668765868969,PIGR;Polymeric immunoglobulin receptor,1.34999007344449,1.23004743378215,1.48162838956131,2.59055626825122e-10
primary,Nervous system disorders,G99 (other disorders of nervous system in diseases classified elsewhere),0.510558833462463,PIGR;Polymeric immunoglobulin receptor,1.36480308591987,1.20917424890094,1.54046239822712,4.78491714432546e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0666693603781971,LCN2;Neutrophil gelatinase-associated lipocalin,2.56717043069953,1.84262421599918,3.57661858724914,2.51344185131964e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369794087336068,LCN2;Neutrophil gelatinase-associated lipocalin,1.55538322620804,1.34448029994165,1.79936960063627,2.82462164223232e-09
primary,Nervous system disorders,G81 (hemiplegia),0.973664500718608,LCN2;Neutrophil gelatinase-associated lipocalin,1.2782645820244,1.1681977048793,1.39870189338101,9.09318153099251e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,XCL1;Lymphotactin,1.47777130763824,1.28363997170907,1.70126210293317,5.48078162770096e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0669357220198838,ADGRG1;Adhesion G-protein coupled receptor G1,2.55748974605754,1.78849715441425,3.65712284475599,2.66147108275492e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.985309217281415,ADGRG1;Adhesion G-protein coupled receptor G1,1.28944164189375,1.1797036191213,1.40938768085503,2.12370567628557e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,ADGRG1;Adhesion G-protein coupled receptor G1,2.51301210690959,2.1630592651753,2.91958244101202,2.09077858780462e-33
primary,Nervous system disorders,G81 (hemiplegia),0.968594650043399,ADGRG1;Adhesion G-protein coupled receptor G1,1.2533870489813,1.14624671218557,1.37054185443084,7.27697814618658e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376072393935832,MMP12;Macrophage metalloelastase,1.62166865870051,1.41279010404352,1.86142954362774,6.33668454770875e-12
primary,Nervous system disorders,G81 (hemiplegia),0.9575198665751,MMP12;Macrophage metalloelastase,1.36869507728601,1.25368260123727,1.4942587643301,2.40955499848862e-12
primary,Nervous system disorders,G93 (other disorders of brain),0.883611763081596,MMP12;Macrophage metalloelastase,1.28347354098396,1.17093699646898,1.40682576037261,9.7997511117473e-08
primary,Nervous system disorders,G20 (parkinson's disease),0.790273556231003,AHNAK;Neuroblast differentiation-associated protein AHNAK,0.692852520332319,0.622101340162573,0.7716501861343,2.44221963996763e-11
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0613302734143156,EPHB6;Ephrin type-B receptor 6,3.43875927766497,2.43940949537078,4.84751141297395,1.78462630809047e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372004669845855,EPHB6;Ephrin type-B receptor 6,1.67225237120559,1.45210399660986,1.92577666581137,9.38612147439872e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0659246907356419,CXCL16;C-X-C motif chemokine 16,2.23940465423949,1.60782839725559,3.11907241717431,1.85001658734002e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374306659943369,CXCL16;C-X-C motif chemokine 16,1.61141893981682,1.39968886487854,1.85517729315201,3.16965047004865e-11
primary,Nervous system disorders,G81 (hemiplegia),0.96142640717865,CXCL17;C-X-C motif chemokine 17,1.23690442912793,1.13683428039707,1.34578328009418,7.83532077304713e-07
primary,Nervous system disorders,G40 (epilepsy),0.822129991858132,NECTIN2;Nectin-2,1.28845055796475,1.17011850884664,1.41874932134523,2.51876216976011e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0667242326713242,NECTIN2;Nectin-2,3.90931539585899,2.83372678119873,5.39316174223234,1.00225434050825e-16
primary,Nervous system disorders,G62 (other polyneuropathies),0.99994094836919,NECTIN2;Nectin-2,1.33519063208814,1.22407486765024,1.45639296347789,6.99829943989265e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37492148241206,NECTIN2;Nectin-2,2.0954738631904,1.82231501199873,2.40957830144746,3.02448839861426e-25
primary,Nervous system disorders,G81 (hemiplegia),0.961557368990266,NECTIN2;Nectin-2,1.43075703193127,1.30968648147443,1.56301963361201,2.0137213345403e-15
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0664166275980621,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,3.4276231711879,2.51632337910736,4.66895499251448,5.63247996257036e-15
primary,Nervous system disorders,G62 (other polyneuropathies),0.9952588064731,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.3077741799532,1.19931879565572,1.42603727378189,1.24163771506427e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373207237484856,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,2.19822823375774,1.91940426474069,2.51755581482076,5.16224329466725e-30
primary,Nervous system disorders,G81 (hemiplegia),0.96496378939127,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.30349203411027,1.19397674790492,1.42305240530885,3.22856642406039e-09
primary,Nervous system disorders,G20 (parkinson's disease),1.51819689725826,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,0.78648812246477,0.732809636637796,0.844098570559458,2.75595685344022e-11
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0661723205075806,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,2.39359512964113,1.73541070805845,3.30140733720122,1.03783128275094e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373780832051706,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,1.4386180957141,1.25010754148769,1.6555551875586,3.87430882123406e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0664166275980621,TGFBR2;TGF-beta receptor type-2,3.93938239957427,2.93232237745599,5.29230135451178,8.87356573659283e-20
primary,Nervous system disorders,G62 (other polyneuropathies),0.9952588064731,TGFBR2;TGF-beta receptor type-2,1.31412445454169,1.2048751208099,1.4332797251749,6.88832466157562e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373207237484856,TGFBR2;TGF-beta receptor type-2,1.96436982067517,1.71280531971762,2.25288230247648,4.61508380861924e-22
primary,Nervous system disorders,G81 (hemiplegia),0.96496378939127,TGFBR2;TGF-beta receptor type-2,1.38251126409169,1.26628564211874,1.5094046175414,4.85324999148334e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375541838956473,SIT1;Signaling threshold-regulating transmembrane adapter 1,1.43671553162347,1.24607887850557,1.65651754027292,6.07186089981899e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.985828712261244,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.33430088702582,1.22289556416461,1.45585519261744,8.9634304511042e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37260925577247,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.44220912366633,1.2519176425256,1.66142490986093,3.93567267717546e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.066222507625622,MUC13;Mucin-13,2.66417963430774,1.8872706776514,3.76090891884835,2.53795078856084e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367314987655807,MUC13;Mucin-13,2.37685987586058,2.05297318044564,2.75184445821626,4.98932049571901e-31
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376644159088247,ACP5;Tartrate-resistant acid phosphatase type 5,1.55147869629294,1.34696570844642,1.78704337456902,1.12976962417854e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0631372182209334,HS6ST2;Heparan-sulfate 6-O-sulfotransferase 2,3.22467941681686,2.17316525013871,4.78498233881598,6.0717678175431e-09
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00889159322433,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.24810310716533,1.14494614545865,1.36055426911955,4.77241345418575e-07
primary,Nervous system disorders,G40 (epilepsy),0.804002144005717,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.37887309749334,1.25120531902211,1.51956756424024,9.12289366621736e-11
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0588523786169691,VSIG4;V-set and immunoglobulin domain-containing protein 4,3.49959266466652,2.57418275712255,4.75768427268843,1.30391482768458e-15
primary,Nervous system disorders,G62 (other polyneuropathies),0.987722335904297,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.32177659400896,1.21102261273606,1.44265957224591,4.15380441183201e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378691258706955,VSIG4;V-set and immunoglobulin domain-containing protein 4,2.10010048319254,1.83569885306202,2.40258473341028,3.16998205850877e-27
primary,Nervous system disorders,G81 (hemiplegia),0.969060816920234,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.44475324345796,1.32344185598595,1.57718446416165,1.99103873792058e-16
primary,Nervous system disorders,G93 (other disorders of brain),0.871386512280424,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.2858997637778,1.17148244688242,1.4114920858475,1.23167321443897e-07
primary,Nervous system disorders,G40 (epilepsy),0.826693227091633,RBP5;Retinol-binding protein 5,1.27388559157984,1.15702864435402,1.40254479295172,8.17743578996765e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0669357220198838,RBP5;Retinol-binding protein 5,2.60222341078334,1.92680727021788,3.51439751359418,4.44024039291946e-10
primary,Nervous system disorders,G62 (other polyneuropathies),0.985309217281415,RBP5;Retinol-binding protein 5,1.25144785332999,1.1459068123004,1.36670950272149,6.0454089624095e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,RBP5;Retinol-binding protein 5,1.55305775186735,1.34849152892997,1.78865667962275,1.00272378817413e-09
primary,Nervous system disorders,G40 (epilepsy),0.822129991858132,FAM3C;Protein FAM3C,1.28720240744144,1.16803549209268,1.41852713289945,3.51293086727783e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0667242326713242,FAM3C;Protein FAM3C,4.07406539005651,2.94448549941625,5.63698099574506,2.28019724935149e-17
primary,Nervous system disorders,G62 (other polyneuropathies),0.99994094836919,FAM3C;Protein FAM3C,1.32037764088818,1.20940385761381,1.44153427623194,5.48139573469102e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37492148241206,FAM3C;Protein FAM3C,2.36529835746921,2.0528814171958,2.7252603452803,1.03450686997927e-32
primary,Nervous system disorders,G56 (mononeuropathies of upper limb),2.65049053252048,PRELP;Prolargin,1.22802529641798,1.16209754565515,1.29769323950537,2.96774616194513e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0627450980392156,PRELP;Prolargin,2.7331102140636,1.92646593836553,3.87751026034565,1.75732458293156e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.993136541524907,PRELP;Prolargin,1.27477335168115,1.16653253394073,1.39305767381106,8.21382756981063e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368721438798125,PRELP;Prolargin,1.81594696730147,1.56880585476345,2.10202134192611,1.31594536054561e-15
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0634127974951945,SFRP1;Secreted frizzled-related protein 1,2.28108451182214,1.64292688989944,3.16711996258905,8.43066611691537e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372616640900622,SFRP1;Secreted frizzled-related protein 1,1.51029346473131,1.31169345142921,1.73896297730597,9.93565959394049e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,3.26452152592769,2.33774188799453,4.55871576240934,3.80625419225388e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.57442347026654,1.36081998879828,1.82155559451703,1.05089811552639e-09
primary,Nervous system disorders,G81 (hemiplegia),0.96374751762003,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.25458298008383,1.1463571632397,1.37302622986001,8.33041162103013e-07
primary,Nervous system disorders,G45 (transient cerebral ischaemic attacks and related syndromes),1.30937512590145,NPPB;Natriuretic peptides B,1.22968385152035,1.13774284522369,1.32905461109942,1.84138611566883e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367331456748717,NPPB;Natriuretic peptides B,1.55079955189527,1.34212203601384,1.79192292923038,2.67140218271341e-09
primary,Nervous system disorders,G81 (hemiplegia),0.951961921523139,NPPB;Natriuretic peptides B,1.30760572753251,1.19414367314321,1.43184842588936,6.98862257579573e-09
primary,Nervous system disorders,G09 (sequelae of inflammatory diseases of central nervous system),0.0249608568381401,PRAP1;Proline-rich acidic protein 1,3.7704974841991,2.27209852986396,6.25705755780007,2.81007431157057e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0612828544191747,PRAP1;Proline-rich acidic protein 1,2.42646024199304,1.68493251438327,3.49432944982248,1.90027802595036e-06
primary,Nervous system disorders,G62 (other polyneuropathies),0.960684772463405,PRAP1;Proline-rich acidic protein 1,1.30699913340725,1.18426356058252,1.44245486527258,1.03022522267464e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336012350724242,PRAP1;Proline-rich acidic protein 1,2.29851444554161,1.9617897440792,2.69303510853209,7.22142405699523e-25
primary,Nervous system disorders,G81 (hemiplegia),0.921292083712465,PRAP1;Proline-rich acidic protein 1,1.40680038842082,1.27269790487492,1.55503307209063,2.42621444795438e-11
primary,Nervous system disorders,"G98 (other disorders of nervous system, not elsewhere classified)",0.0410284463894967,PRAP1;Proline-rich acidic protein 1,3.02474071712788,1.98482974593461,4.60949178366087,2.61533963682258e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369438767489388,ANG;Angiogenin,1.46069051861515,1.25865147684756,1.69516091659949,6.08106193725765e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.988245712905563,GPKOW;G-patch domain and KOW motifs-containing protein,1.27293230722106,1.16485534222791,1.39103680948746,9.77636677534035e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373697866243271,CCL16;C-C motif chemokine 16,1.43564398252089,1.24070167140031,1.66121614249314,1.19440843995983e-06
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00659903476804,AREG;Amphiregulin,1.31214098632103,1.20069230849645,1.43393436919699,1.99062023980136e-09
primary,Nervous system disorders,G40 (epilepsy),0.826693227091633,AREG;Amphiregulin,1.3511239019119,1.22694424585027,1.48787184461878,9.48274246865043e-10
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0669357220198838,AREG;Amphiregulin,2.73169604758284,1.93758157227332,3.85127697494794,9.79446909209933e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.985309217281415,AREG;Amphiregulin,1.39004160856647,1.2716326236307,1.51947633116656,4.16785273626733e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,AREG;Amphiregulin,2.4100020123629,2.07743263724582,2.79581132762667,3.66205380537119e-31
primary,Nervous system disorders,G81 (hemiplegia),0.968594650043399,AREG;Amphiregulin,1.46644833997038,1.34048871454876,1.60424381828965,6.54078792160573e-17
primary,Nervous system disorders,G83 (other paralytic syndromes),0.262074129539498,AREG;Amphiregulin,1.5303559602747,1.28754600340009,1.818955873393,1.38436622830007e-06
primary,Nervous system disorders,G93 (other disorders of brain),0.880341033012788,AREG;Amphiregulin,1.35719434812797,1.23518103568217,1.49126034595667,2.09040451254473e-10
primary,Nervous system disorders,G99 (other disorders of nervous system in diseases classified elsewhere),0.500492610837438,AREG;Amphiregulin,1.44561763908147,1.27659011230571,1.6370253366987,6.28361375506933e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0666248628311647,SEMA3F;Semaphorin-3F,2.44208017468565,1.7705950269886,3.36822112831513,5.25356690274974e-08
primary,Nervous system disorders,G93 (other disorders of brain),0.878283695502003,SEMA3F;Semaphorin-3F,1.25582458933023,1.14463421805359,1.37781605188095,1.46570065398939e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0666248628311647,COL4A1;Collagen alpha-1(IV) chain,2.37769082948888,1.74268569258487,3.24408107824079,4.66322114264011e-08
primary,Nervous system disorders,G62 (other polyneuropathies),1.00041274396116,COL4A1;Collagen alpha-1(IV) chain,1.36403548533133,1.2522770364867,1.48576772633557,1.09591859255182e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374362994903959,COL4A1;Collagen alpha-1(IV) chain,1.90944175770918,1.66874952445518,2.18485025622636,5.01175309898664e-21
primary,Nervous system disorders,G93 (other disorders of brain),0.878283695502003,COL4A1;Collagen alpha-1(IV) chain,1.2585138091265,1.14783615996328,1.3798633141273,9.79893989864742e-07
primary,Nervous system disorders,G47 (sleep disorders),2.5765193818207,ADAMTSL2;ADAMTS-like protein 2,1.227462608203,1.15733570162101,1.30183874257592,8.5989814322594e-12
primary,Nervous system disorders,G62 (other polyneuropathies),0.960684772463405,ADAMTSL2;ADAMTS-like protein 2,1.43564666718938,1.30427981700986,1.58024476506669,1.51782436934411e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336012350724242,ADAMTSL2;ADAMTS-like protein 2,1.91224461225297,1.63098866663246,2.24200175752326,1.38697710727918e-15
primary,Nervous system disorders,G81 (hemiplegia),0.921292083712465,ADAMTSL2;ADAMTS-like protein 2,1.2962825280123,1.17555514984512,1.42940838858249,1.9646288110774e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0632023858900673,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,3.56690334039567,2.58339676230824,4.92483370164096,1.10626151102985e-14
primary,Nervous system disorders,G62 (other polyneuropathies),0.990491283676703,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.27107304620581,1.16460352989365,1.38727613932139,7.70172931401438e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.82373215293634,1.58653467457347,2.0963922307894,2.85093085163481e-17
primary,Nervous system disorders,G81 (hemiplegia),0.969759341355288,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.30930278182769,1.19885297139163,1.42992828596136,2.05433412221915e-09
primary,Nervous system disorders,G20 (parkinson's disease),1.51813605523388,HNMT;Histamine N-methyltransferase,0.752608901743306,0.702091569089239,0.806761089181048,1.083036338979e-15
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0615201428854931,HNMT;Histamine N-methyltransferase,2.67806301813532,1.92281014021651,3.72996864282008,5.62004746787065e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.985290312307171,HNMT;Histamine N-methyltransferase,1.37408506085288,1.25731435040713,1.50170063186479,2.32738991312385e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373156547111014,HNMT;Histamine N-methyltransferase,1.50357124159581,1.30318975097282,1.73476385681084,2.28627187633508e-08
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00590897413094,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.23909709728685,1.13678344641853,1.35061925940416,1.08461897901985e-06
primary,Nervous system disorders,G40 (epilepsy),0.819459156956408,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.2968258343449,1.17682812617759,1.42905935643024,1.54889423645188e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0632023858900673,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,3.27451931707263,2.393814827497,4.47924235187955,1.16293321428528e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.990491283676703,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.33029919483856,1.21901801252935,1.45173896496916,1.52051218892635e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.07187215385865,1.80887917127012,2.37310169198352,7.15244846760878e-26
primary,Nervous system disorders,G81 (hemiplegia),0.969759341355288,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.38952034509974,1.27266745862413,1.51710234779905,2.1404211210819e-13
primary,Nervous system disorders,G93 (other disorders of brain),0.871277675001491,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.32242571985444,1.2048531766985,1.4514712816084,4.03405824292487e-09
primary,Nervous system disorders,G99 (other disorders of nervous system in diseases classified elsewhere),0.504102006523673,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.39825098706348,1.23794377491968,1.57931714059539,6.82981516023087e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37335545810122,CRIP2;Cysteine-rich protein 2,1.64106741852358,1.42486998076574,1.89006878416538,6.30574469034145e-12
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0612953756044405,HEPH;Hephaestin,3.16281788359753,2.16749337422874,4.61520071237304,2.34150656324011e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.342885689631681,HEPH;Hephaestin,2.11596774178475,1.80270938554889,2.48366127128716,4.7892423319083e-20
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.337845498038682,CFP;Properdin,0.65807124056221,0.561713972687858,0.770957780492554,2.21648255607647e-07
primary,Nervous system disorders,G51 (facial nerve disorders),0.405256531318854,THBS2;Thrombospondin-2,1.46543769059912,1.27785263850156,1.68055968295898,4.54391340701864e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607307277892056,THBS2;Thrombospondin-2,2.3434680218734,1.65534649116968,3.31763917635312,1.57339049573171e-06
primary,Nervous system disorders,G62 (other polyneuropathies),0.988348102882518,THBS2;Thrombospondin-2,1.34356947562017,1.23128627654741,1.4660919805588,3.29679337771141e-11
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,THBS2;Thrombospondin-2,2.01331143525988,1.75470304620697,2.31003356614112,1.93670956659161e-23
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,ITGA5;Integrin alpha-5,1.64017286227597,1.42669542597787,1.88559307695451,3.52868828785496e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376013092269326,PRCP;Lysosomal Pro-X carboxypeptidase,1.79118046486293,1.55502151561057,2.063204544438,6.46956369040569e-16
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0666248628311647,CCDC80;Coiled-coil domain-containing protein 80,2.40368672785621,1.74113071720573,3.31836652387853,9.79847417393292e-08
primary,Nervous system disorders,G62 (other polyneuropathies),1.00041274396116,CCDC80;Coiled-coil domain-containing protein 80,1.23550452080086,1.13259552791866,1.34776394863973,1.87865547049711e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374362994903959,CCDC80;Coiled-coil domain-containing protein 80,1.48720198259487,1.29158543895956,1.71244554972361,3.46754891475417e-08
primary,Nervous system disorders,G81 (hemiplegia),0.962085959435314,CCDC80;Coiled-coil domain-containing protein 80,1.24834026527083,1.14258145459155,1.36388824764667,9.05913929279264e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.996736177614478,RARRES2;Retinoic acid receptor responder protein 2,1.26008144334652,1.15648088879164,1.37296280401596,1.28352955881472e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368377967489182,RARRES2;Retinoic acid receptor responder protein 2,1.48906505406522,1.29782298201422,1.7084878030107,1.37106671701757e-08
primary,Nervous system disorders,G81 (hemiplegia),0.96257102134057,RARRES2;Retinoic acid receptor responder protein 2,1.23859274599227,1.135023344538,1.3516127203966,1.56535411792737e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0662742193286811,CD300E;CMRF35-like molecule 2,2.95758156921795,2.17198346424805,4.02732750159591,5.81618960459775e-12
primary,Nervous system disorders,G62 (other polyneuropathies),0.981503929926094,CD300E;CMRF35-like molecule 2,1.36732011510753,1.25269791182636,1.49243028149695,2.49614273919591e-12
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372406800811105,CD300E;CMRF35-like molecule 2,1.83812927112383,1.60316910475783,2.10752515585224,2.68919416910807e-18
primary,Nervous system disorders,G81 (hemiplegia),0.966815758120275,CD300E;CMRF35-like molecule 2,1.42056767428303,1.30130162861106,1.55076461355989,4.28333873486089e-15
primary,Nervous system disorders,G93 (other disorders of brain),0.881498350871682,CD300E;CMRF35-like molecule 2,1.28865965322724,1.17450524216374,1.41390914424224,8.38114191513696e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.989598522406921,CTSO;Cathepsin O,1.29473855717124,1.18665800413935,1.41266306347606,6.32012022103965e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37420505661548,CTSO;Cathepsin O,1.89579029532376,1.64678866268284,2.18244206150206,5.42058608613978e-19
primary,Nervous system disorders,G81 (hemiplegia),0.96142640717865,CTSO;Cathepsin O,1.27920141743586,1.17100167180254,1.39739874482933,4.73770245090168e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.985309217281415,IGSF3;Immunoglobulin superfamily member 3,1.30715528191089,1.19714928071289,1.42726973031304,2.34631531600448e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372164461247637,IGSF3;Immunoglobulin superfamily member 3,1.85056992007681,1.6095298489245,2.1277076851861,5.40681570800206e-18
primary,Nervous system disorders,G40 (epilepsy),0.820837253999079,ACVRL1;Serine/threonine-protein kinase receptor R3,1.30494779874936,1.18407705140968,1.43815704850748,8.00541204620298e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0633086693309065,ACVRL1;Serine/threonine-protein kinase receptor R3,3.30314510372996,2.37672862285027,4.59066612460391,1.11889612076139e-12
primary,Nervous system disorders,G62 (other polyneuropathies),0.992161920825478,ACVRL1;Serine/threonine-protein kinase receptor R3,1.26304901297994,1.15638202634646,1.3795551754033,2.13111936567275e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373983418089716,ACVRL1;Serine/threonine-protein kinase receptor R3,1.89149278456836,1.64273456795412,2.17792029453055,8.04279861367626e-19
primary,Nervous system disorders,G81 (hemiplegia),0.971393453997581,ACVRL1;Serine/threonine-protein kinase receptor R3,1.38138960658923,1.26412482141079,1.50953229686854,9.44402606384044e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0581530588508955,GM2A;Ganglioside GM2 activator,3.00702118542481,2.11697052218298,4.27128120814339,7.83304365953827e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.339700784103864,GM2A;Ganglioside GM2 activator,1.64287763617632,1.40052567987279,1.927167038946,1.08369026969852e-09
primary,Nervous system disorders,G81 (hemiplegia),0.920767383855101,GM2A;Ganglioside GM2 activator,1.36359483168552,1.23639712172151,1.50387835132657,5.39160284649358e-10
primary,Nervous system disorders,G20 (parkinson's disease),1.51283857836229,SCG2;Secretogranin-2,0.781250676947437,0.727886560858716,0.838527118169036,7.998369005181e-12
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.066364772017489,SCG2;Secretogranin-2,3.29768982064697,2.37867309000521,4.57177499459366,8.13131971877337e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374868210394783,SCG2;Secretogranin-2,2.23411454977424,1.94467425998796,2.56663438407616,7.00663839082279e-30
primary,Nervous system disorders,G62 (other polyneuropathies),0.989598522406921,HGF;Hepatocyte growth factor,1.27363434671718,1.16781809889919,1.38903862739133,4.61536987010882e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37420505661548,HGF;Hepatocyte growth factor,1.56756312310362,1.36424578594309,1.80118140750987,2.26658486387007e-10
primary,Nervous system disorders,G81 (hemiplegia),0.96142640717865,HGF;Hepatocyte growth factor,1.24563259058701,1.14062704098962,1.36030489807285,1.01690114637676e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376877024241829,TGFA;Protransforming growth factor alpha,1.6299990904728,1.41722829144149,1.87471351721307,7.59271550612069e-12
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0649414542949916,IGFBP6;Insulin-like growth factor-binding protein 6,2.92674883335456,2.08453888194983,4.10923432885547,5.55673340598086e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370056886404346,IGFBP6;Insulin-like growth factor-binding protein 6,1.54905135605591,1.31921779118592,1.81892642725925,9.25006824631586e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0641050545864252,STC1;Stanniocalcin-1,2.58477587624529,1.87100693572742,3.57083995940513,8.43541283353487e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376940563856451,STC1;Stanniocalcin-1,1.6424669879244,1.42850874805597,1.88847132374421,3.21135595507251e-12
primary,Nervous system disorders,G81 (hemiplegia),0.978038413098236,DNER;Delta and Notch-like epidermal growth factor-related receptor,0.799704894867582,0.732102005890454,0.873550289071144,7.05147107495094e-07
primary,Nervous system disorders,G81 (hemiplegia),0.961052099140111,LAMP3;Lysosome-associated membrane glycoprotein 3,1.40687266248184,1.29066515404078,1.53354313645334,8.43892696790331e-15
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,RSPO3;R-spondin-3,2.71699540301591,1.98770089786218,3.71387064721317,3.65824646851019e-10
primary,Nervous system disorders,G62 (other polyneuropathies),0.982264665757162,RSPO3;R-spondin-3,1.24359510042327,1.13927709780713,1.35746498966187,1.07720563547999e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,RSPO3;R-spondin-3,1.51869755436139,1.31899744548959,1.74863284952547,6.28005987464533e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.97951044029092,DPY30;Protein dpy-30 homolog,1.29073097266184,1.18378457749018,1.40733920298298,7.32999351185399e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374341976993566,DPY30;Protein dpy-30 homolog,1.46899077964861,1.27883918807439,1.68741615897927,5.40493573558341e-08
primary,Nervous system disorders,G45 (transient cerebral ischaemic attacks and related syndromes),1.33494185586583,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.23646164141416,1.14617528955508,1.33386001654429,4.0980193267507e-08
primary,Nervous system disorders,G62 (other polyneuropathies),1.00041274396116,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.30258030828731,1.19441819332586,1.42053718623738,2.27654302970683e-09
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374362994903959,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.71314376624237,1.49515853899024,1.96290994384929,9.00551455042197e-15
primary,Nervous system disorders,G81 (hemiplegia),0.962085959435314,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.41249765041306,1.29349417582764,1.54244962962111,1.46124111177119e-14
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0600903293337727,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,3.51268292519622,2.51739840397674,4.90146546270676,1.45342041121745e-13
primary,Nervous system disorders,G62 (other polyneuropathies),0.989598522406921,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.32736904240501,1.21633202638566,1.44854245100387,2.10095695747386e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37420505661548,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,2.32513687939807,2.02424005997719,2.67076104995073,7.93282581121266e-33
primary,Nervous system disorders,G81 (hemiplegia),0.96142640717865,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.36472846414713,1.24915027871394,1.49100057262197,5.69018023176889e-12
primary,Nervous system disorders,G93 (other disorders of brain),0.8746754134208,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.27166412967632,1.15884066764125,1.39547196078043,3.97903236331479e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,SMOC1;SPARC-related modular calcium-binding protein 1,2.45085581642708,1.77730843098356,3.37965776125325,4.55836560747455e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.982264665757162,SMOC1;SPARC-related modular calcium-binding protein 1,1.25326330604053,1.14803136002674,1.36814112310579,4.53361023876721e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,SMOC1;SPARC-related modular calcium-binding protein 1,1.69937415008412,1.47678444158195,1.9555138994291,1.33418576538351e-13
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0612828544191747,CKB;Creatine kinase B-type,2.49708814030214,1.79617148586958,3.47152219567656,5.21064505243935e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.960684772463405,CKB;Creatine kinase B-type,1.29309970274073,1.17695216049004,1.42070926700364,8.65022840179433e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336012350724242,CKB;Creatine kinase B-type,1.6657782216256,1.42823253602525,1.94283284664865,7.99770006555179e-11
primary,Nervous system disorders,G81 (hemiplegia),0.921292083712465,CKB;Creatine kinase B-type,1.29858047443289,1.17975417686848,1.42937510342575,9.4961819557078e-08
primary,Nervous system disorders,G40 (epilepsy),0.823429036290402,LGALS9;Galectin-9,1.27711798665346,1.16122768113694,1.40457412299789,4.66225774794864e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0627438677672986,LGALS9;Galectin-9,2.42261377135003,1.78930191277812,3.28008227299234,1.04504011498187e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.993117010816126,LGALS9;Galectin-9,1.41943504657144,1.30336029582621,1.54584719044097,8.50119298839115e-16
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368714207264454,LGALS9;Galectin-9,1.7221422147731,1.50465026961296,1.97107186154726,2.99355177702695e-15
primary,Nervous system disorders,G81 (hemiplegia),0.972514194777893,LGALS9;Galectin-9,1.41501531764748,1.29838880391276,1.54211769474834,2.5753023606453e-15
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,DSG2;Desmoglein-2,1.6001517910914,1.39062593968433,1.84124693885275,5.19973822692975e-11
primary,Nervous system disorders,G47 (sleep disorders),2.63184208947463,LEP;Leptin,1.23936105986108,1.14514267692519,1.34133140581602,1.04017503631133e-07
primary,Nervous system disorders,G62 (other polyneuropathies),0.99994094836919,CCL3;C-C motif chemokine 3,1.37284357416463,1.26155064331754,1.49395467324948,2.03649542769147e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.376877024241829,CCL3;C-C motif chemokine 3,1.51288941676315,1.32010661400228,1.73382540703641,2.63030724064029e-09
primary,Nervous system disorders,G93 (other disorders of brain),0.879568319728025,CCL3;C-C motif chemokine 3,1.26401588944927,1.15375503540795,1.38481403742286,4.87422756269269e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0625390869293308,ANGPTL4;Angiopoietin-related protein 4,2.74113022876992,1.95864809002296,3.83621487154854,4.10204747893167e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.991826253993766,ANGPTL4;Angiopoietin-related protein 4,1.27058182054395,1.16487270137381,1.38588376291489,6.53638393688068e-08
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.36751050728179,ANGPTL4;Angiopoietin-related protein 4,2.19377090930334,1.90697523531103,2.52369863718795,4.25168945562124e-28
primary,Nervous system disorders,G81 (hemiplegia),0.973250303528766,ANGPTL4;Angiopoietin-related protein 4,1.25183891018831,1.14681676740637,1.36647867523387,5.05641706976184e-07
primary,Nervous system disorders,G40 (epilepsy),0.798879731870251,RNASE1;Ribonuclease pancreatic,1.30119368402207,1.17036106618888,1.44665185151134,1.11861604434354e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0612494895875867,RNASE1;Ribonuclease pancreatic,3.02900669810934,2.14021486463107,4.28689741801826,4.00753081544324e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.3380984796914,RNASE1;Ribonuclease pancreatic,1.83491358828053,1.56289614252236,2.15427486500968,1.22163933262682e-13
primary,Nervous system disorders,G81 (hemiplegia),0.927567862501705,RNASE1;Ribonuclease pancreatic,1.35950810466395,1.23283164369902,1.4992008812342,7.53986291672063e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373189089460553,CTSD;Cathepsin D,1.62816938985064,1.40726514752431,1.8837498865869,5.66097184257883e-11
primary,Nervous system disorders,G81 (hemiplegia),0.961922164114842,CTSD;Cathepsin D,1.28328545949681,1.17042560668227,1.4070279743999,1.09342902884641e-07
primary,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00017684855868,FSTL3;Follistatin-related protein 3,1.23400304339894,1.13243051092699,1.34468605042382,1.60499767684378e-06
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0608798114689709,FSTL3;Follistatin-related protein 3,3.2485820048727,2.45778517768345,4.29381914180538,1.25066048046416e-16
primary,Nervous system disorders,G62 (other polyneuropathies),0.994681898759109,FSTL3;Follistatin-related protein 3,1.37624812058083,1.26287978873885,1.49979349284997,3.3092908858381e-13
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.36930088200051,FSTL3;Follistatin-related protein 3,1.91769406561791,1.67960076192302,2.18953849788424,6.17120780769432e-22
primary,Nervous system disorders,G81 (hemiplegia),0.976032114605061,FSTL3;Follistatin-related protein 3,1.41436814372901,1.29754708997592,1.54170685707644,3.22171782281234e-15
primary,Nervous system disorders,G93 (other disorders of brain),0.872351789211322,FSTL3;Follistatin-related protein 3,1.26698651719061,1.15508258307718,1.38973165924322,5.28125314151742e-07
primary,Nervous system disorders,G40 (epilepsy),0.804884818207049,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.33052075482749,1.2076953200511,1.46583782319518,7.52675102989388e-09
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607307277892056,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,3.93078573737362,2.90927013513132,5.31098034746176,4.87501253163317e-19
primary,Nervous system disorders,G62 (other polyneuropathies),0.988348102882518,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.39763082392087,1.28147938660807,1.5243100594416,3.95184468809949e-14
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.38013873104205,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,2.22746522667154,1.95178080702985,2.54208941811518,1.49622760977183e-32
primary,Nervous system disorders,G81 (hemiplegia),0.967729271356784,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.42497127882825,1.30580935337794,1.5550073525149,1.88905608006511e-15
primary,Nervous system disorders,G93 (other disorders of brain),0.872190540087219,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.29780162098349,1.18280781056851,1.42397524972196,3.65800999841822e-08
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0660630319045583,ANGPTL7;Angiopoietin-related protein 7,2.6221659218036,1.88875904600911,3.64035536242507,8.46287104290355e-09
primary,Nervous system disorders,G62 (other polyneuropathies),0.982264665757162,ANGPTL7;Angiopoietin-related protein 7,1.25664200983646,1.15074825704373,1.37228028043479,3.65342234319176e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373163336702169,ANGPTL7;Angiopoietin-related protein 7,1.7180454285937,1.49022600124885,1.98069292324661,8.90895158291275e-14
primary,Nervous system disorders,G81 (hemiplegia),0.963244613434727,VWA1;von Willebrand factor A domain-containing protein 1,1.24768879631595,1.14310965127367,1.36183552533024,7.24894911644621e-07
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370049602393512,ICAM1;Intercellular adhesion molecule 1,1.58657199858077,1.37907221777223,1.82529288476778,1.08687203198992e-10
primary,Nervous system disorders,G81 (hemiplegia),0.962239968451148,ICAM1;Intercellular adhesion molecule 1,1.27496233484225,1.16728710104925,1.39256996312668,6.81619195753931e-08
primary,Nervous system disorders,G62 (other polyneuropathies),0.949496789471287,FCAMR;High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor,1.2726321095502,1.15422626111484,1.40318457552151,1.30764271092295e-06
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.342885689631681,FCAMR;High affinity immunoglobulin alpha and immunoglobulin mu Fc receptor,1.55222787502088,1.3220569265615,1.82247173142417,7.9061246757206e-08
primary,Nervous system disorders,G40 (epilepsy),0.827348121106305,COLEC12;Collectin-12,1.27758545029019,1.16000656802813,1.40708219054981,6.5883811115362e-07
primary,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0627450980392156,COLEC12;Collectin-12,3.33179078707245,2.47133473908667,4.49183579757529,2.88818029696338e-15
primary,Nervous system disorders,G62 (other polyneuropathies),0.993136541524907,COLEC12;Collectin-12,1.32583801386749,1.21501895699252,1.4467646195144,2.40059117604051e-10
primary,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368721438798125,COLEC12;Collectin-12,2.12512831852575,1.85859908651048,2.42987872047178,2.88728787524135e-28
primary,Nervous system disorders,G81 (hemiplegia),0.976462729380329,COLEC12;Collectin-12,1.39100412246035,1.27437384334981,1.51830836673142,1.50793101858691e-13
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0625562028384877,CDH3;Cadherin-3,3.43927715773535,2.44672768234924,4.83446827902108,1.15937276031809e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375417945759928,CDH3;Cadherin-3,1.51291606450106,1.31289968840497,1.7434043426472,1.04765035779269e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.337853262110213,CSF1R;Macrophage colony-stimulating factor 1 receptor,1.45890388081832,1.24442812694832,1.7103442837524,3.23373367765687e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0627809955850783,CST6;Cystatin-M,2.2649398130015,1.58253111009673,3.24161232837042,7.84558324229131e-06
sensitivity,Nervous system disorders,G20 (parkinson's disease),1.51748405542115,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,0.787680739522813,0.733438808022911,0.845934167415674,5.52298833224372e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0598229241445321,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,2.51769632805215,1.79180160302814,3.53766554822516,1.03317616108151e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368974251580605,PTPRN2;Receptor-type tyrosine-protein phosphatase N2,1.50523673982492,1.30740556740669,1.73300290239161,1.28230862636124e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.064526221109851,KLK4;Kallikrein-4,3.73104868523723,2.74257238074112,5.07579103084554,5.09798711495903e-17
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.980661358019848,KLK4;Kallikrein-4,1.27317475043441,1.16738672188309,1.38854923973175,4.84701492304828e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,KLK4;Kallikrein-4,2.02509742438416,1.77177033414784,2.3146451315993,4.24207322466734e-25
sensitivity,Nervous system disorders,G30 (alzheimer's disease),1.36429951500335,NPTXR;Neuronal pentraxin receptor,0.786145519622378,0.72886331570855,0.847929597638671,4.56368168000767e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591470988348021,CCN5;CCN family member 5,2.69343357280713,1.92487604594988,3.76885796173157,7.45104988428445e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,CCN5;CCN family member 5,1.52218918039108,1.31416951480216,1.76313624292866,2.09458446454138e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.059375642284592,SRPX;Sushi repeat-containing protein SRPX,2.37106734565807,1.65757927707921,3.39166906547743,2.28064740265972e-06
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.94827981126025,SRPX;Sushi repeat-containing protein SRPX,1.26048356375364,1.14358762605635,1.38932844173219,3.13256921867166e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.342637854630179,SRPX;Sushi repeat-containing protein SRPX,1.57572463503807,1.34524199009505,1.84569627156111,1.74423001432626e-08
sensitivity,Nervous system disorders,G40 (epilepsy),0.825089038385437,ANGPT2;Angiopoietin-2,1.2695680177826,1.15281354274526,1.39814713482474,1.24027380015331e-06
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.980661358019848,ANGPT2;Angiopoietin-2,1.28399193381869,1.1757882872409,1.40215318012748,2.61735104265907e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,ANGPT2;Angiopoietin-2,1.82585530997726,1.58657594831545,2.10122157499726,4.45326528475765e-17
sensitivity,Nervous system disorders,G81 (hemiplegia),0.965928015831031,ANGPT2;Angiopoietin-2,1.29849220441715,1.18837612971961,1.41881174046294,7.59654070260361e-09
sensitivity,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00385949865502,GDF15;Growth/differentiation factor 15,1.30191603626268,1.19760073710408,1.41531757034199,5.95204134712768e-10
sensitivity,Nervous system disorders,G40 (epilepsy),0.816101243864456,GDF15;Growth/differentiation factor 15,1.29719628925596,1.18177252310225,1.42389349893003,4.43414005219946e-08
sensitivity,Nervous system disorders,G51 (facial nerve disorders),0.399061032863849,GDF15;Growth/differentiation factor 15,1.36059108551514,1.19387474531083,1.55058820806306,3.89343316626167e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0642886364964641,GDF15;Growth/differentiation factor 15,2.35370298898946,1.8821768242472,2.94335669688936,6.16699493548216e-14
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.988725403990073,GDF15;Growth/differentiation factor 15,1.29731688012791,1.19235284888548,1.41152100155419,1.47656933960229e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372181842982131,GDF15;Growth/differentiation factor 15,1.94169893639713,1.73165840791334,2.17721621214478,6.59816567409629e-30
sensitivity,Nervous system disorders,G72 (other myopathies),0.0954588844947497,GDF15;Growth/differentiation factor 15,1.79928951416568,1.42359855417922,2.27412618977626,8.84845940665583e-07
sensitivity,Nervous system disorders,G81 (hemiplegia),0.960374780402108,GDF15;Growth/differentiation factor 15,1.27474820005478,1.16992937686693,1.38895817617179,2.94182338730961e-08
sensitivity,Nervous system disorders,G93 (other disorders of brain),0.871117738233043,GDF15;Growth/differentiation factor 15,1.28276405628174,1.17211289888418,1.40386103220504,6.28954759286729e-08
sensitivity,Nervous system disorders,G99 (other disorders of nervous system in diseases classified elsewhere),0.50303183918579,GDF15;Growth/differentiation factor 15,1.31987732189883,1.17386980426878,1.48404545250911,3.48336966183849e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.343369694704631,COL5A1;Collagen alpha-1(V) chain,1.51432160230324,1.28983591459585,1.77787723946328,4.00074472201775e-07
sensitivity,Nervous system disorders,G30 (alzheimer's disease),1.38192966801656,VGF;Neurosecretory protein VGF,0.752851197660422,0.694721614249714,0.815844669567175,4.38216802065221e-12
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0609956364660066,PRRT3;Proline-rich transmembrane protein 3,3.12008670959906,2.21052639273178,4.40390176178183,9.72355812977386e-11
sensitivity,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",0.956456667134371,C7;Complement component C7,1.27443541393889,1.15641682525527,1.40449843761402,1.00298598208851e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.338943431510051,C7;Complement component C7,1.73730176621723,1.48005784295553,2.03925639884076,1.42523817611756e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0649798168750615,KLK6;Kallikrein-6,2.38680102558626,1.693117753763,3.36469163061949,6.85104010674449e-07
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.993690851735015,PLA2G15;Phospholipase A2 group XV,1.21953990906947,1.1175324160891,1.33085856696491,8.45480009084938e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371637564889098,PLA2G15;Phospholipase A2 group XV,1.41936345274973,1.2316166511313,1.63573024865418,1.31261298458667e-06
sensitivity,Nervous system disorders,G81 (hemiplegia),0.967125608146703,PLA2G15;Phospholipase A2 group XV,1.25949628741464,1.15286957460923,1.37598470195466,3.18939062117441e-07
sensitivity,Nervous system disorders,G30 (alzheimer's disease),1.37717648486319,GFAP;Glial fibrillary acidic protein,2.08629160108162,1.93631168904347,2.24788843106859,3.64543359213457e-83
sensitivity,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00586925723537,GFAP;Glial fibrillary acidic protein,1.45122295598563,1.328011046983,1.58586637721443,1.9251806097993e-16
sensitivity,Nervous system disorders,G40 (epilepsy),0.814505566470203,GFAP;Glial fibrillary acidic protein,1.29284820981,1.17021845008176,1.42832861120259,4.38501375532495e-07
sensitivity,Nervous system disorders,G41 (status epilepticus),0.0667435228444875,GFAP;Glial fibrillary acidic protein,2.66560880933706,1.92075945034874,3.69930254573276,4.52594032694254e-09
sensitivity,Nervous system disorders,G91 (hydrocephalus),0.236683996520542,GFAP;Glial fibrillary acidic protein,1.68333668591468,1.40262475653082,2.02022842171613,2.2065380516078e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0643889875319505,SPP1;Osteopontin,2.3239970363845,1.66661926341555,3.24066950603661,6.66078791849949e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372762934483498,SPP1;Osteopontin,1.43146719775615,1.24126527448855,1.65081419771141,8.17135979491572e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648712404167485,PODXL2;Podocalyxin-like protein 2,2.73657104756976,1.97190988211025,3.79775017425383,1.73322132411314e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648712404167485,SEZ6L;Seizure 6-like protein,2.5320797425595,1.82708671729084,3.50909880850477,2.40387166467917e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371637564889098,SEZ6L;Seizure 6-like protein,1.4347072724118,1.2426876398482,1.65639770728124,8.48879530349338e-07
sensitivity,Nervous system disorders,G40 (epilepsy),0.825089038385437,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.27970490364479,1.16409974645555,1.4067906512297,3.30129059421869e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.064526221109851,EDA2R;Tumor necrosis factor receptor superfamily member 27,3.35146308890152,2.61396133664223,4.29704321897041,1.46214430455038e-21
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.980661358019848,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.35174032114715,1.24098551438483,1.47237971324811,4.84507661195387e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,EDA2R;Tumor necrosis factor receptor superfamily member 27,2.09666317207339,1.85357213243314,2.37163495296961,5.25599859079166e-32
sensitivity,Nervous system disorders,G72 (other myopathies),0.0958116616479605,EDA2R;Tumor necrosis factor receptor superfamily member 27,2.23384585395223,1.76057448292974,2.83434035174454,3.6795793522809e-11
sensitivity,Nervous system disorders,G81 (hemiplegia),0.965928015831031,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.27513749514673,1.16946758940236,1.39035544572895,3.65197505925299e-08
sensitivity,Nervous system disorders,G99 (other disorders of nervous system in diseases classified elsewhere),0.504912129633253,EDA2R;Tumor necrosis factor receptor superfamily member 27,1.37664639651493,1.22292388796796,1.5496919470488,1.21546516274963e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.365307565401838,CRLF1;Cytokine receptor-like factor 1,1.40791693257978,1.21652301866544,1.62942259096701,4.45279292660521e-06
sensitivity,Nervous system disorders,G20 (parkinson's disease),1.5127814189256,ITGA11;Integrin alpha-11,0.741344097333522,0.690189878323515,0.796289670295112,2.31771081266178e-16
sensitivity,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",0.997905386713038,ITGA11;Integrin alpha-11,0.794442370873178,0.727663114929674,0.867350107061003,2.7955557247327e-07
sensitivity,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00451831531386,CHI3L1;Chitinase-3-like protein 1,1.24085581704847,1.13657955651366,1.35469897366971,1.44602391955982e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0645109265381824,CHI3L1;Chitinase-3-like protein 1,2.37943001982716,1.69558242133853,3.33908110157523,5.32288807927436e-07
sensitivity,Nervous system disorders,G62 (other polyneuropathies),1.00293195834597,CHI3L1;Chitinase-3-like protein 1,1.26514777723151,1.1584420185471,1.38168235665458,1.68149330857472e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.362969087132745,CHI3L1;Chitinase-3-like protein 1,1.6207483102192,1.40232993417146,1.87318620323853,6.22067287974256e-11
sensitivity,Nervous system disorders,G81 (hemiplegia),0.965520027470862,CHI3L1;Chitinase-3-like protein 1,1.24710192270322,1.14013337905459,1.3641063705193,1.39130685276988e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373348082887225,LILRA5;Leukocyte immunoglobulin-like receptor subfamily A member 5,1.42967130795602,1.24128172275778,1.64665281967705,7.11895703247853e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.057205619880097,OCLN;Occludin,2.56761283786794,1.77912449747673,3.70555050786743,4.70531407644879e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,SUSD2;Sushi domain-containing protein 2,1.45621030796623,1.2646826568676,1.67674352890972,1.75371802334568e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.064526221109851,MOG;Myelin-oligodendrocyte glycoprotein,2.65487085362803,1.92861435652817,3.65461307782225,2.12556189290001e-09
sensitivity,Nervous system disorders,G40 (epilepsy),0.817357998854909,IGFBP2;Insulin-like growth factor-binding protein 2,1.24722117142521,1.1345051953246,1.37113576637806,4.8491852077582e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0643889875319505,IGFBP2;Insulin-like growth factor-binding protein 2,2.70984766274777,2.04232360678651,3.59554887917778,4.88340372600751e-12
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.990273401569563,IGFBP2;Insulin-like growth factor-binding protein 2,1.32227964888641,1.21422416701261,1.43995113699711,1.34057788436218e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372762934483498,IGFBP2;Insulin-like growth factor-binding protein 2,1.83280016340162,1.60742112393888,2.08977995183592,1.43477358237287e-19
sensitivity,Nervous system disorders,G81 (hemiplegia),0.961858028191042,IGFBP2;Insulin-like growth factor-binding protein 2,1.23331594401311,1.13037364184506,1.34563312647149,2.40811320962087e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374517147395046,C1QA;Complement C1q subcomponent subunit A,1.56388260229961,1.35714679404864,1.80211072560492,6.35416764054725e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370561192136968,DPP6;Dipeptidyl aminopeptidase-like protein 6,1.65838970236541,1.44046325038296,1.90928606070336,1.95891110641504e-12
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591470988348021,OGN;Mimecan,4.07387093564967,2.90762578319013,5.70789559518978,3.27399569233949e-16
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,OGN;Mimecan,1.90848241127095,1.6604780758535,2.19352797672947,9.03587717781584e-20
sensitivity,Nervous system disorders,G81 (hemiplegia),0.969953181485944,OGN;Mimecan,1.28615244832458,1.17562609268239,1.40706992693315,4.03586257990038e-08
sensitivity,Nervous system disorders,G30 (alzheimer's disease),1.3827205714024,SYT1;Synaptotagmin-1,1.50523920967521,1.39097552454494,1.62888924956813,3.21876831595616e-24
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.063580369560898,PTGDS;Prostaglandin-H2 D-isomerase,3.45361222275512,2.46558009588882,4.83757854999386,5.65695534543038e-13
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369649032155491,PTGDS;Prostaglandin-H2 D-isomerase,1.69114821350352,1.45440700673885,1.96642498749298,8.58949406572113e-12
sensitivity,Nervous system disorders,G81 (hemiplegia),0.965539208855089,PTGDS;Prostaglandin-H2 D-isomerase,1.23413329521506,1.12467053205156,1.3542499309376,9.02579941299616e-06
sensitivity,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00978164213022,SSC4D;Scavenger receptor cysteine-rich domain-containing group B protein,0.79778810051843,0.730226062188846,0.871601119550574,5.6213358276189e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0572534154623706,STC2;Stanniocalcin-2,2.28917541554425,1.59841671737225,3.2784467443178,6.20506825220437e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.377157300264602,STC2;Stanniocalcin-2,1.40495491148884,1.2151854684125,1.6243597003306,4.38152780171832e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0649286768322675,CST3;Cystatin-C,2.99507031422651,2.20469977334721,4.06878355756431,2.25762143123155e-12
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.998519980266403,CST3;Cystatin-C,1.27101002405313,1.16342888723125,1.38853908388682,1.0690617406132e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.366048058567689,CST3;Cystatin-C,1.67811754333144,1.45367457710361,1.93721382597726,1.58690845228651e-12
sensitivity,Nervous system disorders,G72 (other myopathies),0.0924741760944417,CST3;Cystatin-C,2.06317163316023,1.566455455169,2.71739434008852,2.55325215450251e-07
sensitivity,Nervous system disorders,G81 (hemiplegia),0.962050271069492,CST3;Cystatin-C,1.27680960763748,1.16702080594389,1.39692691497205,9.98882253190047e-08
sensitivity,Nervous system disorders,G20 (parkinson's disease),0.812933660033433,IGSF9;Protein turtle homolog A,0.77962575471403,0.704386671861035,0.862901502391478,1.52683719889493e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.335308980141207,RNASE4;Ribonuclease 4,1.61645984286309,1.3780092534946,1.89617189939953,3.68805978851593e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0625562028384877,SCARA5;Scavenger receptor class A member 5,4.7684695163243,3.39589860151622,6.69581286024316,1.90064495599551e-19
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375417945759928,SCARA5;Scavenger receptor class A member 5,1.96342022629194,1.7051572702516,2.26079966479776,6.82425313114002e-21
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0675095127040628,EPHA2;Ephrin type-A receptor 2,3.77213315214812,2.78030774003541,5.11777466668264,1.47164221105644e-17
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.978802864588677,EPHA2;Ephrin type-A receptor 2,1.2753930067185,1.16555705810525,1.39557931572284,1.19543131965084e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370362791839741,EPHA2;Ephrin type-A receptor 2,2.00722292136517,1.73935350465092,2.31634561075742,1.51623458297005e-21
sensitivity,Nervous system disorders,G81 (hemiplegia),0.973739775732354,EPHA2;Ephrin type-A receptor 2,1.29092871523637,1.17965330634267,1.41270061200315,2.81782422975721e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37277748502059,IGFBP1;Insulin-like growth factor-binding protein 1,1.44105672527507,1.25358332684949,1.65656677221412,2.77263214627111e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0616118453741429,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.48987422798275,1.84534649360077,3.35951740915378,2.39504733561398e-09
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.98875687744199,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.31126653652217,1.20154210263975,1.43101097000707,1.21732453573191e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37172504273844,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.94031958029796,1.69905904647322,2.21583827913599,1.31241137768392e-22
sensitivity,Nervous system disorders,G72 (other myopathies),0.0954008824581627,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,2.04411271495312,1.5794065827039,2.64554854791077,5.53503597024586e-08
sensitivity,Nervous system disorders,G81 (hemiplegia),0.971859876924302,TNFRSF10B;Tumor necrosis factor receptor superfamily member 10B,1.30475157590209,1.19484015686611,1.4247735691141,3.12863851811846e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0616118453741429,GGT5;Glutathione hydrolase 5 proenzyme,2.98065791072104,2.12118308398943,4.18838036556215,3.12139520303785e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37172504273844,GGT5;Glutathione hydrolase 5 proenzyme,1.86131316157105,1.61686489191569,2.14271872854685,5.20488419748888e-18
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0642886364964641,DPT;Dermatopontin,2.45923665574514,1.76089842028454,3.43452232070451,1.29154847792087e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0653789004457652,TAFA5;Chemokine-like protein TAFA-5,3.45307708407377,2.47808604397882,4.81167366142405,2.46348696935771e-13
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370561192136968,TAFA5;Chemokine-like protein TAFA-5,1.67644283914343,1.45079505911108,1.93718649320276,2.46952689206436e-12
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648215443241863,AOC3;Membrane primary amine oxidase,3.61668218930992,2.62481705878328,4.98335303586259,3.82653810760851e-15
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.36740868813486,AOC3;Membrane primary amine oxidase,2.39955003299398,2.08343866741376,2.76362364340141,6.15191485520276e-34
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0610705068852071,SPON1;Spondin-1,2.36692012101851,1.68260313580597,3.3295497554144,7.47636352314744e-07
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.991898834222485,SPON1;Spondin-1,1.33723304726164,1.22476161020193,1.46003288133258,8.99315966549073e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.366516907070229,SPON1;Spondin-1,1.75963784665132,1.52730219749372,2.02731676576433,5.21185516012404e-15
sensitivity,Nervous system disorders,G20 (parkinson's disease),1.51419308927018,ITGAM;Integrin alpha-M,0.730400417882915,0.679808768255598,0.784757118994609,9.64623040980432e-18
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0646197227226443,AMBP;Protein AMBP,3.48260454813265,2.5650271268178,4.72842345871054,1.27382268895614e-15
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372154973165667,AMBP;Protein AMBP,1.73050481199959,1.5037891415066,1.99140080327584,1.94219004442939e-14
sensitivity,Nervous system disorders,G81 (hemiplegia),0.965368390071618,AMBP;Protein AMBP,1.26795145919089,1.1606077468568,1.38522330840747,1.43990950763045e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0653789004457652,IL12A_IL12B;Interleukin-12,2.27446084907619,1.62749041042882,3.17861913092153,1.49445423963335e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.36740868813486,ITIH3;Inter-alpha-trypsin inhibitor heavy chain H3,1.68197013338813,1.45380744131397,1.94594101613126,2.73371982157138e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372181842982131,NOTCH3;Neurogenic locus notch homolog protein 3,1.45817606345547,1.26660149704331,1.67872644789854,1.53192305506066e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0608690529953464,AGRN;Agrin,3.0138815532473,2.16625656149184,4.19316999587011,5.83666482483016e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.990586474457442,AGRN;Agrin,1.31243905755761,1.20239347442635,1.43255624422321,1.16435991399845e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.365307565401838,AGRN;Agrin,1.62754919924843,1.41134665104996,1.87687156376754,2.11520316623267e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0598253100945239,VWC2;Brorin,3.48593751299616,2.48244725723023,4.89507292012806,5.62659981140988e-13
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.986098609860986,VWC2;Brorin,1.25902629358821,1.15096761439507,1.37723006983092,4.88058706540784e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370983505195763,VWC2;Brorin,1.82664000749592,1.58373014168592,2.10680698002804,1.28214323866733e-16
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,NPY;Pro-neuropeptide Y,1.4919739090003,1.29182241676335,1.72313633534464,5.21077219096217e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0572383634407125,PALM2;Paralemmin-2,2.75049858848622,1.99679637823454,3.78869000751766,5.92383051757087e-10
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.962090422722784,PALM2;Paralemmin-2,1.33847318752763,1.21903622356563,1.46961217320538,9.76999217171076e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336654070766059,PALM2;Paralemmin-2,1.54773941887206,1.3283333762724,1.80338561954433,2.14115518076842e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.993160868272376,IL1RN;Interleukin-1 receptor antagonist protein,1.26777646357321,1.16303683773424,1.38194862745823,6.93286713326967e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648088139987038,COL18A1;Collagen alpha-1(XVIII) chain,3.00974415475146,2.16589679866604,4.18235988096926,5.24845604768565e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.992731785144478,COL18A1;Collagen alpha-1(XVIII) chain,1.24012497541055,1.13591244638471,1.35389832159315,1.54357132255598e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373222283334642,COL18A1;Collagen alpha-1(XVIII) chain,1.79527460783823,1.55747207032366,2.06938601273213,6.95309353839918e-16
sensitivity,Nervous system disorders,G81 (hemiplegia),0.962219598583235,COL18A1;Collagen alpha-1(XVIII) chain,1.27255742737907,1.16422240657025,1.39097340580166,1.09969989125062e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0597240747745416,LAYN;Layilin,4.09678563530251,2.95117603696354,5.68710654037761,3.55569377836102e-17
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.984424920127795,LAYN;Layilin,1.24798811128522,1.14225912945,1.36350350437487,9.35225472380855e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370355621042571,LAYN;Layilin,2.10095184466397,1.82922592384614,2.41304182061669,8.10424159212259e-26
sensitivity,Nervous system disorders,G81 (hemiplegia),0.971493546649644,LAYN;Layilin,1.25444245670126,1.14780044930817,1.37099256070441,5.70370923821052e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0625562028384877,RGMB;RGM domain family member B,3.03588637779633,2.12262721412786,4.34207478239471,1.18465237821227e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375417945759928,RGMB;RGM domain family member B,1.44937068941183,1.25248352282088,1.67720800876879,6.28789836326481e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591470988348021,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,3.26686859416594,2.35687191507448,4.52821824694301,1.18970900128741e-12
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.986770551128161,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.34296192285152,1.23021179841198,1.46604570737913,4.37659917694793e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.71905936578803,1.49529424269017,1.97631009251192,2.64868672984542e-14
sensitivity,Nervous system disorders,G81 (hemiplegia),0.969953181485944,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.37613558796189,1.26001157092868,1.50296171888282,1.26287010790536e-12
sensitivity,Nervous system disorders,G93 (other disorders of brain),0.867786647603161,TNFRSF1B;Tumor necrosis factor receptor superfamily member 1B,1.28229524900822,1.16766090913228,1.4081837396192,1.95063314848977e-07
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.983626102853509,"POLR2F;DNA-directed RNA polymerases I, II, and III subunit RPABC2",1.31850186212208,1.20894953188411,1.43798158200207,4.17462659068041e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372181842982131,CCL15;C-C motif chemokine 15,1.6336996164874,1.41796858340671,1.88225216562892,1.09796675608226e-11
sensitivity,Nervous system disorders,G12 (spinal muscular atrophy and related syndromes),0.565727842326175,NEFL;Neurofilament light polypeptide,2.0316909928129,1.83297216647002,2.25195361161781,1.60424436530817e-41
sensitivity,Nervous system disorders,G20 (parkinson's disease),1.51727499847663,NEFL;Neurofilament light polypeptide,1.20247622134185,1.12132496713788,1.28950046174687,2.31491918703534e-07
sensitivity,Nervous system disorders,G23 (other degenerative diseases of basal ganglia),0.119483991170335,NEFL;Neurofilament light polypeptide,1.80836155840176,1.43721832916907,2.27534777391539,4.31062152933799e-07
sensitivity,Nervous system disorders,G30 (alzheimer's disease),1.36104022359946,NEFL;Neurofilament light polypeptide,1.41562552098765,1.31641359379576,1.52231458647675,6.88511250905464e-21
sensitivity,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00533068488152,NEFL;Neurofilament light polypeptide,1.51875885974239,1.39819994424058,1.64971289231372,4.03936098377325e-23
sensitivity,Nervous system disorders,G35 (multiple sclerosis),0.232453815097263,NEFL;Neurofilament light polypeptide,1.55957547128301,1.30837532318735,1.85900452838129,7.06537407799576e-07
sensitivity,Nervous system disorders,G40 (epilepsy),0.815874707884055,NEFL;Neurofilament light polypeptide,1.48557348771955,1.35250408737343,1.63173524429128,1.37933810952787e-16
sensitivity,Nervous system disorders,G45 (transient cerebral ischaemic attacks and related syndromes),1.33919443876507,NEFL;Neurofilament light polypeptide,1.22486725713075,1.13653950908725,1.3200595189127,1.08658112851575e-07
sensitivity,Nervous system disorders,G55 (nerve root and plexus compressions in diseases classified elsewhere),1.57057411400903,NEFL;Neurofilament light polypeptide,1.24419394624002,1.16099044105731,1.33336031126193,6.13267899463276e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648245685114658,NEFL;Neurofilament light polypeptide,3.14615960166319,2.43271738866905,4.06883277327702,2.4311374294371e-18
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.983420026007802,NEFL;Neurofilament light polypeptide,1.60085039726259,1.47312709137463,1.73964759009654,1.37948691473833e-28
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.364719469941037,NEFL;Neurofilament light polypeptide,2.17945345714221,1.92745991178231,2.46439230347304,1.85783501717761e-35
sensitivity,Nervous system disorders,G81 (hemiplegia),0.955995778192741,NEFL;Neurofilament light polypeptide,1.31524599908606,1.20522692951135,1.43530815297436,7.83931867149633e-10
sensitivity,Nervous system disorders,G83 (other paralytic syndromes),0.265612327656123,NEFL;Neurofilament light polypeptide,1.64195221733078,1.40203731071336,1.9229210687879,7.60500502843765e-10
sensitivity,Nervous system disorders,G99 (other disorders of nervous system in diseases classified elsewhere),0.51498317180974,NEFL;Neurofilament light polypeptide,1.43391664121716,1.27529103075435,1.61227271608998,1.6868395564152e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0608690529953464,IL10RB;Interleukin-10 receptor subunit beta,2.99464886267972,2.15379483502126,4.16377719220432,6.92098622789728e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.990586474457442,IL10RB;Interleukin-10 receptor subunit beta,1.26272912342655,1.15651708349059,1.37869544852474,1.95337249071931e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.365307565401838,IL10RB;Interleukin-10 receptor subunit beta,1.58215002060912,1.3703465861495,1.82669020597709,3.93519748147238e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0539234287312016,IGFBP4;Insulin-like growth factor-binding protein 4,3.17322530458219,2.26004195405308,4.45538580183554,2.57348692368952e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.983573717948718,IGFBP4;Insulin-like growth factor-binding protein 4,1.34128114210609,1.22720518875571,1.46596112748961,9.51021554511586e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375541838956473,IGFBP4;Insulin-like growth factor-binding protein 4,1.80253854652509,1.56562852870351,2.07529765339636,2.49754993435568e-16
sensitivity,Nervous system disorders,G81 (hemiplegia),0.966560605150987,IGFBP4;Insulin-like growth factor-binding protein 4,1.37978585835669,1.26180466727725,1.50879852032027,1.67748536842587e-12
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0653789004457652,ADAMTS15;A disintegrin and metalloproteinase with thrombospondin motifs 15,2.41327767253218,1.73234678208295,3.36186102284887,1.90259710463726e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370561192136968,VMO1;Vitelline membrane outer layer protein 1 homolog,1.48666118258667,1.28652722194524,1.71792825997745,7.64688560826167e-08
sensitivity,Nervous system disorders,G09 (sequelae of inflammatory diseases of central nervous system),0.0262435400516795,"NOS3;Nitric oxide synthase, endothelial",3.49568805207473,2.16629053884117,5.64090307293448,2.95661784612567e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.064526221109851,CLMP;CXADR-like membrane protein,3.28051361083606,2.49662050114321,4.31053479932285,1.50012791544857e-17
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.980661358019848,CLMP;CXADR-like membrane protein,1.25898612609303,1.14972655242569,1.37862873772082,6.61836121066842e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,CLMP;CXADR-like membrane protein,1.75901442751886,1.5360926705473,2.01428716870129,3.12830233337768e-16
sensitivity,Nervous system disorders,G81 (hemiplegia),0.965928015831031,CLMP;CXADR-like membrane protein,1.26141003560911,1.15150859759045,1.38180060597455,5.93994272285597e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372682926829268,IL18R1;Interleukin-18 receptor 1,1.60700612538563,1.39367398767822,1.85299339003176,6.67345223644162e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0610681007820656,SCGB1A1;Uteroglobin,2.3769649565594,1.68161106089045,3.35985088116608,9.41162938764282e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.064499736137443,FAS;Tumor necrosis factor receptor superfamily member 6,2.3454436527463,1.73156682902513,3.17695270895494,3.66835791472069e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648215443241863,IL18BP;Interleukin-18-binding protein,2.92026230505679,2.11891590526384,4.02466747696329,5.82556479757762e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.996887190196619,IL18BP;Interleukin-18-binding protein,1.28442208543632,1.17718193503683,1.40143171115259,1.83326211777494e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.36740868813486,IL18BP;Interleukin-18-binding protein,1.69951660901729,1.4747402893755,1.95855278731738,2.34962909264768e-13
sensitivity,Nervous system disorders,G81 (hemiplegia),0.96636422681021,IL18BP;Interleukin-18-binding protein,1.27106337914917,1.16344910920029,1.38863152761759,1.07228123378736e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.064526221109851,SLITRK2;SLIT and NTRK-like protein 2,3.09156413888623,2.23247416474879,4.2812449862876,1.08449035699234e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,SLITRK2;SLIT and NTRK-like protein 2,1.70663960821749,1.48392903449131,1.96277496068752,6.77445150677455e-14
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0608690529953464,CSF1;Macrophage colony-stimulating factor 1,2.56030770539689,1.83267630023804,3.5768321691415,3.5672439867764e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.990586474457442,CSF1;Macrophage colony-stimulating factor 1,1.35615106934385,1.24278189320959,1.47986201998222,7.92941012645885e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.365307565401838,CSF1;Macrophage colony-stimulating factor 1,1.74898432660494,1.51795565779861,2.01517492226742,1.04177334467559e-14
sensitivity,Nervous system disorders,G81 (hemiplegia),0.973872668607854,CSF1;Macrophage colony-stimulating factor 1,1.24683854875257,1.14166195222445,1.36170463036486,9.27207672449949e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0612212655028043,CD83;CD83 antigen,2.64574228348525,1.8715516116132,3.74018658485624,3.61924713625274e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.998355882178159,CD83;CD83 antigen,1.2780189702401,1.16963343023563,1.39644819143424,5.78329779690822e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375308641975308,CD83;CD83 antigen,1.58934556634743,1.37774116346853,1.83344984983163,2.07369729316766e-10
sensitivity,Nervous system disorders,G81 (hemiplegia),0.969644199944591,CD83;CD83 antigen,1.26080464553816,1.15273185706406,1.37900964952881,4.00824806382643e-07
sensitivity,Nervous system disorders,G93 (other disorders of brain),0.87513425355026,CD83;CD83 antigen,1.25892433635787,1.14521381705059,1.3839253954828,1.8676913461137e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0615885882306194,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,3.16717197140811,2.33768602770304,4.29098611943598,1.0027845895157e-13
sensitivity,Nervous system disorders,G62 (other polyneuropathies),1.00430416068866,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.26728866839597,1.16076479064105,1.38358828764773,1.23768659018425e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367632447041055,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.73239395163404,1.5028509037184,1.99699703825082,3.53421770347736e-14
sensitivity,Nervous system disorders,G72 (other myopathies),0.0933762466722295,HSPG2;Basement membrane-specific heparan sulfate proteoglycan core protein,1.98814595704114,1.50824790174132,2.62073916491812,1.08500521634222e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0608690529953464,BTN2A1;Butyrophilin subfamily 2 member A1,3.2559606020411,2.31227117498264,4.58479072729151,1.37839890810005e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.990586474457442,BTN2A1;Butyrophilin subfamily 2 member A1,1.25865469396821,1.15291329831339,1.37409434080234,2.77507057057721e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.365307565401838,BTN2A1;Butyrophilin subfamily 2 member A1,1.78513779154239,1.54686578496425,2.06011210912296,2.22863444407133e-15
sensitivity,Nervous system disorders,G81 (hemiplegia),0.973872668607854,BTN2A1;Butyrophilin subfamily 2 member A1,1.26210196301463,1.15538097829965,1.37868062133895,2.41634523654542e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0646229653863241,CD28;T-cell-specific surface glycoprotein CD28,2.87356666572273,2.06180512589448,4.00493008706172,4.60539284193738e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367617354770946,CD28;T-cell-specific surface glycoprotein CD28,1.51862031638705,1.31505307353791,1.75369930822568,1.2733494934991e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591470988348021,RELT;Tumor necrosis factor receptor superfamily member 19L,2.60489647402944,1.81763095228465,3.73314815743101,1.84393428822761e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,RELT;Tumor necrosis factor receptor superfamily member 19L,1.53936820503527,1.32257990532213,1.79169096788624,2.54586831049076e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0625562028384877,CD74;HLA class II histocompatibility antigen gamma chain,3.29822121598765,2.42981385564748,4.47699446783025,1.94001171525367e-14
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.988235294117647,CD74;HLA class II histocompatibility antigen gamma chain,1.28986306955005,1.18272338126841,1.40670825024596,8.76588791020355e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375417945759928,CD74;HLA class II histocompatibility antigen gamma chain,1.82049233697714,1.58836710181904,2.08654053914679,7.39061791896787e-18
sensitivity,Nervous system disorders,G81 (hemiplegia),0.967621883141049,CD74;HLA class II histocompatibility antigen gamma chain,1.30102880748219,1.19211112527133,1.41989779477419,3.65000456480441e-09
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.974275876038079,LTBP3;Latent-transforming growth factor beta-binding protein 3,1.30829997337126,1.19620194919296,1.43090288515082,4.10677821490017e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0605705353653771,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,3.20340169577208,2.28539087267968,4.49016513855382,1.40481614153232e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373287470439932,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.80216716858202,1.56449821902815,2.07594132355896,3.2779008806967e-16
sensitivity,Nervous system disorders,G81 (hemiplegia),0.963232702924938,TNFRSF4;Tumor necrosis factor receptor superfamily member 4,1.25121657208283,1.14522697286128,1.36701540162234,6.95439695292748e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.064526221109851,HSPB6;Heat shock protein beta-6,2.65813174421443,1.99213011177597,3.54678859971724,3.06356967745677e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.980661358019848,HSPB6;Heat shock protein beta-6,1.30222325056945,1.19220491931489,1.42239422673927,4.52869613783113e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,HSPB6;Heat shock protein beta-6,1.80368091224503,1.57700282825189,2.06294166054433,7.45360585460547e-18
sensitivity,Nervous system disorders,G71 (primary disorders of muscles),0.046927243219991,HSPB6;Heat shock protein beta-6,2.42912481406247,1.71688959338583,3.43682400139517,5.3641020528571e-07
sensitivity,Nervous system disorders,G72 (other myopathies),0.0958116616479605,HSPB6;Heat shock protein beta-6,2.22750248215372,1.73591177163256,2.85830615880589,3.06995027935257e-10
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.980746089049338,CSTB;Cystatin-B,1.24443475442162,1.1396956723937,1.35879945455952,1.08827227128145e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372795771036332,CDH2;Cadherin-2,1.44677045921693,1.25320395356328,1.6702347257294,4.65804638334476e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0634782091210251,REG1A;Lithostathine-1-alpha,2.43571459223,1.74255364133396,3.4046042739095,1.88629716698422e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.3690549415663,REG1A;Lithostathine-1-alpha,1.84956069189223,1.60492630850799,2.1314840032581,1.96878911653227e-17
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.952583056282568,IFI30;Gamma-interferon-inducible lysosomal thiol reductase,1.33354062703615,1.21226431825473,1.46694955644344,3.28294370656856e-09
sensitivity,Nervous system disorders,G81 (hemiplegia),0.967621883141049,CXCL13;C-X-C motif chemokine 13,1.2527340102708,1.14663499731952,1.3686504460075,6.0250776310852e-07
sensitivity,Nervous system disorders,G93 (other disorders of brain),0.86626109897033,CXCL13;C-X-C motif chemokine 13,1.26616600866215,1.15306245855251,1.3903638520189,7.6878498440544e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591470988348021,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,3.62521133587516,2.61910163698419,5.01781108612895,8.16320304848567e-15
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.986770551128161,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.24486055605816,1.14006866584443,1.3592846207045,1.05140045734754e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,PIK3IP1;Phosphoinositide-3-kinase-interacting protein 1,1.83139702642517,1.5937471958196,2.10448374572613,1.43293632787953e-17
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0625562028384877,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,3.54519757518817,2.53749973502719,4.95307474267987,1.19357706036093e-13
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.988235294117647,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.27475646896731,1.16788323036584,1.39140969997913,5.51819328627293e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375417945759928,TNFRSF21;Tumor necrosis factor receptor superfamily member 21,1.6693766204523,1.45165272998151,1.91975549203715,6.61665626399762e-13
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,CD99L2;CD99 antigen-like protein 2,1.53533166679071,1.33607236412915,1.76430812457287,1.49417506407292e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0553633217993079,PALM;Paralemmin-1,3.10910759776965,2.19265841740143,4.4085982466731,1.93601776827964e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0616118453741429,ADAM22;Disintegrin and metalloproteinase domain-containing protein 22,2.97909561130554,2.10393276009996,4.21829576952747,7.67905449117408e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37172504273844,ADAM22;Disintegrin and metalloproteinase domain-containing protein 22,1.47577382992255,1.28001721455501,1.70146805239757,8.31972063468332e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0625562028384877,THY1;Thy-1 membrane glycoprotein,2.75319682288511,1.96170152016573,3.86403979791191,4.73438784758288e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375417945759928,THY1;Thy-1 membrane glycoprotein,1.69727327595671,1.47247380988079,1.95639240164825,2.92499298275804e-13
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0609696135313206,CHRDL1;Chordin-like protein 1,3.08252506746907,2.25913337252058,4.20602028510322,1.24826030971279e-12
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.99025525703239,CHRDL1;Chordin-like protein 1,1.36716478131897,1.25263563015398,1.49216539453629,2.45075325977618e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.365911237016052,CHRDL1;Chordin-like protein 1,2.00984472792205,1.75373531966754,2.3033554636522,1.04586341264643e-23
sensitivity,Nervous system disorders,G81 (hemiplegia),0.975484786378685,CHRDL1;Chordin-like protein 1,1.32191013667723,1.2104933207984,1.44358203339566,5.22497675883255e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591470988348021,HAVCR2;Hepatitis A virus cellular receptor 2,3.05131750189318,2.21660860831667,4.20035294567869,7.84127359373621e-12
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.986770551128161,HAVCR2;Hepatitis A virus cellular receptor 2,1.31902033694941,1.20790428025066,1.44035804635538,6.96876536739352e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,HAVCR2;Hepatitis A virus cellular receptor 2,1.72476342177431,1.50209037697807,1.9804459882603,1.08640653456991e-14
sensitivity,Nervous system disorders,G81 (hemiplegia),0.969953181485944,HAVCR2;Hepatitis A virus cellular receptor 2,1.2720525357361,1.16420413964426,1.38989168529077,1.01794841320822e-07
sensitivity,Nervous system disorders,G93 (other disorders of brain),0.867786647603161,HAVCR2;Hepatitis A virus cellular receptor 2,1.25850116554965,1.1456512006902,1.38246717913415,1.61333432545524e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0603794616938761,NPC2;NPC intracellular cholesterol transporter 2,2.73130288349603,1.93226692064187,3.86075824292207,1.26808904154236e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.339148412274384,NPC2;NPC intracellular cholesterol transporter 2,1.5787812210327,1.34256812298036,1.85655394405783,3.34228901285085e-08
sensitivity,Nervous system disorders,G81 (hemiplegia),0.926249156368544,NPC2;NPC intracellular cholesterol transporter 2,1.37617047797478,1.24670132335819,1.51908492352278,2.38820091853146e-10
sensitivity,Nervous system disorders,G20 (parkinson's disease),1.5210095578278,XG;Glycoprotein Xg,0.797621401624133,0.729409496104904,0.872212253509445,7.14260061838325e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0646007478025957,XG;Glycoprotein Xg,3.70108763973549,2.83226513792591,4.83642916532668,9.114433455629e-22
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372031093967222,XG;Glycoprotein Xg,2.16116001861401,1.88270102909056,2.48080420305069,6.63449960756354e-28
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,CNTN4;Contactin-4,1.44792890522922,1.25528461141985,1.67013766880083,3.75095485707529e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648712404167485,DLL1;Delta-like protein 1,3.9191797410478,2.81444137365908,5.45755544471331,6.21849908149564e-16
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.993690851735015,DLL1;Delta-like protein 1,1.30503310542916,1.19455296483017,1.42573117844817,3.6586410401016e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371637564889098,DLL1;Delta-like protein 1,1.91721938553994,1.65969569689728,2.21470127274641,9.22349999125999e-19
sensitivity,Nervous system disorders,G81 (hemiplegia),0.967125608146703,DLL1;Delta-like protein 1,1.30305071705186,1.19144599406152,1.42510963960798,6.86346465688621e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0550610259704505,ATRAID;All-trans retinoic acid-induced differentiation factor,3.09029992045924,2.09992799970093,4.54775287521787,1.04344657719284e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.950320992199544,ATRAID;All-trans retinoic acid-induced differentiation factor,1.3094300717036,1.18836402806234,1.44282986710513,5.13655052461787e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.33045713236644,ATRAID;All-trans retinoic acid-induced differentiation factor,1.50675596426471,1.27757276014212,1.77705224052735,1.11702522892035e-06
sensitivity,Nervous system disorders,G81 (hemiplegia),0.977941759898436,PRSS8;Prostasin,1.27035822904494,1.15937236423436,1.3919686891691,2.89204210228382e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0608690529953464,SMOC2;SPARC-related modular calcium-binding protein 2,2.83678936052605,1.99965002609342,4.02439115394376,5.10055558071381e-09
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.990586474457442,SMOC2;SPARC-related modular calcium-binding protein 2,1.26230047419922,1.15173333261007,1.38348213258062,6.34399490136859e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.365307565401838,SMOC2;SPARC-related modular calcium-binding protein 2,1.73899231938848,1.49563771498906,2.02194305250871,6.30996604969676e-13
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0642776795757673,GPR37;Prosaposin receptor GPR37,3.57496514346568,2.50502578506515,5.10189390192732,2.2098220315119e-12
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.969074241966354,GPR37;Prosaposin receptor GPR37,1.25634716907136,1.14645808111392,1.37676922971315,1.02569101980834e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.365645404319437,GPR37;Prosaposin receptor GPR37,1.84161293681943,1.58469021458883,2.14019003704183,1.64584698387892e-15
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648712404167485,NBL1;Neuroblastoma suppressor of tumorigenicity 1,3.97070197395839,2.85959663338641,5.51353081826999,1.82142707448507e-16
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.993690851735015,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.28524189401916,1.17674077348483,1.40374733617,2.45267125725128e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371637564889098,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.87011472607715,1.61888478206716,2.16033230247853,1.81743385288947e-17
sensitivity,Nervous system disorders,G81 (hemiplegia),0.967125608146703,NBL1;Neuroblastoma suppressor of tumorigenicity 1,1.30187344418724,1.19064115007281,1.42349730191696,7.07239195294271e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0616118453741429,ASGR1;Asialoglycoprotein receptor 1,2.50766468563395,1.82444332031511,3.44674022237617,1.47050393396638e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.98875687744199,ASGR1;Asialoglycoprotein receptor 1,1.28694378235797,1.17908848054583,1.40466498170105,1.61473475724425e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37172504273844,ASGR1;Asialoglycoprotein receptor 1,1.67480730247004,1.45673700739776,1.92552223645204,4.30642829798067e-13
sensitivity,Nervous system disorders,G81 (hemiplegia),0.971859876924302,ASGR1;Asialoglycoprotein receptor 1,1.25867898409824,1.15229793168888,1.37488121903383,3.28430790243193e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0646197227226443,CD5;T-cell surface glycoprotein CD5,3.18997369772156,2.31558824804142,4.39453439132038,1.27301859408276e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372154973165667,CD5;T-cell surface glycoprotein CD5,1.55287818209472,1.34887285922482,1.7877375409656,9.08852376514942e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0605705353653771,BSG;Basigin,2.89889065394204,2.06275926957771,4.0739446175088,8.7706560494458e-10
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.989691529808333,BSG;Basigin,1.26942225932048,1.16192812521756,1.38686106092543,1.26091922617006e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373287470439932,BSG;Basigin,1.63737415101867,1.41905479308915,1.88928160031639,1.4431177174166e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0651388642150766,TFF3;Trefoil factor 3,2.8871290505533,2.10745912282147,3.95524357473143,4.06503224172791e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.363277393879565,TFF3;Trefoil factor 3,1.87227071849102,1.620331956883,2.16338240348117,1.81112269798938e-17
sensitivity,Nervous system disorders,G81 (hemiplegia),0.961177145343433,TFF3;Trefoil factor 3,1.31980759848969,1.20702596617461,1.44312727799192,1.13989140822857e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0650759219088937,NPDC1;Neural proliferation differentiation and control protein 1,2.96404360723889,2.14074746941416,4.10396584890884,5.96562671494629e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372795771036332,NPDC1;Neural proliferation differentiation and control protein 1,1.68904961843941,1.46668853069852,1.94512233090934,3.38941223736139e-13
sensitivity,Nervous system disorders,G72 (other myopathies),0.0946558864129363,NPDC1;Neural proliferation differentiation and control protein 1,1.97712895294579,1.49661666386023,2.6119172604252,1.60108576034212e-06
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.988084290438083,NFASC;Neurofascin,1.25424503168881,1.14857240843978,1.36963990076429,4.5440281141885e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372682926829268,NFASC;Neurofascin,1.85142686111692,1.60338081843897,2.137846095354,4.74308142257702e-17
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372181842982131,REG1B;Lithostathine-1-beta,1.5821957302591,1.37474156904253,1.82095557828635,1.57182422244743e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0610705068852071,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,3.02883708786946,2.14431976392267,4.27821179434151,3.19254097397311e-10
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.991898834222485,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.34220730881005,1.22945828507183,1.46529612407132,4.88581025294217e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.366516907070229,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.79526597952676,1.55554252999167,2.07193302343422,1.22678060533068e-15
sensitivity,Nervous system disorders,G81 (hemiplegia),0.977102250296091,TNFRSF14;Tumor necrosis factor receptor superfamily member 14,1.27039378518727,1.16300770107084,1.38769534196243,1.08901406528259e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.061170527645132,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,2.64304002944001,1.9700987450226,3.54584287456217,9.00322180977494e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.991549072772972,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.28413708022381,1.17779035854193,1.40008621130772,1.42722622936123e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367117339386164,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.81020289553887,1.58319601131787,2.06975920833051,3.94297766901973e-18
sensitivity,Nervous system disorders,G81 (hemiplegia),0.978705735808766,LAIR1;Leukocyte-associated immunoglobulin-like receptor 1,1.33949946300656,1.22840702778389,1.46063867334901,3.66432954506756e-11
sensitivity,Nervous system disorders,G20 (parkinson's disease),1.51754848538114,"FABP4;Fatty acid-binding protein, adipocyte",0.792220266486291,0.732687545043767,0.856590172546361,5.10695326189491e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0642886364964641,"FABP4;Fatty acid-binding protein, adipocyte",2.90933360323573,2.16577309843631,3.90817580153146,1.32470967808119e-12
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.988725403990073,"FABP4;Fatty acid-binding protein, adipocyte",1.27948560505753,1.16334537769181,1.40722045657462,3.849226328285e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372181842982131,"FABP4;Fatty acid-binding protein, adipocyte",2.00986408131698,1.74679972322651,2.31254537750138,1.78859418267402e-22
sensitivity,Nervous system disorders,G81 (hemiplegia),0.960374780402108,"FABP4;Fatty acid-binding protein, adipocyte",1.27547659818387,1.1582341316639,1.40458695529685,7.58011951499062e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367617354770946,CALB2;Calretinin,1.54072751383242,1.32636669497271,1.78973226701012,1.55721202730661e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.33570163941965,RNASE6;Ribonuclease K6,1.57643248680249,1.34188575739866,1.8519753799786,3.05968628828457e-08
sensitivity,Nervous system disorders,G81 (hemiplegia),0.928378907599806,RNASE6;Ribonuclease K6,1.30063881150368,1.17953609967132,1.43417511211491,1.3545700993094e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0617161059128011,EFNA4;Ephrin-A4,3.38410599005631,2.44054261176071,4.69247014854328,2.67404265523698e-13
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.990435112522214,EFNA4;Ephrin-A4,1.25987671808946,1.15304563320354,1.37660583334751,3.22220009178856e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372354194460484,EFNA4;Ephrin-A4,2.08024971558751,1.80609626394472,2.39601784555508,3.02637688316469e-24
sensitivity,Nervous system disorders,G81 (hemiplegia),0.973507819980849,EFNA4;Ephrin-A4,1.2658446071682,1.15783399370009,1.38393118375817,2.21295430091337e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607207080968728,INHBB;Inhibin beta B chain,2.7918249352921,1.90121768771316,4.09962863258123,1.62688548138261e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.343369694704631,INHBB;Inhibin beta B chain,1.78266836440969,1.511856661902,2.10198928082847,6.1296888755808e-12
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0646229653863241,SORCS2;VPS10 domain-containing receptor SorCS2,3.109760989206,2.23757140474722,4.32192393479391,1.42153088638298e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367617354770946,SORCS2;VPS10 domain-containing receptor SorCS2,1.54213665039762,1.33298160402574,1.78410972913446,5.71175490645759e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0628191618707951,SCARB2;Lysosome membrane protein 2,3.42356692652071,2.52226246216292,4.64694324091693,2.90610564933164e-15
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.981747225496971,SCARB2;Lysosome membrane protein 2,1.38702002086487,1.26861312442525,1.51647850809646,6.67905803007535e-13
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374956930622833,SCARB2;Lysosome membrane protein 2,1.7777646173028,1.54551019047688,2.04492151136096,7.96785407940783e-16
sensitivity,Nervous system disorders,G81 (hemiplegia),0.966497461928934,SCARB2;Lysosome membrane protein 2,1.33308873309092,1.21865642861385,1.45826627470004,3.42007227907743e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0572383634407125,YAP1;Transcriptional coactivator YAP1,3.37125703434894,2.46573127381569,4.609331970738,2.63919574334308e-14
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.962090422722784,YAP1;Transcriptional coactivator YAP1,1.26064710427428,1.14606429075703,1.38668583807402,1.89708326322957e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.336654070766059,YAP1;Transcriptional coactivator YAP1,1.72355359248274,1.47741625290981,2.01069737814879,4.38292449272258e-12
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0644075543828302,WFDC2;WAP four-disulfide core domain protein 2,3.13413503005266,2.32142465990054,4.23136815778638,8.72100652930824e-14
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.985601466941718,WFDC2;WAP four-disulfide core domain protein 2,1.29132686580312,1.17942247364048,1.41384882144718,3.23558797861981e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.363681705771109,WFDC2;WAP four-disulfide core domain protein 2,1.92196172818925,1.66641899297893,2.21669154047558,2.81954496788721e-19
sensitivity,Nervous system disorders,G81 (hemiplegia),0.97426929802648,WFDC2;WAP four-disulfide core domain protein 2,1.38382469359734,1.26396303799949,1.51505283385553,2.10080061212588e-12
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0646235190443552,GFRA1;GDNF family receptor alpha-1,4.89408854348291,3.62467145465142,6.60807551004759,3.54814049696279e-25
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.978216032528629,GFRA1;GDNF family receptor alpha-1,1.32636201478027,1.21461460490969,1.44839045005785,3.1816480404411e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372176842765078,GFRA1;GDNF family receptor alpha-1,2.09138829394647,1.82306611602353,2.39920261674145,6.15844476961561e-26
sensitivity,Nervous system disorders,G81 (hemiplegia),0.965425218790471,GFRA1;GDNF family receptor alpha-1,1.33285929726914,1.22022739286159,1.45588758022439,1.78876401694631e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0642886364964641,MFAP5;Microfibrillar-associated protein 5,2.3841400570799,1.69810155228214,3.34734033081465,5.20951989936693e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0646197227226443,HAVCR1;Hepatitis A virus cellular receptor 1,2.84882965376381,2.09852588397282,3.86739589830532,1.91010633784448e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.982086737900691,HAVCR1;Hepatitis A virus cellular receptor 1,1.32032034086748,1.21024892199616,1.44040268974844,3.93541651057933e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372154973165667,HAVCR1;Hepatitis A virus cellular receptor 1,2.22467801667422,1.94861414763288,2.53985237861773,2.77852085496551e-32
sensitivity,Nervous system disorders,G81 (hemiplegia),0.965368390071618,HAVCR1;Hepatitis A virus cellular receptor 1,1.25296180543705,1.14762902094209,1.36796234430821,4.8190109241236e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372795771036332,IGSF8;Immunoglobulin superfamily member 8,1.50476035256509,1.30642234469513,1.73320957640251,1.45762784745034e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0650297560398849,CTSZ;Cathepsin Z,2.2872292497953,1.63244379364417,3.20465406618436,1.52451470556689e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368589111838215,CTSZ;Cathepsin Z,1.61820889709013,1.40136045458255,1.86861276558693,5.49723002066606e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37172504273844,SNCG;Gamma-synuclein,1.8216022329052,1.56788166184989,2.11638083132508,4.62833775107496e-15
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0642886364964641,COL6A3;Collagen alpha-3(VI) chain,4.0188344330673,3.0288258864068,5.33243930359031,5.43011418870318e-22
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.988725403990073,COL6A3;Collagen alpha-3(VI) chain,1.39549514144968,1.27854006938206,1.52314873537823,8.51856617733741e-14
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372181842982131,COL6A3;Collagen alpha-3(VI) chain,1.97767437644302,1.72135845157277,2.27215658404308,6.04775448943117e-22
sensitivity,Nervous system disorders,G72 (other myopathies),0.0954588844947497,COL6A3;Collagen alpha-3(VI) chain,2.01593771345247,1.53440829073927,2.64858114300332,4.79228390706252e-07
sensitivity,Nervous system disorders,G81 (hemiplegia),0.960374780402108,COL6A3;Collagen alpha-3(VI) chain,1.30347052116655,1.192658089034,1.42457877506733,5.01590946846574e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370887337986041,GFRA3;GDNF family receptor alpha-3,1.49845479675279,1.29746321817565,1.73058222110421,3.71681636994114e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0550610259704505,EFCAB14;EF-hand calcium-binding domain-containing protein 14,2.58403407632519,1.76154648002424,3.79055119085923,1.19667248529254e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.33045713236644,EFCAB14;EF-hand calcium-binding domain-containing protein 14,1.54131650995727,1.30981300447476,1.8137372096252,1.88765381175319e-07
sensitivity,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00367882277671,PI3;Elafin,1.32858903077649,1.21222951279182,1.45611766919814,1.23581476732694e-09
sensitivity,Nervous system disorders,G81 (hemiplegia),0.961076405574243,PI3;Elafin,1.25815723991557,1.14558989284621,1.38178561999975,1.56937384080846e-06
sensitivity,Nervous system disorders,G40 (epilepsy),0.819184385909235,CKAP4;Cytoskeleton-associated protein 4,1.34537831619725,1.22169509725399,1.48158310347827,1.64337369565345e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0607664412427717,CKAP4;Cytoskeleton-associated protein 4,3.39453836791859,2.43792878691869,4.72650833490311,4.60553685761434e-13
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.990936080690509,CKAP4;Cytoskeleton-associated protein 4,1.36568419698898,1.2516772578485,1.49007526837337,2.42967312043771e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.374495117838516,CKAP4;Cytoskeleton-associated protein 4,1.84346785279996,1.60350120046262,2.11934591837314,8.24430208301728e-18
sensitivity,Nervous system disorders,G81 (hemiplegia),0.962426099424508,CKAP4;Cytoskeleton-associated protein 4,1.34401094046973,1.23040640432949,1.46810468618025,5.323517950225e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0592463859704558,EFNA1;Ephrin-A1,3.53521266767083,2.513011530412,4.97320782432356,4.11162177978821e-13
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.988431978448617,EFNA1;Ephrin-A1,1.2822067353081,1.17419048510332,1.40015962735791,3.08960717791173e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.379259259259259,EFNA1;Ephrin-A1,1.92023116184443,1.67111788577079,2.20647971415713,3.4838705503944e-20
sensitivity,Nervous system disorders,G81 (hemiplegia),0.969605825550102,EFNA1;Ephrin-A1,1.26104424457018,1.1540648949859,1.37794035125121,2.92863620883897e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0653789004457652,"ST3GAL1;CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1",2.40599565365748,1.76082244633706,3.28756320517201,3.54612400547477e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370561192136968,"ST3GAL1;CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1",1.50305477712714,1.31003355752625,1.72451587218174,6.21518376481627e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.061170527645132,"FABP1;Fatty acid-binding protein, liver",2.3326336655274,1.67264972787086,3.25303004382033,5.99421601859769e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367117339386164,"FABP1;Fatty acid-binding protein, liver",1.50268767848149,1.30331260050358,1.7325622864289,2.05271059186521e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.064526221109851,ADM;Pro-adrenomedullin,2.85334159373207,2.18104838546819,3.73286457318725,2.03537228642689e-14
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,ADM;Pro-adrenomedullin,1.75697882617089,1.53556920723341,2.01031290616626,2.38443328520469e-16
sensitivity,Nervous system disorders,G81 (hemiplegia),0.965928015831031,ADM;Pro-adrenomedullin,1.35074022699341,1.23760036110821,1.47422319688438,1.62630184840077e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0642886364964641,NOTCH1;Neurogenic locus notch homolog protein 1,2.6965028446196,1.92940891478552,3.76857779360363,6.32055730514984e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372181842982131,NOTCH1;Neurogenic locus notch homolog protein 1,1.659819576006,1.44299953674912,1.90921823239068,1.29766400885399e-12
sensitivity,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",0.997654914742239,PLAUR;Urokinase plasminogen activator surface receptor,1.24186596584853,1.13741215011066,1.35591225835145,1.3500610112188e-06
sensitivity,Nervous system disorders,G40 (epilepsy),0.821994895190626,PLAUR;Urokinase plasminogen activator surface receptor,1.28917568096623,1.1682962002228,1.42256213456639,4.27221945677839e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0615726855621983,PLAUR;Urokinase plasminogen activator surface receptor,2.69602464556611,1.90864181020767,3.80823098950611,1.8226540513621e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.990118734560522,PLAUR;Urokinase plasminogen activator surface receptor,1.39855956538635,1.27958174186036,1.52860016202632,1.41772305379964e-13
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.369531529383716,PLAUR;Urokinase plasminogen activator surface receptor,2.00331263301519,1.73808075499135,2.30901901081014,8.92391594345255e-22
sensitivity,Nervous system disorders,G81 (hemiplegia),0.981172630657166,PLAUR;Urokinase plasminogen activator surface receptor,1.3492181195425,1.23418311285033,1.47497524082762,4.47044284284973e-11
sensitivity,Nervous system disorders,G40 (epilepsy),0.825916125410953,CD302;CD302 antigen,1.29830229517372,1.17882046151085,1.42989446203962,1.15904242160678e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0653789004457652,CD302;CD302 antigen,3.50971775474067,2.61941939996998,4.702614143456,4.07840275048565e-17
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.983626102853509,CD302;CD302 antigen,1.26159978838373,1.15520702458198,1.3777911596632,2.34445202935017e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370561192136968,CD302;CD302 antigen,1.65341285850484,1.43571072784891,1.90412596886079,2.9363399640201e-12
sensitivity,Nervous system disorders,G81 (hemiplegia),0.97075814424394,CD302;CD302 antigen,1.29696310776369,1.18716929261835,1.41691106176616,8.3289520287521e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0617136486701704,DKK4;Dickkopf-related protein 4,2.40779992014611,1.71581346548423,3.37886406190399,3.71557802628905e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370348246819186,DKK4;Dickkopf-related protein 4,1.71872683436228,1.49213616177875,1.97972678822792,5.99049709386616e-14
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.94827981126025,CD80;T-lymphocyte activation antigen CD80,1.29844432202768,1.17933364546744,1.42958497273914,1.03757625881665e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.342637854630179,CD80;T-lymphocyte activation antigen CD80,1.70861430692974,1.46064148433896,1.9986854277018,2.14770206304434e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373953819671158,CD4;T-cell surface glycoprotein CD4,1.56589243730957,1.35874438277173,1.80462135212024,5.84976224239347e-10
sensitivity,Nervous system disorders,G40 (epilepsy),0.80183011368888,SHISA5;Protein shisa-5,1.29301500032303,1.16383106663851,1.43653820471496,1.71000270158716e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0593702189847692,SHISA5;Protein shisa-5,3.10431532471059,2.20754487317504,4.3653806327265,7.38479818707068e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.959644542164811,SHISA5;Protein shisa-5,1.29297872878341,1.17456955717821,1.4233248110931,1.57664122709721e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.335762088577236,SHISA5;Protein shisa-5,1.69376327364518,1.44300565445105,1.98809617848699,1.14838124715832e-10
sensitivity,Nervous system disorders,G81 (hemiplegia),0.924569754668619,SHISA5;Protein shisa-5,1.41417051508118,1.28304410739013,1.55869797009004,2.95084286888113e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372795771036332,NRCAM;Neuronal cell adhesion molecule,1.6902409311408,1.46534459003556,1.94965363419016,5.80622881554562e-13
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37172504273844,CDCP1;CUB domain-containing protein 1,1.40723179305871,1.22770947106888,1.61300484036434,9.28524459655166e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0654584134517039,CD59;CD59 glycoprotein,2.83943447198623,2.075920668768,3.8837650407366,6.54465499154635e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.380554873557574,CD59;CD59 glycoprotein,1.53845949594411,1.32595209797505,1.78502498263336,1.34802185227162e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0651671636485712,FOLR1;Folate receptor alpha,2.27114253640112,1.64716100049918,3.13150227517973,5.58891988283603e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373333333333333,FOLR1;Folate receptor alpha,1.59546399017873,1.38854977753644,1.83321144487398,4.34659511487856e-11
sensitivity,Nervous system disorders,G81 (hemiplegia),0.967588745102695,FOLR1;Folate receptor alpha,1.25177228447065,1.14515319613869,1.3683181057804,7.65104610909298e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370561192136968,CALB1;Calbindin,1.41522065173604,1.2278673903477,1.63116107557267,1.64136932805463e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0650759219088937,REN;Renin,4.06945328291911,2.83568557950254,5.84001630560405,2.63134731247292e-14
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372795771036332,REN;Renin,2.07360270102022,1.770975183378,2.42794376908023,1.29715685904686e-19
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648712404167485,NECTIN4;Nectin-4,3.71333556356378,2.62960738767085,5.24369572137569,9.25817114497899e-14
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371637564889098,NECTIN4;Nectin-4,1.58632866402809,1.37072905421336,1.83583956477912,5.98031944929963e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375417945759928,MSR1;Macrophage scavenger receptor types I and II,1.5375414596175,1.33977659781343,1.76449845735543,9.13251618139823e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0592930444697833,B2M;Beta-2-microglobulin,2.81747068220319,2.00044031295831,3.96819689827952,3.06468044843751e-09
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.958349534548615,B2M;Beta-2-microglobulin,1.28544211362728,1.16899375138325,1.41349038481288,2.18618775744104e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.337606642638806,B2M;Beta-2-microglobulin,1.49756273445998,1.27806872934105,1.75475237923985,5.91091817960762e-07
sensitivity,Nervous system disorders,G81 (hemiplegia),0.925608501885498,B2M;Beta-2-microglobulin,1.27338839940409,1.15609847645084,1.40257776371687,9.48435660597532e-07
sensitivity,Nervous system disorders,G81 (hemiplegia),0.964509229184821,RETN;Resistin,1.24587479699462,1.14059892101073,1.36086750670508,1.05803659729857e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371347600899052,VEGFD;Vascular endothelial growth factor D,1.78080232395304,1.55580763067878,2.03833485224197,5.58524171062005e-17
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591470988348021,CD300LG;CMRF35-like molecule 9,3.79365856636413,2.71373982477305,5.30332539131735,6.1533881651176e-15
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,CD300LG;CMRF35-like molecule 9,1.71146668863758,1.48487982769085,1.97262981939164,1.20768647140815e-13
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.060472465520941,PGF;Placenta growth factor,2.63763284605559,1.94306130832277,3.58048765666412,4.97207754820366e-10
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.988084290438083,PGF;Placenta growth factor,1.29011251301494,1.17817533193218,1.41268472622676,3.78212718967714e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372682926829268,PGF;Placenta growth factor,1.65297930476357,1.42995261305376,1.91079099896991,1.07364582861277e-11
sensitivity,Nervous system disorders,G81 (hemiplegia),0.963624635953167,PGF;Placenta growth factor,1.29717637859861,1.18357061254414,1.42168666521486,2.63667517948835e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648712404167485,FGFR2;Fibroblast growth factor receptor 2,2.30195515068869,1.63415693707343,3.24264909664797,1.84804323763338e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371637564889098,FGFR2;Fibroblast growth factor receptor 2,1.58693370930532,1.37104445039841,1.83681761521133,6.02958722564459e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.060472465520941,CLEC7A;C-type lectin domain family 7 member A,3.03461482145175,2.13935777089408,4.30451009170199,4.85105639148067e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372682926829268,CLEC7A;C-type lectin domain family 7 member A,1.586433934619,1.37337068989215,1.83255158089064,3.5724189840439e-10
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.995692677551838,PIGR;Polymeric immunoglobulin receptor,1.36483761047655,1.24743065188287,1.49329479771855,1.22408945128737e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.379597626515893,PIGR;Polymeric immunoglobulin receptor,1.69539678377235,1.46558586180176,1.96124316516804,1.21698135797459e-12
sensitivity,Nervous system disorders,G81 (hemiplegia),0.970679475632943,PIGR;Polymeric immunoglobulin receptor,1.27498841065935,1.16454760875201,1.39590295415895,1.47830685918302e-07
sensitivity,Nervous system disorders,G93 (other disorders of brain),0.867133429905037,PIGR;Polymeric immunoglobulin receptor,1.29653096454411,1.1774748774855,1.42762497456544,1.26160471879667e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0650538727383614,LCN2;Neutrophil gelatinase-associated lipocalin,2.41027184951772,1.7198055897084,3.37794598607076,3.24754071492471e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368043270501636,LCN2;Neutrophil gelatinase-associated lipocalin,1.46789504446826,1.26695512228269,1.70070417150394,3.21768929666265e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370561192136968,ADGRG1;Adhesion G-protein coupled receptor G1,1.66048038491884,1.43268515810133,1.92449478038441,1.63029920416321e-11
sensitivity,Nervous system disorders,G20 (parkinson's disease),0.790383665404248,AHNAK;Neuroblast differentiation-associated protein AHNAK,0.699520256016704,0.627978858938059,0.779211882076973,8.46873401795658e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0597240747745416,EPHB6;Ephrin type-B receptor 6,3.35926812431909,2.37342889161445,4.75459044546737,8.1119543772426e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370355621042571,EPHB6;Ephrin type-B receptor 6,1.70221271094005,1.47799169420216,1.96044952393998,1.56822525341714e-13
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372792036693666,CXCL16;C-X-C motif chemokine 16,1.57358490565877,1.36466264368374,1.81449200414325,4.43908285187744e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0651723116421447,NECTIN2;Nectin-2,3.52552004227301,2.53257903057925,4.90776059439531,8.27969566537472e-14
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.998375658650608,NECTIN2;Nectin-2,1.2792081318296,1.17206871845639,1.39614121490596,3.43785007790341e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373348082887225,NECTIN2;Nectin-2,1.83527057332584,1.59272797441854,2.11474786116278,4.62099463278679e-17
sensitivity,Nervous system disorders,G81 (hemiplegia),0.963688532700108,NECTIN2;Nectin-2,1.34163584533924,1.22749006251725,1.4663961823103,9.29376388087427e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648712404167485,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,2.8871249167727,2.09761775777439,3.97378895852497,7.7703470417722e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.993690851735015,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.26033689901301,1.15534871864075,1.37486550457469,1.84841732325987e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371637564889098,TNFRSF12A;Tumor necrosis factor receptor superfamily member 12A,1.87590204124194,1.63423826051774,2.153301971538,3.87837079369932e-19
sensitivity,Nervous system disorders,G20 (parkinson's disease),1.51408035819488,EPS8L2;Epidermal growth factor receptor kinase substrate 8-like protein 2,0.78314532810453,0.729614862695773,0.840603222727504,1.31812297817283e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648712404167485,TGFBR2;TGF-beta receptor type-2,3.76286504978137,2.78606273452694,5.08213731420888,5.53301976978075e-18
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.993690851735015,TGFBR2;TGF-beta receptor type-2,1.27759395309748,1.17076077500948,1.39417577342224,3.83191689256189e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371637564889098,TGFBR2;TGF-beta receptor type-2,1.84145634935949,1.60254591920259,2.11598397647395,7.21662353793322e-18
sensitivity,Nervous system disorders,G81 (hemiplegia),0.967125608146703,TGFBR2;TGF-beta receptor type-2,1.31732874551711,1.20603339890294,1.43889466522589,9.3773521773704e-10
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.984039361574463,MAD1L1;Mitotic spindle assembly checkpoint protein MAD1,1.31564934901735,1.20548717770176,1.43587857389721,7.81492267788712e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367617354770946,MUC13;Mucin-13,1.64000823706584,1.41308185693766,1.90337665467775,7.49030347789224e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0611692742030349,HS6ST2;Heparan-sulfate 6-O-sulfotransferase 2,3.16048066564761,2.11381641731909,4.72540470217406,2.05629169990774e-08
sensitivity,Nervous system disorders,G40 (epilepsy),0.803132616773884,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.31721124658039,1.19411364530688,1.4529986110928,3.71459239062745e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0572534154623706,VSIG4;V-set and immunoglobulin domain-containing protein 4,3.11594447778274,2.25600364649663,4.30367654932744,5.28081870555852e-12
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.986119086750757,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.25583380038773,1.149740221448,1.37171728428361,4.22635351598158e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.377157300264602,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.79250660970689,1.55949277160655,2.06033654297278,2.1356816288595e-16
sensitivity,Nervous system disorders,G81 (hemiplegia),0.971277100807089,VSIG4;V-set and immunoglobulin domain-containing protein 4,1.35441341873438,1.23963897588825,1.47981448190052,1.88217505549469e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0653789004457652,RBP5;Retinol-binding protein 5,2.18993761809702,1.60209800551618,2.99346653865365,8.85864883463177e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0651723116421447,FAM3C;Protein FAM3C,3.52624895208758,2.50840674419932,4.95710342864183,4.09964228782987e-13
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.998375658650608,FAM3C;Protein FAM3C,1.25388937722448,1.14792214988096,1.36963867321442,5.10877779869896e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373348082887225,FAM3C;Protein FAM3C,1.94028175480934,1.67908549778693,2.24210934643171,2.58037634916471e-19
sensitivity,Nervous system disorders,G56 (mononeuropathies of upper limb),2.64686763630454,PRELP;Prolargin,1.23394933661813,1.16740998266438,1.30428126189672,1.06229180062236e-13
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.061170527645132,PRELP;Prolargin,2.67981758937255,1.87785091303893,3.82427713640418,5.54628762565588e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.991549072772972,PRELP;Prolargin,1.28217722601545,1.17286059328438,1.40168273051874,4.58229185609678e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367117339386164,PRELP;Prolargin,1.80974908616749,1.56241148852437,2.0962414696383,2.54706054718986e-15
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370976105947584,SFRP1;Secreted frizzled-related protein 1,1.49765403727118,1.29908785621763,1.72657115114999,2.61335937617058e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.064526221109851,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,3.34846341602388,2.38267594580584,4.70572058621184,3.38226466376711e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,TNFRSF19;Tumor necrosis factor receptor superfamily member 19,1.5543748022892,1.34163265016634,1.80085139228837,4.26860533842276e-09
sensitivity,Nervous system disorders,G45 (transient cerebral ischaemic attacks and related syndromes),1.31562943442124,NPPB;Natriuretic peptides B,1.22772339232493,1.13576797577602,1.32712381420331,2.40420949430393e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.365645404319437,NPPB;Natriuretic peptides B,1.46004459458638,1.2620411074651,1.68911314027055,3.58295019920889e-07
sensitivity,Nervous system disorders,G81 (hemiplegia),0.953971863867812,NPPB;Natriuretic peptides B,1.29731288995539,1.1843643595911,1.42103291171769,2.1338658607682e-08
sensitivity,Nervous system disorders,G09 (sequelae of inflammatory diseases of central nervous system),0.0251118619304173,PRAP1;Proline-rich acidic protein 1,3.90602333182037,2.30558834832374,6.61740777785315,4.0716903433209e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.335762088577236,PRAP1;Proline-rich acidic protein 1,1.59463511761194,1.3488538007109,1.88520146288727,4.65685046768168e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.986409025541309,GPKOW;G-patch domain and KOW motifs-containing protein,1.26198240917627,1.15448436185258,1.37948997292153,3.01589522058762e-07
sensitivity,Nervous system disorders,"G31 (other degenerative diseases of nervous system, not elsewhere classified)",1.00307265338487,AREG;Amphiregulin,1.24804124117866,1.14120423303344,1.36488009297203,1.21754977079067e-06
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.983626102853509,AREG;Amphiregulin,1.30909160237515,1.19692533379184,1.43176919647954,3.7913947677409e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370561192136968,AREG;Amphiregulin,1.742108506599,1.49890361970156,2.02477464786487,4.63306607117047e-13
sensitivity,Nervous system disorders,G81 (hemiplegia),0.97075814424394,AREG;Amphiregulin,1.33733802608937,1.22198965520637,1.46357457970672,2.68095430548284e-10
sensitivity,Nervous system disorders,G93 (other disorders of brain),0.875897845171588,AREG;Amphiregulin,1.29806255041376,1.18047541692853,1.42736253599484,7.25904983330619e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0650759219088937,SEMA3F;Semaphorin-3F,2.42944134647605,1.75123760236361,3.37029381278776,1.06693800405625e-07
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.998872559685108,COL4A1;Collagen alpha-1(IV) chain,1.32353372185636,1.21414316176906,1.44278003455423,1.90896859029226e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372795771036332,COL4A1;Collagen alpha-1(IV) chain,1.62094535520764,1.41086771718778,1.86230346939004,9.08862448861011e-12
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.959644542164811,ADAMTSL2;ADAMTS-like protein 2,1.35584883974308,1.2303918490101,1.49409806128972,7.98676440692758e-10
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0616118453741429,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,3.50901981985344,2.52870571340594,4.8693764683038,5.92378870017395e-14
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37172504273844,TNFRSF9;Tumor necrosis factor receptor superfamily member 9,1.69100139996835,1.46832483906361,1.94744763462457,3.05563340596236e-13
sensitivity,Nervous system disorders,G20 (parkinson's disease),1.51366503153468,HNMT;Histamine N-methyltransferase,0.750633020485907,0.700195997394598,0.804703159601557,6.34386354145654e-16
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0599101347978033,HNMT;Histamine N-methyltransferase,2.61367106654811,1.86101724497022,3.67072173166244,2.9502279597003e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.983494912266645,HNMT;Histamine N-methyltransferase,1.35630505123356,1.24041963088324,1.4830169937667,2.26378770542113e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371509607318339,HNMT;Histamine N-methyltransferase,1.42885093084935,1.23691134969194,1.6505750255243,1.24215792215338e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0616118453741429,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,2.6174502794153,1.87413315826567,3.65558121363756,1.6477535981487e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.98875687744199,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.25216654937845,1.14611057900744,1.36803646707475,6.3541348981431e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37172504273844,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.66460217764772,1.44542055447888,1.91702020650213,1.5036219075683e-12
sensitivity,Nervous system disorders,G81 (hemiplegia),0.971859876924302,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.24891358555183,1.14251990907606,1.36521484814851,9.93824529930605e-07
sensitivity,Nervous system disorders,G93 (other disorders of brain),0.866693354683747,TNFRSF10A;Tumor necrosis factor receptor superfamily member 10A,1.25877303737059,1.14521615527282,1.38358994702945,1.83396263908465e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.37172504273844,CRIP2;Cysteine-rich protein 2,1.49802848005965,1.29945522856285,1.72694624465955,2.54342318584212e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.059375642284592,HEPH;Hephaestin,2.93428447040151,1.99906332196533,4.30702982673641,3.85370037009941e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.342637854630179,HEPH;Hephaestin,1.79616281853126,1.52582006555832,2.11440453792541,1.9661018763758e-12
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.986770551128161,THBS2;Thrombospondin-2,1.29793868908183,1.18838102885964,1.41759654496675,6.79555393131932e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,THBS2;Thrombospondin-2,1.66056591164149,1.44375741897845,1.9099324517112,1.20597642773625e-12
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,ITGA5;Integrin alpha-5,1.4776010104897,1.2831064931575,1.70157719397667,5.90041841055209e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0650759219088937,CCDC80;Coiled-coil domain-containing protein 80,2.42360539576742,1.7408506663019,3.37413382324793,1.57330138687401e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372795771036332,CCDC80;Coiled-coil domain-containing protein 80,1.47188921994776,1.27618469999721,1.69760527281292,1.09497650242158e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0647338067401624,CD300E;CMRF35-like molecule 2,2.94631803025768,2.15028570654613,4.03704024492862,1.76454777313411e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.979890598559678,CD300E;CMRF35-like molecule 2,1.34457553691786,1.2314841075993,1.46805254190597,3.97560232580964e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370850011773016,CD300E;CMRF35-like molecule 2,1.75786576761306,1.53110530479724,2.01821001289985,1.19174364330871e-15
sensitivity,Nervous system disorders,G81 (hemiplegia),0.9690227219121,CD300E;CMRF35-like molecule 2,1.37007080307883,1.25472146623733,1.49602446117234,2.27011132485822e-12
sensitivity,Nervous system disorders,G93 (other disorders of brain),0.877175652448781,CD300E;CMRF35-like molecule 2,1.26983374145586,1.15685435786324,1.39384678804177,5.04241440754398e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372682926829268,CTSO;Cathepsin O,1.48881915558455,1.29145486949386,1.71634528654046,4.13639565392644e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.983626102853509,IGSF3;Immunoglobulin superfamily member 3,1.27154603055119,1.16398868248009,1.38904212055183,9.95745248320821e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.370561192136968,IGSF3;Immunoglobulin superfamily member 3,1.5114184451951,1.31066054357328,1.74292705130805,1.34353297972289e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0617161059128011,ACVRL1;Serine/threonine-protein kinase receptor R3,3.41257756800189,2.45572785999628,4.74225415907744,2.64280611821325e-13
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372354194460484,ACVRL1;Serine/threonine-protein kinase receptor R3,1.88945640362543,1.63692186188162,2.18095046827551,3.55052273897812e-18
sensitivity,Nervous system disorders,G81 (hemiplegia),0.973507819980849,ACVRL1;Serine/threonine-protein kinase receptor R3,1.24539042516809,1.13844858268015,1.36237800696187,1.66286956059658e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0561613703374362,GM2A;Ganglioside GM2 activator,2.87600990156045,2.00177671762278,4.13204573769672,1.10460995306054e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.339395641691828,GM2A;Ganglioside GM2 activator,1.56535180414116,1.33230426278066,1.83916417531677,5.08335413394286e-08
sensitivity,Nervous system disorders,G81 (hemiplegia),0.923928336928993,GM2A;Ganglioside GM2 activator,1.30694822496436,1.18445083778995,1.44211444514206,9.75710226540925e-08
sensitivity,Nervous system disorders,G20 (parkinson's disease),1.50867587103381,SCG2;Secretogranin-2,0.767766164714417,0.715279224633218,0.824104578156247,2.58238228155051e-13
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0648228176318063,SCG2;Secretogranin-2,3.0086282313409,2.14845572377554,4.21318611980257,1.44394095916936e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.373324949895861,SCG2;Secretogranin-2,1.84359757094396,1.60060040056589,2.12348566349778,2.20005264722889e-17
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375308641975308,TGFA;Protransforming growth factor alpha,1.45168651786332,1.25879903272503,1.67413041427596,2.98990529659233e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0633751213039431,IGFBP6;Insulin-like growth factor-binding protein 6,2.76811965636952,1.95087370301786,3.92772039529059,1.17430819470904e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0625562028384877,STC1;Stanniocalcin-1,2.3928702428152,1.71749187614122,3.33383119797633,2.51554679767805e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.375417945759928,STC1;Stanniocalcin-1,1.52942020469142,1.32841367866222,1.76084167160486,3.41685950138978e-09
sensitivity,Nervous system disorders,G81 (hemiplegia),0.963232702924938,LAMP3;Lysosome-associated membrane glycoprotein 3,1.26075453487974,1.15166351920057,1.38017916754295,5.22114932026729e-07
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.064526221109851,RSPO3;R-spondin-3,2.90297352394153,2.12270397966484,3.97005675847279,2.51417893835338e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,RSPO3;R-spondin-3,1.59781460471809,1.38717279972612,1.84044230938963,8.17980826278397e-11
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.97788446403274,DPY30;Protein dpy-30 homolog,1.27043145863183,1.16476185447165,1.3856876278057,6.58131775996099e-08
sensitivity,Nervous system disorders,G45 (transient cerebral ischaemic attacks and related syndromes),1.34140031047247,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.237733328999,1.14723897242185,1.33536589197358,3.67372719573995e-08
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.998872559685108,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.28057124971796,1.17359127761684,1.39730309595876,2.75693182291984e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372795771036332,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.59683111469391,1.39084167285919,1.83332845039994,3.09996248800794e-11
sensitivity,Nervous system disorders,G81 (hemiplegia),0.964236316933412,NTproBNP;N-terminal prohormone of brain natriuretic peptide,1.38906425472699,1.27143918153873,1.51757121518397,3.34856220466555e-13
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.060472465520941,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,2.89017387143509,2.04927172606689,4.07613343846693,1.44956505086827e-09
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.988084290438083,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.2497745841101,1.14460012674476,1.36461326064127,6.65698770765509e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372682926829268,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.85040794918196,1.60512319864191,2.13317556016438,2.2154539335671e-17
sensitivity,Nervous system disorders,G81 (hemiplegia),0.963624635953167,TNFRSF11A;Tumor necrosis factor receptor superfamily member 11A,1.27100404665077,1.16286646533191,1.38919758610593,1.25120437455283e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,SMOC1;SPARC-related modular calcium-binding protein 1,1.51639822648929,1.31548083812364,1.74800233850592,9.40939884938977e-09
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0593702189847692,CKB;Creatine kinase B-type,2.70724331052398,1.94930149172344,3.7598936713976,2.80101383562481e-09
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.959644542164811,CKB;Creatine kinase B-type,1.27997560732247,1.16452490394365,1.40687206412874,3.08686939582343e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.335762088577236,CKB;Creatine kinase B-type,1.72652224881652,1.48094973135566,2.01281583874542,3.02891208284351e-12
sensitivity,Nervous system disorders,G81 (hemiplegia),0.924569754668619,CKB;Creatine kinase B-type,1.26754937384885,1.15119023071419,1.39566977922306,1.39389235967271e-06
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0611693206259002,LGALS9;Galectin-9,2.28768739335069,1.66879998600926,3.13609399183362,2.71938268543666e-07
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.991529449018366,LGALS9;Galectin-9,1.39257051236155,1.27764018859829,1.51783941144375,4.88085694641768e-14
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367110093553862,LGALS9;Galectin-9,1.62180193099625,1.41271934945194,1.8618287520473,6.58195630922711e-12
sensitivity,Nervous system disorders,G81 (hemiplegia),0.974732096959152,LGALS9;Galectin-9,1.34573127323084,1.2336370302213,1.46801094275406,2.20518509436079e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,DSG2;Desmoglein-2,1.5396815503411,1.33774994079209,1.77209447309497,1.77965363108052e-09
sensitivity,Nervous system disorders,G47 (sleep disorders),2.61807498037953,LEP;Leptin,1.21676658790526,1.12707225455092,1.3135989493704,5.11843656657362e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.372795771036332,LEP;Leptin,1.62770394387532,1.33599744559842,1.98310269052987,1.33276254334318e-06
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.998355882178159,CCL3;C-C motif chemokine 3,1.34698782954098,1.23712619998246,1.4666056001055,6.79092271878545e-12
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0609696135313206,ANGPTL4;Angiopoietin-related protein 4,2.46875817566707,1.74962046436883,3.48347944828231,2.68592263632177e-07
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.99025525703239,ANGPTL4;Angiopoietin-related protein 4,1.23945274929714,1.13569417416783,1.35269084995166,1.48982838625594e-06
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.365911237016052,ANGPTL4;Angiopoietin-related protein 4,1.94565583036375,1.68782403840591,2.24287397506424,4.44500115674196e-20
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0593363457939659,RNASE1;Ribonuclease pancreatic,2.66016886666379,1.83932137146929,3.84734201914615,2.02671553013272e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.337853262110213,RNASE1;Ribonuclease pancreatic,1.56246108537519,1.32701646509995,1.83967924100169,8.54670677675447e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0592908810624925,FSTL3;Follistatin-related protein 3,3.14716887203851,2.35082779880429,4.21326985930912,1.33392155651651e-14
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.993101807802093,FSTL3;Follistatin-related protein 3,1.34702251101586,1.2349298882237,1.46928960298578,1.81483272848673e-11
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367697934170208,FSTL3;Follistatin-related protein 3,1.82312183820315,1.59119067774557,2.08885916906102,5.12642110985244e-18
sensitivity,Nervous system disorders,G81 (hemiplegia),0.978275937184387,FSTL3;Follistatin-related protein 3,1.33830239183292,1.22646371779458,1.46033940180991,5.96086035652009e-11
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.0591470988348021,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,3.55109643477793,2.59249446042337,4.86415152726427,2.92344827221442e-15
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.986770551128161,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.33354551999708,1.22151710207325,1.45584834701532,1.28165788294706e-10
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.378623545651745,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.94508913147674,1.69633972757151,2.23031487613937,1.57926360401444e-21
sensitivity,Nervous system disorders,G81 (hemiplegia),0.969953181485944,TNFRSF1A;Tumor necrosis factor receptor superfamily member 1A,1.31614639613597,1.20488971557168,1.4376762567351,1.08609052936846e-09
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.371616335471757,ANGPTL7;Angiopoietin-related protein 7,1.45418338670828,1.25922640747076,1.67932415460202,3.42552534884901e-07
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.368448159740105,ICAM1;Intercellular adhesion molecule 1,1.48525761836593,1.28667495694485,1.71448910310033,6.58855995178416e-08
sensitivity,Nervous system disorders,G59 (mononeuropathy in diseases classified elsewhere),0.061170527645132,COLEC12;Collectin-12,3.27190162017874,2.40601610345644,4.44940505458345,4.09690755026159e-14
sensitivity,Nervous system disorders,G62 (other polyneuropathies),0.991549072772972,COLEC12;Collectin-12,1.28530790842694,1.1769933290608,1.40359029968598,2.29590872227494e-08
sensitivity,Nervous system disorders,G63 (polyneuropathy in diseases classified elsewhere),0.367117339386164,COLEC12;Collectin-12,2.02391254609858,1.76484124141833,2.32101443354943,6.21189885169129e-24
sensitivity,Nervous system disorders,G81 (hemiplegia),0.978705735808766,COLEC12;Collectin-12,1.30738013328945,1.19683911363706,1.42813081010174,2.7396106679076e-09
